

2014

**Scientific
Report**



Sant Pau Biomedical Research Institute

HSCSP Research Institute Board of Trustees

President

Enric Argelagués Vidal

Secretary

Joaquim Jornet Porta

Members

Alberto Salazar Soler

Managing Director,
Hospital de la Santa Creu i Sant Pau

Designated by the Hospital de la Santa Creu i Sant Pau Foundation

Jordi Sierra Gil

Francisco Blanco Vaca

Josep M. Foracada i Casanovas

Designated by the Generalitat de Catalunya

Carles Constante Beitia

Andreu Mas-Collell

Designated by the Autonomous University of Barcelona

Antonio Escartín Siquier

Manuel Armengol Carrasco

Designated by the Board of the Research Institute of Sant Pau Hospital

Josep M. Ventura Ferrero

Antoni Esteve Cruella

IIB Sant Pau Steering Committee

Chair

Alberto Salazar Soler

Managing Director,
Hospital de la Santa Creu i Sant Pau Healthcare
Management Foundation

Members

Jordi Bachs i Ferrer

Hospital de la Santa Creu i Sant Pau
Private Foundation

Lluís Tort i Bardolet

Autonomous University of Barcelona

Lina Badimon Maestro

Catalan Institute of Cardiovascular Sciences

Helena Isábal Roca

Puigvert Foundation

Jordi Sierra Gil

Blood and Tissue Bank

Xavier Bonfill i Cosp

Iberoamerican Cochrane Centre

Jaume Sellarès Sallas

Barcelona-Sardenya Primary Care Centre

Conrad Casas i Segalà

Public Health Agency of Barcelona

Jaume Kulisevsky Bojarski

Hospital de la Santa Creu i Sant Pau
Research Institute

Summary

IIB Sant Pau · 2014 Scientific Report

- 04 Presentation
- 05 IIB Sant Pau Scientific Structure
- 06 Who We Are
- 07 Strategic Objectives
- 08 IIB Sant Pau Entities
- 10 Vertical Areas of Research
- 11 Transversal Areas of Research
- 11 Associated Groups
- 12 Organization Chart
- 14 Financial Data
- 16 Scientific Outcomes
- 18 Publications with an Impact Factor
- 19 Publications by Thematic Area and Quartile
- 20 Research Resources
- 21 Research Training
- 22 Doctoral Theses
- 25 Patents
- 26 Technology Transfer Agreements
- 27 Clinical Guidelines
- 30 Research Support Services
- 40 Scientific and Technical Service Platform

44 Areas of Research

- 46 Area 1. Cardiovascular Diseases
- 78 Area 2. Genetic, Metabolic and Inflammatory Diseases
- 116 Area 3. Haematological and Oncological Diseases
- 138 Area 4. Neurological, Mental Disorders and Ageing
- 180 Area 5. Uronephrology and Experimental Surgery
- 194 Area T1. Epidemiology, Public Health and Healthcare Services
- 220 Area T2. Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment
- 230 Associated Groups

Presentation



Dear Friends of the IIB Sant Pau

I am pleased to present you the IIB-Sant Pau Scientific Report for the year 2014.

We continue the upward trend in both competitive projects and technology transfer agreements that shows, once more, the continuous growth and creation of good quality scientific knowledge of our Institution despite the unfavourable conditions and context in which we were immersed.

This upward trend is also reflected in the economic balance of the annual closure of the managing institution of the IIB Sant Pau, the Research Institute of Sant Pau Hospital with many efforts could rectify the negative results of 2013 product of the economic downturn.

These results confirm the consolidation of the IIB Sant Pau as a leading research centre. Noteworthy, they have again been produced thanks to the continuous efforts of our Researchers and the entire Research Support Team who overcome every year and keep the bar high up within the set of Accredited Health Institutes in Spain.

Cordially,

Jaume Kulisevsky
IIB Sant Pau Manager

IIB Sant Pau Scientific Structure

IIB Sant Pau has seven research areas that can be divided into two research lines: vertical, transversal and associated groups.

The vertical line has five main areas:

- Cardiovascular Diseases
- Genetic, Metabolic and Inflammatory Diseases
- Haematological and Oncological Diseases
- Neurological and Mental Disorders
- Uronephrology and Experimental Surgery

The transversal line consists of two areas:

- Epidemiology, Public Health and Healthcare Services
- Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment

Activities in the transversal line complement and support research in the vertical line.


Who We Are

The Sant Pau Biomedical Research Institute (IIB Sant Pau) conducts research into basic, clinical and epidemiological medicine and healthcare services. Ten entities cooperate to perform high-level research into new techniques and processes aimed at improving the quality of life of patients. Stakeholders include the following:

- Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation
- Hospital de la Santa Creu i Sant Pau Private Foundation
- Hospital de la Santa Creu i Sant Pau Research Institute
- Autonomous University of Barcelona - Ageing Institute
- Catalan Institute of Cardiovascular Sciences
- Puigvert Foundation
- Blood and Tissue Bank
- Iberoamerican Cochrane Centre
- Barcelona-Sardenya Primary Health Care Centre
- Public Health Agency of Barcelona

IIB Sant Pau was founded in 2009 as an association of healthcare entities carrying out their own research. Throughout 2010, IIB Sant Pau became consolidated as a research centre, while continuing to implement an accreditation process as a Healthcare Research Institute with the Spanish Ministry of Science and Innovation. This accreditation was finally obtained in early 2011. The institutions participating in IIB Sant Pau, which together form a natural alliance for historical and geographical proximity reasons, jointly implement research activities and cooperate in other scientific areas. The cooperation between these institutes represents a qualitative leap in terms of fostering translational research projects that bridge the gap between basic and clinical research.

The knowledge developed in this kind of research is channelled to society by the application of discoveries to clinical practice and to healing patients. The most tangible benefits are the application of technology to health and the scientific communication of new knowledge. This research infrastructure also generates employment and spotlights Catalonia's contributions to biomedical research. The success as a research centre ultimately translates to patient health.




Strategic Objectives

IIB Sant Pau's mission is to manage, promote, develop and communicate research into the health sciences.

To fulfil its mission, IIB Sant Pau has set itself a number of strategic objectives that guide its activities:

- Promote and consolidate relationships and knowledge exchanges between IIB Sant Pau researchers and with other public and private organizations, prioritizing the implementation of joint projects and the creation of multidisciplinary teams so as to strengthen alliances and implement translational research with a bearing on clinical activities.
- Organize courses, conferences, open days, seminars and workshops aimed at communicating scientific advances to society and at facilitating innovation and technology transfers to the productive sector.
- Organize and participate in continuous professional development, whether by developing teaching activities or arranging grant-aided stays abroad for researchers.
- Participate in developing policies aimed at coordinating biomedical research in Catalonia, while ensuring a strong presence in national and international research projects and networks of excellence.
- Acquire, maintain and optimize use of scientific and technological infrastructures and equipment.



IIB Sant Pau Entities

Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation



The Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation (HSCSP Healthcare Management Foundation) is a high-technology specialist care hospital performing patient care, teaching and research activities in the clinical, epidemiological and healthcare services fields. It offers accredited specialist and undergraduate health science training courses.

Hospital de la Santa Creu i Sant Pau Research Institute



Institut de Recerca

The Hospital de la Santa Creu i Sant Pau Research Institute (HSCSP RI) promotes, manages and communicates biomedical research conducted in the HSCSP. It raises and manages funds and other resources for health science research in the basic, clinical, epidemiological and healthcare service fields.

Hospital de la Santa Creu i Sant Pau Private Foundation



The Hospital de la Santa Creu i Sant Pau Private Foundation (HSCSP Private Foundation), which owns the HSCSP, is responsible for building, improving and maintaining buildings and premises used for medical care and associated and complementary activities.

Autonomous University of Barcelona (UAB) - Ageing Institute



The UAB, a leading university renowned for quality and innovation in research, coordinates an influential scientific and technological centre, called Esfera UAB, responsible for promoting new business projects. The UAB also projects its productive activity in such a way as to disseminate new knowledge in society.

The Ageing Institute, attached to this university, is a non-profit foundation governed by a board of trustees formed by the UAB, the UAB Foundation and the Agrupació Mútua del Comerç i de la Indústria. Its mission is to improve knowledge of different aspects related to ageing with the aim of enhancing the quality of life of older people and promoting actions that contribute to adapting society and people to the challenges of demographic change.



Catalan Institute of Cardiovascular Sciences (ICCC)

The ICCC performs basic and clinical research into cardiovascular and heart diseases. The fact that it competes successfully at the international level enables it to avail of the infrastructure necessary to transfer basic research to the development of therapies and diagnostic methods, ultimately improving medical care for patients.



Puigvert Foundation

The Puigvert Foundation has the aim of deepening medical knowledge and perfecting medical techniques in the field of research and treatment of urinary and male reproductive system disorders and diseases. More specifically, it performs urology, nephrology and andrology research, focusing particularly on medical care, teaching, training and studies.



Iberoamerican Cochrane Centre

This independent, not-for-profit organization has as its main aim the promotion of medical practice based on the best available scientific evidence. To this end, it ensures that valid, useful, up-to-date and thoroughly reviewed information is made available for clinical and healthcare decision making.



Barcelona-Sardenya Primary Care Centre

Part of the public healthcare system, this teaching and care centre provides primary care services in its catchment area of Barcelona and has a research unit which performs clinical trials and epidemiology studies.



Public Health Agency of Barcelona


This autonomous body, created by the Barcelona Health Consortium, has as its main mission to analyse and monitor the health of the population of Barcelona with a view to improving health and preventing risk. It is also responsible for epidemiological surveillance and the provision of medical care to substance abusers. It has an excellent track record in the public health and applied research fields.



Blood and Tissue Bank

The Blood and Tissue Bank is a public healthcare body which carries out patient care, teaching and research activities in the blood transfusion and tissue bank fields.

Vertical Areas of Research



Cardiovascular Diseases

The incorporation of new technologies that facilitate molecular profiling and gene regulation has led to innovative research into heart disease. The great diversity of the groups in this area gives research varied perspectives, whether in developing or testing the effectiveness of new biomarkers (as in the investigation of the metabolic and genetic bases of diseases) or improving the range of results and possible applications in short-term therapies.



Genetic, Metabolic and Inflammatory Diseases

Identifying the genes and mutations responsible for genetic diseases is an essential component of knowledge and understanding of the physiological bases of metabolic pathways and also in the development of new forms of treatment for common diseases affecting large proportions of the population, such as diabetes and obesity, known but with a hereditary diseases, infectious diseases (AIDS, tuberculosis, etc) and rare diseases (not well know but with a devastating impact on those affected).



Haematological and Oncological Diseases

A broad range of research is conducted in this area, particularly in head-and-neck, breast, ovary, colorectal and haematological cancers, among others. Research in covers a wide range of fields, with disciplines that include nanomedicine, new anticancer agents and predictive molecular markers. Initiatives of specific relevance include the GAIT (Genetic Analysis of Idiopathic Thrombophilia) project, a world pioneer in the identification of genes influencing the risk of thromboembolic disease, and research into antitumour immunotherapy in animals and humans.



Neurological, Mental Disorders and Ageing

This area covers research in a broad range of disciplines. Besides the study of ageing and the most common neurodegenerative disorders such as Alzheimer and Parkinson, neurological research is also focused on stroke, neuroimmunology and neuromuscular diseases. Research into cognitive, affective, psychotic and personality disorders ranges from identification and evaluation of new therapeutic targets to neurogenesis and the effects of deep-brain stimulation. Research in this field has the support of the Drug Research Centre, which assesses the effectiveness of new drugs and therapies in humans.



Urology and Experimental Surgery

IIB Sant Pau promotes experimental surgery in the knowledge that this area has a promising future both as an independent research line and as a complement to general surgery. This interdisciplinary approach provides valuable new insights and ensures techniques and procedures of great clinical relevance. Current areas of interest include the development of minimally invasive techniques and the application of deep-brain stimulation in different pathologies. In the fields of andrology, urology and nephrology research, the Puigvert Foundation is a leading centre in Spain.

Transversal Areas of Research



Epidemiology, Public Health and Healthcare Services

Research in these fields aims to determine the magnitude and distribution and identify the determinants of public health problems in order to evaluate the effectiveness and efficiency of public interventions and prevention practices. This area also aims to reduce patient risk and make healthcare safer by promoting evidence-based medical practice and ensuring the use of conscious, explicit and rational decision making concerning patient care.



Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and their Treatment

This area focuses on the structure of proteins associated with neurodegenerative diseases and inflammatory processes and on factors linked to the innate immune system. Research is also conducted in the area of osteoporosis, ageing-related macular degeneration and coagulation-cascade factors closely linked to cardiovascular disease and haemophilia. Such studies are vital to the understanding of diseases of the heart, blood and nervous systems and to advances in the fields of cancer and epidemiology.

Associated Groups



This area includes HSCSP Research Institute groups that do not form part of IIB Sant Pau because they have not, as yet, been accredited by the External Scientific Committee.

Organization Chart



Steering Committee

Chair

Dr. Alberto Salazar
Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation

Members

Dr. Jordi Bachs
Hospital de la Santa Creu i Sant Pau Private Foundation

Dr. Lluís Tort
Autonomous University of Barcelona

Dr. Lina Badimon
Catalan Institute of Cardiovascular Sciences

Dr. Helena Isábal
Puigvert Foundation

Dr. Jordi Sierra
Blood and Tissue Bank

Dr. Xavier Bonfill
Iberoamerican Cochrane Centre

Mr. Conrad Casas
Public Health Agency of Barcelona

Mr. Jaume Sellarès
Barcelona-Sardenya Primary Care Centre

Dr. Jaume Kulisevsky
Hospital de la Santa Creu i Sant Pau Research Institute

Executive Committee

Chair

Dr. Jaume Kulisevsky
IIB Sant Pau Manager

Representatives of Associated Entities

Dr. Manel Trias
Autonomous University of Barcelona

Dr. Ramon Mangues
Hospital de la Santa Creu i Sant Pau Research Institute

Dr. Xavier Bonfill
Iberoamerican Cochrane Centre

Dr. Juan Cinca
Hospital de la Santa Creu i Sant Pau Healthcare Management Foundation

Dr. Gemma Craywinckel
Hospital de la Santa Creu i Sant Pau Private Foundation

Dr. Lina Badimon
Catalan Institute of Cardiovascular Sciences

Dr. Helena Isabal
Puigvert Foundation

Dr. Jordi Sierra
Blood and Tissue Bank

Dr. Carme Borrell
Public Health Agency of Barcelona

Dr. Carlos Brotons
Barcelona-Sardenya Primary Care Centre

Internal Scientific Committee

Chair

Dr. Jaume Kulisevsky
IIB Sant Pau Manager

Vice-Chair

Dr. Antonio López Pousa
Chair, Clinical Research Ethics Committee

4 members designated by the IIB Sant Pau Manager

Dr. Antoni Salvà
Autonomous University of Barcelona -
Ageing Institute

Dr. Carlos Brotons
Barcelona-Sardenya Primary Care Centre

Dr. Lina Badimon
Catalan Institute of Cardiovascular Sciences

Dr. Sílvia Mateu
Puigvert Foundation

2 members each representing IIB Sant Pau thematic areas

Cardiovascular Diseases

Dr. Jordi Ordóñez
Hospital de la Santa Creu i Sant Pau:
Cardiovascular biochemistry

Dr. Luis Vila
Hospital de la Santa Creu i Sant Pau
Research Institute: Vascular biology and
inflammation

Genetic, Metabolic, Inflammatory and Infectious Diseases

Dr. Cándido Juárez
Hospital de la Santa Creu i Sant Pau:
Inflammatory diseases

Dr. Carlos Guarner
Hospital de la Santa Creu i Sant Pau:
Cirrhosis complications

Haematological and Oncological Diseases

Dr. Josep Nomdedéu
Hospital de la Santa Creu i Sant Pau:
Haematological diagnosis

Dr. Jaime Prat
Hospital de la Santa Creu i Sant Pau:
Molecular cancer pathology

Neurological, Mental Disorders and Ageing

Dr. Víctor Pérez
Hospital de la Santa Creu i Sant Pau: Clinical
psychiatry

Dr. Alberto Lleó
Hospital de la Santa Creu i Sant Pau Research
Institute: Neurobiology of dementia

Urology and Experimental Surgery

Dr. José Ballarín
Puigvert Foundation: Nephrology research

Dr. Manel Trias
Hospital de la Santa Creu i Sant Pau:
General and digestive surgery

Epidemiology, Public Health and Healthcare Services

Dr. Gerard Urrútia
Hospital de la Santa Creu i Sant Pau:
Clinical epidemiology and healthcare
services

Dr. Carles Ariza
Public Health Agency of Barcelona:
Evaluation of public health policies and
programmes

Molecular, Genomic, Cellular and Kinetic-Dynamic Bases for Diseases and Treatments

Dr. Jordi Sierra
Blood and Tissue Bank: Generation of
advanced treatments

Dr. José Manuel Soria
Hospital de la Santa Creu i Sant Pau Research
Institute: Genomics and bioinformatics for
genetically complex disease

External Scientific Committee

Dr. José López-Barneo
Physiology professor
Institute of Biomedicine of Seville (Spain)

Dr. Ángel María Carracedo
Genomic medicine group researcher
Institute of Legal Medicine
Faculty of Medicine and Dentistry
Santiago de Compostela University
(Spain)

Dr. Vicente Vicente
Haematology group researcher
Faculty of Internal Medicine
Murcia General University Hospital (Spain)

Dr. José Palacios
Head of the pathology/anatomy
Department
Ramón y Cajal Hospital (Madrid, Spain)

Dr. Agustín Gómez de la Cámara
Clinical epidemiology group researcher
Doce de Octubre Teaching Hospital
(Madrid, Spain)

Dr. John Louis McGregor
Director of Research-INSERM Unit 689
Cardiovascular Research Centre–
Lariboisière Hospital (Paris, France)

Dr. Jordi Alonso
Health Services Research Unit
Hospital del Mar Municipal
Institute for Medical Research (Barcelona,
Spain)

Mr. Guillem López Casasnovas
Professor
Faculty of Economics and Business
Sciences
Pompeu Fabra University (Barcelona,
Spain)

Financial Data

Public/Private Income Summary 2005-2014



In millions of euros

Income Statement year ending 31 December 2014


Income from activities	13,185,336
Services	4,333,475
Collaborations with partners and sponsors	1,524,193
Government grants	6,100,684
Other grants, donations and legacies	1,330,487
Repayment of grants, donations, etc	-103,5034
Stocks and supplies	-1,219,051
Material and equipment for activities	-1,219,051
Other income	283,794
Additional and management income	283,794
Personnel expenditure	-8,293,137
Salaries	-6,356,780
Social security	-1,936,357
Other operating expenses	-3,742,227
External services	-3,369,180
Repairs and maintenance	-114,529
Freelance services	-422,451
Insurance	-62,550
Banking	-23,062
Sundry	-252
Other services	-2,746,335
Taxes	-19,572
Loss, deterioration and variation in provisions for operations	-9,638
Other operating expenses	-343,838
Depreciation of fixed assets	-1,280,457
Grants, donations and bequests transferred to results	911,259
Deterioration and gains/losses on disposal of fixed assets	-1,924
Gains/losses from disposal and other	-1,924
Other gains/losses	-183,208
Incidental expenses	-222,175
Incidental income	38,967
OPERATIONAL PROFIT/LOSS	-339,614
Financial income	462,460
From investments in equity instruments	0.00
Negotiable costs	462,460
Financial expenditure	-181,526
Debts with third parties	-181,526
Exchange differences	-277
FINANCIAL PROFIT/LOSS	280,657
OVERALL PROFIT/LOSS	-58,953

In euros

Scientific Outcomes


Outcomes for IIB Sant Pau's scientific activities are summarized in the following pages as follows:

- **Publications with an Impact Factor (IF):** This figure shows IIB Sant Pau publications over the years with an impact factor, one of the most important indicators used to identify the relevance of a science journal in its field and to give an approximate idea of the quality of the publications of researchers.
- **Publications by Thematic Area:** This figure reflects the relative importance of each of the thematic areas covered by IIB Sant Pau.
- **Publications by Quartile:** This figure depicts IIB Sant Pau publications by quartiles that reflect the importance of the scientific journal. The journals in a specific category are listed in descending order according to their impact factor and the list is divided into four equal quartiles. Thus, journals in the top quartile (Q1) are the most important journals in their category.
- **Research Resources and Training:** These tables show the list of institutions providing support to IIB Sant Pau and sharing its vision of research.
- **Doctoral Theses:** This table reflects the potential of up-and-coming IIB Sant Pau staff members and their ability to generate new ideas and drive new projects.
- **Patents:** This table shows the patents requested by IIB Sant Pau researchers between 2009 (foundation year) and 2014.
- **Technology Transfer Agreements:** This table reflects agreements signed between 2009 (foundation year) and 2014.
- **Clinical Guidelines.**



Publications with an Impact Factor

Production status



Publications

275 250 367 461 514 534 664 654 933

Total IF



1,001.03 975.36 1,722.76 2,158.53 2,448.88 2,298.44 3,269.47 2,848.27 4,074.22

Mean IF

3.64 3.9 4.69 4.68 4.78 4.30 4.92 4.35 4.37

Publications by Thematic Area and Quartile

Indexed publications



Research Resources

Centre	Active		Granted	
	2013	2014	2013	2014
AGAUR (Agència de Gestió d'Ajuts Universitaris i de Recerca)	19	19	-	23
European Comission	6	5	1	1
American Grants	1	1	1	-
EAES (European Association for Endoscopic Surgery)	1	1	-	-
COIB (Col·legi Oficial d'Infermeria de Barcelona)	3	2	-	-
Fundació Marató TV3	9	9	2	5
Fundación Mútua Madrileña (FMM)	1	2	2	-
Fundación Mapfre	1	1	-	-
MICINN - ISCIII (Instituto de Salud Carlos III)	110	113	23	21
MINECO (Ministerio de Economía y Competitividad)	8	6	1	6
Ministerio de Sanidad y Política Social	12	11	1	-
SEPAR (Sociedad Española de Neumología y Cirugía Torácica)	1	9	8	4
SERAM (Sociedad Española de Radiología Médica)	2	-	-	-
AECC (Asociación Española Contra el Cáncer)	1	3	2	-
Merk Serono	2	1	-	-
Fundació Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears	1	1	-	-
SOCAP (Societat Catalana de Pneumologia)	1	1	-	-
ISHLT	1	-	-	-
Sociedad Española de Diabetes	1	1	1	-
Fundació Catalana de Pneumologia	3	21	-	-
Sociedad Española de Cardiología	3	-	-	-
Asociación Española de Artroscopia	1	1	-	-
FAME	1	-	-	-
AFM Telethon	-	1	1	1
Societat Catalana de Psiquiatria i Salut Mental	-	1	1	-
Fundación Alfonso Martín Escudero	-	1	1	-
CIBERER	-	1	1	-
GILEAD	-	1	1	1
Grupo Español de Investigación en Sarcomas	-	-	-	1
Mutual Médica	-	-	-	1
ASEM / FEDER / FIG	-	-	-	1
	189	194	47	66

Source: Hospital de la Santa Creu i Sant Pau Research Institute

Research Training

Centre	Active		Granted	
	2013	2014	2013	2014
AGAUR (Agència de Gestió d'Ajuts Universitats i Recerca)	6	3	4	2
Departament de Salut (Generalitat de Catalunya)	4	3	-	-
MINECO (Ministerio de Economía y Competitividad)	6	6	2	-
ISCIII (Instituto de Salud Carlos III)	28	27	10	12
Fundació Gestió Sanitària	5	5	5	-
Fundació Casa del Corazón	-	-	-	1
American Grants	-	-	-	1
Fundación J. L. Castaño	-	-	-	1
	49	44	21	17

Doctoral Theses

IIB Sant Pau Accredited Groups	Institution	Candidate	Director(s)	Thesis title	Defended at
Genetic Diseases	HSCSP	Laura Alías Andreu	Eduardo F. Tizzano, Cristina Fillats	Anàlisi qualitativa i quantitativa dels gens SMN1 i SMN2	Universitat de Barcelona
Microbiology and Infectious Diseases	HSCSP	Noemí Alonso Louro	Beatriz Mirelis, Alba Rivera	Caracterización molecular de los genes blaAmpC cromosómicos y adquiridos en aislados clínicos de Escherichia coli en el área de Barcelona*	Universitat Autònoma de Barcelona
Chronic Respiratory Diseases	HSCSP	Óscar Amor Carro	David Ramos Barbón	Role of the effector and regulatory arms of the adaptive immune response in the pathophysiology of experimental asthma	Universidade de Santiago de Compostela
Emerging Processes in Prevalent Diseases	HSCSP	Aitor Alquezar Arbé	Salvador Benito, Miquel Santaló	Troponina T d'elevada sensibilitat per a l'exclusió precoç de l'infart agut de miocardi sense elevació del segment st.	Universitat Autònoma de Barcelona
Clinical Epidemiology and Healthcare Services	HSCSP	Manel Balcells Diaz	Xavier Bonfill Cosp	Anàlisi de l'estructura i el procés d'innovació de quatre grans hospitals de Barcelona	Universitat Autònoma de Barcelona
Oncology/Haematology and Transplantation	HSCSP	Pere Barba Suñol	Jordi Sierra Gil, Rodrigo Martino Bofarull	Evaluación de la función hepática en el trasplante alogénico de progenitores hematopoyéticos con acondicionamiento de toxicidad reducida	Universitat Autònoma de Barcelona
Clinical Epidemiology and Healthcare Services	HSCSP	Xavier Basurto Oña	Xavier Bonfill Cosp	Manejo farmacológico del dolor agudo en urgencias. Compendio de evidencias	Universitat Autònoma de Barcelona
Inflammatory Diseases	HSCSP	Consol Benaiges Martínez	Cándido Juárez Rubio	Teixit adipós epicàrdic i senyalització a través dels receptors toll like (TLR): Paper en la patofisiologia de l'aterosclerosi	Universitat Autònoma de Barcelona
Nuclear Medicine	HSCSP	M. del Valle Camacho Martí	Montserrat Estorch Cabrera	Utilidad de la gammagrafía de inervación miocárdica con 123I-MIBG en el diagnóstico clínico de la demencia de cuerpos de Levy	Universitat Autònoma de Barcelona
Generation of Advanced Therapy Medicines	BST	Marta Caminal-Bobet	Joaquim Vives, Francesc Gòdia	Tissue engineering for bone regeneration: in vitro development and in vivo testing in sheep	Universitat Autònoma de Barcelona
Multi-organ Damage	HSCSP	Iván Castellví Barranco	Carmen Pilar Simeon Aznar, Héctor Corominas Macías, Jordi Casademont Pou	Utilidad de los antagonistas de los receptores de la endotelina para prevención primaria de hipertensión pulmonar en pacientes afectos de esclerosis sistémica	Universitat Autònoma de Barcelona
Clinical Epidemiology and Healthcare Services	HSCSP	Evelina Chapman Heller	Xavier Bonfill Cosp	Análisis y generación de evidencias científicas en relación a la salud materna	Universitat Autònoma de Barcelona
Transport and Health: Injuries and Mobility	ICCC	Eva Cirera	Catherine Pérez	Evolució de les lesions en la gent gran. Espanya 2000-2010	Universitat Pompeu Fabra
Palliative Care	HSCSP	Nadia Collette	Pilar Barreto Martin	Art therapy for terminal patients	Universidad de Valencia

IIB Sant Pau Accredited Groups	Institution	Candidate	Director(s)	Thesis title	Defended at
Health Inequalities	ASPB	Marco Antonio Cornejo	Glòria Pérez, Carme Borrell	Salud bucal y su atención en las personas mayores institucionalizadas de Barcelona y el impacto en su calidad de vida	Universitat Pompeu Fabra
Multi-organ Damage	HSCSP	César Díaz Torné	César Díaz López, Sílvia Vidal Alcorisa, Jordi Casademont Pou	Avenços clínics i immunològics en la resposta al tractament amb teràpia deplectora de limfòcits B (Rituximab) en pacients amb artritis reumatoide	Universitat Autònoma de Barcelona
Angiology, Vascular Biology and Inflammation	HSCSP	Jaime Félix Dilmé Muñoz	Luis Vila Navarro, Secundino Llagostera Pujol, Xavier Rius i Cornadó	Estudio la influencia de los factores de riesgo cardiovascular en los niveles locales de factores angiogénicos en el aneurisma de aorta abdominal	Universitat Autònoma de Barcelona
Clinical Psychiatry	HSCSP	Albert Feliu Soler	Xavier Borras, Joaquim Soler	Caracterización del Trastorno Límite de la Personalidad y efectos del entrenamiento en mindfulness	Universitat Autònoma de Barcelona
General and Digestive Surgery	HSCSP	Sonia Fernández Ananin	Eduard Targarona	Abordage laparoscòpic en el càncer de recto. Factores predictivos de la calidad del mesorrecto	Universitat Autònoma de Barcelona
Chronic Respiratory Diseases	HSCSP	Ana M. Fortuna Gutiérrez	Pere Casan Clará, Mercedes Mayos Pérez	Utilidad de la medición de óxido nítrico en aire espirado en la patología respiratoria	Universitat Autònoma de Barcelona
Oncology/Haematology and Transplantation / Haematological Diagnosis	HSCSP	Montserrat Hoyos Colell	Jordi Sierra Gil, Josep Francesc Nomdedéu Guinot	Impacto de las alteraciones moleculares en el pronóstico de la Leucemia Mieloide Aguda (LMA) "de novo"	Universitat Autònoma de Barcelona
Neuromuscular Diseases	HSCSP	Eugenia Martínez Hernández	Isabel Illa Sendra	Biomarcadores en el diagnóstico y tratamiento de la miastenia	Universitat Autònoma de Barcelona
Health Inequalities	ASPB	Roshanak Mehdipanah	Carme Borrell	Urban Renewal and Health: The effects of the Neighbourhoods Law on health and health inequalities in Barcelona*	Universitat Pompeu Fabra
Pharmacokinetic/ Pharmacodynamic Modelling and Simulation / Pharmacy	HSCSP	Maria Rita Moreira da Silva	Maria Antonia Mangués, Marta Valle	Análisis farmacocinético poblacional de vancomicina en neonatos: diseño de una nueva estrategia de dosificación	Universitat Autònoma de Barcelona
Oncogenesis and Antitumour Drugs	HSCSP	María José Moreno Jiménez	Ramon Mangués, Isolda Casanova	Desenvolupament de models animals de linfoma difús de cèl·lula gran i paper de CXCR4 en la disseminació	Universitat de Barcelona
Nuclear Medicine	HSCSP	Paloma Pifarré Montaner	Alejandro Fernández	Técnica de relajación vs fármaco de síntesis en el tratamiento de la ansiedad del paciente oncológico: estudio del metabolismo cerebral mediante PET con FDG	Universitat Autònoma de Barcelona
Clinical Epidemiology and Healthcare Services	HSCSP	Salvador Rico Amaro	Ignasi Gich Saladich	Pharmacological characterization of unconventional heparins	Universitat Autònoma de Barcelona
Clinical Psychiatry	HSCSP	Irene Cristina Romera Fernández	Víctor Pérez, Inmaculada Gilaberte	Remisión y funcionalidad en el trastorno depresivo mayor	Universitat Autònoma de Barcelona
Oncology/Haematology and Transplantation	HSCSP	Isabel Sánchez-Ortega	Jordi Sierra Gil, Rafael F. Duarte Palomino	Avances en la profilaxis antifúngica primaria en la fase precoz del trasplante alogénico	Universitat Autònoma de Barcelona
Clinical Epidemiology and Healthcare Services	HSCSP	Judit Sanz i Buxó	M. Teresa Puig Reixach	Estudi epidemiològic, genètic i clínic del registre de famílies amb càncer de mama i ovari hereditaris de l'Hospital de la Santa Creu i Sant Pau (1995-2005)	Universitat Autònoma de Barcelona

*European thesez

IIB Sant Pau Accredited Groups	Institution	Candidate	Director(s)	Thesis title	Defended at
Genetic Diseases / Clinical Oncology	HSCSP	Ana Sebio García	Montserrat Baiget, Agustí Barnadas	Estudios farmacogenéticos en el cáncer colorrectal: la vía del receptor del factor de crecimiento epidérmico*	Universitat Autònoma de Barcelona
Clinical Epidemiology and Healthcare Services	HSCSP	Pamela Serón Silva	Xavier Bonfill Cosp	Actividad física y ejercicio en la enfermedad cardiovascular	Universitat Autònoma de Barcelona
Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases / Biomarkers for Disease Status	ICCC	Rosa Suades Soler	Lina Badimon, Teresa Padró	Role of microparticles in atherothrombosis	Universitat Pompeu Fabra
Oncology/Haematology and Transplantation	HSCSP	David Valcárcel Ferreiras	Jordi Sierra Gil, Rodrigo Martino Bofarull	Transplante de progenitores hematopoyéticos con acondicionamiento de intensidad reducida: aplicabilidad en leucemia mieloide aguda y síndromes mielodisplásicos	Universitat Autònoma de Barcelona
Endocrinology, Diabetes and Nutrition	HSCSP	Irene Vinagre Torres	Alberto de Leiva, Antonio Pérez	Biomarcadores de la inflamación en la diabetes mellitus tipo 2: efecto del control glucémico y del fenotipo de las LDL	Universitat Autònoma de Barcelona
Inflammatory Diseases	HSCSP	Carlos Zamora Atenza	Silvia Vidal Alcorisa	Anàlisi de l'expressió del receptor scavenger CD36 en els leucòcits: conseqüències funcionals en la inflamació	Universitat Autònoma de Barcelona

* *European theseež*

Patents

IIB Sant Pau Group	Researchers	Organizations	Title	Application Number	Year
Reproductive Health	Dr. Ramon Rovira	HSCSP RI	Procedimiento y dispositivo para el aprendizaje y entrenamiento de operaciones de cirugía laparoscópica e intervenciones similares	P201331528	2013
Lipids and Cardiovascular Pathology / Molecular and Therapeutic Pathologies of Ischaemic and Atherothrombotic Diseases	Vicenta Llorente-Cortés, Lina Badimon	CSIC-ICCC	LRP1 as a key receptor for cholesteryl ester transfer from very low density lipoproteins to ischaemic myocardium	PCT/ES2012/070483	2011
Oncogenesis and Antitumour Drugs	Ramon Mangues, Isolda Casanova, Ma Virtudes Céspedes, Esther Vazquez, Ugutz Unzueta, Neus Ferrer, Antonio P Villaverde	HSCSP RI, UAB, CIBERBBN	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	PCT/EP2012/050513	2011
Nephrology	Jordi Bover	Puigvert Foundation, Biomedical Reserach Foundation of the Hospital General Universitario Gregorio Marañón, University of Alcalá	Method for diagnosing kidney failure	ES 2397461	2011
Andrology	Lluís Bassas	Puigvert Foundation, IDIBELL	In vitro method for predicting semen fecundity	EP 2532757	2011
Molecular and Therapeutic Pathologies of Ischaemic and Atherothrombotic Diseases, Biomarkers for Disease Status	Lina Badimon, Judit Cubedo, Teresa Padró	CSIC-ICCC	APO J isoforms as biomarkers of tissue lesions	ES 2364169	2010
Regulation of Cardiac Rhythm and Contraction	Raúl Benítez, Enrique Álvarez, Leif Hove	CSIC-ICCC, UPC	Method for detecting local intracellular calcium release events	PCT/ES2010/000102	2009
Oncogenesis and Antitumour Drugs	Ramon Mangues, Isolda Casanova, Fernando Palomera, Mercedes Álvarez, Savina Svetlana	HSCSP RI, Fundació Bosch i Gimpera Foundation	Antitumour 1,2-diphenylpyrrole compounds and their preparation	PCT/EP2010/060983	2009

Technology Transfer Agreements

IIB Sant Pau Group	Organizations	Company	Application Number	Year
Clinical and Translational Cardiology	HSCSP RI, Genetrix	Transactel Therapeutics	PCT/ES2008/000543	2012
Clinical Oncology	University of Valencia, USC, ICN	Nanotargets	PCT/EP2009/067136	2011
Oncogenesis and Antitumour Drug	HSCSP RI, Bosch i Gimpera Foundation	Argon Pharma	PCT/EP2010/060983	2009

Clinical Guidelines

PUBMED

Panel de Expertos del Grupo de Estudio de Sida (GESIDA), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Sociedad Española de Nefrología (SEN), Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC), Gorriñ J.L., Gutiérrez F., Trullàs J.C., Arazo P., Arribas J.R., Barril G., Cervero M., Cofán F., Domingo P., Estrada V., Fulladosa X., Galindo M.J., Gràcia S., Iribarren J.A., Knobel H., López-Aldeguer J., Lozano F., Martínez-Castelao A., Martínez E., Mazuecos M.A., Miralles C., Montañés R., Negredo E., Palacios R., Pérez-Elías M.J., Portilla J., Praga M., Quereda C., Rivero A., Santamaría J.M., Sanz J., Sanz J., Miró J.M. [Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients]. *ENFERM INFECC MICROBIOL CLIN*. 2014 Nov;32(9):583-97. doi: 10.1016/j.eimc.2014.09.002. Epub 2014 Oct 7. Spanish. PubMed PMID: 25303781.

de Luna A.B., Cygankiewicz I., Baranchuk A., Fiol M., Birnbaum Y., Nikus K, Goldwasser D., Garcia-Niebla J., Sclarovsky S., Wellens H., Breithardt G. Prinzmetal angina: ECG changes and clinical considerations: a consensus paper. *ANN NONINVASIVE ELECTROCARDIOL*. 2014 Sep;19(5):442-53. doi: 10.1111/anec.12194. PubMed PMID: 25262663.

de Luna A.B., Zareba W., Fiol M., Nikus K., Birnbaum Y., Baranowski R., Goldwasser D., Kligfield P., Piotrowicz R., Breithardt G., Wellens H. Negative T wave in ischemic heart disease: a consensus article. *ANN NONINVASIVE ELECTROCARDIOL*. 2014 Sep;19(5):426-41. doi: 10.1111/anec.12193. PubMed PMID: 25262662.

Ars E., Bernis C., Fraga G., Martínez V., Martins J., Ortiz A., Rodríguez-Pérez J.C., Sans L., Torra R.; Spanish Working Group on Inherited Kidney Disease. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. *NEPHROL DIAL TRANSPLANT*. 2014 Sep;29 Suppl 4:iv95-105. doi: 10.1093/ndt/gfu186. PubMed PMID: 25165191.

de Miguel Novoa P., Vela E.T., García N.P., Rodríguez M.M., Guerras I.S., Martínez de Salinas Santamaría M.L., Masó A.A.; Área de Conocimiento del Grupo de Neuroendocrino de la SEEN (Grupo Insuficiencia Adrenal). Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult. *ENDOCRINOL NUTR*. 2014 Sep;61 Suppl 1:1-35. doi: 10.1016/S1575-0922(14)73526-0. English, Spanish. PubMed PMID: 25128212.

Hurtado Suazo J.A., García Reymundo M., Calvo Aguilar M.J., Ginovart Galiana G., Jiménez Moya A., Trincado Aguinagalde M.J., Demestre Guasch X. [Recommendations for the perinatal management and follow up of late preterm newborns]. *AN PEDIATR (BARC)*. 2014 Nov;81(5):327.e1-7. doi: 10.1016/j.anpedi.2014.06.006. Epub 2014 Aug 6. Spanish. PubMed PMID: 25106929.

Mata P., Alonso R., Ruiz A., Gonzalez-Juanatey J.R., Badimón L., Díaz-Díaz J.L., Muñoz M.T., Muñoz O., Galve E., Irigoyen L., Fuentes-Jiménez F., Dalmau J., Pérez-Jiménez F.; other collaborators. [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document]. *SEMERGEN*. 2015 Jan-Feb;41(1):24-33. doi: 10.1016/j.semerg.2014.05.001. Epub 2014 Jul 17. Spanish. PubMed PMID: 25042971.

Bernabeu-Wittel M., Alonso-Coello P., Rico-Blázquez M., Rotaèche del Campo R., Sánchez Gómez S., Casariego Vales E. [Development of clinical practice guidelines for patients with comorbidity and multiple diseases]. *ATEN PRIMARIA*. 2014 Aug-Sep;46(7):385-92. doi: 10.1016/j.aprim.2013.11.013. Epub 2014 Jun 23. Spanish. PubMed PMID: 24968962.

Bernabeu-Wittel M., Alonso-Coello P., Rico-Blázquez M., Rotaèche del Campo R., Sánchez Gómez S., Casariego Vales E. Development of clinical practice guidelines for patients with comorbidity and multiple diseases. *Rev Clin Esp*. 2014 August - September;214(6):328-335. doi: 10.1016/j.rce.2014.04.001. Epub 2014 May 22. English, Spanish. PubMed PMID: 24856043.

Sánchez-Regaña M., Aldunce Soto M.J., Belinchón Romero I., Ribera Pibernat M., Lafuente-Urrez R.F., Carrascosa Carrillo J.M., Ferrándiz Foraster C., Puig Sanz L., Daudén Tello E., Vidal Sarró D., Ruiz-Villaverde R., Fonseca Capdevila E., Rodríguez Cerdeira M.C., Alsina Gibert M.M., Herrera Acosta E., Marrón Moya S.E.; en representación del Grupo Español de Psoriasis de la Academia

- Española de Dermatología y Venereología. Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles). *ACTAS DERMOSIFILIOGR*. 2014 Dec;105(10):923-34. doi: 0.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish. PubMed PMID: 24852726.
- Underwood S.R., de Bondt P, Flotats A., Marcasa C., Pinto F., Schaefer W., Verberne H.J. The current and future status of nuclear cardiology: a consensus report. *EUR HEART J CARDIOVASC IMAGING*. 2014 Sep;15(9):949-55. doi: 10.1093/ehjci/jeu060. Epub 2014 May 12. PubMed PMID: 24819850.
- García-San Miguel L., Cobo J., Martínez J.A., Arnau J.M., Murillas J., Peña C., Segura F., Gurguí M., Gálvez J., Giménez M., Gudiol F.; Grupo REIPI. ['Third day intervention': an analysis of the factors associated with following the recommendations on the prescribing of antibiotics]. *ENFERM INFECC MICROBIOL CLIN*. 2014 Dec;32(10):654-61. doi: 10.1016/j.eimc.2013.09.021. Epub 2014 May 9. Spanish. PubMed PMID: 24813928.
- Mata P., Alonso R., Ruiz A., Gonzalez-Juanatey J.R., Badimón L., Díaz-Díaz J.L., Muñoz M.T., Muñiz O., Galve E., Irigoyen L, Fuentes-Jiménez F., Dalmau J., Pérez-Jiménez F.; otros colaboradores. [Diagnosis and treatment of familial hypercholesterolemia in Spain: Consensus document]. *ATEN PRIMARIA*. 2015 Jan;47(1):56-65. doi: 10.1016/j.aprim.2013.12.015. Epub 2014 Apr 3. Spanish. PubMed PMID: 24704195.
- Cañete J.D., Daudén E., Queiro R., Aguilar M.D., Sánchez-Carazo J.L., Carrascosa J.M., Carretero G., García-Vivar M.L., Lázaro P., López-Esteban J.L., Montilla C., Ramírez J., Rodríguez-Moreno J., Puig L. Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. *ACTAS DERMOSIFILIOGR*. 2014 Apr;105(3):216-32. doi: 10.1016/j.adengl.2013.07.003. Epub 2014 Mar 20. PubMed PMID: 24657018.
- Ortega Ruiz F., Díaz Lobato S., Galdiz Iturri J.B., García Rio F., Güell Rous R., Morante Velez F., Puente Maestu L., Tàrrega Camarasa J.; SEPAR. Continuous home oxygen therapy. *ARCH BRONCONEUMOL*. 2014 May;50(5):185-200. doi: 10.1016/j.arbres.2013.11.025. Epub 2014 Jan 23. English, Spanish. PubMed PMID:24461631.
- Martínez E., Jódar Gimeno E., Reyes García R., Carpintero P., Casado J.L., del Pino Montes J., Domingo Pedrol P, Estrada V., Maalouf J., Negredo E., Ocampo A., Muñoz-Torres M. [Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients]. *ENFERM INFECC MICROBIOL CLIN*. 2014 Apr;32(4):250-8. doi: 10.1016/j.eimc.2013.07.008. Epub 2013 Dec 12. Spanish. PubMed PMID: 24332711.
- Montañés Bermúdez R., Gràcia Garcia S., Fraga Rodríguez G.M., Escribano Subias J., Diez de Los Ríos Carrasco M.J., Alonso Melgar A., García Nieto V.; miembros de la Comisión de Función Renal de la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC). [Consensus document: recommendations for the use of equations to estimate glomerular filtration rate in children]. *AN PEDIATR (BARC)*. 2014 May;80(5):326.e1-326.e13. doi: 10.1016/j.anpedi.2013.06.013. Epub 2013 Sep 20. Spanish. PubMed PMID: 24055321.
- Masia J., Olivares L., Koshima I., Teo T.C., Suominen S., Van Landuyt K., Demirtas Y., Becker C., Pons G., Garusi C., Mitsunaga N. Barcelona consensus on supermicrosurgery. *J RECONSTR MICROSURG*. 2014 Jan;30(1):53-8. doi: 10.1055/s-0033-1354742. Epub 2013 Sep 13. PubMed PMID: 24037459.
- Ruutu T., Gratwohl A., de Witte T., Afanasyev B., Apperley J., Bacigalupo A., Dazzi F., Dreger P., Duarte R., Finke J., Garderet L., Greinix H., Holler E., Kröger N., Lawitschka A., Mohty M., Nagler A., Passweg J., Ringdén O., Socié G., Sierra J., Sureda A., Wiktor-Jedrzejczak W., Madrigal A., Niederwieser D. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. *BONE MARROW TRANSPLANT*. 2014 Feb;49(2):168-73. doi: 10.1038/bmt.2013.107. Epub 2013 Jul 29. Erratum in: *Bone Marrow Transplant*. 2014 Feb;49(2):319. Dosage error in article text. PubMed PMID: 23892326.
- Arguis M.J., Navarro R., Regueiro A., Arbelo E., Sierra P., Sabaté S., Galán J., Ruiz A., Matute P, Roux C., Gomar C., Rovira I., Mont L., Fita G. [Perioperative management of atrial fibrillation]. *REV ESP ANESTESIOLOG REANIM*. 2014 May;61(5):262-71. doi: 10.1016/j.redar.2013.01.004. Epub 2013 Mar 21. Spanish. PubMed PMID: 23522980.

ISI Web of Knowledge

Aparicio J., Maroto P., Garcia del Muro X., Sanchez-Munoz A., Guma J., Margeli M., Saenz A., Sagastibelza N., Castellano D., Arranz J., A., Hervas D., Bastus R., Fernandez-Aramburo A., Sastre J., Terrasa J., Lopez-Brea M., Dorca J., Almenar D., Carles J., Hernandez A., Germa J.R. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) SO ANNALS OF ONCOLOGY. NOV 2014.

Sattar N.A., Ginsberg H., Ray K., Chapman M.J., Arca M., Averna M., Betteridge, D.J., Bhatnagar D., Bilianou E., Carmena R., Ceska, R., Corsini A., Erbel R., Flynn, P.D., Garcia-Moll X., Gumprecht, J., Ishibashi S., Jambart S., Kastelein J.J.P., Maher V., Marques da Silva P., Masana L., Odawara M., Pedersen T.R., Rotella, C., Salti I., Teramoto T., Tokgozoglu L., Toth P.P., Valensi P., Verges B. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. ATHEROSCLEROSIS SUPPLEMENTS. JUN 2014. Published by Elsevier Ireland Ltd.

Other

Beltran-Calvo, C., Martin-Lopez, J.E., Sola-Arnau I., Aceituno-Velasco L., Alomar-Castell M., Barona-Vilar M., Corona-Paez I., Costa-Sampere D., Fillol Crespo M., Espiga-Lopez I., Garcia-Carrascosa L., Martin-Seco Y., Martinez-Romero M.D., Elisabeth-Muller A., Olza-Fernandez I., Parra-Casado M., Quintana-Pantaleon R., Tejero-Lainez C., Torrejon-Cardoso R., Velasco-Juez C. [Guía de práctica clínica de atención en el embarazo y puerperio] 27/08/2014. <http://portal.guiasalud.es/web/guest/catalogo-gpc>

Álvarez Ariza M., Atienza Merino G., Ávila González M.J., González García A., Guitián Rodríguez D., de las Heras Liñero E., Louro González A., Rodríguez-Arias Palomo J.L, Triñanes Pego Y. [Guía de Practica Clinica sobre el Manejo de la Depresion en el Adulto] 16/07/2014. <http://portal.guiasalud.es/web/guest/catalogo-gpc>.

Research Support Services

The main objective of the research support services, which are divided into two blocks, is the sharing and pooling of resources as an effective way to optimize funds and boost research.

Research Support Services

These provide facilities and equipment that are exclusively available to any specific research group but are shared among groups at all institutions within IIB Sant Pau.

IIB Sant Pau has 14 services:

- Clinical Trial Documentation Management
- Research Institute Management
- Research Institute Projects Unit
- Tumour Bank
- Quality and Information Systems Unit
- Radioactivity Unit
- Centre for Drug Research (CIM Sant Pau)
- Central Clinical Research and Clinical Trials Unit (UCICEC Sant Pau)
- Animal Housing
- Transfer and Innovation Unit
- Author Editing
- Communications Coordination Team
- Clinical Research Ethics Committee
- Clinical Research Ethics Committee Secretariat

Scientific and Technical Service Platforms

The main aim of these support services is to manage, allocate and optimize the top-level research resources available to IIB Sant Pau. They provide researchers with support and scientific and technical assessment and advise on the most appropriate methods to prepare samples and to plan optimal work flows for each objective.

IIB Sant Pau has 5 platforms:

- Genomics and Transcriptomics Platform
- Functional and Cellular Analysis Platform
- Microscopy and Immunohistochemistry Platform
- Innovation Platform i2Health Sant Pau
- Biobank

The platforms also have access to equipment available for general use to complement their functioning.



Manager:
Rosa M. Antonijoan
rantonijoana@santpau.cat

Coordinator:
M. Teresa Mas
mmas@santpau.cat

Staff:
Pilar Matamoros
M. Àngels Piera

Clinical Trial Documentation Management

Functions:

- > Manage and supervise all documentation associated with active clinical trials in the experimental phase and destruction of documentation for terminated clinical trials located in the external archive.
- > Store the supplies until the end of the studies, when they are destroyed or recycled.
- > Oversee and manage documentation of completed trials for the Centre for Drug Research (CIM)
- > Maintain and update the clinical workstation database and manage clinical studies.
- > Manage restricted access by clinical trial monitors to the clinical workstation.
- > Supervise data processing and management.
- > Coordinate researchers and monitors; draw up agendas for meetings and study monitoring.
- > Provide logistical support to the cold area and the clinical materials store associated with clinical trials in the experimental phase.
- > Ship biological samples to central laboratory services.

Facilities:

Several areas have been designated to implement these functions:

- > Head office and administration area
- > Data processing and management area
- > Clinical trial monitoring meeting rooms
- > Documentation filing area
- > Cold room.
- > Archive.

Research Support Services



Coordinator:

Hilda Herrero
hherrero@santpau.cat

Staff:

Management Control Unit
Soraya González, Sandra Parera,
Laura San Martín

Administrative-Financial Unit
Ana Espallargas, Cristina Requena,
Núria García, Declan de la Fuente

Human Resources Unit
Rafael Fernández

General Secretariat
Rosa M. García
Amanda García
Marta Lorente
Magda Sanz

Research Institute Management

Functions:

- > Management of HSCSP Research Institute and IIB Sant Pau finances: manage accounts and fiscal matters; design, administer and control budget-related issues; manage and monitor financial and material resources.
- > Management of public body funding requirements: fulfil obligations imposed by government and official regional and state entities; ensure compliance with current fiscal, financial, labour and legal regulations and with HSCSP Research Institute–IIB Sant Pau management policies.
- > Administration and management of activities, providing management support for research groups in different areas; project management, human resources, procurement, invoicing, control and monitoring of projects, general administration, management of services (courses, travel and continuing professional development).
- > Design, elaboration, development and maintenance of information systems for management area units, both for HSCSP Research Institute–IIB Sant Pau and research groups.



Coordinator:

Fabiola Fernández

Staff:

Eva José
Eva Rodríguez
Amanda García
Marta Lorente

Research Institute Projects Unit

Functions:

- > Search of public and private funding, broadcast, assessment and review for the success of the application submission, send applications, register and monitoring until its resolution.
- > Registration of granted projects, economic monitoring of both national and international projects and agreements, costs validation (concept/balance), preparing annual and final reports, manage incidences, interlocutor with official entities.
- > Activity reports: scientific report, Board, Direction and others.
- > Internal and external audits from different financial entities.
- > Researchers: meetings for starting and managing projects.
- > Interaction with different transversal areas to implement the regulations of the calls.



Coordinator:

Jordi Virgili
jvirgili@santpau.cat

Staff:

Susana Daniel
Cati Pérez
Montserrat Campmany

Quality and Information Systems Unit

Functions:

> General:

- Support management with strategic projects (accreditation, CERCA evaluation, biobank legalization, evaluation of research groups, etc).
- Manage IIB Sant Pau research groups: creation, dissolution and changes in composition.
- Manage new laboratory works performed under the contingency plan.
- Implement the functional plan for the new research building.
- Support management of the IIB Sant Pau Internal Scientific Committee, External Scientific Committee, Executive Committee and Delegate Committee.
- Implement policies for the dissemination of research among the general public and especially among secondary pupils and health science university students.
- Manage the HSCSP Research Institute Biosafety Committee.
- Participate in the Animal Experimentation Ethics Committee.
- Participate in the UCICEC Sant Pau Technical Committee.
- Represent the HSCSP Research Institute before external organizations.

> Quality:

- Implement policies to improve quality under GLP, GCP, GMP and ISO 9001 standards.

- Lead the quality assurance programme at CIM Sant Pau and in clinical trials where the HSCSP Research Institute acts as sponsor.
- Oversee auditing for protocols, databases, experimental phases, facilities, processes and final reports for clinical trials.
- Oversee supplier audits.
- Monitor non-conformity in internal and external audits.
- Draw up own SOPs and provide support for SOPs preparation by other units.
- Establish mechanisms to assess quality and good scientific practices in IIB Sant Pau.

> Information systems:

- Design mechanisms and implement tools for the collection and organization of data and information to feed decision making.
- Manage and transform information and data to contribute to the fulfillment of objectives and strategies.
- Respond to external requests for data and information (statistical surveys, SIRECS, etc).
- Implement policies to improve information systems.
- Develop new indicators of use for the institution.
- Update research group staff details on the intranet.

Research Support Services



Coordinator:
Montserrat Ribas
mribas@santpau.cat

Supervisor in charge:
Josep Julve
jjulve@santpau.cat

Radioactivity Unit

Functions:

- > The Radioactivity Unit provides groups with specific research laboratories in which to work with radioactive isotopes in liquid form. These areas are fully equipped and adapted for the handling of radioactive material and apply optimum measures for the safety and radioprotection of staff and the environment.
- > This area has been authorized by the nuclear safety authority and its staff supervise compliance with the corresponding laws, guidelines and regulations.
- > Services include support for:
 - In vitro labelling of proteins, lipoproteins and liposomes.
 - Cellular proliferation and toxicity.
 - Nucleic acid labelling.
 - Immunoassay techniques.
 - Determination of enzymatic activities using radiolabelled substrates.
 - Analysis and separation of labelled molecules.
 - Cellular cholesterol efflux.
 - Metabolism in vivo.

Facilities:

The Radioactivity Unit has the following facilities:

- > 1 room for radioactive material storage.
- > 7 equipped laboratories, one of them refrigerated.
- > 1 room for gamma- and beta- counters.
- > 1 room for radioactive waste storage.
- > 1 room for controlled disposal of radioactive waste.
- > Radioactive liquid waste containers for controlled radioactive waste disposal.
- > Shielding accessories for radiation safety (table top shields, shielded containers, protective equipment, etc)
- > Portable radiation and environmental contamination detectors.
- > 1 ventilated rack for in vivo studies.
- > 2 chemical safety cabinets for gas extraction.
- > 1 vertical laminar air flow cabinet for cell cultures.
- > 1 CO₂ incubator for cell cultures.



Manager:
Jaime Prat
jprat@santpau.cat

Coordinators:
Lluís Catasús
lcatasus@santpau.cat
Íñigo Espinosa
iespinosa@santpau.cat

Staff:
María Jesús Nagel
Jorge Pena

Tumour Bank

Functions:

- > Create and maintain a collection of healthy and diseased tissue samples in optimal conditions for use in research projects that may include morphology, phenotype and molecular analyses and which may also be used in diagnosis.
- > Guarantee the quality of stored material by means of morphology analyses of samples, assuring anatomical and pathological correlation with definitive diagnoses for tissues.
- > Supply material to research groups on a non-profit basis (investigators may apply for samples as long as their project complies with current regulations and is scientifically, technically and ethically viable).

Equipment:

- > 4 fast-freeze apparatus (isopentane bath, stored at -50°C).
- > Storage and cryopreservation systems: 2 freezers -80°C and 1 deposit for liquid nitrogen.
- > 1 cryostat.
- > 1 manual tissue arrayer.



Coordinator:
Rosa M. Antonijoan
rantonijoana@santpau.cat

Staff:
M. Rosa Ballester
Judith Claramunt
Susana Clos
Sonia Coma
M. Ángeles Funes
Consuelo García
Ignasi Gich
Sandra Giménez
Ana Gomis
Mireia González
David Martínez
Joan Martínez
Maribel Martínez
Pura Martínez
Esteve Mercader
Sara Mora
Montserrat Punes

Centre for Drug Research (CIM Sant Pau)

Functions:

Perform clinical drug trials and/or clinical research in compliance with methodological, ethical and legal requirements in the context of international GCP guidelines concerning:

- > Clinical trials that are not of therapeutic interest for participants (phase I, special populations, psychopathological research, biomarkers, proof of concept).
- > Clinical trials in neuropsychopharmacology.
- > Clinical trials in initial developmental phases.

Facilities:

Three separate work areas have been designated for the trials:

Healthcare:

- > Admission zone.
- > 24 beds distributed in 4 units: trials in healthy volunteers and patients.
- > 2 individual rooms for CNS studies.
- > Ambulatory zone.
- > 4 consulting rooms for complementary testing, mainly related to CNS.
- > 3 cubicles to evaluate psychomotor performance.

Logistical support:

- > Rest area for clinical trial participants with bathrooms and kitchen.
- > Areas for the preparation, centrifugation and separation of biological samples.
- > Cold room.
- > Archives.

Management, administration and data processing:

- > Offices.
- > Area for monitors.
- > IT equipment for clinical trial activities of a non-experimental nature.

Communications Coordination Team

Functions:

- > Coordinate IIB Sant Pau communications.
- > Prepare IIB Sant Pau annual reports and other communication materials.
- > Provide an effective news distribution service and generate positive media coverage.
- > Respond to media enquiries.
- > Update website content.
- > Establish standards concerning graphics and linguistic style to ensure visual uniformity in all IIB Sant Pau communications.

Research Support Services



Coordinator:

Rosa M. Antonijoan
rantonijoana@santpau.cat

Staff:

Claudia E. Delgado
Nadia Llaveró
Pablo Bros
Enrique Peña

Central Clinical Research and Clinical Trials Unit (UCICEC Sant Pau)

Functions:

It provides comprehensive support to researchers in the development of independent research projects (not sponsored by the pharmaceutical industry) on the methodological, regulatory, administrative, economic and practical aspects, subject to compliance with the ethical, good clinical practice and legislation.

UCICEC Sant Pau is part of the Spanish Clinical Research Network (SCReN), a functional organization network to support the conduction of multi-center clinical trials.

Knowledge management:

- > One-stop information for independent research group projects.
- > Comprehensive assessment and project coordination.
- > Point of communication between researchers and technical units.
- > Pharmacovigilance activities for trials including drugs or medical devices.
- > Knowledge management:
 - Study of dimensionality and feasibility of projects.
 - Identification of each project needs.
 - Advice on the preparation of documentation: protocol, annexes, monitoring report, final report.
 - Advice on the submission of documentation to Spanish Agency for Medicines and Medical Devices (AEMPS), Clinical Research Ethics Committee (CEIC), Autonomous Communities (CCAA) and other relevant authorities.
 - Advice on project registration in public databases.
 - Identification of spinoff projects.
 - Advice on the presentation of research results.

Methodological and statistical support unit:

- > Advice on study design.
- > Data entry.
- > Data processing.
- > Development of statistical reports.
- > Electronic CRFs validation and management.
- > Documentation and reports.

Documentation, archiving, monitoring and follow-up unit:

- > Support in document creation: EudraCT form and annexes / application forms / evaluation forms follow form.
- > Support in the processing of initial applications, clarifications and amendments: AEMPS, CEIC, other health authorities regarding clinical trials, and other post-authorization studies.
- > Comprehensive monitoring of clinical trials and observational studies.
- > Management of initial, follow-up and final reports.
- > Development and file custody promoter (Master File), file preparation investigator.
- > Other communications to CEIC, autonomous communities and competent authorities.

Unit of management and financial management:

- > Management of clinical trials contracts with participating centers.
- > Management of collaboration agreements with laboratories / companies for funding.
- > Management of clinical trial-related contracts (CRO's, E-CRDs, statistics, etc.).
- > Management of clinical trial-related client and supplier invoices.
- > Management of clinical trial insurance policies.
- > Preparation of financial reports for the submission of studies to ethics committees.
- > Management of payment of fees to the competent authorities.



Coordinator:
M. Antònia Rubio
arubioc@santpau.cat

Staff:
Animal welfare advisor:
M. Antonia Rubio

Veterinary surgeon:
Eder Fredy Mateus

Animal care workers:
Margarita Domingo
Luis Garcia

Animal Housing

Functions:

- > Produce different small rodent strains in-house for research and teaching purposes.
- > Manage the purchase and transportation of animals from domestic and international breeding and supply centres.
- > Receive and house incoming animals and deliver them to users once quarantine and health requirements are met.
- > House and maintain experimental animals while ensuring their welfare.
- > Regularly check rodent health status.
- > Perform twice-yearly health checks.
- > Clean and sterilize of materials and maintain the pathogen-free area.
- > Feed animals according to experimental protocols.
- > Provide support for animal surgery, anaesthesia and euthanasia.
- > Supply laboratory materials and collect samples.
- > Monitor mating, mating plugs, pregnant females and weaning.
- > Provide healthcare.
- > Advise the animal welfare expert.
- > Perform periodic health checks with sentinel screening in all rooms.
- > Maintain monitoring protocols.
- > Ensure the hygiene and safety of facilities and equipment.
- > Manage waste disposal.
- > Attend training in relation to all protocols developed in the animal house.
- > Advise on the drafting of research projects involving the use of animals.
- > Attend training in relation to all protocols developed in the animal house.
- > Advise on the drafting of research projects involving the use of animals.

Facilities:

Conventional Animal Facility:

- > Mice rooms (2), total capacity 2400.
- > Rat room, capacity 200.
- > Quarantine room.
- > Washroom.
- > Clean-storage room.
- > Standard storeroom.
- > Surgery room.
- > CO2 euthanasia equipment.
- > Treatment room.
- > Office.
- > Shower.
- > WC.

Pathogen-free area:

- > Pre-changing room.
- > Changing room.
- > Air shower.
- > Work room.
- > Mice room and changing area.
- > S.A.S.
- > Autoclave and washing area.
- > storage room.

Research Support Services



innovacio@iibspau.cat

Coordinator:

Alfons Hervàs
ahervas@santpau.cat

Staff:

Marina Passarell
Miquel Arrieta



President:

Antonio López Pousa
alopezp@santpau.cat

Vice-president:

Gerard Urrutia
GUrrutia@santpau.cat

Secretary:

Milagros Alonso
MAlonsoMa@santpau.cat

Members:

Ester Amado
Ester Bajo
Isabel Carbonell
Josep Corbella
Francesc Jané
Xavier León
Jordi Mancebo
Estela Moreno
Miguel Ortín
M. Virtudes Pacheco

Transfer and Innovation Unit

Functions:

- > Facilitate collaboration between institute's research groups and industry.
- > Support to public and private funding of technology development projects.
- > Support the submission of European projects.
- > Analysis of the business viability of technological projects.
- > Intellectual Property protection.
- > Technology Transfer.
- > Support the creation of spin-offs and start-ups.
- > Legal support to agreements with third parties.

Clinical Research Ethics Committee

The Ethics Committee for Clinical Research (CEIC) of the HSCSP Healthcare Management Foundation is an independent body that, according to the laws that accredit it, has the mission to ensure the protection of rights, safety and welfare of the subjects involved in a trial and provide public assurance of that

protection, protection by reviewing the protocol, the suitability of the researchers, facilities, equipment and methods to be used in obtaining and documenting the informed consent of the subjects.

Its specific functions are:

- > Evaluate the methodological, ethical and legal aspects of:
 - Clinical trials with drugs and health products.
 - Observational studies.
 - Pharmacogenetic and pharmacogenomic studies.
 - Studies evaluating surgical or psychological treatments.
 - Studies involving invasive procedures or the use of health data or biological samples.
- > Evaluate the relevant amendments in projects approved by the CEIC.
- > Monitor of clinical drug trials and clinical research with medical devices.



Coordinator:
Milagros Alonso
malonsoma@santpau.cat

Administrative Staff:
Marisol Mogollón
Albert Querol
Romy Rodríguez

Clinical Research Ethics Committee Secretariat

The Clinical Research Ethics Committee is an independent agency whose mission is to protect the rights, safety and wellbeing of persons participating in HSCSP research projects which may entail physical or psychological harm. The Secretariat of the Clinical Research Ethics Committee evaluates the methodological, ethical and

legal aspects as well as any other relevant information regarding all research projects listed in the minutes of the Committee's meetings. It also advises researchers in the HSCSP and the HSCSP Research Institute regarding the preparation and presentation of clinical research projects.

Functions:

- > Receive, log and validate documentation for clinical research projects submitted to the Committee for evaluation.
- > Arrange and call Committee meetings, inform members of the agenda and provide them with copies of protocol summaries and patient informed consent and information sheets.
- > Prepare and submit reports to the Committee containing a methodological, ethical and legal description and analysis (and any other relevant information) of the research projects listed in agendas.
- > Act as a reference point in communications with and between researchers, sponsors, medical administrators and managers and healthcare authorities regarding all aspects of the activities of the Committee and of the research projects evaluated by the Committee.
- > Prepare and sign the reports of the Committee and communicate its decisions to the corresponding sponsors and researchers.
- > Prepare the minutes of meetings and distribute them to Committee members within the established period.
- > Manage all documentation associated with the operations and activities of the Committee and with the research projects evaluated by the Committee.
- > Administer contracts for all clinical trials to be performed at the HSCSP.
- > Certify the actions of the Committee.
- > Prepare the annual report of the Committee.
- > Ensure compliance with the SOPs of the Committee.



Coordinator:
Carolyn Newey
cnewey@santpau.cat

Author Editing

Functions:

- > Review and edit research papers, abstracts, posters, presentations and other scientific documents written in English.
- > Assist in the preparation and delivery of presentations, lectures, speeches, etc in English for meetings, conferences and similar events.

Scientific and Technical Service Platforms



sequenciacio_ir@santpau.cat
transcriptomica@santpau.cat

Coordinator:
Elena Serrano
eserrano@santpau.cat

Technical Staff:
Genomics Laboratory:
Eva Companys
ecompanysa@santpau.cat

Transcriptomics Laboratory:
Elena Serrano
eserrano@santpau.cat

Genomics and Transcriptomics Platform

> GENOMICS LABORATORY

Functions:

- > Next-generation sequencing: full transcriptome genotyping, RNA-Seq, Ampli-Seq, ChIP-Seq, amplicon sequencing and sequencing and identification of microorganisms.
- > Sanger sequencing: mutational analysis, microorganism identification and validation of cell lines.
- > Analysis of fragments: microsatellite instability, loss of heterozygosity studies in pathological conditions, mutation detection and genotyping, quantification of gene copy numbers, methylation studies and studies of polymorphisms associated with disease states.

Equipment:

- > Ion Torrent Personal Genome Machine.
- > Ion OneTouch (TM) System.
- > 3130xl Genetic Analyzer capillary electrophoresis sequencer.


> TRANSCRIPTOMICS LABORATORY

Functions:

- > Hybridization and analysis of Affymetrix microarrays:
 - RNA and micro-RNA expression profiles in normal conditions and in diseases and treatment.
 - Loss of heterozygosity, copy number analysis and genome-wide mutation detection.
 - Genome-wide linkage and association studies.
- > Real time quantitative PCR (gene expression, allelic discrimination).
- > Nucleic acid quality assessment.
- > Quantification of nucleic acids (Bioanalyzer, Nanodrop).

Equipment:

- > Affymetrix array platform (upgrade 7G).
- > Real time quantitative PCR ABI 7900HT (384-well plates and TLDA).
- > Bioanalyzer 2100
- > Nanodrop 2000.



citometria@santpau.cat

Coordinator:

Elena Serrano
eserrano@santpau.cat

Technical Staff:

Flow Cytometry Laboratory:
 Marta Soler
msolerC@santpau.cat

Cell Culture Laboratory:

Rosa Antón
RAnton@santpau.cat

Functional and Cellular Analysis Platform

> FLOW CYTOMETRY LABORATORY

Functions:

- > Conventional cytometry in homogenous (cell line) or heterogeneous (biological fluid) samples:
 - Detection of the presence of proteins and determination of cell populations (cell markers).
 - Studies of signalling cascades (cell cycle, cell proliferation, apoptosis, intracellular calcium determination).
 - Quantification of transfection efficiency.
 - Phenotype changes and relative and absolute presence.
 - Production of mediators.
 - Detection of minority populations.
- > Cell sorter:
- Separation of cell populations in sterile conditions.

Equipment:

- > FACSCalibur (BD) conventional flow cytometry.
- > MACSQuant (Milteny Biotech) conventional flow cytometry.
- > FACSria (BD) flow cytometry cell sorter.

> CELL CULTURE LABORATORY

Functions:

- > To make adequate facilities and equipment available to researchers working with cell cultures in a BSL2 laboratory.

Equipment:

- > 3 CO₂ incubators.
- > 2 hypoxia incubators (2-21% O₂).
- > 2 IIA biosafety cabinets (BSL2).
- > 2 hypoxia cabinets (BSL1).
- > Culture baths.
- > Olympus inverted microscope with high-resolution colour camera.
- > Refrigerated centrifuge.
- > Fridge 4°C and freezer -20°C.
- > Thermo-desinfector and autoclave.

Scientific and Technical Service Platforms



ihq@santpau.cat
microscopia@santpau.cat

Coordinator:
Elena Serrano
eserrano@santpau.cat

Technical Staff:
Immunohistochemistry Laboratory:
Montserrat Gómez
mgomezy@santpau.cat

Microscopy Laboratory:
Eva Companys
eCompanysa@santpau.cat



info@i2healthsantpau.eu

Coordinators:
Alfons Hervàs
ahervas@santpau.cat

Josep M. Colomé (i2Cat Foundation)
josep.colome@i2cat.net

Microscopy and Immunohistochemistry Platform

> IMMUNOHISTOCHEMISTRY LABORATORY

Functions:

- > Tissue processing.
- > Paraffin and OCT-block preparation.
- > Block cutting with microtome/cryostat.
- > Automatic immunostaining (simple and dual).
- > Staining (Giemsa, haematoxylin-eosin, trichromic, PAS, Oil Red, etc).
- > Preparation of tissue arrays.
- > Image acquisition and analysis using high-resolution colour microscopy and specialist software.

Equipment:

- > Tissue processor (Sakura).
- > Paraffin bath (Sakura).
- > Microtome (Microm).
- > Cryostat (Leica).
- > Immune autostainer AS48 (Dako).
- > Autostainer (Sakura).
- > Semiautomatic tissue arrayer.

> MICROSCOPY LABORATORY

Functions:

- > Confocal microscopy in live and fixed cells:
 - Immunofluorescence of 2 to 5 fluorochromes.
 - Reconstruction of 3D and 4D images.
 - Colocalization studies.
- Inter- and intra-interactions (FRET and FLIM).
- Molecular diffusion times (FCS).
- > Conventional fluorescence microscopy (immunofluorescence with 1 or 2 fluorochromes, FISH) in live and fixed cells.

Equipment:

- > Confocal multispectral Leica SP5 AOBS with high-resolution scanning system and high-speed tandem scanning, FLIM/FCS modules and time-lapse incubation system.
- > Zeiss digital time-lapse microscope.

Innovation Platform i2Health Sant Pau

Functions:

- > Promote the development of the information and communication technologies in the health sector.
- > Support researchers and healthcare staff undertaking e-health projects.
- > Provide a dedicated space within the hospital to create a living lab by bringing together medical staff, engineers, technologists, industry and health administration.



PLAN AVANZA



biobanc@santpau.cat

Coordinator:

Elena Serrano
eserrano@santpau.cat

Technical Staff:

Iris Rodriguez
irodriguezR@santpau.cat

Biobank

Functions:

- > Create and maintain a collection of healthy and diseased biological human samples in optimal conditions for use in research projects.
- > Facilitate collaboration projects by putting investigators in touch and making biological human sample cession possible.
- > Supply (non-profit) human biological samples to research groups, in accordance with legal regulations.
- > Obtain, process and store human biological samples in accordance with international standards, maintaining sample traceability and security in accordance with legal requirements.
- > Provide training in legal and ethical regulations governing biological human sample management.

Grants:

- > HSCSP Research Institute. Biobank Network 2009. Amount: €138,000.



Coordinator:

Elena Serrano
eserrano@santpau.cat

Technical Staff:

Image Analysis Laboratory:
Rosa Anton
ranton@santpau.cat

Other Equipment:

Elena Serrano
eserrano@santpau.cat

Equipment for General Use

> **IMAGE ANALYSIS LABORATORY**

Equipment:

- > Revolution 4200 microarray scanner (Vidar).
- > Image Station 4000MM Pro (Kodak) gel documentation: luminescence, fluorescence, absorption.

> **OTHER EQUIPMENT**

Equipment:


- > Precision weighing balances (Sartorius).
- > Bioanalyzer 2100 (Agilent).
- > Nanodrop 2000 (Thermo).
- > Infinite 200 (Tecan) microplate reader: spectrophotometer, fluorometer, luminometer.

Grants:

- > HSCSP Research Institute. Innovation Network 2009. Amount: €123,414.
- > Kulisevsky, J. Expert system integrating teleassistance and medicine to prevent dependence and promote autonomy of the elderly in the home environment. E-HEALTH Platform for Healthy Ageing. Plan Avanza. Amount: €60,848.55.

Areas of Research

46



Area 1
Cardiovascular Diseases

78



Area 2
Genetic, Metabolic and
Inflammatory Diseases

116



Area 3
Haematological and
Oncological Diseases

138



Area 4
Neurological,
Mental Disorders and Ageing

180



Area 5
Uronephrology
and Experimental Surgery

194



Area T1
Epidemiology, Public Health
and Healthcare Services

220



Area T2
Molecular, Genomic, Cellular
and Kinetic-Dynamic Bases for
Diseases and their Treatment

230



Associated Groups

AREA 1

Cardiovascular Disease

- 48 Clinical and Translational Cardiology
- 54 Thrombosis and Haemostasis
- 56 Cardiovascular Biochemistry
- 60 Angiology, Vascular Biology and Inflammation
- 62 Molecular Pathology and Therapeutics of Ischaemic and Atherothrombotic Diseases
- 66 Inflammation and Vascular Remodelling
- 68 Biomarkers for Cardiovascular Disease
- 70 Atherosclerosis and Vascular Biology
- 72 Regulation of Cardiac Rhythm and Contraction
- 74 Lipids and Cardiovascular Pathology

eases



Clinical and Translational Cardiology

Coordinator

Juan Cinca HSCSP
jcinca@santpau.cat

Members

Concepción Alonso HSCSP
 Jesús Álvarez HSCSP RI
 Gerard Amorós HSCSP RI
 Laia Angli HSCSP RI
 Dabit Arzamendi HSCSP
 Antonio José Barros HSCSP
 Francesc Xavier Borràs HSCSP
 Francesc Carreras HSCSP
 Andreu Ferrero HSCSP RI
 Sebastian Raúl Gaido HSCSP RI
 Joan Garcia HSCSP
 Xavier Garcia-Moll HSCSP
 José M. Guerra HSCSP
 José Alberto Hidalgo HSCSP
 Esther Jorge HSCSP RI
 Laia de Lama HSCSP RI
 Rubén Gabriel Leta HSCSP
 Vicente Martí HSCSP
 Roser Martínez HSCSP RI
 Sonia Mirabet HSCSP
 Santiago Ramón Montero HSCSP
 Guillem Pons HSCSP
 Enrique Rodríguez HSCSP
 Eulàlia Roig HSCSP
 Marianela Sánchez HSCSP RI
 Antoni Serra HSCSP
 Alessandro Sionis HSCSP
 M. Teresa Subirana HSCSP
 Beatriz Vaquerizo HSCSP
 Montserrat Vila HSCSP
 David Vilades HSCSP
 Xavier Viñolas HSCSP
 Miquel Vives HSCSP RI



Main Lines of Research

- ▶ Electrophysiology and arrhythmias clinical and experimental.
- ▶ Heart failure.
- ▶ Ischemic heart disease.
- ▶ Valvular heart disease.
- ▶ Cardiac imaging.
- ▶ Percutaneous valve repair.

Challenges

Electrophysiology

- ▶ Describe the mechanisms and clinical significance of the electrocardiographic alterations in patients with acute myocardial infarction, using translational research in pig heart models.
- ▶ Characterize the ECG patterns and prognosis in patients with left circumflex coronary occlusion.
- ▶ Describe the behaviour of myocardial electrical impedance in normal and acute ischemic models using new bioimpedance methods developed in our laboratory.

Heart failure

- ▶ Develop new risk scores for ambulatory heart failure patients predicting death and re-hospitalizations.
- ▶ Research on new biomarkers in patients with heart failure included in the Spanish registry Redinscor II (RIC) (1500 patients). Our group is the national coordinator.
- ▶ Develop new markers for early detection of cardiac graft rejection in transplanted patients.
- ▶ Develop palliative care programs for patients with advanced heart failure.

Ischaemic heart disease

- ▶ Settle a Program for patients with refractory angina.
- ▶ Treat complex atherosclerotic coronary artery lesions using international techniques.

Valvular heart disease

- ▶ Implement new percutaneous techniques for the treatment of mitral valve regeneration and degenerative aortic stenosis.
- ▶ Implement devices for the treatment of prosthetic valve leak.

Cardiac imaging

- ▶ Implement new imaging software analysis to detect structural abnormalities of the myocardium (fibrosis, necrosis).
- ▶ Implement new software analysis for fusion imaging in patients submitted to coronary interventions.
- ▶ Implement new percutaneous techniques for the treatment of mitral regurgitation in patients with heart failure or myocardial infarction.

Collaborations with other IIB Sant Pau Groups

- ▶ Vicenta Llorente-Cortés, ICC - CSIC.
- ▶ Leif Hove Madsen, ICC - CSIC.
- ▶ Jordi Ordóñez Llanos, HSCSP - Biochemistry Laboratory.
- ▶ Antoni Capdevila, HSCSP - Radiodiagnostics.
- ▶ María Poca Sans, HSCSP - Digestive Disorders.
- ▶ Enric Álvarez, HSCSP - Anaesthesiology.
- ▶ Ricard Serra, HSCSP - Psychiatry.

External Collaborations**Juan Cinca Cuscollola (HSCSP), Programme 6: Clinical and Translational Cardiology, RD12/0042-RIC (Cardiovascular Research Network):**

- ▶ Alfredo Bardají Ruiz. Hospital Universitari Joan XXIII (Tarragona)
- ▶ Fernando Worner Diz. Hospital Universitari Arnau de Vilanova (Lleida)
- ▶ Andrés Grau Sepúlveda. Hospital Son Dureta (Palma de Mallorca)
- ▶ Xavier Rosell Ferrer. Universitat Politècnica Catalunya – UPC (Barcelona)
- ▶ Rafael Vázquez García. Hospital Universitario Virgen de Valme (Sevilla) / Hospital Puerta del Mar (Cádiz)
- ▶ Joaquín Lucena Romero. Instituto de Medicina Legal (Sevilla)
- ▶ José M. Cubero Gómez. Hospital Virgen del Rocío (Sevilla)
- ▶ Antonio Fernández Romero. CHARE Utrera SAS (Sevilla)
- ▶ Josep Brugada Terradellas. Hospital Clínic (Barcelona)
- ▶ Julián Pérez-Villacastín. Hospital Clínic San Carlos (Madrid)
- ▶ Juan Francisco Delgado Jiménez. Hospital 12 de Octubre (Madrid)
- ▶ Jose Luis Zamorano. Hospital Ramón y Cajal (Madrid)

- ▶ Mariano Valdés Chavarri. Hospital Universitario Virgen de la Arrixaca (Murcia)
- ▶ José Ramón González. Hospital Clínico Universitario (Santiago de Compostela)
- ▶ Luis Alonso-Pulpón Rivera. Hospital Puerta del Hierro (Madrid)
- ▶ Covadonga García González. Hospital Guadarrama (Madrid)
- ▶ José Miguel Rivera. Hospital La Fe (Valencia)
- ▶ Alfonso Castro Beiras. Complejo Hospitalario Universitario A Coruña
- ▶ Francisco Fernández Avilés. Hospital Gregorio Marañón (Madrid)
- ▶ Ignacio Flores Hernández. Centro Nacional de Investigaciones Cardiovasculares - CNIC (Madrid)

Antoni Serra Peñaranda TEAM:

- ▶ Eulogio García. Hospital Clínico San Carlos (Madrid)
- ▶ Carlos Macaya Miguel. Hospital Clínico San Carlos (Madrid)
- ▶ Andrés Iníguez Romo. Complejo Hospitalario de Vigo

Xavier Viñolas Prat, RETAC Group - European Network for the Treatment of Arrhythmias in Cardiology:

- ▶ Philippe Lagrange. Clinique Saint Pierre (Perpignan)
- ▶ Benoît Guy-Moyat. Hospital Universitaire de Limoges (France)
- ▶ Franck Halimi. C.M.C. Parly II (Le Chesnay)
- ▶ Luc de Roy. Clinique Universitaire de Saint Godinne (Yvoir-Belgium)
- ▶ Serge Boveda. Clinique Pasteur (Toulouse)
- ▶ Julio Martí. Hospital del Mar (Barcelona)
- ▶ Pascal Defaye. Hospital Universitaire de Grenoble
- ▶ Antonio Curnis. Spedali Civili (Brescia-Italy)
- ▶ Marc Zimmermann. Hôpital de la Tour (Geneve-Switzerland)
- ▶ Thomas Arentz. Herzzentrum Brad Krozingen (Germany)

- ▶ Juan Cinca Cuscollola. Caracterització electrofisiològica i metabòlica de la repolarització cardíaca en el cor humà aïllat. MAR-ATÓ TV3 2008 Malalties cardiovasculars. 08/0630. Duration: 26/03/09-31/01/14. €130,480.
- ▶ José María Guerra Ramos. Estudio comparativo de los efectos electromecánicos de la estimulación biventricular epicárdica y endocárdica del ventrículo izquierdo en un modelo animal de insuficiencia cardíaca. FIS Project 2010. PI10/01149. Duration: 01/01/11-30/04/14. €152,150.
- ▶ Juan Cinca Cuscollola. Desarrollo preclínico de una nueva técnica para guiar la ablación eléctrica de las arritmias ventriculares en pacientes con infarto crónico mediante bioimpedancia. Proyectos de Investigación en Salud 2013. PI13/00765. Duration: 01/01/14-31/12/16. €140,250.
- ▶ Juan Cinca Cuscollola. REDINSCOR. Grupo HSCSP. Retics 2006. RD06/0003/0000. Duration: 01/01/07-31/12/14. €910,209.89.
- ▶ Juan Cinca Cuscollola. REDINSCOR. Grupo HSCSP. Retics 2006. RD06/0003. Duration: 01/01/07-31/12/14. €511,230.

Note: Total amount granted to PI. It does not include indirect costs.

Clinical and Translational Cardiology

*TIF: 231.7020 **MIF: 4.2128

Alegret J.M., Vinolas X., Arias M.A., Martinez-Rubio A., Rebollo P., Rafols C., Martinez-Sande J.L., New oral anticoagulants vs vitamin K antagonists: Benefits for health-related quality of life in patients with atrial fibrillation. (2014) *INT J MED SCI*, 11 (7), 680-684.

IF: 2.0030

Alfonso F., Perez-Vizcayno M.J., Cardenas A., Garcia Del Blanco B., Seidelberger B., Iniguez A., Gomez-Recio M., Masotti M., Velazquez M.T., Sanchis J., Garcia-Touchard A., Zueco J., Bethencourt A., Melgares R., Cequier A., Dominguez A., Mainar V., Lopez-Minguez J.R., Moreu J., Marti V., Moreno R., Jimenez-Quevedo P., Gonzalo N., Fernandez C., Macaya C., A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: The RIBS v clinical trial (restenosis intra-stent of bare metal stents: Paclitaxel-eluting balloon vs. everolimus-eluting stent). (2014) *J AM COLL CARDIOL*, 63 (14), 1378-1386.

IF: 16.5030

Almendral J., Pombo M., Martinez-Alday J., Gonzalez-Rebollo J.M., Rodriguez-Font E., Martinez-Ferrer J., Castellanos E., Garcia-Fernandez F.J., Ruiz-Mateas F., Update on arrhythmias and cardiac pacing 2013. (2014) *REV ESP CARDIOL*, 67 (4), 294-304.

IF: 3.7920

Alonso-Martin C., Response to ECG, October 2014. (2014) *REV ESP CARDIOL*, 67 (11), 952.

IF: 3.7920

Alonso-Martin C., Rodriguez-Font E., Guerra J.M., Vinolas X., An unusual onset of supraventricular tachycardia with 2:1 Atrioventricular block: What is the mechanism?. (2014) *J CARDIOVASC ELECTR*, 25 (7), 799-802.

IF: 2.9580

Alvarez E., Vieira S., Garcia-Moll X., Citalopram, escitalopram and prolonged QT: Warning or alarm?. (2014) *REV PSIQUIATR SALUD*, 7 (3), 147-150.

IF: 1.6220

Battle M., Recarte-Pelz P., Roig E., Castel M.A., Cardona M., Farrero M., Ortiz J.T., Campos B., Pulgarin M.J., Ramirez J., Perez-Villa F., Garcia De Frutos P., AXL receptor tyrosine kinase is increased in patients with heart failure. (2014) *INT J CARDIOL*, 173 (3), 402-409.

IF: 4.0360

Brugaletta S., Cola C., Martin-Yuste V., Vilahur G., Oriol J., Padro T., Guerra J.M., Borrás R., Badimon L., Sabate M., Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. (2014) *INT J CARDIOVASC IMAG*, 30 (3), 469-476.

IF: 1.8100

Carrasco-Chinchilla F., Arzamendi D., Romero M., Gimeno De Carlos F., Alonso-Briales J.H., Li C.-H., Mesa M.D., Arnold R., Serrador Frutos A.M., Pan M., Roig E., Rodriguez-Bailon I., De La Fuente Galan L., Hernandez J.M., Serra A., Suarez De Lezo J., Initial experience of percutaneous treatment of mitral regurgitation with MitraClip® therapy in Spain. (2014) *REV ESP CARDIOL*, 67 (12), 1007-1012.

IF: 3.7920

Cinca J., Rossello X., Bardaji A., Worner F., The reply. (2014) *AM J MED*, 127 (5).

IF: 5.0030

Cubedo J., Padro T., Cinca J., Mata P., Alonso R., Badimon L., Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. (2014) *EUR J CLIN INVEST*, 44 (3), 266-275.

IF: 2.7340

Descalzo M., Vidal-Perez R., Leta R., Alomar X., Pons-Llado G., Carreras F., Usefulness of coronary artery calcium for detecting significant coronary artery disease in asymptomatic individuals. (2014) *REV CLIN ESP*, 214 (5), 235-241.

IF: 1.0630

Diaz-Manera J., Alejaldre A., Llauger J., Mirabet S., Rojas-Garcia R., Ramos-Fransi A., Gallardo E., Illa I., Cranial, axial and proximal myopathy and hypertrophic cardiomyopathy caused by a mutation in the globular head region of the MYH7 gene. (2014) *EUR J NEUROL*, 21 (6).

IF: 4.0550

Feliu-Soler A., Pascual J.C., Borrás X., Portella M.J., Martin-Blanco A., Armario A., Alvarez E., Perez V., Soler J., Effects of dialectical behaviour therapy-mindfulness training on emotional reactivity in borderline personality disorder: Preliminary results. (2014) *CLIN PSYCHOL PSYCHOT*, 21 (4), 363-370.

IF: 2.6320

Fernandez-Rodriguez D., Regueiro A., Brugaletta S., Martin-Yuste V., Masotti M., Cequier A., Iniguez A., Serra A., Hernandez-Andolin R., Mainar V., Valgimigli M., Tsepili M., Den Heijer P., Bethencourt A., Vazquez N., Serruys P.W., Sabate M., Optimization in stent implantation by manual thrombus aspiration in ST-segment-elevation myocardial infarction: Findings from the EXAMINATION trial. (2014) *CIRC-CARDIOVASC INTE*, 7 (3), 294-300.

IF: 6.2180

Fontenla A., Lopez Gil M., Martinez Ferrer J., Alzueta J., Fernandez Lozano I., Vinolas X., Rodriguez A., Fernandez De La Concha J., Anguera I., Arribas F., Clinical profile and incidence of ventricular arrhythmia in patients undergoing defibrillator generator replace-

ment in Spain. (2014) *REV ESP CARDIOL*, 67 (12), 986-992.

IF: 3.7920

Freixa X., Arzamendi D., Tzikas A., Noble S., Basmadjian A., Garceau P., Ibrahim R., Cardiac Procedures to Prevent Stroke: Patent Foramen Ovale Closure/Left Atrial Appendage Occlusion. (2014) *CAN J CARDIOL*, 30 (1), 87-95.

IF: 3.7110

Garcia-Dorado Garcia D., Diez J., Cinca J., Marrugat J., Fernandez-Aviles Diaz F., Cooperative research in biomedicine. Spain's Cardiovascular network, red de investigación cardiovascular. (2014) *REV ESP CARDIOL*, 67 (4), 254-258.

IF: 3.7920

Gomez-Doblas J.J., Muniz J., Alonso Martin J.J., Roig E., New data about atrial fibrillation, comment to the OFRECE study. Response. (2014) *REV ESP CARDIOL*, 67 (6), 499-500.

IF: 3.7920

Gomez-Doblas J.J., Muniz J., Martin J.J.A., Rodriguez-Roca G., Lobos J.M., Awamleh P., Permanyer-Miralda G., Chorro F.J., Anguita M., Roig E., Prevalence of atrial fibrillation in Spain. OFRECE study results. (2014) *REV ESP CARDIOL*, 67 (4), 259-269.

IF: 3.7920

Gonzalez-Garcia M., Ferrer M.J., Borrás X., Munoz-Moreno J.A., Miranda C., Puig J., Perez-Alvarez N., Soler J., Feliu-Soler A., Clotet B., Fumaz C.R., Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. (2014) *AIDS BEHAV*, 18 (4), 676-685.

IF: 3.7280

Gonzalez-Vilchez F., Arizon J.M., Segovia J., Almenar L., Crespo-Leiro M.G., Palomo J., Delgado J.F., Mirabet S., Rabago G., Perez-Villa F., Diaz B., Sanz M.L., Pascual D., De La Fuente L., Guinea G., Chronic renal dysfunction in maintenance heart transplant patients: The ICEBERG study. (2014) *TRANSPL P*, 46 (1), 14-20.

IF: 0.9820

Gonzalez-Vilchez F., Gomez-Bueno M., Almenar L., Crespo-Leiro M.G., Arizon J.M., Palomo J., Delgado J., Roig E., Lage E., Manito N., Spanish heart transplantation registry. 25th official report of the Spanish society of cardiology working group on heart failure and heart transplantation (1984-2013). (2014) *REV ESP CARDIOL*, 67 (12), 1039-1051.

IF: 3.7920

Gonzalez-Vilchez F., Vazquez De Prada J.A., Paniagua M.J., Gomez-Bueno M., Arizon J.M., Almenar L., Roig E., Delgado J., Lambert J.L., Perez-Villa F., Sanz-Julve M.L., Crespo-Leiro M., Segovia J., Lopez-Granados A., Mar-

*TIF: 231.7020 **MIF: 4.2128

tinez-Dolz L., Mirabet S., Escribano P., Diaz-Molina B., Farrero M., Blasco T., Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?. (2014) *INT J CARDIOL*, 171 (1), 15-23.

IF: 4.0360

Gutierrez M., Hidalgo A., Carreras F., Epipericardial fat necrosis. (2014) *REV ESP CARDIOL*, 67 (12), 1053.

IF: 3.7920

Iglesias P.P., Ruano S.D., Alvarez-Garcia J., Myocardial injury after noncardiac surgery. (2014) *REV ESP CARDIOL*, 67 (10), 794-796.

IF: 3.7920

Jimenez-Quevedo P., Gonzalez-Ferrer J.J., Sabate M., Garcia-Moll X., Delgado-Bolton R., Llorente L., Bernardo E., Ortega-Pozzi A., Hernandez-Antolin R., Alfonso F., Gonzalo N., Escaned J., Banuelos C., Regueiro A., Marin P., Fernandez-Ortiz A., Das Neves B., Del Trigo M., Fernandez C., Tejerina T., Redondo S., Garcia E., Macaya C., Selected CD133<sup>+</sup> progenitor cells to promote angiogenesis in patients with refractory angina final results of the PROGENITOR randomized trial. (2014) *CIRC RES*, 115 (11), 950-960.

IF: 11.0190

Kalra P.R., Garcia-Moll X., Zamorano J., Kalra P.A., Fox K.M., Ford I., Ferrari R., Tardif J.-C., Tendera M., Greenlaw N., Steg Ph.G., Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: A prospective analysis of 22,272 patients. (2014) *PLOS ONE*, 9 (7).

IF: 3.2340

Li C.-H., Arzamendi D., Serra A., Four mitraClips® deployed in a mitral valve. (2014) *REV ESP CARDIOL*, 67 (5), 405.

IF: 3.7920

Li C.-H., Leta R., Pons-Llado G., Myocardial hypoperfusion in acute aortic dissection. (2014) *REV ESP CARDIOL*, 67 (4), 323.

IF: 3.7920

Marin F., Diaz-Castro O., Ruiz-Nodar J.M., De La Villa B.G., Sionis A., Lopez J., Fernandez-Ortiz A., Martinez-Selles M., Update on ischemic heart disease and critical care cardiology. (2014) *REV ESP CARDIOL*, 67 (2), 120-126.

IF: 3.7920

Martinez-Selles M., Gomez Doblas J.J., Carro Hevia A., Garcia de la Villa B., Ferreira-Gonzalez I., Alonso Tello A., Andion Ogando R., Ripoll Vera T., Arribas Jimenez A., Carrillo P., Rodriguez Pascual C., Casares i Romeva M., Borrás X., Cornide L., Lopez-Palop R., Prospective registry of symptomatic severe aortic stenosis in octogenarians: A need for intervention. (2014) *J*

INTERN MED, 275 (6), 608-620.

IF: 6.0630

Masia J., Olivares L., Koshima I., Teo T.C., Suominen S., Van Landuyt K., Demirtas Y., Becker C., Pons G., Garusi C., Mitsunaga N., Barcelona consensus on supermicrosurgery. (2014) *J RECONSTR MICROSURG*, 30 (1), 53-58.

IF: 1.3120

Mendez A.B., Cardona M., Ordonez-Llanos J., Mirabet S., Perez-Villa F., Roig E., Predictive value of high-sensitive troponin T to rule out acute rejection after heart transplantation. (2014) *REV ESP CARDIOL*, 67 (9), 775-776.

IF: 3.7920

Mont L., Bisbal F., Hernandez-Madrid A., Perez-Castellano N., Vinolas X., Arenal A., Arribas F., Fernandez-Lozano I., Bodegas A., Cobos A., Matia R., Perez-Villacastin J., Guerra J.M., Avila P., Lopez-Gil M., Castro V., Arana J.I., Brugada J., Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: A multicentre, randomized, controlled trial (SARA study). (2014) *EUR HEART J*, 35 (8), 501-507.

IF: 15.2030

Noriega F.J., Vives-Borrás M., Sole-Gonzalez E., Garcia-Picart J., Arzamendi D., Cinca J., Influence of the extent of coronary atherosclerotic disease on ST-segment changes induced by ST elevation myocardial infarction. (2014) *AM J CARDIOL*, 113 (5), 757-764.

IF: 3.2760

Pons G., Masia J., Loschi P., Nardulli M.L., Duch J., A case of donor-site lymphoedema after lymph node-superficial circumflex iliac artery perforator flap transfer. (2014) *J PLAST RECONSTR AES*, 67 (1), 119-123.

IF: 1.4210

Pons G., Masia J., Sanchez-Porro L., Larranaga J., Clavero J.A., Paramuscular perforators in DIEAP flap for breast reconstruction. (2014) *ANN PLAS SURG*, 73 (6), 659-661.

IF: 1.4940

Pons Llado G., The integral nature of cardiac magnetic resonance imaging in the work-up for ischemic heart disease. (2014) *REV ESP CARDIOL*, 67 (9), 683-684.

IF: 3.7920

Porta-Sanchez A., Marti-Aguasca G., Pijuan-Domenech M.A., Dos-Subira L., Subirana-Domenech M.-T., Casaldaliga-Ferrer J., Percutaneous closure of baffle leaks in patients with atrial switch operation for D-transposition of the great arteries. (2014) *REV ESP CARDIOL*, 67 (8), 671-674.

IF: 3.7920

Puig T., Ferrero-Gregori A., Roig E., Vazquez R., Gonzalez-Juanatey J.R., Pascual-Figal D., Delgado J., Alonso-Pulpon L., Borrás X., Mendez A., Cinca J., Prognostic value of body

mass index and waist circumference in patients with chronic heart failure (Spanish REDINSCOR registry). (2014) *REV ESP CARDIOL*, 67 (2), 101-106.

IF: 3.7920

Ribas N., Domingo M., Gastellurrutia P., Ferrero-Gregori A., Rull P., Noguero M., Garcia C., Puig T., Cinca J., Bayes-Genis A., Chronobiology of death in heart failure. (2014) *REV ESP CARDIOL*, 67 (5), 387-393.

IF: 3.7920

Rossello X., Wiegerinck R.F., Alguersuari J., Bardaji A., Worner F., Sutil M., Ferrero A., Cinca J., New electrocardiographic criteria to differentiate acute pericarditis and myocardial infarction. (2014) *AM J MED*, 127 (3), 233-239.

IF: 5.0030

Ruiz-Nodar J.M., Marin F., Sionis A., Fernandez-Ortiz A., Dynamic prognostic stratification in ST-elevation myocardial infarction. Response. (2014) *REV ESP CARDIOL*, 67 (7), 588.

IF: 3.7920

Ruys T.E.P., Roos-Hesseling J.W., Hall R., Subirana-Domenech M.T., Grando-Ting J., Estensen M., Crepaz R., Fesslova V., Gurvitz M., De Backer J., Johnson M.R., Pieper P.G., Heart failure in pregnant women with cardiac disease: Data from the ROPAC. (2014) *HEART*, 100 (3), 231-238.

IF: 5.5950

Sabate M., Brugaletta S., Cequier A., Iniguez A., Serra A., Hernandez-Antolin R., Mainar V., Valgimigli M., Tespili M., Den Heijer P., Bethencourt A., Vazquez N., Backx B., Serruys P.W., The EXAMINATION trial (everolimus-eluting stents versus bare-metal stents in st-segment elevation myocardial infarction): 2-year results from a multicenter randomized controlled trial. (2014) *JACC-CARDIOVASC INTE*, 7 (1), 64-71.

IF: 7.3450

Sabate M., Raber L., Heg D., Brugaletta S., Kelbaek H., Cequier A., Ostojic M., Iniguez A., Tuller D., Serra A., Baumbach A., Von Birgelen C., Hernandez-Antolin R., Roffi M., Mainar V., Valgimigli M., Serruys P.W., Juni P., Windecker S., Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: A pooled analysis of the EXAMINATION (clinical evaluation of the xience-V stent in acute myocardial INfArction) and COMFORTABLE-AMI. (2014) *JACC-CARDIOVASC INTE*, 7 (1), 55-63.

IF: 7.3450

Sattar N.A., Ginsberg H., Ray K., Chapman M.J., Arca M., Averna M., Betteridge D.J., Bhatnagar D., Biliannou E., Carmena R., Ceska R., Corsini A., Erbel R., Flynn P.D., Garcia-Moll X., Gumprecht J., Ishibashi S., Jambart S.,

Clinical and Translational Cardiology

*TIF: 231.7020 **MIF: 4.2128

Scientific Production

Kastelein J.J.P., Maher V., Marques da Silva P., Masana L., Odawara M., Pedersen T.R., Rotella C.M., Salti I., Teramoto T., Tokgozoglu L., Toth P.P., Valensi P., Verges B., The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. (2014) *ATHEROSCLEROSIS SUPP*, 15 (1), 1-15.

IF: 2.2930

Scalone G., Brugaletta S., Martin-Yuste V., Seixo F., Cotes C., Gomez-Monteros O., Alvarez-Contreras L., Camprecios M., Mirabet S., Brossa V., Sabate M., RAndomized comparison of raDial vs. femorAL access for routine catheterization of heart transplant patients (RADIAL e heart transplant study). (2014) *TRANSPL P*, 46 (10), 3262-3267.

IF: 0.9820

Shiratori Y., Cola C., Brugaletta S., Alvarez-Contreras L., Martin-Yuste V., Del Blanco B.G., Ruiz-Salmeron R., Diaz J., Pinar E., Marti V., Garcia-Picart J., Sabate M., Randomized comparison between polymer-free versus polymer-based paclitaxel-eluting stent two-

year final clinical results. (2014) *CIRC-CARDIOVASC INTE*, 7 (3), 312-321.

IF: 6.2180

Subirana M.T., Baron-Esquivias G., Manito N., Oliver J.M., Ripoll T., Lambert J.L., Zunzunegui J.L., Bover R., Garcia-Pinilla J.M., 2013 update on congenital heart disease, clinical cardiology, heart failure, and heart transplant. (2014) *REV ESP CARDIOL*, 67 (3), 211-217.

IF: 3.7920

Tziakas D., Chalikias G., Stakos D., Altun A., Sivri N., Yetkin E., Gur M., Stankovic G., Mehmedbegovic Z., Voudris V., Chatzikiyiakou S., Garcia-Moll X., Serra A., Passadakis P., Thodis E., Vargemezis V., Kaski J.C., Konstantinides S., Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. (2014) *AM J CARDIOL*, 113 (9), 1487-1493.

IF: 3.2760

Vilades D., Leta R., Moustafa A.-H., Alomar X., Carreras F., Pons-Llado G., Correlation be-

tween Agatston scores obtained by cardiac computed tomography studies with and without contrast in asymptomatic population. (2014) *REV ESP CARDIOL*, 67 (8), 678-679.

IF: 3.7920

Vilades Medel D., Marti-Almor J., Montiel Serrano J., Sionis A., Leta Petracca R., Atrioesophageal fistula secondary to pulmonary vein cryo-ablation. (2014) *EUR HEART J-CARD IMG*, 15 (1), 116.

IF: 4.1050

Zamorano J.L., Garcia-Moll X., Ferrari R., Greenlaw N., Demographic and clinical characteristics of patients with stable coronary artery disease: Results from the CLARIFY registry in Spain. (2014) *REV ESP CARDIOL*, 67 (7), 538-544.

IF: 3.7920

Other Publications

▶ Almendral J., Pombo M., Martinez-Alday J., Gonzalez-Rebollo J.M., Rodriguez-Font E., Martinez-Ferrer J., Castellanos E., Garcia-Fernandez F.J., Ruiz-Mateas F., Update on arrhythmias and cardiac pacing 2013. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (4), 294-304.

▶ Erbel R., Eggebrecht H., Roguin A., Schroeder E., Philipp S., Heitzer T., Schwacke H., Ayzenberg O., Serra A., Delarche N., Luchner A., Slagboom T., Prospective, multi-center evaluation of a silicon carbide coated cobalt chromium bare metal stent for percutaneous coronary interventions: Two-year results of the ENERGY Registry. (2014) *CARDIOVASCULAR REVASCULARIZATION MEDICINE*, 15 (8), 381-387.

▶ Garcia-Dorado Garcia D., Diez J., Cinca J., Marrugat J., Fernandez-Aviles Diaz F., Cooperative research in biomedicine. Spain's cardiovascular network, Red de Investigación Cardiovascular. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (4), 254-258.

▶ Gomez-Doblas J.J., Muniz J., Alonso Martin J.J., Roig E., New data about atrial fibrillation, comment to the OFRECE study. Response. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (6), 499-500.

▶ Gomez-Doblas J.J., Muniz J., Martin J.J., Rodriguez-Roca G., Lobos J.M., Awamleh P., Permanyer-Miralda G., Chorro F.J., Anguita M., Roig E., Prevalence of atrial fibrillation in Spain. OFRECE study results. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (4), 259-269.

▶ Hidalgo A., Guerra J.M., Gallego O., Franquet T., Microwave ablation of a sarcoma lung metastasis in a patient with a pacemaker. (2014) *RADIOLOGIA*, 56 (2), 171-174.

▶ Li C.-H., Arzamendi D., Serra A., Four MitraClips deployed in a mitral valve. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (5), 405.

▶ Li C.-H., Leta R., Pons-Llado G., Myocardial hypoperfusion in acute aortic dissection. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (4), 323.

▶ Marin F., Diaz-Castro O., Ruiz-Nodar J.M., Garcia de la Villa B., Sionis A., Lopez J., Fernandez-Ortiz A., Martinez-Selles M., Update on ischemic heart disease and critical care cardiology. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (2), 120-126.

▶ Ribas N., Domingo M., Gastelurrutia P., Ferrero-Gregori A., Rull P., Noguero M., Garcia C., Puig T., Cinca J., Bayes-Genis A., Chronobiology of death in heart failure. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (5), 387-393.

▶ Ruiz-Nodar J.M., Marin F., Sionis A., Fernandez-Ortiz A., Dynamic prognostic stratification in ST-elevation myocardial infarction. Response. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (7), 588.

▶ Subirana M.T., Baron-Esquivias G., Manito N., Oliver J.M., Ripoll T., Lambert J.L., Zunzunegui J.L., Bover R., Garcia-Pinilla J.M., 2013 update on congenital heart disease, clinical cardiology, heart failure, and heart transplant. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (3), 211-217.

▶ Zamorano J.L., Garcia-Moll X., Ferrari R., Greenlaw N., Demographic and clinical characteristics of patients with stable coronary artery disease: results from the CLARIFY registry in Spain. (2014) *REVISTA ESPAÑOLA DE CARDIOLOGÍA (English ed.)*, 67 (7), 538-544.

Thrombosis and Haemostasis

Coordinators

Juan Carlos Souto HSCSP
jsouto@santpau.cat

Members

Montserrat Borrell HSCSP
Marina Carrasco HSCSP
Inmaculada Coll HSCSP
Biel Cuevas HSCSP RI
Jordi Fontcuberta HSCSP
Dolors Llobet HSCSP
Raquel Macho HSCSP RI
José Mateo HSCSP
Juan Antonio Millón HSCSP RI
Agnès Morera HSCSP RI
Joaquim Murillo HSCSP RI
Vanessa Orantes HSCSP
Isabel Tirado HSCSP
Cristina Vallvé HSCSP
Miguel Vázquez HSCSP RI
Noèlia Vilalta HSCSP RI



Main Lines of Research

- ▶ Investigation of the genetic basis of venous and arterial thrombosis. GAIT-1 and GAIT-2 projects.
- ▶ Investigation of new antithrombotic drugs: thrombin inhibitors, molecules against activated factor X, low molecular weight heparin with oral activity, among others.
- ▶ Biomarkers of prothrombotic states in patients under 55 years with venous thromboembolic disease, acute ischaemic stroke, or acute myocardial infarction. VEREMA project.
- ▶ Applied clinical development of the self-management model of oral anticoagulant treatment.
- ▶ Mathematical models of prediction of the individual risk of thromboembolic disease. RETROVE and PAN projects.
- ▶ CITA project. Centre for Antithrombotic Therapy Management. Research into a new ambulatory management model for patients receiving any kind of antithrombotic therapy (anti vitamin-K, new oral anticoagulants, low molecular weight heparins, antiplatelets) by incorporating new educational programmes, specialized nursing and new communication technologies.

Challenges

- ▶ Study QTL detected in GAIT-1 families in relation to phenotypes of haemostasis with thrombosis risk (resistance to activated protein C, factor VIII, homocysteine, factor XII, body mass index and others).
- ▶ Replicate QTL related to thrombosis in GAIT-1 families by means of the linkage analysis using new GAIT-2 families.
- ▶ Conduct genome-wide association study (GWAS) of phenotypes involved in GAIT-1.
- ▶ GWAS of phenotypes included in GAIT-2.
- ▶ Analyse RNA expression in the GAIT-2 families.
- ▶ Investigate miRNA associated with thromboembolic disease in GAIT-2.
- ▶ Complete recruitment for the RETROVE project.
- ▶ Recruit team for the MIRTO project (Modelling Individual Risk of Thrombosis in Oncology), with the goal of establishing an individual risk score for venous thromboembolism (RETROVO sub-project) and for ischaemic stroke (SINO subproject) in patients with cancer.
- ▶ Research plasma proteins associated with the risk of venous thromboembolism by using high affinity proteomics developed at Karolinska Institutet. VEREMA project, joint collaboration between the European case-control studies VEBIOS (Sweden), RETROVE (from our unit) and MARTHA (France).
- ▶ Continue collaboration with the RCV Spanish cardiovascular patient network and with other European groups, mainly with the goal of applying GAIT project findings to cohorts of patients with venous and arterial thrombosis in Spain and other European countries.
- ▶ Evaluate the effectiveness of an educational programme for patients taking antiplatelet therapy (aspirin and/or clopidogrel) in reducing severe complications: EDUCANT clinical trial.

Collaborations	Collaborations with other IIB Sant Pau Groups	External Collaborations
	<ul style="list-style-type: none"> ▶ Genomics of Complex Diseases (GAIT1, GAIT 2, RETROVE, VEREMA and MIRTO design). ▶ Stroke Unit (HERO, EDUCANT and MIRTO design). ▶ Clinical and Translational Cardiology (EDUCANT). ▶ Vascular Surgery (EDUCANT). ▶ Medical Oncology (MIRTO design). ▶ Clinical Haematology (MIRTO design). ▶ Digestive Diseases (HEPACO). 	<ul style="list-style-type: none"> ▶ Cardiovascular Research Network (RIC). ▶ Karolinska Institutet, Stockholm, Sweden: GAIT2 and VEREMA. ▶ La Timone Hospital, Marseilles, France: GAIT2 and VEREMA. ▶ Pierre and Marie Curie University, INSERM, UMR-S 1166, Paris, France: GAIT2 and VEREMA. ▶ Université de Genève, Switzerland: GAIT2. ▶ Texas Research Institute (formerly Southwest Foundation for Biomedical Research), San Antonio, USA: GAIT1 and GAIT2. ▶ Universitat Politècnica de Catalunya, Barcelona, Spain. Centre for Biomedical Engineering Research: RETROVE and MIRTO design. ▶ Thrombosis Group of the Spanish Medical Oncology Society (SEOM): ONCOTHROMB and MIRTO.

Active Grants	<ul style="list-style-type: none"> ▶ Jordi Fontcuberta Boj. Ajuts de suport als Grups de Recerca de Catalunya. Grup Trombosi i Hemostàsia. AGAUR 2009. SGR 1147. Duration: 29/09/09-30/04/14. €43,680. ▶ Jordi Fontcuberta Boj. RECAVA. Retics 2006. RD06/0014/0016. Duration: 01/01/07-31/12/14. €761,461.33. ▶ Juan Carlos Souto Andrés. Búsqueda de un algoritmo aplicable en la clínica para definir el perfil individual de Riesgo de En- 	<p>fermedad TROMboembólica Venosa (RETROVE). Proyectos de Investigación en Salud 2012. PI12/00612. Duration: 01/01/13-31/12/15. €51,500.</p> <ul style="list-style-type: none"> ▶ Juan Carlos Souto Andrés. Red Cardiovascular. Redes Temáticas de Investigación Cooperativa en Salud 2012. RD12/0042/0032. Duration: 01/01/13-31/12/16. €44,000. <p>Note: Total amount granted to PI. It does not include indirect costs.</p>
---------------	---	---

***TIF: 16.4490 **MIF: 3.2898**

Scientific Production	<p>Cegarra-Sanmartin V., Gonzalez-Rodriguez R., Paniagua-Iglesias P., Santamaria-Ortiz A., Cueva L.F., Galan-Serrano J., Victoria Moral-Garcia M., Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. (2014) J CARDIOTHOR VASC AN, 28 (4), 1020-1024. IF: 1.4630</p> <p>Lopez S., Buil A., Souto J.C., Casademont J., Martinez-Perez A., Almasy L., Soria J.M., A genome-wide association study in the genetic analysis of idiopathic thrombophilia project suggests sex-specific regulation of</p>	<p>mitochondrial DNA levels. (2014) MITOCHONDRION, 18 (1), 34-40. IF: 3.2490</p> <p>Rico S., Antonijoan R.-M., Ballester M.R., Gutierro I., Ayani I., Martinez-Gonzalez J., Borrell M., Fontcuberta J., Gich I., Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. (2014) THROMB RES, 133 (6), 1029-1038. IF: 2.4470</p>	<p>Soria JM, Morange PE, Vila J, Souto JC, Moyano M, Trégouët DA, Mateo J, Saut N, Salas E, Elosua R. Multilocus genetic risk scores for venous thromboembolism risk assessment. (2014) J AM HEART ASSOC, 3 (5). IF: 4.3060</p> <p>Souto J.C., Pena G., Ziyatdinov A., Buil A., Lopez S., Fontcuberta J., Soria J.M., A genome-wide study of body mass index and its genetic correlation with thromboembolic risk. Results from the GAIT project. (2014) THROMB HAEMOSTASIS, 112 (5), 1036-1043. IF: 4.9840</p>
-----------------------	---	--	---

Other Publications	<ul style="list-style-type: none"> ▶ Vilalta N., Souto J.C., Venous thrombophilia research. Present and future. (2014) ANGIOLOGIA, 66 (4), 190-198.
--------------------	--

*Total Impact Factor **Mean Impact Factor


Cardiovascular Biochemistry

Coordinator

Jordi Ordóñez HSCSP
jordonez@santpau.cat

Members

Sonia Benítez HSCSP RI
Rosa Bonet HSCSP
Agustina Castellví HSCSP
Montserrat Estruch HSCSP RI
Julia Freixa HSCSP
Maria Martínez HSCSP RI
Javier Mercé HSCSP
Inmaculada Porcel HSCSP
Ivy Mariel Rentería HSCSP RI
José Luis Sánchez HSCSP RI



Main Lines of Research

Atherosclerosis mechanisms

- ▶ Analysis of apolipoprotein J (apoJ) as a marker of CVR.
- ▶ Use of mimetic peptides derived from apoJ as therapeutic tools.
- ▶ Involvement of LDL(-) on lipid accumulation in cardiomyocytes and heart failure.

Inflammatory mechanisms induced by LDL(-) on monocytes from patients with diabetes.

- ▶ Diagnosis of chronic or acute cardiovascular diseases

- ▶ Development of algorithms for ruling-out acute coronary disease.
- ▶ Assessment of new biomarkers of acute cardiovascular disease: cardiac troponins, natriuretic peptides, ST-2.
- ▶ Development of methods for point-of-care biomarker measurement.
- ▶ Vulnerability markers in atheromatous plaque: electronegative LDL, LDL size, HDL function, myeloperoxidase, phospholipase.

Challenges

- ▶ Determine the intracellular mechanisms involved in the inflammatory response induced by LDL(-) and the components of the particle that entail atherogenicity.
- ▶ Analyse the therapeutic potential of mimetic peptides derived from apo J to delay the development of atherosclerosis in animal models.
- ▶ Demonstrate that electronegative LDL is a marker of vulnerable atheromatous plaque.
- ▶ Find new markers of cardiovascular risk in diseases such as diabetes, HIV or cardiac failure.

Active Grants

- ▶ Jordi Ordóñez Llanos. Ajuts de suport als Grups de Recerca de Catalunya. Grup Bioquímica Cardiovascular. AGAUR 2009. SGR 1205. Duration: 04/08/09-30/04/14. €46,800.
- ▶ Sonia Benítez González. Efecto de la modificación de la LDL sobre la expresión y activación de CD14, TLR4 y moléculas de adhesión en monocitos de individuos normolipémicos y diabéticos de tipo 2. Proyectos de Investigación en Salud 2012. PI12/00967. Duration: 01/01/13-31/12/15. €36,500.
- ▶ José Luis Sánchez Quesada. Implicación de la apolipoproteína J (clusterina) en la arteriosclerosis. Utilización terapéutica de péptidos miméticos con actividad chaperona. Proyectos de Investigación en Salud 2013. PI13/00364. Duration: 01/01/14-31/12/16. €85,500.
- ▶ Jordi Ordóñez Llanos. Red Cardiovascular. Redes Temáticas de Investigación Cooperativa en Salud 2012. RD12/0042/0043. Duration: 01/01/13-31/12/16. €22,250.

Note: Total amount granted to PI. It does not include indirect costs.

Collaborations with other IIB Sant Pau Groups

- ▶ Metabolic Bases of Cardiovascular Risk (Dr F. Blanco Vaca).
- ▶ Endocrinology, Diabetes and Nutrition (Dr A. Pérez).
- ▶ Angiology, Vascular Biology and Inflammation (Dr L. Vila).
- ▶ Clinical and Translational Cardiology (Dr J. Cinca).
- ▶ Lipids and Cardiovascular Pathology (Dr C. Llorente).

External Collaborations

Research into atherosclerosis mechanisms

- ▶ Dr Petri Kovanen, Wihuri Research Institute, Helsinki, Finland.
- ▶ Dr Kati Öörni, Wihuri Research Institute, Helsinki, Finland. Pre-doctoral stay by Montserrat Estruch (4 months).
- ▶ Dr Olga Gursky, Boston University School of Medicine, Boston, USA. Post-doctoral stay by Anna Rull (6 months).
- ▶ Dr Sandra Villegas, Biochemistry and Molecular Biology Department, UAB, Barcelona, Spain (ISCIII/FIS coordinated project under PI10/00265).

Research into diagnosis

- ▶ Dr Daniel Podzamczar, HIV Unit, Infectious Disease Service, Bellvitge University Hospital, Barcelona, Spain (ATADAR, SPIRAL and BICOMBO clinical trials).
- ▶ Formation and maintenance of a bank of samples within the Cardiovascular Research Network (RIC), Programme 6 (Clinical and Translational Heart Failure).
- ▶ Cardiovascular Research Network (RIC): Dr Francisco Marín, Cardiology, Hospital Virgen de Arrixaca, Murcia, Spain, 3-month stay by Dr Juan Antonio Vilchez (during a Rio Hortega contract) in our collaborative studies laboratory.

- ▶ Dr Mariano Valdés, Hospital Virgen de Arrixaca, Murcia, Spain, 3-week stay by Dr Carmen Puche in our collaborative studies laboratory.
- ▶ Dr Laura Dos (D. Garcia-Dorado), Integrated Adult Congenital Heart Disease Unit of Vall d'Hebron University Hospital, Barcelona, Spain (Evedes study).
- ▶ Dr Domingo Pascual-Figal, Cardiology Department, Virgen de la Arrixaca University Hospital, Murcia, Spain.
- ▶ Dr Rafael Vázquez, Cardiology Service, Puerta del Mar University Hospital, Cadiz, Spain.
- ▶ Dr Antoni Bayes-Genís, Cardiology Department, Germans Trias i Pujol University Hospital, Barcelona, Spain.

IFCC Task Force on Clinical Applications of Cardiac Biomarkers (Dr Jordi Ordóñez-Llanos, member)

- ▶ Dr Fred S. Apple, Department of Laboratory Medicine and Pathology, University of Minnesota, USA.
- ▶ Dr Paul O. Collinson, Cardiovascular and Laboratory Departments, St. George's Hospital, London, UK.
- ▶ Dr Alan S. Jaffe, Mayo Clinic, Cardiovascular Division, Rochester, New York, USA.
- ▶ Dr James L. Januzzi, Cardiology Division, Massachusetts General Hospital, Boston, USA.

Participation in multicentre studies

- ▶ MUSIC (sudden death in heart failure) Risk Score, Spanish Society of Cardiology.
- ▶ MAGGIC (meta-analysis global group in chronic heart failure), European Society of Cardiology.

*TIF: 29.9060 **MIF: 3.3229

Alcantara-Aragon V., Martinez-Couselo S., Tundidor-Rengel D., Webb S.M., Carreras G., Espinos J.J., Chico A., Blanco-Vaca F., Corcoy R., Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis. (2014) HORM-INT J ENDOCRINO, 13 (4), 585-587.

IF: 1.1980

Lipinski M.J., Baker N.C., Escarcega R.O., Torguson R., Chen F., Aldous S.J., Christ M., Collinson P.O., Goodacre S.W., Mair J., Inoue K., Lotze U., Sebbane M., Cristol J.-P., Freund Y., Chenevier-Gobeaux C., Meune C., Eggers K.M., Pracon R., Schreiber D.H., Wu A.H.B., Ordoez-Llanos J., Jaffe A.S., Twerenbold R., Mueller C., Waksman R., Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. (2014) AM HEART J, 169 (1), 6-16.e6.

IF: 4.4630

Julve J., Pardina E., Perez-Cuellar M., Ferrer R., Rossell J., Baena-Fustegueras J.A., Fort J.M., Lecube A., Blanco-Vaca F., Sanchez-Quesada J.L., Peinado-Onsurbe J., Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. (2014) ATHEROSCLEROSIS, 234 (1), 200-205.

IF: 3.9940

Martin-Campos J.M., Julve J., Roig R., Martinez S., Errico T.L., Martinez-Couselo S., Escola-Gil J.C., Mendez-Gonzalez J., Blanco-Vaca F., Molecular analysis of chylomicronemia in a clinical laboratory setting: Diagnosis of 13 cases of lipoprotein lipase deficiency. (2014) CLIN CHIM ACTA, 429, 61-68.

IF: 2.8240

Mendez A.B., Cardona M., Ordonez-Llanos J., Mirabet S., Perez-Villa F., Roig E., Predictive

value of high-sensitive troponin T to rule out acute rejection after heart transplantation. (2014) REV ESP CARDIOL, 67 (9), 775-776.

IF: 3.7920

Minambres I., Sanchez-Quesada J.L., Sanchez-Hernandez J., Rodriguez J., De Leiva A., Perez A., Vitamin D concentrations in familial combined hyperlipidemia: Effects of lipid lowering treatment. (2014) DIABETOL METAB SYNDR, 6 (1).

IF: 2.1730

Saumoy M., Ordonez-Llanos J., Martinez E., Ferrer E., Domingo P., Ribera E., Negredo E., Curto J., Sanchez-Quesada J.L., Di Yacovo S., Lez-Cordon A.G., Podzamczar D., Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: A substudy of the ATADAR randomized study. (2014) J ANTIMICROB CHEMOTH, 70 (4), 1130-1138.

Cardiovascular Biochemistry

*TIF: 29.9060 **MIF: 3.3229

Scientific Production

IF: 5.3130

Vinagre I, Sanchez-Quesada J.L., Sanchez-Hernandez J., Santos D., Ordonez-Llanos J., De Leiva A., Perez A., Inflammatory biomarkers in type 2 diabetic patients: Effect of glycemic control and impact of ldl sub-fraction phenotype. (2014) *CARDIOVASC DIABETOL*, 13 (1).

IF: 4.0150

Zapata L., Betbese A.J., Roglan A., Ordonez-Llanos J., Use of B-type natriuretic peptides to detect the existence and severity of diastolic dysfunction in non-cardiac critically ill patients: A pilot study. (2014) *MINERVA ANESTESIOL*, 80 (2), 194-203.

IF: 2.1340

Other Publications

- ▶ Estruch M., Sanchez-Quesada J.L., Ordonez-Llanos J., Benitez S., Ceramide-enriched LDL induces cytokine release through TLR4 and CD14 in monocytes. Similarities with electronegative LDL. (2014) *CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS*, 26 (3), 131-137.

Angiology, Vascular Biology and Inflammation

Coordinator

Luis Vila HSCSP RI
lvila@santpau.cat

Members

Sonia Alcolea HSCSP RI
Judith Alonso HSCSP RI
Sergio Bellmunt HSCSP
Mercedes Camacho HSCSP RI
Jaume Dilmé HSCSP
José Román Escudero HSCSP
Josep Maria Romero HSCSP
Laura Sigüero HSCSP RI
Olga Solá HSCSP RI
Begoña Soto



Main Lines of Research

Cardiovascular Research

- ▶ Inflammatory mechanisms involved in vascular disorders.
- ▶ Genetic basis of vascular pathologies: atherothrombosis, aortic aneurism and chronic venous insufficiency.
- ▶ New, more effective targets. Research into pharmacologic targets for NSAIDs of cardiovascular interest.

Cancer Research

- ▶ Role of inflammatory mediators in head and neck squamous carcinoma and in regulating gene expression in tumour relapse.

Challenges

- ▶ Increase cooperation between clinicians and experimental researchers to enhance the translation level of our research by setting up training programmes for clinical physicians.
- ▶ Increase the number of researchers with PhDs in the group.
- ▶ Increase funding sources by establishing collaborations with the industrial sector.
- ▶ Improve research quality in terms of standard evaluation indexes.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Ear, Nose and Throat Cancers (Xavier León, Jacinto Gracia and Miquel Quer).
- ▶ Genomics of Complex Diseases (José Manuel Soria, PI).
- ▶ Thrombosis and Haemostasis (Juan Carlos Souto, PI).
- ▶ Atherosclerosis and Vascular Biology (José Martínez, PI).
- ▶ Inflammation and Vascular Remodelling (Cristina Rodríguez, PI).
- ▶ General and Digestive Surgery (Eduard Targarona and Carmen Balagué).

External Collaborations

- ▶ Dr Mercedes Salices. Pharmacology Group, Universidad Autónoma de Madrid, Spain.
- ▶ Dr Juan Miguel Redondo. CNIC, Madrid, Spain.
- ▶ Dr Alicia García Arroyo. CNIC, Madrid, Spain.
- ▶ Dr Francesc-Xavier Avilés-Jurado. Otorhinolaryngology Department, Hospital Universitari de Tarragona Joan XXIII, ISPV, Universitat Rovira i Virgili, Tarragona, Spain.

Active Grants

- ▶ Luis Vila Navarro. RECAVA. Retics 2006. RD06/0014/1005. Duration: 01/01/08-31/12/14. €127,811.57.
- ▶ Luis Vila Navarro. Red Cardiovascular. Redes Temáticas de Investigación Cooperativa en Salud 2012. RD12/0042/0051. Duration: 01/01/13-31/12/16. €49,217.39.
- ▶ Luis Vila Navarro. PGE-Sintasa Microsomal-1 como diana para la generación de nuevos fármacos antiinflamatorios de interés cardiovascular: estudio en el contexto del aneurisma abdominal de aorta. MICINN SAF 2010. SAF2010-21392. Duration: 01/01/11-31/08/14. €120,000.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Luis Vila Navarro. Papel de las vías de la PGE2 y glutatión reducido/Nfr2-ARE en la hipervascularización asociada al aneurisma de aorta abdominal. Universitat Autònoma de Barcelona. Proyectos de I+D+i Retos Investigación 2013. SAF2013-46707-R. Duration: 01/01/14-31/12/16. €110,000.

Note: Total amount granted to PI. It does not include indirect costs.

Theses

- ▶ Jaime Félix Dilmé Muñoz. Estudio la influencia de los factores de riesgo cardiovascular en los niveles locales de factores angiogénicos en el aneurisma de aorta abdominal. Universitat Autònoma de Barcelona. Directors: Luis Vila Navarro, Secundino Llagostera Pujol, Xavier Rius i Cornadó. Date of defense: 31 October 2014. Awarded best thesis at the 61th Congreso de la Sociedad Española de Angiología y Cirugía Vascolar.

Awards

- ▶ Camacho M, Dilmé JF, Solà-Vilà, Bellmunt S, Romero, JM, Escudero JR, Vila L. Efecto de los factores de riesgo cardiovascular en la expresión del eje COX2/mPGES-1/EP4 en pacientes de aneurisma aórtico abdominal (AAA). Special mention. XXVII Congreso Nacional SEA. Barcelona 20-21 February 2014.

*TIF: 13.2120 **MIF: 1.8874

Scientific Production

Bellmunt Montoya S., Sirvent Gonzalez M., Florit Lopez S., Dilme Munoz J., Gimenez Gaibar A., Escudero Rodriguez J.R., Study to develop a waiting list prioritization score for varicose vein surgery. (2014) ANN VASC SURG, 28 (2), 306-312.

IF: 1.1700

Bellmunt S., Alonso-Coello P., Cilostazol : Same evidence, different conclusions. (2014) CHEST, 145 (2), 435-436.

IF: 7.4830

Bellmunt S., Roque M., Osorio D., Pardo H., Escudero J.-R., Bonfill X., Healthcare quality indicators of peripheral artery disease based on systematic reviews. (2014) EUR J VASC ENDOVASC, 48 (1), 60-69.

IF: 2.4900

Dilme J.F., Bellmunt S., Camacho M., Sola-Villa D., Romero J.M., Escudero J.R., Vila L. Influence of cardiovascular risk factors on levels of matrix metalloproteinases 2 and 9 in human abdominal aortic aneurysms. (2014) EUR J VASC ENDOVASC, 48 (4), 374-381

IF: 2.4900

Dilme J.-F., Sola-Villa D., Bellmunt S., Romero J.-M., Escudero J.-R., Camacho M., Vila L., Active smoking increases microsomal PGE-synthase-1/PGE-receptor-4 axis in human abdominal aortic aneurysms. (2014) MEDIAT INFLAMM, 2014.

IF: 3.2360

Lozano Sanchez F.S., Marinel Io Roura J., Carrasco Carrasco E., Gonzalez-Porras J.R., Escudero Rodriguez J.R., Sanchez Nevarez I.,

Diaz Sanchez S., Venous leg ulcer in the context of chronic venous disease. (2014) PHLEBOLOGY, 29 (4), 220-226.

IF: 1.7740

Rivera J., van der Graaf G.B., Escudero J.R., Bellmunt S., van de Vosse F., A computational fluid dynamics study on hemodynamics for different locations of the distal anastomosis of a bypass nearby a collateral vessel in the femoropopliteal area. (2014) INT J NUMER METH BIO, 30 (11), 1263-1277.

IF: 2.0520

Other Publications

- ▶ Rodriguez-Calvo R., Guadall A., Calvayrac O., Alonso J., Ferran B., Marti I., Navarro M.T., De Diego A., Osada J., Rodriguez C., Martinez-Gonzalez J., The nuclear receptor NOR-1 regulates the activation of vascular cells and vascular remodelling in response to hemodynamic stress. (2014) CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 26 (2), 66-75.

Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases

Coordinator

Lina Badimon ICCC
lbadimon@csic-iccc.org

Researchers

Rosa Aledo ICCC
Mónica Amado ICCC
Gemma Arderiu ICCC
María Azorín ICCC
María Teresa Béjar ICCC
María Borrell ICCC
M. Ángeles Cánovas ICCC
Sandra Camino ICCC
Laura Casani ICCC
Pablo Catalina ICCC
Ona Catot ICCC
Gemma Chiva ICCC
Javier Crespo ICCC
Judit Cubedo ICCC
Rafael Escate ICCC
Sonia Espinosa ICCC
Raquel Ferrer ICCC
Sergi Florit ICCC
Olaya García ICCC
Joaquim Gordo ICCC
Sonia Huertas ICCC
Josep Oriol Juan ICCC
Emil Kozarov ICCC
Sergio López ICCC
Josep Moreno ICCC
Anna Navarrete ICCC
Raquel de la Torre ICCC
Lourdes Maria Varela ICCC
Carolina Romero ICCC
Gemma Vilahur ICCC



Main Lines of Research

- ▶ Physiopathological role of LRP family proteins in chronic diseases.
- ▶ Identification and characterization of transcription factors and genetic targets. Role of lipids and inflammation.
- ▶ Vascular impact of ischaemia and angiogenesis in heart disease. Cell therapy.
- ▶ Research into new targets to inhibit the transformation of silent atherosclerosis into ischaemic syndromes: tissue-factor-mediated angiogenic switch.

Challenges

- ▶ Broaden the experimental focus to include transgenic animal models with/without cardiovascular risk factors in order to proceed to in-depth analysis of molecules involved in the modulation of new proteins identified by post-genomic technologies and systems biology approaches.
- ▶ Maintain present scientific networks and establish new multidisciplinary collaborations.
- ▶ Increase international funding for the extension of new and established platforms in order to implement proposed activities.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Clinical and Translational Cardiology (PI: Juan Cinca).
- ▶ Biomarkers for Cardiovascular Disease (PI: Teresa Padró).
- ▶ Cerebrovascular Diseases (PI: Joan Martí Fàbregas).
- ▶ Inflammation and Vascular Remodelling (PI: Cristina Rodríguez).
- ▶ Endocrinology, Diabetes and Nutrition (PI: Alberto de Leiva).
- ▶ Pharmacological Research in Humans (PI: Rosa M. Antonijoan).

National Collaborations

- ▶ Department of Internal Medicine, Hospital Clínic, Barcelona (R. Estruch).
- ▶ Department of Cardiology, Thorax Institute, Hospital Clínic, University of Barcelona (Salvatore Brugaletta, Victoria Martín-Yuste, Clarissa Cola, Manel Sabaté).
- ▶ Quirúrgica Cirujanos Asociados (Alberto Díez-Caballero).

- ▶ Department of Plastic Surgery, Centro Médico Teknon, Barcelona (Fabrizio Moscattiello, Javier Herrero).
- ▶ Centro Laparoscópico Doctor Ballesta SLU, Barcelona (Carlos Ballesta-López).
- ▶ Fundación Jiménez Díaz, Madrid (Rodrigo Alonso, Pedro Mata).
- ▶ Cell Therapy Network (TerCel), RD12/0019.
- ▶ Cardiovascular Research Network (RIC), RD12/0042.

International Collaborations

- ▶ Experimental, Diagnostic and Speciality Medicine, University of Bologna, Bologna, Italy (Raffaele Bugiardini).
- ▶ School of Healthcare Science, John Dalton Building, Manchester Metropolitan University, UK (Mark Slevin).
- ▶ Atherothrombosis Research Unit, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, USA (Juan José Badimon).
- ▶ Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, University of Talca, Chile (Ivan Palomo).

Active Grants

- ▶ Lina Badimon. Safer and faster evidence-based translation (SAFE-T). European Commission. 115003, IMI-JU. Duration: Sept 2009-June 2015.
- ▶ Lina Badimon, Gemma Vilahur. Biomarker for cardiovascular risk assessment in Europe (BiomarCaRe). European Commission GA 278913, FP7. Duration: Oct 2011-Oct 2015.
- ▶ Gemma Vilahur. Functional and molecular effects of different HDL forms in myocardial remodelling post-infarction: application of a systems biology approach to identify regulated genes and gene products. National Plan for Scientific Research and Technological Development. SAF2012-40208. Duration: Jan 2013-Dec 2015.
- ▶ Gemma Arderiu. Peripheral vascular disease and angiogenesis: role of tissue factor in the stabilization of neovessels. ISCIII Project. PI12/02332. Duration: Jan 2013-Dec 2015.
- ▶ Lina Badimon. Cell Therapy Network (TerCel). ISCIII Project. RD12/0019/0026. Duration: Jan 2013-Dec 2017.
- ▶ Lina Badimon. Cardiovascular Research Network (RIC). ISCIII Project. RD12/0042/0027. Duration: Jan 2013-Dec 2017.
- ▶ Gemma Vilahur G. Functional and molecular effects of different HDL constituents on cardiac remodelling post myocardial infarction: magnetic resonance assessment and identification of molecular targets modulated by HDL. Sociedad Española de Cardiología. Duration: Oct 2012-Dec 2014.
- ▶ Lina Badimon. Proteomic characterization of intracoronary thrombus in STEMI patients, Fundación Española de Trombosis y Hemostasia (FETH). Duration: Jan 2013-Dec 2014.
- ▶ Lina Badimon. Ticagrelor: does it afford cardioprotection in the setting of acute myocardial infarction? Astra Zeneca AB. Duration: June 2013-Dec 2014.
- ▶ Lina Badimon. Comparative study of fibrin adhesives by confocal microscopy. Grifols Institute, SA. Duration: Oct 2013-Mar 2014.
- ▶ Lina Badimon. Transcriptomic profile of cardiac markers and endothelial function in humans: effect from the moderate consumption of Beer. Beer and Health Information Centre. Duration: Nov 2013-Mar 2016.

Grants Awarded in 2014

- ▶ Lina Badimon. Ajuts de suport als Grups de Recerca de Catalunya, AGAUR 2014 SGR 1303. Duration: Jan 2014-Dec 2016.
- ▶ Lina Badimon. Earch of new targets to inhibit the transformation of silent atherosclerosis into ischemic syndromes: tissue factor mediated angiogenic switch. National Plan for Scientific Research and Technological Development. SAF2013-42962-R. Duration: Jan 2014-Dec 2016.

Awards

- ▶ Lina Badimon. "Rey Jaime I" Prize to Clinical Research (Generalitat de València) Valencia, Spain (November 2014).
- ▶ Sonia Espinosa. Young Investigation Award. 23rd Biennial International Congress on Thrombosis 2014. Valencia, Spain (5/14/2014 to 5/17/2014).
- ▶ Gemma Chiva. ImmunoTools Special Award 2014 (Germany, May 2014).
- ▶ Gemma Chiva. Extraordinary Doctoral Award (curs 2012/2013). Faculty of Medicine, Universitat de Barcelona (June 2014).
- ▶ Judit Cubedo. Massachusetts Institute of Technology (MIT) review Award. Winner of Innovator under 35 in Spain (Madrid, November 2014).

Theses

- ▶ Rosa Suades Soler. Role of microparticles in atherothrombosis. Universitat Pompeu Fabra. Directors: Lina Badimon, Teresa Padró. Date of defense: 21 November 2014.

Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases

*TIF: 176.9240 **MIF: 4.7817

Scientific Production

Aledo R., Costales P., Ciudad C., Noe V., Llorente-Cortes V., Badimon L., Molecular and functional characterization of LRP1 promoter polymorphism c.1-25 C>G (rs138854007). (2014) *ATHEROSCLEROSIS*, 233 (1), 178-185.

IF: 3.9940

Alonso R., Andres E., Mata N., Fuentes-Jimenez F., Badimon L., Lopez-Miranda J., Padro T., Muniz O., Diaz-Diaz J.L., Mauri M., Ordovas J.M., Mata P., Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation. (2014) *J AM COLL CARDIOL*, 63 (19), 1982-1989.

IF: 16.5030

Arderiu G., Espinosa S., Pena E., Aledo R., Badimon L., Monocyte-secreted Wnt5a interacts with FZD 5 in microvascular endothelial cells and induces angiogenesis through tissue factor signaling. (2014) *J MOL CELL BIOL*, 6 (5), 380-393.

IF: 6.7710

Arderiu G., Pena E., Badimon L., Angiogenic Microvascular Endothelial Cells Release Microparticles Rich in Tissue Factor That Promotes Postischemic Collateral Vessel Formation. (2014) *ARTERIOSCL THROM VAS*, 35 (2), 348-357.

IF: 6.0000

Badimon L., Vilahur G., Experimental cell therapy: The search for the best stem cell continues. (2014) *J AM COLL CARDIOL*, 64 (16), 1695-1697.

IF: 16.5030

Badimon L., Vilahur G., HDL particles – more complex than we thought. (2014) *THROMB HAEMOSTASIS*, 112 (5), 857.

IF: 4.9840

Badimon L., Vilahur G., Thrombosis formation on atherosclerotic lesions and plaque rupture. (2014) *J INTERN MED*, 276 (6), 618-632.

IF: 6.0630

Bendjama K., Guionaud S., Aras G., Arber N., Badimon L., Bamberger U., Bratfalean D., Brott D., David M., Doessegger L., Firat H., Gallas J.-F., Gautier J.-C., Hoffmann P., Kraus S., Padro T., Saadoun D., Szczyzny P., Thomann P., Vilahur G., Lawton M., Cacoub P., Translation strategy for the qualification of drug-induced vascular injury biomarkers. (2014) *TOXICOL PATHOL*, 42 (4), 658-671.

IF: 2.1370

Borrell-Pages M., Romero J.C., Badimon L., LRP5 negatively regulates differentiation of monocytes through abrogation of Wnt signalling. (2014) *J CELL MOL MED*, 18 (2), 314-325.

IF: 4.014

Brugaletta S., Cola C., Martin-Yuste V., Vilahur G., Oriol J., Padro T., Guerra J.M., Borrás R., Badimon L., Sabate M., Qualitative and quantitative

accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. (2014) *INT J CARDIOVAS IMAG*, 30 (3), 469-476.

IF: 1.8100

Bugiardini R., Badimon L., Manfrini O., Boytsov S., Bozidarka K., Daullxhiu I., Dilic M., Dorobantu M., Erglis A., Gafarov V., Gale C.P., Goncalvesova E., Goudev A., Gustiene O., Hall A., Karpova I., Kedev S., Manak N., Milicic D., Ostojic M., Parkhomenko A.N., Popovici M., Studenkan M., Toth K., Trninic D., Vasiljevic Z., Zakke I., Zaliunas R., Vaccarino V., Goudev A., Erglis A., Zaliunas R., Gustiene O., Knezevic B., Dorobantu M., Ojstic M., Studenkan M., Manak N., Lovric M., Korac R., Mandic D., Vujo-ovic V., Blagojevic M., Milekic J., Trendafilova E., Somleva D., Krivokapic L., Rajovic G., Sahmanovic O., Saranovic M., Radoman C., Tomic S.C., Ljubic V., Velickovic M., Radojicic S., Arsenescu-Georfescu C., Garbea S., Radu C., Olinic D., Calin P., Chifor A., Babes K., Lonescu D.D., Craiu E., Petrescu H., Magda I., Luminita S., Benedek I., Marinescu S., Tiberiu N., Gheorghe G., Malaescu I., Trocan N., Doina D., Putnikovic B., Arandjelovic A., Nikolic N.M., Zdravkovic M., Saric J., Radovanovic S., Matic I., Srbliak N., Davidovic G., Simovic S., Zivkovic S., Petkovic-Curic S., Perspectives: Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional Countries) project. (2014) *EUR HEART J SUPPL*, 16 (SUPPLA), A1-A6.

IF: 15.8000

Bugiardini R., Manfrini O., Stakic M.M., Cenko E., Boytsov S., Merkely B., Becker D., Dilic M., Vasiljevic Z., Koller A., Badimon L., Exploring in-hospital death from myocardial infarction in Eastern Europe: From the international registry of acute coronary syndromes in transitional countries (ISACS-TC); on the behalf of the working group on coronary pathophysiology & microcirculation of the European Society of Cardiology. (2014) *CURR VASC PHARMACOL*, 12 (6), 903-909.

IF: 2.9660

Castellano J., Badimon L., Llorente-Cortes V., Amyloid- β increases metallo- and cysteine protease activities in human macrophages. (2014) *J VASC RES*, 51 (1), 58-67.

IF: 2.9010

Chiva-Blanch G., Badimon L., Estruch R., Latest Evidence of the Effects of the Mediterranean Diet in Prevention of Cardiovascular Disease. (2014) *CURR ATHEROSCLER REP*, 16 (10), 446.

IF: 3.4170

Covel CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. (2014) *THROMBOSIS AND HAEMOSTASIS*, 111(3), 385-391.

IF: 4.984

Cubedo J., Padro T., Badimon L., Glycoproteome of human apolipoprotein A-I: N- and O-glycosylated forms are increased in patients with acute myocardial infarction. (2014) *TRANSL RES*, 164 (3), 209-222.

IF: 5.0300

Cubedo J., Padro T., Cinca J., Mata P., Alonso R., Badimon L., Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. (2014) *EUR J CLIN INVEST*, 44 (3), 266-275.

IF: 2.7340

De Gonzalo-Calvo D., Llorente-Cortes V., Orbe J., Paramo J.A., Badimon L., Altered atherosclerotic-related gene expression signature in circulating mononuclear leukocytes from hypercholesterolemic patients with low HDL cholesterol levels. (2014) *INT J CARDIOL*, 173 (2), 337-338.

IF: 4.0360

Ferrer-Lorente R., Bejar M.T., Badimon L., Notch signaling pathway activation in normal and hyperglycemic rats differs in the stem cells of visceral and subcutaneous adipose tissue. (2014) *STEM CELLS DEV*, 23 (24), 3034-3048.

IF: 3.7270

Ferrer-Lorente R., Bejar M.T., Tous M., Vilahur G., Badimon L., Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: Effects on differentiation potential and function. (2014) *DIABETOLOGIA*, 57 (1), 246-256.

IF: 6.6710

Knezevic B., Vasiljevic Z., Music L., Krivokapic L., Ljubic V., Tomic S.C., Omer S., Radojicic S., Radoman C., Rajovic G., Riger L., Saranovic M., Velickovic M., Rajic D., Zivkovic S., Lasica R., Bankovic-Milenkovic N., Ljubica D., Jovanovic D., Jelica M., Radakovic G., Zdravkovic M., Ricci B., Manfrini O., Martelli I., Koller A., Badimon L., Bugiardini R., Management of heart failure complicating acute coronary syndromes in Montenegro and Serbia. (2014) *EUR HEART J SUPPL*, 16 (SUPPLA), A61-A66.

IF: 1.0000

Kozarov E., Padro T., Badimon L., View of statins as antimicrobials in cardiovascular risk modification. (2014) *CARDIOVASC RES*, 102 (3), 362-374.

IF: 5.9400

Llorente-Cortes V., De Gonzalo-Calvo D., Orbe J., Paramo J.A., Badimon L., Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells. (2014) *EUR J CLIN INVEST*, 44 (6), 539-548.

IF: 2.7340

Manfrini O., Dorobantu M., Vasiljevic Z., Kedev S., Knezevic B., Milicic D., Dilic M., Trninic D., Daullxhiu I., Gustiene O., Ricci B., Martelli I., Cenko E., Koller A., Badimon L., Bugiardini R.,

*TIF: 176.9240 **MIF: 4.7817

Scientific Production

Acute coronary syndrome in octogenarian patients: Results from the international registry of acute coronary syndromes in transitional countries (ISACS-TC) registry. (2014) EUR HEART J SUPPL, 16 (SUPPL.A), A87-94
IF: 1.0000

Nasarre L, Juan-Babot O, Gastellurrutia P, Lluçia-Valdeperas A, Badimon L, Bayes-Genis A, Llorente-Cortes V, Low density lipoprotein receptor-related protein 1 is upregulated in epicardial fat from type 2 diabetes mellitus patients and correlates with glucose and triglyceride plasma levels. (2014) ACTA DIABETOLOGICA, 51 (1), 23-30.
IF: 2.3990

Roura S, Cal R, Galvez-Monton C, Revuelta-Lopez E, Nasarre L, Badimon L, Bayes-Genis A, Llorente-Cortes V, Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: Potential impact in ventricular remodeling. (2014) INT J CARDIOL, 176 (3), 805-814.
IF: 4.0360

Ryden L, Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., Deaton C., Escaned J., Hammes H.-P., Huikuri H., Marre M., Marx N., Mellbin L., Ostergren J., Patrono C., Seferovic P., Uva M.S., Taskinen M.-R., Tendera M., Tuomilehto J., Valensi P., Zamorano J.L., Badimon L., ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). (2014) DIABETES VASC DIS RE, 11 (3), 133-173.
IF: 2.8290

Samouillan V, Revuelta-Lopez E, Dandurand J, Nasarre L, Badimon L, Lacabanne C, Llorente-Cortes V, Cardiomyocyte intracellular cholesteryl ester accumulation promotes tropoelastin physical alteration and degrada-

tion: Role of LRP1 and cathepsin S. (2014) INT J BIOCHEM CELL B, 55, 209-219.
IF: 4.0460

Santos-Gallego C.G., Badimon L, Badimon J.J., Perspectives: Direct and specific inhibition of factor Xa: An emerging therapeutic strategy for atherothrombotic disease. (2014) EUR HEART J SUPPL, 16 (SUPPL.A), A56-60.
IF: 1.0000

Tous M., Ferrer-Lorente R, Badimon L, Selective inhibition of sphingosine kinase-1 protects adipose tissue against LPS-induced inflammatory response in Zucker diabetic fatty rats. (2014) AM J PHYSIOL-ENDOC M, 307 (5), E437-E446.
IF: 3.7850

Trnincic D., Dilic M., Vasiljevic Z., Kulic M., Srdic S., Dobrijevic N., Sabanovic-Bajramovic N., Begic A., Kukavica N., Vukcevic V., Davidovic G., Panic G., Saric J., Zrnic M., Matic I., Trifunovic N., Martelli I., Cenko E., Manfrini O., Koller A., Badimon L., Bugiardini R., Clinical profile of patients with no-reperfusion therapy in Bosnia and Herzegovina and Serbia. (2014) EUR HEART J SUPPL, 16 (SUPPL.A), A67-A73.
IF: 1.0000

Vasiljevic Z., Krljanac G., Davidovic G., Panic G., Radovanovic S., Mickovski N., Srdljak N., Markovic-Nikolic N., Curic-Petkovic S., Panic M., Cenko E., Manfrini O., Martelli I., Koller A., Badimon L., Bugiardini R., Gender differences in case fatality rates of acute myocardial infarction in Serbia. (2014) EUR HEART J SUPPL, 16 (SUPPL.A), A48-A55.
IF: 1.0000

Vilahur G., Badimon J.J., Bugiardini R., Badimon L., Perspectives: The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide. (2014) EUR HEART J SUPPL, 16 (SUPPL.A), A7-A11.
IF: 1.0000

Vilahur G., Casani L., Mendieta G., Lamuela-Raventos R.M., Estruch R., Badimon L., Beer

elicits vasculoprotective effects through Akt/eNOS activation. (2014) EUR J CLIN INVEST, 44 (12), 1177-1188.
IF: 2.7340

Vilahur G., Casani L., Pena E., Juan-Babot O., Mendieta G., Crespo J., Badimon L., HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. (2014) INT J CARDIOL, 175 (3), 528-538.
IF: 4.0360

Vilahur G., Cubedo J., Padro T., Casani L., Juan-Babot O., Crespo J., Bendjama K., Lawton M., Badimon L., Roflumilast-induced local vascular injury is associated with a coordinated proteome and microparticle change in the systemic circulation in pigs. (2014) TOXICOL PATHOL, 43 (4), 569-580.
IF: 2.1370

Windecker S., Kolh P., Alfonso F., Collet J.-P., Cremer J., Falk V., Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G., Neumann F.-J., Richter D.J., Schauerte P., Uva M.S., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W., Witkowski A., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Lancellotti P., Linhart A., Nihoyanopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Achenbach S., Pepper J., Anyanwu A., Badimon L., Bauersachs J., Baumhauer A., Beygui F., Bonaros N., De Carlo M., Dobrev D., Dunning J., Eeckhout E., Gielen S., Luckraz H., Mahrholdt H., Montalescot G., Paparella D., Rastan A.J., Sanmartin M., Sergeant P., Silbe S.R., Tamargo J., Ten Berg J., Thiele H., Van Geuns R.-J., Wagner H.-O., Wassmann S., Wendler O., Zamorano J.L., 2014 ESC/EACTS Guidelines on myocardial revascularization. (2014) EUR HEART J, 35 (37), 2541-2619.
IF: 15.2030

Other Publications

- ▶ Badimon L., Mendieta G., Vilahur G., Gene Expression, Atherogenesis, and the Mediterranean Diet. (2014) The Mediterranean Diet: An Evidence-Based Approach, 367-378.
- ▶ Badimon L., Mendieta G., Vilahur G., The mechanisms of action of new antiplatelet agents. How do they work? (2014) REVISTA ESPANOLA DE CARDIOLOGIA SUPLEMENTOS, 14 (S1), 3-9.
- ▶ Garcia-Gomez C., Bianchi M., De la Fuente D., Badimon L., Padro T., Corbella E., Pinto X., Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?. (2014) WORLD JOURNAL OF ORTHOPAEDICS, 5 (3), 304-311.

- ▶ Slevin M., Baldellou M., Hill E., Alexander Y., McDowell G., Murgatroyd C., Carroll M., Degens H., Krupinski J., Rovira N., Chowdhury M., Serracino-Inglott F., Badimon L., Novel methods for accurate identification, isolation, and genomic analysis of symptomatic microenvironments in atherosclerotic arteries. (2014) METHODS IN MOLECULAR BIOLOGY, 1135, 289-305.

*Total Impact Factor **Mean Impact Factor


Inflammation and Vascular Remodelling

Coordinator

Cristina Rodríguez ICCC
crodriguez@csic-iccc.org

Members

Silvia Aguiló ICCC
María Galán HSCSP IR
Estefanía Segalés ICCC
Saray Varona ICCC



Main Lines of Research

- ▶ Inflammation and vascular remodelling: regulation of vascular homeostasis by extracellular matrix components and modifying enzymes.
- ▶ Molecular and cellular mechanisms in atherosclerosis: identification of new therapeutic targets.
- ▶ Molecular basis of abdominal aortic aneurysm (AAA): new pharmacological strategies.
- ▶ Epigenetics in cardiovascular diseases.

Challenges

- ▶ Identify new therapeutic targets, progression markers and biomarkers in atherosclerosis and AAA.
- ▶ Establish genetically modified animal models that could become useful disease models in atherosclerosis and AAA.
- ▶ Expand and consolidate the scientific staff.
- ▶ Increase regular funding through national and international calls.
- ▶ Set up new stable collaborations within IIB Sant Pau and with national and international groups and consolidate those already established.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Angiology, Vascular Biology and Inflammation (PI: Luis Vila).
- ▶ Regulation of Cardiac Rhythm and Contraction (PI: Leif Hove-Madsen).
- ▶ Atherosclerosis and Vascular Biology (PI: José Martínez González).

External Collaborations

- ▶ Jain K. Mukesh. Case Western Reserve University School of Medicine (Cleveland, Ohio, USA).
- ▶ Mark Slevin. Manchester Metropolitan University (United Kingdom).
- ▶ Nadia Mercader. Universidad de Berna (Switzerland).
- ▶ Vicente Andrés. Centro Nacional de Investigaciones Cardiovasculares (Spain).

- ▶ José Manuel Redondo. Centro Nacional de Investigaciones Cardiovasculares (Spain).
- ▶ Jesús Egido. Fundación Jiménez Díaz (Madrid, Spain).
- ▶ Jesús Osada. CIBEROBN, Universidad de Zaragoza (Spain).
- ▶ Manel Vázquez Carrera. CIBERDEM, Universitat de Barcelona (Spain).
- ▶ Mercedes Salaices. Universidad Autónoma de Madrid (Spain).
- ▶ Victoria Cachafeiro. Universidad Complutense de Madrid (Spain).
- ▶ Francisco Marín. Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia (Spain).
- ▶ Jerzy Krupinski. Hospital Mútua Universitària de Terrassa (Barcelona, Spain).
- ▶ Francisco Sánchez. Hospital de la Princesa (Madrid, Spain).

Active Grants	<ul style="list-style-type: none"> ▶ Cristina Rodríguez Sinovas. Mecanismos epigenéticos implicados en el remodelado de la matriz extracelular asociado al aneurisma de aorta abdominal: nuevas estrategias terapéuticas. Instituto de Salud Carlos III. PI12/01952. Duration: 2013-2015. €153,065.* ▶ José Martínez González. Red de Investigación Cardiovascular (RIC). MINECO-ISCIII. RD12/0042/0053. Duration: 2013-2016. €205,000.* 	<ul style="list-style-type: none"> ▶ Maria Galán Arroyo. Ayudas para Contratos Postdoctorales de Perfeccionamiento Sara Borrell 2012. FIS12/00589. Duration: 2013-2016. <p>Note: Total amount granted to PI. It does not include indirect costs.</p> <p>* Grants applied for by other research institutes.</p>
---------------	--	---

Awards	<ul style="list-style-type: none"> ▶ Martí-Pàmies I, Calvayrac O, Ferrán B, Aguiló S, Rodríguez C, Martínez-González J. Modulación de la migración de las CMLV por vitronectina: estudios de regulación transcripcional. Special mention. XXVII Congreso de la Sociedad Española de Aterosclerosis. Barcelona, February 2014. 	<ul style="list-style-type: none"> ▶ Miana M, Galán M, Martínez-Martínez E, Varona S, Jurado-López R, Martínez-González J, Rodríguez C, Cachofeiro V. La inhibición de la lisil oxidasa mejora las alteraciones metabólicas y del tejido adiposo en animales obesos. Special mention. XXVII Congreso de la Sociedad Española de Aterosclerosis. Barcelona, February 2014.
--------	--	--

*TIF: 8.9690 **MIF: 4.4845

Scientific Production	<p>Orriols M., Guadall A., Galan M., Marti-Pamies I., Varona S., Rodriguez-Calvo R., Briones A.M., Navarro M.A., de Diego A., Osada J., Martinez-Gonzalez J., Rodriguez C., Lysyl oxidase (LOX) in vascular remodelling: Insight from a new animal model. (2014) THROMB HAEMOSTASIS, 112 (4), 812-824. IF: 4.9840</p>	<p>Shatat M.A., Tian H., Zhang R., Tandon G., Hale A., Fritz J.S., Zhou G., Martinez-Gonzalez J., Rodriguez C., Champion H.C., Jain M.K., Hamik A., Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension. (2014) AM J RESP CELL MOL, 50 (3), 647-653. IF: 3.9850</p>
-----------------------	--	--

Other Publications	<ul style="list-style-type: none"> ▶ Rodriguez-Calvo R., Guadall A., Calvayrac O., Alonso J., Ferran B., Marti I., Navarro M.T., De Diego A., Osada J., Rodriguez C., Martinez-Gonzalez J., The nuclear receptor NOR-1 regulates the activation of vascular cells and vascular remodelling in response to hemodynamic stress. (2014) CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 26 (2), 66-75.
--------------------	---

Biomarkers for Cardiovascular Disease

Coordinator

Teresa Padró ICCIC
tpadro@csic-iccc.org

Members

M. Dolores Fernández ICCIC
Maisa Inés García ICCIC
Montserrat Gómez-Pardo ICCIC
Esther Peña ICCIC
Mónica Pescador ICCIC
Ilaia Ramaola ICCIC
Rosa Suades ICCIC



Main Lines of Research

- ▶ Identification of new biomarkers of atherothrombosis and ischaemic heart disease with potential use in diagnosis and prognosis research is based on cell culture studies, animal models of cardiovascular disease and human samples of patients with coronary heart disease risk factors.

Challenges

- ▶ Advance research aiming to identify and characterize new biomarkers of vascular injury, atherothrombotic disease and/or ischaemic, coronary and cerebrovascular syndromes using postgenomic techniques.
- ▶ Generate new information on potential soluble biomarkers (in serum, plasma) and in microparticles circulating in blood, as well as in blood and/or vascular cells studies include proteomic and lipidomic techniques based on liquid chromatography and bidimensional electrophoresis, antibody array systems and mass spectrometry (MALDI-ToF/ToF; linear ion trap).
- ▶ Validate biomarkers identified in the diagnosis and prognosis of cardiovascular and/or cerebrovascular disease using specific quantitative techniques (confocal microscope, ELISA, multiplex assays, etc).
- ▶ Characterize molecular and functional mechanisms for selected biomarkers in cardiovascular pathology (biology of systems).
- ▶ Consolidate the lipidomic platform.
- ▶ Lead the Biobank in the SAFE-T European project.

Collaborations

External Collaborations

- ▶ Department of Cardiology, Thorax Institute, Hospital Clínic, University of Barcelona, Spain (Salvatore Brugaletta, Victoria Martín-Yuste, Clarissa Cola, Manel Sabaté).
- ▶ Fundación Jiménez Díaz, Madrid (Rodrigo Alonso, Pedro Mata).
- ▶ Red TERCEL.
- ▶ Member of IIB Sant Pau Biobank External Committee.
- ▶ Member of IIB Sant Pau Training Committee.
- ▶ Member of the Local Organizing Committee of the Congress of the MLTD (Valencia, 2014).

Theses

- ▶ Rosa Suades Soler. Role of microparticles in atherothrombosis. Universitat Pompeu Fabra. Directors: Lina Badimon, Teresa Padró. Date of defense: 21 November 2014.

Active Grants

- ▶ Teresa Padró. Safer and faster evidence-based translation (SAFE-T). European Commission. 115003, IMI-JU. Duration: Sept 2009-June 2015.
- ▶ Teresa Padró. Biomarker for Cardiovascular Assessment in Europe (BiomarCaRE). FP7-Health-2011/ GA 278913. Duration: Oct 2011-Oct 2016.
- ▶ Teresa Padró. Patología molecular y celular de la arterioesclerosis: papel regulador de la matriz extracelular. ISCIII Project. PI13/02850. Duration: Jan 2014-Dec 2016.
- ▶ Teresa Padró. Proteomic characterization of intracoronary thrombus in STEMI patients. Fundación Española de Trombosis y Hemostasia (FETH). Duration: Jan 2013-Dec 2014.
- ▶ Teresa Padró. Cell Therapy Network (TerCel), RD12/0019/0026, ISCIII Project. Duration: Jan 2013-Dec 2017.

Grants Awarded in 2014

- ▶ Teresa Padró. Proyecto de investigación traslacional en cardiología. Sociedad Española de Cardiología. 2014.

*TIF: 57.0020 **MIF: 5.1820

Scientific Production

Alonso R., Andres E., Mata N., Fuentes-Jimenez F., Badimon L., Lopez-Miranda J., Padro T., Muniz O., Diaz-Diaz J.L., Mauri M., Ordovas J.M., Mata P., Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation. (2014) *J AM COLL CARDIOL*, 63 (19), 1982-1989.
IF: 16.5030

Arderiu G., Espinosa S., Pena E., Aledo R., Badimon L., Monocyte-secreted Wnt5a interacts with FZD 5 in microvascular endothelial cells and induces angiogenesis through tissue factor signaling. (2014) *J MOL CELL BIOL*, 6 (5), 380-393.
IF: 6.7710

Arderiu G., Pena E., Badimon L., Angiogenic Microvascular Endothelial Cells Release Microparticles Rich in Tissue Factor That Promotes Postischemic Collateral Vessel Formation. (2014) *ARTERIOSCL THROM VAS*, 35 (2), 348-357.
IF: 6.0000

Bendjama K., Guionaud S., Aras G., Arber N., Badimon L., Bamberger U., Bratfalean D., Brott D., David M., Doessegger L., Firat H., Gallas J.-F., Gautier J.-C., Hoffmann P., Kraus S., Padro T., Saadoun D., Szczesny P,

Thomann P., Vilahur G., Lawton M., Cacoub P., Translation strategy for the qualification of drug-induced vascular injury biomarkers. (2014) *TOXICOL PATHOL*, 42 (4), 658-671.
IF: 2.1370

Brugaletta S., Cola C., Martin-Yuste V., Vilahur G., Oriol J., Padro T., Guerra J.M., Borras R., Badimon L., Sabate M., Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. (2014) *INT J CARDIOVAS IMAG*, 30 (3), 469-476.
IF: 1.8100

Cubedo J., Padro T., Badimon L., Glycoproteome of human apolipoprotein A-I: N- and O-glycosylated forms are increased in patients with acute myocardial infarction. (2014) *TRANSL RES*, 164 (3), 209-222.
IF: 5.0300

Cubedo J., Padro T., Cinca J., Mata P., Alonso R., Badimon L., Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. (2014) *EUR J CLIN INVEST*, 44 (3), 266-275.
IF: 2.7340

Kozarov E., Padro T., Badimon L., View of statins as antimicrobials in cardiovascular

risk modification. (2014) *CARDIOVASC RES*, 102 (3), 362-374.
IF: 5.9400

Munoz-Torrero J.F.S., Rivas M.D., Zamorano J., Alonso R., Joya-Vazquez P., Padro T., Mata P., Rs1801275 Interleukin-4 receptor alpha polymorphism in familial hypercholesterolemia. (2014) *J CLIN LIPIDOL*, 8 (4), 418-422.
IF: 3.9040

Vilahur G., Casani L., Pena E., Juan-Babot O., Mendieta G., Crespo J., Badimon L., HMG-CoA reductase inhibition prior reperfusion improves reparative fibrosis post-myocardial infarction in a preclinical experimental model. (2014) *INT J CARDIOL*, 175 (3), 528-538.
IF: 4.0360

Vilahur G., Cubedo J., Padro T., Casani L., Juan-Babot O., Crespo J., Bendjama K., Lawton M., Badimon L., Roflumilast-induced local vascular injury is associated with a coordinated proteome and microparticle change in the systemic circulation in pigs. (2014) *TOXICOL PATHOL*, 43 (4), 569-580.
IF: 2.1370

IF: 2.1370

Other Publications

- ▶ Garcia-Gomez C., Bianchi M., De la Fuente D., Badimon L., Padro T., Corbella E., Pinto X., Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship? (2014) *WORLD JOURNAL OF ORTHOPAEDICS*, 5 (3), 304-311.

Atherosclerosis and Vascular Biology

Coordinator

José Martínez ICCC
jmartinez@csic-iccc.org

Members

Beatriz Ferran ICCC
Ingrid Martí ICCC
Maria del Mar Orriols ICCC
Ricardo Rodríguez ICCC



Main Lines of Research

- ▶ Identification and characterization of master genes involved in the onset, development and complication of ischaemic heart disease (IHD), abdominal aortic aneurysm (AAA) and cardiac hypertrophy.
- ▶ Mechanisms involving nuclear receptors in IHD, AAA and cardiac hypertrophy.
- ▶ Identification and validation of new targets for diagnosis, prognosis and treatment of cardiovascular diseases.
- ▶ Development of new (genetically modified) animal models for IHD, AAA and cardiac hypertrophy.

Challenges

- ▶ Incorporate new PhD and postdoctoral students as well as staff investigators to preserve the core group and implement new technical expertise and experimental approaches.
- ▶ Find affinities with other IIB Sant Pau groups in order to increase critical mass and implement joint strategies to optimize resources and access to alternative funding sources.
- ▶ Consolidate present relationships with national collaborators and expand our international collaborations.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Inflammation and Vascular Remodelling (PI: Cristina Rodríguez).
- ▶ Angiology, Vascular Biology and Inflammation (PI: Luis Vila).
- ▶ Regulation of Cardiac Rhythm and Contraction (PI: Leif Hove-Madsen).

External Collaborations

- ▶ José Luis de la Pompa. Centro Nacional de Investigaciones Cardiovasculares, CNIC.
- ▶ Jain K. Mukesh. Case Western Reserve University School of Medicine, Cleveland.
- ▶ Mark Slevin. Manchester Metropolitan University.
- ▶ Jerzy Krupinski. Hospital Mútua Universitària de Terrassa.
- ▶ Francisco Marín. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia.
- ▶ Jesús Osada. Universidad de Zaragoza.

- ▶ Mercedes Salaices. Universidad Autónoma de Madrid, UAM.
- ▶ Vicente Andrés García. Centro Nacional de Investigaciones Cardiovasculares, CNIC.
- ▶ Juan Miguel Redondo. Centro Nacional de Investigaciones Cardiovasculares, CNIC.
- ▶ Victoria Cachafeiro. Universidad Complutense de Madrid, UCM.
- ▶ Jose Luis Martín Ventura. Fundación Jiménez Díaz-UAM.
- ▶ Francisco Sánchez Madrid. Hospital de la Princesa-UAM.
- ▶ Manuel Vázquez Carrera. Universidad de Barcelona.

Active Grants

- ▶ José Martínez González. Mecanismos celulares y moleculares que involucran al receptor nuclear NOR-1 en enfermedades cardiovasculares. MINECO. SAF2012-40127. Duration: 2013-2015. €169,400.*
- ▶ José Martínez González. Red de Investigación Cardiovascular (RIC). MINECO-ISCIII. RD12/0042/0053. Duration: 2013-2016. €205,000.*
- ▶ José Martínez González. Análisis de las propiedades anti-inflamatorias del receptor nuclear NOR-1 en la cardiopatía isquémica (FEC/SEC-2012). Fundación Española del Corazón (FEC)-Sociedad Española de Cardiología (SEC). Duration: 2013-2014. €18,000.*

Note: Total amount granted to PI. It does not include indirect costs.
* Grants applied for by other research institutes.

Awards

- ▶ Martí Pàmies I, Calvayrac O, Ferrán B, Aguiló S, Rodríguez C, Martínez-González J. Modulación de la migración de las CMLV humanas por vitronectina: estudios de regulación transcripcional. Special mention. XXVII Congreso Nacional de la Sociedad Española de Arteriosclerosis. Barcelona 2014.
- ▶ Miana M, Galán M, Martínez-Martínez E, Varona S, Jurado López R, Martínez-González J, Rodríguez C, Cachofeiro V. La inhibición de la Lisil Oxidasa mejora las alteraciones metabólicas y del tejido adiposo en animales obesos. Special mention. XXVII Congreso Nacional de la Sociedad Española de Arteriosclerosis. Barcelona 2014.

*TIF: 8.9690 **MIF: 4.4845

Scientific Production

Orriols M., Guadall A., Galan M., Martí-Pamies I., Varona S., Rodríguez-Calvo R., Briones A.M., Navarro M.A., de Diego A., Osada J., Martínez-Gonzalez J., Rodríguez C., Lysyl oxidase (LOX) in vascular remodelling: Insight from a new animal model. (2014) THROMB HAEMOSTASIS, 112 (4), 812-824. **IF: 4.9840**

Shatat M.A., Tian H., Zhang R., Tandon G., Hale A., Fritz J.S., Zhou G., Martínez-Gonzalez J., Rodríguez C., Champion H.C., Jain M.K., Hamik A., Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension. (2014) AM J RESP CELL MOL, 50 (3), 647-653. **IF: 3.9850**

Other Publications

- ▶ Rodríguez-Calvo R., Guadall A., Calvayrac O., Alonso J., Ferran B., Martí I., Navarro M.T., De Diego A., Osada J., Rodríguez C., Martínez-Gonzalez J., The nuclear receptor NOR-1 regulates the activation of vascular cells and vascular remodelling in response to hemodynamic stress. (2014) CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 26 (2), 66-75.

Regulation of Cardiac Rhythm and Contraction

Coordinator

Leif Hove-Madsen
lhove@csic-iccc.org

ICCC

Members

Cristina Espinosa
Carmen Tarifa

HSCSP
ICCC



Main Lines of Research

- ▶ Receptor-mediated changes in intracellular calcium homeostasis in atrial fibrillation.
- ▶ Contribution of genetic variants to electrical remodelling and arrhythmogenesis.
- ▶ Effects of development and ageing on calcium handling in cardiac myocytes.
- ▶ Functional effects of lipid accumulation in cardiomyocytes.

Challenges

- ▶ The goal is to consolidate the group as a reference in research on calcium handling in atrial fibrillation and to establish it within other lines of research by including emerging technology and fields of research. Specifically we aim to:
 - Develop computational tools and models to improve the analysis and understanding of intracellular calcium handling in cardiac myocytes.
 - Incorporate emerging technology such as stretching and measurements of force development in single cardiomyocytes.
- Consolidate current national and international collaborations and establish new strategic collaborations within emerging fields of research such as the use of super-resolution fluorescence imaging (STORM, STED-techniques), the detection and role of Reactive Oxygen Species in diseased cardiomyocytes, and the role of telomere length in cardiac senescence and regeneration.
- Achieve international funding for incorporation of scientific expertise and participation in multidisciplinary international research projects.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Clinical and Translational Cardiology (PI: Juan Cinca)
- ▶ Lipids and Cardiovascular Pathology (PI: Vicenta Lorente)
- ▶ Atherosclerosis and Vascular Biology (PI: José Martínez)

National Collaborations

- ▶ Diego Franco, Amelia Aranega. Departamento de Biología Experimental, Universidad de Jaén.
- ▶ Blas Echebarria. Departament de Física Aplicada, Universitat Politècnica de Catalunya.
- ▶ Raul Benitez. Enginyeria de Sistemes, Automàtica i Informàtica Industrial, Universitat Politècnica de Catalunya.

- ▶ Vicente Andrés. Fisiopatología Cardiovascular Molecular y Genética, CNIC.

- ▶ Ignacio Flores. Regeneración y envejecimiento, CNIC.

International Collaborations

- ▶ SR Wayne Chen. Department of Physiology and Pharmacology, University of Calgary, Canada.
- ▶ Glen F Tibbits. Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby & Child and Family Research Institute, Vancouver, Canada.
- ▶ Edwin Moore. Cardiovascular Research Group, University of British Columbia, Vancouver, Canada.

Active Grants

- ▶ Leif Hove-Madsen. Functional cellular bases of PITX2 involvement in human atrial fibrillation. Ministerio de Ciencia y Tecnología. CNIC2009-08. Duration: Jul 2011-May 2015. €187,000.*
- ▶ Leif Hove-Madsen. Effects of atrial fibrillation on the distribution and frequency of spontaneous calcium release events in human atrial myocytes. Ministerio de Ciencia y Tecnología. SAF2011-30312. Duration: Jan 2012-Jul 2015. €181,500.*
- ▶ Leif Hove-Madsen. Cristina Espinosa Molina. European Union, Marie Curie FP7-PEOPLE-2012_I EF. Duration: Apr 2013-Mar 2015. €166,000.*
- ▶ Cinca J. Red de Investigación Cardiovascular. Instituto de Salud Carlos III. RD12/0042/0002. Duration: Jan 2014-Dec 2017.*
- ▶ Leif Hove-Madsen. Grup de Recerca Emergent: Anàlisi i Control del Ritme Cardíac AGAUR 2014. SGR 1465. Duration: 2014-2017. €22,000.*

Note: Total amount granted to PI. It does not include indirect costs.

*Grants applied for by other research institutes.

***TIF: 6.9440 **MIF: 3.4720**

Scientific Production

Lin E., Ribeiro A., Ding W., Hove-Madsen L., Sarunic M.V., Beg M.F., Tibbits G.F., Optical mapping of the electrical activity of isolated adult zebrafish hearts: Acute effects of temperature. (2014) AM J PHYSIOL-REG I, 306 (11).
IF: 3.1060

Lugo C.A., Cantalapiedra I.R., Penaranda A., Hove-Madsen L., Echebarria B., Are SR Ca content fluctuations or SR refractoriness the key to atrial cardiac alternans?: Insights from a human atrial model. (2014) AM J PHYSIOL-HEART C, 306 (11).
IF: 3.8380

Other Publications

- ▶ Dan P, Zeng Z, Li Y, Qu Y, Hove-Madsen L, Tibbits GF. Phenotype-dependent role of the L-type calcium current in embryonic stem cell derived cardiomyocytes. AM J STEM CELLS. 2014 Mar 13;3(1): 37-45.

Lipids and Cardiovascular Pathology

Coordinator

Vicenta Llorente-Cortes ICCC
cllorente@csic-iccc.org

Members

David de Gonzalo HSCSP RI
Laura Nasarre ICCC
Elena Revuelta Pérez ICCC



Main Lines of Research

- ▶ Molecular mechanisms involved in the modulation of LRP1 by cardiovascular risk factors.
- ▶ Impact of LRP1 on vascular and myocardial cholesterol accumulation.
- ▶ Impact of lipoproteins on LRP1-Intracellular signal pathways under normoxic and hypoxic conditions.
- ▶ Alterations in LRP1 expression and LRP1-intracellular signal pathways in hypoxia/ischaemia in in vitro and in vivo models.
- ▶ Lipids and diabetic cardiomyopathy.
- ▶ Lipids and breast cancer.
- ▶ LRP1 and inflammation.
- ▶ Circulating non-coding RNAs as biomarkers of cardiovascular disease.
- ▶ Role of non-coding RNAs in vascular lipid accumulation.
- ▶ Role of non-coding RNAs in myocardial lipid accumulation.

Challenges

- ▶ Develop transgenic mice with tissue-specific LRP1 modulation to proceed to in-depth analysis of LRP1-dependent mechanisms.
- ▶ Maintain and amplify relationship with IIB Sant Pau groups regarding translation in this research area.
- ▶ Maintain and strengthen international collaborations to set up future applications for European funding.
- ▶ Establish collaborations with companies with the aim of developing new products useful for prognosis, diagnosis and treatment.

Research Networks

- ▶ RD12/0042/0027. Red de Investigación Cardiovascular RIC. Programa 1: Research Programme on Adverse Ventricular Remodeling (Coordinator: Francisco Fernández-Avilés). 01.2013-12.2015.

Awards

- ▶ David de Gonzalo Calvo. Merck Serono Research Award in Cardiometabolism 2014, Foundation 2000. 29 March 2014.

Patents

- ▶ Vicenta Llorente-Cortés, Lina Badimon (inventors). LRP1 as a crucial receptor for the transfer of cholesteryl esters from VLDL to ischemic myocardium. PCT/ES2012/070483: patented in USA, in revision in Europe. Consejo Superior de Investigaciones Científicas and Institut Català de Ciències Cardiovasculars.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Cardiovascular Biochemistry (PI: Jordi Ordóñez)
- ▶ Regulation of Cardiac Rhythm and Contraction (PI: Leif Hove-Madsen)
- ▶ Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases (PI: Lina Badimon)
- ▶ Clinical and Translational Cardiology (PI: Juan Cinca)
- ▶ Metabolic Bases of Cardiovascular Risk (PI: Francisco Blanco)
- ▶ Molecular Bases of Disease (PI: Pablo Fuentes)
- ▶ Clinical Oncology (PI: Agustí Barnadas)
- ▶ Oncogenesis and Antitumour Drug (PI: Ramon Mangués)
- ▶ Enrique Lerma (researcher of Molecular Pathology of Gineacologic Cancer)
- ▶ Lluís Guirado (researcher at Fundació Puigvert)

National Collaborations

- ▶ Dr. Bayés-Genís. Grupo ICREC (Insuficiencia Cardíaca y Regeneración Cardíaca). Hospital Germans Trias i Pujol. Badalona.
- ▶ Marta Casado Pinna. Unidad de Patología Médica Experimental. Consejo Superior de Investigaciones Científicas. Valencia.
- ▶ Francisco Tinahones. Endocrinology Department, Biomedical Research Laboratory. Hospital Virgen de la Victoria, Málaga.

- ▶ Eduardo Iglesias Gutiérrez. Grupo ITS (Intervenciones Translocionales para la Salud). Universidad de Oviedo.
- ▶ Rocío Toro. Departamento de Medicina. Facultad de Medicina, Universidad de Cádiz.

International Collaborations

- ▶ Colette Lacabanne & Valerie Samouillan. Group Physique des Polymères, Institut Carnot, CIRIMAT, Université Paul Sabatier. Toulouse, France.
- ▶ Max Bown. Vascular Surgery group. Department of Cardiovascular Sciences University of Leicester, New England.
- ▶ Fulvia Ortolani. Department of Experimental Clinical Medicine. Università degli Studi di Udine. Italy.
- ▶ Gustavo Alberto Chiabrando. CIBICI-CONICET/FCQ-Universidad Nacional de Córdoba, Argentina.
- ▶ Claudia Huesca Gómez. Departamento de Biomedicina Cardiovascular. Instituto Nacional de Cardiología "Ignacio Chávez". México D.F.

Other Collaborations

- ▶ InnoPharma BioFarma-USEF Research Group. University of Santiago de Compostela.
- ▶ Teresa Tarragó. Iproteos. Parc Científic. Barcelona. Spain.

Active Grants

International Research Projects

- ▶ Vicenta Llorente-Cortés. Estudio de los aspectos moleculares y celulares que regulan el tráfico intracelular del receptor de la alfa 2-Macroglobulina, LRP1, y sus implicancias en el control de la migración celular. CONICET-CSIC 2013; PICT-2012-2607. Duration: 01.06.2013-30.05.2016. €29,728.*

National Research Projects

- ▶ Vicenta Llorente Cortés. Ajuts de suport als Grups de Recerca de Catalunya. AGAUR 2014. SGR 170. Duration: 2014-2016.*
- ▶ Vicenta Llorente-Cortés. Interferència de l'acumulació de lípids al sistema cardiovascular mitjançant peptidomimètics LRP1: Una nova estratègia terapèutica a la cardiomiopatia. AGAUR. Convocatòria d'ajuts per a projectes innovadors amb potencial d'incorporació al sector productiu (LLAVOR). 2014 LLAV 00001. Duration: 20/03/15-31/11/15. €25,000.*

- ▶ Vicenta Llorente-Cortés. Myocardial cholesteryl ester accumulation, LRP1 and cardiac dysfunction in type 2 diabetes. FIS PI14/01729. Duration: 01/09/14-01/09/17. €110,715.*
- ▶ David de Gonzalo Calvo. Regulation of LRP1 receptor gene expression by microRNAs; a new therapeutic target in the treatment of atherosclerosis? Basic Research Award, Atherosclerosis Spanish Foundation (FEA), Atherosclerosis Spanish Society (SEA) 2013. Duration: 01/01/14-31/12/15. €9,000.*
- ▶ David de Gonzalo Calvo. Identification of miRNAs implicated in the formation of "foam cells" in vascular cells: pathophysiological mechanism and therapeutic potential. Merck Serono Research Award in Cardiometabolism 2014, Foundation 2000. Duration: 30/06/14-01/07/16. €25,000.*

Note: Total amount granted to PI. It does not include indirect costs.

* Grants applied for by other research institutes.

Grants Awarded in 2014

- ▶ David de Gonzalo Calvo. Contratos Sara Borrell 2014. FIS. CD14/00109. €280,598.

Note: Total amount granted to PI. It does not include indirect costs.

Lipids and Cardiovascular Pathology

*TIF: 28.1820 **MIF: 3.5228

Scientific Production

Aledo R., Costales P., Ciudad C., Noe V., Llorente-Cortes V., Badimon L., Molecular and functional characterization of LRP1 promoter polymorphism c.1-25 C>G (rs138854007). (2014) *ATHEROSCLEROSIS*, 233 (1), 178-185.

IF: 3.9940

Castellano J., Badimon L., Llorente-Cortes V., Amyloid- β increases metallo- and cysteine protease activities in human macrophages. (2014) *J VASC RES*, 51 (1), 58-67.

IF: 2.9010

De Gonzalo-Calvo D., Llorente-Cortes V., Orbe J., Paramo J.A., Badimon L., High triglyceride-low HDL cholesterol lipid profile is associated with a dysregulated gene expression in mononuclear leukocyte from hypercholesterolemic patients. (2014) *INT J CARDIOL*, 178 (1), 102-104.

IF: 4.0360

De Gonzalo-Calvo D., Llorente-Cortes V., Orbe J., Paramo J.A., Badimon L., Altered atherosclerotic-related gene expression signature in circulating mononuclear leukocytes from hypercholesterolemic patients with low HDL cholesterol levels. (2014) *INT J CARDIOL*, 173 (2), 337-338.

IF: 4.0360

Llorente-Cortes V., De Gonzalo-Calvo D., Orbe J., Paramo J.A., Badimon L., Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells. (2014) *EUR J CLIN INVEST*, 44 (6), 539-548.

IF: 2.7340

Nasarre L., Juan-Babot O., Gastelurrutia P., Lucia-Valldeperas A., Badimon L., Bayes-Genis A., Llorente-Cortes V., Low density lipoprotein receptor-related protein 1 is upregulated in epicardial fat from type 2 diabetes mellitus patients and correlates with glucose and triglyceride plasma levels. (2014)

ACTA DIABETOL, 51 (1), 23-30.

IF: 2.3990

Roura S., Cal R., Galvez-Monton C., Revuelta-Lopez E., Nasarre L., Badimon L., Bayes-Genis A., Llorente-Cortes V., Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: Potential impact in ventricular remodeling. (2014) *INT J CARDIOL*, 176 (3), 805-814.

IF: 4.0360

Samouillan V., Revuelta-Lopez E., Dandurand J., Nasarre L., Badimon L., Lacabanne C., Llorente-Cortes V., Cardiomyocyte intracellular cholesteryl ester accumulation promotes tropoelastin physical alteration and degradation: Role of LRP1 and cathepsin S. (2014) *INT J BIOCHEM CELL B*, 55 (1), 209-219.

IF: 4.0460

Other Publications

- ▶ David de Gonzalo-Calvo; Vicenta Llorente-Cortés. Low-density lipoprotein receptor-related protein 1 (LRP1) as a modulator of the vascular inflammatory response to modified LDL. *Biohelikon: Cell Biology* (ISSN: 2348-3741). 2, pp. a12. 2014.

AREA 2

Genetic, Metabolic Inflammatory Disease

80 Genetic Diseases

84 Metabolic Bases of Cardiovascular Risk

86 Inflammatory Diseases

88 Endocrinology, Diabetes and Nutrition

92 Pituitary Gland Disorders

94 Digestive Diseases



and ases

98 Microbiology and Infectious Diseases

104 Multi-organ Damage

108 Chronic Respiratory Diseases

112 Research Group in HIV and AIDS

Genetic Diseases

Coordinator

Montserrat Baiget Bastus HSCSP
mbaiget@santpau.cat

Members

Lissette Albelo HSCSP
 Laura Alias CIBERER
 Manel Baena HSCSP RI
 Maria Jesus Barcelo HSCSP
 Aleyda Benítez CIBERER
 Monica Cornet HSCSP
 Montserrat Domenech HSCSP
 María Pía Gallano HSCSP
 Lidia González CIBERER
 Ana Isabel Iturbe HSCSP
 Adriana Maria Lasa HSCSP
 Sara Moron HSCSP
 Elisabeth del Rio HSCSP
 María José Rodríguez
 Julia Salazar CIBERER
 Ana Sebío HSCSP
 Ivana Gabriela Sullivan HSCSP RI
 Adoración Vencesla HSCSP RI



Main Lines of Research

- ▶ Study of the clinical heterogeneity of genetic autosomal recessive transmission of waist dystrophy and autosomal dominant transmission.
- ▶ Spinal atrophy and SMN genes: 1.- studies of molecular pathology, disease mechanisms and SMN gene expression. 2.- Identification of modifying genes. 3.- study of biomarkers for validation processing in spinal muscular atrophy. 4.- study of the neuromuscular junction in human development.
- ▶ Hereditary breast cancer and BRCA mutations: 1. Identification of mutations and genetic variants. 2. Molecular characterization of Circulating tumor cells (CTCSS) through expression profiles in patients with breast cancer. 3. Analysis of free circulating tumor DNA (cfDNA) as a predictor of response to the treatment of breast cancer.
- ▶ Pharmacogenetics: adverse reactions to medications.
- ▶ Congenital coagulopathies: Molecular Pathology of haemophilias.
- ▶ Duchenne and Becker muscular dystrophy: molecular pathology of DMD gene.

Challenges

Pharmacogenetics

- ▶ Colorectal and lung cancer treatments.
- ▶ Chronic inflammatory disease treatment.
- ▶ HIV infection treatment.

Muscular Dystrophies

- ▶ Post-transcriptional regulation of the dystrophin gene using nonsense-mediated decay analysis in DNA from patients with Duchenne muscular dystrophy.
- ▶ Genes associated with new phenotypic forms of limb girdle muscular dystrophy.
- ▶ Workflow development for the analysis of DMD gene by NGS techniques.

Hereditary Breast/Ovarian Cancer

- ▶ DNA studies to classify DNA variants found in the BRCA genes as pathogenic or neutral.
- ▶ CTCs as prognostic markers in patients with locally advanced and disseminated breast cancer.
- ▶ Workflow development for the analysis of BRCA1 and BRCA2 genes by NGS techniques.

Hereditary Motor Neurone Diseases

- ▶ Development of neuromuscular junction studies in health and disease.
- ▶ Broadening of the spectrum of motor neuron diseases to include bulbar and spinal muscular atrophy, distal muscular atrophies and amyotrophic lateral sclerosis.

Theses

- ▶ Laura Alías Andreu. Anàlisi qualitativa i quantitativa dels gens SMN1 i SMN2. Universitat de Barcelona. Directors: Eduardo F. Tizzano, Cristina Fillats.
- ▶ Ana Sebío García. Estudios farmacogenéticos en el cáncer colorrectal: la vía del receptor del factor de crecimiento epidérmico. Universitat Autònoma de Barcelona. Directors: Montserrat Baiget, Agustí Barnadas. Date of defense: 21 November 2014.

Collaborations

External Collaborations

- ▶ Sara Moron López. Investigación traslacional en la atrofia muscular espinal: Modificadores del fenotipo, modelos de neurona motora a partir de iPSCs y patología del desarrollo neuromuscular. Ayudas CIBERER 2013 para el inicio de tesis doctorales en Enfermedades Raras. Duration: 01/03/13-28/02/14. €12,400.

Active Grants

- ▶ Montserrat Baiget Bastus. Ajuts de suport als Grups de Recerca de Catalunya. Grup de Genètica en Malalties Neurològiques. AGAUR 2009. SGR 1299. Duration: 04/08/09-30/04/14. €42,640.
- ▶ Montserrat Baiget Bastus. Estudios farmacogenéticos en el tratamiento del cáncer colorrectal con terapias biológicas. MINECO-ISCIII Project 2011. PI11/01711. Duration: 01/01/12-31/12/14. €56,636.
- ▶ M. Pia Gallano Petit. Elaboración de paneles de diagnóstico molecular en patología monogénica hereditaria mediante el sistema de nanofluidos y secuenciación masiva. MINECO-ISCIII Project 2011. PI11/02586. Duration: 01/01/12-31/12/14. €78,250.
- ▶ Eduardo Tizzano Ferrari. Investigación traslacional en la atrofia muscular espinal: Modificadores del fenotipo, modelos de neurona motora a partir de iPSCs y patología del desarrollo neuromuscular. MINECO-ISCIII Project 2011. PI11/02606. Duration: 01/01/12-31/12/14. €107,127.
- ▶ Montserrat Baiget Bastus. Estudio farmacogenético fase II randomizado para evaluar eficacia y seguridad del esquema FOLFIRI con altas dosis de irinotecán (FOLFIRIAD) en pacientes con cáncer colorrectal metastásico de acuerdo con el genotipo

UGT1A 1. Ministerio de Sanidad y Servicios Sociales e Igualdad: EC 2011. EC11-336. Duration: 01/01/12-30/06/15. €63,500.

- ▶ Eduardo Tizzano Ferrari. Modificadores del fenotipo en la atrofia muscular espinal: hacia una mejor caracterización de pacientes para futuros ensayos clínicos. X Convocatoria de Ayudas a la Investigación Médica 2013. FMM 2013-1. Duration: 08/10/13-08/10/15. €34,285.
- ▶ Ana Sebio García. FIS Postdoc Contract "RIO HORTEGA" 2011. CM11/00102. Duration: 30/01/12-30/01/14. €43,200.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Ana Sebio Garcia. Contratos Juan Rodés 2014. JR14/00006. €135,000.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 54.2440 **MIF: 3.6163

Scientific Production

Alias L., Barcelo M.J., Bernal S., Martinez-Hernandez R., Also-Rallo E., Vazquez C., Santana A., Millan J.M., Baiget M., Tizzano E.F., Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene. (2014) CLIN GENET, 85 (5), 470-475.
IF: 3.9310

Alias L., Bernal S., Barcelo M.J., Martinez-Hernandez R., Martinez E., Baiget M., Tizzano E.F., Analysis of the C9orf72 gene in spinal muscular atrophy patients. (2014) AMYOTROPH LAT SCL FR, 15 (7-8), 563-568.
IF: 2.4050

Alvarez-Satta M., Castro-Sanchez S., Pereiro I., Pineiro-Gallego T., Baiget M., Ayuso C., Valverde D., Overview of Bardet-Biedl syndrome in Spain: Identification of novel mutations in BBS1, BBS10 and BBS12 genes. (2014) CLIN GENET, 86 (6), 601-602.
IF: 3.9310

Bladen C.L., Thompson R., Jackson J.M., Garland C., Wegel C., Ambrosini A., Pisano P., Walter M.C., Schreiber O., Lusakowska A., Jedrzejska M., Kostera-Pruszczyk A., Van Der Pol L., Wadman R.I., Gredal O., Karaduman A., Topaloglu H., Yilmaz O., Matyushenko V., Rasic V.M., Kosac A., Karcagi V.,

Garami M., Herczegfalvi A., Monges S., Moresco A., Chertkoff L., Chamova T., Guegueltcheva V., Butoianu N., Craiu D., Kornigut L., Campbell C., Haberlova J., Strenkova J., Alejandro M., Jimenez A., Ortiz G.G., Enriquez G.V.G., Rodrigues M., Roxburgh R., Dawkins H., Youngs L., Lahdetie J., Angelkova N., Saugier-veber P., Cuisset J.-M., Bloetzer C., Jeannet P.-Y., Klein A., Nascimento A., Tizzano E., Salgado D., Mercuri E., Sejersen T., Kirschner J., Rafferty K., Straub V., Bushby K., Verschuuren J., Beroud C., Lochmuller H., Mapping the differences in care for 5,000 Spinal Muscular Atrophy

Genetic Diseases

*TIF: 54.2440 **MIF: 3.6163

Scientific Production

patients, a survey of 24 national registries in North America, Australasia and Europe. (2014) *J NEUROL*, 261 (1), 152-163.

IF: 3.3770

Dias M.M., Pignon J.-P., Karapetis C.S., Boige V., Glimelius B., Kweekel D.M., Lara P.N., Laurent-Puig P., Martinez-Balibrea E., Paez D., Punt C.J.A., Redman M.W., Toffoli G., Wadelius M., Mckinnon R.A., Sorich M.J., The effect of the UGT1A1 28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis. (2014) *PHARMACOGENOMICS J*, 14 (5), 424-431.

IF: 4.2290

Fernandez-Rozadilla C., Cazier J.B., Tomlinson I., Brea-Fernandez A., Lamas M.J., Baiget M., Lopez-Fernandez L.A., Cloufent J., Bujanda L., Gonzalez D., De Castro L., Hemminki K., Bessa X., Andreu M., Jover R., Xicola R., Llor X., Moreno V., Castells A., Castellvi-Bel S., Carracedo A., Ruiz-Ponte C., A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. (2014) *HUM GENET*, 133 (5), 525-534.

IF: 4.8240

Freixenet N., Moreno-Rosel M.S., Barcelo M.J., Serrano A., Paya M., Crespo L., Perez-Lucena M.J., Altes A., Baiget M., Felez J., Detection of hereditary hemochromatosis and biochemical iron overload in primary care: A multicenter case finding study in Spain. (2014) *AM J HEMATOL*, 89 (9), 940-940.

IF: 3.7980

Gutierrez-Enriquez S., Bonache S., Ruiz De Garibay G., Osorio A., Santamarina M., Ramon Y Cajal T., Esteban-Cardenosa E., Tenes A., Yanowsky K., Barroso A., Montalban G., Blanco A., Cornet M., Gadea N., Infante M., Caldes T., Diaz-Rubio E., Balmana J., Lasa A., Vega A., Benitez J., De La Hoya M., Diez O., About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. (2014) *INT J CANCER*, 134 (9), 2088-2097.

IF: 5.0850

Martin-Blanco A., Ferrer M., Soler J., Salazar J., Vega D., Andion O., Sanchez-Mora C., Arranz M.J., Ribases M., Feliu-Soler A., Perez V., Pascual J.C., Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. (2014) *J PSYCHIATR RES*, 57 (1), 34-40.

IF: 3.9570

Martinez-Hernandez R., Bernal S., Alias L., Tizzano E.F., Abnormalities in early markers of muscle involvement support a delay in myogenesis in spinal muscular atrophy. (2014) *J NEUROPATH EXP NEUR*, 73 (6), 559-567.

IF: 3.7970

Paez D., Gerger A., Zhang W., Yang D., Labonte M.J., Benhanim L., Kahn M., Lenz F., Lenz C., Ning Y., Wakatsuki T., Loupakis F., Lenz H.-J., Association of common gene variants in the WNT/ β -catenin pathway with colon cancer recurrence. (2014)

PHARMACOGENOMICS J, 14 (2), 142-150.**IF: 4.2290**

Real L.M., Neukam K., Herrero R., Guardiola J.M., Reiberger T., Rivero-Juarez A., Salazar J., Mandorfer M., Merino D., Soriano V., Rivero A., Macias J., Pineda J.A., Caruz A., IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians. (2014) *PLOS ONE*, 9 (4).

IF: 3.2340

Salazar J., Moya P., Altes A., Diaz-Torne C., Casademont J., Cerda-Gabarro D., Corominas H., Baiget M., Polymorphisms in genes involved in the mechanism of action of methotrexate: Are they associated with outcome in rheumatoid arthritis patients?. (2014) *PHARMACOGENOMICS*, 15 (8), 1079-1090.

IF: 3.2180

Sebio A., Paez D., Salazar J., Berenguer-Llargo A., Pare-Brunet L., Lasa A., Del Rio E., Tobena M., Martin-Richard M., Baiget M., Barnadas A., Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. (2014) *PHARMACOGENOMICS J*, 14 (3), 256-262.

IF: 4.2290

Other Publications

- ▶ Sullivan I., Salazar J., Majem M., Pallares C., Del Rio E., Paez D., Baiget M., Barnadas A., Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. (2014) *CANCER LETTERS*, 353 (2), 160-166.

Metabolic Bases of Cardiovascular Risk

Coordinator

Francisco Blanco HSCSP
fblancova@santpau.cat

Members

Lidia Cedo CIBERDEM
Juan Carlos Escola HSCSP RI
Josep Julve HSCSP RI
Teresa Laura HSCSP RI
Jesús María Martín HSCSP RI
Susana Martínez HSCSP
Carmen Mayoral HSCSP
Karen Alejandra Méndez HSCSP RI
Antonio Pérez HSCSP
Helena Quesada HSCSP RI
Rosa Roig HSCSP
Sheila Ruiz HSCSP RI
David Santos CIBERDEM
Edgar Zapico HSCSP



Main Lines of Research

- ▶ HDL and susceptibility to diabetes, arteriosclerosis and breast cancer: this relationship is being analysed through the study of metabolic disorders, genetic modification, and dietary or drug intervention.
- ▶ Genetic determinants of metabolic factors of cardiovascular risk: dyslipidaemia, type 2 diabetes, hyperhomocysteinaemia.
- ▶ Positive health effects of phytosterols.
- ▶ Development, validation and application of new clinical laboratory methods in the field of metabolic and cardiovascular medicine.

Challenges

- ▶ Analyse the effects of diabetes mellitus and hyperhomocysteinaemia in reverse cholesterol transport in vivo.
- ▶ Determine the pathogenic relevance of alterations in cholesterol metabolism in diabetic retinopathy.
- ▶ Compare the effects of niacine and fenofibrate in the HDL of patients with type 2 diabetes.
- ▶ Study anti-cancer mechanisms of HDL genetic modification and phytosterol consumption.
- ▶ Develop new molecular techniques to diagnose metabolic inherited diseases to be used in the clinical laboratory.

Active Grants

- ▶ Francisco Blanco Vaca. Funcionalidad de las lipoproteínas de alta densidad (HDL) y efectos pleiotrópicos en diabetes, retinopatía y cáncer de mama. MINECO-ISCI III Project 2011. PI11/01076. Duration: 01/01/12-31/12/14. €73,009.
 - ▶ Juan Carlos Escola Gil. Estrategias terapéuticas y nutricionales basadas en la mejora de las funciones antioxidante y antiinflamatoria de las HDL en la diabetes mellitus tipo 2 y el cáncer de mama. Proyectos de Investigación en Salud 2012. PI12/00291. Duration: 01/01/13-31/12/15. €164,000.
 - ▶ Josep Julve. Molecular studies of monogenic familial dyslipemias and construction of a diagnostic/prognosis criteria in mutation-negative patients with familial hypercholesterolemia. Contratos Miguel Servet 2013 - Tipo I. CP13/00070. Duration: 01/01/14-31/12/16. €121,500.
 - ▶ Teresa Laura Errico. MINECO-ISCI III Contracte Predoc formació 2012. FI12/00226. Duration: 01/09/12-31/08/16. €85,200.
 - ▶ Josep Julve Gil. Contratos Miguel Servet 2013 - Tipo I. MS13/00070. Duration: 01/01/2014-31/12/2018. €202,500.
 - ▶ Helena Quesada Vázquez. Ayudas para Contratos de Perfeccionamiento "Sara Borrell 2012". CD12/00533. Duration: 14/01/13-13/01/16. €75,600.
- Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded
in 2014

- ▶ Francisco Blanco Vaca. Avances en el diagnóstico molecular de pacientes con dislipemias hereditarias, con especial referencia a la base poligénica de algunas de ellas y a la hipercolesterolemia familiar. Proyectos de Investigación en Salud 2014. PI14/01648. €76,500.
- ▶ Karen Alejandra Méndez Lara. Estratègies terapèutiques i nutricionals basades en la milloria de les funcions antioxidant i antiinflamatòria de les lipoproteïnes d'alta densitat (HDL) en la

diabetis tipus 2 i el càncer de mama. Ajuts per contractar personal investigador novell any 2014 (FI-DGR). FI00171. Duration: 01/10/14-30/09/17. €18,146.88.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 44.6010 **MIF: 2.6236

Scientific Production

Alcantara-Aragon V., Martinez-Couselo S., Tundidor-Rengel D., Webb S.M., Carreras G., Espinos J.J., Chico A., Blanco-Vaca F., Corcoy R., Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis. (2014) HORM-INT J ENDOCRINO, 13 (4), 585-587.

IF: 1.1980

Amezaga N., Sanjurjo L., Julve J., Aran G., Perez-Cabezas B., Bastos-Amador P., Armengol C., Vilella R., Escola-Gil J.C., Blanco-Vaca F., Borrás F.E., Valledor A.F., Sarrias M.-R., Human scavenger protein AIM increases foam cell formation and CD36-mediated oxLDL uptake. (2014) J LEUKOCYTE BIOL, 95 (3), 509-520.

IF: 4.2890

Bullich G., Ballarin J., Oliver A., Ayasreh N., Silva I., Santin S., Diaz-Encarnacion M.M., Torra R., Ars E., HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. (2014) CLIN J AM SOC NEPHRO, 9 (2), 335-343.

IF: 4.6130

Escola-Gil J.C., Cedo L., Blanco-Vaca F., High-density lipoprotein cholesterol targeting for novel drug discovery: Where have we gone wrong? (2014) EXPERT OPIN DRUG DIS, 9 (2), 119-124.

IF: 3.5390

Escola-Gil J.C., Quesada H., Julve J., Martin-Campos J.M., Cedo L., Blanco-Vaca F., Sitos-terolemia: Diagnosis, investigation, and management. (2014) CURR ATHEROSCLER REP, 16 (7).

IF: 3.4170

Julve J., Pardina E., Perez-Cuellar M., Ferrer R., Rossell J., Baena-Fustegueras J.A., Fort J.M., Lecube A., Blanco-Vaca F., Sanchez-Quesada

J.L., Peinado-Onsurbe J., Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. (2014) ATHEROSCLEROSIS, 234 (1), 200-205.

IF: 3.9940

Krall P., Pineda C., Ruiz P., Ejarque L., Vendrell T., Camacho J.A., Mendizabal S., Oliver A., Ballarin J., Torra R., Ars E., Cost-effective PKHD1 genetic testing for autosomal recessive polycystic kidney disease. (2014) PEDIATR NEPHROL, 29 (2), 223-234.

IF: 2.8560

Martin-Campos J.M., Julve J., Roig R., Martinez S., Errico T.L., Martinez-Couselo S., Escola-Gil J.C., Mendez-Gonzalez J., Blanco-Vaca F., Molecular analysis of chylomicronemia in a clinical laboratory setting: Diagnosis of 13 cases of lipoprotein lipase deficiency. (2014) CLIN CHIM ACTA, 429 (1), 61-68.

IF: 2.8240

Minambres I., De Leiva A., Perez A., Hypovitaminosis D and metabolic syndrome. (2014) MED CLIN-BARCELONA, 143 (12), 542-547.

IF: 1.4170

Minambres I., Sanchez-Quesada J.L., Sanchez-Hernandez J., Rodriguez J., De Leiva A., Perez A., Vitamin D concentrations in familial combined hyperlipidemia: Effects of lipid lowering treatment. (2014) DIABETOL METAB SYNDR, 6 (1).

IF: 2.1730

Perez A., Jansen-Chaparro S., Saigi I., Bernal-Lopez M.R., Minambres I., Gomez-Huelgas R., Glucocorticoid-induced hyperglycemia. (2014) J DIABETES, 6 (1), 9-20.

IF: 1.9320

Perez A., Mediavilla J.J., Minambres I., Gonzalez-Segura D., Glycemic control in patients with type 2 diabetes mellitus in Spain. (2014)

REV CLIN ESP, 214 (8), 429-436.

IF: 1.0630

Perez A., Reales P., Barahona M.J., Romero M.G., Minambres I., Efficacy and feasibility of basal-bolus insulin regimens and a discharge-strategy in hospitalised patients with type 2 diabetes-the HOSMIDIA study. (2014) INT J CLIN PRACT, 68 (10), 1264-1271.

IF: 2.5660

Remacha A.F., Sarda M.P., Canals C., Queralto J.M., Zapico E., Remacha J., Carrascosa C., Role of serum holotranscobalamin (holoTC) in the diagnosis of patients with low serum cobalamin. Comparison with methylmalonic acid and homocysteine. (2014) ANN HEMATOLOG, 93 (4), 565-569.

IF: 2.6340

Remacha A.F., Zapico E., Sarda M.P., Rojas E., Simo M., Remacha J., Homs R., Queralto J.M., Immune complexes and persistent high levels of serum vitamin B12. (2014) INT J LAB HEMATOL, 36 (1), 92-97.

IF: 1.8190

Rico Santana N., Zapico Muniz E., Cocho D., Bravo Y., Delgado Mederos R., Marti-Fabregas J., Analysis of peptidome profiling of serum from patients with early onset symptoms of ischemic stroke. (2014) J STROKE CEREBROVASC, 23 (2), 235-240.

IF: 1.6690

Vinagre I., Sanchez-Quesada J.L., Sanchez-Hernandez J., Santos D., Ordonez-Llanos J., De Leiva A., Perez A., Inflammatory biomarkers in type 2 diabetic patients: Effect of glycemic control and impact of ldl sub-fraction phenotype. (2014) CARDIOVASC DIABETOL, 13 (1).

IF: 4.0150


Inflammatory Diseases

Coordinator

Cándido Juárez HSCSP
cjuarez@santpau.cat

Members

Manuela Agustí HSCSP
Oscar de la Calle HSCSP
Elisabeth Canto HSCSP RI
Carmen Hayles HSCSP
Laura Martínez HSCSP
María Ángeles Martínez HSCSP
María Esther Moga HSCSP
Juan Camilo Nieto HSCSP RI
María Àngels Ortíz HSCSP RI
Elena Pérez HSCSP
Luis Rodés HSCSP
María Victoria Rubiales HSCSP
María Teresa Sanz HSCSP RI
Silvia Vidal HSCSP RI
Carlos Zamora HSCSP RI



Main Lines of Research

- ▶ The role of the natural immune system in the development of autoimmune and inflammatory processes.
- ▶ Immunological response and clinical course in immunomodulator treatment.
- ▶ The role of autoantibodies, components of the adaptive immunity system, in the pathogenesis of autoimmune processes and their use as diagnostic and prognostic markers in these diseases.
- ▶ Mechanisms involved in immunodeficiency.
- ▶ Study of lymphocyte subpopulations involved in chronic graft rejection in cardiac posttransplant patients.

Challenges

- ▶ Role of cells and molecules of the innate immune response in the development and control of inflammatory processes, in the appearance of autoimmune phenomena, immunodeficiencies, infections, cardiovascular diseases and development of tumours.
- ▶ Role of TLR and STAT signalling in inflammatory diseases.
- ▶ Involvement of STAT family of transcription factors in response to superantigens.
- ▶ Study of mechanisms involved in immunodeficiency caused by alterations of the CD8a molecule.
- ▶ Role of perivascular adipocytes and TLR signalling pathways in the development of atherosclerosis.
- ▶ Inflammation and rejection in heart transplantation.
- ▶ Effects of immunobiological treatments on immunological variables.
- ▶ Analysis of the evolution of immunological parameters and their correlation with clinical response to treatment with immunomodulators.
- ▶ Effects of rituximab, tocilizumab and adalimumab in immunological variables and their correlation with the clinical response in patients with inflammatory diseases.

Theses

- ▶ Carlos Zamora Atenza. Anàlisi de l'expressió del receptor scavenger CD36 en els leucòcits: conseqüències funcionals en la inflamació. Universitat Autònoma de Barcelona. Director: Silvia Vidal Alcorisa.
- ▶ Consol Benaiges Martínez. Teixit adipós epicàrdic i senyalització a través dels receptors toll like (TLR): Paper en la patofisiologia de l'aterosclerosi. Universitat Autònoma de Barcelona. Director: Cándido Juárez Rubio.

Active Grants

- ▶ Oscar de la Calle Martín, Redirección de la especificidad de las células T contra péptidos del antígeno tumoral WT1 restringidos por la HLA-A2. Estudio preclínico traslacional. FIS Project 2009. PI09/0310. Duration: 01/01/10-30/06/14. €86,500.
- ▶ Juárez Rubio, Cándido. Mecanismos implicados en la acción del rtuximab en miastenia gravis: efecto diferencial sobre los autoanticuerpos anti-AchR y ANTI-MuSK. MINECO-ISCIII Project 2011. PI11/00927. Duration: 01/01/12-31/12/15. €66,500.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Vidal Alcorisa, Silvia. Estudio de la interacción entre el linfocito T y plaquetas: su aplicación en el desarrollo de una terapia celular para regular la respuesta inmune en la artritis reumatoide. Proyectos de Investigación en Salud 2014. PI14/00741. €41,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 41.2900 **MIF: 4.1290

Scientific Production

Canto E., Garcia Planella E., Zamora-Atenza C., Nieto J.C., Gordillo J., Ortiz M.A., Meton I., Serrano E., Vegas E., Garcia-Bosch O., Juarez C., Vidal S., Interleukin-19 impairment in active Crohn's disease patients. (2014) PLOS ONE, 9 (4).

IF: 3.2340

Cuenca S., Sanchez E., Santiago A., El Khader I., Panda S., Vidal S., Nieto J.C., Juarez C., Sancho F., Guarner F., Soriano G., Guarner C., Manichanh C., Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. (2014) J INNATE IMMUN, 6 (3), 263-271.

IF: 4.3520

Diaz-Torne C., Ortiz de Juana M.A., Geli C., Canto E., Laiz A., Corominas H., Casademont J., de Llobet J.M., Juarez C., Diaz-Lopez C., Vidal S., Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis. (2014) IMMUNOLOGY, 142 (3), 354-362.

IF: 3.7950

Gallardo E., Martinez-Hernandez E., Titulaer M.J., Huijbers M.G., Martinez M.A., Ramos A., Querol L., Diaz-Manera J., Ro-

jas-Garcia R., Hayworth C.R., Verschuuren J.J., Balice-Gordon R., Dalmau J., Illa I., Cortactin autoantibodies in myasthenia gravis. (2014) AUTOIMMUN REV, 13 (10), 1003-1007.

IF: 7.9330

Guillen-Gomez E., Guirado L., Belmonte X., Maderuelo A., Santin S., Juarez C., Ars E., Facundo C., Ballarin J.A., Vidal S., Diaz-Encarnacion M.M., Monocyte implication in renal allograft dysfunction. (2014) CLIN EXP IMMUNOL, 175 (2), 323-331.

IF: 3.0370

Labrador-Horrillo M., Martinez M.A., Selva-O'Callaghan A., Trallero-Araguas E., Grau-Junyent J.M., Vilardell-Tarres M., Juarez C., Identification of a novel myositis-associated antibody directed against cortactin. (2014) AUTOIMMUN REV, 13 (10), 1008-1012.

IF: 7.9330

Lopez-Pelayo H., Wallace P., Segura L., Miquel L., Diaz E., Teixido L., Baena B., Struzzo P., Palacio-Vieira J., Casajuana C., Colom J., Gual A., A randomised controlled non-inferiority trial of primary care-based facilitated access to an alcohol reduction website (EFAR Spain): The study protocol.

(2014) BMJ OPEN, 4 (12).

IF: 2.2710

Nieto J.C., Sanchez E., Roman E., Vidal S., Oliva L., Guarner-Argente C., Poca M., Torras X., Juarez C., Guarner C., Soriano G., Cytokine production in patients with cirrhosis and TLR4 polymorphisms. (2014) WORLD J GASTROENTERO, 20 (46), 17516-17524.

IF: 2.3690

Roman E., Torrades Ma.T., Nadal Ma.J., Cardenas G., Nieto J.C., Vidal S., Bascunana H., Juarez C., Guarner C., Cordoba J., Soriano G., Randomized pilot study: Effects of an exercise programme and leucine supplementation in patients with cirrhosis. (2014) DIGEST DIS SCI, 59 (8), 1966-1975.

IF: 2.6130

Zamora-Atenza C., Diaz-Torne C., Geli C., Diaz-Lopez C., Ortiz M.A., Moya P., Castellvi I., Nieto J.C., Canto E., Casademont J., Juarez C., Llobet J.M., Vidal S., Adalimumab regulates intracellular TNF α production in patients with rheumatoid arthritis. (2014) ARTHRITIS RES THER, 16 (4).

IF: 3.7530

- ▶ Fuentes-Finkelstein P., Barnadas M., Gelpi C., Puig L., Pemphigus herpetiformis with progression to pemphigus foliaceus: A case report. (2014) ACTAS DERMATO-SIFILIOGRAFICAS, 105 (5), 526-528.
- ▶ Gelpi C., Perez E., Roldan C., Efficiency of a solid-phase chemiluminescence immunoassay for detection of antinuclear and cytoplasmic autoantibodies compared with gold standard immunoprecipitation. (2014) AUTOIMMUNITY HIGHLIGHTS, 5 (2), 47-54.

- ▶ Labrador-Horrillo M., Martinez M.A., Selva-O'Callaghan A., Trallero-Araguas E., Balada E., Vilardell-Tarres M., Juarez C., Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. (2014) JOURNAL OF IMMUNOLOGY RESEARCH, 2014, 290797.

Other Publications

Endocrinology, Diabetes and Nutrition

Coordinator

Alberto de Leiva HSCSP
aleiva@santpau.cat

Researchers

Valeria Alcántara
Olga Bell CIBERBBN
Eulàlia Brugués HSCSP RI
Ana Chico HSCSP
Joel Cisneros
Rosa Corcoy HSCSP
José M. Cubero HSCSP
Cintia González HSCSP
Miguel Ángel María
Eugenia Mato CIBERBBN
Gabriela Monroy
Antonio Pérez HSCSP
Aleida Pujol
Diana Tundidor



Main Lines of Research

- ▶ Endocrine neoplasms: investigation of tumour dedifferentiation mechanisms through genomic, proteomic and bioinformatic procedures.
- ▶ Autoimmune diabetes mellitus (classic type 1 and LADA) and gestational diabetes.
- ▶ Telemedicine and intelligent systems for therapeutic optimization of diabetes mellitus.
- ▶ Prediction, prevention and optimization of the treatment of obesity, hyperlipidaemia, metabolic syndrome and complications.
- ▶ Diabetes and endocrine disorders in pregnancy.
- ▶ History of insulin: old and new controversies about the discovery of insulin.

Active Grants

- ▶ Alberto de Leiva Hidalgo. Ajuts de suport als Grups de Recerca de Catalunya. Grup Diabetis i Altres Malalties Endocrinològiques. AGAUR 2009. SGR 806. Duration: 17/09/09-30/04/14. €47,840.
- ▶ Rosa Corcoy Pla. Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention (DALI). 7th Framework Programme. HEALTH-F2-2009-242187. Duration: 01/03/10-31/12/15. €143,257.
- ▶ Cintia González Blanco. Intensificación y monitorización telemática personalizada de la modificación del estilo de vida en el tratamiento de la obesidad y la prevención del riesgo cardiometabólico. Proyectos de

Investigación en Salud 2012. PI12/00931. Duration: 01/01/13-31/12/15. €68,000.

- ▶ Miguel Ángel María María. Evaluación del impacto de la implantación de un programa de manejo de tratamiento de la hiperglucemia durante la hospitalización y al alta del paciente no crítico en un gran hospital con la inclusión de una enfermera consultora. III Ayuda Guido Ruffino de Investigación en Educación Terapéutica en Diabetes. Duration: 29/05/2013-30/11/2014. €5,455.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Alberto de Leiva Hidalgo. Grup de Recerca en Endocrinologia, Diabetis i Nutrició (ED-UAB-HSP). AGAUR 2014. SGR 569. Duration: 04/09/14-31/12/16. €50,000.
- ▶ Valeria Alcántara Aragón. Intensificación y monitorización telemática personalizada de la modificación del estilo de vida en el tratamiento de la obesidad y la prevención

del riesgo cardiometabólico (PREDIRCAM 2). Ajuts per contractar personal investigadors novells any 2014 (FI-DGR) 2014. FI00149. Duration: 01/03/14-28/02/17. €18,146.88.

Note: Total amount granted to PI. It does not include indirect costs.

Theses

- ▶ Irene Vinagre Torres. Biomarcadores de la inflamación en la diabetes mellitus tipo 2: efecto del control glucémico y del fenotipo de las LDL. Universitat Autònoma de Barcelona. Directors: Alberto de Leiva, Antonio Pérez. Date of defense: December 2014.

Challenges

Endocrine Neoplasms

- ▶ Molecular markers of the epithelial lineage: expression of the ABCG2 gene/BCRP1 transporter.
- ▶ Importance of thyroglobulin and antithyroglobulin antibodies as prognostic prediction markers in differentiated thyroid cancer of epithelial lineage.
- ▶ Transcriptomics and proteomics as prediction and prognosis instruments for epithelial thyroid cancer.
- ▶ Intramural CELL-NANO-THYROID project: investigation of human mesenchymal cell capacity as an instrument for administering anti-tumour cell drugs in the form of conjugated nanoparticles.

Autoimmune Diabetes Mellitus and Gestational Diabetes

- ▶ Classic type 1 autoimmune diabetes mellitus: discovery of genes that influence susceptibility to autoimmune diabetes (classic type 1).
- ▶ LADA type diabetes: prevalence of metabolic syndrome among patients with LADA compared to prevalence among patients with classic type 1 diabetes, type 2 diabetes and the general non-diabetic population in European countries.
- ▶ Diabetes and pregnancy: clinical research aimed at optimizing care for women with pre-gestational and gestational diabetes at different pre-conception, pregnancy, birth and postpartum stages.

Telemedicine and Intelligent Systems for Therapeutic Optimization of Diabetes Mellitus

- ▶ Development of a technological platform for the prediction, prevention and treatment of obesity, DM, HTA, dyslipidemia and cardiometabolic risk.

Optimization of the Treatment of Obesity, Hyperlipidaemia, Metabolic Syndrome and Complications

- ▶ Optimal treatment and prevention of cardiovascular risk associated with, obesity, hyperlipidaemia, metabolic syndrome and diabetes mellitus 2.

History of Insulin: Old and New Controversies about the Discovery of Insulin

- ▶ To demonstrate with documented evidence (heuristics) demonstrating that European research on the development of pancreatic extracts achieved beneficial results in the opotherapy of both experimental and clinical diabetes.
- ▶ Research into impaired glucose tolerance in women suffering from polycystic ovary syndrome.
- ▶ Acquisition of information to help assess the clinical and socioeconomic relevance of cardiometabolic risk.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Ramon Mangués).
- ▶ Ophthalmology (Fernando Rodríguez Álvarez).
- ▶ Cardiovascular Biochemistry (Jorge Ordóñez, José Luis Quesada, Francisco Blanco).
- ▶ General and Digestive Surgery (Antonio Moral, Ignacio Pérez).
- ▶ Reproductive Health (Juan Adelantado).

External Collaborations

CIBER-BBN

- ▶ Bioengineering and Telemedicine Group at the Universidad Politécnica de Madrid, Spain (GBT-UPM). PI: Enrique J. Gómez Aguilera.
- ▶ Biomedical Engineering Research Group at the Universidad de Sevilla, Spain (GIB-US). PI: Laura Roa Romero.

CELL-NANO-THYROID

- ▶ Molecular Oncology Group at HVH, PI: S. Schwartz, Jr.
- ▶ Development of New Drugs Group at the Universidad del País Vasco, Spain. PI: JL Pedraz.

CONCEPTT: Women with Type 1 Diabetes in Pregnancy Trial

- ▶ Sansum Diabetes Research Institute (SDRI). Santa Barbara (California) USA.

- ▶ University of Toronto, Mount Sinai Hospital, Department Endocrinology & Metabolism. Toronto, Canada.
- ▶ Dalhousie University, Staff Endocrinologist, Department of Medicine. Halifax, Canada.
- ▶ University of British Columbia, BC Women's Diabetes Pregnancy Service. Vancouver, Canada.
- ▶ McMaster University, Endocrinology/General Internal Medicine. Hamilton, Canada.
- ▶ University of Ottawa, The Ottawa Hospital, Division of Endocrinology and Metabolism. Ottawa, Canada.
- ▶ Sunnybrook Health Sciences Centre, Department of Endocrinology. Toronto, Canada.
- ▶ University of Western Ontario, Department of Medicine: Endocrinology & Metabolism. London, Ontario, Canada.
- ▶ Centre de Recherche du CHUL. Unité de recherche sur le diabète. Québec, Canada.
- ▶ McGill University, Department of Medicine, Division of Endocrinology & Metabolism, Metabolic Day Centre and Antenatal Clinic. Montréal, Canada.
- ▶ University of Calgary, Departments of Medicine and Obstetrics & Gynaecology. Calgary, Canada.
- ▶ Charles H. Best Diabetes Centre. Ajax, Canada.
- ▶ Yale University. Diabetes Clinic. New Haven, US.
- ▶ Tel-Aviv University, Helen Schneider Hospital for Women; Rabin Medical Center. ISRAEL

Endocrinology, Diabetes and Nutrition

Collaborations

- ▶ Universitat Autònoma de Barcelona. Hospital de la Santa Creu i Sant Pau. Servei d'Endocrinologia i Nutrició. Barcelona, Spain.
 - ▶ Health and Social Secretariat. Assembly of First Nations. Ottawa, Canada.
 - ▶ CIHR Institute of Aboriginal Peoples' Health. Ottawa, Canada.
 - ▶ Community Programs Directorate First Nations and Inuit Health Branch. Ottawa, Canada.
 - ▶ University of Western Ontario. Department of Epidemiology and Biostatistics and the Division of Endocrinology. London, Ontario, Canada.
 - ▶ Royal University Hospital. Department of Medicine. Saskatoon, Canada.
 - ▶ Sunnybrook Health Sciences Centre. Centre for Mother, Infant, and Child Research (CMICR). Toronto, Canada.
 - ▶ Jaeb Center for Health Research. Tampa, US.
 - ▶ University of Waterloo. Office of Research. Waterloo, Canada.
 - ▶ Juvenile Diabetes Research Foundation (JDRF). Canada.
 - ▶ Juvenile Diabetes Research Foundation International (JDRF). US.
 - ▶ JDRF Lay Review Committee Members (LRC).
 - ▶ JDRF Canadian Clinical Trial Network (CCTN).
- Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention (DALI)**
- ▶ Medizinische Universität Graz (MUG), Austria.
 - ▶ Medical Research Council (MRC), United Kingdom.
 - ▶ Medical University Vienna (MUV), Austria.
 - ▶ University Central Hospital (HUCH), Finland.
- ▶ Recherche en Santé Lawson S.A. (LAWSON), Switzerland.
 - ▶ Katholieke Universiteit Leuven (K.U.Leuven), Belgium.
 - ▶ Copenhagen University Hospital (CUH), Denmark.
 - ▶ Akademia Medyczna im Karola Marcinkowskiego (PUM), Poland.
 - ▶ BAP Health Outcomes Research (S.L. BAP), Spain.
 - ▶ Università degli studi di Padova (UNIPD), Italy.
 - ▶ National University of Ireland (NUI), Ireland.
 - ▶ Vrije Universiteit Medisch Centrum (VU), Netherlands.
- Action LADA European Consortium**
- ▶ David Leslie, Co-Ordinator, St. Bartholomew's Hospital, UK.
 - ▶ Rhys Williams and Mark Airey, Nuffield Institute for Health, UK.
 - ▶ Henning Beck-Nielsen, Odense University Hospital, Denmark.
 - ▶ David Hadden and Stephen Hunter, Royal Victoria Hospital, UK.
 - ▶ Umberto Di Mario, University of Rome "La Sapienza", Italy.
 - ▶ Werner Scherbaum and Jochen Seissler, University of Dusseldorf, Germany.
 - ▶ Hubert Kolb, Germany, University of Dusseldorf, Germany.
 - ▶ Guntram Scherthaner, Rudolfstiftung Hospital, Austria.
 - ▶ Jaakko Tuomilehto and Johan Eriksson, National Public Health Inst., Finland.
 - ▶ Alberto de Leiva, Hospital de Sant Pau, Spain.
 - ▶ Charles Thivolet, Hospital Edouard Herriot, France.
 - ▶ Type 1 Diabet Genetics European Network (ET1DGC), Asia-Pacific, North America and United Kingdom.

*TIF: 44.5170 **MIF: 2.7823

Scientific Production

Alcantara-Aragon V., Martinez-Couselo S., Tundidor-Rengel D., Webb S.M., Carreras G., Espinos J.J., Chico A., Blanco-Vaca F., Corcoy R., Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis. (2014) HORM-INT J ENDOCRINO, 13 (4), 585-587.

IF: 1.1980

Amor A.J., Halperin I., Alfayate R., Borrás V.M., Escribano A., Gonzalez C., Gutierrez A., Mauri M., Perez P., Pico A., Vourliotaki I., Oriola J., Identification of four novel mutations in the thyroid hormone receptor-β gene in 164 Spanish and 2 Greek patients with resistance to thyroid hormone. (2014) HORM-INT J ENDOCRINO, 13 (1), 74-78.

IF: 1.1980

Aulinas A., Ramirez M.-J., Barahona M.-J., Vallasi E., Resmini E., Mato E., Santos A., Crespo I., Bell O., Surrallés J., Webb S.M., Telomere length analysis in Cushing's syndrome. (2014) EUR J ENDOCRINOL, 171 (1), 21-29.

IF: 4.0690

Balsells M., Garcia-Patterson A., Gich I., Corcoy R., Ultrasound-guided compared to conventional treatment in gestational diabetes leads to improved birthweight but more insulin treatment: Systematic review and meta-analysis. (2014) ACTA OBSTET GYN SCAN, 93 (2), 144-151.

IF: 2.4260

Galjaard S., Pasman SA, Ameye L, Timmerman D, Devlieger R. on behalf of the DALI Core Investigator Group (Rosa Corcoy. Intima-media thickness measurements in the fetus and mother during pregnancy: a feasibility study. Ultrasound Med Biol. 2014 Sep;40(9):1949-57. doi:10.1016/j.ultrasmedbio.2014.02.018. Epub 2014 May 29. PubMed PMID: 24882524.

IF: 2.099

Gonzalez C., Aulinas A., Colom C., Tundidor D., Mendoza L., Corcoy R., Mato E., Alcantara V., Urgell Rull E., De Leiva A., Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma. (2014) CLIN ENDOCRINOL, 80 (2), 301-306.

IF: 3.4570

Hawa M.I., Kolb H., Schloot N., Beyan H., Paschou S.A., Buzzetti R., Mauricio D., De Leiva A., Yderstraede K., Beck-Neilsen H., Tuomilehto J., Sarti C., Thivolet C., Hadden D., Hunter S., Scherthaner G., Scherbaum W.A., Williams R., Brophy S., Pozzilli P., Leslie R.D., Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7 (Diabetes Care (2013) 36, (908-913)). (2014) DIABETES CARE, 37 (5), 1494.

IF: 8.4200

Inka Miñambres, Jose Luis Sánchez-Quesada, Irene Vinagre, Joan Sánchez-Hernández, Eulalia Urgell, Alberto de Leiva, Antonio Pérez. Hypovitaminosis D in type 2 diabetes: relation with features of the metabolic syndrome and glycemic control. Endocrine Research: 1-6. Posted online on December 23, 2014.

IF: 1.409

Julve J., Pardina E., Perez-Cuellar M., Ferrer R., Rossell J., Baena-Fustegueras J.A., Fort J.M., Lecube A., Blanco-Vaca F., Sanchez-Quesada J.L., Peinado-Onsurbe J., Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. (2014) ATHEROSCLEROSIS, 234 (1), 200-205.

IF: 3.9940

Mato E., Gonzalez C., Moral A., Perez J.I., Bell O., Lerma E., de Leiva A., ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).

(2014) J MOL ENDOCRINOL, 52 (3), 289-300.

IF: 3.0810

Minambres I., De Leiva A., Perez A., Hypovitaminosis D and metabolic syndrome. (2014) MED CLIN-BARCELONA, 143 (12), 542-547.

IF: 1.4170

Minambres I., Sanchez-Quesada J.L., Sanchez-Hernandez J., Rodriguez J., De Leiva A., Perez A., Vitamin D concentrations in familial combined hyperlipidemia: Effects of lipid lowering treatment. (2014) DIABETOL METAB SYNDR, 6 (1).

IF: 2.1730

Perez A., Jansen-Chaparro S., Saigi I., Bernal-Lopez M.R., Minambres I., Gomez-Huelgas R., Glucocorticoid-induced hyperglycemia. (2014) J DIABETES, 6 (1), 9-20.

IF: 1.9320

Perez A., Mediavilla J.J., Minambres I., Gonzalez-Segura D., Glycemic control in patients with type 2 diabetes mellitus in Spain. (2014) REV CLIN ESP, 214 (8), 429-436.

IF: 1.0630

Perez A., Reales P., Barahona M.J., Romero M.G., Minambres I., Efficacy and feasibility of basal-bolus insulin regimens and a discharge-strategy in hospitalised patients with type 2 diabetes-the HOSMIDIA study. (2014) INT J CLIN PRACT, 68 (10), 1264-1271.

IF: 2.5660

Vinagre I., Sanchez-Quesada J.L., Sanchez-Hernandez J., Santos D., Ordonez-Llanos J., De Leiva A., Perez A., Inflammatory biomarkers in type 2 diabetic patients: Effect of glycemic control and impact of ldl subfraction phenotype. (2014) CARDIOVASC DIABETOL, 13 (1).

IF: 4.0150

Other Publications

▶ Alcántara-Aragón V, Gonzalez C, Corcoy R, Ubeda J, Chico A. Carbohydrate-to-Insulin Ratio in a Mediterranean Population of Type 1 Diabetic Patients on Continuous Subcutaneous Insulin Infusion Therapy. J Diabetes Sci Technol. 2014 Dec 17. pii: 1932296814563571. [Epub ahead of print] PubMed PMID: 25519294.

▶ Alejandra de Leiva-Pérez, Eulalia Brugués, Alberto de Leiva. PREVENTION OF T2DM: eHEALTH. Diapedia (The Living Text Book of Diabetes). November 2014

▶ Chico A., Tundidor D., Jordana L., Saigi I., Maria M.A., Corcoy R., De Leiva A., Changes in insulin requirements from the onset of continuous subcutaneous insulin infusion (CSII) until optimization of glycemic control. (2014) Journal of Diabetes Science and Technology, 8 (2), 371-377.

▶ de Leiva Pérez, A., Brugués, E., de Leiva, A.. Prevention of T2DM: eHealth [internet]. 2014 Nov 6; Diapedia 0104770160 rev.o.11. Available from: <http://dx.doi.org/10.14496/dia.0104770160.11>

▶ Martin Vaquero P, Martinez-Brocca M.A, García-Lopez JM, en representación del Grupo de trabajo de Nuevas de Nuevas Tecnologías de la Sociedad Española de Diabetes. (Cintia González, Ana Chico). Documento de posicionamiento sobre la eficiencia de las tecnologías aplicadas al manejo de la diabetes. Av Diabetol 2014;30:131-49.

▶ Monografía GEDE (2014): Uso de fármacos en diabetes y embarazo. Grupo Español de Diabetes y Embarazo (SED, SEGO) (Rosa Corcoy, Ana Chico).

Pituitary Gland Disorders

Coordinator

Susan Webb HSCSP
swebb@santpau.cat

Members

Anna Aulinas HSCSP RI
M. Antònia Martínez CIBERER
Eugenia Resmini CIBERER
Olga Roig HSCSP RI
Eulalia Urgell HSCSP
Elena Valassi HSCSP RI



Main Lines of Research

- ▶ Morbimortality, low-grade inflammation and cardiovascular risk in patients with acromegaly or Cushing syndrome.
- ▶ ERCUSYN: European Registry on Cushing syndrome. Initiated with funding from SANCO, EU Public Health Programme.
- ▶ Neuroradiological, neuropsychological and clinical study of endogenous hypercortisolism: comparison of Cushing syndrome and chronic major depressive disorder.
- ▶ Validation of psychological properties of specific questionnaires to evaluate health-related quality of life (HRQoL) in Cushing syndrome and acromegaly.
- ▶ Study of signal transduction of GH in muscle by gene expression in a C2C12 cell line stimulated with GH.
- ▶ Aetiology of cardiopathy in acromegaly and its relation to body composition.
- ▶ Role of telomeres in endocrine diseases.

Challenges

- ▶ Investigate the neuropsychological, neuroradiological and clinical correlation of patients with endogenous hypercortisolism (due to Cushing syndrome or chronic major depressive disorder) or exogenous exposure to low-dose glucocorticoids (due to treatment of adrenal insufficiency or rheumatoid arthritis). Similar studies for acromegaly.
- ▶ Study gene expression in cultured muscle cells after exposure to GH using microarrays.
- ▶ Correlate neuropsychological status and circadian rhythm of cortisol in patients with hypercortisolism (Cushing syndrome) and without hypercortisolism (non-functioning pituitary adenomas) compared to normal controls.
- ▶ Evaluate long-term morbidity and mortality in patients who have had Cushing syndrome or acromegaly in the last 25 years.
- ▶ Analyse and update the European database of patients with Cushing syndrome (ERCUSYN), which at the end of 2013 included over 1100 patients from 57 centres in 36 countries.
- ▶ Conduct in vitro molecular analysis of operated pituitary adenomas within the RE-MAH (Molecular Registry of Pituitary Adenomas) study, sponsored by the Spanish Endocrinology and Nutrition Society.
- ▶ Investigate correlations of telomere length and different clinical and biochemical parameters in patients with Cushing syndrome.

Awards

- ▶ Maria Antonia Martínez Momblán. Impacto de un programa educativo para el paciente con síndrome de Cushing: Estudio Multicéntrico. Premi extraordinari de doctorat del curs 2013-2014.
- ▶ María-José Barahona, Eugenia Resmini, David Viladés, Guillem Pons-Lladó, Rubén Leta, Teresa Puig, Susan M. Webb. Coronary Artery Disease Detected by Multislice Computed Tomography in Patients After Long-Term Cure of Cushing's Syndrome. J Clin Endocrinol Metab 2013 Mar;98(3):1093-9. Premi Almirall 2014 de la SEEN.
- ▶ Anna Aulinas. Does hypercortisolism of Cushing's syndrome affect telomere length? European Society of Endocrinology Young Investigators Award. 16th European Congress of Endocrinology. Wrocław, Poland, 3-7 May 2014.

Active Grants

- ▶ Susan Webb Youdale. Etiopatogenia de la cardiopatia en la acromegalia y su relación con la composición corporal. MINECO-ISCI III Proyecto 2011. PI11/00001. Duration: 01/01/12-31/12/14. €164,227.
 - ▶ Susan Webb Youdale. Etiopatogenia de la cardiopatia en la acromegalia y su relación con la composición corporal. Merck Serono 2012. Duration: 04/06/12-04/06/15. €16.667.
 - ▶ Susan Webb Youdale. Contractes per a la intensificació de l'activitat investigadora en el SNS 2013. INT13/00248. Duration: 01/01/14-31/12/14. €30,000.
 - ▶ Elena Valassi. Subprograma Juan de la Cierva 2012. JLC-2012-13447. Duration: 01/12/13-30/11/16. €86,400.
- Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Webb Youdale, Susan. Estudio de microarquitectura y resistencia óseas y de factores que las determinan en el síndrome de Cushing o acromegalia en remisión. Modelo para investigar la interacción hueso-grasa corporal. Proyectos de Investigación en Salud 2014. PI14/00194. €91,500.
- Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 48.5800 **MIF: 4.0483

Scientific Production

- Aulinas A., Ramirez M.-J., Barahona M.-J., Valassi E., Resmini E., Mato E., Santos A., Crespo I., Bell O., Surralles J., Webb S.M., Telomere length analysis in Cushing's syndrome. (2014) EUR J ENDOCRINOL, 171 (1), 21-29.
IF: 4.0690
- Aulinas A., Webb S.M., Health-related quality of life in primary and secondary adrenal insufficiency. (2014) EXPERT REV PHARM OUT, 14 (6), 873-888.
IF: 1.6690
- Badia X., Valassi E., Roset M., Webb S.M., Disease-specific quality of life evaluation and its determinants in Cushing's syndrome: What have we learnt?. (2014) PITUITARY, 17 (2), 187-195.
IF: 3.2010
- Clemmons D.R., Molitch M., Hoffman A.R., Klibanski A., Strasburger C.J., Kleinberg D.L., Ho K., Webb S.M., Bronstein M.D., Bouillon R., Ben-Shlomo A., Hamrahian A.H., Chanson P., Barkan A.L., Merriam G.R., Blackman M.R., Salvatori R., Growth hormone should be used only for approved indications. (2014) J CLIN ENDOCR METAB, 99 (2), 409-411.
IF: 6.2090
- Crespo I., Esther G.-M., Santos A., Valassi E., Yolanda V.-G., De Juan-Delago M., Webb S.M., Gomez-Anson B., Resmini E., Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome. (2014) CLIN ENDOCRINOL, 81 (6), 826-833.
IF: 3.4570
- Crespo I., Webb S.M., Perception of health and cognitive dysfunction in acromegaly patients. (2014) ENDOCRINE, 46 (3), 365-367.
IF: 3.8780
- De Liano A.G., Reig O., Mellado B., Martin C., Rull E.U., Maroto J.P., Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. (2014) BRIT J CANCER, 110 (9), 2201-2208.
IF: 4.8360
- Gonzalez C., Aulinas A., Colom C., Tundidor D., Mendoza L., Corcoy R., Mato E., Alcantara V., Urgell Rull E., De Leiva A., Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma. (2014) CLIN ENDOCRINOL, 80 (2), 301-306.
IF: 3.4570
- Mo D., Blum W.F., Rosilio M., Webb S.M., Qi R., Strasburger C.J., Ten-year change in quality of life in adults on growth hormone replacement for growth hormone deficiency: An analysis of the hypopituitary control and complications study. (2014) J CLIN ENDOCR METAB, 99 (12), 4581-4588.
IF: 6.2090
- Santos A., Resmini E., Crespo I., Pires P., Vives-Gilabert Y., Granell E., Valassi E., Gomez-Anson B., Martinez-Momblan M.A., Mataro M., Webb S.M., Small cerebellar cortex volume in patients with active Cushing's syndrome. (2014) EUR J ENDOCRINOL, 171 (4), 461-469.
IF: 4.0690
- Sesnilo G., Resmini E., Bernabeu I., Aller J., Soto A., Mora M., Pico A., Fajardo C., Torres E., Alvarez-Escola C., Garcia R., Blanco C., Camara R., Gaztambide S., Salinas I., Pozo C.D., Castells I., Villabona C., Biagetti B., Webb S.M., Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. (2014) CLIN ENDOCRINOL, 81 (6), 883-890.
IF: 3.4570
- Webb S.M., Ware J.E., Forsythe A., Yang M., Badia X., Nelson L.M., Signorovitch J.E., McLeod L., Maldonado M., Zgliczynski W., De Block C., Portocarrero-Ortiz L., Gadelha M., Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease. (2014) EUR J ENDOCRINOL, 171 (1), 89-98.
IF: 4.0690

Other Publications

- ▶ Crespo I., Santos A., Resmini E., Valassi E., Martinez-Momblan M.A., Webb S.M., Improving quality of life in patients with pituitary tumors. (2014) US ENDOCRINOLOGY, 10 (1), 79-83.
- ▶ Miguel Novoa P.D., Vela E.T., Garcia N.P., Rodriguez M.M., Guerras I.S., Martinez de Salinas Santamaria M.D.L.T., Maso A.A., Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult. (2014) ENDOCRINOLOGIA Y NUTRICION, 61 (S1), 1-35.

Digestive Diseases

Coordinator

Carlos Guarner HSCSP
cguarner@santpau.cat

Members

Edilmar A. Alvarado HSCSP RI
Mercedes G. Blasi HSCSP
Xavier Cussó HSCSP
Bibiana Escuredo HSCSP
Antoni Farré HSCSP
Adolfo Gallego HSCSP
Esther García HSCSP
Cristina Gely HSCSP RI
Cristina Gómez HSCSP
Dolores González HSCSP
Jorge Gordillo HSCSP
Carlos Guarner Argente HSCSP
Patricia Huelin HSCSP
Jordina Llao HSCSP RI
Laura Marín HSCSP RI
Juan Camilo Nieto HSCSP RI
Maria Poca HSCSP
Eva María Román HSCSP RI
Sergio Sainz HSCSP
Elisabet Sánchez CIBEREHD
Germán Soriano HSCSP
Javier Torras HSCSP
Cándido Villanueva HSCSP



Main Lines of Research

Experimental research

- ▶ Experimental rat model of cirrhosis and ascites.
- ▶ Mechanisms and prevention of bacterial translocation in rats with cirrhosis.
- ▶ Experimental model of spontaneous and induced bacterial peritonitis: physiopathology and treatment.
- ▶ MiRNAs expression profile in inflammatory bowel disease after stimulation with toll-like receptor ligands.

Clinical investigation

- ▶ Physiopathology, diagnosis, treatment and prevention of bacterial infections, ascites and hepatorenal syndrome in cirrhosis.
- ▶ Diagnosis and treatment of hepatic encephalopathy in cirrhosis.
- ▶ Cognitive impairment, falls and quality of life in patients with cirrhosis.

- ▶ Physiopathology, diagnosis, treatment and prevention of digestive haemorrhage due to portal hypertension of non-varicose origin.
- ▶ Diagnosis and treatment of chronic hepatitis B and C.
- ▶ Diagnosis and treatment of hepatocarcinoma.
- ▶ Physiopathology, diagnosis and treatment of intestinal inflammatory disease (inflammatory bowel disease).
- ▶ Diagnosis and treatment in advanced gastrointestinal endoscopy.
- ▶ Diagnosis and treatment of acute pancreatitis.
- ▶ Prevention of acute post-ERCP pancreatitis.
- ▶ Chronic pancreatitis and pancreatic neoplasms: molecular studies, early detection and treatment.

Challenges

- ▶ Consolidate the CIBEREHD research group by studying complications in cirrhosis.
- ▶ Expand the hepatology research lab and develop new research.
- ▶ Consolidate the portal hypertension research group.
- ▶ Consolidate the pancreatic illness research line.
- ▶ Consolidate the inflammatory bowel disease research line.
- ▶ Consolidate the polyps and colon cancer research line.
- ▶ Develop a digestive endoscopy research line.

Collaborations

- ▶ Carlos Guarner Argente. Beca per a la intensificació de la recerca de la Societat Catalana de Digestologia (2014-2015).

Active Grants

- ▶ Germán Soriano Pastor. Relación de polimorfismos de toll-like receptors (TLR) TLR2, TLR4 y TLR9 con la incidencia de infecciones, la evolución de la enfermedad y la respuesta inflamatoria en pacientes cirróticos. FIS Project 2009. PI09/0357. Duration: 01/01/10-30/06/14. €56,500.
- ▶ Cándido Villanueva Sánchez. Prevención del desarrollo de hipertensión portal clínicamente significativa en la cirrosis compensada mediante vasodilatación hepática selectiva. Estudio multicéntrico, doble ciego, aleatorizado. FIS Project 2010. PI10/01552. Duration: 01/01/11-30/06/15. €93,000.
- ▶ Carlos Guarner Aguilar. Estudio clínico y experimental de traslocación bacteriana en la cirrosis mediante pirosecuenciación. MINECO-ISCI11 Project 2011. PI11/01026. Duration: 01/01/12-31/12/14. €62,600.
- ▶ Eva María Román. Estudio del síndrome de fragilidad en los pacientes con cirrosis hepática: relación con las caídas, la calidad de vida y el pronóstico. Proyectos de Investigación en Salud 2012. PI12/00629. Duration: 01/01/13-31/12/15. €31,500.
- ▶ Carlos Guarner Argente. Ensayo clínico multicéntrico, aleatorizado y doble ciego sobre el uso de antibiótico profiláctico en la punción por ecoendoscopia de lesiones quísticas del páncreas. Proyectos de Investigación en Salud 2013. PI13/00609. Duration: 01/01/14-31/12/16. €33,750.
- ▶ Cándido Villanueva Sánchez. Prevención de la descompensación de la cirrosis a largo plazo mediante el tratamiento de la hipertensión portal: Estudio multicéntrico a doble-cego. Proyectos de Investigación en Salud 2013. PI13/02535. Duration: 01/01/14-31/12/16. €218,750.
- ▶ Cándido Villanueva Sánchez. Estudio aleatorizado y controlado comparando acenocumarol versus bemiparina en pacientes que necesitan reiniciar la anticoagulación tras un episodio de hemorragia digestiva grave. Ministerio de Sanidad, Servicios Sociales e Igualdad: EC 2010. EC10-135. Duration: 01/01/11-30/06/15. €25,480.
- ▶ Abelardo Margolles. MICROBILE. La microbiota de la bilis humana: ecología, funcionalidad y relación con la dieta de algunos trastornos biliares. MINECO 2014.*

Note: Total amount granted to PI. It does not include indirect costs.

* Grants applied for by other research institutes.

Grants Awarded in 2014

- ▶ Carlos Guarner Aguilar. Estudio de las alteraciones de la barrera intestinal en la cirrosis hepática. Proyectos de Investigación en Salud 2014. PI14/00680. €81,500.
- ▶ Adolfo Gallego Moya. Estudio de pacientes con hepatitis crónica B en "zona gris de decisión terapéutica o que no cumplen estrictamente la indicación de tratamiento antiviral según las guías clínicas. Gilead 2014. 0146. Duration: 17/07/14-16/07/15. €6,000.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 110.3530 **MIF: 4.7980

Scientific Production

- Ampuero J., Banales J.M., Soriano G., Crespo J., Olcoz J.L., Diago M., Calleja J.L., Romero-Gomez M., La poliquistosis hepática del adulto (PHA) en España: Análisis de una encuesta estructurada analizando la experiencia y actitud de los especialistas de digestivo españoles. (2014) REV ESP ENFERM DIG, 106 (4), 263-275.
IF: 1.4140
- Andreu M., Marquez L., Domenech E., Gisbert J.P., Garcia V., Marin-Jimenez I., Penalva M., Gomollon F., Calvet X., Merino O., Garcia-Planella E., Vazquez-Romero N., Esteve M., Nos P., Gutierrez A., Vera I., Cabriada J.L., Martin M.D., Canas-Ventura A., Panes J., Disease severity in familial cases of IBD. (2014) J CROHNS COLITIS, 8 (3), 234-239.
IF: 6.2340
- Bakker O.J., Van Brunschot S., Farre A., Johnson C.D., Kalfarentzos F., Louie B.E., Olah A., O'Keefe S.J., Petrov M.S., Powell J.J., Besselink M.G., Van Santvoort H.C., Rovers M.M., Gooszen H.G., Timing of enteral nutrition in acute pancreatitis: Meta-analysis of individuals using a single-arm of randomised trials. (2014) PANCREATOLOGY, 14 (5), 340-346.
IF: 2.8370
- Cabre E., Manosa M., Garcia-Sanchez V., Gutierrez A., Ricart E., Esteve M., Guardiola J., Aguas M., Merino O., Ponferrada A., Gisbert J.P., Garcia-Planella E., Cena G., Cabriada J.L., Montoro M., Domenech E., Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database. (2014) J CROHNS COLITIS, 8 (7), 654-661.
IF: 6.2340
- Canas-Ventura A., Marquez L., Ricart E., Domenech E., Gisbert J.P., Garcia-Sanchez V., Marin-Jimenez I., Rodriguez-Moranta F., Gomollon F., Calvet X., Merino O., Garcia-Planella E., Vazquez-Romero N., Esteve M., Iborra M., Gutierrez A., Vera M., Andreu M., Panes J., Garcia V., Penalva M., Garcia-Planella E., Vera I., Nos P., Vazquez N., Gento E., Fernandez-Salazar L., Barrio J., Martin M.D., Munoz F., Ponferrada A., Hinojosa J., Piqueras M., Mendoza J.C., Cabriada J.L., Munoz C., Vilar P., Montoro M.A., Algaba A., Botella B., Saro C., Barreiro M., Aldeguer X., Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. (2014) J CROHNS COLITIS, 8 (10), 1287-1293.
IF: 6.2340
- Canto E., Garcia Planella E., Zamora-Atenza C., Nieto J.C., Gordillo J., Ortiz M.A., Meton I., Serrano E., Vegas E., Garcia-Bosch O., Juarez C., Vidal S., Interleukin-19 impairment in active Crohn's disease patients. (2014) PLOS ONE, 9 (4).
IF: 3.2340
- Castillejo A., Vargas G., Castillejo M.I., Navarro M., Barbera V.M., Gonzalez S., Hernandez-Illan E., Brunet J., Ramon Y Cajal T., Balmana J., Oltra S., Iglesias S., Velasco A., Solanes A., Campos O., Sanchez Heras A.B., Gallego J., Carrasco E., Gonzalez Juan D., Segura A., Chirivella I., Juan M.J., Tena I., Lazaro C., Blanco I., Pineda M., Capella G., Soto J.L., Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. (2014) EUR J CANCER, 50 (13), 2241-2250.
IF: 5.4170
- Cuenca S., Sanchez E., Santiago A., El Khader I., Panda S., Vidal S., Nieto J.C., Juarez C., Sancho F., Guarner F., Soriano G., Guarner C., Manichanh C., Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. (2014) J INNATE IMMUN, 6 (3), 263-271.
IF: 4.3520
- Fernandez-Rozadilla C., Cazier J.B., Tomlinson I., Brea-Fernandez A., Lamas M.J., Baiget M., Lopez-Fernandez L.A., Clofent J., Bujanda L., Gonzalez D., De Castro L., Hemminki K., Bessa X., Andreu M., Jover R., Xicola R., Llor X., Moreno V., Castells A., Castellvi-Bel S.,

*Total Impact Factor **Mean Impact Factor

Digestive Diseases

*TIF: 110.3530 **MIF: 4.7980

Scientific Production

Carracedo A., Ruiz-Ponte C., A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. (2014) *HUM GENET*, 133 (5), 525-534.

IF: 4.8240

Igea F., Casellas J.A., Gonzalez-Huix F., Gomez-Oliva C., Baudet J.S., Cacho G., Simon M.A., De La Morena E., Lucendo A., Vida F., Roses L.L., Sedation for gastrointestinal endoscopy. (2014) *ENDOSCOPY*, 46 (8), 720-731.

IF: 5.0530

Igea F., Casellas J.A., Gonzalez-Huix F., Gomez-Oliva C., Baudet J.S., Cacho G., Simon M.A., De-La-Morena E., Lucendo A., Vida F., Lopez-Roses L., Sedation for gastrointestinal endoscopy. Clinical practice guidelines of the sociedad española de endoscopia digestiva. (2014) *REV ESP ENFERM DIG*, 106 (3), 195-211.

IF: 1.4140

Jalan R., Saliba F., Pavesi M., Amoros A., Moreau R., Gines P., Levesque E., Durand F., Angeli P., Caraceni P., Hopf C., Alessandria C., Rodriguez E., Solis-Munoz P., Laleman W., Trebicka J., Zeuzem S., Gustot T., Mookerjee R., Elkrief L., Soriano G., Cordoba J., Morando F., Gerbes A., Agarwal B., Samuel D., Bernardi M., Arroyo V., Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. (2014) *J HEPATOL*, 61 (5), 1038-1047.

IF: 11.3360

Llao J., Naves J.E., Ruiz-Cerulla A., Marin L., Manosa M., Rodriguez-Alonso L., Cabre E., Garcia-Planella E., Guardiola J., Domenech E., Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. (2014) *J CROHNS COLITIS*, 8 (11), 1523-1528.

IF: 6.2340

Marin-Jimenez I., Garcia Sanchez V., Gisbert J.P., Lazaro Perez Calle J., Lujan M., Gordillo Abalos J., Tabernero S., Julia B., Romero C., Cea-Calvo L., Garcia-Vicuna R., Vanaclocha F., Immune-mediated inflammatory diseases in patients with inflammatory bowel disease. Baseline data from the Aquiles study. (2014) *GASTROENT HEPAT-BARC*, 37 (9), 495-502.

IF: 0.8380

Marinello F.G., Targarona E.M., Balague C., Poca M., Mones J., Trias M., Laparoscopic approach of achalasia. Long-term clinical and functional results and quality of life. (2014) *CIR ESPAN*, 92 (3), 188-194.

IF: 0.7430

Naves J.E., Llao J., Ruiz-Cerulla A., Romero C., Manosa M., Lobaton T., Cabre E., Garcia-Planella E., Guardiola J., Domenech E., Long-term comparative efficacy of cyclosporine or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. (2014) *INFLAMM BOWEL DIS*, 20 (8), 1375-1381.

IF: 4.4640

Nieto J.C., Sanchez E., Roman E., Vidal S., Oliva L., Guarner-Argente C., Poca M., Torras X., Juarez C., Guarner C., Soriano G., Cytokine production in patients with cirrhosis and TLR4 polymorphisms. (2014) *WORLD J GASTROENTERO*, 20 (46), 17516-17524.

IF: 2.3690

Puente A., Hernandez-Gea V., Graupera I., Roque M., Colomo A., Poca M., Aracil C., Gich I., Guarner C., Villanueva C., Drugs plus ligation to prevent rebleeding in cirrhosis: An updated systematic review. (2014) *LIVER INT*, 34 (6), 823-833.

IF: 4.8500

Rodriguez E., Elia C., Sola E., Barreto R., Graupera I., Andrealli A., Pereira G., Poca M., Sanchez J., Guevara M., Soriano G., Alessandria

C., Fernandez J., Arroyo V., Gines P., Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. (2014) *J HEPATOL*, 60 (5), 955-961.

IF: 11.3360

Rodriguez E., Elia C., Sola E., Barreto R., Graupera I., Andrealli A., Pereira G., Poca M., Sanchez J., Guevara M., Soriano G., Alessandria C., Fernandez J., Arroyo V., Gines P., Erratum: Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis" [*J Hepatol* 2014; 60: 955-961]. (2014) *J HEPATOL*, 61 (2), 456.

IF: 11.3360

Roman E., Torrades Ma.T., Nadal Ma.J., Cardenas G., Nieto J.C., Vidal S., Bascunana H., Juarez C., Guarner C., Cordoba J., Soriano G., Randomized pilot study: Effects of an exercise programme and leucine supplementation in patients with cirrhosis. (2014) *DIGEST DIS SCI*, 59 (8), 1966-1975.

IF: 2.6130

Ulzurrun E., Stephens C., Ruiz-Cabello F., Robles-Diaz M., Saenz-Lopez P., Hallal H., Soriano G., Roman E., Fernandez M.C., Lucena M.I., Andrade R.J., Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. (2014) *PLOS ONE*, 9 (4).

IF: 3.2340

Zamora-Atenza C., Diaz-Torne C., Geli C., Diaz-Lopez C., Ortiz M.A., Moya P., Castellvi I., Nieto J.C., Canto E., Casademont J., Juarez C., Llobet J.M., Vidal S., Adalimumab regulates intracellular TNF α production in patients with rheumatoid arthritis. (2014) *ARTHRITIS RES THER*, 16 (4).

IF: 3.7530

Other Publications

- ▶ Villanueva C., Escorsell A., Optimizing general management of acute variceal bleeding in cirrhosis. (2014) *CURRENT HEPATITIS REPORTS*, 13 (3), 198-207.

Microbiology and Infectious Diseases

Coordinator

Pere Coll HSCSP
pcoll@santpau.cat

Members

María Natividad de Benito HSCSP
Cristina Canal F. Puigvert
Ana Pilar Cortes HSCSP
María Ángeles Cotura HSCSP
Montserrat Español HSCSP RI
Paula Andrea Espinal HSCSP RI
Carme Facundo F. Puigvert
Manel Flores HSCSP RI
Àngels Fontanet HSCSP
María Luz Gálvez HSCSP
Eva Gil HSCSP RI
Laura Gómez HSCSP RI
Lluís Guirado F. Puigvert
Mercè Gurguí HSCSP
María Karuna Lamarca HSCSP RI
Joaquín López-Contreras HSCSP
Francesca March HSCSP
Núria Margall HSCSP
Ana María Marin HSCSP
Mar Martí HSCSP RI
Esther Martín HSCSP
Beatriz Mirelis HSCSP
Elisenda Miró HSCSP
Carmen Muñoz HSCSP
Isabel Mur HSCSP
Ferran Navarro HSCSP
Virginia Pomar HSCSP
Núria Prim HSCSP
Núria Rabella HSCSP
María Alba Rivera HSCSP
Fernando Sánchez HSCSP
Núria Serra F. Puigvert
Joan Villarroya HSCSP RI



Main Lines of Research

Clinical Microbiology

- ▶ Study of resistance mechanisms.
- ▶ Tuberculosis, epidemiology and antituberculosis resistance mechanisms.
- ▶ Molecular biology applications in infectious disease detection, taxonomy and epidemiology.
- ▶ Medical care projects.

Kidney Transplantation

- ▶ Vaccines in patients at high risk of CMV infection post-transplantation.
- ▶ Detection of patients IgG positive for CMV but with posttransplantation risk of CMV infection.

- ▶ Biomarkers for BKV in urine samples.
- ▶ Medical care projects.

Infectious Pathologies

- ▶ Restricted-use policies for antibiotic and antimicrobial agents and suitable use of antimicrobial agents.
- ▶ Study of infections associated with foreign bodies (joint prostheses, catheters, cardiac prostheses and pacemakers).
- ▶ Study of infections due to multiresistant microorganisms or requiring isolation.
- ▶ Tuberculosis.

Challenges

Clinical Microbiology Resistance Mechanisms

- ▶ Study of increased resistance as a result of gene carrier-vector spread.
- ▶ Continuity of work in the context of the Spanish Network for Research into Infectious Pathologies (REIPI), heading certain projects (e.g., epidemiology of class C beta-lactamases in Spain) and cooperating with a project on the epidemiology of resistance to amoxicillin-clavulanic acid among others.
- ▶ Advancement of other research lines, both in-house and in cooperation with other centres, leading to two doctoral theses.

Tuberculosis, Epidemiology and Resistance Mechanisms

- ▶ Prospective monitoring of primary and acquired Mycobacterium tuberculosis resistance to first-second-line drugs.

- ▶ Molecular detection of resistance using a molecular antibiogram.
- ▶ Study of the epidemiology and spread of resistant strains and assessment of the impact of immigration and the contribution of new Mycobacterium tuberculosis families (Beijing, EAI, CAS).

Molecular Biology Applications to Infectious Disease Detection, Taxonomy and Epidemiology

- ▶ Study of the usefulness of the 16S RNA gene for microbiological diagnosis and molecular identification.
- ▶ Genotype characterization of Cryptosporidium spp. oocysts from stool samples collected by the HSCSP Microbiology Unit.

Medical Care

- ▶ Government health department agreement (ongoing) regarding the development of epidemiological surveillance sup-

Challenges

port functions for nosocomial infections and flaccid paralysis.

- ▶ Study of mycoses in depth, especially invasive fusariosis and aspergillosis and respiratory tract viral infections in patients with onco-haematological diseases.
- ▶ Multicentre studies of HIV (ongoing).
- ▶ Monitoring of congenital infection in prenat women with Chagas disease.

Kidney Surgery

- ▶ Vaccine in patients with high risk of CMV infection post- transplantation: Phase 2 randomized, double-blind, placebo-controlled trial of MCMV5322A/MCMV3068A for the prevention of cytomegalovirus disease in high-risk kidney allograft recipients, Clinical trial sponsored by Genetech.
- ▶ Detection of patients IgG positive for CMV with high or low risk of CMV infection post- transplantation: Translational study to assess the clinical utility of determination pre-transplant of IFN-γ secreted by CD8 + T-cell-specific guide for the prevention of CMV infection in patients of low risk of CMV infection. Clinical trial sponsored by Consejería de Sanidad y Bienestar Social de Andalucía, Spain.
- ▶ Biomarkers for BKV in urine sample: Determination of a diagnostic and prognostic biomarker in urine by proteomics of nephropathy by BK virus in renal transplant receptors, sponsored by the Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Infectious Pathologies

Restricted-use Antibiotic and Antimicrobial Policies

- ▶ To minimize resistance, reduce cost and improve compliance with surgical prophylaxis (at the time of administration) through suitable use of antimicrobial agents.

Epidemic Cutbreaks and Infections Caused by Multiresistant Microorganisms and Microorganisms Requiring Isolation

- ▶ To study epidemiology for our hospital.
- ▶ To reduce incidence.
- ▶ To prevent/contain epidemic outbreaks and work with the Microbiology Unit in epidemiology and molecular studies.

Infections Associated with Foreign Bodies (Joint Prostheses, Catheters, Cardiac Prostheses, Pacemakers)

- ▶ To reduce incidence.
- ▶ To develop effective conservative treatment regimes.

Infections in Transplant Patients (Heart, Haemopoietic Progenitors)

- ▶ To study current epidemiology.
- ▶ To assess the efficacy of prophylaxis and other preventive measures.

Tuberculosis

- ▶ To cooperate with studies of resistance and with new treatment regimes for tuberculosis.

Other Projects

To continue with the government health department agreement regarding the development of support functions as follows:

- ▶ Epidemiological surveillance of nosocomial infections (VINCat).
- ▶ Tuberculosis control: Barcelona-Dreta Tuberculosis Operations Committee (coordinator: Dr Sambeat).
- ▶ New influenza control: Barcelona-Dreta Epidemiological Surveillance Operations Committee (coordinator: Dr López-Contreras).
- ▶ Database for monitoring CMV infections after renal transplantation.
- ▶ Database for monitoring BK virus infections after renal transplantation.
- ▶ Observational and multicentre case-controlled (1:2) study to compare the evolution of renal transplantation in patients with HIV infection (Dr Canal, Dr Facundo and Dr Serra), sponsored by the Andalusian Organ and Tissue Transplantation Society.
- ▶ Observational, epidemiological and retrospective study of management of CMV infection in a cohort of patients receiving solid organ transplantation in Catalonia (Dr Canal, Dr Facundo and Dr Serra), sponsored by the Catalan Transplantation Society.

Collaborations

External Collaborations

- ▶ Quality control agreement as referral centre for the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), Jan 2013.
- ▶ Study of Bacillus cereus var. toyoi resistance to tetracycline and chloramphenicol, collaboration Agreement with Rubinum SA, 2013-2014.
- ▶ Evaluation of new commercial preparations, agreement with Izasa Distribuciones Tecnicas SA, 2013-2014.

- ▶ Validation of reactive syphilis BIOFLASH-BIO-FLASH HBeAg, Anti-HBe BIO-FLASH, all chemiluminescence immunoassays operating in the autoanalyzer BIO-FLASH, as well as other serological markers. Cooperation agreement, Biokit SA, 2014.

Microbiology and Infectious Diseases

Active Grants

- ▶ Ferran Navarro. Implicación de plásmidos y bacteriófagos en la difusión de las resistencias a antimicrobianos y factores de virulencia bacterianos en humanos. Proyectos de Investigación en Salud 2013. PI13/00329. Duration: 01/01/14-31/12/16. €50,300.
- ▶ Mercè Gurguí Ferrer. Red Española de Investigación en Patología Infecciosa (REIPI). Grupo Clínico. Retics 2006. RD06/0008/0007. Duration: 01/01/08-31/12/14. €30,000.
- ▶ Pere Coll Figa. Red Española de Investigación en Patología Infecciosa (REIPI). Retics 2006. RD06/0008/0013. Duration: 01/01/07-30/06/14. €365,886.73.
- ▶ Pere Coll Figa. Red Española de Investigación en Patología Infecciosa. Redes Temáticas de Investigación Cooperativa en Salud 2012. RD12/0015/0017. Duration: 01/01/13-31/12/16. €51,400.
- ▶ Pedro Domingo Pedrol. Red de sida (RIS). Redes Temáticas de Investigación Cooperativa en Salud 2012. RD12/0017/0014. Duration: 01/01/13-31/12/16. €29,500.
- ▶ Natividad de Benito Hernández. Estudio multicéntrico sobre la utilidad de la monitorización de niveles plasmáticos de colistina y colistimetato sódico en pacientes con infecciones por bacilos gram negativos multiresistentes tratados con colistina. Ministerio de Sanidad, Servicios Sociales e Igualdad: EC 2011 -318. Duration: 01/01/12-30/06/15. €25,680.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Navarro Risueño, Ferran. Contractes per a la intensificació de l'activitat investigadora en el SNS 2014. INT14/00020. €30,000.

Note: Total amount granted to PI. It does not include indirect costs.

Theses

- ▶ Noemí Alonso Louro. Caracterización molecular de los genes blaAmpC cromosómicos y adquiridos en aislados clínicos de *Escherichia coli* en el área de Barcelona. Universitat Autònoma de Barcelona. Directors: Beatriz Mirelis, Alba Rivera.

*TIF: 221.4560 **MIF: 3.9546

Scientific Production

Barcos-Munoz F, Moliner-Calderon E, Morales-Prieto R, Carrara-Scialpini L, Neonatal sepsis and meningitis due to *Streptococcus pneumoniae*. (2014) ENFERM INFECC MICR CL, 32 (1), 58-59.

IF: 2.1720

Benito N, Franco M, Coll P, Galvez M.L., Jordan M, Lopez-Contreras J, Pomar V, Monllau J.C., Mirelis B, Gurgui M., Etiology of surgical site infections after primary total joint arthroplasties. (2014) J ORTHOP RES, 32 (5), 633-637.

IF: 2.9860

Berenguer J., Polo R., Lozano F, Aldeguez J.L., Antela A, Arribas J.R., Asensi V., Blanco J.R., Clotet B., Domingo P., Galindo M.J., Gatell J.M., Gonzalez-Garcia J., Iribarren J.A., Locutura J., Lopez J.C., Mallolas J., Martinez E., Miralles C., Miro J.M., Moreno S., Palacios R., Elias M.J.P., Pineda J.A., Podzamczar D., Portilla J., Pulido F., Ribera E., Riera M., Rubio R., Santos J., Sanz J., Tuset M., Vidal F., Rivero A., Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). (2014) ENFERM INFECC MICR CL, 32 (7), 447-458.

IF: 2.1720

Berenguer J., Polo R., Lozano F, Aldeguez J.L., Antela A, Arribas J.R., Asensi V., Blanco J.R., Clotet B., Domingo P., Galindo M.J., Gatell J.M., Gonzalez-Garcia J., Iribarren J.A., Locutura J., Lopez J.C., Mallolas J., Martinez E., Miralles C., Miro J.M., Moreno S.,

Palacios R., Elias M.J.P., Pineda J.A., Podzamczar D., Portilla J., Pulido F., Ribera E., Riera M., Rubio R., Santos J., Sanz J., Tuset M., Vidal F., Rivero A., GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014). (2014) ENFERM INFECC MICR CL, 32 (7).

IF: 2.1720

Cabrerizo M., Calvo C., Rabella N., Munoz-Almagro C., del Amo E., Perez-Ruiz M., Sanbonmatsu-Gamez S., Moreno-Docon A., Otero A., Trallero G., Rabella N., Marti N., Munoz-Almagro C., del Amo E., Roda D., Perez E., Fons C., Martinez-Rienda I., Soria L.M., Ojeda E., Megias G., Cilla A., Gomez-Saez F., Perez-Ruiz M., Sanbonmatsu S., Perez C., Pena M.J., Colino E., Romero M.P., Garcia M.L., Calvo C., Aguado I., Mensalvas A.I., Moreno-Docon A., Garcia-Costa J., Reis-Iglesias L., Rey-Cao S., Portugues M.M., Gonzalez-Duran M.L., Omenaca M., Cabrerizo M., Trallero G., Otero A., Fedele G., Varela C., Saiz M., Design and validation of a real-time RT-PCR for the simultaneous detection of enteroviruses and parechoviruses in clinical samples. (2014) J VIROL METHODS, 208 (), 125-128.

IF: 1.7810

Canal C., Pellicer R., Facundo C., Garcia-Garcia S., Montanes-Bermudez R., Ruiz-Garcia C., Furlano M., Da Silva I.K., Ballarin J.A., Bover J., Tables for estimating the glomerular filtration rate using the new CKD-EPI equation from serum creatinine concentration. (2014) NEFROLOGIA,

34 (2), 223-229.

IF: 1.2230

Castellsague X, Pawlita M., Roura E., Margall N., Waterboer T., Bosch F.X., De Sanjose S., Gonzalez C.A., Dillner J., Gram I.T., Tjonneland A., Munk C., Pala V., Palli D., Khaw K.-T., Barnabas R.V., Overvad K., Clavel-Chapelon F., Boutron-Ruault M.-C., Fagherazzi G., Kaaks R., Lukanova A., Steffen A., Trichopoulos A., Trichopoulos D., Klinaki E., Tumino R., Sacerdote C., Mattiello A., Bueno-De-Mesquita H.B., Peeters P.H., Lund E., Weiderpass E., Quiros J.R., Sanchez M.-J., Navarro C., Barricarte A., Larranaga N., Ekstrom J., Hortlund M., Lindquist D., Wareham N., Travis R.C., Rinaldi S., Tommasino M., Franceschi S., Riboli E., Prospective seroepidemiologic study on the role of Human Papillomavirus and other infections in cervical carcinogenesis: Evidence from the EPIC cohort. (2014) INT J CANCER, 135 (2), 440-452.

IF: 5.0850

Curran A., Monteiro P., Domingo P., Villar J., Imaz A., Martinez E., Fernandez I., Knobel H., Podzamczar D., Iribarren J.A., Penaranda M., Crespo M., Ribera E., Navarro J., Vall d'Hebron H., Clinic H., Sant Pau H., del Mar H., Bellvitge H., Iburguren M., Donosti H., Penaranda M., Riera M., Son Espases H., Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: Same results as in clinical trials? The PIMOCS study group. (2014) J ANTIMICROB CHEMOTH, 69 (5), 1390-1396.

IF: 5.3130

*TIF: 221.4560 **MIF: 3.9546

de Quintana-Schmidt C., Pascual-Sedano B., Alvarez-Holzappel M.J., Gironell A., Leidinger A., Benito N., Rodriguez-Rodriguez R., Molet-Teixido J., Complications related with implanted devices in patients with Parkinson's disease treated with deep brain stimulation. A study of a series of 124 patients over a period of 16 years. (2014) *REV NEUROLOGIA*, 59 (2), 49-56.

IF: 0.8300

Del Mar Gutierrez M., Mateo M.G., Vidal F., Domingo P., Drug safety profile of integrase strand transfer inhibitors. (2014) *EXPERT OPIN DRUG SAF*, 13 (4), 431-445.

IF: 2.9110

Domingo P., Del Mar Gutierrez M., Gallego-Escuredo J.M., Torres F., Mateo M.G., Villarroya J., De Los Santos I., Domingo J.C., Villarroya F., Del Rio L., Estrada V., Giral M., Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A clinical and molecular study. (2014) *PLOS ONE*, 9 (2).

IF: 3.2340

Domingo P., Gutierrez M.D.M., Gallego-Escuredo J.M., Torres F., Mateo M.G., Villarroya J., Lamarca K., Domingo J.C., Vidal F., Villarroya F., Giral M., A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz. (2014) *JAIDS-J ACQ IMM DEF*, 66 (5), 457-465.

IF: 4.5560

Domingo P., Lamarca M.K., Gallego-Escuredo J.M., Torres F., Domingo J.C., Villarroya J., Del Mar Gutierrez M., Mateo M.G., Vidal F., Villarroya F., Giral M., Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. (2014) *J ANTIMICROB CHEMOTH*, 70 (6), 1825-1832.

IF: 5.3130

Egana-Gorrone L., Martinez E., Domingo P., Lonca M., Escriba T., Fontdevila J., Vidal F., Negro E., Gatell J.M., Arnedo M., Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. (2014) *ANTIMICROB AGENTS CH*, 58 (11), 6717-6723.

IF: 4.4760

Esteva-Font C., Guillen-Gomez E., Diaz J.M., Guirado L., Facundo C., Ars E., Ballarin J.A., Fernandez-Llama P., Renal sodium transporters are increased in urinary exosomes of cyclosporine-treated kidney transplant

patients. (2014) *AM J NEPHROL*, 39 (6), 528-535.

IF: 2.6690

Frentz D., *et al.* Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. (2014) *BMC INFECT DIS*, 14 (1).

IF: 2.6130

Garcia de Olalla P., *et al.* Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. (2014) *AIDS*, 28 (16), 2461-2473.

IF: 5.5540

Gasch O., Camoez M., Dominguez M.A., Padilla B., Pintado V., Almirante B., Martin-Gandul C., Lopez-Medrano F., de Gopegui E.R., Ramon Blanco J., Garcia-Pardo G., Calbo E., Horcajada J.P., Granados A., Jover-Saenz A., Duenas C., Pujol M., Jover A., Barcenilla F., Garcia M., Pujol M., Gasch O., Dominguez M.A., Camoez M., Duenas C., Ojeda E., Martinez J.A., Marco F., Chaves F., Lagarde M., Lopez-Medrano F., Montejo J., Bereciartua E., Hernandez J.L., A. Von Wichmann M., Goenaga A., Garcia-Arenzana J.M., Padilla B., Padilla C., Cercenado E., Garcia-Pardo G., Tapiol J., Horcajada J.P., Montero M., Salvador M., Arnaiz A., Fernandez C., Calbo E., Xercavins M., Granados A., Fontanals D., Pintado V., Loza E., Torre-Cisneros J., Lara R., Rodriguez-Lopez F., Rodriguez M., Natera C., Blanco J.R., Olarte I., Benito N., Mirelis B., Murillas J., Espejo H., Morera M.A., Rodriguez-Bano J., Lopez E., Pascual A., Martin C., Lepe J., Molina J., Sorde R., Almirante B., Larrosa N., Lack of association between genotypes and haematogenous seeding infections in a large cohort of patients with methicillin-resistant *Staphylococcus aureus* bacteraemia from 21 Spanish hospitals. (2014) *CLIN MICROBIOL INFECT*, 20 (4), 361-367.

IF: 5.7680

Gasch O., Camoez M., Dominguez M.A., Padilla B., Pintado V., Almirante B., Martin C., Lopez-Medrano F., De gopegui E.R., Blanco J.R., Garcia-Pardo G., Calbo E., Montero M., Granados A., Jover A., Duenas C., Pujol M., Jover A., Barcenilla F., Garcia M., Gasch O., Dominguez M.A., Camoez M., Duenas C., Ojeda E., Martinez J.A., Marco F., Chaves F., Lagarde M., Lopez-Medrano F., Montejo J.M., Bereciartua E., Hernandez J.L., von Wichmann M.A., Goenaga A., Garcia-Arenzana J.M., Padilla B., Padilla C., Cercenado E., Garcia-Prado G., Tapiol J., Horcajada J.P., Montero M., Salvador M., Arnaiz A., Fernandez C., Calbo E., Xercavins M., Granados A., Fontanals D., Pintado V., Loza E., Torre-Cisneros J., Lara R., Rodri-

guez-Lopez F., Rodriguez M., Natera C., Blanco J.R., Olarte I., Benito N., Mirelis B., Murillas J., Ruiz de Gopegui E., Espejo H., Morera M.A., Rodriguez-Bano J., Lopez-Cortes L.E., Pascual A., Martin C., Lepe J.A., Molina J., Sorde R., Almirante B., Larrosa N., Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant *Staphylococcus aureus* persistent bacteraemia treated with daptomycin. (2014) *J ANTIMICROB CHEMOTH*, 69 (2), 568-571.

IF: 5.3130

Genebat M., Vera F., Hernandez-Quero J., Domingo P., Guardiola J.M., Martinez-Madrid O., Martinez L., De La Llana F.G., Sanchez-Villegas J., Alvarez H., Marino A., Lluich J.F., Martinez-Perez M.A., Marin J., Ruiz-Mateos E., Leal M., Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfecting subjects. (2014) *ANTIVIR RES*, 104 (1), 59-61.

IF: 3.9380

Geretti A.M., Conibear T., Hill A., Johnson J.A., Tambuyzer L., Thys K., Vingerhoets J., Van Delft Y., Rieger A., Vetter N., Greil R., Pedersen C., Storgaard M., Morlat P., Katlama C., Durant J., Cotte L., Duvivier C., Rey D., Esser S., Stellbrink C., Schmidt W., Stoll M., Stephan C., Fatkenheuer G., Stoeckl A., Rockstroh J., Banhegyi D., Itzchak L., Shahar E., Maayan S., Turner D., Lazzarin A., Antinori A., Carosi G., Minoli L., Di Perri G., Filice G., Andreoni M., Duiculescu D., Rugina S., Erscoiu S., Streinu A., Pronin A., Pokrovsky V., Gruzdev B., Yakovlev A., Voronin E., Clotet B., Gatell J., Arribas J., Podzamczar D., Domingo P., Alvarez C.M., Quero J.H., Furrer H., Feher J., Johnson M., Fox J., Nelson M., Fisher M., Orkin C., Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. (2014) *J ANTIMICROB CHEMOTH*, 69 (4), 1090-1097.

IF: 5.3130

Gorriz J.L., Gutierrez F., Trullas J.C., Arazo P., Arribas J.R., Barril G., Cervero M., Cofan F., Domingo P., Estrada V., Fulladosa X., Galindo M.J., Gracia S., Iribarren J.A., Knobel H., Lopez-Aldeguer J., Lozano F., Martinez-Castelao A., Martinez E., Mazuecos M.A., Miralles C., Montanes R., Negro E., Palacios R., Perez-Elias M.J., Portilla J., Praga M., Quereda C., Rivero A., Santamaria J.M., Sanz J., Sanz J., Miro J.M., Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients. (2014) *ENFERM INFECT MICR CL*, 32 (9), 583-597.

IF: 2.1720

Microbiology and Infectious Diseases

*TIF: 221.4560 **MIF: 3.9546

Scientific Production

Guillen-Gomez E., Guirado L., Belmonte X., Maderuelo A., Santin S., Juarez C., Ars E., Facundo C., Ballarin J.A., Vidal S., Diaz-Encarnacion M.M., Monocyte implication in renal allograft dysfunction. (2014) CLIN EXP IMMUNOL, 175 (2), 323-331.

IF: 3.0370

Guinea J., Zaragoza O., Escribano P., Martin-Mazuelos E., Peman J., Sanchez-Reus F., Cuenca-Estrella M., Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. (2014) ANTIMICROB AGENTS CH, 58 (3), 1529-1537.

IF: 4.4760

Gutierrez F., Fulladosa X., Barril G., Domingo P., Renal tubular transporter-mediated interactions of HIV drugs: Implications for patient management. (2014) AIDS REV, 16 (4), 199-212.

IF: 3.7870

Gutierrez S.G., *et al.* Predictive factors of severe multilobar pneumonia and shock in patients with influenza. (2014) EMERG MED J, 31 (4), 301-307.

IF: 1.8430

Juncosa-Morros T., Guardia-Llobet C., Bosch-Mestres J., Dopico-Ponte E., Sanfeliu-Sala I., Sierra-Soler M., Sanchez-Reus F., Gimenez-Perez M., Lite-Lite J., Andreu-Domingo A., Streptococcus agalactiae late-onset neonatal infections in Barcelona (1996-2010). (2014) ENFERM INFECC MICR CL, 32 (9), 574-578.

IF: 2.1720

Marti-Carrizosa M., Sanchez-Reus F., March F., Coll P., Fungemia in a Spanish hospital: The role of Candida parapsilosis over a 15-year period. (2014) SCAND J INFECT DIS, 46 (6), 454-461.

IF: 1.4950

Martinez E., Gonzalez-Cordon A., Ferrer E., Domingo P., Negredo E., Gutierrez F., Portilla J., Curran A., Podzamczek D., Murillas J., Bernardino J., Santos I., Carton J., Peraire J., Pich J., Perez I., Gatell J., Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. (2014) HIV MED, 15 (6), 330-338.

IF: 3.9880

Martinez E., Jodar Gimeno E., Reyes Garcia R., Carpintero P., Casado J.L., Del Pino Montes J., Domingo Pedrol P., Estrada V., Maalouf J., Negredo E., Ocampo A., Munoz-Torres M., Consensus statement: Recommendations for the management of metabolic bone disease in human immunodeficiency virus patients. (2014) ENFERM INFECC MICR CL, 32 (4), 250-258.

IF: 2.1720

Massanella M., Ouchi D., Marfil S., Llibre J.M., Puertas M.C., Buzon M.J., Richman D.D., Orna E., Stevenson M., Gatell J.M., Domingo P., Negredo E., Martinez-Picado J., Clotet B., Blanco J., Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals. (2014) PLOS ONE, 9 (12).

IF: 3.2340

Mateo M.G., Gutierrez M.D.M., Vidal F., Domingo P., An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. (2014) EXPERT OPIN PHARMACO, 15 (12), 1749-1760.

IF: 3.5340

Meije Y., Fortun J., Len O., Aguado J.M., Moreno A., Cisneros J.M., Gurgui M., Carratala J., Munoz P., Montejo M., Blanes M., Bou G., Perez J.L., Torre-Cisneros J., Ramos A., Pahissa A., Gavalda J., Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): Experience from the RESITRA-REIPI cohort. (2014) TRANSPL INFECT DIS, 16 (3), 387-396.

IF: 2.0640

Miguel L.G.-S., Cobo J., Martinez J.A., Arnau J.M., Murillas J., Pena C., Segura F., Gurgui M., Galvez J., Gimenez M., Gudiol F., 'Third day intervention': An analysis of the factors associated with following the recommendations on the prescribing of antibiotics. (2014) ENFERM INFECC MICR CL, 32 (10), 654-661.

IF: 2.1720

Millan O., Rafael-Valdivia L., San Segundo D., Boix F., Castro-Panete M.J., Lopez-Hoyos M., Muro M., Valero-Hervas D., Rimola A., Navasa M., Munoz P., Miras M., Andres A., Guirado L., Pascual J., Brunet M., Should IFN- γ , IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. (2014) CLIN IMMUNOL, 154 (2), 141-154.

IF: 3.6720

Molto J., Valle M., Ferrer E., Domingo P., Curran A., Santos J.R., Mateo M.G., Di Yacovo M.S., Miranda C., Podzamczek D., Clotet B., Coll J., Gel S., Llibre J.M., Mothe B., Negredo E., Perez-Alvarez N., Sirera G., Rozas N., Vila A., Del Mar Gutierrez M., Mateo G., Burgos J., Navarro J., Ribera E., Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: A randomized clinical trial. (2014) J ANTIMICROB CHEMOTH, 70 (4), 1139-1145.

IF: 5.3130

Moure R., Espanol M., Tudo G., Vicente E., Coll P., Gonzalez-Martin J., Mick V., Salvado M., Alcaide F., Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array. (2014) J ANTIMICROB CHEMOTH, 69 (4), 947-954.

IF: 5.3130

Moure R., Espanol M., Tudo G., Vicente E., Coll P., Gonzalez-Martin J., Mick V., Salvado M., Alcaide F., Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array-authors' response. (2014) J ANTIMICROB CHEMOTH, 69 (8), 2299-2300.

IF: 5.3130

Negredo E., Diez-Perez A., Bonjoch A., Domingo P., Perez-Alvarez N., Gutierrez M., Mateo G., Puig J., Echeverria P., Escrig R., Clotet B., Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: Changes in bone turnover markers and circulating sclerostin levels. (2014) J ANTIMICROB CHEMOTH, 70 (7), 2104-2107.

IF: 5.3130

Negredo E., Domingo P., Ferrer E., Estrada V., Curran A., Navarro A., Isernia V., Rosales J., Perez-Alvarez N., Puig J., Bonjoch A., Echeverria P., Podzamczek D., Clotet B., Peak bone mass in young HIV-infected patients compared with healthy controls. (2014) JAIDS-J ACQ IMM DEF, 65 (2), 207-212.

IF: 4.5560

Oteo J., Gonzalez-Lopez J.J., Ortega A., Quintero-Zarate J.N., Bou G., Cercenado E., Conejo M.C., Martinez-Martinez L., Navarro F., Oliver A., Bartolome R.M., Campos J., Inhibitor-resistant TEM-1 and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates. (2014) ANTIMICROB AGENTS CH, 58 (7), 3874-3881.

IF: 4.4760

Oteo J., Miro E., Perez-Vazquez M., Navarro F., Evolution of carbapenemase-producing Enterobacteriaceae at the global and national level: What should be expected in the future?. (2014) ENFERM INFECC MICR CL, 32 (S4), 17-23.

IF: 2.1720

Peraire J., Vilades C., Pacheco Y.M., Lopez-Dupla M., Domingo P., Gutierrez M., Rosado I., Leal M., Richart C., Vidal F., Evaluation of the pharmacogenetics of immune recovery

*TIF: 221.4560 **MIF: 3.9546

Scientific Production

ery in treated HIV-infected patients. (2014) EXPERT OPIN DRUG MET, 10 (1), 81-101.

IF: 2.8310

Perez-Llarena F.J., Zamorano L., Kerff F., Beceiro A., Garcia P., Miro E., Larrosa N., Gomez-Bertomeu F., Mendez J.A., Gonzalez-Lopez J.J., Oliver A., Galleni M., Navarro F., Bou G., Genetic and kinetic characterization of the novel AmpC β -lactamases DHA-6 and DHA-7. (2014) ANTIMICROB AGENTS CH, 58 (11), 6544-6549.

IF: 4.4760

Pozniak A., Markowitz M., Mills A., Stellbrink H.-J., Antela A., Domingo P., Girard P.-M., Henry K., Nguyen T., Piontkowsky D., Garner W., White K., Guyer B., Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. (2014) LANCET INFECT DIS, 14 (7), 590-599.

IF: 22.4330

Prim N., Grenzner E., Munoz C., Larvae in a traveller's faeces. Not always what it seems. (2014) ENFERM INFECC MICR CL, 32 (5), 330-331.

IF: 2.1720

Quiros P., Colomer-Lluch M., Martinez-Castillo A., Miro E., Argente M., Jofre J., Navarro F., Muniesa M., Antibiotic resistance genes in the bacteriophage DNA fraction of human fecal samples. (2014) ANTIMICROB AGENTS CH, 58 (1), 606-609.

IF: 4.4760

Ribas F., Villarroya J., Elayne H., Giralt M., Villarroya F., FGF21 expression and release in muscle cells: Involvement of MyoD and regulation by mitochondria-driven signaling. (2014) BIOCHEM J, 463 (), 191-199.

IF: 4.3960

Rivera A., Larrosa N., Mirelis B., Navarro F., Importance of quality control for the detection of β -lactam antibiotic resistance in Enterobacteriaceae. (2014) ENFERM INFECC MICR CL, 32 (SUPPL.1), 30-36.

IF: 2.1720

Rodriguez-Pardo D., Pigrau C., Lora-Tamayo J., Soriano A., del Toro M.D., Cobo J., Palomino J., Euba G., Riera M., Sanchez-Somolinos M., Benito N., Fernandez-Sampedro M., Sorli L., Guio L., Iribarren J.A., Baraia-Etxaburu J.M., Ramos A., Bahamonde A., Flores-Sanchez X., Corona P.S., Ariza J., Amat C., Larrosa M.N., Puig M., Murillo O., Cabo X., Goenaga M.A., Elola M., De la Herran G., Garcia-Arenzana J.M., Garcia-Ramiro S., Martinez-Pastor J.C., Tornero E., Garcia-Lechuz J.M., Marin M., Villanueva M., Lopez I., Cisterna R., Santamaria J.M., Gomez M.-J., Puente A., Cano P., Horcajada J.P., Gonzalez-Minguez P., Portillo E., Puig L., Franco M., Jordan M., Coll P., Amador-Mellado J., Fuster-Foz C., Garcia-Paino L., Nieto I., Muniain M.A., Suarez A.I., Praena J., Gomez M.-J., Puente A., Maseguer M.A., Garagorri E., Pintado V., Marinescu C., Ramirez A., Montaner F., Munez E., Alvarez T., Garcia R., Puente E., Salas C., Farinas M.C., Perez J.M., Achabal B.V., Montejo Baranda J.M., Gram-negative prosthetic joint infection: Outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. (2014) CLIN MICROBIOL INFECC, 20 (11), O911-O919.

IF: 5.7680

Roura E., Castellsague X., Pawlita M., Travier N., Waterboer T., Margall N., Bosch F.X., De Sanjose S., Dillner J., Gram I.T., Tjonneland A., Munk C., Pala V., Palli D., Khaw K.-T., Barnabas R.V., Overvad K., Clavel-Chapelon F., Boutron-Ruault M.-C., Fagherazzi G., Kaaks R., Lukanova A., Steffen A., Trichopoulou A., Trichopoulos D., Klinaki E., Tumino R., Sacerdote C., Panico S., Bueno-De-Mesquita H.B., Peeters P.H., Lund E., Weiderpass E., Redondo M.L., Sanchez M.-J., Tormo M.-J., Barricarte A., Larranaga N., Ekstrom J., Hortlund M., Lindquist D., Wareham N., Travis R.C., Rinaldi S., Tommasino M., Franceschi S., Riboli E., Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort. (2014) INT J CANCER, 135 (2), 453-466.

IF: 5.0850

Saumoy M., Ordonez-Llanos J., Martinez E., Ferrer E., Domingo P., Ribera E., Negro E., Curto J., Sanchez-Quesada J.L., Di Yacovo

S., Lez-Cordon A.G., Podzamczar D., Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: A substudy of the ATADAR randomized study. (2014) J ANTIMICROB CHEMOTH, 70 (4), 1130-1138.

IF: 5.3130

Segundo D.S., Millan O., Munoz-Cacho P., Boix F., Paz-Artal E., Talayero P., Morales J.M., Muro M., De Cos M.A., Guirado L., Llorente S., Pascual J., Arias M., Brunet M., Lopez-Hoyos M., High proportion of pre-transplantation activated regulatory T cells (CD4+CD25highCD62L+CD45RO+) predicts acute rejection in kidney transplantation: Results of a multicenter study. (2014) TRANSPLANTATION, 98 (11), 1213-1218.

IF: 3.8280

Tornero E., Senneville E., Euba G., Petersdorf S., Rodriguez-Pardo D., Lakatos B., Ferrari M.C., Pilares M., Bahamonde A., Trebbe R., Benito N., Sorli L., del Toro M.D., Baraiaetxaburu J.M., Ramos A., Riera M., Jover-Saenz A., Palomino J., Ariza J., Soriano A., Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: A multi-national study. (2014) CLIN MICROBIOL INFECC, 20 (11), 1219-1224.

IF: 5.7680

Vidal F., Leal M., Alcamí J., Domingo P., Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. (2014) PHARMACOGENOMICS, 15 (5), 569-572.

IF: 3.2180

Villarroya J., Flachs P., Redondo-Angulo I., Giralt M., Medrikova D., Villarroya F., Kopecky J., Planavila A., Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids. (2014) LIPIDS, 49 (11), 1081-1089.

IF: 1.8540

Other Publications

► Egana-Gorrondo L., Martinez E., Perez I., Escriba T., Domingo P., Gatell J.M., Arnedo M., Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults. (2014) THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69 (11), 3076-3084.

► Pomar V., Domingo P., Acute viral meningitis. (2014) CNS Infections: A Clinical Approach, 9781447164012, 45-55.

► Vilades C., Escote X., Lopez-Dupla M., Martinez E., Domingo P., Asensi V., Leal M., Peraire J., Inza M.-I., Arnedo M., Gutierrez M., Valle-Garay E., Ferrando-Martinez S., Olona M., Alba V., Sirvent J.-J., Gatell J.M., Vidal F., Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). (2014) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69 (6), 1653-1659.

*Total Impact Factor **Mean Impact Factor

Multi-organ Damage

Coordinator

Jordi Casademont HSCSP
jcasademont@santpau.cat

Members

J Asuncion Acosta HSCSP RI
uan Antonio Arroyo HSCSP
Judith Ballart HSCSP RI
Montserrat Barceló HSCSP
María Teresa Benet HSCSP RI
César Díaz Torné HSCSP RI
Jordi Farrerons HSCSP
David Filella HSCSP
Esther Francia HSCSP
Miquel Franco HSCSP
Carne Geli HSCSP
Sílvia Herrera HSCSP RI
M. de los Ángeles Izquierdo HSCSP RI
Ana María Laiz HSCSP
Josep María de Llobet HSCSP
Berta Paula Magallares HSCSP RI
Jorge Malouf HSCSP RI
Jordi Mascaró HSCSP
Laia Matas HSCSP
Jaume Monmany HSCSP
Patricia Moya HSCSP RI
Mireia Pares HSCSP RI
Raquel Pérez HSCSP RI
María Carmen Rius HSCSP RI
Arturo Rodríguez HSCSP
Domingo Ruíz HSCSP
Natalia Sola HSCSP
Olga Herminia Torres HSCSP



Main Lines of Research

Bone Metabolism and Osteoporosis

- ▶ Analysis of genetic influence on osteoporosis by means of aggregation studies in families of three or more generations with a minimum of 15 members.
- ▶ Bone structure study with quantitative CT of hip and spine, analysing the contribution of trabecular and cortical components using HRCT.
- ▶ Description of fat values and percentages in a normal population (in collaboration with the HIV Unit and CETIR Medical Group).
- ▶ Analysis of the influence of an intervention (physical exercise) on changes in the muscle compartment of patients with cirrhosis measured by DXA and HRQCT (in collaboration with the Gastroenterology Department).
- ▶ Description of bone structure in patients with a history of acromegaly assessed by DXA and HRQCT.

Hypertension and Vascular Risk

- ▶ Hypertension and quality of life.
- ▶ Refractory hypertension.
- ▶ Use of alirocumab in hypercholesterolaemia.

Clinical Management, Internal Medicine and Geriatrics

- ▶ Health care quality indexes (mortality, re-admissions, etc).
- ▶ Perioperative medicine.
- ▶ Potentially inappropriate prescribing to older patients admitted to hospital.

Rheumatology and Rheumatoid Arthritis

- ▶ Immunomodulation due to anti-CD20 (rituximab) treatment and study of polymorphisms.

- ▶ Pharmacokinetics of methotrexate.
- ▶ Evaluation of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate or antiTNF therapy.
- ▶ Evaluation of tofacitinib in patients with moderately to severely active rheumatoid arthritis with inadequate response to biologic DMARD.
- ▶ Evaluation of the JAK-STAT pathway in patients with rheumatoid arthritis treated with tocilizumab.

Systemic Sclerosis

- ▶ Capillaroscopy patterns and correlation with auto-antibodies and pulmonary function tests.
- ▶ Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
- ▶ Use of endothelin receptor antagonism to prevent pulmonary arterial hypertension (in collaboration with Vall d'Hebron University Hospital, Barcelona, Spain).
- ▶ Genetic studies in systemic sclerosis and collaboration with DUO Registry and LAUDES study.
- ▶ Study of capillaroscopy patterns in diffuse connective tissue diseases: QuantiCAP study.

Gout

- ▶ Epidemiology of hyperuricaemia and gout.

Sjögren Syndrome

- ▶ Clinical and epidemiological findings in Spanish patients with primary Sjögren syndrome (in collaboration with Spanish Society of Rheumatology).

Challenges

- ▶ To establish stable work relations between the HSCSP Bone Metabolism and Genomics of Complex Diseases Groups and the Bone Metabolism Unit of Hospital del Mar-Municipal Institute for Medical Research and the Faculty of Biology of the University of Barcelona.
- ▶ To strengthen ties between the HSCSP Rheumatology and Immunology departments regarding the study of immunological diseases.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Digestive Diseases (Dr Germán Soriano), Study by densitometry and ergospirometry of the effects of an exercise programme in overweight patients with liver cirrhosis.
- ▶ Orthopaedic Surgery and Traumatology Service (Dr José Carlos González Rodríguez), Randomized, double-blind, placebo-controlled clinical trial of parallel groups assessing the efficacy of subcutaneous denosumab for periprosthetic resorption decrease in patients with total knee prosthesis, IIBSP-DEN-2012-24, Eudra No: 2012-001285-15.
- ▶ Cardiovascular Risk Group (Dr Laiz Matas), Longitudinal epidemiological study for the assessment of arterial stiffness in patients with renal insufficiency and treatment with vitamin D3 and vitamin D analogues, IIBSP-VIT-2013-138.

External Collaborations

- ▶ Dr Luis del Rio, Standardized measures of different tissues using dual-energy X-ray absorptiometry, CETIR Medical Group, Barcelona, Spain.
- ▶ Internal Medicine Pneumonia Study (ENEMI), coordinated by the Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- ▶ Dr César Díaz Torné, panellist for the Guidelines to Clinical Practice for Gout (GuipClinGot), Spanish Rheumatology Society.

Active Grants

- ▶ Jordi Casademont Pou. Fenotipos intermediarios en el riesgo de desarrollar osteoporosis. El proyecto GAO (Genetic Analysis of Ostoporosis). MINECO-ISCIII Project 2011. PI11/01175. Duration: 01/01/12-31/12/14. €139,955.
- ▶ Olga Torres Bonafonte. Estudio sobre la utilización inapropiada de medicamentos en pacientes de edad avanzada hospitalizados en servicios de medicina interna de diferentes hospitales españoles.

Ministerio de Sanidad, Servicios Sociales e Igualdad: EC 2010. EC10-077. Duration: 01/01/11-30/06/15. €22,790.88.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Jordi Casademont Pou. Estudio GAO: de los fenotipos intermediarios al análisis global del genoma. Proyectos de Investigación en Salud 2014. PI14/01036. €76,000.

Note: Total amount granted to PI. It does not include indirect costs.

Awards

- ▶ Casademont J. Situación actual de la enseñanza de la Patología General en España. Premio de Educación Médica 2014 al mejor proyecto o trabajo en la enseñanza de grado. Cátedra de Educación Médica Fundación Lilly-Universidad Complutense de Madrid.

Theses

- ▶ César Díaz Torné. Avenços clínics i immunològics en la resposta al tractament amb teràpia deplectora de limfòcits B (Rituximab) en pacients amb artritis reumatoide. Universitat Autònoma de Barcelona. Directors: César Díaz López, Silvia Vidal Alcorisa, Jordi Casademont Pou. Date of defense: 27 January 2014.
- ▶ Iván Castellví Barranto. Utilidad de los antagonistas de los receptores de la endotelina para prevención primaria de hipertensión pulmonar en pacientes afectados de esclerosis sistémica. Universitat Autònoma de Barcelona. Directors: Carmen Pilar Simeon Aznar, Héctor Corominas Macías, Jordi Casademont Pou. Date of defense: 4 December 2014.

Multi-organ Damage

*TIF: 93.7730 **MIF: 3.2336

Athanasiadis G., Malouf J., Hernandez-Sosa N., Martin-Fernandez L., Catalan M., Casademont J., Soria J.M., Linkage and association analyses using families identified a locus affecting an osteoporosis-related trait. (2014) *BONE*, 60 (1), 98-103.

IF: 3.9730

Barcelo M., Torres O., Ruiz D., Casademont J., Appropriateness of medications prescribed to elderly patients with advanced heart failure and limited life expectancy who died during hospitalization. (2014) *DRUG AGING*, 31 (7), 541-546.

IF: 2.8380

Benito N., Franco M., Coll P., Galvez M.L., Jordan M., Lopez-Contreras J., Pomar V., Monllau J.C., Mirelis B., Gurgui M., Etiology of surgical site infections after primary total joint arthroplasties. (2014) *J ORTHOP RES*, 32 (5), 633-637.

IF: 2.9860

De-La-Cueva-Ariza L., Romero-Garcia M., Delgado-Hito P., Acosta-Mejuto B., Jover-Sancho C., Ricart-Basagana M.-S.-O.-S.-C.T., Juando-Prats C., Sola-Sole N., Sola-Ribo M., Development of an instrument to measure the degree of critical patient's satisfaction with nursing care: Research protocol. (2014) *J ADV NURS*, 70 (1), 201-210.

IF: 1.7410

Diaz-Torne C., Ortiz de Juana M.A., Geli C., Canto E., Laiz A., Corominas H., Casademont J., de Llobet J.M., Juarez C., Diaz-Lopez C., Vidal S., Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis. (2014) *IMMUNOLOGY*, 142 (3), 354-362.

IF: 3.7950

Diaz-Torne C., Pou M.A., Castellvi I., Corominas H., Taylor W.J., Concerns of patients with gout are incompletely captured by OMERACT-endorsed domains of measurement for chronic gout studies. (2014) *JCR-J CLIN RHEUMATOL*, 20 (3), 138-140.

IF: 1.0840

Feliu-Soler A., Pascual J.C., Borrás X., Portella M.J., Martin-Blanco A., Armario A., Alvarez E., Perez V., Soler J., Effects of dialectical behaviour therapy-mindfulness training on emotional reactivity in borderline personality disorder: Preliminary results. (2014) *CLIN PSYCHOL PSYCHOT*, 21 (4), 363-370.

IF: 2.6320

Gonzalez-Garcia M., Ferrer M.J., Borrás X., Munoz-Moreno J.A., Miranda C., Puig J., Perez-Alvarez N., Soler J., Feliu-Soler A., Clotet B., Fumaz C.R., Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. (2014) *AIDS BEHAV*, 18 (4), 676-685.

IF: 3.7280

Haro J.M., Tyrovolas S., Garin N., Diaz-Torne C., Carmona L., Sanchez-Riera L., Perez-Ruiz F., Murray C.J.L., The burden of disease in Spain: Results from the global burden of disease study 2010. (2014) *BMC MED*, 12 (1).

IF: 7.2490

Julia A., Rodriguez J., Fernandez-Sueiro J.L., Gratacos J., Queiro R., Montilla C., Torre-Alonso J.C., Perez-Venegas J.J., Manrique-Arija S., Munoz-Fernandez S., Gonzalez C., Roig D., Zarco P., Erra A., Castaneda S., Garcia A., Salvador G., Diaz-Torne C., Blanco R., Dominguez A.W., Mosquera J.A., Vela P., Tornero J., Sanchez-Fernandez S., Corominas H., Ramirez J., Avila G., Alonso A., Tortosa R., Lopez-Lasanta M., Canete J.D., Marsal S., PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. (2014) *PHARMACOGENOMICS*, 15 (14), 1763-1769.

IF: 3.2180

Lopez S., Buil A., Souto J.C., Casademont J., Martinez-Perez A., Almasy L., Soria J.M., A genome-wide association study in the genetic analysis of idiopathic thrombophilia project suggests sex-specific regulation of mitochondrial DNA levels. (2014) *MITOCHONDRION*, 18 (1), 34-40.

IF: 3.2490

Marquez A., Ferreira-Iglesias A., Davila-Fajardo C.L., Montes A., Pascual-Salcedo D., Perez-Pampin E., Moreno-Ramos M.J., Garcia-Portales R., Navarro F., Moreira V., Magro C., Caliz R., Ferrer M.A., Alegre-Sancho J.J., Joven B., Carreira P., Balsa A., Vasilopoulos Y., Sarafidou T., Cabeza-Barrera J., Narvaez J., Raya E., Canete J.D., Fernandez-Nebro A., Ordonez M.D.C., De la Serna A.R., Magallares B., Gomez-Reino J.J., Gonzalez A., Martin J., Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis. (2014) *ARTHRITIS RES THER*, 16 (2).

IF: 3.7530

Martin-Blanco A., Ferrer M., Soler J., Salazar J., Vega D., Andion O., Sanchez-Mora C., Arranz M.J., Ribases M., Feliu-Soler A., Perez V., Pascual J.C., Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. (2014) *J PSYCHIATR RES*, 57 (1), 34-40.

IF: 3.9570

Martin-Blanco A., Soler J., Villalta L., Feliu-Soler A., Elices M., Perez V., Arranz M.J., Ferraz L., Alvarez E., Pascual J.C., Exploring the interaction between childhood maltreatment and temperamental traits on the severity of borderline personality disorder. (2014) *COMPR PSYCHIAT*, 55 (2),

311-318.

IF: 2.2520

Martinez E., Jodar Gimeno E., Reyes Garcia R., Carpintero P., Casado J.L., Del Pino Montes J., Domingo Pedrol P., Estrada V., Maalouf J., Negredo E., Ocampo A., Munoz-Torres M., Consensus statement: Recommendations for the management of metabolic bone disease in human immunodeficiency virus patients. (2014) *ENFERM INFECC MICR CL*, 32 (4), 250-258.

IF: 2.1720

Montes A., Perez-Pampin E., Narvaez J., Canete J.D., Navarro-Sarabia F., Moreira V., Fernandez-Nebro A., Del Carmen Ordonez M., De La Serna A.R., Magallares B., Vasilopoulos Y., Sarafidou T., Caliz R., Ferrer M.A., Joven B., Carreira P., Gomez-Reino J.J., Gonzalez A., Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. (2014) *PHARMACOGENET GENOM*, 24 (5), 238-245.

IF: 3.4810

Rodriguez-Pardo D., Pigrau C., Lora-Tamayo J., Soriano A., del Toro M.D., Cobo J., Palomino J., Euba G., Riera M., Sanchez-Somolinos M., Benito N., Fernandez-Sampedro M., Sorli L., Guio L., Iribarren J.A., Baraia-Etxaburu J.M., Ramos A., Bahamonde A., Flores-Sanchez X., Corona P.S., Ariza J., Amat C., Larrosa M.N., Puig M., Murillo O., Cabo X., Goenaga M.A., Elola M., De la Herran G., Garcia-Arenzana J.M., Garcia-Ramiro S., Martinez-Pastor J.C., Tornero E., Garcia-Lechuz J.M., Marin M., Villanueva M., Lopez I., Cisterna R., Santamaria J.M., Gomez M.-J., Puente A., Cano P., Horcajada J.P., Gonzalez-Minguez P., Portillo E., Puig L., Franco M., Jordan M., Coll P., Amador-Mellado J., Fuster-Foz C., Garcia-Paino L., Nieto I., Muniain M.A., Suarez A.I., Praena J., Gomez M.-J., Puente A., Maseguer M.A., Garagorri E., Pintado V., Marinescu C., Ramirez A., Montaner F., Munez E., Alvarez T., Garcia R., Puente E., Salas C., Farinas M.C., Perez J.M., Achabal B.V., Montejo Baranda J.M., Gram-negative prosthetic joint infection: Outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. (2014) *CLIN MICROBIOL INFECC*, 20 (11), O911-O919.

IF: 5.7680

Salazar J., Moya P., Altes A., Diaz-Torne C., Casademont J., Cerdá-Gabaroi D., Corominas H., Baiget M., Polymorphisms in genes involved in the mechanism of action of methotrexate: Are they associated with outcome in rheumatoid arthritis patients?. (2014) *PHARMACOGENOMICS*, 15 (8), 1079-1090.

IF: 3.2180

San-Jose A., Agusti A., Vidal X., Barbe J., Torres O.H., Ramirez-Duque N., Garcia J., Fernandez-Moyano A., Lopez-Soto A., For-

*TIF: 93.7730 **MIF: 3.2336

Scientific Production

miga F, Aguilera C., Ballarin E., Perez E., Bocabegra C.P., Toscano A., Pal C., Teixidor T., Hernandez M.G., De la Rosa Morales R., Martinez M.N.B., Bosch X., Palau M., Rovira J., Navarro M., Chivite D., Roson B., Vallano A., Cabot C., Ballesteros I., Ruiz D., Turbau M., Ponte P., Ortiz G., Cobas P.-C.R., Gil P., An inter-rater reliability study of the prescribing indicated medications quality indicators of the Assessing Care Of Vulnerable Elders (ACOVE) 3 criteria as a potentially inappropriate prescribing tool. (2014) ARCH GERONTOL GERIAT, 58 (3), 460-464.

IF: 1.8530

San-Jose A., Agusti A., Vidal X., Formiga F., Lopez-Soto A., Fernandez-Moyano A., Garcia J., Ramirez-Duque N., Torres O.H., Barbe J., Inappropriate prescribing to older patients admitted to hospital: A comparison of different tools of misprescribing and underprescribing. (2014) EUR J INTERN MED, 25 (8), 710-716.

IF: 2.8910

Sarrion P., Mellibovsky L., Urreiziti R., Civit S., Cols N., Garcia-Giralt N., Yoskovitz G., Aranguren A., Malouf J., Di Gregorio S., Del Rio L., Guerri R., Nogues X., Diez-Perez A., Grinberg D., Balcells S., Genetic analysis of high bone mass cases from the BARCOS cohort of spanish postmenopausal women. (2014) PLOS ONE, 9 (4).

IF: 3.2340

Soler J., Cebolla A., Feliu-Soler A., Demarzo M.M.P., Pascual J.C., Banos R., Garcia-Campayo J., Relationship between meditative practice and self-reported mindfulness: The MINDSENS composite index. (2014) PLOS ONE, 9 (1).

IF: 3.2340

Soler J., Franquesa A., Feliu-Soler A., Cebolla A., Garcia-Campayo J., Tejedor R., Demarzo M., Banos R., Pascual J.C., Portella M.J., Assessing Decentering: Validation, Psychometric Properties, and Clinical Usefulness of the Experiences Questionnaire in a Spanish Sample. (2014) BEHAV THER, 45 (6), 863-871.

IF: 3.6940

Soler J., Vega D., Elices M., Feliu-Soler A., Soto T., Martin-Blanco A., Marco-Pallares J., Torrubia R., Pascual J.C., Testing the reinforcement sensitivity theory in borderline personality disorder compared with major depression and healthy controls. (2014) PERS INDIV DIFFER, 61-62 (), 43-46.

IF: 1.9510

Sosa N.H.-D., Athanasiadis G., Malouf J., Laiz A., Marin A., Herrera S., Farrerons J., Soria J.M., Casademont J., Heritability of bone mineral density in a multivariate family-based study. (2014) CALCIFIED TISSUE INT, 94 (6), 590-596.

IF: 3.2720

Tejedor R., Feliu-Soler A., Pascual J.C., Cebolla A., Portella M.J., Trujols J., Soriano J., Perez V.,

Soler J., Psychometric properties of the Spanish version of the Philadelphia Mindfulness Scale. (2014) REV PSIQUIATR SALUD, 7 (4), 157-165.

IF: 1.6220

Trujols J., De Diego-Adelino J., Feliu-Soler A., Iraurgi I., Puigdemont D., Alvarez E., Perez V., Portella M.J., The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. (2014) J AFFECT DISORDERS, 169 (), 189-196.

IF: 3.3830

Valcarcel De Laiglesia M.A., Alfonso F., Miro O., Casademont J., Burbano Santos P., Burillo-Putze G., Fernandez Perez C., Martin-Sanchez F.J., Characteristics and longevity of electronic citations in four leading biomedical journals in Spain. (2014) REV ESP CARDIOL, 67 (10), 837-843.

IF: 3.7920

Zamora-Atenza C., Diaz-Torne C., Geli C., Diaz-Lopez C., Ortiz M.A., Moya P., Castellvi I., Nieto J.C., Canto E., Casademont J., Juarez C., Llobet J.M., Vidal S., Adalimumab regulates intracellular TNF α production in patients with rheumatoid arthritis. (2014) ARTHRITIS RES THER, 16 (4).

IF: 3.7530

Other Publications

▶ Aguilera X., Gonzalez J.C., Celaya F., Jordan M., Diaz-Torne C., Monllau J.C., Total knee arthroplasty in a patient with subcutaneous and intra-articular tophaceous gout - A case report. (2014) BULLETIN OF THE NYU HOSPITAL FOR JOINT DISEASES, 72 (2), 173-175.

▶ De La Serna A.R., Pereira A.A., Lopez B.M., Abatacept en monoterapia: Manejo de la artritis reumatoide en la práctica clínica habitual. (2014) DOLOR, 29 (3), 117-119.

▶ Lopez B.M., Pereira A.A., De La Serna A.R., Fracturas y osteoporosis en la infancia. (2014) DOLOR, 29 (3), 110-116.

▶ Lopez-Ferrer A., Laiz-Alonso A., Actualización en artritis psoriásica. (2014) ACTAS DERMO-SIFILIOGRAFICAS, 105 (10), 913-922.

▶ Malouf Sierra J., Ácido zoledrónico y metabolismo fosfocálcico. (2014) DOLOR, 29 (2), 45-52.

▶ Ortiz-Sanjuan F., Blanco R., Calvo-Rio V., Narvaez J., Rubio Romero E., Olive A., Castaneda S., Gallego Flores A., Hernandez M.V., Mata C., Ros Vilamajo I., Sifuentes Giraldo W.A., Caracuel M.A., Freire M., Gomez Arango C., Llobet J., Manrique Arijia S., Marras

C., Moll-Tuduri C., Plasencia-Rodriguez C., Rosello R., Urruticoechea A., Velloso-Feijoo M.L., Del Blanco J., Gonzalez-Vela M.C., Rueda-Gotor J., Pina T., Loricera J., Gonzalez-Gay M.A., Efficacy of tocilizumab in conventional treatment-refractory adult-onset still's disease: Multicenter retrospective open-label study of thirty-four patients. (2014) ARTHRITIS RHEUMATOL, 66 (6), 1659-1665. IF: 0.0000

▶ Osuna-Pozo C.M., Serra-Rexach J.A., Vina J., Gomez-Cabrera M.D.C., Salva A., Ruiz D., Masanes F., Lopez-Soto A., Formiga F., Cuesta F., Cruz-Jentoft A., Prevalence of sarcopenia in geriatric outpatients and nursing homes. The ELLI study. (2014) REVISTA ESPANOLA DE GERIATRIA Y GERONTOLOGIA, 49 (2), 72-76.

▶ Penacoba Toribio P., Corica Albani M.E., Mayos Perez M., Rodriguez de la Serna A., Rituximab in the treatment of shrinking lung syndrome in systemic lupus erythematosus. (2014) REUMATOLOGIA CLINICA, 10 (5), 325-327.

▶ Pereira A.A., Lopez B.M., De La Serna A.R., Dolor y fracturas vertebrales. (2014) DOLOR, 29 (3), 101-109.

Chronic Respiratory Diseases

Coordinator

Vicente Plaza HSCSP
vplaza@santpau.cat
David Ramos Barbón
DRamosB@santpau.cat

Members

Pedro Antonio Anton HSCSP
Carmen Burgues HSCSP
Teresa Bigorra HSCSP RI
Sonia Nadia Brienza HSCSP RI
Nuria Calaf HSCSP
Abilio Castellano HSCSP
Diego Castillo HSCSP
Josep Lluís Cisneros HSCSP
Ana María Fortuna HSCSP
Ana María Giménez HSCSP
Jordi Giner HSCSP
Carme Granel HSCSP
Maria Rosa Güell HSCSP
Iñigo Martín HSCSP
Mercedes Mayos HSCSP
Rosa Maria Miralda HSCSP
Fátima Morante HSCSP
Ana María Muñoz HSCSP RI
Luis Daniel Paz
Meritxell Peiro HSCSP
Patricia Peñacoba HSCSP RI
Maria Carme Puy HSCSP
Julio Rubio HSCSP
Ester Sánchez HSCSP RI
Jesús María Sauret HSCSP
Macarena Segura HSCSP
Oriol Sibila HSCSP
Íngrid Solanes HSCSP
Lorena C. Soto HSCSP RI
Anna Torredemer HSCSP RI
Alfonso Torrego HSCSP
Montserrat Torrejon HSCSP



Main Lines of Research

Asthma

- ▶ Asthma exacerbations.
- ▶ Severe asthma.
- ▶ Good clinical practice guidelines for asthma.
- ▶ Bronchial inflammation.
- ▶ Experimental asthma and pathogenic mechanisms.
- ▶ Multicentre biobank specializing in bronchial biopsies for research into asthma.
- ▶ Bronchial thermoplasty.
- ▶ Clinical trials.

COPD and Respiratory Failure

- ▶ Non-invasive mechanical ventilation.
- ▶ Respiratory rehabilitation.
- ▶ Pathophysiology.
- ▶ Exacerbation.

Obstructive Sleep Apnoea (OSA)

- ▶ Physiology and clinical, diagnostic and treatment consequences of sleep disorders.
- ▶ Obesity-hypoventilation syndrome.
- ▶ Analysis of airway inflammation in patients with OSA.

Challenges

- ▶ Consolidate a leading clinical trial unit in respiratory diseases.
- ▶ Capture pre-clinical development contracts from the pharmaceutical and biotech industry, using the capabilities of our basic research lab and experimental animal models.
- ▶ Recruit research trainees seeking a doctoral degree.
- ▶ Support the development of multidisciplinary research networks such as the Barcelona Respiratory Network and the Programme for Integrated Research for Asthma of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), and collaborate with or become involved in existing networks such as CIBER-Respiratory Disorders.

Theses

- ▶ Óscar Amor Carro. Role of the effector and regulatory arms of the adaptive immune response in the pathophysiology of experimental asthma. Universidad de Santiago de Compostela. Director: David Ramos Barbón. Date of defense: 24 January 2014.
- ▶ Ana M. Fortuna Gutiérrez. Utilidad de la medición de óxido nítrico en aire espirado en la patología respiratoria. Universitat Autònoma de Barcelona. Directors: Pere Casan Clará, Mercedes Mayos Pérez. Date of defense: 5 December 2014.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Ear, Nose and Throat Cancers (collaboration of Dr. V. Plaza in the EPONA study).
- ▶ Genetics and Vascular Surgery Departments (collaboration of Dr. V. Plaza in the TAGA study).

External Collaborations

- ▶ Dr. V. Plaza, Emergent Asthma Group, SEPAR.
- ▶ Dr. V. Plaza, INASMA Group.
- ▶ Drs. V. Plaza and D. Ramos Barbón, Integrated Research Programme (PII) for Asthma, SEPAR.
- ▶ Drs. V. Plaza and D. Ramos Barbón, group associated with CIBER-Respiratory.
- ▶ Dr. D. Castillo Villegas, National Institute for Rare Diseases, Instituto de Salud Carlos III, Madrid, Spain.
- ▶ Dr. D. Castillo Villegas, International Working Group on Langerhans Cell Histiocytosis and EUROHISTIONET.

- ▶ Dr. D. Ramos Barbón (PI), Multicentre Biobank of Bronchial Biopsies for Asthma Research, with collaborators as follows:
 - Dr. Carlos Martínez Rivera from Hospital Universitario Germans Trias i Pujol, Badalona, Spain.
 - Dr. Antolín López Viña from Hospital Universitario Puerta de Hierro, Madrid, Spain.
 - Dr. Francisco Javier González Barcala from Complejo Hospitalario de Pontevedra, Spain.
 - Dr. Teresa Bazús González from Hospital Universitario Central de Asturias, Oviedo, Spain.
 - Dr. Luis Pérez de Llano from Hospital Lucus Augusti, Lugo, Spain (pending approval).
 - Dr. Patrick Berger from Université Bordeaux 2, Bordeaux, France.
 - Dr. James G Martin from McGill University, Montreal, Canada.
- ▶ Astrid del Carmen Crespo Lessmann. Expresión de receptores Toll-Like 2 y 4 en pacientes asmáticos. Relación con el fenotipo inflamatorio, la gravedad y el nivel de control del asma. Beca Maria Ravà 2012. Duration: 01/01/12-31/12/14. €5,555.55.

Active Grants

- ▶ David Ramos. Interacción entre regulación inmunitaria y mecanismos de remodelación de vías respiratorias en el asma: efectos patogénicos versus potencial terapéutico. Ayudas para proyectos de investigación SEPAR 2013. Duration: 30/05/13-29/05/15.
- ▶ M. Teresa Garriga. Estudio EPONA: Evaluación y nuevas perspectivas en la fisiopatogenia, detección y uso del óxido nítrico nasal y la nariz electrónica. Ayudas para proyectos de investigación SEPAR 2013. Duration: 30/05/13-29/05/15.
- ▶ Anna Mola. Estudio de los cambios hemodinámicos cerebrales en pacientes con síndrome de apnea hipopnea obstructiva del sueño (SAHS) mediante técnicas de espectroscopia óptica transcraneal. Ayudas para proyectos de investigación SEPAR 2013. Duration: 30/05/13-29/05/15.
- ▶ Fátima Morante. Impacto de la rehabilitación respiratoria precoz en las exacerbaciones, en los pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) reingresadores. Ayudas para proyectos de investigación SEPAR 2013. Duration: 30/05/13-29/05/15.
- ▶ Diego Castillo. Caracterización genética y funcional de la histiocitosis pulmonar de células de langerhans: Implicaciones diagnósticas y terapéuticas. Ayudas a la Investigación EPID-FUTURO 2013. Duration: 21/06/13-20/06/16. €4,361.80.

- ▶ Diego Castillo. Caracterización genética y funcional de la histiocitosis pulmonar de células de langerhans: implicaciones diagnósticas y terapéuticas. X Convocatoria de Ayudas a la Investigación Médica FMM 2013. Duration: 09/10/13-09/10/15. €23,161.
- ▶ Maria Rosa Güell Rous. Efectes de l'entrenament després de la cirurgia de resecció en malalts amb càncer de pulmó. Beca Boehringer. SOCAP 2012. Duration: 01/08/12-31/07/15. €48,000.
- ▶ Oriol Sibila Vidal. Estudio de los mecanismos de defensa pulmonar en la EPOC grave y su relación con la infección de la vía aérea. FIS Project 2009. PI09/2567. Duration: 01/01/10-30/06/14. €36,500.
- ▶ Alfonso Torrego Fernández. Ensayo aleatorizado del rendimiento diagnóstico y seguridad de la biopsia pulmonar transbronquial con criosondas frente a pinzas convencionales en el diagnóstico de enfermedades pulmonares difusas. FIS Project 2010. PI10/0100. Duration: 01/01/11-30/06/14. €45,700.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Mercedes Mayos Perez. Proyecto PASHOS: Plataforma Avanzada para el estudio del Síndrome de Apnea Hipopnea del Sueño (SAHS): Estudio de validación de un modelo de criba del SAHS en Atención Primaria. Proyectos de Investigación en Salud 2014. PI14/01985. €19,400.
- ▶ David Ramos Barbon. Mecanismos patogénicos versus terapéuticos de las células madre mesenquimales sobre la remodelación bronquial en asma: prueba de concepto para subiguiente de-

- sarrollo farmacéutico. Proyectos de Investigación en Salud 2014. PI14/00257. €121,500.
- ▶ Astrid del Carmen Crespo Lessmann. Caracterización fenotípica del asmático hipersecretor. Papel de las mucinas y de los receptores Toll-Like. BECA VIFOR PHARMA / FUCAP 2014. Duration: 01/06/2014-31/05/2016. €5,181.82.

Note: Total amount granted to PI. It does not include indirect costs.

Chronic Respiratory Diseases

*TIF: 147.3360 **MIF: 5.2620

Barnadas A., Manso L., de la Piedra C., Meseguer C., Crespo C., Gomez P., Calvo L., Martinez P., Ruiz-Borrego M., Perello A., Anton A., Codes M., Margeli M., Murias A., Salvador J., Segui M.T., de Juan A., Gavila J., Luque M., Perez D., Zamora P., Arizcuma A., Chacon J.I., Heras L., Martin-Fernandez M., Mahillo-Fernandez I., Tusquets I., Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). (2014) *BONE*, 68 (1), 32-40.

IF: 3.9730

Casanova C., Marin J.M., Martinez-Gonzalez C., de Lucas-Ramos P., Mir-Viladrich I., Cosio B., Peces-Barba G., Calle-Rubio M., Solanes-Garcia I., Agüero R., de Diego-Damia A., Feu-Collado N., Alfageme I., Irigaray R., Balcells E., Llunell A., Galdiz J.B., Marin M., Soler-Cataluna J.J., Lopez-Campos J.L., Soriano J.B., de-Torres J.P., de Lucas P., Marin J.M., Soler Cataluna J.J., Bonachera J.C., Bautista C.L., Domenech A., Michavila I.A., Marin Trigo J.M., Gonzalez C.M., Piqueras B.G.-C., Lopez C.C., Acosta A.S., Macario C.C., Gonzalez J.A., Balbin R.A., Campos E.M., Marin A., Moreno A., Marquez Perez F.L., Riesco Miranda J.A., Rodriguez J.T., Gomez R.G., Romero G.P.-B., de Miguel Diez J., Rio F.G., Lobato S.D., New GOLD classification: Longitudinal data on group assignment. (2014) *RESP RES*, 15 (1).

IF: 3.0930

Casanova C., Marin J.M., Martinez-Gonzalez C., de Lucas-Ramos P., Mir-Viladrich I., Cosio B., Peces-Barba G., Calle-Rubio M., Solanes-Garcia I., Agüero R., de Diego-Damia A., Feu-Collado N., Alfageme I., Irigaray R., Balcells E., Llunell A., Galdiz-Iturri J.B., Marin M., Soler J.J., Lopez-Campos J.L., Soriano J.B., de-Torres J.P., Erratum: New GOLD classification: Longitudinal data on group assignment [*Respir Res*, 15, (2014) 3, 10.1186/1465-9921-15-3]. (2014) *RESP RES*, 15 (1).

IF: 3.0930

Castillo D., Martin-Arroyo I., Moreno A., Balcells E., Villar A., Vicens-Zygmunt V., Vendrell M., Belda S., Portillo K., Kettou D., Aparicio F., Molina-Molina M., Adult pulmonary Langerhans' cell histiocytosis: Approach to the reality of the Spanish population. (2014) *MED CLIN-BARCELONA*, 143 (10), 433-439.

IF: 1.4170

Castillo Villegas D., Barril Farre S., Triple Therapy in Idiopathic Pulmonary Fibrosis. (2014) *ARCH BRONCONEUMOL*, 50 (6), 260-261.

IF: 1.8230

De Miguel-Diez J., Jimenez-Garcia R., Hernandez-Barrera V., Lopez De Andres A., Villa-Asensi J.R., Plaza V., Carrasco-Garrido P., National trends in hospital admissions for asthma exacerbations among pediatric and young adult population in Spain (2002-2010). (2014) *RESP MED*, 108 (7), 983-991.

IF: 3.0860

De Torres J.P., Marin J.M., Martinez-Gonzalez C., De Lucas-Ramos P., Mir-Viladrich I., Cosio B., Peces-Barba G., Calle-Rubio M., Solanes-Garcia I., Balbin R.A., De Diego-Damia A., Feu-Collado N., Michavila I.A., Irigaray R., Balcells E., Casanovas A.L., Iturri J.B.G., Royo M.M., Soler-Cataluña J.J., Lopez-Campos J.L., Soriano J.B., Casanova C., Clinical application of the COPD assessment test: Longitudinal data from the COPD history assessment in Spain (CHAIN) Cohort. (2014) *CHEST*, 146 (1), 111-122.

IF: 7.4830

Giner Donaire J., Quality Spirometry: What Do We Base Our Definition On?. (2014) *ARCH BRONCONEUMOL*, 50 (6), 260.

IF: 1.8230

Guell Rous M.R., Diaz Lobato S., Rodriguez Trigo G., Morante Velez F., San Miguel M., Cejudo P., Ortega Ruiz F., Munoz A., Galdiz Iturri J.B., Garcia A., Servera E., Pulmonary rehabilitation. (2014) *ARCH BRONCONEUMOL*, 50 (8), 332-344.

IF: 1.8230

Lara Gallego B., Abaitua Borda I., Galan Gil G., Castillo Villegas D., Casanova Espinosa A., Cano Jimenez E., Ojanguren Arranz I., de la Paz M.P., Respiratory diseases registries in the national registry of rare diseases. (2014) *ARCH BRONCONEUMOL*, 50 (9), 397-403.

IF: 1.8230

Laserna E., Sibila O., Fernandez J.F., Maselli D.J., Mortensen E.M., Anzueto A., Waterer G., Restrepo M.I., Impact of macrolide therapy in patients hospitalized with pseudomonas aeruginosa community-acquired pneumonia. (2014) *CHEST*, 145 (5), 1114-1120.

IF: 7.4830

Marinas-Pardo L., Mirones I., Amor-Carro O., Fraga-Iriso R., Lema-Costa B., Cubillo I., Rodriguez Milla M.A., Garcia-Castro J., Ramos-Barbon D., Mesenchymal stem cells regulate airway contractile tissue remodeling in murine experimental asthma. (2014) *ALLERGY*, 69 (6), 730-740.

IF: 6.0280

Martin-Loeches I., Valles X., Menendez R., Sibila O., Montull B., Cilloniz C., Artigas A., Torres A., Predicting treatment failure in patients with community acquired pneu-

monia: A case-control study. (2014) *RESP RES*, 15 (1).

IF: 3.0930

Masa J.F., Duran-Cantolla J., Capote F., Cabello M., Abad J., Garcia-Rio F., Ferrer A., Mayos M., Gonzalez-Mangado N., De La Pena M., Aizpuru F., Barbe F., Montserrat J.M., Effectiveness of home single-channel nasal pressure for sleep apnea diagnosis. (2014) *SLEEP*, 37 (12), 1953-1961B.

IF: 4.5910

Ortega Ruiz F., Diaz Lobato S., Galdiz Iturri J.B., Garcia Rio F., Guell Rous R., Morante Velez F., Puente Maestu L., Tarrega Camarasa J., Continuous Home Oxygen Therapy. (2014) *ARCH BRONCONEUMOL*, 50 (5), 185-200.

IF: 1.8230

Otti A.G., Jaus M.O., Barale D., Baiguera S., Comin C., Lavorini F., Fontana G., Sibila O., Rombola G., Jungebluth P., MacChiarini P., The first tissue-engineered airway transplantation: 5-year follow-up results. (2014) *LANCET*, 383 (9913), 238-244.

IF: 45.2170

Pajares Ruiz V., Torrego Fernandez A., Puzo Ardanuy C., Gil de Bernabe A., Use of an occlusion balloon in transbronchial lung cryobiopsy. (2014) *ARCH BRONCONEUMOL*, 50 (7), 306-310.

IF: 1.8230

Pajares V., Puzo C., Castillo D., Lerma E., Angeles Montero M., Ramos-Barbon D., Amor-Carro O., De Bernabe A.G., Franquet T., Plaza V., Hetzel J., Sanchis J., Torrego A., Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: A randomized trial. (2014) *RESPIROLOGY*, 19 (6), 900-906.

IF: 3.3450

Pallero M., Puy C., Guell R., Pontes C., Marti S., Torres F., Anton A., Munoz X., Ambulatory adaptation to noninvasive ventilation in restrictive pulmonary disease: A randomized trial with cost assessment. (2014) *RESP MED*, 108 (7), 1014-1022.

IF: 3.0860

Rodrigo G.J., Plaza V., Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: A systematic review. (2014) *CHEST*, 146 (2), 309-317.

IF: 7.4830

Rodrigo G.J., Plaza V., Efficacy and safety of indacaterol and glycopyrronium in COPD: An update. (2014) *CHEST*, 146 (2).

IF: 7.4830

Rodriguez E., Ferrer J., Zock J.-P., Serra I., Anto J.M., De Batlle J., Kromhout H., Vermeulen R., Donaire-Gonzalez D., Benet M., Balcells E., Monso E., Gayete A., Garcia-Ay-

*TIF: 147.3360 **MIF: 5.2620

Scientific Production

merich J., Guerra S., Gea J., Orozco-Levi M., Vollmer I., Barbera J.A., Gomez F.P., Pare C., Roca J., Rodriguez-Roisin R., Agusti A., Freixa X., Rodriguez D.A., Gimeno E., Portillo K., Andreu J., Pallisa E., Casan P., Guell R., Gimenez A., Marin A., Morera J., Farrero E., Escarrabill J., Ferrer A., Sauleda J., Togores B., Galdiz J.B., Lopez L., Belda J., Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. (2014) PLOS ONE, 9 (2).

IF: 3.2340

Salord N., Gasa M., Mayos M., Fortuna-Gutierrez A.M., Montserrat J.M., Sanchez-de-la-Torre M., Barcelo A., Barbe F., Vilarrasa N., Monasterio C., Impact of OSA on biological markers in morbid obesity and metabolic syndrome. (2014) J CLIN

SLEEP MED, 10 (3), 263-270.

IF: 3.0530

Selva A., Bolibar I., Torrego A., Pallares M.C., Impact of a program for rapid diagnosis and treatment of lung cancer on hospital care delay and tumor stage. (2014) TUMORI, 100 (6), e243-e249.

IF: 1.2690

Sibila O., Ferrer M., Agusti C., Torres A., Corticosteroids as adjunctive treatment in community-acquired pneumonia. (2014) MINERVA ANESTESIOLOGICA, 80 (12), 1336-1344.

IF: 2.1340

Sibila O., Garcia-Bellmunt L., Giner J., Merino J.L., Suarez-Cuartin G., Torrego A., Solanes I., Castillo D., Valera J.L., Cosio B.G., Plaza V., Agusti A., Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary

Disease. (2014) RESP MED, 108 (11), 1608-1614.

IF: 3.0860

Sibila O., Mortensen E.M., Anzueto A., Latorre E., Restrepo M.I., Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. (2014) EUR RESPIR J, 43 (1), 36-42.

IF: 7.6360

Torrego A., Sola I., Munoz A.M., Roque I Figuls M., Yepes-Nunez J.J., Alonso-Coello P., Plaza V., Bronchial thermoplasty for moderate or severe persistent asthma in adults.. (2014) COCHRANE DB SYST REV, 3.

IF: 6.0320

Other Publications

► Giner J., Plaza V., Rigau J., Sola J., Bolibar I., Sanchis J., Spirometric standards and patient characteristics: an exploratory study of factors affecting fulfillment in routine clinical practice. (2014) RESPIRATORY CARE, 59 (12), 1832-1837.

► Penacoba Toribio P., Corica Albani M.E., Mayos Perez M., Rodriguez de la Serna A., Rituximab in the treatment of shrinking

lung syndrome in systemic lupus erythematosus. (2014) REUMATOLOGIA CLINICA, 10 (5), 325-327.

► Sintes H., Sibila O., Waterer G.W., Chalmers J.D., Severity assessment tools in CAP. (2014) EUROPEAN RESPIRATORY MONOGRAPH, 63, 88-104.

Research Group in HIV and AIDS

Coordinator

Pere Domingo HSCSP

Members

Josep Cadafalch HSCSP
 M. del Mar Gutiérrez HSCSP RI
 Maria Karuna Lamarca HSCSP RI
 Gracia Maria Mateo HSCSP RI
 Jessica Muñoz HSCSP RI
 Paola Helena Ponte HSCSP RI
 Maria Antònia Sambeat HSCSP
 Joan Villarroya HSCSP RI



Main Lines of Research

- ▶ Medical care projects.
- ▶ Study of pathogenic mechanisms altering body fat distribution.
- ▶ Study of metabolic disorders associated with antiretroviral treatment.
- ▶ Body composition changes.
- ▶ New antiretroviral drugs.
- ▶ Cardiovascular risk associated with antiretroviral treatment.
- ▶ Comorbid conditions associated with HIV-1 infection.
- ▶ Pharmacogenetics (toxicokinetics).
- ▶ Bacterial meningitis.

Challenges

Medical Care Projects

- ▶ Continuing with, expanding and, as appropriate, consolidating the care team for HIV-1 infected patients, consisting currently of 3 staff physicians, 4 grant-aided research assistants (including a Río Hortega-funded research assistant) and 2 nurses).
- ▶ Continuing with participation in multicentre projects (especially the AIDS network, Gesida, VACH, EuroSIDA and ART collaboration).
- ▶ Exploration of possible participation in clinical trials of new antiretroviral drugs.
- ▶ Increasing the number of HIV-1 infected patients attended to in our hospital (given current mortality rates, an estimated annual increase of 50 patients is required).
- ▶ Continuing with current clinical research and mixed basic research-clinical research lines.

Pathogenic mechanisms altering body fat distribution

- ▶ Study of metabolism in pyrimidines and derivatives in the genesis of lipodystrophy associated with HIV-1 and antiretroviral treatment.
- ▶ Development of an animal (mouse) model of lipodystrophy.
- ▶ Development of in vitro models (adipo-

cyte cultures) to study the adipose toxicity of antiretroviral drugs.

- ▶ Study of new manifestations of the lipodystrophy syndrome.
- ▶ Development of measurements for antiretroviral drug concentrations in adipose tissue.
- ▶ Exploration of the role of inflammation in the pathogenesis of lipodystrophy associated with HIV-1 and antiretroviral treatment.
- ▶ Metabolism of uridine and its role in the pathogenesis of lipodystrophy.

Metabolic disorders associated with antiretroviral treatment

- ▶ In vivo assessment of metabolic toxicity associated with antiretroviral treatment.
- ▶ Development of in vitro models (adipocyte cultures) to study the adipose toxicity of antiretroviral drugs.
- ▶ Study of factors contributing factors to hepatic steatosis in patients receiving antiretroviral treatment.
- ▶ Study of the pathogenic role of FGF21 in insulin resistance in HIV-1- infected patients.
- ▶ Study of role of FABP4 in metabolic disorders associated with antiretroviral treatment.

Challenges

Body composition

- ▶ Definition of normal fat distribution in the general population.
- ▶ Establishment of abnormal fat distribution patterns.
- ▶ Development of a definition of lipodystrophy associated with HIV-1 and antiretroviral treatment.

New antiretroviral drugs

- ▶ Clinical trials of new antiretroviral drugs (phases 2 and 3).
- ▶ Ritonavir and non-ritonavir pharmacokinetic potentiation of antiretroviral drugs.

Cardiovascular risk associated with antiretroviral treatment

- ▶ Establishment of a multicentre cardiovascular risk cohort.
- ▶ Study of antiretroviral treatment-dependent and non-treatment-dependent factors in multicentre cohorts.
- ▶ Development of in vitro models (adipose cultures) to study adipose toxicity for antiretroviral drugs.

Comorbid conditions associated with HIV-1 infection

- ▶ Study of ageing in different tissues associated with HIV-1 infection and antiretroviral treatment.
- ▶ Study of fragility in patients with HIV-1 infection and the role of HAART.

- ▶ Evaluation of the neurocognitive function in patients with HIV-1 infection with and without antiretroviral treatment.
- ▶ Participation in multicentre cohort studies to determine the incidence of specific comorbidities (cancer, HCV, cardiovascular disease, osteogenesis/osteoporosis): EuroSIDA, ART Collaboration, Gesida, VACH, etc.
- ▶ Treatment of HCV in patients with HIV-1 and its prognostic significance.

Pharmacogenetics (toxicogenetics)

- ▶ Role of enzyme polymorphism of the pyrimidine pathways in the pathogenesis of lipodystrophy.
- ▶ Role of enzyme polymorphism of the pyrimidine pathways in the pathogenesis of clinical toxicity (neuropathy, pancreatitis).
- ▶ Role of IL28B polymorphism in spontaneous HCV clearance in the response to antiviral treatment based on interferon and ribavirin.

Bacterial meningitis

- ▶ Identification of prognostic factors in adult bacterial meningitis.
- ▶ Continuation with a cohort study of adult bacterial meningitis.
- ▶ Identification of host-intrinsic factors in the pathogenesis and prognosis of adult bacterial meningitis and meningococcal disease.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Microbiology and Infectious Diseases (Dr. Pere Coll)

Active Grants

- ▶ Pere Domingo Pedrol. Determinación de niveles de FGF23 en pacientes con infección por VIH y su posible relación con comorbilidades asociadas en la infección o al tratamiento. Estudio observacional, transversal. I Convocatoria de Proyectos de Investigación en VIH y Hepatitis - ISCIII and Gilead España. Duration: 26/07/13-16/01/15. €37,731.48.
- ▶ Pere Domingo Pedrol. Estudio piloto, prospectivo, transversal y observacional sobre la implicación de los fenómenos de senescencia adipocitaria en la patogénesis de la lipoatrofia asociada al VIH-1 y al TARGA. MINECO-ISCIII Project 2011. P111/02512. Duration: 01/01/12-31/12/14. €63,636.

- ▶ Pere Domingo Pedrol. Red de SIDA. Retics 2006. RD06/0006/0022. 01/01/07-28/02/14. €202,883.25.
- ▶ Pere Domingo Pedrol. Contractes per a la intensificació de l'activitat investigadora en el SNS 2013. INT13/00232. Duration: 01/01/14-31/12/14. €30,000.
- ▶ Joan Villarroya Terrade. FIS Contracte Postdoc "Sara Borrell" 2011. CD11/00029. Duration: 16/01/12-15/01/15. €75,600.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Pere Domingo Pedrol. El sistema FGF23/alpha-Klotho como mediador de las comorbilidades no directamente relacionadas con la infección por VIH en el eje cardio-osteo-renal. Proyectos de Investigación en Salud 2014. P114/00700. €116,500.

Note: Total amount granted to PI. It does not include indirect costs.

Research Group in HIV and AIDS

*TIF: 121.6790 **MIF: 4.5066

Scientific Production

Berenguer J., Polo R., Lozano F., Aldeguez J.L., Antela A., Arribas J.R., Asensi V., Blanco J.R., Clotet B., Domingo P., Galindo M.J., Gatell J.M., Gonzalez-Garcia J., Iribarren J.A., Locutura J., Lopez J.C., Mallolas J., Martinez E., Miralles C., Miro J.M., Moreno S., Palacios R., Elias M.J.P., Pineda J.A., Podzamczar D., Portilla J., Pulido F., Ribera E., Riera M., Rubio R., Santos J., Sanz J., Tuset M., Vidal F., Rivero A., Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). (2014) ENFERM INFECC MICR CL, 32 (7), 447-458.

IF: 2.1720

Berenguer J., Polo R., Lozano F., Aldeguez J.L., Antela A., Arribas J.R., Asensi V., Blanco J.R., Clotet B., Domingo P., Galindo M.J., Gatell J.M., Gonzalez-Garcia J., Iribarren J.A., Locutura J., Lopez J.C., Mallolas J., Martinez E., Miralles C., Miro J.M., Moreno S., Palacios R., Elias M.J.P., Pineda J.A., Podzamczar D., Portilla J., Pulido F., Ribera E., Riera M., Rubio R., Santos J., Sanz J., Tuset M., Vidal F., Rivero A., GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014). (2014) ENFERM INFECC MICR CL, 32 (7).

IF: 2.1720

Curran A., Monteiro P., Domingo P., Villar J., Imaz A., Martinez E., Fernandez I., Knobel H., Podzamczar D., Iribarren J.A., Penaranda M., Crespo M., Ribera E., Navarro J., Vall d'Hebron H., Clinic H., Sant Pau H., del Mar H., Bellvitge H., Ibaguren M., Donosti H., Penaranda M., Riera M., Son Espases H., Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: Same results as in clinical trials? The PIMOCS study group. (2014) J ANTIMICROB CHEMOTH, 69 (5), 1390-1396.

IF: 5.3130

Del Mar Gutierrez M., Mateo M.G., Vidal F., Domingo P., Drug safety profile of integrase strand transfer inhibitors. (2014) EXPERT OPIN DRUG SAF, 13 (4), 431-445.

IF: 2.9110

Domingo P., Del Mar Gutierrez M., Gallego-Escuredo J.M., Torres F., Mateo M.G., Villarroya J., De Los Santos I., Domingo J.C., Villarroya F., Estrada V., Giralt M., Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A clinical and molecular study. (2014) PLOS ONE, 9 (2).

IF: 3.2340

Domingo P., Gutierrez M.D.M., Gallego-Escuredo J.M., Torres F., Mateo M.G., Villarroya J., Lamarca K., Domingo J.C., Vidal F., Villarroya F., Giralt M., A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz. (2014) JAIDS-J ACQ IMM DEF, 66 (5), 457-465.

IF: 4.5560

Domingo P., Lamarca M.K., Gallego-Escuredo J.M., Torres F., Domingo J.C., Villarroya J., Del Mar Gutierrez M., Mateo M.G., Vidal F., Villarroya F., Giralt M., Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients. (2014) J ANTIMICROB CHEMOTH, 70 (6), 1825-1832.

IF: 5.3130

Egana-Gorrone L., Martinez E., Domingo P., Lonca M., Escriba T., Fontdevila J., Vidal F., Negredo E., Gatell J.M., Arnedo M., Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients. (2014) ANTIMICROB AGENTS CH, 58 (11), 6717-6723.

IF: 4.4760

Frentz D., *et al.* Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. (2014) BMC INFECT DIS, 14 (1).

IF: 2.6130

Garcia de Olalla P., *et al.* Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. (2014) AIDS, 28 (16), 2461-2473.

IF: 5.5540

Genebat M., Vera F., Hernandez-Quero J., Domingo P., Guardiola J.M., Martinez-Madrid O., Martinez L., De La Llana F.G., Sanchez-Villegas J., Alvarez H., Marino A., Lluch J.F., Martinez-Perez M.A., Marin J., Ruiz-Mateos E., Leal M., Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfecting subjects. (2014) ANTIVIR RES, 104 (1), 59-61.

IF: 3.9380

Geretti A.M., Conibear T., Hill A., Johnson J.A., Tambuyzer L., Thys K., Vingerhoets J., Van Delft Y., Rieger A., Vetter N., Greil R., Pedersen C., Storgaard M., Morlat P., Katlama C., Durant J., Cotte L., Duvivier C., Rey D., Esser S., Stellbrink C., Schmidt W., Stoll M., Stephan C., Fatkenheuer G., Stoehr A., Rockstroh J., Banhegyi D., Itzchak L., Sha-

har E., Maayan S., Turner D., Lazzarin A., Antinori A., Carosi G., Minoli L., Di Perri G., Filice G., Andreoni M., Duiculescu D., Rugina S., Erscoiu S., Streinu A., Pronin A., Pokrovsky V., Gruzdev B., Yakovlev A., Voronin E., Clotet B., Gatell J., Arribas J., Podzamczar D., Domingo P., Alvarez C.M., Quero J.H., Furrer H., Feher J., Johnson M., Fox J., Nelson M., Fisher M., Orkin C., Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. (2014) J ANTIMICROB CHEMOTH, 69 (4), 1090-1097.

IF: 5.3130

Gorritz J.L., Gutierrez F., Trullas J.C., Arazo P., Arribas J.R., Barril G., Cervero M., Cofan F., Domingo P., Estrada V., Fulladosa X., Galindo M.J., Gracia S., Iribarren J.A., Knobel H., Lopez-Aldeguez J., Lozano F., Martinez-Castelao A., Martinez E., Mazuecos M.A., Miralles C., Montanes R., Negredo E., Palacios R., Perez-Elias M.J., Portilla J., Praga M., Quereda C., Rivero A., Santamaria J.M., Sanz J., Sanz J., Miro J.M., Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients. (2014) ENFERM INFECC MICR CL, 32 (9), 583-597.

IF: 2.1720

Gutierrez F., Fulladosa X., Barril G., Domingo P., Renal tubular transporter-mediated interactions of HIV drugs: Implications for patient management. (2014) AIDS REV, 16 (4), 199-212.

IF: 3.7870

Martinez E., Gonzalez-Cordon A., Ferrer E., Domingo P., Negredo E., Gutierrez F., Portilla J., Curran A., Podzamczar D., Murillas J., Bernardino J., Santos I., Carton J., Paire J., Pich J., Perez I., Gatell J., Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. (2014) HIV MED, 15 (6), 330-338.

IF: 3.9880

Martinez E., Jodar Gimeno E., Reyes Garcia R., Carpintero P., Casado J.L., Del Pino Montes J., Domingo Pedrol P., Estrada V., Maaouf J., Negredo E., Ocampo A., Munoz-Torres M., Consensus statement: Recommendations for the management of metabolic bone disease in human immunodeficiency virus patients. (2014) ENFERM INFECC MICR CL, 32 (4), 250-258.

IF: 2.1720

Massanella M., Ouchi D., Marfil S., Llibre J.M., Puertas M.C., Buzon M.J., Richman D.D., Orna E., Stevenson M., Gatell J.M., Domingo P., Negredo E., Martinez-Picado J., Clotet B., Blanco J., Different plasma markers of inflammation are influenced by

*TIF: 121.6790 **MIF: 4.5066

Scientific Production

immune recovery and cART composition or intensification in treated HIV infected individuals. (2014) PLOS ONE, 9 (12).

IF: 3.2340

Mateo M.G., Gutierrez M.D.M., Vidal F., Domingo P., An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes. (2014) EXPERT OPIN PHARMACO, 15 (12), 1749-1760.

IF: 3.5340

Molto J., Valle M., Ferrer E., Domingo P., Curran A., Santos J.R., Mateo M.G., Di Yacovo M.S., Miranda C., Podzamcz D., Clotet B., Coll J., Gel S., Llibre J.M., Mothe B., Negredo E., Perez-Alvarez N., Sirera G., Rozas N., Vila A., Del Mar Gutierrez M., Mateo G., Burgos J., Navarro J., Ribera E., Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: A randomized clinical trial. (2014) J ANTIMICROB CHEMOTH, 70 (4), 1139-1145.

IF: 5.3130

Negredo E., Diez-Perez A., Bonjoch A., Domingo P., Perez-Alvarez N., Gutierrez M., Mateo G., Puig J., Echeverria P., Escrig R., Clotet B., Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: Changes in bone turnover markers and circulating sclero-

stin levels. (2014) J ANTIMICROB CHEMOTH, 70 (7), 2104-2107.

IF: 5.3130

Negredo E., Domingo P., Ferrer E., Estrada V., Curran A., Navarro A., Isernia V., Rosales J., Perez-Alvarez N., Puig J., Bonjoch A., Echeverria P., Podzamcz D., Clotet B., Peak bone mass in young HIV-infected patients compared with healthy controls. (2014) JAIDS-J ACQ IMM DEF, 65 (2), 207-212.

IF: 4.5560

Peraire J., Vilades C., Pacheco Y.M., Lopez-Dupla M., Domingo P., Gutierrez M., Rosado I., Leal M., Richart C., Vidal F., Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients. (2014) EXPERT OPIN DRUG MET, 10 (1), 81-101.

IF: 2.8310

Pozniak A., Markowitz M., Mills A., Stellbrink H.-J., Antela A., Domingo P., Girard P.-M., Henry K., Nguyen T., Piontkowsky D., Garner W., White K., Guyer B., Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. (2014) LAN-

CET INFECT DIS, 14 (7), 590-599.

IF: 22.4330

Ribas F., Villarroya J., Elayne H., Giralt M., Villarroya F., FGF21 expression and release in muscle cells: Involvement of MyoD and regulation by mitochondria-driven signaling. (2014) BIOCHEM J, 463 (), 191-199.

IF: 4.3960

Saumoy M., Ordonez-Llanos J., Martinez E., Ferrer E., Domingo P., Ribera E., Negredo E., Curto J., Sanchez-Quesada J.L., Di Yacovo S., Lez-Cordon A.G., Podzamcz D., Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: A substudy of the ATADAR randomized study. (2014) J ANTIMICROB CHEMOTH, 70 (4), 1130-1138.

IF: 5.3130

Vidal F., Leal M., Alcamí J., Domingo P., Current situation of the pharmacogenetics of immune recovery in treated HIV-infected patients. (2014) PHARMACOGENOMICS, 15 (5), 569-572.

IF: 3.2180

Villarroya J., Flachs P., Redondo-Angulo I., Giralt M., Medrikova D., Villarroya F., Kopecky J., Planavila A., Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids. (2014) LIPIDS, 49 (11), 1081-1089.

IF: 1.8540

Other Publications

▶ Egana-Gorrón L., Martínez E., Pérez I., Escriba T., Domingo P., Gatell J.M., Arnedo M., Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults. (2014) THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69 (11), 3076-3084.

▶ Pomar V., Domingo P., Acute viral meningitis. (2014) CNS Infections: A Clinical Approach, 9781447164012, 45-55.

▶ Vilades C., Escote X., Lopez-Dupla M., Martínez E., Domingo P., Asensi V., Leal M., Peraire J., Inza M.-I., Arnedo M., Gutierrez M., Valle-Garay E., Ferrando-Martínez S., Olona M., Alba V., Sirvent J.-J., Gatell J.M., Vidal F., Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS). (2014) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69 (6), 1653-1659.

AREA 3

Haematological and Oncological D

118 Clinical Oncology

122 Oncogenes and Antitumour Drugs

126 Haematological Diagnosis

128 Molecular Pathology of Gynaecologic Cancer

132 Ear, Nose and Throat Cancers

134 Oncology/Haematology and Transplantation

iseases



Clinical Oncology

Coordinator

Agustí Barnadas HSCSP
abarnadasm@santpau.cat

Members

Rosa Alfonso HSCSP RI
 María Carmen Alonso HSCSP
 Nuria Calvo HSCSP
 Daniel Escuin HSCSP RI
 David Fisas HSCSP RI
 Óscar Gallego HSCSP
 Antonio López HSCSP
 Margarita Majem HSCSP
 José Pablo Maroto HSCSP
 Cristina Martín HSCSP RI
 Marta Martín HSCSP
 Dulce Menéndez HSCSP RI
 Eva Merino HSCSP RI
 María Pilar Millet HSCSP RI
 María Belén Ojeda HSCSP
 David Páez HSCSP
 María Cinta Pallarés HSCSP
 Maitane Pérez HSCSP RI
 Olga Pich HSCSP RI
 Teresa Ramón y Cajal HSCSP
 María Quintana HSCSP RI
 Romina Ribas HSCSP RI
 Patricia Sanz HSCSP RI
 Ana Sebio HSCSP
 Ariadna Tibau HSCSP RI
 María Tobeña HSCSP
 Tania Vázquez HSCSP RI



Main Lines of Research

Clinical

- ▶ Development of new therapeutic strategies.
- ▶ Studies to improve tumour staging.
- ▶ Studies to detect residual disease.

Translational

- ▶ Personalized anticancer therapy.
- ▶ Studies of predictive and prognostic molecular markers.

Challenges

- ▶ Consolidate clinical research into cancer.
- ▶ Foster translational research into cancer in cooperation with other internal and external research groups.
- ▶ Consolidate the bank of tumours, DNA and serum for patients with cancer diagnosed and treated in our hospital.
- ▶ Develop new early-stage drugs (phase 0/1 studies).

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangués).
- ▶ Molecular Pathology of Gynaecologic Cancer (Dr. Jaime Prat).
- ▶ Genetic Diseases (Dr. Montserrat Baiget).

- ▶ Breast Cancer (Dr. E Lerma).

External Collaborations

- ▶ Tumoural progression modelling group at the Biomedical Research Institute (IRB) (Dr. A. Nebreda).
- ▶ Methylation and resistance to chemotherapy in ovarian cancer (Dr. M. Esteller).

Active Grants

- ▶ Escuin Borrás, Daniel. Mecanismos de acción y resistencia a los taxanos en cáncer de mama. FIS Project 2010. PI10/00307. Duration: 01/01/11-31/03/14. €146,500.
- ▶ Barnadas Molins, Agustí. Desarrollo de un algoritmo predictor de la respuesta al tratamiento en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado. MINECO-ISCI11 Project 2011. PI11/00525. Duration: 01/01/12-31/12/15. €182,409.
- ▶ Escuin Borrás, Daniel. Perfil de expresión de miRNAs en tumor primario de mama y sus ganglios linfáticos centinela: implicaciones en los mecanismos de invasión y su valor como marcadores metastásicos.

FIS Project 2013. PI13/00110. Duration: 01/01/14-31/12/16. €76,000.

- ▶ Arroyo Solera, Irene. Desenvolupament d'una signatura genética per predir la resposta al tractament de quimioradioteràpia en pacients amb carcinoma escatós de cap i coll localment avançat. AGAUR Ajuts per contractar personal investigador novell any 2013 (FI-DGR). 2013 FI00188. Duration: 01/02/13-31/01/16. €39,306.
- ▶ Sullivan, Ivana Gabriela. FIS Contratos Río Hortega 2013. CM13/00117. Duration: 01/01/14-31/12/15. €53,732.

Note: Total amount granted to PI. It does not include indirect costs.

- ▶ Judit Sanz i Buxó. Estudi epidemiològic, genètic i clínic del registre de famílies amb càncer de mama i ovari hereditaris de l'Hospital de la Santa Creu i Sant Pau (1995-2005). Universitat Autònoma de Barcelona Director: M. Teresa Puig Reixach. Date of defense: 12 June 2014.
- ▶ Ana Sebío García. Estudios farmacogenéticos en el cáncer colorrectal: la vía del receptor del factor de crecimiento epidérmico. Universitat Autònoma de Barcelona. Directores: Montserrat Baiget, Agustí Barnadas. Date of defense: 21 November 2014.

*TIF: 202.2650 **MIF: 5.3228

- Alba E., Albanell J., De La Haba J., Barnadas A., Calvo L., Sanchez-Rovira P., Ramos M., Rojo F., Burgues O., Carrasco E., Caballero R., Porras I., Tibau A., Camara M.C., Lluch A., Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: Results from the GEICAM/2006-14 trial. (2014) BRIT J CANCER, 110 (5), 1139-1147.
IF: 4.8360
- Andres R., Pajares I., Balmana J., Llorca G., Ramon Y Cajal T., Chirivella I., Aguirre E., Robles L., Lastra E., Perez-Segura P., Bosch N., Yague C., Lerma E., Godino J., Miramar M.D., Moros M., Astier P., Saez B., Vidal M.J., Arcusa A., Ramon Y Cajal S., Calvo M.T., Tres A., Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). (2014) CLIN TRANSL ONCOL, 16 (3), 280-284.
IF: 2.0770
- Aparicio J., Garcia-Mora C., Martin M., Petriz Ma.L., Feliu J., Sanchez-Santos Ma.E., Ayuso J.R., Fuster D., Conill C., Maurel J., A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: A Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study. (2014) PLOS ONE, 9 (1).
IF: 3.2340
- Balana C., Gil M.J., Perez P., Reynes G., Gallego O., Ribalta T., Capellades J., Gonzalez S., Verger E., Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study. (2014) TARGET ONCOL, 9 (4), 321-329.
IF: 4.0000
- Bancroft E.K., Page E.C., Castro E., Lilja H., Vickers A., Sjoberg D., Assel M., Foster C.S., Mitchell G., Drew K., Maehle L., Axcrona K., Evans D.G., Bulman B., Eccles D., McBride D., Van Asperen C., Vasen H., Kiemeny L.A., Ringelberg J., Cybulski C., Wokolorczyk D., Selkirk C., Hulick P.J., Bojesen A., Skytte A.-B., Lam J., Taylor L., Oldenburg R., Cremers R., Verhaegh G., Van Zelst-Stams W.A., Oosterwijk J.C., Blanco I., Salinas M., Cook J., Rosario D.J., Buys S., Conner T., Ausems M.G., Ong K.-R., Hoffman J., Domchek S., Powers J., Teixeira M.R., Maia S., Foulkes W.D., Taherian N., Ruijs M., Den Enden A.T.H.-V., Izatt L., Davidson R., Adank M.A., Walker L., Schmutzler R., Tucker K., Kirk J., Hodgson S., Harris M., Douglas F., Lindeman G.J., Zgajnar J., Tischkowitz M., Clowes V.E., Susman R., Ramon Y Cajal T., Patcher N., Gadea N., Spigelman A., Van Os T., Liljegren A., Side L., Brewer C., Brady A.F., Donaldson A., Stefansdottir V., Friedman E., Chen-Shtoyerman R., Amor D.J., Copakova L., Barwell J., Giri V.N., Murthy V., Nicolai N., Teo S.-H., Greenhalgh L., Strom S., Henderson A., McGrath J., Gallagher D., Aaronson N., Ardern-Jones A., Bangma C., Dearnaley D., Costello P., Eyfjord J., Rothwell J., Falconer A., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Kote-Jarai Z., Lubinski J., Axcrona U., Melia J., McKinley J., Mitra A.V., Moynihan C., Rennert G., Suri M., Wilson P., Killick E., Moss S., Eeles R.A., Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. (2014) EUR UROL, 66 (3), 489-499.
IF: 13.9380
- Barnadas A., Manso L., de la Piedra C., Messeguer C., Crespo C., Gomez P., Calvo L., Martinez P., Ruiz-Borrego M., Perello A., Anton A., Codes M., Margeli M., Murias A., Salvador J., Segui M.T., de Juan A., Gavila J., Luque M., Perez D., Zamora P., Arizcuma A., Chacon J.I., Heras L., Martin-Fernandez M., Mahillo-Fernandez I., Tusquets I., Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study). (2014) BONE, 68, 32-40.
IF: 3.9730
- Castellano D., Anton Aparicio L.M., Esteban E., Sanchez-Hernandez A., Germa J.R., Batista N., Maroto P., Perez-Valderrama B., Luque R., Mendez-Vidal M.J., Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program. (2014) EXPERT OPIN DRUG SAF, 13 (9), 1165-1173.
IF: 2.9110
- Castellano D.E., Bellmunt J., Maroto J.P., Font-Pous A., Morales-Barrera R., Ghanem I., Suarez C., Martin Lorente C., Etxaniz O., Capdevila L., Coronado C., Alfaro V., Siguero M., Fernandez-Teruel C., Carles J., Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen. (2014) CANCER CHEMOTH PHARM, 73 (4), 857-867.
IF: 2.7690
- Castillejo A., Vargas G., Castillejo M.I., Navarro M., Barbera V.M., Gonzalez S., Hernandez-Illan E., Brunet J., Ramon Y Cajal T., Balmana J., Oltra S., Iglesias S., Velasco A., Solanes A., Campos O., Sanchez Heras A.B., Gallego J., Carrasco E., Gonzalez Juan D., Segura A., Chirivella I., Juan M.J., Tena I., Lazaro C., Blanco I., Pineda M., Capella G., Soto J.L., Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. (2014) EUR J CANCER, 50 (13), 2241-2250.
IF: 5.4170
- Costa C., Molina M.A., Drozdowskyj A., Gimenez-Capitan A., Bertran-Alamillo J., Karachaliou N., Gervais R., Massuti B., Wei J., Moran T., Majem M., Felip E., Carcereny E., Garcia-Campelo R., Viteri S., Taron M., Ono M., Giannikopoulos P., Bivona T., Rosell R., The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-Mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. (2014) CLIN CANCER RES, 20 (7), 2001-2010.
IF: 8.7220
- De Liano A.G., Reig O., Mellado B., Martin C., Rull E.U., Maroto J.P., Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. (2014) BRIT J CANCER, 110 (9), 2201-2208.
IF: 4.8360
- Dias M.M., Pignon J.-P., Karapetis C.S., Boige V., Glimelius B., Kweeekel D.M., Lara P.N., Laurent-Puig P., Martinez-Balibrea E., Paez D., Punt C.J.A., Redman M.W., Toffoli G., Wadehus M., Mckinnon R.A., Sorich M.J., The effect of the UGT1A1 28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis. (2014) PHARMACOGENOMICS J, 14 (5), 424-431.
IF: 4.2290
- Fernandez-Martos C., Brown G., Estevan R., Salud A., Montagut C., Maurel J., Safont M.J., Aparicio J., Feliu J., Vera R., Alonso V., Gallego J., Martin M., Pera M., Sierra E., Serra J., Delgado S., Roig J.V., Santos J., Pericay C., Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: The GEMCAD 0801 phase II multicenter trial. (2014) ONCOLOGIST, 19 (10), 1042-1043.
IF: 4.8650

Clinical Oncology

*TIF: 202.2650 **MIF: 5.3228

Scientific Production

Gallego O., Cuatrecasas M., Benavides M., Segura P.P., Berrocal A., Erill N., Colomer A., Quintana M.J., Balana C., Gil M., Gallardo A., Murata P., Barnadas A., Efficacy of erlotinib in patients with relapsed glioblastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. (2014) *J NEURO-ONCOL*, 116 (2), 413-419.

IF: 3.0700

Gallego O., Cuatrecasas M., Benavides M., Segura P.P., Berrocal A., Erill N., Colomer A., Quintana M.J., Balana C., Gil M., Gallardo A., Murata P., Barnadas A., Erratum: Efficacy of erlotinib in patients with relapsed glioblastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [*J Neurooncol*, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]. (2014) *J NEURO-ONCOL*, 120 (3), 667.

IF: 3.0700

Garcia Del Muro X., Gallardo E., Garcia Carbonero I., Lainez N., Jose Mendez M., Maroto P., Ochoa De Olza M., Puente J., Reynes G., Rubio J., Santander C., Suarez C., Vazquez Estevez S., Castellano D., Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. (2014) *CANCER CHEMOTH PHARM*, 73 (6), 1095-1107.

IF: 2.7690

Gianni L., Eiermann W., Semiglazov V., Lluch A., Tjulandin S., Zambetti M., Moliterni A., Vazquez F., Byakhov M.J., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Magazzu D., Heinzmann D., Steinseifer J., Valagussa P., Baselga J., Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. (2014) *LANCET ONCOL*, 15 (6), 640-647.

IF: 24.6900

Girones R., Aparicio J., Roure P., Germa-Lluch J.R., Garcia del Muro X., Vazquez-Estevez S., Saenz A., Sastre J., Arranz Arijia J., Gallardo E., Gonzalez-Billalabeitia E., Sanchez-Hernandez A., Terrasa J., Hernandez A., Santander C., Cillan E., Sagastibelza N., Almenar-Cubells D., Lopez Brea M., Maroto J.P., Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base. (2014) *CLIN TRANSL ONCOL*, 16 (11), 959-965.

IF: 2.0770

Gonzalez Lopez J.A., Artigas Raventos V., Rodriguez Blanco M., Lopez-Pousa A., Bague S., Abellan M., Trias Folch M., Differences between en bloc resection and enucleation of retroperitoneal sarcomas. (2014) *CIR ES-*

PAN, 92 (8), 525-531.

IF: 0.7430

Gutierrez-Enriquez S., Bonache S., Ruiz De Garibay G., Osorio A., Santamarina M., Ramon Y Cajal T., Esteban-Cardenosa E., Tenes A., Yanowsky K., Barroso A., Montalban G., Blanco A., Cornet M., Gadea N., Infante M., Caldes T., Diaz-Rubio E., Balmana J., Lasa A., Vega A., Benitez J., De La Hoya M., Diez O., About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. (2014) *INT J CANCER*, 134 (9), 2088-2097.

IF: 5.0850

Hitt R., Grau J.J., Lopez-Pousa A., Berrocal A., Garcia-Giron C., Irigoyen A., Sastre J., Martinez-Trufero J., Brandariz Castelo J.A., Verger E., Cruz-Hernandez J.J., A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. (2014) *ANN ONCOL*, 25 (1), 216-225.

IF: 7.0400

Maroto P., Rini B., Molecular biomarkers in advanced renal cell carcinoma. (2014) *CLIN CANCER RES*, 20 (8), 2060-2071.

IF: 8.7220

Martin-Liberal J., Lopez-Pousa A., Broto J.M., Cubedo R., Gallego O., Brendel E., Tirado O.M., Del Muro X.G., Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: A Spanish group for research on sarcomas (GEIS) study. (2014) *INVEST NEW DRUG*, 32 (2), 287-294.

IF: 2.9190

Mur P., Pineda M., Romero A., del Valle J., Borrás E., Canal A., Navarro M., Brunet J., Rueda D., Ramon y Cajal T., Lazaro C., Caldes T., Blanco I., Soto J.L., Capella G., Identification of a founder EPCAM deletion in Spanish Lynch syndrome families. (2014) *CLIN GENET*, 85 (3), 260-266.

IF: 3.9310

Osorio A., *et al.* DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. (2014) *PLOS GENET*, 10 (4).

IF: 7.5280

Paez D., Gerger A., Zhang W., Yang D., Labonte M.J., Benhanim L., Kahn M., Lenz F., Lenz C., Ning Y., Wakatsuki T., Loupakis F., Lenz H.-J., Association of common gene variants in the WNT/ β -catenin pathway with colon cancer recurrence. (2014) *PHARMA-COGENOMICS J*, 14 (2), 142-150.

IF: 4.2290

Peiro G., Ortiz-Martinez F., Gallardo A., Perez-Balaguer A., Sanchez-Paya J., Ponce J.J., Ti-

bau A., Lopez-Vilaro L., Escuin D., Adrover E., Barnadas A., Lerma E., Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. (2014) *BRIT J CANCER*, 111 (4), 689-695.

IF: 4.8360

Reguart N., Rosell R., Cardenal F., Cardona A.F., Isla D., Palmero R., Moran T., Rolfo C., Pallares M.C., Insa A., Carcereny E., Majem M., De Castro J., Queralt C., Molina M.A., Taron M., Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. (2014) *LUNG CANCER*, 84 (2), 161-167.

IF: 3.9580

Remon J., Molina-Montes E., Majem M., Lianes P., Isla D., Garrido P., Felip E., Vinolas N., De Castro J., Artal A., Sanchez M.-J., Lung cancer in women: An overview with special focus on Spanish women. (2014) *CLIN TRANSL ONCOL*, 16 (6), 517-528.

IF: 2.0770

Remon J., Moran T., Majem M., Reguart N., Dalmau E., Marquez-Medina D., Lianes P., Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins. (2014) *CANCER TREAT REV*, 40 (1), 93-101.

IF: 7.5880

Remon J., Moran T., Reguart N., Majem M., Carcereny E., Lianes P., Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome. (2014) *CANCER TREAT REV*, 40 (6), 723-729.

IF: 7.5880

Reynes G., Balana C., Gallego O., Iglesias L., Perez P., Garcia J.L., A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. (2014) *ANTI-CANCER DRUG*, 25 (6), 717-722.

IF: 1.7840

Rodriguez Faba O., Palou J., Breda A., Maroto P., Fernandez Gomez J.M., Wong A., Villavicencio H., Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma. (2014) *UROL INT*, 92 (2), 169-173.

IF: 1.4260

Schmidt S., Riel R., Frances A., Lorente Garin J.A., Bonfill X., Martinez-Zapata M.J., Morales Suarez-Varela M., dela Cruz J., Emparanza J.I., Sanchez M.-J., Zamora J., Goni J.M.R., Alonso J., Ferrer M., Becerra V., Pardo Y., Fores M.F., Garin O., Villagran C.O., Sunol R., Osorio D., Cosp X.B., Canovas E., Pardo G.S., Bolivar I,

*TIF: 202.2650 **MIF: 5.3228

Scientific Production

Bachs J., Maroto J.P., Quintana M.J., Martinez Zapata M.J., Lorente C.M., Algaba F., Redorta P., Esquena S., Puigvert F., Vernooij R., Martinez A., Pijoan Zubizarreta J.I., Martinez L., Castro Diaz D.M., Bastida J.L., Pacheco A.S., Lopez C.G., Cozar Olmo J.M., Martinez C., Chan D.C., Sanchez Perez M.J., Diaz Moratinos A.I., Luis A.M., Hervas A., Ocana C.V., Varona C., Burgos J., Polo Rubio J.A., Lopez-Fando Lavalle L., Jimenez Cidre M.A., Garcia A.M., Farras N.P., Lopez R.M., Garcia S.S., Abaira V., Dos Santos V.G., De la Camara A.G., De la Cruz J., Martinez J.P., Munoz H.G., Cabeza Rodriguez M.A., Diaz I.R., Sanz Jaka J.P., Velasquez M.J., Gonzalez A.L., Morales M., Camps C., Diaz C.C., Vidal E.M., Ballester F.S., Juan Escudero J.U., Peidro J.P., Torrecilla J.L., Ramos Campos M.M., Cebollada M.M.,

Bladder cancer index: Cross-cultural adaptation into Spanish and psychometric evaluation. (2014) HEALTH QUAL LIFE OUT, 12 (1).

IF: 2.1200

Sebio A., Paez D., Salazar J., Berenguer-Llargo A., Pare-Brunet L., Lasa A., Del Rio E., Tobena M., Martin-Richard M., Baiget M., Barnadas A., Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. (2014) PHARMACOGENOMICS J, 14 (3), 256-262.

IF: 4.2290

Selva A., Bolibar I., Torrego A., Pallares M.C., Impact of a program for rapid diagnosis and treatment of lung cancer on hospital care delay and tumor stage. (2014) TUMORI, 100

(6), e243-e249.

IF: 1.2690

Vera-Badillo F.E., Ocana A., Templeton A.J., Tibau A., Amir E., Tannock I.F., Raising concern about the american society of clinical oncology conflict of interest policy amendment. (2014) J CLIN ONCOL, 32 (28), 3197.

IF: 18.4280

Vidal J., Clave S., De Muga S., Gonzalez I., Pijuan L., Gimeno J., Remon J., Reguart N., Vinolas N., Girones R., Bernet L., Majem M., Bosch-Barrera J., Porta R., Alonso N., Palmero R., Taus A., Albanell J., Espinet B., Salido M., Arriola E., Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. (2014) J THORAC ONCOL, 9 (12), 1816-1820.

IF: 5.2820

Other Publications

- ▶ Hidalgo A., Guerra J.M., Gallego O., Franquet T., Microwave ablation of a sarcoma lung metastasis in a patient with a pacemaker. (2014) RADIOLOGIA, 56 (2), 171-174.
- ▶ Sullivan I., Salazar J., Majem M., Pallares C., Del Rio E., Paez D., Baiget M., Barnadas A., Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. (2014) CANCER LETTERS, 353 (2), 160-166.

Oncogenesis and Antitumour Drugs

Coordinator

Ramon Mangues HSCSP RI
rmangues@santpau.cat

Members

Patricia Álamo HSCSP RI
Irene Arroyo HSCSP RI
M. Carmen Cabrera CIBERBBN
Isolda Casanova CIBERBBN
Virtudes Céspedes CIBERBBN
Luis Carlos Navas HSCSP RI
Miguel Ángel Pavon HSCSP RI
Víctor Turrado HSCSP



Main Lines of Research

- ▶ Development of novel animal models of disseminated disease in solid tumours and haematological neoplasms for the mechanistic study of metastases and preclinical drug development.
- ▶ Identification of prognostic biomarkers in head and neck squamous cell carcinoma and their functional validation in vivo.
- ▶ Development of nanoconjugates for targeted delivery of antitumour drugs or toxins to metastasis stem cells.

Challenges

- ▶ Obtain funding to ensure stable employment of senior researchers, attract post-doctoral fellows and reinforce current collaborations with clinicians.
- ▶ Develop molecular markers for therapeutic decision-making in head and neck carcinomas.
- ▶ Achieve antimetastatic effects by targeting antitumour drugs to metastasis stem cells in solid tumors and haematological neoplasias.
- ▶ Enhance international collaboration and participation in EU networks and industrial projects.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Desarrollo de un algoritmo predictor de la respuesta al tratamiento en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado. IP: Agustí Barnadas. P111/00525. Duration: 2012-2014. €220,715.
- ▶ Irene Arroyo Solera (GOA). Beca AGAUR. Desenvolupament de models metastàtics de carcinoma de cap i coll i paper de Serpina1 en disseminació. AGAUR, Generalitat de Catalunya. FI DGR-2013. Duration: 2012-2015.
- ▶ Isolda Casanova (GOA). La Enfermedad Mínima Residual en Leucemia Mieloide Aguda: implicación del microambiente de la médula ósea y evaluación de nuevas nanopartículas para terapia génica dirigida. P111/00872. IP: Jordi Sierra. Duration: 2012-2014. €213,565.
- ▶ María José Moreno Jiménez (GOA). Contrato de Formación de Personal Investigador. Desarrollo de modelos animales en linfoma difuso de células grandes y papel de CXCR4 en disseminación, Instituto de Salud Carlos III. FPI FI10/00758. Duration: 2011-2014.

- ▶ Miguel Ángel Pavón (GOA) Desarrollo de un algoritmo predictor de la respuesta al tratamiento en pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado. P111/00525. IP: Agustí Barnadas. Duration: 2012-2014. €220,715.

National Collaborations

- ▶ Eduard Batlle, Biomedical Research Institute (IRB) and Barcelona Scientific Park (PCB).
- ▶ Roger Gomis, Biomedical Research Institute (IRB) and Barcelona Scientific Park (PCB).

International Collaborations

- ▶ Achilea Bittencourt. Visiting Researcher, International Cooperation with Brasil, MCT/CNPq 046/2010.
- ▶ Paolo Micheli, Institute for Cancer Research and Treatment, Candioli, Turin (Italy).
- ▶ Arne Östman, Cancer Center Karolinska, Karolinska Institutet, Stockholm (Sweden).
- ▶ Alberto Bardelli, University of Torino, Medical School, Turin (Italy).

Active Grants

- ▶ Ramon Mangues Bafalluy. Ajuts de suport als Grups de Recerca de Catalunya. Grup Oncogènesi i Antitumorals. AGAUR 2009. SGR 1437. Duration: 29/09/09-30/04/14. €69,680.
- ▶ Ramon Mangues Bafalluy. Genotoxic nanoparticles targeting colorectal cancer stem cells. MARATÓ TV3 Ajuts per a la recerca biomèdica en càncer 2013. 20132030. Duration: 15/04/14-14/04/17. €142,000.
- ▶ Ramon Mangues Bafalluy. La enfermedad residual mínima en leucemia mieloide aguda: implicación del microambiente de la médula ósea y evaluación de nuevas nanopartículas para terapia dirigida. MINECO-ISCI Project 2011. PI11/00872. Duration: 01/01/12-30/06/15. €182,400.
- ▶ Ramon Mangues Bafalluy. Modelos de cáncer de colon metastásico para el estudio de la recidiva tumoral. FIS Project 2012. PI12/01861. Duration: 01/01/13-31/12/15. €181,500.
- ▶ Ramon Mangues Bafalluy. Oncogenesis por HTLV-1 inhibición de las adhesiones focales como estrategia terapéutica. MICINN Proyectos Internacionales Bilaterales 2010. PIB2010BZ-00563. Duration: 15/12/10-14/12/14. €90,000.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Mangues Bafalluy, Ramon. Grup d'oncogènesi i antitumorals (GOA). AGAUR 2014. SGR 1041. 04/09/14-31/12/16. €30,000.
- ▶ Mangues Bafalluy, Ramon. Terapia de nanoconjugados dirigida a células iniciadoras de metástasis en cancer colorectal. MINECO Acciones de Dinamización Europea Investigación 2014. EUIN2013-50829. 01/10/14.30/09/16. €22,000.
- ▶ Mangues Bafalluy, Ramon. NM13. NanoMets. Drug nanconjugates and nanovesicles for the treatment of metastatic colorectal cancer. CIBER-BBN Intramural Project. 2014-2015.*
- ▶ Carme Cabrera Rodríguez (GOA). Ayudas para personal técnico de apoyo a infraestructuras. Plataforma de Servicios en Nanotoxicología. Centro de Investigación en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). MINECO. PTA2013-8426-I. Duration: 2014-2017. €36,000.

Note: Total amount granted to PI. It does not include indirect costs.

* Grant applied for by other research institutes.

Research Network Participation

- ▶ COST Action CM1106. European Union. Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells. EU RTD Framework Programme. MC Member: Ramon Mangues. Management Committee Member & Biology and Pharmacology Working Group Member, Duration: 28/03/12-27/03/16.
- ▶ ATMP-EATRIS, European Union. Member of the Working Group on Advanced therapies and biologicals of ATMP (Advanced Therapy Medicinal Products), EATRIS (European Infrastructure for Translational Medicine) Network.
- ▶ ETP Nanomedicine, European Union, Member of the European Technology Platform on Nanomedicine.
- ▶ TME-AACR member. Member of the Tumor Microenvironment Working Group, American Association for Cancer Research (AACR).
- ▶ CB06/01/1031. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Instituto de Salud Carlos III. 2010-2015. €80,000-117,000/year.
- ▶ ICTS 141007: NANBIOSIS. Recognition by MINECO as Infraestructura Científica y Técnica Singular (ICTS) en Ciencias de la Salud y Biotecnología (Producción y Caracterización de Nanomateriales, Biomateriales y Sistemas en Biomedicina), Unitat de Natotoxicologia, Institut d'Investigacions Biomèdiques Sant Pau and CIBER-BBN. Coordinators: Centro de Investigación Biomédica en Red (CIBER-BBN) y Centro de Cirugía Mínima Invasiva Jesus Usón (JUSMISC). Financing agency: MINECO. Grant date: 8/10/14.
- ▶ OncoCat. Member of the Catalan Cancer Research Network. Xarxa ConnectEU, Biocat, Generalitat de Catalunya.
- ▶ NanoBioMed. Member of the Catalan Network on Nanobiotechnology, Xarxa Connect-EU. Biocat.

Doctoral Theses

- ▶ María José Moreno Jiménez. Desenvolupament de models animals de linfoma difús de cèl·lula gran i paper de CXCR4 en la disseminació. Universitat de Barcelona. Directors: Ramon Mangues, Isolda Casanova. Date of defense: 10 June 2014.

Oncogenesis and Antitumour Drugs

*TIF: 70.4580 **MIF: 10.0654

Scientific Production

Alamo P, Gallardo A, Pavon M.A., Casanova I., Trias M., Mangues M.A., Vazquez E., Villaverde A., Mangues R., Cespedes M.V., Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. (2014) DIS MODEL MECH, 7 (3), 387-396.

IF: 4.9730

Bosch R, Dieguez-Gonzalez R., Moreno M.J., Gallardo A., Novelli S., Espinosa I., Cespedes M.V., Pavon M.A., Briones J., Granena A., Sierra J., Mangues R., Casanova I., Focal adhesion protein expression in human diffuse large B-cell lymphoma. (2014) HISTOPATHOLOGY, 65 (1), 119-131.

IF: 3.4530

Cespedes M.V., Unzueta U., Tatkiwicz W., Sanchez-Chardi A., Conchillo-Sole O., Alamo P., Xu Z., Casanova I., Corchero J.L., Pesarrodona M., Cedano J., Daura X., Ratera I., Veciana J., Ferrer-Miralles N., Vazquez E., Villaverde A., Mangues R., In vivo architectonic stability of fully de novo designed protein-only nanoparticles. (2014) ACS NANO, 8 (5), 4166-4176.

IF: 12.8810

Motllo C., Ribera J.-M., Morgades M., Granada I., Montesinos P., Gonzalez-Campos J., Fernandez-Abellan P., Tormo M., Bethencourt C., Brunet S., Hernandez-Rivas J.-M., Moreno M.-J., Sarra J., Del Potro E., Barba P., Bernal T., Grande C., Grau J., Cervera J., Feliu E., Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. (2014) CANCER-AM CANCER SOC, 120 (24), 3958-3964.

IF: 4.8890

Ribera J.-M., Oriol A., Morgades M., Montesinos P., Sarra J., Gonzalez-Campos J., Brunet S., Tormo M., Fernandez-Abellan P., Guardia R., Bernal M.-T., Esteve J., Barba P., Moreno M.-J., Bermudez A., Cladera A., Escoda L., Garcia-Boyerero R., Del Potro E., Bergua J., Amigo M.-L., Grande C., Rabunal M.-J., Hernandez-Rivas J.-M., Feliu E., Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial.

(2014) J CLIN ONCOL, 32 (15), 1595-1604.

IF: 18.4280

Unzueta U., Saccardo P., Domingo-Espin J., Cedano J., Conchillo-Sole O., Garcia-Fruitos E., Cespedes M.V., Corchero J.L., Daura X., Mangues R., Ferrer-Miralles N., Villaverde A., Vazquez E., Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. (2014) NANOMED-NANOTECHNOL, 10 (3), 535-541.

IF: 6.1550

Urosevic J., Garcia-Albeniz X., Planet E., Real S., Cespedes M.V., Guiu M., Fernandez E., Bellmunt A., Gawrzak S., Pavlovic M., Mangues R., Dolado I., Barriga F.M., Nadal C., Kemeny N., Batlle E., Nebreda A.R., Gomis R.R., Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. (2014) NAT CELL BIOL, 16 (7), 685-694.

IF: 19.6790

Haematological Diagnosis

Coordinator

Josep Nomdedéu HSCSP
jnomdedeu@santpau.cat

Members

Anna M. Aventín HSCSP
Ramón Ayats HSCSP
Elena Bussaglia HSCSP
Maite Carricondo HSCSP
Montserrat Espadaler HSCSP
Camino Estivill HSCSP
Nieves Fernández HSCSP
Francisca Fuentes HSCSP
Carmen Hernández HSCSP
Clara Martínez HSCSP
Elisabeth Martínez HSCSP
Rosa Ortin HSCSP
Angel Remacha HSCSP
María Pilar Sarda HSCSP
Marta Serra HSCSP
Josep Úbeda HSCSP



Main Lines of Research

Malignant Haemopathologies

- ▶ Diagnostic activities: morphological, immunophenotyping, cytogenetic and molecular characterization (particularly of acute leukaemias).
- ▶ Biological characteristics responding to therapy.
- ▶ New treatments using cell line models aimed at molecular targets.
- ▶ Genomic (microarrays) and proteomic platforms for diagnosis.
- ▶ Murine models development.

Noncancerous Haemopathologies

- ▶ Diagnosis and characterization of thrombocytopenias, thrombocytopathies and other platelet pathologies, especially complex pathologies (of genetic, mixed or unknown origin) and including unusual presentations of common diseases.
- ▶ In the framework of the GAIT-2 (genetic analysis of idiopathic thrombophilia, phase 2) project, to seek new phenotypes that favour the development of thrombosis, specifically related to the structure and function of platelets and other blood cells.

Challenges

- ▶ Consolidate characterization of haematological tumours and complex, rare and genetic noncancerous haematopathologies.
- ▶ Include the results of mass-analysis genomic and proteomic platforms in diagnostic algorithms and establish prognostic factors for haematological disorders, preferably complex or genetic neoplasms and noncancerous pathologies.
- ▶ Develop functional cell culture and animal (murine) models.
- ▶ Consolidate cooperation with the GAIT-2 project, especially regarding platelet and other blood cell participation in thrombosis generation.
- ▶ Promote interaction and stable links with internal groups (clinical haematology, pathology, gastrointestinal, haemostasis and thrombosis, complex disease genomics areas) and with other groups in Spain and abroad, especially those with complementary technologies.

Collaborations

Collaborations with other IIB Sant Pau Group

- ▶ Oncology / Haematology and Transplantation (PI: Jordi Sierra).
- ▶ Genetic Diseases (PI: Baiget).
- ▶ Molecular Bases of Disease (PI: Pablo Fuentes Prior).

External Collaborations

- ▶ Dr. Anna Bigas, IMIM Hospital del Mar.
- ▶ Dr. Pablo Menéndez, Josep Carreras Foundation (Hospital Clínic).
- ▶ Dr. Alberto Villanueva, IDIBELL-Bellvitge Biomedical Research Institute.

Active Grants

► Josep Nomdedéu Guinot. Niveles de ARNm de WT1 en neoplasias mieloides. Aplicación de los métodos de PCR digital en la estratificación pronóstica y en el manejo de las recaídas. Proyectos de Investigación en Salud 2013. PI13/02729. Duration: 01/01/14-31/12/16. €57,500.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

► Josep Nomdedéu Guinot. Ajuts de suport als Grups de Recerca de Catalunya. Grup Diagnòstic Hematològic. AGAUR 2014. SGR 383. 04/09/14-31/12/16. €30,000.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 23.3320 **MIF: 4.6664

Scientific Production

Díaz-Beyá M., Brunet S., Nomdedéu J., Tejero R., Díaz T., Pratcorona M., Tormo M., Ribera J.M., Escoda L., Duarte R., Gallardo D., Heras I., Queipo de Llano M.P., Bargay J., Monzo M., Sierra J., Navarro A., Esteve J.; Cooperative AML group CETLAM (Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias). MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. (2014) LEUKEMIA, 28(4), 804-12.

IF: 10.431

Pujol-Moix N., Noris P., Schlegel N., Klersy C., Heller P.G., Civaschi E., Pujol-Moix N., Fabris F., Favier R., Gresele P., Latger-Cannard V., Cuker A., Nurden P., Greinacher A., Cattaneo M., De Candia E., Pecci A., Hurtaud-Roux M.-F., Glembotsky A.C., Muniz-Díaz E., Randi M.L., Trillot N., Bury L., Lecompte T., Marconi

C., Savoia A., Balduini C.L., Bayart S., Bauters A., Benabdallah-Guedira S., Boehlen F., Borg J.-Y., Bottega R., Bussel J., De Rocco D., de Maistre E., Faleschini M., Falcinelli E., Ferrari S., Ferster A., Fierro T., Fleury D., Fontana P., James C., Lanza F., Duchez V.L.C., Loffredo G., Magini P., Martin-Coignard D., Menard F., Mercier S., Mezzasoma A., Minuz P., Nichele I., Notarangelo L.D., Pippucci T., Podda G.M., Pouymayou C., Rigouzzo A., Royer B., Sie P., Siguret V., Trichet C., Tucci A., Saposnik B., Veneri D., Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. (2014) HAEMATOLOGICA, 99 (8), 1387-1394.

IF: 5.8140

Remacha A.F., Sarda M.P., Canals C., Queralto J.M., Zapico E., Remacha J., Carrascosa C., Role of serum holotranscobalamin (holoTC) in the diagnosis of patients with low serum cobalamin. Comparison with methylmalonic

acid and homocysteine. (2014) ANN HEMATOLOGY, 93 (4), 565-569.

IF: 2.6340

Remacha A.F., Zapico E., Sarda M.P., Rojas E., Simo M., Remacha J., Homs R., Queralto J.M., Immune complexes and persistent high levels of serum vitamin B12. (2014) INT J LAB HEMATOL, 36 (1), 92-97.

IF: 1.8190

Rozman M., Navarro J.-T., Arenillas L., Aventin A., Gimenez T., Alonso E., Perea G., Camos M., Navarrete M., Tuset E., Florensa L., Milla F., Nomdedeu J., de la Banda E., Diaz-Beya M., Pratcorona M., Garrido A., Navarro B., Brunet S., Sierra J., Esteve J., Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. (2014) ANN HEMATOLOGY, 93 (10), 1695-1703.

IF: 2.6340

Molecular Pathology of Gynaecologic Cancer

Coordinator

Jaime Prat HSCSP
jprat@santpau.cat

Members

Emanuela d'Angelo HSCSP
Silvia Bagué HSCSP
Cristina Bértolo HSCSP RI
Íñigo Espinosa HSCSP
Bárbara García-Valdecasas HSCSP
Allan González HSCSP
Enrique Lerma HSCSP
Laura López HSCSP
Anna Mozos HSCSP
Josefina Muñoz HSCSP
M. Jesús Nagel HSCSP RI
Mónica Pascual HSCSP RI
Laia Pau HSCSP RI
Cristina Pons HSCSP
Justyna Szafranska HSCSP
Tania Vázquez HSCSP RI



Main Lines of Research

- ▶ Pathogenic mechanisms of gynaecological cancer (endometrial/ovarian cancer). in common cancers (endometrial, ovarian, etc).
- ▶ Molecular mechanisms of stromal response and immunosuppression in endometrial cancer. ▶ Clinical application of tumour markers.
- ▶ Clinical application of prognostic factors ▶ Molecular biology of uterine and extra-uterine sarcomas.

Challenges

- ▶ Progress as a productive translational gynaecological cancer research group, capable of competing with other highly visible groups in Barcelona that publish regular articles in reputable journals.
- ▶ Cooperate with other groups at the national and international levels.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Experimental Immunology (Silvia Vidal).

External Collaborations

Molecular alterations related with progression in endometrial cancer (Spanish Association Against Cancer, AECC):

- ▶ Dr. Jaume Reventós, Vall d'Hebron Hospital Research Institute (VHIR), Barcelona, Spain.
- ▶ Dr. Xavier Matias-Guiu, Institute for Biomedical Research, Lleida (IRB Lleida), Spain.
- ▶ Dr. Miguel Abal, Santiago de Compostela University Hospital Complex (CHUS), Spain.
- ▶ Dr. Gema Moreno, Fundación MD Anderson Internacional, Madrid, Spain.

Active Grants

- ▶ Prat Díaz de Losada, Jaime. Interacción tumor-estroma en la progresión del carcinoma de endometrio: papel de los miRNAs en la invasión miometrial. MINECO-ISCI III Project 2011. PI11/01561. Duration: 01/01/12-30/06/15. €119,364.
- ▶ Espinosa, Íñigo. La importancia de la vía CSF1 en los leiomiomas uterinos. FIS Proyectos de Investigación en Salud 2012. PI12/01645. Duration: 01/01/13-31/12/15. €70,000.
- ▶ Prat Díaz de Losada, Jaime. Red Temática de Investigación Cooperativa de Cáncer (RTICC). Retics 2006. RD06/0020/0015. Duration: 01/01/07-31/12/14. €415,115.89.
- ▶ Prat Díaz de Losada, Jaime. Red Temática de Investigación Cooperativa en Cáncer (RTICC). Retics 2012. RD12/0036/0011. Duration: 01/01/13-31/12/16. €38,500.
- ▶ Prat Díaz de Losada, Jaime. Alteraciones moleculares relacionadas con la progresión tumoral en el cáncer de endometrio. AECC 2011. Duration: 08/09/11-07/09/16. €262,000.

Note: Total amount granted to PI. It does not include indirect costs.

- Jaime Prat. Method to predict risk of recurrence in endometrial carcinoma. IR Sant Pau, IRB Lleida, VHIR, Servicio Andaluz de Salud, Servizo Galego de Saúde, Fundación MD Anderson Internacional España. Application number: EP14155510. 2014.

*TIF: 95.8013 **MIF: 4.5620

Alemanya L., De Sanjose S., Tous S., Quint W., Vallejos C., Shin H.-R., Bravo L.E., Alonso P., Lima M.A., Guimera N., Klaustermeier J., Llombart-Bosch A., Kasamatsu E., Tatti S.A., Felix A., Molina C., Velasco J., Lloveras B., Clavero O., Lerma E., Laco J., Bravo I.G., Guarch R., Pelayo A., Ordi J., Andujar M., Sanchez G.I., Castellsague X., Munoz N., Bosch F.X., Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. (2014) INT J CANCER, 135 (1), 88-95. **IF: 5.0850**

Andres R., Pajares I., Balmana J., Llorc G., Ramon Y Cajal T., Chirivella I., Aguirre E., Robles L., Lastra E., Perez-Segura P., Bosch N., Yague C., Lerma E., Godino J., Miramar M.D., Moros M., Astier P., Saez B., Vidal M.J., Arcusa A., Ramon Y Cajal S., Calvo M.T., Tres A., Association of BRCA1 germline mutations in young on-set triple-negative breast cancer (TNBC). (2014) CLIN TRANSL ONCOL, 16 (3), 280-284. **IF: 2.0770**

Bosch R., Dieguez-Gonzalez R., Moreno M.J., Gallardo A., Novelli S., Espinosa I., Cespedes M.V., Pavon M.A., Briones J., Granena A., Sierra J., Manges R., Casanova I., Focal adhesion protein expression in human diffuse large B-cell lymphoma. (2014) HISTOPATHOLOGY, 65 (1), 119-131. **IF: 3.4530**

Cuenca S., Sanchez E., Santiago A., El Khader I., Panda S., Vidal S., Nieto J.C., Juarez C., Sancho F., Guarner F., Soriano G., Guarner C., Manichanh C., Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. (2014) J INNATE IMMUN, 6 (3), 263-271. **IF: 4.3520**

D'Angelo E., Prat J., Diagnostic use of immunohistochemistry in uterine mesenchymal tumors. (2014) SEMIN DIAGN PATHOL, 31 (3), 216-222. **IF: 2.5610**

Espinosa I., Catusas L., Dangelo E., Mozos A., Pedrola N., Bertolo C., Ferrer I., Zannoni G.F., West R.B., Van De Rijn M., Matias-Guiu X., Prat J., Stromal signatures in endometrioid endometrial carcinomas. (2014) MODERN PATHOL, 27 (4), 631-639. **IF: 6.1870**

Gonzalez Lopez J.A., Artigas Raventos V., Rodriguez Blanco M., Lopez-Pousa A., Bague S., Abellan M., Trias Folch M., Differences between en bloc resection and enucleation of retroperitoneal sarcomas. (2014) CIR ES-

PAN, 92 (8), 525-531.

IF: 0.7430

Mancikova V., Buj R., Castelblanco E., Inglada-Perez L., Diez A., De Cubas A.A., Curras-Freixes M., Maravall F.X., Mauricio D., Matias-Guiu X., Puig-Domingo M., Capel I., Bella M.R., Lerma E., Castilla E., Reverter J.L., Peinado M.A., Jorda M., Robledo M., DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival. (2014) INT J CANCER, 135 (3), 598-610. **IF: 5.0850**

IF: 5.0850

Marchino T., Ibanez N., Prieto S., Novelli S., Szafranska J., Mozos A., Graell X., Buil J.A., An aggressive primary orbital natural killer/T-cell lymphoma case: Poor response to chemotherapy. (2014) OPHTHAL PLAST RECONS, 30 (5), e131-e134. **IF: 0.8810**

IF: 0.8810

Mato E., Gonzalez C., Moral A., Perez J.I., Bell O., Lerma E., de Leiva A., ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1). (2014) J MOL ENDOCRINOL, 52 (3), 289-300. **IF: 3.0810**

IF: 3.0810

Mozos A., Catusas L., D'Angelo E., Serrano E., Espinosa I., Ferrer I., Pons C., Prat J., The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma. (2014) HUM PATHOL, 45 (5), 942-951. **IF: 2.7690**

IF: 2.7690

Mutch D.G., Prat J., 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. (2014) GYNECOL ONCOL, 133 (3), 401-404. **IF: 3.7740**

IF: 3.7740

Nieto J.C., Sanchez E., Roman E., Vidal S., Oliva L., Guarner-Argente C., Poca M., Torres X., Juarez C., Guarner C., Soriano G., Cytokine production in patients with cirrhosis and TLR4 polymorphisms. (2014) WORLD J GASTROENTERO, 20 (46), 17516-17524. **IF: 2.3690**

IF: 2.3690

Pajares V., Puzo C., Castillo D., Lerma E., Angeles Montero M., Ramos-Barbon D., Amor-Carro O., De Bernabe A.G., Franquet T., Plaza V., Hetzel J., Sanchis J., Torrego A., Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: A randomized trial. (2014) RESPIROLOGY, 19 (6), 900-906. **IF: 3.3450**

IF: 3.3450

Peiro G., Ortiz-Martinez F., Gallardo A., Perez-Balaguer A., Sanchez-Paya J., Ponce J.J., Tibaou A., Lopez-Vilaro L., Escuin D., Adrover E., Barnadas A., Lerma E., Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. (2014) BRIT J CANCER, 111 (4), 689-695. **IF: 4.8360**

IF: 4.8360

Prat J., Staging classification for cancer of the ovary, fallopian tube, and peritoneum. (2014) INT J GYNECOL OBSTET, 124 (1), 1-5. **IF: 1.5370**

IF: 1.5370

Prat J., The results of conservative (fertility-sparing) treatment in borderline ovarian tumors vary depending on age and histological type. (2014) ANN ONCOL, 25 (7), 1255-1258. **IF: 7.0400**

IF: 7.0400

Ramos P., Karnezis A.N., Craig D.W., Sekulic A., Russell M.L., Hendricks W.P.D., Corneveaux J.J., Barrett M.T., Shumansky K., Yang Y., Shah S.P., Prentice L.M., Marra M.A., Kiefer J., Zismann V.L., McEachron T.A., Salhia B., Prat J., D'Angelo E., Clarke B.A., Pressey J.G., Farley J.H., Anthony S.P., Roden R.B.S., Cunniffe H.E., Huntsman D.G., Trent J.M., Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. (2014) NAT GENET, 46 (5), 427-429. **IF: 29.3520**

IF: 29.3520

Roman E., Torrades Ma.T., Nadal Ma.J., Cardenas G., Nieto J.C., Vidal S., Bascunana H., Juarez C., Guarner C., Cordoba J., Soriano G., Randomized pilot study: Effects of an exercise programme and leucine supplementation in patients with cirrhosis. (2014) DIGEST DIS SCI, 59 (8), 1966-1975. **IF: 2.6130**

IF: 2.6130

Simonetti S., Serrano C., Hernandez-Losa J., Bague S., Orellana R., Valverde C., Lleonart M.E., Aizpurua M., Carles J., Ramon y Cajal S., Romagosa C., Schwannomas, benign tumors with a senescent phenotype. (2014) HISTOL HISTOPATHOL, 29 (6), 721-730. **IF: 2.0960**

IF: 2.0960

Ulzurrun E., Stephens C., Ruiz-Cabello F., Robles-Diaz M., Saenz-Lopez P., Hallal H., Soriano G., Roman E., Fernandez M.C., Lucena M.I., Andrade R.J., Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. (2014) PLOS ONE, 9 (4). **IF: 3.2340**

IF: 3.2340

Molecular Pathology of Gynaecologic Cancer

Other Publications

- ▶ Matias-Guiu X, Prat J, Molecular pathology of endometrial cancer. (2014) MOLECULAR SURGICAL PATHOLOGY, 151-170.
- ▶ Salgado-Lopez L, de Quintana-Schmidt C, Gomez-Anson B, Bague-Rosell S, Molet-Teixido J, Inflammatory myofibroblastic tumor in the brain. (2014) REVISTA DE NEUROLOGIA, 59 (6), 281-282.

Ear, Nose and Throat Cancers

Coordinator

Miquel Quer HSCSP
mquer@santpau.cat

Members

Carolina Bothe HSCSP
Jacinto García HSCSP
Juan Ramón Gras HSCSP
Julia de Juan HSCSP
Katarzyna Kolanczak HSCSP
Xavier León HSCSP
Joan Lop Gros HSCSP
Montserrat López HSCSP
Humbert Massegur HSCSP
Joan Montserrat HSCSP
César Orús HSCSP
M. del Prado Venegas HSCSP



Main Lines of Research

- ▶ Genetic and molecular predictors of response to head and neck cancer (with the Oncogenesis and Antitumour Drugs group).
- ▶ Molecular mechanisms of inflammation in head and neck cancer (with the Inflammation Laboratory).
- ▶ Nasosinal endoscopic surgery: innovations in skull base techniques.
- ▶ Internal ear: aspects related to severe deafness, cochlear implants and otoneurological surgery of tumours.

Challenges

- ▶ Promote clinical and translational research into head and neck cancer with a very large database of head and neck cancers.
- ▶ Study relevant clinical issues in depth (second-third neoplasms, staging concerns, prognostic factors, etc) and investigate translational aspects such as genetic and molecular predictors.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Angiology, Vascular Biology and Inflammation (Dr Vila).
- ▶ Oncogenesis and Antitumour Drugs (Dr Mangues).
- ▶ Translational Molecular Oncology (Dr Matilde Parreño).

External Collaborations

- ▶ Catalan Institute of Oncology: Epidemiology (Dr X Bosch).
- ▶ Catalan Institute of Oncology: Oncology (Dr Ricard Mesia).
- ▶ Hospital Joan XXIII: Head and Neck Cancer (Dr FJ Avilés).
- ▶ Hospital Central de Asturias: Head and Neck Cancer (Dr C Suárez).

Active Grants

- ▶ León Vintró, Francisco J. Papel del EJE IL-1/NF-κB en los carcinomas escamosos de cabeza y cuello. MINECO-ISCIII Project 2011. PI11/02380. Duration: 01/01/12-31/12/14. €69,500.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ León Vintró, Francisco J. Herramienta de predicción de respuesta a la radioterapia basada en la expresión de genes relacionados con la transición epitelial-mesenquimal en cáncer de cabeza y cuello. FIS Project 2014. PI14/01918. €71,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 8.4110 **MIF: 1.6822

Scientific Production

Esteller E., Agüero A., Martel M., López M., Quer M., León X., Stomal recurrence in head and neck cancer patients with temporary tracheostomy. (2014) AURIS NASUS LARYNX, 41 (5), 467-470.

IF: 1.1350

Gras-Cabrerizo J.R., Adema-Alcover J.M., Gras-Albert J.R., Kolanczak K., Montserrat-Gili J.R., Mirapeix-Lucas R., Del Campo F.S., Masegur-Solench H., Anatomical and surgical study of the sphenopalatine artery branches. (2014) EUR ARCH OTO-RHINO-L, 271 (7), 1947-1951.

IF: 1.5450

León X., Pedemonte G., García J., López M., Martel M., Quer M., Elective treatment of the neck for second primary tumors of the head and neck. (2014) EUR ARCH OTO-RHINO-L, 271 (5), 1187-1190.

IF: 1.5450

León X., Reply to letter to the editor. (2014) HEAD NECK-J SCI SPEC, 36 (9), 1376.

IF: 2.6410

Simo R., Bradley P., Chevalier D., Dikkers F., Eckel H., Matar N., Peretti G., Piazza C., Remacle M., Quer M., European Laryngological Society: ELS recommendations for the fol-

low-up of patients treated for laryngeal cancer. (2014) EUR ARCH OTO-RHINO-L, 271 (9), 2469-2479.

IF: 1.5450

Other Publications

- ▶ Bothe C., López M., Quer M., León X., García J., Lop J., Aetiology and treatment of vocal fold paralysis: Retrospective study of 108 patients. (2014) ACTA OTORRINOLARINGOLOGICA ESPANOLA, 65 (4), 225-230.

- ▶ Gras-Cabrerizo J.R., Gras-Albert J.R., Monjas-Canovas I., García-Garrigos E., Montserrat-Gili J.R., Sánchez del Campo F., Kolanczak K., Masegur-Solench H., Pedicle flaps based on the sphenopalatine artery: Anatomical and surgical study. (2014) ACTA OTORRINOLARINGOLOGICA ESPANOLA, 65 (4), 242-248.

- ▶ Lop Gros J., García Lorenzo J., Quer Agustí M., Bothe González C., Sarcoidosis and true vocal fold paresis: 2 Cases and a review of the literature. (2014) ACTA OTORRINOLARINGOLOGICA ESPANOLA, 65 (6), 378-380.

Oncology/Haematology and Transplantation

Coordinator

Jordi Sierra HSCSP
jsierra@santpau.cat

Members

Carmen Álvarez	HSCSP RI
Anna Barata	HSCSP RI
Silvia Borrell	HSCSP RI
Rosa Bosch	HSCSP RI
Javier Briones	HSCSP
Salut Brunet	HSCSP
Laura Escribà	HSCSP IR
Albert Esquirol	HSCSP RI
Irene García	HSCSP IR
Anna Garrido	HSCSP RI
Miguel Granell	HSCSP
Montserrat Hoyos	HSCSP RI
Rodrigo Martino	HSCSP
Sara Miqueleiz	HSCSP RI
Carolina Moreno	HSCSP IR
Silvana Novelli	HSCSP
Manuel Víctor Pallares	HSCSP RI
Maria Josefa Rosal	HSCSP RI
Jessica de Rueda	HSCSP RI
Silvana Saavedra	HSCSP
Patricia Sanz	HSCSP RI



Main Lines of Research

- ▶ Study of the molecular and cellular pathophysiology of haematological cancers.
- ▶ Study of the prognostic value of clinical and biological parameters in haematological malignancies.
- ▶ Design of new modalities of chemotherapy, biotherapy and drug treatment targeting molecular mechanisms.
- ▶ Design of new modalities of haematopoietic stem-cell transplantation and cell therapy.
- ▶ Psychological intervention and quality of life in patients with haematological malignancies.

Challenges

- ▶ Identify new prognostic parameters for risk and therapeutic stratification.
- ▶ Evaluate targeted therapy in cell lines and animal models (with the Oncogenesis and Antitumour Drugs group).
- ▶ Reduce toxicity and increase availability of allogeneic transplants.
- ▶ Molecularly characterize acute myeloid leukaemia and determine the prognostic value of known genes and other genes of uncertain significance (with the Haematology Laboratory).
- ▶ Model leukaemia and lymphoma in animals to better understand cell pathophysiology and test new drugs (with the Oncogenesis and Antitumour Drugs group).
- ▶ Molecularly characterize and determine the prognostic significance of cell pathophysiology and immunotherapy for lymphoproliferative diseases and evaluate antitumour immunotherapy in animals and humans.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangués).
- ▶ Haematological Diagnosis (Dr. Josep Nomdedéu).
- ▶ Microbiology and Infectious Diseases (Dr. Pere Coll).

External Collaborations

- ▶ Haematologic cancer programme groups, Carlos III Health Institute Cooperative Cancer Research Network (RTICC): J.Sierra, coordinator.

- ▶ European Research Initiative on Chronic Lymphocytic Leukemia (ERIC): C. Moreno, coordinator.
- ▶ Spanish lymphoma transplantation groups (GELTAMO): J. Briones, S. Novelli
- ▶ Spanish haematologic malignancies consortium (PETHEMA): J. Sierra, M. Granell, S. Brunet
- ▶ Spanish CETLAM acute myeloid leukaemia and myelodysplasia group hospitals: coordinator, S. Brunet.
- ▶ European Leukaemia Network of Excellence groups.

Active Grants

- ▶ Sierra Gil, Jordi. Ajuts de suport als Grups de Recerca de Catalunya. Grup Hematologia Oncològica i Trasplantament. AGAUR 2009 SGR 1246. Duration: 04/09/09-30/04/14. €46,800.
- ▶ Sierra Gil, Jordi. Avaluació de les adhesions focals com a noves dianes terapèutiques en leucèmia mieloide aguda. MARATÓ TV3 2010 Malalties minoritàries. 100830. Duration: 04/03/11-31/12/14. €219,000.
- ▶ Briones, Javier. Memory stem T cells transduced with a chimeric antigen receptor targeting CD30 for the treatment of Hodgkin lymphoma. MARATÓ TV3 Ajuts per a la recerca biomèdica en càncer 2013. 20130710. Duration: 15/04/14-14/04/17. €153,970.
- ▶ Moreno Atanasio, Carolina. Caracterización inmunofenotípica de las células residuales leucémicas post-tratamiento en pacientes con leucemia linfática crónica (LLC). MINECO-ISCIII Projecte 2011. PI11/01740. Duration: 01/01/12-31/12/14. €61,250.
- ▶ Sierra Gil, Jordi. La enfermedad residual mínima en leucemia mieloide aguda: implicación del microambiente de la médula ósea y evaluación de nuevas nanopartículas para terapia dirigida. MINECO-ISCIII Projecte 2011. PI11/00872. Duration: 01/01/12-31/12/14. €26,100.
- ▶ Sierra Gil, Jordi. Red Temática de Investigación Cooperativa de Cáncer. (RTICC). Retics 2006. RD06/0020/0101. Duration: 01/01/07-31/12/14. €337,286.73.
- ▶ Sierra Gil, Jordi. Red Temática de Investigación Cooperativa en Cáncer (RTICC). Retics 2012. RD12/0036/0071. Duration: 01/01/13-31/12/16. €79,000.
- ▶ Brunet Mauri, Salut. Tratamiento de la leucemia mieloide aguda de novo con la combinación de idarrubicina en dosis creciente, citarabina y sensibilización ("priming") con G-CSF. Estudio prospectivo en fase I/II de toxicidad y eficacia. MSSSI EC 2011. EC11-364. Duration: 01/01/12-30/06/15. €93,135.
- ▶ Moreno Jiménez, M^a José. FIS Contracte Predoc formació 2010. FI10/00758. Duration: 01/09/10-31/08/14. €85,200.
- ▶ Del Canto González, Alejandra. MINECO-ISCIII Contracte Predoc formació 2012. FI12/00037. Duration: 01/09/12-31/08/14. €15,600.
- ▶ García Cadenas, Irene. Becas de investigación en universidades o centros en el extranjero 2013. Alfonso Martín Escudero 2013. Duration: 31/01/14-30/01/15. €25,200.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Sierra Gil, Jordi. Terapia dirigida de Auristatina E o Ara-C a células de leucemia mieloide aguda que expresan CXCR4, receptor implicado en adhesión al estroma y quimiorresistencia. FIS. Proyectos de Investigación en Salud 2014. PI14/00450. €191,500.
- ▶ Pallares López, Víctor. Contratos Sara Borrell 2013. FIS. CD13/00074. Duration: 01/01/14-31/12/16. €80,598.
- ▶ Jordi Sierra Gil. Ajuts de suport als Grups de Recerca de Catalunya, Grup Hematologia Oncològica i Trasplantament. AGAUR 2014 SGR 1281. Duration: 2014-2017. €18,000.

Note: Total amount granted to PI. It does not include indirect costs.

Doctoral Theses

- ▶ David Valcárcel Ferreira. Transplante de progenitores hematopoyéticos con acondicionamiento de intensidad reducida: aplicabilidad en leucemia mieloide aguda y síndromes mielodisplásicos. Universitat Autònoma de Barcelona. Directors: Jordi Sierra Gil, Rodrigo Martino Bofarull. Date of defense: 9 April 2014.
- ▶ Isabel Sánchez-Ortega. Avances en la profilaxis antifúngica primaria en la fase precoz del trasplante alogénico. Universitat Autònoma de Barcelona. Directors: Jordi Sierra Gil, Rafael F. Duarte Palomino. Date of defense: 24 July 2014.
- ▶ Pere Barba Suñol. Evaluación de la función hepática en el trasplante alogénico de progenitores hematopoyéticos con acondicionamiento de toxicidad reducida. Universitat Autònoma de Barcelona. Directors: Jordi Sierra Gil, Rodrigo Martino Bofarull. Date of defense: 14 October 2014.
- ▶ Montserrat Hoyos Colell. Impacto de las alteraciones moleculares en el pronóstico de la Leucemia Mieloide Aguda (LMA) "de novo". Universitat Autònoma de Barcelona. Directors: Jordi Sierra Gil, Josep Francesc Nomdedéu Guinot. Date of defense: 25 November 2014.

Oncology/Haematology and Transplantation

*TIF: 207.3400 **MIF: 6.9113

Barba P, Martino R, Perez-Simon J.A., Fernandez-Aviles F., Castillo N., Pinana J.L., Lopez-Anglada L., Rovira M., Bosch F., Carerras E., Corral L.L., Sierra J., Valcarcel D., Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. (2014) BIOL BLOOD MARROW TR, 20 (1), 66-72.

IF: 3.4040

Bennett T.A., Montesinos P, Moscardo F., Martinez-Cuadron D, Martinez J, Sierra J, Garcia R., De Oteyza J.P., Fernandez P, Serrano J, Fernandez A, Herrera P, Gonzalez A, Bethancourt C, Rodriguez-Macias G, Alonso A, Vera J.A., Navas B, Lavilla E., Lopez J.A., Jimenez S., Simiele A., Vidriales B., Gonzalez B.J., Burgaleta C., Hernandez Rivas J.A., Mascunano R.C., Bautista G., Perez Simon J.A., De La Fuente A., Rayon C., Troconiz I.F., Janda A., Bosanquet A.G., Hernandez-Campo P., Primo D., Lopez R., Liebana B., Rojas J.L., Gorrochategui J., Sanz M.A., Ballesteros J., Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine. (2014) CL LYMPH MYELOM LEUK, 14 (4), 305-318.

IF: 2.0200

Bosch R, Dieguez-Gonzalez R., Moreno M.J., Gallardo A., Novelli S., Espinosa I., Cespedes M.V., Pavon M.A., Briones J., Granena A., Sierra J., Mangués R., Casanova I., Focal adhesion protein expression in human diffuse large B-cell lymphoma. (2014) HISTOPATHOLOGY, 65 (1), 119-131.

IF: 3.4530

Briones J., Novelli S., Garcia-Marco J.A., Tomas J.F., Bernal T., Grande C., Canales M.A., Torres A., Moraleda J.M., Panizo C., Jarque I., Palmero F., Hernandez M., Gonzalez-Barca E., Lopez D., Caballero D., Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase II clinical trial. (2014) HAEMATOLOGICA, 99 (3), 505-510.

IF: 5.8140

Briones J., Novelli S., Garcia-Marco J.A., Tomas J.F., Bernal T., Grande C., Canales M.A., Torres A., Moraleda J.M., Panizo C., Jarque I., Palmero F., Hernandez M., Gonzalez-Barca E., Lopez D., Caballero D., Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multi-

center, phase II clinical trial. (2014) HAEMATOLOGICA, 99 (7).

IF: 5.8140

Byrd J.C., Brown J.R., O'Brien S., Barrientos J.C., Kay N.E., Reddy N.M., Coutre S., Tam C.S., Mulligan S.P., Jaeger U., Devereux S., Barr P.M., Furman R.R., Kipps T.J., Cymbalista F., Pocock C., Thornton P., Caligaris-Cappio F., Robak T., Delgado J., Schuster S.J., Montillo M., Schuh A., De Vos S., Gill D., Bloor A., Dearden C., Moreno C., Jones J.J., Chu A.D., Fardis M., McGreivy J., Clow F., James D.F., Hillmen P., Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (2014) NEW ENGL J MED, 371 (3), 213-223.

IF: 55.8730

Diez Campelo M., Sanchez-Barba M., de Soria V.G.G., Martino R., Sanz G., Insunza A., Bernal T., Duarte R., Amigo M.L., Xicoy B., Tormo M., Iniesta F., Bailen A., Benlloch L., Cordoba I., Lopez-Villar O., del Canizo M.C., Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients. (2014) LEUKEMIA RES, 38 (10), 1199-1206.

IF: 2.3510

Díaz-Beyá M., Brunet S., Nomdedéu J., Tejero R., Díaz T., Pratorcorona M., Tormo M., Ribera J.M., Escoda L., Duarte R., Gallardo D., Heras I., Queipo de Llano M.P., Bargay J., Monzo M., Sierra J., Navarro A., Esteve J.; Cooperative AML group CETLAM (Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias). MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. (2014) LEUKEMIA, 28(4), 804-12.

IF: 10.431

Dreger P., Schetelig J., Andersen N., Corradini P., Van Gelder M., Gribben J., Kimby E., Michallet M., Moreno C., Stilgenbauer S., Monteserrat E., Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents?. (2014) BLOOD, 124 (26), 3841-3849.

IF: 10.4520

Ferrer G., Bosch R., Hodgson K., Tejero R., Roue G., Colomer D., Monteserrat E., Moreno C., B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. (2014) BRIT J HAEMATOL, 164 (4), 570-578.

IF: 4.7110

García Cadenas I., Valcarcel D., Martino R., Pinana J.L., Barba P., Novelli S., Esquirol A., Garrido A., Saavedra S., Granell M., Moreno C., Briones J., Brunet S., Sierra J., Impact of cyclosporine levels on the development of acute

graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. (2014) MEDIAT INFLAMM, 2014 ().

IF: 3.2360

García-Delgado R., de Miguel D., Bailen A., Gonzalez J.R., Bargay J., Falantes J.F., Andreu R., Ramos F., Tormo M., Brunet S., Figueredo A., Casano J., Medina T., Badiella L., Jurado A.F., Sanz G., Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. (2014) LEUKEMIA RES, 38 (7), 744-750.

IF: 2.3510

Harrison S.J., Hsu A.K., Neeson P., Younes A., Sureda A., Engert A., Prince H.M., Li M., Savage P., Bugarini R., Williams D., Squier M., Ritchie D.S., Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. (2014) LEUKEMIA LYMPHOMA, 55 (5), 1053-1060.

IF: 2.8910

Marchino T., Ibanez N., Prieto S., Novelli S., Szafranska J., Mozos A., Graell X., Buil J.A., An aggressive primary orbital natural killer/T-cell lymphoma case: Poor response to chemotherapy. (2014) OPHTHAL PLAST RECONS, 30 (5), e131-e134.

IF: 0.8810

Mateos M.-V., Oriol A., Martínez-López J., Teruel A.-I., De La Guía A.L., López J., Bengochea E., Perez M., Martínez R., Palomera L., De Arriba F., Gonzalez Y., Hernandez J.M., Granell M., Bello J.-L., Bargay J., Penalver F.-J., Martín-Mateos M.-L., Paiva B., Montalbán M.-A., Blade J., Lahuerta J.-J., San-Miguel J.F., GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?. (2014) BLOOD, 124 (12), 1887-1893.

IF: 10.4520

Motillo C., Ribera J.-M., Morgades M., Granada I., Montesinos P., Gonzalez-Campos J., Fernandez-Abellan P., Tormo M., Bethencourt C., Brunet S., Hernandez-Rivas J.-M., Moreno M.-J., Sarra J., Del Potro E., Barba P., Bernal T., Grande C., Grau J., Cervera J., Feliu E., Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. (2014) CANCER-AM CANCER SOC, 120 (24), 3958-3964.

IF: 4.8890

Okí Y., Buglio D., Zhang J., Ying Y., Zhou S., Sureda A., Ben-Yehuda D., Zinzani P.L., Prince H.M., Harrison S.J., Kirschbaum M., Johnston P.B., Shen A., Von Tresckow B., Younes A., Im-

*TIF: 207.3400 **MIF: 6.9113

mune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. (2014) BLOOD CANCER J, 4 (8).

IF: 3.4670

Onida F., Brand R., van Biezen A., Schaap M., von dem Borne P.A., Maertens J., Beelen D.W., Carreras E., Alessandrino E.P., Volin L., Kuball J.H.E., Figuera A., Sierra J., Finke J., Kroger N., de Witte T., Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: A retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. (2014) HAEMATOLOGICA, 99 (10), 1582-1590.

IF: 5.8140

Pinana J.L., Montesinos P., Martino R., Vazquez L., Rovira M., Lopez J., Batlle M., Figuera A., Barba P., Lahuerta J.J., Deben G., Perez-Lopez C., Garcia R., Rosique P., Lavilla E., Gascon A., Martinez-Cuadron D., Sanz M.A., Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. (2014) ANN HEMATOL, 93 (2), 299-307.

IF: 2.6340

Pinana J.L., Sanz J., Picardi A., Ferra C., Martino R., Barba P., Gonzalez-Vicent M., Pascual M.J., Martin C., Verdeguer A., de Heredia C.D., Montesinos P., Ribera J.-M., Sanz M., Arcese W., Sanz G., Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. (2014) HAEMATOLOGICA, 99 (2), 378-384.

IF: 5.8140

Ribera J.-M., Oriol A., Morgades M., Montesinos P., Sarra J., Gonzalez-Campos J., Brunet S., Tormo M., Fernandez-Abellan P., Guardia R., Bernal M.-T., Esteve J., Barba P., Moreno M.-J., Bermudez A., Cladera A., Escoda L., Garcia-Boyer R., Del Potro E., Bergua J., Amigo M.-L., Grande C., Rabunal M.-J., Hernandez-Rivas J.-M., Feliu E., Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial. (2014) J CLIN ONCOL, 32 (15), 1595-1604.

IF: 18.4280

Robin M., Giannotti F., Deconinck E., Mohty M., Michallet M., Sanz G., Chevallier P., Cahn

J.-Y., Legrand F., Rovira M., Passweg J., Sierra J., Nguyen S., Maillard N., Yakoub-Agha I., Linkesch W., Cannell P., Marcatti M., Bay J.-O., Chalandon Y., Kroger N., Gluckman E., Rocha V., Olavarria E., Ruggeri A., Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. (2014) BIOL BLOOD MARROW TR, 20 (11), 1841-1846.

IF: 3.4040

Rodrigues C.A., Rocha V., Dreger P., Brunstein C., Sengeloev H., Finke J., Mohty M., Rio B., Petersen E., Guilhot F., Niederwieser D., Cornelissen J.J., Jindra P., Nagler A., Fegueux N., Schoemans H., Robinson S., Ruggeri A., Gluckman E., Canals C., Sureda A., Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: Similar outcomes with umbilical cord blood and unrelated donor peripheral blood. (2014) HAEMATOLOGICA, 99 (2), 370-377.

IF: 5.8140

Rozman M., Navarro J.-T., Arenillas L., Aventin A., Gimenez T., Alonso E., Perea G., Camos M., Navarrete M., Tuset E., Florensa L., Milla F., Nomdedeu J., de la Banda E., Diaz-Beya M., Pratorcorona M., Garrido A., Navarro B., Brunet S., Sierra J., Esteve J., Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. (2014) ANNALS OF HEMATOLOGY, 93 (10), 1695-1703.

IF: 2.6340

Ruggeri A., Sanz G., Bittencourt H., Sanz J., Rambaldi A., Volt F., Yakoub-Agha I., Ribera J.M., Mannone L., Sierra J., Mohty M., Solano C., Nabhan S., Arcese W., Gluckman E., Labopin M., Rocha V., Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia working party of EBMT. (2014) LEUKEMIA, 28 (4), 779-786.

IF: 10.4310

Ruutu T., Gratwohl A., De Witte T., Afanashev B., Apperley J., Bacigalupo A., Dazzi F., Dreger P., Duarte R., Finke J., Garderet L., Greinix H., Holler E., Kroger N., Lawitschka A., Mohty M., Nagler A., Passweg J., Ringden O., Socie G., Sierra J., Sureda A., Wiktor-Jedrzejczak W., Madrigal A., Niederwieser D., Erratum: Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice (Bone Marrow Transplantation (2014) 49 (319) DOI:10.1038/bmt.2013.210). (2014) BONE MARROW TRANSPL, 49 (2), 319.

IF: 3.5700

Sanchez-Garcia J., del Canizo C., Lorenzo I., Nomdedeu B., Luno E., de Paz R., Xicoy B., Valcarcel D., Brunet S., Marco-Betes V., Garcia-Pintos M., Osorio S., Tormo M., Bailen A., Cervero C., Ramos F., Diez-Campelo M., Such E., Arrizabalaga B., Azaceta G., Bargay J., Arilla M.J., Falantes J., Serrano-Lopez J., Sanz G.F., Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. (2014) BRIT J HAEMATOL, 166 (2), 189-201.

IF: 4.7110

Vallejo C., Batlle M., Vazquez L., Solano C., Sampol A., Duarte R., Hernandez D., Lopez J., Rovira M., Jimenez S., Valcarcel D., Belloch V., Jimenez M., Jarque I., Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. (2014) HAEMATOLOGICA, 99 (10), 1632-1637.

IF: 5.8140

Xicoy B., Jimenez M.-J., Garcia O., Bargay J., Martinez-Robles V., Brunet S., Arilla M.-J., Perez De Oteyza J., Andreu R., Casano F.-J., Cervero C.-J., Bailen A., Diez M., Gonzalez B., Vicente A.-I., Pedro C., Bernal T., Luno E., Cedena M.-T., Palomera L., Simiele A., Calvo J.-M., Marco V., Gomez E., Gomez M., Gallardo D., Munoz J., De Paz R., Grau J., Ribera J.-M., Benlloch L.-E., Sanz G., Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. (2014) LEUKEMIA LYMPHOMA, 55 (6), 1300-1303.

IF: 2.8910

Xicoy B., Ribera J.-M., Muller M., Garcia O., Hoffmann C., Oriol A., Hentrich M., Grande C., Wasmuth J.-C., Esteve J., Van Lunzen J., Del Potro E., Knechten H., Brunet S., Mayr C., Escoda L., Schommers P., Alonso N., Vall-Llovera F., Perez M., Morgades M., Gonzalez J., Fernandez A., Thoden J., Gokbuget N., Hoelzer D., Fatkenheuer G., Wyen C., Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: Parallel study of 81 patients. (2014) LEUKEMIA LYMPHOMA, 55 (10), 2341-2348.

IF: 2.8910

AREA 4

Neurological, Mental and Ageing

- 140 Cerebrovascular Diseases
- 144 Neuromuscular Diseases
- 148 Parkinson Disease and Movement Disorders
- 152 Molecular Neuropharmacology
- 154 Pharmacological Research in Humans
- 156 Clinical Psychiatry
- 160 Genetics in Neurodegenerative Diseases

tal Disorders



164 Human Neuropsychopharmacology

166 Neurobiology of Dementia

170 Neuroradiology

172 Ageing Institute

176 Addictive Behaviours

178 Molecular Physiology of the Synapse


Cerebrovascular Diseases

Coordinator

Joan Martí Fàbregas HSCSP
jmartí@santpau.cat

Members

Pol Camps HSCSP RI
Elena Cortés HSCSP
Raquel Delgado HSCSP
Calra Gregori HSCSP RI
Daniel Guisado HSCSP
Elena Jiménez HSCSP RI
Rebeca Marín HSCSP RI
Gemma Mateu HSCSP
Luis Antonio Prats HSCSP RI



Main Lines of Research

- ▶ Brain neurorepair after stroke.
- ▶ Role of statins in ischemic and haemorrhagic stroke.
- ▶ Prevention of cerebral haemorrhage with anticoagulants.
- ▶ Endothelial progenitor cells in stroke.
- ▶ Aetiological classification of brain haemorrhage.
- ▶ Pathophysiology of hematoma growth in acute cerebral haemorrhage.
- ▶ Benefits and risks of intravenous thrombolysis.
- ▶ Sonothrombolysis.
- ▶ Non-invasive monitoring of cerebral flow with applied optic methods.
- ▶ Participation in clinical trials.

Challenges

- ▶ Enhance cooperation with other groups in the framework of Spanish stroke research.
- ▶ Network (RETICS/INVICTUS) and also intrahospital cooperation (the Catalan Institute of Cardiovascular Sciences and the Haemostasis-Thrombosis group) and extra-hospital cooperation (with groups managed by Dr. García-Verdugo in Valencia, Dr. Arús at the Autonomous University of Barcelona, Dr. Anna Planas at Clinic Hos-
- pital, Dr. Turgut Durduran at ICFO). To obtain funding from FIS, regional authorities and private companies.
- ▶ Increase the number of contracted and grant-aided researchers and professionally develop existing researchers.

Active Grants

- ▶ Joan Martí Fàbregas. Sonothrombolysis potentiated by microbubbles as a novel treatment of acute ischemic stroke: a prospective randomized study. TELEMATÓ 2011. Lesions Medul·lars i Cerebrals. 112410. Duration: 11/06/12-10/06/15. €159,939.
- ▶ Joan Martí Fàbregas. Hemorragia cerebral por anticoagulantes orales en la prevención secundaria del ictus: Valor predictivo de la leucoaraiosis y los micro-sangrados detectados mediante Resonancia Magnética. MINECO-ISCIII Project 2011. PI11/00296. Duration: 01/01/12-31/12/14. €31,191.
- ▶ Joan Martí Fàbregas. RENEVAS. Retics 2006. RD06/0026/0019. Duration: 01/01/07-31/12/14. €208,143.37.
- ▶ Martí Fàbregas, Joan. INVICTUS. Redes Temáticas de Investigación Cooperativa en Salud 2012. RD12/0014/0002. Duration: 01/01/13-31/12/16. €41,305.10.

Note: Total amount granted to PI. It does not include indirect costs.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Neuroradiology.
- ▶ Thrombosis and Haemostasis.
- ▶ Cardiovascular Biochemistry.
- ▶ Neurobiology of Dementia.
- ▶ Molecular Pathology and Therapeutic of Ischaemic and Atherothrombotic Diseases.

External Collaborations

- ▶ Dr. García-Verdugo, Universidad de Valencia, Spain.
- ▶ Dr. Carles Arús, Facultad de Ciencias, Universidad Autónoma de Barcelona, Spain.
- ▶ Dr. Turgut Durduran, Instituto de Ciencias Fotónicas, Castelldefels, Barcelona, Spain.
- ▶ Dr. Tomás Sobrino, Hospital General Universitario, Santiago de Compostela, Spain.
- ▶ Dr. Israel Fernández, Dr. Joan Montaner, Hospital Vall d'Hebron, Barcelona, Spain.
- ▶ Dr. Blanca Fuentes, Hospital La Paz, Madrid, Spain.

- ▶ Dr. Patricia Martínez, Hospital La Paz, Madrid, Spain.
- ▶ Dr. Antonio Gil. Hospital Gregorio Marañón, Madrid, Spain.
- ▶ Dr. Ángel Chamorro, Hospital Clínico de Barcelona, Spain.
- ▶ Dr. Antonio Dávalos, Hospital Germans Trias i Pujol, Badalona, Spain.
- ▶ Dr. Francesc Purroy, Hospital Arnau de Vilanova, Lleida, Spain.
- ▶ RETICS (cooperative health research network) / INVICTUS (ictus research)
- ▶ Clinical trials:
 - IMPACT-24b: Implant in the sphenopalatine ganglion to increase cerebral blood flow 24 hours after stroke onset.
 - IMPACT-24Bt: Implant in the sphenopalatine ganglion to increase cerebral blood flow 24 hours after stroke onset (rt-PA port).
 - CLEAR III: Evaluation of thrombolytic therapy in intraventricular haemorrhage.
 - LIFE: Multicentre, randomized, double-blind, parallel group, placebo-controlled study of the effect of treatment with F2695 (75 mg OD) in 3 months to improve functional capacity in patients with ischaemic stroke.

*TIF: 79.3280 **MIF: 5.6663

Scientific Production

Abilleira S., Cardona P., Ribo M., Millan M., Obach V., Roquer J., Canovas D., Marti-Fabregas J., Rubio F., Alvarez-Sabin J., Davalos A., Chamorro A., De Miquel M.A., Tomasello A., Castano C., Macho J.M., Ribera A., Gallofre M., Sanahuja J., Purroy F., Serena J., Castellanos M., Silva Y., Van Eendenburg C., Pellise A., Ustrell X., Mares R., Baiges J., Garces M., Saura J., Insa J.M.S., Aragones J.M., Otermin P., Cocho D., Palomeras E., De La Ossa N.P., Gomis M., Lopez-Cancio E., Dorado L., Garcia-Bermejo P., Rubiera M., Santamarina E., Pagola J., Molina C., Coscojuela P., Quesada H., Cano L., Aja L., Mora P., Cervera A., Amaro S., Urra X., Blasco-Andaluz J., Roman L.S., Delgado-Mederos R., Dinia L., Carrera-Giraldo D., Rodriguez-Campello A., Ois A., Cuadrado-Godia E., Vivas E., Del Carmen Garcia M., Estela J., Perendreu J., Krupinski J., Huertas-Folch S., Nicolas-Herrerias M.C., Gomez-Choco M., Garcia S., Martinez R., Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy. (2014) *STROKE*, 45 (4), 1046-1052.

IF: 5.7230

Abilleira S., Ribera A., Davalos A., Ribo M., Chamorro A., Cardona P., Molina C.A., Martinez-Yelamos A., Urra X., Dorado L., Roquer J., Marti-Fabregas J., Aja L., Tomasello A., Castano C., Blasco J., Canovas D., Castellanos M., Krupinski J., Guimaraens L., Perendreu J., Ustrell X., Purroy F., Gomez-

Choco M., Baiges J.J., Cocho D., Saura J., Gallofre M., Functional outcome after primary endovascular therapy or IV thrombolysis alone for stroke. An observational, comparative effectiveness study. (2014) *CEREBROVASC DIS*, 38 (5), 328-336.

IF: 3.7540

Alonso de Lecinana M., Egido J.A., Casado I., Ribo M., Davalos A., Masjuan J., Caniego J.L., Martinez Vila E., Diez Tejedor E., Fuentes Secretaria B., Alvarez-Sabin J., Arenillas J., Calleja S., Castellanos M., Castillo J., Diaz-Otero F., Lopez-Fernandez J.C., Freijo M., Gallego J., Garcia-Pastor A., Gil-Nunez A., Gilo F., Irimia P., Lago A., Maestre J., Marti-Fabregas J., Martinez-Sanchez P., Molina C., Morales A., Nombela F., Purroy F., Rodriguez-Yanez M., Roquer J., Rubio F., Segura T., Serena J., Simal P., Tejada J., Vivancos J., Guidelines for the treatment of acute ischaemic stroke. (2014) *NEUROLOGIA*, 29 (2), 102-122.

IF: 1.3810

Arboix A., Blanco-Rojas L., Marti-Vilalta J.L., Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: Translation of knowledge to prevention strategies. (2014) *EXPERT REV NEUROTHOR*, 14 (3), 261-276.

IF: 2.7830

Chamorro A., Amaro S., Castellanos M., Segura T., Arenillas J., Marti-Fabregas J., Gallego J., Krupinski J., Gomis M., Canovas D., Carne X., Deulofeu R., Roman L.S.,

Oleaga L., Torres F., Planas A.M., Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): A randomised, double-blind phase 2b/3 trial. (2014) *LANCET NEUROL*, 13 (5), 453-460.

IF: 21.8960

Fuentes B., Gallego J., Gil-Nunez A., Morales A., Purroy F., Roquer J., Segura T., Tejada J., Lago A., Diez-Tejedor E., Alonso de Lecinana M., Alvarez-Sabin J., Arenillas J., Calleja S., Casado I., Castellanos M., Castillo J., Davalos A., Diaz-Otero F., Egido J.A., Lopez-Fernandez J.C., Freijo M., Garcia Pastor A., Gilo F., Irimia P., Maestre J., Masjuan J., Marti-Fabregas J., Martinez-Sanchez P., Martinez-Vila E., Molina C., Nombela F., Ribo M., Rodriguez-Yanez M., Rubio F., Serena J., Simal P., Vivancos J., Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological subtype. (2014) *NEUROLOGIA*, 29 (3), 168-183.

IF: 1.3810

Marti-Fabregas J., Delgado-Mederos R., Marin R., De La Ossa N.P., De Lecinana M.A., Rodriguez-Yanez M., Sanahuja J., Purroy F., De Arce A.M., Carrera D., Dinia L., Guardia-Laguarta C., Lleo A., Prognostic value of plasma β -amyloid levels in patients with acute intracerebral hemorrhage. (2014) *STROKE*, 45 (2), 413-417.

IF: 5.7230

Pearce L.A., McClure L.A., Anderson D.C., Jacova C., Sharma M., Hart R.G., Benavente

*Total Impact Factor **Mean Impact Factor

Cerebrovascular Diseases

*TIF: 79.3280 **MIF: 5.6663

Scientific Production

O.R., Martí-Vilalta J.L., Marín R., Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: A secondary analysis from the SPS3 randomised trial. (2014) LANCET NEUROL, 13 (12), 1177-1185.

IF: 21.8960

Purroy F., Jimenez Caballero P.E., Gorospe A., Torres M.J., Alvarez-Sabin J., Martinez-Sanchez P., Canovas D., Freijo M., Egido J.A., Ramirez-Moreno J.M., Alonso-Arias A., Rodriguez-Campello A., Casado-Naranjo I., Marti-Fabregas J., Silva Y., Cardona P., Morales A., Garcia-Pastor A., Arenillas J.F., Segura T., Jimenez C., Masjuan J., How predictors and patterns of stroke recurrence after a TIA differ during the first year of follow-up. (2014) J NEUROL, 261 (8), 1614-1621.

IF: 3.3770

Rico Santana N., Zapico Muniz E., Cocho D., Bravo Y., Delgado Mederos R., Marti-Fabregas J., Analysis of peptidome profiling of serum from patients with early onset symptoms of ischemic stroke. (2014) J STROKE CEREBROVASC, 23 (2), 235-240.

IF: 1.6690

Urta X., San Roman L., Gil F., Millan M., Canovas D., Roquer J., Cardona P., Ribo M., Marti-Fabregas J., Abilleira S., Chamorro A., Medical and endovascular treatment of patients with large vessel occlusion presenting with mild symptoms: An observational multicenter study. (2014) CEREBROVASC DIS, 38 (6), 418-424.

IF: 3.7540

Vivancos J., Gilo F., Frutos R., Maestre J., Garcia-Pastor A., Quintana F., Roda J.M., Ximenez-Carrillo A., Diez Tejedor E., Fuentes B., Alonso de Lecinana M., Alvarez-Sabin J., Arenillas J., Calleja S., Casado I., Castellanos M., Castillo J., Davalos A., Diaz-Otero F., Egido J.A., Fernandez J.C., Freijo M., Gallego J., Gil-Nunez A., Irimia P., Lago A., Masjuan J., Marti-Fabregas J., Martinez-Sanchez P., Martinez-Vila E., Molina C., Morales A., Nombela F., Purroy F., Ribo M., Rodriguez-Yanez M., Roquer J., Rubio F., Segura T., Serena J., Simal P., Tejada J., Diez-Tejedor E., Fuentes B., Alonso de Lecinana M., Alvarez-Sabin J., Arenillas J., Calleja S., Casado I., Castellanos M., Castillo J., Davalos A., Diaz-Otero F., Antonio Egido J., Fernandez J.C.L., Freijo M., Gallego J., Pastor A.G., Gil-Nunez A., Gilo F., Irimia P.,

Lago A., Maestre J., Masjuan J., Marti-Fabregas J., Martinez-Sanchez P., Martinez-Vila E., Molina C., Morales A., Nombela F., Purroy F., Ribo M., Rodriguez-Yanez M., Roquer J., Rubio F., Segura T., Serena J., Simal P., Tejada J., Vivancos J., Larracochea J., Matias-Guiu J., Correas Callero E., Frutos R., Quintana F., Maria Roda J., Ximenez-Carrillo A., Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment. (2014) NEUROLOGIA, 29 (6), 353-370.

IF: 1.3810

Zirak P., Delgado-Mederos R., Dinia L., Carrera D., Marti-Fabregas J., Durduran T., Transcranial diffuse optical monitoring of microvascular cerebral hemodynamics after thrombolysis in ischemic stroke. (2014) J BIOMED OPT, 19 (1).

IF: 2.8590

Zirak P., Delgado-Mederos R., Dinia L., Marti-Fabregas J., Durduran T., Microvascular versus Macrovascular Cerebral Vasomotor Reactivity in Patients with Severe Internal Carotid Artery Stenosis or Occlusion. (2014) ACAD RADIOL, 21 (2), 168-174.

IF: 1.7510

Neuromuscular Diseases

Coordinator

Isabel Illa HSCSP
iilla@santpau.cat

Members

Josefa Araque CIBERER
Elisabet Arribas HSCSP RI
Izaskun Belmonte HSCSP RI
Jorge Alberto Diaz HSCSP RI
Eduard Gallardo HSCSP RI
Jaume Llauger HSCSP RI
Maria Cinta Lleixa HSCSP RI
Noemí de Luna CIBERER
Gisela Nogales HSCSP RI
Esther Ortiz HSCSP RI
Irene Pedrosa HSCSP RI
Patricia Piñol HSCSP RI
Ricardo Rojas HSCSP RI
Sonia Segovia HSCSP RI
Ana María Siles HSCSP RI
Xavier Suárez HSCSP RI



Main Lines of Research

Autoimmune neuromuscular diseases

- ▶ Characterization of new target antigens in Myasthenia Gravis, and immune neuropathies (CIDP, GBS, MMN). Their use as diagnostic and therapeutic biomarkers.
- ▶ Pathogenesis of newly recognized paranodal antigens in CIDP.
- ▶ Analysis of the innate immunity in inflammatory myopathies.
- ▶ Analysis of the impact of new immunomodulating therapies on IgG4 mediated Neuromuscular Diseases (NMD).
- ▶ Functional aspects of immune system cells (response to ligands, production of antibodies, etc).
- ▶ IGOS data base for Guillain Barre syndrome.
- ▶ NMD-ES Spanish registry for neuromuscular diseases.

Muscular dystrophy, dysferlinopathy and distal myopathies

- ▶ Muscle MRI analysis as a biomarker of different muscular dystrophies.
- ▶ Study of miRNA profiles and muscle secretome in muscular dystrophies.
- ▶ Role of PDGF in muscular dystrophies fibrosis.
- ▶ Natural history of Dysferlinopathies. The international COS-study Jain Foundation.
- ▶ To evaluate the frequency of carriers of mutations in the dyferlin gene in normal population.

Amyotrophic lateral sclerosis

- ▶ Epidemiology of ALS in Catalonia.
- ▶ Gene profile of ALS patients in Spain.
- ▶ Biomarkers profile in different phenotypes of ALS.

Challenges

- ▶ Advance in the knowledge of the immunological mechanisms involved in the pathogenesis of autoimmune neuromuscular diseases (MG, CIDP, MMN).
- ▶ Advance in the knowledge of the pathogenetic mechanisms of inflammatory myopathies (DM, PM, IBM).
- ▶ Search for new antigens and develop diagnostic tests with new biomarkers in immune-mediated neuropathies and Myasthenia Gravis.
- ▶ Implement new diagnostic and disease follow-up methods for muscular dystro-

phies resulting from dysferlinopathy and other myopathies research (biomarkers (miRNA, secretome), MRI, etc).

- ▶ Advance in the knowledge of the pathogenetic mechanisms involved in muscular dystrophy resulting from dysferlin deficiency and other muscular dystrophies.
- ▶ Cleanroom access to manipulate cells for use in humans.
- ▶ Use of the NMD.ES registry to perform research in different NMD.

Collaborations

External Collaborations

- ▶ Jerome Devaux, Marseilles, France.
- ▶ Silvere van der Maarel, Leiden, The Netherlands.
- ▶ Xavier Navarro, Dept Medicina, UAB, Barcelona, Spain.
- ▶ R. Martí, Hospital Vall Hebron, Barcelona, Spain.

- ▶ AFM TÉLÉTHON 2013. Aida Alejaldre Monforte. New biomarkers in dysferlinopathies.. Duration: 01/10/13-30/09/14. €16,500.

Awards

- ▶ Luis Querol. PK Thomas award to the best presentation on neuropathies at the EFNS meeting in Istanbul.
- ▶ Isabel Illa Sendra. Premio Sociedad Española de Neurología - Enfermedades Neuromusculares por su trabajo en el proyecto nacional de bases de datos de pacientes con ENM-ES. May 2014.

Doctoral Theses

- ▶ Eugenia Martínez Hernández. Biomarcadores en el diagnóstico y tratamiento de la miastenia. Universitat Autònoma de Barcelona. Director: Isabel Illa Sendra.

Active Grants

- ▶ Eduard Gallardo Vigo. Ajuts de suport als Grups de Recerca de Catalunya. Grup Malalties Neuromusculars. AGAUR 2009. SGR 1004. Duration: 17/09/09-30/04/14. €43,680.
- ▶ Isabel Illa Sendra. Role of RLR innate immunity in initiating and perpetuating dermatomyositis. Research Grant Application 2013. Duration: 01/01/14-31/12/15. €28,744.40.
- ▶ Isabel Illa Sendra. Estudios inmunológicos relevantes para el desarrollo de estrategias terapéuticas en enfermedades neuromusculares. FIS Project 2009. PI09/1964. Duration: 01/01/10-28/02/14. €499,500.
- ▶ Eduard Gallardo Vigo. Búsqueda de biomarcadores de distrofias musculares con debilidad de cinturas. Proyectos de Investigación en Salud 2012. PI12/02291. Duration: 01/01/13-31/12/15. €90,500.
- ▶ Ricardo Rojas. Base de datos española de enfermedades neuromusculares. Proyectos de Investigación en Salud 2013. PI13/00772. Duration: 01/01/14-31/12/16. €21,000.

- ▶ Isabel Illa Sendra. Nuevas reactividades antigénicas y estudios de inmunidad innata en enfermedades neuromusculares auto-inmunes. Proyectos de Investigación en Salud 2013. PI13/00937. Duration: 01/01/14-31/12/16. €160,250.
- ▶ Gisela Nogales Gadea. Contracte Postdoc Sara Borrell 2010. Instituto de Salud Carlos III. CD10/00027. Duration: 01/01/2011-31/12/2014. €144,000.
- ▶ Luis Antonio Querol Gutiérrez. Contratos Juan Rodés 2013. Instituto de Salud Carlos III. JR13/00014. Duration: 30/01/2014-31/12/2016. €135,000.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Isabel Illa Sendra. Identification of Novel Biomarkers Treatments for Inflammatory Demyelinating Neuropathies. AFM TÉLÉTHON 2013. 17215. Duration: 30/04/14-31/12/15. €21,000.
- ▶ Eduard Gallardo Vigo. Recerca en Malalties Neuromusculars. AGAUR 2014. SGR 272. Duration: 04/09/14-31/12/16. €30,000.
- ▶ Ricardo Rojas Garcia. Biomakers profile in different phenotypes of Motor Neuron Disease. Ajudes a la recerca biomèdica sobre malalties neutodegeneratives 2014. 544/U/2014 MARATO. Duration: 01/01/15-31/12/17. €120,500.

- ▶ Isabel Illa Sendra. Contratos para la intensificación de la actividad investigadora en el SNS 2014. Instituto de Salud Carlos III. INT14/00079. Duration: 08/01/15-31/12/15. €30,000.
- ▶ Xavier Suárez Calvet. New therapeutic targets in dermatomyositis. Research Grant Application 2014. The Myositis Association. Duration: 23/01/15-22/01/17. €63,136.98.

Note: Total amount granted to PI. It does not include indirect costs.

Neuromuscular Diseases

*TIF: 74.2870 **MIF: 5.7144

Scientific Production

Aragones J.-M., Roura-Poch P., Hernandez-Ocampo E.M., Alonso F., Pont-Lluelles M., Xandri I., Bolibar I., Illa I., Myasthenia gravis: A disease of the very old. (2014) *J AM GERIATR SOC*, 62 (1), 196-197.

IF: 4.5720

Diaz-Manera J., Alejaldre A., Llauger J., Mirabet S., Rojas-Garcia R., Ramos-Fransi A., Gallardo E., Illa I., Cranial, axial and proximal myopathy and hypertrophic cardiomyopathy caused by a mutation in the globular head region of the MYH7 gene. (2014) *EUR J NEUROL*, 21 (6).

IF: 4.0550

Diaz-Manera J., Querol L., Alejaldre A., Rojas-Garcia R., Ramos-Fransi A., Gallardo E., Illa I., Severe exacerbation of Andersen-Tawil syndrome secondary to thyrotoxicosis. (2014) *J HUM GENET*, 59 (8), 465-466.

IF: 2.4620

Dols-Icardo O., Garcia-Redondo A., Rojas-Garcia R., Sanchez-Valle R., Noguera A., Go mez-Tortosa E., Pastor P., Hernandez I., Esteban-Perez J., Suarez-Calvet M., Anton-Aguirre S., Amer G., Ortega-Cubero S., Blesa R., Fortea J., Alcolea D., Capdevila A., Antonell A., Llado A., Munoz-Blanco J.L., Mora J.S., LuciaGalan-Da vila, De Rivera F.J.R., Lleo A., Clarimon J., Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. (2014) *HUM MOL GENET*, 23 (3), 749-754.

IF: 6.3930

Evila A., Vihola A., Sarparanta J., Raheem O., Palmio J., Sandell S., Eymard B., Illa I., Ro-

jas-Garcia R., Hankiewicz K., Negro L., Loppinen T., Nokelainen P., Karppa M., Penttila S., Screen M., Suominen T., Richard I., Hackman P., Udd B., Atypical phenotypes in titinopathies explained by second titin mutations. (2014) *ANN NEUROL*, 75 (2), 230-240.

IF: 9.9770

Gallardo E., Ankala A., Nunez-Alvarez Y., Hegde M., Diaz-Manera J., Luna N.D., Pastoret A., Suelves M., Illa I., Genetic and Epigenetic Determinants of Low Dysferlin Expression in Monocytes. (2014) *HUM MUTAT*, 35 (8), 990-997.

IF: 5.1440

Gallardo E., Martinez-Hernandez E., Titulaer M.J., Huijbers M.G., Martinez M.A., Ramos A., Querol L., Diaz-Manera J., Rojas-Garcia R., Hayworth C.R., Verschuuren J.J., Balice-Gordon R., Dalmau J., Illa I., Cortactin autoantibodies in myasthenia gravis. (2014) *AUTO-IMMUN REV*, 13 (10), 1003-1007.

IF: 7.9330

Gomez A.M., Willcox N., Vrolix K., Hummel J., Nogales-Gadea G., Saxena A., Duimel H., Verheyen F., Molenaar P.C., Buurman W.A., De Baets M.H., Martinez-Martinez P., Losen M., Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. (2014) *J IMMUNOL*, 193 (3), 1055-1063.

IF: 4.9220

Keijzers M., Nogales-Gadea G., De Baets M., Clinical and scientific aspects of acetylcholine receptor myasthenia gravis. (2014)

CURR OPIN NEUROL, 27 (5), 552-557.

IF: 5.3070

Labasque M., Hivert B., Nogales-Gadea G., Querol L., Illa I., Faivre-Sarrailh C., Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. (2014) *J BIOL CHEM*, 289 (11), 7907-7918.

IF: 4.5730

Nogales-Gadea G., Ramos-Fransi A., Suarez-Calvet X., Navas M., Rojas-Garcia R., Mosquera J.L., Diaz-Manera J., Querol L., Gallardo E., Illa I., Analysis of serum miRNA profiles of myasthenia gravis patients. (2014) *PLOS ONE*, 9 (3).

IF: 3.2340

Querol L., Nogales-Gadea G., Rojas-Garcia R., Diaz-Manera J., Pardo J., Ortega-Moreno A., Sedano M.J., Gallardo E., Berciano J., Blesa R., Dalmau J., Illa I., Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. (2014) *NEUROLOGY*, 82 (10), 879-886.

IF: 8.2860

Suarez-Calvet X., Gallardo E., Nogales-Gadea G., Querol L., Navas M., Diaz-Manera J., Rojas-Garcia R., Illa I., Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. (2014) *J PATHOL*, 233 (3), 258-268.

IF: 7.4290

Parkinson Disease and Movement Disorders

Coordinator

Jaime Kulisevsky HSCSP
jkulisevsky@santpau.cat

Members

Fabián Octavio Arenas HSCSP RI
Antonia Campolongo HSCSP RI
María del Mar Carceller HSCSP RI
José Ramón Fernández de Bobadilla HSCSP RI
Carmen García HSCSP
Alexandre Gironell HSCSP
Andrea Horta HSCSP RI
Juan Marín HSCSP RI
Saül Indra Martínez HSCSP RI
Javier Pagonabarraga HSCSP
Riccardo Parenti HSCSP RI
Berta Marta Pascual HSCSP
Jesús Pérez HSCSP RI
Roser Ribosa HSCSP RI
María Victoria Sosti CIBERNED



Main Lines of Research

Cognitive Impairment and Behavioural Dysfunctions in Parkinson Disease

- ▶ Knowledge and detection of the neural correlates of cognitive performance in Parkinson disease using neurophysiological techniques (event-related brain cognitive potentials) and structural and functional neuroimaging (voxel-based morphometry, cortical thickness and spectroscopy).
- ▶ Development of more sensitive tools for cognitive and functional assessment in Parkinson disease to detect subtle changes in cognitive performance and treatment response.
- ▶ Prospective follow-up analysis of cognition and mood in patients with deep-brain stimulation of the subthalamic nucleus.
- ▶ Physiological correlates and pharmacological approach to apathy in Parkinson disease and other movement disorders.
- ▶ Neurophysiological and cognitive correlates of impulse control disorders in Parkinson disease and other movement disorders. Behavioral and pharmacological treatment.
- ▶ Surgery and treatments of continuous infusion in Parkinson disease.
- ▶ Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.
- ▶ Follow-up and etiologic study of weight loss in patients treated with continuous infusion of intraduodenal levodopa.

Essential Tremor and Other Movement Disorders

- ▶ Molecular neuroimaging in essential tremor.
- ▶ Clinical, neurophysiological and neuroimaging assessment of patients with FXTAS (fragile X-associated tremor/ataxia syndrome).

Translational Research - Parkinsonian Animal Models

- ▶ Assessment of behavioural and cognitive • Assessment of behavioural and cognitive modulations exerted by distinct antiparkinsonian drugs in murine models of Parkinson disease with lesions in particular neurotransmitter systems (dopaminergic and noradrenergic lesions).
- ▶ Assessment of behavioural and cognitive traits of murine models of HD

Translational Research - Cell Models

- ▶ Assessment of cell cultures of neurons derived of induced pluripotent cells (iPSCs) obtained from skin fibroblast as in vitro model for the modulation of key factors associated to both cognitive and neurotransmitter disturbances in Parkinson disease.

Huntington Disease

- ▶ Study of the metabolic correlates (18-FDG PET) of disease progression from the pre-manifested to early-stages.
- ▶ Study of the metabolic correlates (18-FDG PET) of apathy and depression in pre-manifested gene carriers.
- ▶ Functional magnetic resonance imaging study of reward sensitivity in pre-manifested an early-stage Huntington's disease.
- ▶ Determination of the prevalence and clinical significance of neuropsychiatric features in Huntington's disease.
- ▶ Development of new instruments for cognitive and functional assessment in Huntington's disease.
- ▶ Prospective observational study of Huntington's disease in a European cohort (Registry Study).
- ▶ Molecular, clinical, behavioural and cognitive characterisation of the BACHD rat model of Huntington's disease.

Main Lines of Research

- ▶ Collaboration in multicentre and Spanish coordinated projects:
 - Relationship between intermediate alleles and clinical manifestations (PI: Esther Cubo, Burgos).
 - Validation of the Spanish version of the Problem Behaviour Assessment Scale (PBA-S; PI: Jesús Ruiz, Barcelona).
 - Study of dietary intake in Huntington's disease (PI: Esther Cubo, Burgos).
 - A multimodal neuroimaging approach to delineate emotional, motor and cognitive cortico-striatal pathways. IDIBELL (PI: Ruth de Diego-Balaguer, Barcelona).

Progressive Supranuclear Palsy

- ▶ Development of a cognitive rating scale.
- ▶ Development of a standardized eye movement evaluation.

Challenges

Cognitive and Behavioural Dysfunctions in Parkinson Disease

- ▶ Study and understanding of the neural substrates of cognitive impairment in Parkinson disease so as to improve diagnostic and therapeutic approaches.
- ▶ Development of specific tools to assess and track cognitive changes in Parkinson disease.

Huntington's Disease

- ▶ Study of the dynamics of mutant Htt protein aggregation and related neural and cognitive correlates along disease stages in Huntington's disease.
- ▶ Validation of new instruments to assess and track subtle cognitive changes in pre-manifested and early-stage Huntington's disease population.

Essential Tremor and Other Movement Disorders

- ▶ Genetic studies and genotype-phenotype correlations in essential tremor.
- ▶ Development of new therapeutic interventions in essential tremor.
- ▶ Neurochemical and structural neuroimaging studies on the pathophysiological bases of essential tremor.

Translational Research - Animal Models of Parkinsonism

- ▶ Behavioural, physiological and pharmacological characterization of animal models of parkinsonism with combined dopaminergic and noradrenergic lesions.
- ▶ Physiopathology of motor, cognitive and behavioural complications linked to antiparkinsonian drugs in animal models of parkinsonism.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Active collaboration with the Reserach groups of Neuroradiology and Nuclear Medicine (Huntington's disease).

External Collaborations

- ▶ Active collaboration with the Cognition and Brain Plasticity Group at the Bellvitge Health Science Campus at the University of Barcelona adscribed to the Department of Basic Psychology, Faculty of Psychology - University of Barcelona and the IDIBELL (Institut d'Investigació Biomèdica de Bellvitge).

Active Grants

- ▶ García Sánchez. Early implementation of music therapy in rehabilitation of Aphasic patients after acute acquired brain injury/ Efectivity of music therapy in the rehabilitation of acute aphasic patients. TELEMARATÓ 2011 Lesions Medul-lars i Cerebrals. 112610. Duration: 16/05/12-15/05/15. €84,073.
- ▶ Jaime Kulisevsky Bojarski. Desarrollo, validación y estudio de la sensibilidad al cambio de una versión alternativa de la Parkinson's Disease - Cognitive Rating Scale. Proyectos de Investigación en Salud 2012. PI12/03005. Duration: 01/01/13-31/12/15. €23,500.
- ▶ Jesús Pérez Pérez. Instituto de Salud Carlos III, Contratos Río Hortega 2013. CM13/00284. Duration: 23/01/14-22/01/16. €53,732.

- ▶ Juan Marín Lahoz. Fundació Privada Hospital de la Santa Creu i Sant Pau. MIA 2013-1. Duration: 01/06/2013-31/05/2014. €45,222.91.
- ▶ Roser Ribosa Nogué. Agència de Gestió d'Ajuts Universitaris i de Recerca, Contractes FI 2010, Duration: 01/02/2011-31/01/2014. €61,833.80.

Note: Total amount granted to PI. It does not include indirect costs.

Parkinson Disease and Movement Disorders

Grants Awarded in 2014

- ▶ Jaime Kulisevsky Bojarski. Grup de Trastorns del Moviment de l'Hospital de la Santa Creu i Sant Pau. AGAUR 2014. SGR 1203. Duration: 04/09/14-31/12/16. €21,000.
- ▶ Jaime Kulisevsky Bojarski. Prediction of apathy and impulse control disorders in Parkinson's disease based on Feedback related negativity. Ajudes a la recerca biomèdica sobre malalties neurodegeneratives 2014. 477/U/2014 MARATÓ. Duration: 01/01/15-31/12/17. €159,686.
- ▶ Javier Pagonabarraga Mora. Blood-based and neurophysiological markers of cognitive deterioration and dementia in Parkinson's disease. Ajudes a la recerca biomèdica sobre malalties neurodegeneratives 2014. 484/U/2014 MARATÓ. Duration: 01/01/15-31/12/17. €159,589.
- ▶ Javier Pagonabarraga Mora. Marcadores en sangre y neurofisiológicos de la progresión del deterioro cognitivo en la enfermedad de Parkinson. Proyectos de Investigación en Salud 2014. P114/02058. €54,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 43.3380 **MIF: 3.3337

Scientific Production

- Carceller-Sindreu M., Portella M.J., Carmona C., Rametti G., Puigdemont D., Figueras M., Fernandez-Vidal A., Villalta L., Alvarez E., Neuropsychological effects of maintenance treatment with Clozapine in treatment-resistant psychotic disorder. (2014) ACTAS ESP PSIQUIATRI, 42 (2), 68-73.
IF: 1.2000
- de Quintana-Schmidt C., Pascual-Sedano B., Alvarez-Holzappel M.J., Gironell A., Leiding A., Benito N., Rodriguez-Rodriguez R., Molet-Teixido J., Complications related with implanted devices in patients with Parkinson's disease treated with deep brain stimulation. A study of a series of 124 patients over a period of 16 years. (2014) REV NEUROLOGIA, 59 (2), 49-56.
IF: 0.8300
- Eberling J., Vincent L., Goldman J.G., Weintraub D., Kulisevsky J., Marras C., Stebbins G., Kiebertz K., Therapeutic development paths for cognitive impairment in Parkinson's disease: Report of a regulatory roundtable. (2014) J PARKINSON DIS, 4 (4), 585-589.
IF: 1.9100
- Emre M., Poewe W., De Deyn P.P., Barone P., Kulisevsky J., Pourcher E., Van Laar T., Storch A., Micheli F., Burn D., Durif F., Pahwa R., Callegari F., Tenenbaum N., Strohmaier C., Long-term safety of rivastigmine in parkinson disease dementia: An open-label, randomized study. (2014) CLIN NEUROPHARMACOL, 37 (1), 9-16.
IF: 2.0090
- Gasso P., Mas S., Papagianni K., Ferrando E., De Bobadilla R.F., Arnaiz J.A., Bioque M., Bernardo M., Lafuente A., Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: Results from a pharmacogenetic clinical trial. (2014) PHARMACOGENOMICS, 15 (1), 17-28.
IF: 3.2180
- Gironell A., Martinez-Horta S., Aguilar S., Torres V., Pagonabarraga J., Pascual-Sedano B., Ribosa-Nogue R., Transcranial direct current stimulation of the cerebellum in essential tremor: A controlled study. (2014) BRAIN STIMUL, 7 (3), 491-492.
IF: 4.3990
- Marras C., Troster A.I., Kulisevsky J., Stebbins G.T., The tools of the trade: A state of the art "How to Assess Cognition" in the patient with Parkinson's disease. (2014) MOVEMENT DISORD, 29 (5), 584-596.
IF: 5.6800
- Martinez-Horta S., Riba J., de Bobadilla R.F., Pagonabarraga J., Pascual-Sedano B., Antonijoan R.M., Romero S., Mananas M.A., Garcia-Sanchez C., Kulisevsky J., Apathy in parkinson's disease: Neurophysiological evidence of impaired incentive processing. (2014) J NEUROSCI, 34 (17), 5918-5926.
IF: 6.3440
- Pagonabarraga J., Kulisevsky J., Dopaminergic treatment in Parkinson's disease: What has each therapeutic family got to offer? (2014) REV NEUROLOGIA, 58 (1), 25-34.
IF: 0.8300
- Pagonabarraga J., Soriano-Mas C., Llebaria G., Lopez-Sola M., Pujol J., Kulisevsky J., Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. (2014) PARKINSONISM RELAT D, 20 (3), 290-296.
IF: 3.9720
- Rami L., Mollica M.A., Garcia-Sanchez C., Saldafia J., Sanchez B., Sala I., Valls-Pedret C., Castellvi M., Olives J., Molinuevo J.L., The subjective cognitive decline questionnaire (SCD-Q): A validation study. (2014) J ALZHEIMERS DIS, 41 (2), 453-466.
IF: 4.1510
- Spataro N., Calafell F., Cervera-Carles L., Casals F., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Lleo A., Navarro A., Clarimon J., Bosch E., Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease†. (2014) HUM MOL GENET, 24 (7), 2023-2034.
IF: 6.3930
- Tolosa E., Hernandez B., Linazasoro G., Lopez-Lozano J.J., Mir P., Marey J., Kulisevsky J., Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: A randomised, double-blind trial. (2014) J NEURAL TRANSM, 121 (4), 357-366.
IF: 2.4020

Molecular Neuropharmacology

Coordinator

Olga Pol
opol@santpau.cat

HSCSP RI

Members

Sergi Leáñez



Main Lines of Research

- ▶ Neuropharmacology of acute and chronic pain.
- ▶ Biochemical and molecular mechanisms involved in drug interactions.
- ▶ New strategies in the treatment of painful diabetic neuropathy.
- ▶ Identification of new targets in the modulation of emotional behavior.

Challenges

- ▶ Investigate new approaches for the treatment of acute and chronic pain (arthritis, neuropathy...).
- ▶ Advance knowledge in the molecular mechanisms involved in the antinociceptive actions of heme oxygenase 1 inducers combined with opioids and cannabinoids.
- ▶ Identify new pharmacological treatments of neuropathic pain and oxidative stress induced by diabetes.
- ▶ Evaluate the contribution of gaseous neurotransmitters in the modulation of emotional behavior.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Metabolic Bases of Cardiovascular Risk (PI: Francisco Blanco)

External Collaborations

- ▶ Prof. Christie Leite-Panissi, Dept. Morphology, Physiology and Basic Pathology, Ribeirão Preto Dentistry School, University of São Paulo, Brazil.

- ▶ Prof. Ana Baamonde, Dept. Farmacología, Facultad de Medicina, Universidad de Oviedo, Spain.
- ▶ Dr. Arnau Hervera, Department of Medicine, Restorative Neurosciences, Imperial College of London, England.

Active Grants	<ul style="list-style-type: none"> ▶ Olga Pol Rigau. Estudio de nuevas dianas terapéuticas en el tratamiento del dolor crónico. FIS Projecte 2009. PI09/0968. Duration: 01/01/10-30/06/14. €55,500. <p>Note: Total amount granted to PI. It does not include indirect costs.</p>
---------------	---

Grants Awarded in 2014	<ul style="list-style-type: none"> ▶ Olga Pol Rigau. Nuevas estrategias en el tratamiento de la neuropatía diabética. Proyectos de Investigación en Salud 2014. PI14/00927. €71,500. <p>Note: Total amount granted to PI. It does not include indirect costs.</p>
------------------------	--

Patents	<ul style="list-style-type: none"> ▶ Olga Pol Rigau. Use of heme oxygenase 1 and cannabinoid 2 receptor inducers or delta-opioid receptor agonists in inflammatory pain. Entity headline: Fundació Institut de Recerca de l'Hospital Santa Creu i Sant Pau & Universitat Autònoma de Barcelona. Patent office: European Patent Office. Application number: EP14183542.1.
---------	---

***TIF: 10.3790 **MIF: 3.4597**

Scientific Production	<p>Carcole M., Castany S., Leanez S., Pol O., Treatment with a heme oxygenase 1 inducer enhances the antinociceptive effects of α-opioid, δ-opioid, and cannabinoid 2 receptors during inflammatory pain. (2014) J PHARMACOL EXP THER, 351 (1), 224-232. IF: 3.9720</p> <p>Gou G., Leanez S., Pol O., The role of gaseous neurotransmitters in the antinociceptive effects of morphine during acute thermal pain. (2014) EUR J PHARMACOL, 737, 41-46. IF: 2.5320</p> <p>Negrete R., Hervera A., Leanez S., Pol O., Treatment with a carbon monoxide-releasing molecule inhibits chronic inflammatory pain in mice: Nitric oxide contribution. (2014) PSYCHOPHARMACOLOGY, 231 (5), 853-861. IF: 3.8750</p>
-----------------------	--

Pharmacological Research in Humans

Coordinator

Rosa Maria Antonijoan HSCSP
rantonijoana@santpau.cat

Members

Maria Rosa Ballester HSCSP RI
Judit Claramunt HSCSP RI
Susana Clos HSCSP RI
Sonia Coma HSCSP RI
Juan Manuel Ferrero HSCSP RI
Maria Àngels Funes HSCSP RI
Ignasi Josep Gich HSCSP
Consuelo García HSCSP RI
Maite Garrido HSCSP RI
Sandra Giménez HSCSP RI
Ana María Gomis HSCSP RI
Mireia González HSCSP RI
Yolanda Lillo HSCSP RI
David Martínez HSCSP RI
Juan Martínez HSCSP RI
Maria Isabel Martínez HSCSP RI
Pura Martínez HSCSP RI
Esteve Mercader HSCSP RI
Sara Mora HSCSP RI
Montserrat Puentes HSCSP RI
Olga Sola HSCSP RI



Main Lines of Research

Clinical Trials with no Therapeutic Benefits to Volunteer Participants

- ▶ Phase I clinical trials (healthy volunteers) whose main objectives include: first-time-in-humans, safety and tolerability (local, systemic/dermatological, ophthalmological, vaginal), pharmacokinetics, bioavailability and bioequivalence (generic drugs), pharmacodynamics, interactions (drug-drug/drug-food), evaluation and characterization of biomarkers, proofs of concept, acceptability and preference studies.
- ▶ Follow-up studies in populations with the same or different characteristics (elderly, obese, postmenopausal, with liver or kidney failure).
- ▶ Collaboration with clinical services to conduct phase II/III studies.

Neuro-Physio-Pharmacology of Sleep/Wake States

- ▶ Investigate human brain activity in sleep and wakefulness, mechanisms involved in these states, problems derived from sleep disturbances and possible interventions.
- ▶ Approach the phenomenon as a continuum: appropriate interpretation of the impact of a certain intervention, whether pharmacological or not, should take into account the complementarity of evaluations performed during sleep and during wakefulness.
- ▶ Develop studies that consider the 24-hour day/night cycle as the phenomenon under study cannot be evaluated without taking this interactivity into account.
- ▶ Develop psychomotor performance tests, subjective evaluation scales, neurophysiologic recordings (quantitative EEG, evoked-sensorial potentials and polysomnography), psychophysiological tests and pupillometric tests.

Challenges

- ▶ Consolidate and strengthen leadership in this field in Spain, conserve relationships with the pharmaceutical industry on a national level and strengthen and extend relations abroad with multinational enterprises and industries from other sectors.
- ▶ Broaden the range of questions to address in research projects along the lines of the neuro-physio-pharmacology of sleep/wake states, focusing on pharmacotherapeutic objectives and also on physiopathologic objectives in related fields, such as dreams.
- ▶ Develop neurophysiologic recording performance in ambulatory conditions, simplifying participation of volunteers but not lowering the quality of data obtained (non-negotiable element of their application as a research variable).
- ▶ Promote dissemination of our activity with a dual objective: to return knowledge generated to society and demystify research in humans, bringing it closer to the community so as to foster participation in clinical trials (particularly in specific sectors of the populations, such as the elderly).
- ▶ Set up educational activities related to our two main research lines: the application of good clinical practices in clinical research into sleep medicine and its medical (pathology, and treatment) and social (quality of life, prevention of accident risk) consequences.

Collaborations	<p>External Collaborations</p> <ul style="list-style-type: none"> Phase I clinical trials for national and international pharmaceutical companies (12 in total). 	
Active Grants	<ul style="list-style-type: none"> Rosa M. Antonijoan Arbos. POLYFARMA: Nuevas Terapias Parkinson. INNPACTO 2011. IPT-2011-1048-900000. Duration: 01/06/11-28/02/14. €84,245.70. Rosa M. Antonijoan Arbos. Supresión de la expresión de alfa-sinucleína y de la actividad de PDE10 como estrategia terapéutica 	<p>combinada para el tratamiento del Parkinson y mejora de las disfunciones cognitivas derivadas. INNPACTO 2012. IPT-2012-1208-300000. Duration: 01/08/12-31/03/15. €53,096.</p> <p>Note: Total amount granted to PI. It does not include indirect costs.</p>
Grants Awarded in 2014	<ul style="list-style-type: none"> Sandra Gimenez Badia. ADENOASMA: Investigación y desarrollo de nuevos moduladores de los receptores de adenosina como medicamentos para tratar enfermedades respiratorias. MINECO. RTC-2014-19871. Duration: 01/01/2015-31/12/2016. €137,130. <p>Note: Total amount granted to PI. It does not include indirect costs.</p>	

*TIF: 25.6450 **MIF: 2.5645

Scientific Production	<p>Balsells M., Garcia-Patterson A., Gich I., Corcoy R., Ultrasound-guided compared to conventional treatment in gestational diabetes leads to improved birthweight but more insulin treatment: Systematic review and meta-analysis. (2014) ACTA OBSTET GYN SCAN, 93 (2), 144-151. IF: 2.4260</p> <p>Catala A., Garces J.R., Alegre M., Gich I.J., Puig L., Mohs micrographic surgery for basal cell carcinomas: Results of a Spanish retrospective study and Kaplan-Meier survival analysis of tumour recurrence. (2014) J EUR ACAD DERMATOL, 28 (10), 1363-1369. IF: 2.8260</p> <p>Garcia-Gea C., Martinez J., Ballester M.R., Gich I., Valiente R., Antonijoan R.M., Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: A randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.. (2014) HUM PSYCHOPHARM CLIN, 29 (2), 120-132. IF: 2.1920</p> <p>Garin N., De Pourcq J.T., Martin-Venegas R., Cardona D., Gich I., Mangues M.A., Viscosity</p>	<p>differences between thickened beverages suitable for elderly patients with dysphagia. (2014) DYSPHAGIA, 29 (4), 483-488. IF: 2.0330</p> <p>Gutarra-Vilchez R.B., Barajas-Nava L., Aleman A., Sola I., Gich I., Bonfill X., Alonso-Coello P., Systematic evaluation of the quality of clinical practice guidelines on the use of assisted reproductive techniques. (2014) HUM FERTIL, 17 (1), 28-36. IF: 0.9090</p> <p>Kotzeva A., Guillamon I., Gracia J., Diaz Del Campo P., Gich I., Calderon E., Gaminde I., Louro-Gonzalez A., Martinez F., Orrego C., Rotaache R., Salcedo F., Alonso-Coello P., Use of clinical practice guidelines and factors related to their uptake: A survey of health professionals in Spain. (2014) J EVAL CLIN PRACT, 20 (3), 216-224. IF: 1.0840</p> <p>Martinez-Horta S., Riba J., de Bobadilla R.F., Pagonabarraga J., Pascual-Sedano B., Antonijoan R.M., Romero S., Mananas M.A., Garcia-Sanchez C., Kulisevsky J., Apathy in parkinson's disease: Neurophysiological evidence of impaired incentive processing.</p>	<p>(2014) J NEUROSCI, 34 (17), 5918-5926. IF: 6.3440</p> <p>Puente A., Hernandez-Gea V., Graupera I., Roque M., Colomo A., Poca M., Aracil C., Gich I., Guarner C., Villanueva C., Drugs plus ligation to prevent rebleeding in cirrhosis: An updated systematic review. (2014) LIVER INT, 34 (6), 823-833. IF: 4.8500</p> <p>Rico S., Antonijoan R.-M., Ballester M.R., Gutierrez I., Ayani I., Martinez-Gonzalez J., Borrell M., Fontcuberta J., Gich I., Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. (2014) THROMB RES, 133 (6), 1029-1038. IF: 2.4470</p> <p>Robleda G., Sillero-Sillero A., Puig T., Gich I., Banos J.-E., Influence of preoperative emotional state on postoperative pain following orthopedic and trauma surgery. (2014) REV LAT-AM ENFERM, 22 (5), 785-791. IF: 0.5340</p>
-----------------------	---	---	--

Clinical Psychiatry

Coordinator

María Jesús Portella HSCSP RI
Mportella@santpau.cat

Members

Saul Alcaraz HSCSP
Saiko Allende CIBERSAM
David Almenta HSCSP
Anna Alonso HSCSP RI
Enric Álvarez HSCSP
María Jesús Arranz HSCSP RI
María del Mar Carceller HSCSP RI
Cristina Carmona CIBERSAM
María Teresa Castillon HSCSP
Iluminada Corripio HSCSP
Anna María Díaz HSCSP
Matilde Elices HSCSP RI
Anna Enfedaque HSCSP
Aina Fernández HSCSP
Eva María Grasa CIBERSAM
Miriam Jubero HSCSP RI
Alejandro Keymer HSCSP
Ana Martín HSCSP RI
Conrad Molins HSCSP
Juan Carlos Pascual HSCSP
Josefina Pérez HSCSP
Víctor Pérez HSCSP
Josep María Pericay HSCSP
M. Dolors Puigdemont HSCSP
Mireia Rabella HSCSP RI
Estela Salagre HSCSP
Joaquín Soler HSCSP
José Antonio Soriano HSCSP
María Carmen Tejedor HSCSP
Thais Tiana
José Alexander Vargas HSCSP



Main Lines of Research

- ▶ Psychotic disorders (first episodes and persistent hallucinations).
- ▶ Affective disorders (major depression and validation of scales).
- ▶ Borderline personality disorder.

Challenges

- ▶ Foster research that reduces the health-care, social and personal costs of mental illness by exploring areas such as epidemiology, etiopathogenesis, physiopathology, prevention and treatment.
- ▶ Foster research into mental health therapies.
- ▶ Foster research to improve quality of life of patients with mental disorders.

Research into Psychotic Disorders

- ▶ Neuroimaging studies in first psychotic episodes.
- ▶ Study of environmental, biological and genetic factors in psychosis.
- ▶ Efficacy and effectiveness studies of anti-psychotic drugs.
- ▶ Efficacy and effectiveness study of psychotherapy for hallucinations.
- ▶ Study of treatment resistance in schizophrenia.

Research into Affective Disorders

- ▶ Identification and evaluation of new therapeutic targets in depression.
- ▶ Neuroimaging studies in first psychotic episodes.
- ▶ Biological and genetic markers in affective disorders.
- ▶ Implementation of new therapeutic programmes, depression evaluation and social aspects of depression.

Research into Personality Disorders

- ▶ Clinical trials regarding the usefulness of mixed treatment in patients with borderline personality disorder and validation of diagnostic instruments.
- ▶ Genetic-neuroimaging studies of borderline personality disorder (BPD).
- ▶ Efficacy and effectiveness studies of psychotherapy for treating borderline personality disorder.

Awards

- ▶ A. Fernández Vidal, E. Salagre, A. Ancochea, A. Feliu, D. Puigdemont, M.J. Portella, J. Trujols, E. Álvarez, V. Pérez, J. de Diego-Adeliño. Remissió en depressió: la felicitat i salut mental positiva del pacient hi tenen res a dir? Premi accésit a la millor comunicació de la Jornada de Cloenda de Psiquiatria 2014, Societat Catalana de Psiquiatria i Salut Mental. 5-6 June 2014.
- ▶ Joana Bauzà, Sara Vieira, Alexandra Roldán, Conrad Molins, Eva Grasa, Santiago Durán-Sindreu, Anna Díaz, María J. Portella, Enric Álvarez, Iluminada Corripio. Podríem preveure el perfil de remissió dels pacients psicòtics a través del seu rendiment neuropsicològic? Premi a la millor comunicació de la Jornada de Cloenda de Psiquiatria 2014, Societat Catalana de Psiquiatria i Salut Mental. 5-6 June 2014.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Addictive Behaviours.
- ▶ Neuroradiology.
- ▶ Neurosurgery.
- ▶ Hypophysis Diseases.
- ▶ CIM – Sant Pau.
- ▶ Pain Clinic Sant Pau.
- ▶ Genetics.
- ▶ Internal Medicine.

External Collaborations

- ▶ Hospital Clínic de Barcelona, Psychiatry Department.
- ▶ Hospital Parc Taulí, Sabadell, Psychiatry Department.
- ▶ Universidad Complutense de Madrid, Medicine-Pharmacology Department.
- ▶ Hospital Universitario de la Princesa, Madrid, Psychiatry Department.
- ▶ Universidad de Valencia, Medicine-Psychiatry Department.
- ▶ Leipzig University, Medicine-Psychiatry Department.
- ▶ Universidad de Cádiz, Medicine-Pharmacology Department.
- ▶ Hospital Benito Menni – FIDMAG, Barcelona, Psychiatry Department.
- ▶ University of Oxford, Medicine-Psychiatry Department.

Doctoral Theses

- ▶ Albert Feliu Soler. Caracterización del Trastorno Límite de la Personalidad y efectos del entrenamiento en mindfulness. Universitat Autònoma de Barcelona. Directors: Joaquim Soler, Xavier Borràs. Date of defense: 11 April 2014.

Active Grants

- ▶ Francisco Javier de Diego Adeliño. Recerca farmacogenètica de la difusió sexual induïda per antidepressius. Beca JPC-SCPiSM al millor Projecte Original de Recerca. JPC 2013. Duration: 01/09/13-30/09/15. €2,700.
- ▶ M. Jesús Portella Moll. PREDI-NU Preventing Depressions and Improving Awareness through Netwrking in the EU. Health Programme. 20101214. Duration: 01/09/11-31/08/14. €35,168.52.
- ▶ Enric Álvarez Martínez. Estimulación Cerebral Profunda en el tratamiento de la esquizofrenia refractaria: Estudio piloto aleatorizado, controlado y cruzado. Proyectos de Investigación en Salud 2012. PI12/00042. Duration: 01/01/13-31/12/15. €91,500.
- ▶ Joaquín Soler. Efectos del Mindfulness en la Actividad y Conectividad Funcional de la Default Mode Network en Pacientes con Trastorno Límite de la Personalidad. Proyectos de Investigación en Salud 2013. PI13/00134. Duration: 01/01/14-31/12/16. €46,150.
- ▶ M. Jesús Portella. Estudio longitudinal de cambios cerebrales en pacientes con un primer episodio de depresión mayor. Proyectos de Investigación en Salud 2013. PI13/01057. Duration: 01/01/14-31/12/16. €56,300.
- ▶ Enric Álvarez Martínez. Ajuts de suport als Grups de Recerca de Catalunya. Grup Psiquiatria Clínica. AGAUR 2009. SGR 179. Duration: 29/09/09-30/04/14. €42,640.
- ▶ Juan Carlos Pascual Mateos. Estudio de la sensibilidad genética al ambiente en pacientes con trastorno límite de la personalidad: estudio caso-control de la interacción gen-ambiente. FIS Projecte 2010. PI10/00253. Duration: 01/01/11-31/12/14. €124,000.
- ▶ Iluminada Corripio Collado. Determinantes clínicos y neurobiológicos de segundos episodios de esquizofrenia. Estudio longitudinal de primeros episodios psicóticos. MINECO-ISCIH Projecte 2011. PI11/00260. Duration: 01/01/12-31/12/14. €75,727.
- ▶ Maria Jesús Portella Moll. Study of structural and functional brain changes after deep brain stimulation of treatment resistant depression: Biomarkers of DBS antidepressant effects and optimization of parameters (localization and stimulation). FIS Contratos Miguel Servet 2010. CP10/00393. Duration: 01/01/11-30/06/15. €121,300.
- ▶ Josefina Pérez Blanco. Metilfenidato de liberación inmediata en la mejoría sintomática de la manía aguda. Ministerio de Sanidad y Política Social: EC 2010. EC10-297. Duration: 01/01/11-30/06/15. €5,980.
- ▶ Maria Serra Blasco. AGAUR Contract FI 2011. 2012 FI-DGR. Duration: 01/03/2012-28/02/2015. €61,863.60.
- ▶ Francisco Javier de Diego Adeliño. Contrato Postdoc Rio Hortega 2011. Instituto de Salud Carlos III. CM11/00287. Duration: 30/01/2012-29/01/2014. €43,200.
- ▶ M. Jesús Portella Moll. Contrato SNS Miguel Servet 2010. Instituto de Salud Carlos III. MS10/00393. Duration: 20/01/2011-19/01/2017. €151,875.

Note: Total amount granted to PI. It does not include indirect costs.

Clinical Psychiatry

Grants Awarded in 2014

- ▶ Iluminada Corripio Collado. Mobile Therapeutic Attention for Patients with Treatment Resistant Schizophrenia (m-RESIST). H2020-PHC-2014-single-stage. PHC26-2014(2). Duration: 01/01/15-31/12/17.
- ▶ Juan Carlos Pascual Mateos. Estudio Epigenómico en el Trastorno Límite de la Personalidad: estudio del patrón de metilación (EWAS-Epigenome-wide association study) y su relación con antecedentes traumáticos. Proyectos de Investigación en Salud 2014. PI14/00214. €81,500.
- ▶ Iluminada Corripio Collado. m-RESIST: Programa de Atención Terapéutica m-Health en Pacientes con Esquizofrenia Resistente. Acciones de Dinamización Europea Investigación 2014. EUIN2013-50935. Duration: 18/09/14.30/09/15. €25,000.
- ▶ Maria del Mar Carceller Sindreu. Contratos predoctorales en investigación en salud 2014. Instituto de Salud Carlos III. FI14/00201. Duration: 30/01/15-29/01/19. €82,400.
- ▶ Francisco Javier de Diego Adeliño. Contratos Juan Rodés 2014. Instituto de Salud Carlos III. JR14/00011. Duration: 31/01/15-30/01/18. €135,000.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 78.4150 **MIF: 3.1366

Scientific Production

Alvarez E., Perez V., Artigas F., Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. (2014) NEUROPSYCH DIS TREAT, 10, 1297-1307.

IF: 1.7410

Alvarez E., Vieira S., Garcia-Moll X., Citalopram, escitalopram and prolonged QT: Warning or alarm?. (2014) REV PSIQUIATR SALUD, 7 (3), 147-150.

IF: 1.6220

Caballo V.E., *et al.* Differences in social anxiety between men and women across 18 countries. (2014) PERS INDIV DIFFER, 64, 35-40.

IF: 1.9510

Carceller-Sindreu M., Portella M.J., Carmona C., Rametti G., Puigdemont D., Figueras M., Fernandez-Vidal A., Villalta L., Alvarez E., Neuropsychological effects of maintenance treatment with Clozapine in treatment-resistant psychotic disorder. (2014) ACTAS ESP PSIQUIATRI, 42 (2), 68-73.

IF: 1.2000

Darba J., Kaskens L., Perez C., Alvarez E., Navarro-Artieda R., Sicras-Mainar A., Pharmacoeconomic outcomes for pregabalin: A systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. (2014) ADV THER, 31 (1), 1-29.

IF: 2.2720

Feliu-Soler A., Pascual J.C., Borrás X., Portella M.J., Martín-Blanco A., Armario A., Alvarez E., Perez V., Soler J., Effects of dialectical behaviour therapy-mindfulness training on emotional reactivity in borderline personality disorder: Preliminary results. (2014) CLIN PSYCHOL PSYCHOT, 21 (4), 363-370.

IF: 2.6320

Gonzalez-Garcia M., Ferrer M.J., Borrás X., Muñoz-Moreno J.A., Miranda C., Puig J.,

Perez-Alvarez N., Soler J., Feliu-Soler A., Clotet B., Fumaz C.R., Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. (2014) AIDS BEHAV, 18 (4), 676-685.

IF: 3.7280

Granero R., Hilker I., Agüera Z., Jimenez-Murcia S., Sauchelli S., Islam M.A., Fagundo A.B., Sanchez I., Riesco N., Dieguez C., Soriano J., Salcedo-Sanchez C., Casanueva F.F., De La Torre R., Menchon J.M., Gearhardt A.N., Fernandez-Aranda F., Food addiction in a Spanish sample of eating disorders: DSM-5 diagnostic subtype differentiation and validation data. (2014) EUR EAT DISORD REV, 22 (6), 389-396.

IF: 2.4610

Hervas A., Toma C., Romaris P., Ribases M., Salgado M., Bayes M., Balmana N., Cormand B., Maristany M., Guijarro S., Arranz M.J., The involvement of serotonin polymorphisms in autistic spectrum symptomatology. (2014) PSYCHIAT GENET, 24 (4), 158-163.

IF: 1.9410

Ivorra J.L., Rivero O., Costas J., Iniesta R., Arrojo M., Ramos-Rios R., Carracedo T., Palomo T., Rodriguez-Jimenez R., Cervilla J., Gutierrez B., Molina E., Arango C., Alvarez M., Pascual J.C., Perez V., Saiz P.A., Garcia-Portilla M.P., Bobes J., Gonzalez-Pinto A., Zorrilla I., Haro J.M., Bernardo M., Baca-Garcia E., Gonzalez J.C., Hoenicka J., Molto M.D., Sanjuan J., Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. (2014) SCHIZOPHR RES, 159 (1), 107-113.

IF: 3.9230

Martin-Blanco A., Ferrer M., Soler J., Salazar J., Vega D., Andion O., Sanchez-Mora C., Arranz M.J., Ribases M., Feliu-Soler A., Perez V., Pascual J.C., Association between

methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. (2014) J PSYCHIATR RES, 57 (1), 34-40.

IF: 3.9570

Martin-Blanco A., Patrizi B., Villalta L., Gasol X., Soler J., Gasol M., Pascual J.C., Asenapine in the treatment of borderline personality disorder: An atypical antipsychotic alternative. (2014) INT CLIN PSYCHOPHARM, 29 (2), 120-123.

IF: 2.4560

Martin-Blanco A., Soler J., Villalta L., Feliu-Soler A., Elices M., Perez V., Arranz M.J., Ferrer L., Alvarez E., Pascual J.C., Exploring the interaction between childhood maltreatment and temperamental traits on the severity of borderline personality disorder. (2014) COMPR PSYCHIAT, 55 (2), 311-318.

IF: 2.2520

Perez De Los Cobos J., Sinol N., Perez V., Trujols J., Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. (2014) BRIT J CLIN PHARMACOL, 77 (2), 337-356.

IF: 3.8780

Perez-Caballero L., Perez-Egea R., Romero-Grimaldi C., Puigdemont D., Molet J., Caso J.-R., Mico J.-A., Perez V., Leza J.-C., Berrocoso E., Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. (2014) MOL PSYCHIATR, 19 (5), 607-614.

IF: 14.4960

Pina-Camacho L., Diaz-Caneja C.M., Saiz P.A., Bobes J., Corripio I., Grasa E., Rodriguez-Jimenez R., Fernandez M., Sanjuan J., Garcia-Lopez A., Tapia-Casellas C., Alvarez-Blazquez M., Fraguas D., Mitjans M., Arias B., Arango C., Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side ef-

*TIF: 78.4150 **MIF: 3.1366

Scientific Production

fects (the SLiM Study): Rationale, objectives, design and sample description. (2014) *REV PSIQUIATR SALUD*, 7 (4), 166-178.

IF: 1.6220

Quezada-Berumen L.D.C., Gonzalez-Ramirez M.T., Cebolla A., Soler J., Garcia-Campayo J., Body awareness and mindfulness: Validation of the Spanish version of the Scale of Body Connection. (2014) *ACTAS ESP PSIQUIATRI*, 42 (2), 57-67.

IF: 1.2000

Romera I., Perez V., Quail D., Berggren L., Lenox-Smith A., Gilaberte I., Individual residual symptoms and functional impairment in patients with depression. (2014) *PSYCHIAT RES*, 220 (1-2), 258-262.

IF: 2.4670

Soler J., Cebolla A., Feliu-Soler A., Demarzo M.M.P., Pascual J.C., Banos R., Garcia-Campayo J., Relationship between meditative practice and self-reported mindfulness: The MINDSENS composite index. (2014) *PLOS ONE*, 9 (1).

IF: 3.2340

Soler J., Franquesa A., Feliu-Soler A., Cebolla A., Garcia-Campayo J., Tejedor R., Demarzo M., Banos R., Pascual J.C., Portella M.J., Assessing Decentering: Validation, Psychometric Properties, and Clinical Usefulness of the Experiences Questionnaire in a Spanish Sample. (2014) *BEHAV THER*, 45 (6), 863-871.

IF: 3.6940

Soler J., Vega D., Elices M., Feliu-Soler A., Soto T., Martin-Blanco A., Marco-Pallares J., Torrubia R., Pascual J.C., Testing the reinforcement sensitivity theory in borderline personality disorder compared with major depression and healthy controls. (2014) *PERS INDIV DIFFER*, 61-62, 43-46.

IF: 1.9510

Tejedor R., Feliu-Soler A., Pascual J.C., Cebolla A., Portella M.J., Trujols J., Soriano J., Perez V., Soler J., Psychometric properties of the Spanish version of the Philadelphia Mindfulness Scale. (2014) *REV PSIQUIATR SALUD*, 7 (4), 157-165.

IF: 1.6220

Tran U.S., Cebolla A., Gluck T.M., Soler J., Garcia-Campayo J., Von Moy T., The seren-

ity of the meditating mind: A cross-cultural psychometric study on a two-factor higher order structure of mindfulness, its effects, and mechanisms related to mental health among experienced meditators. (2014) *PLOS ONE*, 9 (10).

IF: 3.2340

Trujols J., De Diego-Adelino J., Feliu-Soler A., Iraurgi I., Puigdemont D., Alvarez E., Perez V., Portella M.J., The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. (2014) *J AFFECT DISORDERS*, 169, 189-196.

IF: 3.3830

Usall J., Lopez-Carrilero R., Iniesta R., Roca M., Caballero M., Rodriguez-Jimenez R., Oliveira C., Bernardo M., Corripio I., Sindreu S.D., Piqueras J.C.G., Felipe A.E., De Corres B.F., Ibanez A., Huerta R., Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia. (2014) *J CLIN PSYCHIAT*, 75 (6), 608-615.

IF: 5.4980

Other Publications

- ▶ De Diego-Adelino J., Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. (2014) *PSYCHOLOGICAL MEDICINE*, 44 (6), 1171-1182.

Genetics in Neurodegenerative Diseases

Coordinator

Jordi Clarimon

HSCSP RI

jclarimon@santpau.cat

Members

Laia Muñoz

CIBERNED



Main Lines of Research

- ▶ Use of state-of the-art genomic strategies to study the genetic architecture of complex diseases caused by neurodegenerative processes, including Alzheimer disease and other dementias, Parkinson disease, and neuromuscular disorders.
- ▶ Cloning and evaluation of novel genes associated with neurodegenerative disorders through genomic analyses on families with Mendelian pattern of inheritance.
- ▶ Study of the relationship between biomarkers and endophenotypes at the individual genetic background.
- ▶ Evaluation of the effect of novel genes related to neurodegenerative disorders in the Spanish population through multi-centre collaborative studies.

Challenges

- ▶ Assemble a research team of excellence in the international field of genetics of neurodegenerative disorders.
- ▶ Increase our capacity of funding through EU support.
- ▶ Develop a comprehensive genomic database from well-characterized Spanish patients of European origin suffering from neurodegenerative disorders.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Neurobiology of Dementia (Alberto Lleó).
- ▶ Parkinson Disease and Movement Disorders (Jaime Kulisevsky).
- ▶ Neuromuscular Diseases (Isabel Illa).

External Collaborations

National and international consortiums

- ▶ European Early Onset Dementia Consortium (EU-EOD).
- ▶ European Alzheimer Disease Initiative (EADI).
- ▶ International Genomics of Alzheimer Project (IGAP).
- ▶ Dementia Genetics Spanish Consortium (DEGESCO).
- ▶ CIBER-Neurodegenerative Diseases (CIBERNED).

Collaborations with international centres

- ▶ Dr. John Hardy, University College of London, UK.
- ▶ Dr. Andrew Singleton, National Institutes of Health, USA.
- ▶ Dr. Coro Paisán-Ruiz, Mount Sinai School of Medicine, USA.
- ▶ Dr. Ekaterina Rogaeva, University of Toronto, Canada.
- ▶ Dr. Mikko Hiltunen, Kuopio University, Finland.
- ▶ Dr. Martin Ingelsson, Uppsala University, Sweden.
- ▶ Dr. Liana Fidani, Aristotle University of Thessaloniki, Greece.
- ▶ Dr. Philippe Amouyel, Institut Pasteur de Lille, France.
- ▶ Dr. Christine Van Broekhoven, University of Antwerp, Belgium.

Active Grants

- ▶ Jordi Clarimon Echevarria. Variantes genéticas raras y su implicación en la enfermedad de Alzheimer: uso de nuevas tecnologías de ultrasecuenciación para el estudio de genes implicados en la enfermedad. Proyectos de Investigación en Salud 2012. PI12/01311. Duration: 01/01/13-31/12/15. €91,000.
- ▶ Jordi Clarimon Echevarria. Contracte SNS Miguel Servet 2007. Instituto de Salud Carlos III. CP07/00010. Duration: 01/02/08-26/01/14. €150,380.10.
- ▶ Jordi Clarimon Echevarria. Contratos Miguel Servet 2013 (II). Instituto de Salud Carlos III. MSII13/00005. Duration: 27/01/14-26/01/17. €101,250.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Jordi Clarimon Echevarria. Grup de Recerca en Demències. AGAUR SGR 2014. SGR 235. Duration: 04/09/14-31/12/16. €18,000.
- ▶ Jordi Clarimon Echevarria. Convocatoria de proyectos de investigación sobre enfermedades poco frecuentes de RTVE 2014. "Todos somos raros 2014". Duration: 07/01/15-06/01/17. €90,748.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 85.9350 **MIF: 7.1613

Scientific Production

Dols-Icardo O., Garcia-Redondo A., Rojas-Garcia R., Sanchez-Valle R., Noguera A., Go mez-Tortosa E., Pastor P., Hernandez I., Esteban-Perez J., Suarez-Calvet M., Anton-Aguirre S., Amer G., Ortega-Cubero S., Blesa R., Fortea J., Alcolea D., Capdevila A., Antonell A., Llado A., Munoz-Blanco J.L., Mora J.S., LuciaGalan-Da vila, De Rivera F.J.R., Lleo A., Clarimon J., Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. (2014) HUM MOL GENET, 23 (3), 749-754.

IF: 6.3930

Escott-Price V., et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. (2014) PLOS ONE, 9 (6).

IF: 3.2340

Ferrari R., et al. Frontotemporal dementia and its subtypes: A genome-wide association study. (2014) LANCET NEUROL, 13 (7), 686-699.

IF: 21.8960

Fortea J., Vilaplana E., Alcolea D., Carmona-Iragui M., Sanchez-Saudinos M.-B., Sala I., Anton-Aguirre S., Gonzalez S., Medrano S., Pegueroles J., Morenas E., Clarimon J., Blesa R., Lleo A., Cerebrospinal fluid β -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. (2014) ANN NEUROL, 76 (2), 223-230.

IF: 9.9770

Gkampeta A., Fidani L., Clarimon J., Kalinderi K., Katopodi T., Zafeiriou D., Pavlou E., Association of brain-derived neurotrophic factor (BDNF) and elongator protein complex 4 (ELP4) polymorphisms with benign epilepsy with centrotemporal spikes in a

Greek population. (2014) EPILEPSY RES, 108 (10), 1734-1739.

IF: 2.0150

Ruiz A., Dols-Icardo O., Bullido M.J., Pastor P., Rodriguez-Rodriguez E., Lopez de Munain A., de Pancorbo M.M., Perez-Tur J., Alvarez V., Antonell A., Lopez-Arrieta J., Hernandez I., Tarraga L., Boada M., Lleo A., Blesa R., Frank-Garcia A., Sastre I., Razquin C., Ortega-Cubero S., Lorenzo E., Sanchez-Juan P., Combarros O., Moreno F., Gorostidi A., Elcoroaristizabal X., Baquero M., Coto E., Sanchez-Valle R., Clarimon J., Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. (2014) NEUROBIOL AGING, 35 (2).

IF: 5.0130

Spataro N., Calafell F., Cervera-Carles L., Casals F., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Lleo A., Navarro A., Clarimon J., Bosch E., Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease†. (2014) HUM MOL GENET, 24 (7), 2023-2034.

IF: 6.3930

Suarez-Calvet M., Belbin O., Pera M., Badiola N., Magrane J., Guardia-Laguarta C., Munoz L., Colom-Cadena M., Clarimon J., Lleo A., Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A β production. (2014) J NEUROCHEM, 128 (2), 330-339.

IF: 4.2810

Suarez-Calvet M., Dols-Icardo O., Llado A., Sanchez-Valle R., Hernandez I., Amer G., Anton-Aguirre S., Alcolea D., Fortea J., Ferrer I., Van Der Zee J., Dillen L., Van Broeck-

hoven C., Molinuevo J.L., Blesa R., Clarimon J., Lleo A., Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. (2014) J NEUROL NEUROSUR PS, 85 (6), 684-691.

IF: 6.8070

Tajes M., Eraso-Pichot A., Rubio-Moscardo F., Guivernau B., Ramos-Fernandez E., Bosch-Morato M., Guix F.X., Clarimon J., Miscione G.P., Boada M., Gil-Gomez G., Suzuki T., Molina H., Villa-Freixa J., Vicente R., Munoz F.J., Methylglyoxal produced by amyloid- β peptide-induced nitrotyrosination of triosephosphate isomerase triggers neuronal death in alzheimer's disease. (2014) J ALZHEIMERS DIS, 41 (1), 273-288.

IF: 4.1510

Thelen M., Razquin C., Hernandez I., Gorostidi A., Sanchez-Valle R., Ortega-Cubero S., Wolfsgriber S., Drichel D., Fließbach K., Duenkel T., Damian M., Heilmann S., Slotosch A., Lennarz M., Seijo-Martinez M., Rene R., Kornhuber J., Peters O., Luckhaus C., Jahn H., Hull M., Ruther E., Wiltfang J., Lorenzo E., Gascon J., Lleo A., Llado A., Campdelacreu J., Moreno F., Ahmadzadehfar H., Fortea J., Indakoetxea B., Heneka M.T., Wetter A., Pastor M.A., Riverol M., Becker T., Frolich L., Tarraga L., Boada M., Wagner M., Jessen F., Maier W., Clarimon J., Lopez de Munain A., Ruiz A., Pastor P., Ramirez A., Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. (2014) NEUROBIOL AGING, 35 (11), 2657.e13-e19.

IF: 5.0130

Van Der Zee J., Van Langenhove T., Kovacs G.G., Dillen L., Deschamps W., Engelborghs

Genetics in Neurodegenerative Diseases

*TIF: 85.9350 **MIF: 7.1613

Scientific Production

S., Matej R., Vandenbulcke M., Sieben A., Dermaut B., Smets K., Van Damme P., Merlin C., Laureys A., Van Den Broeck M., Mattheijssens M., Peeters K., Benussi L., Binetti G., Ghidoni R., Borroni B., Padovani A., Archetti S., Pastor P., Razquin C., Ortega-Cubero S., Hernandez I., Boada M., Ruiz A., De Mendonca A., Miltenberger-Miltenyi G., Do Couto F.S., Sorbi S., Nacmias B., Bagnoli S., Graff C., Chiang H.-H., Thonberg H., Pernecky R., Diehl-Schmid J., Alexopoulos P., Frisoni G.B., Bonvicini C., Synofzik M., Maetzler W., Vom Hagen J.M., Schols L., Haack T.B., Strom T.M., Prokisch H., Dols-Icardo O., Clarimon J., Lleó A., Santana I., Almeida M.R., Santiago B., Heneka M.T., Jessen F., Ramirez A., Sanchez-Valle R., Llado A., Gelpi E., Sarafov S., Tournev I., Jordanova A., Parobkova E., Fabrizi G.M., Testi S., Salmon E., Strobel T., Santens P., Robberecht W., De Jonghe P., Martin J.-J., Cras P., Vandenberghe R., De Deyn P.P., Cruts M., Sleegers K., Van Broeckhoven C., Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. (2014) ACTA NEUROPATHOL, 128 (3), 397-410.

IF: 10.7620

Other Publications

- ▶ Alcolea D., Carmona-Iragui M., Suarez-Calvet M., Sanchez-Saudinos M.B., Sala I., Anton-Aguirre S., Blesa R., Clarimon J., Fortea J., Lleó A., Relationship between β -Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. (2014) JOURNAL OF ALZHEIMER'S DISEASE : JAD, 42 (1), 157-167.

Human Neuropsychopharmacology

Coordinator



Jordi Riba
jriba@santpau.cat

HSCSP RI

Members

Alejandra Roldan

HSCSP



Main Lines of Research

General Neuropsychopharmacology

- ▶ Pharmacological modulation of the different neurotransmission systems to study the role of these systems in advanced cognitive functions (executive control) and emotions.

Neuropsychopharmacology of Abused Substances

- ▶ Effects on the central nervous system of psychodysleptic drugs such as ayahuasca, salvinorin A, dimethyltryptamine and THC.
- ▶ Assessment of the impact of long-term drug use on brain function (fMRI) and structure (VBM, DTI).

Challenges

- ▶ Consolidate and extend existing research lines through possible cooperation agreements with other groups and according to internal growth.
- ▶ Obtain emerging-group recognition.
- ▶ Obtain stable funding and supporting technical staff.
- ▶ Communicate activities.
- ▶ Maintain existing external cooperation agreements.
- ▶ Establish new cooperation agreements within HSCSP RI.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Pharmacokinetic/Pharmacodynamic Modelling and Simulation.
- ▶ Parkinson Disease and Movement Disorders.
- ▶ Clinical Psychiatry.

External Collaborations

- ▶ Cognition and Brain Plasticity Group (IDIBELL Bellvitge Biomedical Research Institute), Spain.
- ▶ Biomedical Engineering Research Centre, Universitat Politècnica de Catalunya (UPC), Spain.
- ▶ Brain Institute, Federal University of Rio Grande do Norte, Natal, Brazil.
- ▶ Neuroscience and Behaviour Department, Ribeirão Preto Medical School, University of São Paulo, Brazil.
- ▶ Psychiatry and Behavioral Sciences Department, Johns Hopkins School of Medicine, USA.
- ▶ Department of Comparative Biomedical Sciences, Louisiana State University, USA.

Active Grants

- ▶ Jordi Riba Serrano. Farmacología humana de la salvinorina-A: estudio farmacodinámico y de mecanismo de acción mediante bloqueo farmacológico de los efectos. Proyectos de Investigación en Salud 2012. PI12/02758. Duration: 01/01/13-31/12/15. €66,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 6.3440 **MIF: 6.3440

Scientific Production

Martinez-Horta S., Riba J., de Bobadilla R.F., Pagonabarraga J., Pascual-Sedano B., Antonijuan R.M., Romero S., Mananas M.A., Garcia-Sanchez C., Kulisevsky J., Apathy in parkinson's disease: Neurophysiological evidence of impaired incentive processing. (2014) J NEUROSCI, 34 (17), 5918-5926.
IF: 6.3440

Neurobiology of Dementia

Coordinator

Alberto Lleó HSCSP
alleo@santpau.cat

Members

Daniel Alcolea CIBERNED
Sofía Anton HSCSP RI
Olivia Belbin HSCSP RI
Rafael Blesa HSCSP
María Carmona HSCSP RI
Martí Colom HSCSP RI
Oriol Dols CIBERNED
Juan Fortea HSCSP
Estrella Morenas HSCSP RI
Raul Núñez HSCSP RI
Isabel Sala HSCSP
M. Belén
Sánchez-Saudinós HSCSP RI
Eduard Vilaplana CIBERNED



Main Lines of Research

- ▶ Biomarkers in Alzheimer disease and other neurodegenerative dementias:
 - CSF biomarkers in Alzheimer disease, dementia with Lewy bodies and frontotemporal dementia.
 - Amyloid imaging in neurodegenerative dementias.
- Novel MRI markers in preclinical Alzheimer disease.
- ▶ Biomarkers of Alzheimer disease in Down syndrome
- ▶ Molecular basis of neurodegenerative diseases.

Challenges

- ▶ Maintain and increase scientific production and funding in the next 5 years.
- ▶ Develop a training plan for researchers entering the group while maintaining its translational nature.
- ▶ Establish new cooperation agreements to increase number of applications for European and international projects.
- ▶ Establish links with technological innovation groups and companies to foster patent applications and contracts.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Genetics in Neurodegenerative Diseases (PI: Jordi Clarimon).
- ▶ Molecular Physiology of the Synapse (PI: Alex Bayes).
- ▶ Cerebrovascular Diseases (PI: Joan Martí-Fabregas).
- ▶ Neuromuscular Diseases (PI: Isabel Illa).
- ▶ Parkinson Disease and Movement Disorders (PI: Jaume Kulisevsky).
- ▶ Nuclear Medicine (PI: Ignasi Carrió).

External Collaborations

- ▶ Ellen Gelpi, José L Molinuevo, Hospital Clínic-IDIBAPS, Barcelona, Spain.
- ▶ Jordi Magrané, Cornell University, New York, USA.
- ▶ Tiago Outeiro, University Medical Centre, Goettingen, Germany.
- ▶ Martin Ingelsson, MD, PhD, Uppsala University, Sweden.
- ▶ Tara Spire-Jones, University of Edinburgh, UK.
- ▶ Kaj Blennow, Göteborg, Sweden.
- ▶ Pieter J Visser, Amsterdam University, The Netherlands.

Active Grants

- ▶ Alberto Lleó Bisa. Complejo gamma-secretasa: efecto de mutaciones genéticas y papel como diana terapéutica en la enfermedad de Alzheimer. FIS Project 2010. PI10/00018. Duration: 01/01/11-31/12/14. €215,650.
- ▶ Rafael Blesa González. Depósito de amiloide cerebral en la enfermedad de Alzheimer: papel de los factores de riesgo genético y de los genes que intervienen en neuroplasticidad y sinaptogénesis. FIS Project 2010. PI10/01878. Duration: 01/01/11-30/06/15. €271,500.
- ▶ Juan Fortea Ormaechea. Estudios multimodales de líquido cefalorraquídeo y resonancia magnética en la enfermedad de Alzheimer preclínica. MINECO-ISCIII Project 2011. PI11/02425. Duration: 01/01/12-30/06/16. €93,009.
- ▶ Alberto Lleó Bisa. Biomarkers for Alzheimer's disease and Parkinson's disease (BIOMARKAPD). MINECO-ISCIII Joint Programming. PI11/03035. Duration: 01/01/12-31/12/15. €97,000.
- ▶ Rafael Blesa González. Enfermedad de Alzheimer y síndrome de Down. Estudios multimodales de líquido cefalorraquídeo, resonancia magnética y PET de amiloide. Proyectos de Investigación en Salud 2013. PI13/01532. Duration: 01/01/14-31/12/16. €107,500.
- ▶ Olivia Belbin. Search for synaptic biomarkers of Alzheimer's disease. Contratos Miguel Servet 2013 - Tipo I. CP13/00091. Duration: 01/01/14-31/12/16. €121,500.
- ▶ Olivia Belbin. Contrato Juan de la Cierva 2010. Ministerio de Economía y Competitividad. JCI-2010-08286. Duration: 15/01/11-14/01/14. €100,980.
- ▶ Martí Colom Cadena. Contrato predoctoral de formación 2011. Instituto de Salud Carlos III. FI11/00436. Duration: 15/09/11-14/09/15. €85,200.
- ▶ Daniel Andrés Alcolea Rodríguez. Ayudas para contratos de formación en investigación Río Hortega 2012. Instituto de Salud Carlos III. CM12/00143. Duration: 15/07/13-14/07/15. €43,200.
- ▶ Olivia Belbin. Contratos Miguel Servet 2013 - Tipo I. Instituto de Salud Carlos III. MS13/00091. Duration: 15/01/14-14/01/19. €202,500.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Alberto Lleó Bisa. Synaptic markers in preclinical Alzheimer's disease. Ajudes a la recerca biomèdica sobre malalties neurodegeneratives 2014. 8/U/2014 MARATO. Duration: 01/01/15-31/12/17. €159,903.
- ▶ Juan Fortea Ormaechea. Alzheimer's disease in Down's syndrome. CSF, MRI, EEG and PET multimodal studies. Ajudes a la recerca biomèdica sobre malalties neurodegeneratives 2014. 531/U/2014 MARATO. Duration: 01/01/15-31/12/17. €159,200.
- ▶ Juan Fortea Ormaechea. Bolsa d'Ampliació d'Estudis 2014. BA14/00047. €10,500.
- ▶ Alberto Lleó Bisa. Marcadores sinápticos en la enfermedad de Alzheimer. Proyectos de Investigación en Salud 2014. PI14/01561. €111,500.
- ▶ Juan Fortea Ormaechea. La estructura cerebral y el metabolismo en la enfermedad de Alzheimer preclínica. Interacciones entre "nuevos y viejos" biomarcadores. Proyectos de Investigación en Salud 2014. PI14/01126. €101,500.
- ▶ Maria Carmona Iragui. Ayudas para contratos de formación Río Hortega 2014. Instituto de Salud Carlos III. CM14/00029. Duration: 15/01/15-14/01/17. €53,732.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 159.2840 **MIF: 6.6368

Scientific Production

- Alcolea D, Martinez-Lage P, Izagirre A, Clerigue M, Carmona-Iragui M, Alvarez R.M., Fortea J, Balasa M, Morenas-Rodriguez E, Llado A, Grau O, Blennow K, Lleo A, Molinuevo J.L., Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: A multicenter study in Spain. (2014) J ALZHEIMERS DIS, 39 (4), 719-726. **IF: 4.1510**
- Camacho V, Lleo A, Amyloid imaging in depression: A predictor of Alzheimer's disease?. (2014) EUR J NUCL MED MOL I, 41 (4), 711-713. **IF: 5.3830**
- Casals-Coll M, Sanchez-Benavides G, Meza-Cavazos S, Manero R.M., Aguilar M, Badenes D, Molinuevo J.L., Robles A, Barquero M.S., Antunez C, Martinez-Parra C, Frank-Garcia A, Fernandez M, Blesa R, Pena-Casanova J, Spanish multicenter normative studies (NEURONORMA project): Normative data and equivalence of four BNT short-form versions. (2014) ARCH CLIN NEUROPSYCH, 29 (1), 60-74. **IF: 1.9860**
- De La Torre G.G., Suarez-Llorens A, Caballero F.J, Ramallo M.A, Randolph C., Lleo A., Sala I., Sanchez B, Norms and reliability for the Spanish version of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Form A. (2014) J CLIN EXP NEUROPSYCH, 36 (10), 1023-1030. **IF: 2.0830**
- Dols-Icardo O, Garcia-Redondo A, Rojas-Garcia R, Sanchez-Valle R, Noguera A, Gomez-Tortosa E, Pastor P, Hernandez I, Esteban-Perez J, Suarez-Calvet M, Anton-Aguirre S, Amer G, Ortega-Cubero S, Blesa R, Fortea J, Alcolea D, Capdevila A, Antonell A, Llado A, Munoz-Blanco J.L., Mora J.S., LuciaGalan-Davila, De Rivera F.J.R., Lleo A, Clarimon J, Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. (2014) HUM MOL GENET, 23 (3), 749-754. **IF: 6.3930**
- Escott-Price V, *et al.* Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. (2014) PLOS ONE, 9 (6). **IF: 3.2340**
- Ferrari R, *et al.* Frontotemporal dementia and its subtypes: A genome-wide association study. (2014) LANCET NEUROL, 13 (7), 686-699. **IF: 21.8960**
- Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sanchez-Saudinos M.-B., Sala I, Anton-Aguirre S, Gonzalez S, Medrano S, Pegueroles J, Morenas E, Clarimon J, Blesa R, Lleo A, Cerebrospinal fluid β -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. (2014) ANN NEUROL, 76 (2), 223-230. **IF: 9.9770**

*Total Impact Factor **Mean Impact Factor

Neurobiology of Dementia

*TIF: 159.2840 **MIF: 6.6368

Garcia-Ayllon M.-S., Campanari M.-L., Montenegro M.-F., Cuchillo-Ibanez I., Belbin O., Lleo A., Tsim K., Vidal C.J., Saez-Valero J., Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRIMA. (2014) *NEUROBIOL AGING*, 35 (7), 1526-1536.

IF: 5.0130

Gironell A., Martinez-Horta S., Aguilar S., Torres V., Pagonabarraga J., Pascual-Sedano B., Ribosa-Nogue R., Transcranial direct current stimulation of the cerebellum in essential tremor: A controlled study. (2014) *BRAIN STIMUL*, 7 (3), 491-492.

IF: 4.3990

Kleinberger G., Yamanishi Y., Suarez-Calvet M., Czirr E., Lohmann E., Cuyvers E., Struyfs H., Pettkus N., Wenninger-Weinzierl A., Mazaheri F., Tahirovic S., Lleo A., Alcolea D., Fortea J., Willem M., Lammich S., Molinuevo J.L., Sanchez-Valle R., Antonell A., Ramirez A., Heneka M.T., Sleegers K., Van Der Zee J., Martin J.-J., Engelborghs S., Demirtas-Tatlidede A., Zetterberg H., Van Broeckhoven C., Gurvit H., Wyss-Coray T., Hardy J., Colonna M., Haass C., TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. (2014) *SCI TRANSL MED*, 6 (243).

IF: 15.8430

Llufriu S., Martinez-Heras E., Fortea J., Blanco Y., Berenguer J., Gabilondo I., Ibarretxe-Bilbao N., Falcon C., Sepulveda M., Sola-Valls N., Bargallo N., Graus F., Villoslada P., Saiz A., Cognitive functions in multiple sclerosis: Impact of gray matter integrity. (2014) *MULT SCLER J*, 20 (4), 424-432.

IF: 4.8220

Manero R.M., Casals-Coll M., Sanchez-Benavides G., Rodriguez-De Los Reyes O.N., Aguilar M., Badenes D., Molinuevo J.L., Robles A., Barquero M.S., Antunez C., Martinez-Parra C., Frank-Garcia A., Fernandez M., Blesa R., Pena-Casanova J., Diagnostic validity of the alzheimer's disease functional assessment and change scale in mild cognitive impairment and mild to moderate alzheimer's disease. (2014) *DEMENT GERIATR COGN*, 37 (5-6), 366-375.

IF: 3.5470

Marti-Fabregas J., Delgado-Mederos R., Marin R., De La Ossa N.P., De Lecinana M.A., Rodriguez-Yanez M., Sanahuja J., Purroy F., De Arce A.M., Carrera D., Dinia L., Guardia-Laguarta C., Lleo A., Prognostic value of plasma β -amyloid levels in patients with acute intracerebral hemorrhage. (2014) *STROKE*, 45 (2), 413-417.

IF: 5.7230

Podlesniy P., Figueiro-Silva J., Llado A., Antonell A., Sanchez-Valle R., Alcolea D., Lleo A., Molinuevo J.L., Serra N., Trullas R., Reply. (2014)

ANN NEUROL, 75 (3), 460-461.

IF: 9.9770

Querol L., Nogales-Gadea G., Rojas-Garcia R., Diaz-Manera J., Pardo J., Ortega-Moreno A., Sedano M.J., Gallardo E., Berciano J., Blesa R., Dalmaj J., Illa I., Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. (2014) *NEUROLOGY*, 82 (10), 879-886.

IF: 8.2860

Rami L., Mollica M.A., Garcia-Sanchez C., Saldafia J., Sanchez B., Sala I., Valls-Pedret C., Castellvi M., Olives J., Molinuevo J.L., The subjective cognitive decline questionnaire (SCD-Q): A validation study. (2014) *J ALZHEIMERS DIS*, 41 (2), 453-466.

IF: 4.1510

Ramos-Fernandez E., Tajas M., Palomer E., Ill-Raga G., Bosch-Morato M., Guivernau B., Roman-Degano I., Eraso-Pichot A., Alcolea D., Fortea J., Nunez L., Paez A., Alameda F., Fernandez-Busquets X., Lleo A., Elosua R., Boada M., Valverde M.A., Munoz F.J., Posttranslational nitro-glycative modifications of albumin in alzheimer's disease: Implications in cytotoxicity and amyloid- β peptide aggregation. (2014) *J ALZHEIMERS DIS*, 40 (3), 643-657.

IF: 4.1510

Ruiz A., Dols-Icardo O., Bullido M.J., Pastor P., Rodriguez-Rodriguez E., Lopez de Munain A., de Pancorbo M.M., Perez-Tur J., Alvarez V., Antonell A., Lopez-Arrieta J., Hernandez I., Tarraga L., Boada M., Lleo A., Blesa R., Frank-Garcia A., Sastre I., Razquin C., Ortega-Cubero S., Lorenzo E., Sanchez-Juan P., Combarros O., Moreno F., Gorostidi A., Elcoroaristizabal X., Baquero M., Coto E., Sanchez-Valle R., Clarimon J., Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. (2014) *NEUROBIOL AGING*, 35 (2).

IF: 5.0130

Spataro N., Calafell F., Cervera-Carles L., Casals F., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Lleo A., Navarro A., Clarimon J., Bosch E., Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease†. (2014) *HUM MOL GENET*, 24 (7), 2023-2034.

IF: 6.3930

Suarez-Calvet M., Belbin O., Pera M., Badiola N., Magrane J., Guardia-Laguarta C., Munoz L., Colom-Cadena M., Clarimon J., Lleo A., Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A β production. (2014) *J NEUROCHEM*, 128 (2), 330-339.

IF: 4.2810

Suarez-Calvet M., Dols-Icardo O., Llado A., Sanchez-Valle R., Hernandez I., Amer G., An-

ton-Aguirre S., Alcolea D., Fortea J., Ferrer I., Van Der Zee J., Dillen L., Van Broeckhoven C., Molinuevo J.L., Blesa R., Clarimon J., Lleo A., Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. (2014) *J NEUROL NEUROSUR PS*, 85 (6), 684-691.

IF: 6.8070

Thelen M., Razquin C., Hernandez I., Gorostidi A., Sanchez-Valle R., Ortega-Cubero S., Wolfgruber S., Drichel D., Fliessbach K., Duenkel T., Damian M., Heilmann S., Slotosch A., Lennarz M., Seijo-Martinez M., Rene R., Kornhuber J., Peters O., Luckhaus C., Jahn H., Hull M., Ruther E., Wiltfang J., Lorenzo E., Gascon J., Lleo A., Llado A., Campdelacreu J., Moreno F., Ahmadzadehfar H., Fortea J., Indakoetxea B., Heneka M.T., Wetter A., Pastor M.A., Riverol M., Becker T., Frolich L., Tarraga L., Boada M., Wagner M., Jessen F., Maier W., Clarimon J., Lopez de Munain A., Ruiz A., Pastor P., Ramirez A., Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. (2014) *NEUROBIOL AGING*, 35 (11), 2657.e13-e19.

IF: 5.0130

Van Der Zee J., Van Langenhove T., Kovacs G.G., Dillen L., Deschamps W., Engelborghs S., Matej R., Vandenbulcke M., Sieben A., Dermant B., Smets K., Van Damme P., Merlin C., Laureys A., Van Den Broeck M., Mattheijssens M., Peeters K., Benussi L., Binetti G., Ghidoni R., Borroni B., Padovani A., Archetti S., Pastor P., Razquin C., Ortega-Cubero S., Hernandez I., Boada M., Ruiz A., De Mendonca A., Miltenberger-Miltenyi G., Do Couto F.S., Sorbi S., Nacmias B., Bagnoli S., Graff C., Chiang H.-H., Thonberg H., Pernecky R., Diehl-Schmid J., Alexopoulos P., Frisoni G.B., Bonvicini C., Synofzik M., Maetzel W., Vom Hagen J.M., Schols L., Haack T.B., Strom T.M., Prokisch H., Dols-Icardo O., Clarimon J., Lleo A., Santana I., Almeida M.R., Santiago B., Heneka M.T., Jessen F., Ramirez A., Sanchez-Valle R., Llado A., Gelpi E., Sarafov S., Tournev I., Jordanova A., Parobkova E., Fabrizi G.M., Testi S., Salmon E., Strobel T., Santens P., Robberecht W., De Jonghe P., Martin J.-J., Cras P., Vandenbergh R., De Deyn P.P., Cruts M., Sleegers K., Van Broeckhoven C., Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. (2014) *ACTA NEUROPATHOL*, 128 (3), 397-410.

IF: 10.7620

Other
Publications

- ▶ Alcolea D., Carmona-Iragui M., Suarez-Calvet M., Sanchez-Saudinos M.B., Sala I., Anton-Aguirre S., Blesa R., Clarimon J., Fortea J., Lleó A., Relationship between β -Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. (2014) JOURNAL OF ALZHEIMER'S DISEASE : JAD, 42 (1), 157-167.
- ▶ Darba J., Kaskens L., Lacey L., Lleó A., Anderson P., Evaluation of the socioeconomic consequences of progression of Alzheimer's disease in patients with dementia and cognitive impairment. Exploratory analysis of the effectiveness valuation of five clinical measures. (2014) PHARMACOECONOMICS - Spanish Research Articles, 11 (2), 39-50.

Neuroradiology

Coordinator

Beatriz Gómez Anson HSCSP
bgomeza@santpau.cat

Members

María del Valle Camacho HSCSP
Manel de Juan HSCSP
Diego Alfonso López HSCSP



Main Lines of Research

- ▶ Ours is a multidisciplinary research group, which has the added value of combining neuroimaging skills of the members of the Neuroradiology clinical unit at Hospital de la Santa Creu i Sant Pau with technological knowledge from PIC/IFAE investigators at the Universitat Autònoma de Barcelona (Spain).
- ▶ Our main focus is the search for neuroimaging biomarkers in diseases involving

the central nervous system, including neurodegenerative and neuropsychiatric conditions.

- ▶ A secondary focus is the implementation of automatic procedures and software tools to improve neuroradiological practice.

Challenges

- ▶ Achieve visibility for our research group and for neuroradiology –often considered by clinicians more a technical tool rather than a discipline in itself– as a defined field of knowledge.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Pituitary Gland Disorders.
- ▶ Clinical Psychiatry.
- ▶ Digestive Diseases.
- ▶ Parkinson Disease and Movement Disorders.
- ▶ Cerebrovascular Diseases.

External Collaborations

- ▶ PIC (Information Science Port) / IFAE (Institute for High Energy Physics), Universitat Autònoma de Barcelona, Spain.
- ▶ COST-Action in ASL (European project), National Hospital for Neurology and Neurosurgery, London, UK.

Active Grants

- ▶ Beatriz Gómez Anson. Predicció de resposta a la teràpia cognitiuconductual en pacients esquizofrènics amb al·lucinacions auditives persistents, utilitzant RMf. Fundació la Marató TV3. 091230. Duration: 25/05/10-15/06/14. €138,592.80.

Note: Total amount granted to PI. It does not include indirect costs.

Doctoral Theses

- ▶ Esther Granell Moreno. Correlación entre los cambios estructurales cerebrales (RM) y el deterioro cognitivo en el síndrome del temblor y ataxia ligada al síndrome del

cromosoma X frágil (FXTAS). Universitat Autònoma de Barcelona. Directors: Beatriz Gómez Anson, Antonio Martínez Noguera. Date de defensa: 30 June 2014.

*TIF: 29.4940 **MIF: 3.2771

Achury C., Estorch M., Domenech A., Camacho V., Flotats A., Jaller R., Geraldo L., Deportos J., Montes A., Carrio I., Interpretation of thyroid incidentalomas in 18F-FDG PET/CT studies. (2014) REV ESP MED NUCL IMA, 33 (4), 205-209.

IF: 1.0540

Armentano N., Malgosa A., Martinez B., Abello P., De Juan Delago M., Prats-Munoz G., Isidro A., Unilateral cholesteatoma in the first millennium BC. (2014) OTOL NEUROTOL, 35 (3), 561-564.

IF: 1.7870

Camacho V., Lleo A., Amyloid imaging in depression: A predictor of Alzheimer's disease?. (2014) EUR J NUCL MED MOL I, 41 (4), 711-713.

IF: 5.3830

Crespo I., Esther G.-M., Santos A., Valassi E., Yolanda V.-G., De Juan-Delago M., Webb S.M., Gomez-Anson B., Resmini E., Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome. (2014) CLIN EN-

DOCRINOL, 81 (6), 826-833.

IF: 3.4570

De Diego-Adelino J., Pires P., Gomez-Anson B., Serra-Blasco M., Vives-Gilabert Y., Puigdemont D., Martin-Blanco A., Alvarez E., Perez V., Portella M.J., Microstructural white-matter abnormalities associated with treatment resistance, severity and duration of illness in major depression. (2014) PSYCHOL MED, 44 (6), 1171-1182.

IF: 5.9380

Delgado J., Moure J.C., Vives-Gilabert Y., Delfino M., Espinosa A., Gomez-Anson B., Improving the execution performance of freesurfer: A new scheduled pipeline scheme for optimizing the use of CPU and GPU resources. (2014) NEUROINFORMATICS, 12 (3), 413-421.

IF: 2.8250

Santos A., Resmini E., Crespo I., Pires P., Vives-Gilabert Y., Granell E., Valassi E., Gomez-Anson B., Martinez-Momblan M.A., Mataro M., Webb S.M., Small cerebellar cortex volume in pa-

tients with active Cushing's syndrome. (2014) EUR J ENDOCRINOL, 171 (4), 461-469.

IF: 4.0690

Salgado-Lopez L., de Quintana-Schmidt C., Gomez-Anson B., Bague-Rosell S., Molet-Teixido J., Inflammatory myofibroblastic tumor in the brain. (2014) REVISTA DE NEUROLOGIA, 59 (6), 281-282.

IF: 0.8300

Sanchez-Benavides G., Pena-Casanova J., Calsals-Coll M., Gramunt N., Molinuevo J.L., Gomez-Anson B., Aguilar M., Robles A., Antunez C., Martinez-Parra C., Frank-Garcia A., Fernandez-Martinez M., Blesa R., Cognitive and neuroimaging profiles in mild cognitive impairment and Alzheimer's disease: data from the Spanish Multicenter Normative Studies (NEURONORMA Project). (2014) J ALZHEIMERS DIS, 41 (3), 887-901.

IF: 4.1510

Ageing Institute

Coordinator

Antoni Salvà FSiE-UAB
antoni.salva@uab.cat

Members

Anna Barrios FSiE-UAB
Laura Coll-Planas FSiE-UAB
Sara Domènech FSiE-UAB
Alexandre Domingo FSiE-UAB
Jordi González FSiE-UAB
Antonio Rivero FSiE-UAB
Marta Roque HSCSP RI
Xavier Rojano FSiE-UAB
Gabriela del Valle FSiE-UAB



Main Lines of Research

- ▶ Health research into ageing:
 - Healthy ageing: physical activity, nutrition and cognition.
 - Frequent health problems in older adults: falls, frailty and sarcopenia, functional loss, Alzheimer and other dementias, malnutrition and other geriatric syndromes.
 - Epidemiological studies.
- ▶ Health and social services research.
- ▶ Research into caregivers of older adults.
- ▶ Promotion of active ageing among older people.
- ▶ ICT applications to health, social services and active ageing.

Challenges

Health Research Area

- ▶ Area mainly focused on health promotion and disability prevention to improve quality of life among older people.
- ▶ Clinical and epidemiological research undertaken includes both observational and intervention studies, with the main lines of research referring to mobility, nutrition and cognition.

- Comprehensive needs assessment.
- Care quality.
- Good caregiving practices.
- Assessment of dependence.
- Home care services.
- Analysis of economic costs.

Research into ICT Applications to Health, Social Services and Active Ageing

Health and Social Services Research

- ▶ Social care and healthcare as key for the maintenance of autonomy, with a focus on the following topics:
 - Models of social care and healthcare.
 - The organization of health and social services.

- ▶ Interest in this area mainly focuses on the following topics:
 - Social appropriation of ICTs.
 - e-Health development.
- ▶ Development of new technological products to promote active ageing.

Awards

- ▶ XV Premi FiraGran en l'Àmbit Cívic i Social (Entitat), awarded to the Institut de l'Envel·liment UAB, in 16th edition of Saló de la Gent Gran de Catalunya (2014 Fira Gran), for its task of research on improving the quality of life of older people.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ FRAPEM: FIS Fragilitat. EAP Sardenya.
- ▶ FIS Memory Workshops. Public Health Agency of Barcelona and EAP Sardenya.

External Collaborations

- ▶ The group participates usually in CE-funded projects. During 2014 there were two collaborative projects in progress:
 - Profound
 - SAAPHO

- ▶ The Group belongs to the Global Research Network of the International Association of Geriatrics and Gerontology, which jointly organize in Barcelona a yearly course and in 2014 the International Conference on Frailty & Sarcopenia Research.
- ▶ Participation in european groups. Currently:
 - The group of nutrition and cognitive decline of the EUGMS (European Union Geriatric Medicine Society)
 - MOBEX group: about mobility and falls

Active Grants

- ▶ Antoni Salvà Casanovas. Cribado de fragilidad en personas mayores según estado cognitivo. MINECO-ISCI111 Projecte 2011. Duration: 01/01/12-31/12/14. €61,372.
- ▶ Antoni Salvà Casanovas. Secure Active Aging: Participation and Health for the Old (SAAPHO). European Commission. AAL-010000-2011-12. Duration: 2011-2014. €3,078,799.34.*
- ▶ Antoni Salvà Casanovas. Prevention of Falls Network for Dissemination (PROFOUND). European Commission. CIP 325087. Duration: 2012-2015. €1,026,569.*

- ▶ Antoni Salvà Casanovas. Frailty screening in the elderly according to cognitive status. (FRAPEM). FIS Project. PI11/02001. Duration: 2012-2014. €74,266.*
- ▶ Antoni Salvà Casanovas. Active aging, citizenship and participation: Fundación CSIC. Duration: 2012-2014. €207,719.*

* Grants applied for by other research institutes.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 42.8990 **MIF: 3.8999

Scientific Production

Bellmunt S., Roque M., Osorio D., Pardo H., Escudero J.-R., Bonfill X., Healthcare quality indicators of peripheral artery disease based on systematic reviews. (2014) EUR J VASC ENDOVASC, 48 (1), 60-69.

IF: 2.4900

Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group. Effects of Ginkgo biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study. PHYTOMEDICINE. 2014 May 15;21(6):888-92.

IF: 3.1260

Catala-Lopez F, Tobias A., Roque M., Basic concepts for network meta-analysis. (2014) ATEN PRIM, 46 (10), 573-581.

IF: 0.9530

Escribano J., Balaguer A., Roque i Figuls M., Feliu A., Ferre N., Dietary interventions for preventing complications in idiopathic hypercalciuria.. (2014) COCHRANE DB SYST REV, 2.

IF: 6.0320

Gardette V., Lapeyre-Mestre M., Piau A., Gallini A., Cantet C., Montastruc J.-L., Vellas B.,

Andrieu S., Salvà A., A 2-year prospective cohort study of antedementia drug non-persistence in mild-to-moderate Alzheimer's disease in Europe: Predictors of discontinuation and switch in the ICTUS study. (2014) CNS DRUGS, 28 (2), 157-170.

IF: 5.1130

Gine-Garriga M., Roque-Figuls M., Coll-Planas L., Sitja-Rabert M., Salva A., Physical exercise interventions for improving performance-based measures of physical function in community-dwelling, frail older adults: A systematic review and meta-analysis. (2014) ARCH PHYS MED REHAB, 95 (4).

IF: 2.5650

Puente A., Hernandez-Gea V., Graupera I., Roque M., Colomo A., Poca M., Aracil C., Gich I., Guarner C., Villanueva C., Drugs plus ligation to prevent rebleeding in cirrhosis: An updated systematic review. (2014) LIVER INT, 34 (6), 823-833.

IF: 4.8500

Sala-Llonch R., Junque C., Arenaza-Urquijo E.M., Vidal-Pineiro D., Valls-Pedret C., Palacios E.M., Domenech S., Salva A., Bargallo N., Bartres-Faz D., Changes in whole-brain func-

tional networks and memory performance in aging. (2014) NEUROBIOL AGING, 35 (10), 2193-2202.

IF: 5.0130

Schmidt-Hansen M., Baldwin D.R., Hasler E., Zamora J., Abaira V., Roque I Figuls M., PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. (2014) COCHRANE DB SYST REV, 11.

IF: 6.0320

Tobias A., CatalaLopez F, Roque M., Development of an excel spreadsheet for metaanalysis of indirect and mixed treatment comparisons. (2014) REV ESP SALUD PUBLIC, 88 (1), 5-15.

IF: 0.6930

Torrego A., Sola I., Munoz A.M., Roque I Figuls M., Yepes-Nunez J.J., Alonso-Coello P., Plaza V., Bronchial thermoplasty for moderate or severe persistent asthma in adults.. (2014) COCHRANE DB SYST REV, 3.

IF: 6.0320

Ageing Institute

Other Publications

- ▶ Osuna-Pozo C.M., Serra-Rexach J.A., Vina J., Gomez-Cabrera M.D.C., Salva A., Ruiz D., Masanes F., Lopez-Soto A., Formiga F., Cuesta F., Cruz-Jentoft A., Prevalence of sarcopenia in geriatric outpatients and nursing homes. The ELLI study. (2014) REVISTA ESPANOLA DE GERIATRIA Y GERONTOLOGIA, 49 (2), 72-76.
- ▶ Salva A., Roque M., Valles E., Bustins M., Rodo M., Sanchez P., Description of the clinical complexity of patients admitted to long term care hospitals in Catalonia during 2003-2009. (2014) REVISTA ESPANOLA DE GERIATRIA Y GERONTOLOGIA, 49 (2), 59-64.
- ▶ Salva A., Roque M., Valles E., Bustins M., Rodo M., Sanchez P., Erratum to Description of the clinical complexity of patients admitted to long term care hospitals in Catalonia during 2003-2009. (2014) REVISTA ESPANOLA DE GERIATRIA Y GERONTOLOGIA, 49 (6), 306.

Addictive Behaviours

Coordinator

Jose Pérez de los Cobos HSCSP
jperetz@santpau.cat

Members

Francesca Batlle HSCSP
 Maria Cardus HSCSP
 Sílvia Maria Costa HSCSP RI
 Josep Guàrdia HSCSP
 Laura Muñoz HSCSP RI
 Maria Cristina Pinet HSCSP
 Elisa Ribalta HSCSP
 Nuria Siñol HSCSP
 Antonio Tejero HSCSP
 Joan Trujols HSCSP
 Ana Valdeperéz HSCSP



Main Lines of Research

Alcohol

- ▶ Study of the usefulness of the EMCA, IRISA and SPECT scales with IBZM as possible predictors of outcomes in alcohol-dependent patients during the first 12 weeks of recovery.
- ▶ Clinical study with escitalopram for treatment of depression and anxiety associated with alcoholism.
- ▶ Randomized, double-blind, parallel, placebo-controlled study on the efficacy of nalmefene in alcohol-dependent patients.
- ▶ Pharmaco-epidemiological, non-interventional, prospective, multicenter study with Selincro® in alcohol dependence, to determine patterns of use and consumption of alcohol in routine clinical practice in Spain.
- ▶ Prospective observational study for reducing the negative consequences associated with excessive alcohol use (RINCA) through the treatment program to reduce alcohol consumption with nalmefene.

Cocaine

- ▶ Evaluation of cocaine craving during hospitalization conditions.

Smoking

- ▶ Evaluation of the neuropsychiatric safety and efficacy of varenicline and bupropion hydrochloride for smoking cessation in subjects with and without a history of psychiatric disorders.
- ▶ Non-treatment follow-up for cardiac assessments following use of smoking cessation treatments in subjects with and without a history of psychiatric disorders.

Opiates

- ▶ Patient satisfaction concerning maintenance treatment with opioid agonists.
- ▶ Satisfaction of the heroin-dependent patient regarding methadone and methadone pharmacogenetics.

Challenges

- ▶ Establish bidirectional links between clinical practice and investigation both to suggest hypotheses and incorporate recent advances.
- ▶ Participate in controlled clinical trials on the treatment of addictive disorders.
- ▶ Develop clinical research studies into the perspective of patients with addictions.
- ▶ Integrate clinical research in routine medical practice to assess the effectiveness of procedures.
- ▶ Evaluate the validity and reliability of frequently used clinical evaluation procedures.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Clinical Epidemiology and Healthcare Services.
- ▶ Clinical Psychiatry.
- ▶ Genetic Diseases.

External Collaborations

- ▶ DeustoPsych, R+D+I in Psychology and Health, University of Deusto, Bilbao, Spain.

Active Grants

- ▶ José Pérez de los Cobos. Hacia la identificación de los mecanismos que permiten inhibir el craving de cocaína: valoración de factores motivacionales y cognitivos potencialmente relacionados con la ausencia de craving. Proyectos de Investigación en Salud 2012. PI12/00105. Duration: 01/01/13-31/12/15. €74,500.
- ▶ Joan Trujols Albet. Satisfacción con el tratamiento de mantenimiento con agonistas opioides: Revisión sistemática de instrumentos de medida y síntesis cuantitativa de las diferencias en los

niveles de satisfacción en función del medicamento y de la escala. Projectes de investigació sobre drogodependències 2013. 2013I060. Duration: 01/01/14-31/12/16. €15,630.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 18.7010 **MIF: 2.6716

Scientific Production

Cobos J.P.D.L., Trujols J., Sinol N., Batlle F., Development and validation of the scale to assess satisfaction with medications for addiction treatment-methadone for heroin addiction (SASMAT-METHER). (2014) DRUG ALCOHOL DEPEND, 142, 79-85.

IF: 3.4230

Perez De Los Cobos J., Sinol N., Perez V., Trujols J., Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. (2014) BRIT J CLIN PHARMACOL, 77 (2), 337-356.

IF: 3.8780

Perez de los Cobos J., Trujols J., Sinol N., Vasconcelos e Rego L., Iraurgi I., Batlle F., Psychometric properties of the Spanish version of the Cocaine Selective Severity Assessment to evaluate cocaine withdraw-

al in treatment-seeking individuals. (2014) J SUBST ABUSE TREAT, 47 (3), 189-196.

IF: 1.9960

Plans P., Alvarez E., De Ory F., Campins M., Paya T., Balfagon P., Godoy P., Cayla J., Carreras R., Cabero L., Dominguez A., Prevalence of antibody to bordetella pertussis in neonates and prevalence of recent pertussis infection in pregnant women in Catalonia (Spain) in 2003 and 2013. (2014) PEDIATR INFECT DIS J, 33 (11), 1114-1118.

IF: 2.7230

Tejedor R., Feliu-Soler A., Pascual J.C., Cebolla A., Portella M.J., Trujols J., Soriano J., Perez V., Soler J., Psychometric properties of the Spanish version of the Philadelphia Mindfulness Scale. (2014) REV PSIQUIATR SALUD, 7 (4), 157-165.

IF: 1.6220

Trujols J., De Diego-Adelino J., Feliu-Soler A., Iraurgi I., Puigdemont D., Alvarez E., Perez V., Portella M.J., The Spanish version of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16): A psychometric analysis in a clinical sample. (2014) J AFFECT DISORDERS, 169, 189-196.

IF: 3.3830

Trujols J., Iraurgi I., Oviedo-Joekes E., Guardia-Olmos J., A critical analysis of user satisfaction surveys in addiction services: Opioid maintenance treatment as a representative case study. (2014) PATIENT PREFERENCE ADHER, 8, 107-117.

IF: 1.6760

Molecular Physiology of the Synapse

Coordinator


Àlex Bayés
abayesp@santpau.cat

HSCSP RI

Members

Rita Reig

HSCSP RI



Main Lines of Research

- ▶ Molecular and cellular analyses of the vertebrate synapse.
- ▶ Molecular and cellular dysfunctions underlying intellectual disability and autism.
- ▶ Research into animal models of mental and behavioural disorders.
- ▶ Development of new biochemical methods to study the synapse.

Challenges

- ▶ Characterize the molecular roots of cognition and behaviour.
- ▶ Identify the synaptic molecules and mechanisms involved in mental and behavioural disorders, mainly intellectual disabilities and autism spectrum disorders.
- ▶ Identify drugs which might help treat mental and behavioural disorders.
- ▶ Study the reversibility after birth of neurodevelopmental disorders affecting cognition.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Neurobiology of Dementias
- ▶ Molecular Physiology of Synapse. (Alejandro Bayés. AGAUR 2014. SGR 297. Duration: 2014-2016. €19.200.)

External Collaborations

- ▶ Prof. Seth GN Grant. University of Edinburgh, UK.
- ▶ Dr. Noboru Komiyama. University of Edinburgh, UK.

- ▶ Dr. Gavin Rumbaugh. Scripps Research Institute, USA.
- ▶ Dr. Richard Emes, University of Nottingham, UK.
- ▶ Dr. Nael Nadif-Kasri. Radboud University, The Netherlands
- ▶ Dr. Montserrat Milà. Hospital Clínic de Barcelona.
- ▶ Dr. Àngels García-Cazorla. Hospital Sant Joan de Déu, Barcelona.
- ▶ Dr. Mark Collins, University of Sheffield, UK.

Active Grants

- ▶ Alejandro Bayés. Proteomic and Bioinformatic Studies of Synaptic Function and Dysfunction in the Context of Human Intellectual Disabilities. Ministerio de Economía y Competitividad. Program to support non-oriented research projects. BFU2012-34398. Duration: 2013-2015. €150,000.*
 - ▶ Alejandro Bayés. Molecular Analysis of Synaptic Dysfunctions Underlying Human Intellectual Disabilities. European Commission, FP7 Career Integration Grant (CIG). Duration: 2012-2016. Project reference: 304111. €100,000.*
 - ▶ Alejandro Bayés. Proteomic and Bioinformatic Studies of Synaptic Function in the Context of Human Mental and Behavioural Disorders. Spanish Ministry of Economy and Competitiveness, Start-up associated to Ramon y Cajal Career Development Fellowship. 2012-2014. Project Reference: RYC-2011-08391. €15,000.*
 - ▶ Gemma Gou Alsina. Contratos Predoctorales para la Formación de Doctores 2013. MINECO BES-2013-063720. Duration: 12/12/13-11/12/17.
 - ▶ Alejandro Bayés. Contrato Ramón y Cajal 2011. Ministerio de Economía y Competitividad. RYC-2011-08391. Duration: 02/05/2012-01/05/2017. €168,600.
- * Grants applied for by other research institutes.
 Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Alejandro Bayés. Acciones de dinamización "Redes de Excelencia" 2014. Ministerio de Economía y Competitividad. SAF2014-52624-REDT. Duration: 01/12/2014-30/11/2016. €32,000.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 7.4340 **MIF: 3.7170

Scientific Production

Bayés A., Collins M., Galtrey C., Simonnet C., Roy M., Croning M., Gou G., van de Lagemaat L., Milward D., Whittle I., Smith C., Choudhary J., Grant S. Human post-mortem synapse proteome integrity screening for proteomic studies of postsynaptic complexes. MOLECULAR BRAIN 2014 Nov 28;7(1):88.

Gou G., Leanez S., Pol O., The role of gaseous neurotransmitters in the antinociceptive effects of morphine during acute thermal pain. (2014) EUR J PHARMACOL, 737, 41-46.

IF: 2.5320

Sindreu C., Bayes A., Altafaj X., Perez-Clausell J., Zinc transporter-1 concentrates

at the postsynaptic density of hippocampal synapses. (2014) MOL BRAIN, 7 (1).

IF: 4.9020

Other Publications

- ▶ Soto D., Altafaj X., Sindreu C., Bayés A. Glutamate Receptor Mutations in Psychiatric and Neurodevelopmental Disorders. COMMUNICATIVE AND INTEGRATIVE BIOLOGY. 2014 Jan 1;7(1):e27887.

AREA 5

Urology and Experimental Surgery

182 General and Digestive Surgery

186 Neurosurgery

188 Nephrology

Surgery



General and Digestive Surgery

Coordinator

Manel Trias HSCSP
mtrias@santpau.cat

Members

Luis Horacio Allende HSCSP
Vicenç Artigas HSCSP
Carmen Balagué HSCSP
Jesús Bollo HSCSP
Ferran Caballero HSCSP
Gemma Cerdan HSCSP
Montserrat Clos HSCSP
Nuria Freixas HSCSP
Xavier Giménez-Salinas HSCSP
José Antonio González HSCSP
M. Pilar Hernández HSCSP
Carmen Martínez HSCSP
Rodrigo Medrano HSCSP
Antonio Moral HSCSP
José Pérez HSCSP
Xavier Rius HSCSP
Manuel Rodríguez Blanco HSCSP
Sílvia Rofin HSCSP
Pilar Solé HSCSP
Eduard Targarona HSCSP



Main Lines of Research

Gastrointestinal Surgery

- ▶ Application of laparoscopic surgery in diseases of the spleen.
- ▶ Application of laparoscopic surgery in disorders of the oesophagogastric junction.
- ▶ Advanced application of colorectal laparoscopy.
- ▶ New stratification and treatment options in colorectal cancer.

Oncological and Hepatobiliopancreatic Surgery

- ▶ Surgery for liver metastasis in colorectal cancer.
- ▶ Development of diagnostic and therapeutic techniques in the global context of treatment for liver metastasis in colorectal carcinoma.

- ▶ Surgery for primary hepatic tumours: determination of efficient prognostic parameters for surgical resection of hepatocarcinoma and likelihood of tumour recurrence after resection.
- ▶ Introduction of the laparoscopic methodology to biliary lithiasis.
- ▶ Surgery for sarcomas: participation in GIST research through the Spanish Sarcoma Research Group (GEIS) and other entities.
- ▶ Surgery for sarcomas: participation in the development and results of surgery for retroperitoneal tumours.

Emergency Care

- ▶ Collaborative project on clinical safety for the introduction of safe practices for polytraumatized patients.

Challenges

Gastrointestinal Surgery

- ▶ Design, develop and manage a dry laboratory for endoscopic surgery, creating a multifunctional research and teaching space to conduct applied technological research in minimally invasive surgery.

Hepatobiliopancreatic Surgery

- ▶ Development of techniques to study liver volume and function.
- ▶ Development of experimental studies on the function and healing of bilio-intestinal sutures.
- ▶ Studies of the value of nutrition in patients undergoing aggressive surgery for highly debilitating cancer.
- ▶ Suitable stratification of GIST tumours in accordance with an anatomopathological classification.

- ▶ Viability of surgical interventions considering the likelihood of disease recurrence.

Emergency Surgery

- ▶ Consolidation of a multidisciplinary group for polytraumatized patient care.

Breast Surgery

- ▶ Technological innovations in surgery.
- ▶ Possible role of genetic studies in diagnosis and follow-up.

Endocrinal and Cervical Surgery

- ▶ Technical innovations in surgery.

Doctoral Theses

- ▶ Sonia Fernández Ananin. Abordaje laparoscópico en el cáncer de recto. Factores predictivos de la calidad del mesorrecto. Universitat Autònoma de Barcelona. Directors: Manel Trias Folch, Eduard Maria Targarona Soler. Date of defense: 30 October 2014.

Active Grants

- ▶ Eduard Targarona Soler. Design of a 3D model to evaluate 2 volumetric variables (sleeve diameter and antrum size) after sleeve gastrectomy and its influence on weight loss. 2011 EAES (UE). 2011 EAES. Duration: 19/07/12-30/06/15. €45,455.
- ▶ Manel Trias Folch. Development of nanomedicines for substitute enzymatic replacement therapy on Fabry disease. TELEMAR-ATÓ 2010 Malalties minoritaries. 101233. Duration: 23/03/11-31/12/14. €44,888.
- ▶ Carlos Rodríguez-Otero Luppi. MIA 2013-2. Contracte MIA 2013. Duration: 01/06/13-31/05/14. €45,222.91.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 22.8320 **MIF: 1.5221

Scientific Production

Alamo P, Gallardo A., Pavon M.A., Casanova I, Trias M., Mangues M.A., Vazquez E., Villaverde A., Mangues R., Cespedes M.V., Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. (2014) DIS MODEL MECH, 7 (3), 387-396.

IF: 4.9730

Estalella L., Rodriguez-Otero C., Garriga J., Donate T., Targarona E., Hydrocele after peritoneal dialysis: Persistence of the peritoneal-vaginal duct. (2014) CIR ESPAN, 92 (6), 443-444.

IF: 0.7430

Fernandez Ananin S., Targarona E.M., Martinez C., Pernas J.C., Hernandez D., Gich I., Sancho F.J., Trias M., Predicting the pathological features of the mesorectum before the laparoscopic approach to rectal cancer. (2014) SURG ENDOSC, 28 (12), 3458-3466.

IF: 3.2560

Garay M., Bollo J., Balague C., Targarona E., Trias M., Gastrointestinal bleeding as a first symptom of a focal jejunal amyloidosis. (2014) CIR ESPAN, 92 (10), 696-698.

IF: 0.7430

Gonzalez Lopez J.A., Artigas Raventos V., Rodriguez Blanco M., Lopez-Pousa A., Bague S., Abellan M., Trias Folch M., Differences between en bloc resection and enucleation of retroperitoneal sarcomas. (2014) CIR ESPAN, 92 (8), 525-531.

IF: 0.7430

Lopez J., Vilallonga R., Targarona E.M., Balague C., Enriquez L., Rivera R., Balibrea J.M., Perez-Ochoa F., Rodriguez K., Baeza M., Reyes A., Can ligasure™ be used to perform sleeve gas-

trectomy?-Tensile strength and histological changes. (2014) MINIM INVASIV THER, 23 (3), 144-151.

IF: 1.2710

Marinello F.G., Targarona E.M., Balague C., Poca M., Mones J., Trias M., Laparoscopic approach of achalasia. Long-term clinical and functional results and quality of life. (2014) CIR ESPAN, 92 (3), 188-194.

IF: 0.7430

Mato E., Gonzalez C., Moral A., Perez J.I., Bell O., Lerma E., de Leiva A., ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1). (2014) J MOL ENDOCRINOL, 52 (3), 289-300.

IF: 3.0810

Mocanu S.N., Gonzalez Lopez J.A., Villalba Aunon J., Artigas Raventos V., Percutaneous treatment of a tumour obstruction of the afferent loop of a hepaticojejunostomy. (2014) CIR ESPAN, 92 (3), 209-210.

IF: 0.7430

Moreno-Sanz C., Tenias-Burillo J.M., Morales-Conde S., Balague-Ponz C., Diaz-Luis H., Enriquez-Valens P., Manuel-Palazuelos J.C., Martinez-Cortijo S., Olsina-Kissler J., Socas-Macias M., Toledano-Trincado M., Vidal-Perez O., Noguera-Aguilar J.F., Salvador-Sanchis J.L., Feliu-Pala X., Targarona-Soler E.M., 25 years of laparoscopic surgery in Spain. (2014) CIR ESPAN, 92 (4), 232-239.

IF: 0.7430

Navarro S., Koo M., Orrego C., Munoz-Vives J.M., Rivero M., Montmany S., Prat S., Poboperis A., Puig S., Monerri Mdel M., Caballero F., Caceres E., Study on the improvement of

trauma patient care: TRAUMACAT project. (2014) MED CLIN-BARCELONA, 143, 25-31.

IF: 1.4170

Pallares-Segura J.L., Balague-Pons C., Dominguez-Agustin N., Martinez C., Hernandez P., Bollo J., Targarona-Soler E.M., Trias-Folch M., The role of sentinel lymph node in colon cancer evolution. (2014) CIR ESPAN, 92 (10), 670-675.

IF: 0.7430

Palliseria A., Jorba R., Ramia J.M., Rodriguez J.A., Subirana H., De Zarate L.O., Gonzalez J.A., Navarro S., Biological markers of severity in acute pancreatitis. (2014) CENT EUR J MED, 9 (4), 550-555.

IF: 0.1530

Regimbeau J.M., Fuks D., Pessaux P., Bachellier P., Chatelain D., Diouf M., Raventos A., Manton G., Gigot J.-F., Chiche L., Pascal G., Azoulay D., Laurent A., Letoublon C., Boleslawski E., Rivoire M., Mabrut J.-Y., Adham M., Le Treut Y.-P., Delpéro J.-R., Navarro F., Ayav A., Boudjema K., Nuzzo G., Scotte M., Farges O., Tumour size over 3 cm predicts poor short-term outcomes after major liver resection for hilar cholangiocarcinoma. by the HC-AFC-2009 group. (2014) HPB, 17 (1), 79-86.

IF: 2.6750

Trias M., Gonzalez-Calatayud M., Targarona E.M., Balague C., Rodriguez-Luppi C., Martin A.B., Trias M., Minimally invasive therapy for epiphrenic diverticula: Systematic review of literature and report of six cases. (2014) J MINIM ACCESS SURG, 10 (4), 169-174.

IF: 0.8050

General and Digestive Surgery

Other Publications

- ▶ De Vinatea de Cárdenas, J., Velásquez Hawkins C., Huamán Egoávil E. Cirugía del bazo. In: Ciencia y Práctica en Cirugía Laparoscópica. Ed. Amolca. ISBN 978-958-8816-46-3.
- ▶ Marinello F.G., Targarona E.M., Balague C., Poca M., Mones J., Trias M., Long-term clinical status, quality of life and functional outcomes after laparoscopic approach to achalasia. (2014) MINIMALLY INVASIVE SURGERY: EVOLUTION OF OPERATIVE TECHNIQUES, SAFETY EFFECTIVENESS AND LONG-TERM CLINICAL OUTCOMES, 109-124.
- ▶ Park A.E., Targarona E.M., Belyansky I. Spleen (chapter 34). In: Schwartz's Principles of Surgery, 10th Edition, The McGraw-Hill Companies, 2014. ISBN 978-0-07179674-3.
- ▶ Targarona E.M., Luppi C.R., Monclova J.L., Balague C., Trias M., Splenectomy. (2014) REDUCED PORT LAPAROSCOPIC SURGERY, 271-281.
- ▶ Targarona E.M., Luppi C.R., Pallares L., Monclova J.L., Balague C., Trias M., Single-access laparoscopic splenectomy. (2014) SINGLE-ACCESS LAPAROSCOPIC SURGERY: CURRENT APPLICATIONS AND CONTROVERSIES, 9783319069296, 89-100.

Neurosurgery

Coordinator

Joan Molet HSCSP
jmolet@santpau.cat

Members

Ignasi Català HSCSP
Cristian de Quintana HSCSP
Fernando Muñoz HSCSP
Rodrigo Rodríguez HSCSP
Pere Tresserras HSCSP



Main Lines of Research

- ▶ Biomaterials: comparative study of two different cranial bone fixations.
- ▶ Tumour biology: gliomas (prognostic value of different mutations in anaplastic astrocytoma and GBM), pituitary gland adenomas.
- ▶ Biomarkers in anaplastic astrocytomas and glioblastoma multiforme.
- ▶ Anatomy of the skull base.
- ▶ Clinical evaluation of neurostimulation techniques in different neurological entities (treatment-resistant depression and neuropathic pain).

Challenges

- ▶ Monitor the clinical trial on treatment-resistant depression treated using deep brain stimulation techniques (jointly with psychiatry).
- ▶ Evaluate neurostimulation for other disorders: cluster headache.

Collaborations

- ▶ Joan Molet. MOBI-KITS study. Prospective multicentre worldwide study of the relationship between cell phone use and brain tumour development in the youth population, 7th Framework Programme ENV-2008-226873. Coordinators Spain: Carlos Díaz Acedo and Sandra Plans, Coordinator Catalonia: CREAL.
- ▶ Fernando Muñoz, Ignasi Català. IMPACT-24 study. Effects of pterygopalatine ganglion stimulation on cerebral perfusion in patients with stroke, Brainsgate. Principal researcher: Joan Martí (Neurology Group)
- ▶ Fernando Muñoz, Cristian de Quintana, Ignasi Català, Carles Asencio. CLEAR III. Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III. John Hoppinkgs Hospital. Principal researcher: Joan Martí (Neurology Group).
- ▶ Joan Molet, Rodrigo Rodríguez. Estimulación Cerebral Profunda en el tratamiento de la esquizofrenia refractaria: Estudio piloto aleatorizado, controlado y cruzado. Fondo de Investigaciones Sanitarias PI12/00042. Duration: 2013-2015. Principal researcher: Enric Álvarez.
- ▶ Fernando Muñoz i Carles Asencio. Estudi MISTIE III. Minimally Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage Evacuation. Principal researcher: Joan Martí Fàbregas.

*TIF: 22.6830 **MIF: 4.5366

Scientific Production

Asencio-Cortes C., De Quintana-Schmidt C., Clavel-Laria P., Antunez I.C., Graciano G.M., Teixido J.M., Spinal cord metastasis from gliosarcoma. Case report and review of the literature. (2014) NEUROCIRUGIA, 25 (3), 132-135.

IF: 0.2930

Canas-Ventura A., Marquez L., Ricart E., Domenech E., Gisbert J.P., Garcia-Sanchez V., Marin-Jimenez I., Rodriguez-Moranta F., Gomollon F., Calvet X., Merino O., Garcia-Planella E., Vazquez-Romero N., Esteve M., Iborra M., Gutierrez A., Vera M., Andreu M., Panes J., Garcia V., Penalva M., Garcia-Planella E., Vera I., Nos P., Vazquez N., Gento E., Fernandez-Salazar L., Barrio J., Martin M.D., Munoz F., Ponferrada A., Hinojosa J., Piqueras M.,

Mendoza J.C., Cabriada J.L., Munoz C., Vilar P., Montoro M.A., Algaba A., Botella B., Saro C., Barreiro M., Aldegue X., Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. (2014) J CROHNS COLITIS, 8 (10), 1287-1293.

IF: 6.2340

Perez-Caballero L., Perez-Egea R., Romero-Grimaldi C., Puigdemont D., Molet J., Caso J.-R., Mico J.-A., Perez V., Leza J.-C., Berrocoso E., Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. (2014) MOL PSYCHIATR, 19 (5), 607-614.

IF: 14.4960

de Quintana-Schmidt C., Pascual-Sedano B., Alvarez-Holzappel M.J., Gironell A., Leidinger A., Benito N., Rodriguez-Rodriguez R., Molet-Teixido J., Complications related with implanted devices in patients with Parkinson's disease treated with deep brain stimulation. A study of a series of 124 patients over a period of 16 years. (2014) REV NEUROLOGIA, 59 (2), 49-56.

IF: 0.8300

Salgado-Lopez L., de Quintana-Schmidt C., Gómez-Anson B., Bague-Rosell S., Molet-Teixido J. Inflammatory myofibroblastic tumor in the brain. REV NEUROLOGIA, 59 (6): 281-2.

IF: 0.8300

Other Publications

► Julia A., Domenech E., Chaparro M., Garcia-Sanchez V., Gomollon F., Panes J., Manosa M., Barreiro-De Acosta M., Gutierrez A., Garcia-Planella E., Aguas M., Munoz F., Esteve M., Mendoza J.L., Vera M., Marquez L., Tortosa R., Lopez-Lasanta M., Alonso A., Gelpi J.L., Garcia-Montero A.C., Bertranpetit J., Absher D., Myers R.M., Gisbert J.P., Marsal S., A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. (2014) HUMAN MOLECULAR GENETICS, 23 (25), 6927-6934.

► Salgado-Lopez L., de Quintana-Schmidt C., Gomez-Anson B., Bague-Rosell S., Molet-Teixido J., Inflammatory myofibroblastic tumor in the brain. (2014) REVISTA DE NEUROLOGIA, 59 (6), 281-282.

Nephrology

Coordinator

José Ballarín F. Puigvert
jballarin@fundaciopuigvert.es

Members

Elisabet Ars F. Puigvert
Beatriz Bardají F. Puigvert
Jordi Bover F. Puigvert
Gemma Bullich F. Puigvert
Lluïsa Carnero F. Puigvert
Elisabet Coll F. Puigvert
M. Montserrat Díaz F. Puigvert
Joan Manel Díaz F. Puigvert
Estefanía Eugui F. Puigvert
Patricia Fernández-Llama F. Puigvert
Elena Guillén F. Puigvert
Olga Sancho F. Puigvert
Irene Silva F. Puigvert
Roser Torra F. Puigvert



Main Lines of Research

Proteomics Applied to Nephrology and Hypertension

- ▶ Water and sodium renal transport analysed from urinary exosomes, urinary proteomic characterization in diabetic nephropathy: evaluation of renal-angiotensin blockade.

Hereditary Kidney Diseases

- ▶ Genetic and clinical studies in cystic and glomerular inherited kidney diseases such as polycystic kidney disease, Alport, corticoid-resistant nephrotic syndrome, Fabry disease, tuberous sclerosis and familial nephropathies of uncertain origin.

Glomerular Disorders

- ▶ Molecular and clinical studies in disorders such as membranous glomerulopathy and vasculitis with renal involvement, among others.

Kidney Transplantation

- ▶ Protocol biopsies, chronic transplant nephropathy, kidney transplant and associated cardiovascular risk factors, pharmacogenetic and genomic studies.

Chronic Kidney Disease (CKD)

- ▶ Early diagnosis of CKD, epidemiological and clinical studies in CKD-related complications such as renal anaemia, CKD mineral and bone disorders (CKD-MBD) and associated cardiovascular risk; haemodialysis techniques and studies of genetic damage in patients with CKD.
- ▶ Mechanisms of epithelial-mesenchymal transition and renal fibrosis.

Challenges

- ▶ Maintain the level of national and international publication.
- ▶ Continue with both clinical and basic research in all the previously described areas.
- ▶ Participate in the elaboration of clinical nephrology guidelines.
- ▶ Continue with active collection of research samples from CKD and transplant patients.
- ▶ Maintain participation in national working groups and increase international cooperation.
- ▶ Engage in new pharmaceutical clinical studies, including clinical trials.

Collaborations with other IIB Sant Pau Groups**Active collaborations in basic and clinical research projects**

- ▶ Inflammatory Diseases Group: renal fibrosis.
- ▶ Anaesthesiology Group (in collaboration with the Catalan ANES-CARDIOCAT Group): risk of major adverse cardiovascular and cerebrovascular events in non-cardiac surgery associated with the preoperative estimated glomerular filtration rate.
- ▶ Paediatrics Group: nephrotic syndrome evolution, Ig A nephropathy and inherited kidney diseases.
- ▶ Andrology Group: infertility.
- ▶ Urology Group: genetic predisposition to prostate cancer and transplant.

Platforms

- ▶ Biobank platform.

External Collaborations**Participation in national networks**

- ▶ Ars, E. Biobank Network. 2010-2014. Instituto de Salud Carlos III. RD09/0076/00064. €138,000.
- ▶ Ballarín, J. RedinRen. 2007-2014. Instituto de Salud Carlos III. R06/0016/0001. €33,590.
- ▶ Ballarín, J. Kidney research Network. 2013. Instituto de Salud Carlos III. RD12/0021/0033. €69,700.

Other national academic collaborations

- ▶ Department of Biochemistry and Molecular Biology, Universitat de Barcelona, Institute of Biomedicine and Oncology Programme, National Biomedical Research Institute of Liver and Gastrointestinal Diseases (CIBER EHD): renal fibrosis.
- ▶ Laboratory of Proteomics CSIC/Universitat Autònoma de Barcelona: diabetic nephropathy.
- ▶ Mutagenesis Department of Universitat Autònoma de Barcelona: renal impairment in chronic kidney disease.
- ▶ Genomic Regulation Center (CRG): inherited kidney diseases.
- ▶ Universidad de Salamanca: acute kidney injury.

- ▶ Universitat de Lleida: chronic kidney disease.

- ▶ National Scientific Societies (such as Sociedad Española de Nefrología) and investigators of other centres: basic and clinical studies (including public grants, clinical trials, observational studies...) promoted by them.

International academic collaborations

- ▶ Biochemistry and Microbiology Institute UACH (Chile): renal fibrosis and diabetic nephropathy
- ▶ Mayo Clinic (Rochester, USA): Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- ▶ Hospital Tenon (Paris, France): Nephrotic syndrome
- ▶ EURenOmics Platform: membranous nephropathy and nephrotic syndrome.
- ▶ Toronto General Hospital (Canada): molecular genetics of idiopathic nephrotic syndrome
- ▶ University of Melbourne (Australia): Alport syndrome
- ▶ University Medicine Goettingen (Germany): Alport Syndrome
- ▶ EDTA (multinational, Europe): inherited kidney diseases and Chronic Kidney Disease- Mineral and Bone Disorders
- ▶ Addenbrooke's Hospital, Cambridge University Hospitals NHS (United Kingdom): vasculitis
- ▶ EUVAS Group (multinational collaborative Group): vasculitis.

Private national and international collaborations

- ▶ Participation in clinical studies including clinical trials and post-authorisation studies promoted by national and International pharmaceutical companies.
- ▶ Research Joint-Venture with VU Medisch Centrum (Amsterdam, The Netherlands); Medizinische Klinik I (Aachen, Germany) and San Paolo Hospital (Milan, Italy) sponsored by Abbvie Co on effects of vitamina D derivatives in CKD-MBD.

Other collaborations

- ▶ Patient organisations: inherited diseases (AIRG), lupus (ACLECA) and chronic kidney disease (ALCER).

- ▶ Canal C., Facundo C., Serra N., Guirado L. ¿Which patients are more liable to present subclinical acute rejection? Best Communication. 3rd National Congress of the Spanish Society of Transplant.
- ▶ Bover J, et al. Diagnostic Method of renal insufficiency. IX Award of University to Society Transfer Acknowledgement. Universidad de Alcalá Social Board.
- ▶ Górriz JL, Molina P, Bover J et al. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. Nefrología 2013;

33(1) 46-60. César Llamazares 2014. Award To The Best 2013 Published Article in the Journal.

- ▶ Ars E, Torra R, Ballarín J and Santin S. Clinical utility of podocyte gene-analysis in children and adults with cortico-resistant nephrotic syndrome. Iñigo Álvarez de Toledo Award to Nephrology Research. Fundación Iñigo Álvarez de Toledo.
- ▶ Guirado L. Promotion of crossed transplants in Spain. 25TH Anniversary of the National Organisation of Transplants Award. Organización Nacional de Trasplantes.

Nephrology

Active Grants

- ▶ Elisabeth Ars. Enfermedades renales hereditarias quísticas y glomerulares: secuenciación masiva de un panel de genes para mejorar su diagnóstico y del exoma para identificar nuevos genes. FIS Project 2013. PI13/01731. Duration: 01/01/14-31/12/16. €82,280.
- ▶ P. Fernández-Llama. Diabetic nephropathy: characterisation of urinary proteoma and evaluation of renin angiotensin blocker treatment. Instituto de Salud Carlos III. PI10/01261. Duration: 2011-2015. €181,742.*
- ▶ M. Díaz. Involvement of nucleoside transporter ENT1 in the modulation of macrophage-mediated renal fibrosis. Instituto de Salud Carlos III. PI12/01524. Duration: 2013-2015. €41,745.*
- ▶ R. Torra. Genomic study of familial nephropathies of uncertain etiology. Instituto de Salud Carlos III. PI12/01523. Duration: 2013-2015. €109,505.*
- ▶ E. Coll. Prognostic biomarkers and strategies to decrease the morbimortality in chronic kidney disease patients. Instituto de Salud Carlos III. PI12/02559. Duration: 2013-2015. €126,445.*
- ▶ Ballarin, J. Grup d'Investigació en Nefrologia (grup de recerca consolidat). AGAUR 2014. SGR 1441. Duration: 2014-2016.*

* Grants applied for by other research institutes.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Roser Torra Balcells. Contractes per a la intensificació de l'activitat investigadora en el SNS. INT14/00214. €30,000.

Note: Total amount granted to PI. It does not include indirect costs.

Patents

- ▶ J. Bover (co-inventor). Diagnostic Method of renal insufficiency. Co-titularity: Universidad de Alcalá, Fundació Puigvert and Biomedical Research Foundation, Hospital Gregorio Marañón. Application number: 201131506. Publication number: ES2403755 (Spanish Patent and Trademark Office). Concession date: 19/03/2014.

*TIF: 94.8930 **MIF: 3.2722

Scientific Production

Bouchireb K., Boyer O., Gribouval O., Nevo F., Huynh-Cong E., Moriniere V., Campait R., Ars E., Brackman D., Dantal J., Eckart P., Gigante M., Lipska B.S., Liutkus A., Megarbane A., Mohsin N., Ozaltin F., Saleem M.A., Schaefer F., Soulamy K., Torra R., Garcelon N., Mollet G., Dahan K., Antignac C., NPHS2 mutations in steroid-resistant nephrotic syndrome: A mutation update and the associated phenotypic spectrum. (2014) HUM MUTAT, 35 (2), 178-186.

IF: 5.1440

Bover J., Urena P., Brandenburg V., Goldsmith D., Ruiz C., DaSilva I., Bosch R.J., Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease. (2014) SEMIN NEPHROL, 34 (6), 626-640.

IF: 3.4830

Bullich G., Ballarin J., Oliver A., Ayasreh N., Silva I., Santin S., Diaz-Encarnacion M.M., Torra R., Ars E., HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. (2014) CLIN J AM SOC NEPHRO, 9 (2), 335-343.

IF: 4.6130

Canal C., Pellicer R., Facundo C., Garcia-Garcia S., Montanes-Bermudez R., Ruiz-Garcia C., Furlano M., Da Silva I.K., Ballarin J.A., Bover J., Tables for estimating the glomerular filtration rate using the new CKD-EPI equation from serum crea-

tinine concentration. (2014) NEFROLOGIA, 34 (2), 223-229.

IF: 1.2230

Cases-Amenos A., Martinez-Castelao A., Fort-Ros J., Bonal-Bastons J., Ruiz M.P., Vallés-Prats M., Coll-Piera E., Galceran-Gui J.M., Arias M., Perello M., Samon R., Agraz I., Bayes B., Canas L., Castellote E., Craver L., Garcia R., Felip A., Lauzurica R., Pou M., Ballarin J., Puig J.M., Puig C., Cao H., Colado S., Barbosa F., Martinez-Vea A., Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in catalonia: MICENAS I study. (2014) NEFROLOGIA, 34 (2), 189-198.

IF: 1.2230

Chianese C., Gunning A.C., Giachini C., Daguin F., Balercia G., Ars E., Lo Giacco D., Ruiz-Castane E., Forti G., Krausz C., X chromosome-linked CNVs in male infertility: Discovery of overall duplication load and recurrent, patient-specific gains with potential clinical relevance. (2014) PLOS ONE, 9 (6).

IF: 3.2340

Esteva-Font C., Guillen-Gomez E., Diaz J.M., Guirado L., Facundo C., Ars E., Ballarin J.A., Fernandez-Llama P., Renal sodium transporters are increased in urinary exosomes of cyclosporine-treated kidney

transplant patients. (2014) AM J NEPHROL, 39 (6), 528-535.

IF: 2.6690

Guillen-Gomez E., Guirado L., Belmonte X., Maderuelo A., Santin S., Juarez C., Ars E., Facundo C., Ballarin J.A., Vidal S., Diaz-Encarnacion M.M., Monocyte implication in renal allograft dysfunction. (2014) CLIN EXP IMMUNOL, 175 (2), 323-331.

IF: 3.0370

Gutierrez E., Moreno J.A., Praga M., Gutierrez E., Zamora I., Ballarin J.A., Arce Y., Jimenez S., Quereda C., Olea T., Martinez-Ara J., Segarra A., Bernis C., Garcia A., Goicoechea M., de Vinuesa S.G., Rojas-Rivera J., Persistent microhaematuria with negative or low proteinuria. (2014) NEFROLOGIA, 34 (1), 110-114.

IF: 1.2230

Krall P., Pineda C., Ruiz P., Ejarque L., Vendrell T., Camacho J.A., Mendizabal S., Oliver A., Ballarin J., Torra R., Ars E., Cost-effective PKHD1 genetic testing for autosomal recessive polycystic kidney disease. (2014) PEDIATR NEPHROL, 29 (2), 223-234.

IF: 2.8560

Krausz C., Chianese C., Lo Giacco D., Tuttelmann F., Ferlin A., Ntostis P., Vinci S., Balercia G., Ars E., Ruiz-Castane E., Giglio S.,

*TIF: 94.8930 **MIF: 3.2722

Kliesch S., Forti G., Reply: Y-chromosome microdeletions are not associated with SHOX haploinsufficiency. (2014) HUM REPROD, 29 (5), 1114-1115.

IF: 4.5690

Lo Giacco D., Chianese C., Ars E., Ruiz-Castan E., Forti G., Krausz C., Recurrent X chromosome-linked deletions: Discovery of new genetic factors in male infertility. (2014) J MED GENET, 51 (5), 340-344.

IF: 6.3350

Lo Giacco D., Chianese C., Sanchez-Curbelo J., Bassas L., Ruiz P., Rajmil O., Sarquella J., Vives A., Ruiz-Castañ E., Oliva R., Ars E., Krausz C., Clinical relevance of Y-linked CNV screening in male infertility: New insights based on the 8-year experience of a diagnostic genetic laboratory. (2014) EUR J HUM GENET, 22 (6), 754-761.

IF: 4.3490

Martinez-Castelao A., Gorriz J.L., Bover J., Segura-De La Morena J., Cebollada J., Escalada J., Esmatjes E., Facila L., Gamarra J., Gracia S., Hernandez-Moreno J., Llisterri-Caro J.L., Mazon P., Montanes R., Morales-Olivas F., Munoz-Torres M., De Pablos-Velasco P., De Santiago A., Sanchez-Celaya M., Suarez C., Tranche S., Consensus document for the detection and management of chronic kidney disease. (2014) ATEN PRIM, 46 (9), 501-519.

IF: 0.9530

Martinez-Castelao A., Gorriz J.L., Bover J., Segura-de la Morena J., Cebollada J., Escalada J., Esmatjes E., Facila L., Gamarra J., Gracia S., Hernand-Moreno J., Llisterri-Caro J.L., Mazon P., Montanes R., Morales-Olivas F., Munoz-Torres M., De Pablos-Velasco P., De Santiago A., Sanchez-Celaya M., Suarez C., Tranche S., Consensus document for the detection and management of chronic kidney disease. (2014) NEFROLOGIA, 34 (2), 243-262.

IF: 1.2230

Mazzaferro S., Tartaglione L., Rotondi S., Bover J., Goldsmith D., Pasquali M., News on Biomarkers in CKD-MBD. (2014) SEMIN NEPHROL, 34 (6), 598-611.

IF: 3.4830

Mengual L., Ars E., Lozano J.J., Buset M., Izquierdo L., Ingelmo-Torres M., Gaya J.M., Algaba F., Villavicencio H., Ribal M.J., Alcaraz A., Gene expression profiles in prostate cancer: Identification of candidate non-invasive diagnostic markers. (2014) ACTAS UROL ESP, 38 (3), 143-149.

IF: 1.0220

Petzold K., Gansevoort R.T., Ong A.C.M., Devuyt O., Rotar L., Eckardt K.-U., Kottgen A., Pirson Y., Remuzzi G., Sandford R., Tesar V., Ecder T., Chaveau D., Torra R., Budde K., Meur Y.L., Wthrich R.P., Serra A.L., Erratum:

Building a network of ADPKD reference centres across Europe: the EuroCYST initiative(Nephrology Dialysis Transplantation) (2014) 29 :suppl 4 (iv26-iv32) doi: 10.1093/ndt/gfu091). (2014) NEPHROL DIAL TRANSPL, 29 (12), 2353.

IF: 3.5770

Rodriguez-Ribera L., Stoyanova E., Corredor Z., Coll E., Silva I., Diaz J.M., Ballarin J., Marcos R., Pastor S., Time in hemodialysis modulates the levels of genetic damage in hemodialysis patients. (2014) ENVIRON MOL MUTAGEN, 55 (4), 363-368.

IF: 2.6300

Sala M.R., Broner S., Moreno A., Arias C., Godoy P., Minguell S., Martinez A., Torner N., Bartolome R., de Simon M., Guix S., Dominguez A., Alsedá M., Alvarez J., Artigues A., Barrabeig I., J Balanya P., Camps N., Company M., Carol M., Ferrus G., Follia N., Parron I., Recasens A., Rovira A., Torra R., Torres J., Ferrer D., Sanz M., Cornejo T., Bosch A., Pinto R.M., Cases of acute gastroenteritis due to calicivirus in outbreaks: Clinical differences by age and aetiological agent. (2014) CLIN MICROBIOL INFEC, 20 (8), 793-798.

IF: 5.7680

Savigne J., Ars E., Cotton R.G.H., Crockett D., Dagher H., Deltas C., Ding J., Flinter F., Pont-Kingdon G., Smaoui N., Torra R., Storey H., DNA variant databases improve test accuracy and phenotype prediction in Alport syndrome. (2014) PEDIATR NEPHROL, 29 (6), 971-977.

IF: 2.8560

Spithoven E.M., Kramer A., Meijer E., Orskov B., Wanner C., Caskey F., Collart F., Finne P., Fogarty D.G., Groothoff J.W., Hoitsma A., Nogier M.-B., Postorino M., Ravani P., Zurriaga O., Jager K.J., Gansevoort R.T., Areste N., Arias M., Couchoud C., Budde K., Chauveau D., Devuyt O., Ecder T., Eckardt K.U., Gansevoort R.T., Kottgen A., Ong A.C., Petzold K., Pirson Y., Remuzzi G., Torra R., Sandford R.N., Serra A.L., Tesar V., Walz G., Wuthrich R.P., Antignac C., Bindels R., Chauveau D., Devuyt O., Emma F., Gansevoort R.T., Maxwell P.H., Ong A.C., Remuzzi G., Ronco P., Schaefer F., Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. (2014) KIDNEY INT, 86 (6), 1244-1252.

IF: 8.5630

Stoyanova E., Pastor S., Coll E., Azqueta A., Collins A.R., Marcos R., Base excision repair capacity in chronic renal failure patients undergoing hemodialysis treatment.

(2014) CELL BIOCHEM FUNCT, 32 (2), 177-182.

IF: 2.0050

Torra R., Autosomal dominant polycystic kidney disease, more than a renal disease. (2014) MINERVA ENDOCRINOL, 39 (2), 79-87.

IF: 1.4640

Torra R., Treatment of autosomal dominant polycystic kidney disease. (2014) MED CLIN-BARCELONA, 142 (2), 73-79.

IF: 1.4170

Torregrosa J.-V., Morales E., Diaz J.M., Crespo J., Bravo J., Gomez G., Gentil M.A., Rodriguez Benot A., Garcia M.R., Jimenez V.L., Gutierrez Dalmau A., Jimeno L., Saez M.J.P., Romero R., Gomez Alamillo C., Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: A multicentre, retrospective, 3-year study. (2014) NEPHROLOGY, 19 (2), 84-93.

IF: 2.0830

Torregrosa J.V., Morales E., Diaz J.M., Crespo J., Bravo J., Gomez G., Gentil M.A., Rodriguez-Benot A., Rodriguez-Garcia M., Lopez-Jimenez V., Gutierrez-Dalmau A., Jimeno L., Perez-Saez M.J., Romero R., Gomez-Alamillo C., Beltran S., Silva I., Escuin F., Gentil M., Bernal G., Alamillo C.G., Alonso C.G., Rodriguez M., Gutierrez A., Paul J., Gonzalez M.J., Lopez V., Gutierrez E., Pascual J., Saez M.J.P., Ramos A., Benot A.R., Paschoalin R.P., Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after renal transplantation: One-year follow-up multicentre study. (2014) NEFROLOGIA, 34 (1), 62-68.

IF: 1.2230

Torres P.U., Bover J., Mazzaferro S., de Vernejoul M.C., Cohen-Solal M., When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease. (2014) SEMIN NEPHROL, 34 (6), 612-625.

IF: 3.4830

Vervloet M.G., Massy Z.A., Brandenburg V.M., Mazzaferro S., Cozzolino M., Urena-Torres P., Bover J., Goldsmith D., Bone: A new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. (2014) LANCET DIABETES ENDO, 2 (5), 427-436.

IF: 9.1850

Nephrology

Other Publications

- ▶ Bover J., Dasilva I., Furlano M., Lloret M.J., Diaz-Encarnacion M.M., Ballarin J., Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol). (2014) CURRENT VASCULAR PHARMACOLOGY, 12 (2), 313-323.
- ▶ Martinez-Castelao A., Gorris J.L., Bover J., Segura-de la Morena J., Cebollada J., Escalada J., Esmatjes E., Facila L., Gamarra J., Gracia S., Hernandez-Moreno J., Llisterri-Caro J.L., Mazon P., Montanes R., Morales-Olivas F., Munoz-Torres M., de Pablos-Velasco P., de Santiago A., Sanchez-Celaya M., Suarez C., Tranche S., Consensus document for the detection and management of chronic kidney disease. (2014) ENDOCRINOLOGIA Y NUTRICION, 61 (9), e25-e43.
- ▶ Martinez-Castelao A., Gorris J.L., Bover J., Segura-de la Morena J., Cebollada J., Escalada J., Esmatjes E., Facila L., Gamarra J., Gracia S., Hernandez-Moreno J., Llisterri-Caro J.L., Mazon P., Montanes R., Morales-Olivas F., Munoz-Torres M., de Pablos-Velasco P., de Santiago A., Sanchez-Celaya M., Suarez C., Tranche S., Consensus document for the detection and management of chronic kidney disease. (2014) SEMERGEN, 40 (8), 441-459.
- ▶ Mases A., Sabate S., Guilera N., Sadurni M., Arroyo R., Fau M., Rojo A., Castillo J., Bover J., Sierra P., Canet J., ANESCAR-Llisterri-Caro J.L., Mazon P., Montanes R., Morales-Olivas F., Munoz-Torres M., de Pablos-Velasco P., de Santiago A., Sanchez-Celaya M., Suarez C., Tranche S., Consensus document for the detection and management of chronic kidney disease. (2014) HIPERTENSION Y RIESGO VASCULAR, 31 (4), 143-161.
- ▶ Martinez-Castelao A., Gorris J.L., Bover J., Segura-de la Morena J., Cebollada J., Escalada J., Esmatjes E., Facila L., Gamarra J., Gracia S., Hernandez-Moreno J., Llisterri-Caro J.L., Mazon P., Montanes R., Morales-Olivas F., Munoz-Torres M., de Pablos-Velasco P., de Santiago A., Sanchez-Celaya M., Suarez C., Tranche S., Consensus document for the detection and management of chronic kidney disease. (2014) SEMERGEN, 40 (8), 441-459.
- ▶ Mases A., Sabate S., Guilera N., Sadurni M., Arroyo R., Fau M., Rojo A., Castillo J., Bover J., Sierra P., Canet J., ANESCAR-DIOCAT Group, Preoperative estimated glomerular filtration rate and the risk of major adverse cardiovascular and cerebrovascular events in non-cardiac surgery.. (2014) BRITISH JOURNAL OF ANAESTHESIA, 113 (4), 644-651.
- ▶ Petzold K., Gansevoort R.T., Ong A.C., Devuyst O., Rotar L., Eckardt K.U., Kottgen A., Pirson Y., Remuzzi G., Sandford R., Tesar V., Ecder T., Chaveau D., Torra R., Budde K., Le Meur Y., Wuthrich R.P., Serra A.L., Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. (2014) NEPHROLOGY, DIALYSIS, TRANSPLANTATION : official publication of the European Dialysis and Transplant Association - European Renal Association, 29 Suppl 4.

AREA T1

Epidemiology, Public Health and Healthcare Services

196 Clinical Epidemiology and Healthcare Services

202 Evaluation of Public Health Policies and Programmes

206 Transport and Health: Injuries and Mobility

208 Transmissible Diseases

212 Health Inequalities

216 Epidemiology of Addictions

218 Primary Care Research

Public Health and

S




Clinical Epidemiology and Healthcare Services

Coordinator

Xavier Bonfill HSCSP
xbonfill@santpau.cat

Members

René Acosta	HSCSP RI
Pablo Alonso	HSCSP RI
Gerard Álvarez	ACCIB
Valentina Balasso	HSCSP RI
Monica Ballesteros	HSCSP RI
Ignasi Bolibar	HSCSP
Andrea Cervera	ACCIB
Jesus Gaitan	HSCSP
Ignasi Gich	HSCSP
Isabel Ginesta	HSCSP
Meritxell Girós	HSCSP RI
Marta Gorgues	HSCSP
Laura Martínez	HSCSP RI
M. José Martínez	HSCSP RI
Gemma Mas	HSCSP RI
Dimelza Osorio	HSCSP
Héctor Pardo	CIBERESP
Sandra Pequeño	HSCSP RI
Ekaterina Popova	HSCSP RI
Margarita Posso	
Cristina Puchol	ACCIB
M. Teresa Puig	HSCSP
M. Jesús Quintana	HSCSP
Carolina Requeijo	HSCSP
David Rigau	HSCSP RI
Marta Roqué	HSCSP RI
Juliana Sanabria	HSCSP RI
Anna Selva	HSCSP RI
Ivan Solà	HSCSP
Judit Sola	ACCIB
Maroussia Tzanova	ACCIB
Gerard Urrutia	HSCSP
Robin Vernooij	HSCSP RI



Main Lines of Research

- ▶ Evidence-based medicine: systematic reviews, clinical practice guidelines and clinical trials.
- ▶ Health service evaluations.
- ▶ Methodological research.

Areas of interest

- ▶ Evidence-based medicine.
- ▶ Cancer.
- ▶ Perioperative medicine.
- ▶ Cardiovascular medicine.
- ▶ Public health.
- ▶ Appropriateness.

Challenges

- ▶ Become a reference group in Spain and Latin America regarding the preparation of systematic reviews on the effects of healthcare interventions, enhancing the group's capacity to provide technical and methodological support and increasing its scientific production in the framework of the Iberoamerican Cochrane Network.
- ▶ Promote greater use of scientific evidence and evidence-based medicine tools in clinical and healthcare decision making by means of stable agreements with governmental, academic and scientific entities and institutions, thereby ensuring the ongoing development and dissemination of these tools and the implementation of training in their use.
- ▶ Become a reference group for independent applied clinical research that fosters relevant and scientifically sound studies aimed at meeting the real needs of the national healthcare system, whether on the group's own initiative or through networked relationships with similar groups.
- ▶ The group is currently setting up clinical and epidemiological studies (phase 3/4 trials with non-commercial interests, research into healthcare services and results and studies of research methodologies) and applying for additional public funding for new projects aimed at consolidating these research lines.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Locomotor System Research
- ▶ Urology
- ▶ Palliative Care
- ▶ Angiology, Vascular Biology and Inflammation
- ▶ Anaesthesiology
- ▶ Public Health Agency of Barcelona
- ▶ Blood and Tissue Bank
- ▶ Ageing Institute
- ▶ EAP Sardenya

External Collaborations

- ▶ Population Health Research Institute, McMaster University (Canada).
- ▶ Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford (United Kingdom).
- ▶ World Health Organization.
- ▶ European Respiratory Society.
- ▶ Facultad de Ciencias de la Salud, Universidad Tecnológica Equinoccial (Ecuador).

Doctoral Theses

- ▶ Judit Sanz i Buxó. Estudi epidemiològic, genètic i clínic del registre de famílies amb càncer de mama i ovari hereditaris de l'Hospital de la Santa Creu i Sant Pau (1995-2005). Universitat Autònoma de Barcelona Director: M. Teresa Puig Reixach. Date of defense: 12 June 2014.
- ▶ Salvador Rico Amaro. Pharmacological characterization of unconventional heparins. Universitat Autònoma de Barcelona. Director: Ignasi Gich Saladich. Date of defense: 15 July 2014.
- ▶ Xavier Basurto Oña. Manejo farmacológico del dolor agudo en urgencias. Compendio de evidencias. Universitat Autònoma de Barcelona. Director: Xavier Bonfill Cosp. Date of defense: 31 October 2014.
- ▶ Manel Balcells Diaz. Anàlisi de l'estructura i el procés d'innovació de quatre grans hospitals de Barcelona. Director: Xavier Bonfill Cosp. Date of defense: 7 November 2014.
- ▶ Pamela Serón Silva. Actividad física y ejercicio en la enfermedad cardiovascular. Universitat Autònoma de Barcelona. Director: Xavier Bonfill Cosp. Date of defense: 11 November 2014.
- ▶ Evelina Chapman Heller. Análisis y generación de evidencias científicas en relación a la salud materna. Universitat Autònoma de Barcelona Director: Xavier Bonfill Cosp. Date of defense: 19 November 2014.

Active Grants

- ▶ Pablo Alonso Coello. La toma de decisiones compartida en cáncer de pulmón. Proyectos singulares 2013. Duration: 01/02/14-31/01/16. €54,000.
- ▶ Xavier Bonfill Cosp. Ajuts de suport als Grups de Recerca de Catalunya. Grup Epidemiologia Clínica i Serveis Sanitaris. AGAUR 2009. SGR 786. Duration: 29/09/09-30/04/14. €41,600.
- ▶ Pablo Alonso Coello. Developing and Evaluating Communication strategies to support Informed Decisions and practice based on Evidence. DECIDE. FP7-HEALTH-2010. 258583. Duration: 01/01/11-31/12/15. €215,649.75.
- ▶ Xavier Bonfill Cosp. Multicentric, controlled, randomized clinical trial to assess the efficacy and cost-effectiveness of urinary catheters with silver alloy coating versus conventional catheters in spinal cord injured patients. TELEMARATÓ 2011 Lesions Medul·lars i Cerebrals. 112210. Duration: 19/04/12-18/04/15. €158,881.
- ▶ M. José Martínez Zapata. Evaluación de calidad de vida en pacientes con fracturas subcapitales de fémur. Ayudas a la Investigación 2012. MAPFRE 2012. Duration: 14/02/13-30/05/14. €10,101.
- ▶ Pablo Alonso Coello. Evaluación de la vigencia y estrategias de actualización de guías de práctica clínica: análisis del Programa Nacional de GPC para el Sistema Nacional de la Salud. FIS Project 2010. PI10/00346. Duration: 01/01/11-30/06/15. €85,650.
- ▶ Xavier Bonfill Cosp. Análisis y mejora del grado de adecuación de la cirugía programada del aneurisma de aorta abdominal. Proyectos de Investigación en Salud 2012. PI12/02530. Duration: 01/01/13-31/12/15. €48,500,00
- ▶ Maria Teresa Puig Reixac. Retos en salud pública: transferencia del conocimiento en obesidad, enfermedades cardiovasculares y consumo de alcohol. Proyectos de Investigación en Salud 2012. PI12/02257. Duration: 01/01/13-31/12/15. €51,500,00
- ▶ Gerard Urrutia Cuchi. Cohorte prospectiva internacional de evaluación de los eventos vasculares en pacientes sometidos a cirugía cardiaca (estudio CardioVISION). Proyectos de Investigación en Salud 2013. PI13/00502. Duration: 01/01/14-31/12/16. €20,600.
- ▶ Pablo Alonso Coello. Retos globales en el desarrollo de recomendaciones en las guías de práctica clínica: recursos y costes, y valores y preferencias de los pacientes. Proyectos de Investigación en Salud 2013. PI13/02848. Duration: 01/01/14-31/12/16. €25,011.40.
- ▶ Pablo Alonso Coello. Eventos vasculares en cirugía en pacientes sometidos a cirugía no cardíaca. El estudio VISION. FIS Contratos Miguel Servet 2009. CP09/00137. Duration: 01/01/10-30/06/14. €30,000.
- ▶ Pablo Alonso Coello. Ensayo clínico sobre la evaluación de la prescripción diferida de antibióticos en las infecciones respiratorias agudas no complicadas en pediatría (PDA-Pediatría). Ministerio de Sanidad y Servicios Sociales e Igualdad: EC 2011. EC11-339. Duration: 01/01/12-30/06/15. €29,655.
- ▶ M. José Martínez Zapata. Prevención del sangrado postoperatorio: Ensayo clínico, multicéntrico, aleatorizado, controlado, paralelo, que evalúa la eficacia del ácido tranexámico y la cola de fibrina fracturas subcapitales de femur. Ministerio de Sanidad y Servicios Sociales e Igualdad: EC 2011. EC11-341. Duration: 01/01/12-30/06/15. €57,010.
- ▶ Pablo Alonso Coello. FIS Contratos Miguel Servet 2009. CP09/00137. Duration: 01/02/10-31/01/16. €151,875.
- ▶ Laura Martínez García. Ayudas para Contratos de Formación en Investigación Río Hortega 2011. CM11/00035. Duration: 16/01/12-15/01/14. €43,200.
- ▶ Andrea Juliana Sanabria Uribe. Ayudas para Contratos de Formación en Investigación Río Hortega 2012. CM12/00168. Duration: 31/01/13-30/01/15. €43,200.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Xavier Bonfill Cosp. Grup de Recerca Clínica i Sanitària Aplicada. AGAUR 2014. SGR 673. Duration: 04/09/14-31/12/16. €21,000.
- ▶ Pablo Alonso Coello. Retos metodológicos en la elaboración de guías de práctica clínica (GPC) del Sistema Nacional de Salud. Proyectos de Investigación en Salud 2014. PI14/02006. €36,500.
- ▶ Anna Selva Olid. Contratos Río Hortega 2014. CM14/00032. €53,732.

Note: Total amount granted to PI. It does not include indirect costs.

Clinical Epidemiology and Healthcare Services

*TIF: 319.9500 **MIF: 4.7754

Almirall J., Serra-Prat M., Bolibar I., Palomera E., Roig J., Hospital I., Carandell E., Agusti M., Ayuso P., Estela A., Torres A., Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: A population-based case-control study. (2014) *BMJ OPEN*, 4 (6).

IF: 2.2710

Alonso-Coello P., Martinez Garcia L., Clinical guidelines: Old and new challenges. (2014) *MED CLIN-BARCELONA*, 143 (7), 306-308.

IF: 1.4170

Aragones J.-M., Roura-Poch P., Hernandez-Ocampo E.M., Alonso F., Pont-Lluelles M., Xandri I., Bolibar I., Illa I., Myasthenia gravis: A disease of the very old. (2014) *J AM GERIATR SOC*, 62 (1), 196-197.

IF: 4.5720

Arevalo-Rodriguez I., Segura O., Sola I., Bonfill X., Sanchez E., Alonso-Coello P., Diagnostic tools for alzheimer's disease dementia and other dementias: An overview of diagnostic test accuracy (DTA) systematic reviews. (2014) *BMC NEUROL*, 14 (1).

IF: 2.0400

Balsells M., Garcia-Patterson A., Gich I., Corcoy R., Ultrasound-guided compared to conventional treatment in gestational diabetes leads to improved birthweight but more insulin treatment: Systematic review and meta-analysis. (2014) *ACTA OBSTET GYN SCAN*, 93 (2), 144-151.

IF: 2.4260

Bellmunt S., Alonso-Coello P., Cilostazol : Same evidence, different conclusions. (2014) *CHEST*, 145 (2), 435-436.

IF: 7.4830

Bellmunt S., Roque M., Osorio D., Pardo H., Escudero J.-R., Bonfill X., Healthcare quality indicators of peripheral artery disease based on systematic reviews. (2014) *EUR J VASC ENDOVASC*, 48 (1), 60-69.

IF: 2.4900

Bernabeu-Wittel M., Alonso-Coello P., Rico-Blazquez M., Rotaeche Del Campo R., Sanchez Gomez S., Casariego Vales E., Development of clinical practice guidelines for patients with comorbidity and multiple diseases. (2014) *REV CLIN ESP*, 214 (6), 328-335.

IF: 1.0630

Bernabeu-Wittel M., Alonso-Coello P., Rico-Blazquez M., Rotaeche Del Campo R., Sanchez Gomez S., Casariego Vales E., Development of clinical practice guidelines for patients with comorbidity and multiple diseases. (2014) *ATEN PRIM*, 46 (7), 385-392.

IF: 0.9530

Bonfill X., The Cochrane Collaboration turns 20. (2014) *MED CLIN-BARCELONA*, 143 (5), 210-215.

IF: 1.4170

Botto F., *et al.* Myocardial Injury after Noncardiac Surgery: A Large, International, Prospective Cohort Study Establishing Diagnostic Criteria, Characteristics, Predictors, and 30-day Outcomes. (2014) *ANESTHESIOLOGY*, 120 (3), 564-578.

IF: 5.8790

Brotos C., Moral I., Soriano N., Cuixart L., Osorio D., Bottaro D., Puig M., Joaniquet X., Marcos A., Casasa A., Impact of using different score tables for estimating cardiovascular risk. (2014) *REV ESP CARDIOL*, 67 (2), 94-100.

IF: 3.7920

Castells X., Domingo L., Corominas J.M., Tora-Rocamora I., Quintana M.J., Bare M., Vidal C., Natal C., Sanchez M., Saladie F., Ferrer J., Vernet M., Servitja S., Rodriguez-Arana A., Roman M., Espinas J.A., Sala M., Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. (2014) *BREAST CANCER RES TR*, 149 (1), 237-244.

IF: 3.9400

Catala A., Garces J.R., Alegre M., Gich I.J., Puig L., Mohs micrographic surgery for basal cell carcinomas: Results of a Spanish retrospective study and Kaplan-Meier survival analysis of tumour recurrence. (2014) *J EUR ACAD DERMATOL*, 28 (10), 1363-1369.

IF: 2.8260

Catala-Lopez F., Tobias A., Roque M., Basic concepts for network meta-analysis. (2014) *ATEN PRIM*, 46 (10), 573-581.

IF: 0.9530

Chapman E., Reveiz L., Illanes E., Bonfill Cosp X., Antibiotic regimens for management of intra-amniotic infection. (2014) *COCHRANE DB SYST REV*, 12.

IF: 6.0320

Chapman E., Reveiz L., Sangalang S., Manu C., Bonfill X., Munoz S., Abalos E., A survey study identified global research priorities for decreasing maternal mortality. (2014) *J CLIN EPIDEMIOL*, 67 (3), 314-324.

IF: 3.4170

Devereaux P.J., Mrkobrada M., Sessler D.I., Leslie K., Alonso-Coello P., Kurz A., Villar J.C., Sigamani A., Biccard B.M., Meyhoff C.S., Parlow J.L., Guyatt G., Robinson A., Garg A.X., Rodseth R.N., Botto F., Lurati Buse G., Xavier D., Chan M.T.V., Tiboni M., Cook D., Kumar P.A., Forget P., Malaga G., Fleischmann E., Amir M., Eikelboom J., Mizera R., Torres D., Wang C.Y., VanHelder T., Paniagua P., Berwanger O., Srinathan S., Graham M., Pasin L., Le Manach Y., Gao P., Pogue J., Whitlock R., Lamy A., Kearon C., Baigent C., Chow C., Pettit S., Chrolavicius S., Yusuf S., Aspirin in patients undergoing noncardiac surgery.

(2014) *NEW ENGL J MED*, 370 (16), 1494-1503.

IF: 55.8730

Devereaux P.J., Sessler D.I., Leslie K., Kurz A., Mrkobrada M., Alonso-Coello P., Villar J.C., Sigamani A., Biccard B.M., Meyhoff C.S., Parlow J.L., Guyatt G., Robinson A., Garg A.X., Rodseth R.N., Botto F., Lurati Buse G., Xavier D., Chan M.T.V., Tiboni M., Cook D., Kumar P.A., Forget P., Malaga G., Fleischmann E., Amir M., Eikelboom J., Mizera R., Torres D., Wang C.Y., VanHelder T., Paniagua P., Berwanger O., Srinathan S., Graham M., Pasin L., Le Manach Y., Gao P., Pogue J., Whitlock R., Lamy A., Kearon C., Chow C., Pettit S., Chrolavicius S., Yusuf S., Clonidine in patients undergoing noncardiac surgery. (2014) *NEW ENGL J MED*, 370 (16), 1504-1513.

IF: 55.8730

Ebrahim S., Johnston B.C., Akl E.A., Mustafa R.A., Sun X., Walter S.D., Heels-Ansdell D., Alonso-Coello P., Guyatt G.H., Addressing continuous data measured with different instruments for participants excluded from trial analysis: A guide for systematic reviewers. (2014) *J CLIN EPIDEMIOL*, 67 (5), 560-570.

IF: 3.4170

Escribano J., Balaguer A., Roque i Figuls M., Feliu A., Ferre N., Dietary interventions for preventing complications in idiopathic hypercalcaemia. (2014) *COCHRANE DB SYST REV*, 2.

IF: 6.0320

Frutos V., Gonzalez-Comadran M., Sola I., Jacquemin B., Carreras R., Vizcaino M.A.C., Impact of air pollution on fertility: A systematic review. (2014) *GYNECOL ENDOCRINOL*, 31 (1), 7-13.

IF: 1.3330

Gallego O., Cuatrecasas M., Benavides M., Segura P.P., Berrocal A., Erill N., Colomer A., Quintana M.J., Balana C., Gil M., Gallardo A., Murata P., Barnadas A., Efficacy of erlotinib in patients with relapsed glioblastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. (2014) *J NEURO-ONCOL*, 116 (2), 413-419.

IF: 3.0700

Gallego O., Cuatrecasas M., Benavides M., Segura P.P., Berrocal A., Erill N., Colomer A., Quintana M.J., Balana C., Gil M., Gallardo A., Murata P., Barnadas A., Erratum: Efficacy of erlotinib in patients with relapsed glioblastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [*J Neurooncol*, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]. (2014) *J NEURO-ONCOL*, 120 (3), 667.

IF: 3.0700

Garcia-Gea C., Martinez J., Ballester M.R., Gich I., Valiente R., Antonijoan R.M., Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination

*TIF: 319.9500 **MIF: 4.7754

with alcohol: A randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. (2014) *HUM PSYCHOPHARM CLIN*, 29 (2), 120-132.

IF: 2.1920

Garg A.X., Kurz A., Sessler D.I., Cueden M., Robinson A., Mrkobrada M., Parikh C., Mizera R., Jones P.M., Tiboni M., Rodriguez R.G., Popova E., Gomez M.F.R., Meyhoff C.S., Vanholder T., Chan M.T.V., Torres D., Parlow J., De Nadal Clanchet M., Amir M., Bidgoli S.J., Pasin L., Martinsen K., Malaga G., Myles P., Acedillo R., Roshanov P., Walsh M., Dresser G., Kumar P., Fleischmann E., Villar J.C., Painter T., Biccard B., Bergese S., Srinathan S., Cata J.P., Chan V., Mehra B., Leslie K., Whitlock R., Devereaux P.J., Aspirin and clonidine in non-cardiac surgery: Acute kidney injury sub-study protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial. (2014) *BMJ OPEN*, 4 (2).

IF: 2.2710

Garin N., De Pourcq J.T., Martin-Venegas R., Cardona D., Gich I., Mangues M.A., Viscosity differences between thickened beverages suitable for elderly patients with dysphagia. (2014) *DYSPHAGIA*, 29 (4), 483-488.

IF: 2.0330

Gine-Garriga M., Roque-Figuls M., Coll-Planas L., Sitja-Rabert M., Salva A., Physical exercise interventions for improving performance-based measures of physical function in community-dwelling, frail older adults: A systematic review and meta-analysis. (2014) *ARCH PHYS MED REHAB*, 95 (4).

IF: 2.5650

Gonzalez-Comadran M., Avila J.U., Tascon A.S., Jimenez R., Sola I., Brassesco M., Carreras R., Checa M.A., The impact of donor insemination on the risk of preeclampsia: A systematic review and meta-analysis. (2014) *EUR J OBSTET GYN R B*, 182, 160-166.

IF: 1.6950

Gutarra-Vilchez R.B., Barajas-Nava L., Aleman A., Sola I., Gich I., Bonfill X., Alonso-Coello P., Systematic evaluation of the quality of clinical practice guidelines on the use of assisted reproductive techniques. (2014) *HUM FERTIL*, 17 (1), 28-36.

IF: 0.9090

Gutarra-Vilchez R.B., Urrutia G., Glujovsky D., Coscia A., Bonfill Cosp X., Vasodilators for women undergoing fertility treatment. (2014) *COCHRANE DB SYST REV*, 10.

IF: 6.0320

Gutierrez S.G., *et al.* Predictive factors of severe multilobar pneumonia and shock in patients with influenza. (2014) *EMERG MED J*, 31 (4), 301-307.

IF: 1.8430

Guyatt G., Montori V., Schunemann H., Alon-

so-Coello P., Dahm P., Brito Campana J.P., Brozek J., Nasser M., Meerpohl J., Rind D., Jaeschke R., Fack-Ytter Y., Norris S., Letter reply to GRADE guidelines articles 14 and 15. (2014) *J CLIN EPIDEMIOL*, 67 (2), 240.

IF: 3.4170

Jarvinen T.L.N., Jokihaara J., Guy P., Alonso-Coello P., Collins G.S., Michaelsson K., Sievanen H., Conflicts at the heart of the FRAX tool. (2014) *CAN MED ASSOC J*, 186 (3), 165-167.

IF: 5.9590

Khan J., Alonso-Coello P., Devereaux P.J., Myocardial injury after noncardiac surgery. (2014) *CURR OPIN CARDIOL*, 29 (4), 307-311.

IF: 2.6960

Kotzeva A., Guillamon I., Gracia J., Diaz Del Campo P., Gich I., Calderon E., Gaminde I., Louro-Gonzalez A., Martinez F., Orrego C., Rotaache R., Salcedo F., Alonso-Coello P., Use of clinical practice guidelines and factors related to their uptake: A survey of health professionals in Spain. (2014) *J EVAL CLIN PRACT*, 20 (3), 216-224.

IF: 1.0840

Kovacs F.M., Urrutia G., Alarcon J.D., "overviews" should meet the methodological standards of systematic reviews. (2014) *EUR SPINE J*, 23 (2), 480.

IF: 2.0660

Lanas F., Seron P., Puig T., Cardiovascular risk factors among males in 1989 and 2011-12 in a southern Chilean city. (2014) *REV MED CHILE*, 142 (4), 467-474.

IF: 0.3040

Marti-Carvajal A.J., Knight-Madden J.M., Martinez-Zapata M.J., Interventions for treating leg ulcers in people with sickle cell disease. (2014) *COCHRANE DB SYST REV*, 12.

IF: 6.0320

Marti-Carvajal A.J., Sola I., Agreda-Perez L.H., Treatment for avascular necrosis of bone in people with sickle cell disease. (2014) *COCHRANE DB SYST REV*, 7.

IF: 6.0320

Martinez Garcia L., McFarlane E., Barnes S., Sanabria A.J., Alonso-Coello P., Alderson P., Updated recommendations: An assessment of NICE clinical guidelines. (2014) *IMPLEMENT SCI*, 9 (1).

IF: 4.1220

Martinez Garcia L., Sanabria A.J., Garcia Alvarez E., Trujillo-Martin M.M., Etxeandia-Ikobaltzeta I., Kotzeva A., Rigau D., Louro-Gonzalez A., Barajas-Nava L., Diaz Del Campo P., Estrada M.-D., Sola I., Gracia J., Salcedo-Fernandez F., Lawson J., Haynes R.B., Alonso-Coello P., The validity of recommendations from clinical guidelines: A survival analysis. (2014) *CAN MED ASSOC J*, 186 (16), 1211-1219.

IF: 5.9590

Martinez-Zapata M.J., Marti-Carvajal A.J., Sola I., Pijoan J.I., Buil-Calvo J.A., Cordero J.A., Evans J.R., Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. (2014) *COCHRANE DB SYST REV*, 11.

IF: 6.0320

Miralpeix E., Gonzalez-Comadran M., Sola I., Manau D., Carreras R., Checa M.A., Efficacy of luteal phase support with vaginal progesterone in intrauterine insemination: A systematic review and meta-analysis. (2014) *J ASSIST REPROD GEN*, 31 (1), 89-100.

IF: 1.7180

Nicolau P., Miralpeix E., Sola I., Carreras R., Checa M.A., Alcohol consumption and in vitro fertilization: A review of the literature. (2014) *GYNECOL ENDOCRINOL*, 30 (11), 759-763.

IF: 1.3330

Posso M., Brugulat-Guiteras P., Puig T., Mompert-Penina A., Medina-Bustos A., Alcaniz M., Guillen M., Tresserras-Gaju R., Prevalence and determinants of obesity in children and young people in Catalonia, Spain, 2006-2012. (2014) *MED CLIN-BARCELONA*, 143 (11), 475-483.

IF: 1.4170

Puente A., Hernandez-Gea V., Graupera I., Roque M., Colomo A., Poca M., Aracil C., Gich I., Guarner C., Villanueva C., Drugs plus ligation to prevent rebleeding in cirrhosis: An updated systematic review. (2014) *LIVER INT*, 34 (6), 823-833.

IF: 4.8500

Puig M., Caballero F., Ris J., Leal J., Why should we consider organ donation in emergencies? The patient's right to be a donor. (2014) *EMERGENCIAS*, 26 (6), 493.

IF: 2.8950

Puig T., Ferrero-Gregori A., Roig E., Vazquez R., Gonzalez-Juanatey J.R., Pascual-Figal D., Delgado J., Alonso-Pulpon L., Borrás X., Mendez A., Cinca J., Prognostic value of body mass index and waist circumference in patients with chronic heart failure (Spanish REDINSCOR registry). (2014) *REV ESP CARDIOL*, 67 (2), 101-106.

IF: 3.7920

Ribas N., Domingo M., Gastelurrutia P., Ferrero-Gregori A., Rull P., Noguero M., Garcia C., Puig T., Cinca J., Bayes-Genis A., Chronobiology of death in heart failure. (2014) *REV ESP CARDIOL*, 67 (5), 387-393.

IF: 3.7920

Rico S., Antonijuan R.-M., Ballester M.R., Gutierrez I., Ayani I., Martinez-Gonzalez J., Borrell M., Fontcuberta J., Gich I., Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volun-

Clinical Epidemiology and Healthcare Services

*TIF: 319.9500 **MIF: 4.7754

teers and in subjects with varying degrees of renal impairment. (2014) *THROMB RES*, 133 (6), 1029-1038.

IF: 2.4470

Rios E., Seron P., Lanas F., Bonfill X., Quigley E.M.M., Alonso-Coello P., Evaluation of the quality of clinical practice guidelines for the management of esophageal or gastric variceal bleeding. (2014) *EUR J GASTROEN HEPAT*, 26 (4), 422-431.

IF: 2.2530

Robleda G., Sillero-Sillero A., Puig T., Gich I., Banos J.-E., Influence of preoperative emotional state on postoperative pain following orthopedic and trauma surgery. (2014) *REV LAT-AM ENFERM*, 22 (5), 785-791.

IF: 0.5340

Sanclemente G., Acosta J.-L., Tamayo M.-E., Bonfill X., Alonso-Coello P., Clinical practice guidelines for treatment of acne vulgaris: A critical appraisal using the AGREE II instrument. (2014) *ARCH DERMATOL RES*, 306 (3), 269-277.

IF: 1.9020

Schmidt S., Riel R., Frances A., Lorente Garin J.A., Bonfill X., Martinez-Zapata M.J., Morales Suarez-Varela M., dela Cruz J., Emparanza J.J., Sanchez M.-J., Zamora J., Goni J.M.R., Alonso J., Ferrer M., Becerra V., Pardo Y., Fores M.F., Garin O., Villagran C.O., Sunol R., Osorio D., Cosp X.B., Canovas E., Pardo G.S., Bolivar I., Bachs J., Maroto J.P., Quintana M.J., Martinez Zapata M.J., Lorente C.M., Algaba F., Redorta P., Esquena S., Puigvert F., Vernooij R., Martinez A., Pijoan Zubizarreta J.I., Martinez L., Castro Diaz D.M., Bastida J.L., Pacheco A.S., Lopez C.G., Cozar Olmo J.M., Martinez C., Chan D.C., Sanchez Perez M.J., Diaz Moratinos A.I., Luis A.M., Hervas A., Ocana C.V., Varona C., Burgos J., Polo Rubio J.A., Lopez-Fando Lavalle L., Jimenez Cidre M.A., Garcia A.M., Farras N.P., Lopez R.M., Garcia S.S., Abraira V., Dos Santos V.G., De la Camara A.G., De la Cruz J., Martinez J.P., Munoz H.G., Cabeza Rodriguez M.A., Diaz I.R., Sanz Jaka J.P., Velasquez M.J., Gonzalez A.L., Morales M., Camps C., Diaz C.C., Vidal E.M., Ballester F.S., Juan Escudero J.U., Peidro J.P., Torrecilla J.L., Ramos Campos M.M., Cebollada M.M., Bladder cancer index: Cross-cultural adaptation into Spanish and psychometric evaluation. (2014) *HEALTH QUAL LIFE OUT*, 12 (1).

IF: 2.1200

Schmidt-Hansen M., Baldwin D.R., Hasler E., Zamora J., Abraira V., Roque I Figuls M., PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. (2014) *COCHRANE DB SYST REV*, 11.

IF: 6.0320

Schmucker C., Schell L.K., Portalupi S., Oeller P., Cabrera L., Bassler D., Schwarzer G., Scherer R.W., Antes G., Von Elm E., Meerpohl J.J., Bertele V., Bonfill X., Bouesseau M.-C., Boutron I., Gallus S., Garattini S., Ghassan K., La Vecchia C., Lang B., Littmann J., Kleijnen J., Kulig M., Malicki M., Marusic A., Mueller K.F., Pardo H., Perleth M., Ravaud P., Reis A., Strech D., Trinquart L., Tia G.U., Wager E., Wieland A., Wolff R., Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries. (2014) *PLOS ONE*, 9 (12).

IF: 3.2340

Schunemann H.J., Wiercioch W., Etzeandia I., Falavigna M., Santesso N., Mustafa R., Ventresca M., Brignardello-Petersen R., Laisaar K.-T., Kowalski S., Baldeh T., Zhang Y., Raid U., Neumann I., Norris S.L., Thornton J., Harbour R., Treweek S., Guyatt G., Alonso-Coello P., Reinap M., Brozek J., Oxman A., Akl E.A., Guidelines 2.0: Systematic development of a comprehensive checklist for a successful guideline enterprise. (2014) *CAN MED ASSOC J*, 186 (3).

IF: 5.9590

Selva A., Bolibar I., Torrego A., Pallares M.C., Impact of a program for rapid diagnosis and treatment of lung cancer on hospital care delay and tumor stage. (2014) *TUMORI*, 100 (6), e243-e249.

IF: 1.2690

Seron P., Lanas F., Pardo Hernandez H., Bonfill Cosp X., Exercise for people with high cardiovascular risk. (2014) *COCHRANE DB SYST REV*, 8.

IF: 6.0320

Sola I., Carrasco J.M., Diaz Del Campo P., Gracia J., Orrego C., Martinez F., Kotzeva A., Guillamon I., Calderon E., De Gaminde I., Louro A., Rotaache R., Salcedo F., Velazquez P., Alonso-Coello P., Attitudes and perceptions about clinical guidelines: A qualitative study with spanish physicians. (2014) *PLOS ONE*, 9 (2).

IF: 3.2340

Tibau A., Lopez-Vilaro L., Perez-Olabarria M., Vazquez T., Pons C., Gich I., Alonso C., Ojeda B., Cajal T.R.Y., Lerma E., Barnadas A., Escuin D., Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. (2014) *NEOPLASIA*, 16 (10), 861-867.

IF: 4.2520

Tobias A., CatalaLopez F., Roque M., Development of an excel spreadsheet for metaanalysis of indirect and mixed treatment comparisons. (2014) *REV ESP SALUD PUBLICA*, 88 (1), 5-15.

IF: 0.6930

Torrego A., Sola I., Munoz A.M., Roque I Figuls M., Yepes-Nunez J.J., Alonso-Coello P., Plaza V., Bronchial thermoplasty for moderate or severe persistent asthma in adults. (2014) *COCHRANE DB SYST REV*, 3.

IF: 6.0320

Urrutia G., Bonfill X., Systematic reviews: A key tool for clinical and health decision making. (2014) *REV ESP SALUD PUBLICA*, 88 (1), 1-3.

IF: 0.6930

Vernooij R.W.M., Sanabria A.J., Sola I., Alonso-Coello P., Martinez Garcia L., Guidance for updating clinical practice guidelines: A systematic review of methodological handbooks. (2014) *IMPLEMENT SCI*, 9 (1).

IF: 4.1220

Whitlock R., Teoh K., Vincent J., Devereaux P.J., Lamy A., Paparella D., Zuo Y., Sessler D.I., Shah P., Villar J.-C., Karthikeyan G., Urrutia G., Alvezum A., Zhang X., Abbasi S.H., Zheng H., Quantz M., Yared J.-P., Yu H., Noiseux N., Yusuf S., Rationale and design of the steroids in cardiac surgery trial. (2014) *AM HEART J*, 167 (5), 660-665.

IF: 4.4630

- ▶ Akl E.A., Kahale L.A., Agarwal A., Al-Matari N., Ebrahim S., Alexander P.E., Briel M., Brignardello-Petersen R., Busse J.W., Diab B., Iorio A., Kwong J., Li L., Lopes L.C., Mustafa R., Neumann I., Tikkinen K.A.O., Vandvik P.O., Zhang Y., Alonso-Coello P., Guyatt G., Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: A protocol for a methodological study. (2014) *SYSTEMATIC REVIEWS*, 3 (1).
- ▶ Giner J., Plaza V., Rigau J., Sola J., Bolibar I., Sanchis J., Spirometric standards and patient characteristics: an exploratory study of factors affecting fulfillment in routine clinical practice. (2014) *RESPIRATORY CARE*, 59 (12), 1832-1837.
- ▶ Alonso-Coello P., Carrasco-Labra A., Brignardello-Petersen R., Neumann I., Akl E.A., Sun X., Johnston B.C., Briel M., Busse J.W., Glujovsky D., Granados C.E., Iorio A., Irfan A., Garcia L.M., Mustafa R.A., Ramirez-Morera A., Sola I., Tikkinen K.A.O., Ebrahim S., Vandvik P.O., Zhang Y., Selva A., Sanabria A.J., Zazueta O.E., Vernooij R.W.M., Schunemann H.J., Guyatt G.H., Correction: A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic reviews (ARROW): A study protocol. (2014) *SYSTEMATIC REVIEWS*, 3 (1).
- ▶ Ganann R., Ciliska D., Peirson L.J., Warren R.L., Fieldhouse P., Delgado-Noguera M.F., Tort S., Hams S.P., Martinez-Zapata M.J., Wolfenden L., Enhancing nutritional environments through access to fruit and vegetables in schools and homes among children and youth: a systematic review. (2014) *BMC RESEARCH NOTES*, 7, 422.
- ▶ Garcia-Valentin A., Bernabeu E., Pereda D., Josa M., Cortina J.M., Mestres C.A., Silva J., Llamas P., Otero E., Fernandez A.L., Adsuar A., Ginel A., Velasco C., Arnaiz E., Gomez F., Aldamiz G., Blazquez J.A., Aramendi J.I., Lopez J., Cereijo J.M.M., Santos J.M.G., Calleja M., Castano M., Camara M., Castro M.A., Carrascal Y., Validation of EuroSCORE II in Spain. (2014) *CIRUGIA CARDIOVASCULAR*, 21 (4), 246-251.
- ▶ Martin E., Hornero F., Rodriguez R., Castella M., Porras C., Romero B., Maroto L., Perez De La Sota E., Echevarria M., Dalmau M.J., Diez L., Buendia J., Enriquez F., Castano M., Reyes G., Ginel A., Perez M., Garcia R., Barquero J., Heredero A., Jimenez A., Castedo E., Lugo J., Pradas G., Gomez M., Rieta J.J., Muticenter spanish study for perioperative stroke risk prediction after isolated coronary artery bypass surgery: The PACK2 score. (2014) *CIRUGIA CARDIOVASCULAR*, 21 (3), 175-180.
- ▶ Martin E., Hornero F., Rodriguez R., Castella M., Porras C., Romero B., Maroto L., Perez De La Sota E., Echevarria M., Dalmau M.J., Diez L., Buendia J., Enriquez F., Castano M., Reyes G., Ginel A., Perez M., Garcia R., Barquero J., Heredero A., Jimenez A., Castedo E., Lugo J., Pradas G., Gomez M., Rieta J.J., Muticenter spanish study for perioperative stroke risk prediction after isolated coronary artery bypass surgery: The PACK2 score. (2014) *CIRUGIA CARDIOVASCULAR*, 21 (3), 175-180.
- ▶ Ribas N., Domingo M., Gastelurrutia P., Ferrero-Gregori A., Rull P., Noguero M., Garcia C., Puig T., Cinca J., Bayes-Genis A., Chronobiology of death in heart failure. (2014) *REVISTA ESPANOLA DE CARDIOLOGÍA (English ed.)*, 67 (5), 387-393.
- ▶ Salva A., Roque M., Valles E., Bustins M., Rodo M., Sanchez P., Description of the clinical complexity of patients admitted to long term care hospitals in Catalonia during 2003-2009. (2014) *REVISTA ESPANOLA DE GERIATRIA Y GERONTOLOGIA*, 49 (2), 59-64.
- ▶ Salva A., Roque M., Valles E., Bustins M., Rodo M., Sanchez P., Erratum to Description of the clinical complexity of patients admitted to long term care hospitals in Catalonia during 2003-2009. (2014) *REVISTA ESPANOLA DE GERIATRIA Y GERONTOLOGIA*, 49 (6), 306.
- ▶ Schunemann H.J., Wiercioch W., Etzeandia I., Falavigna M., Santesso N., Mustafa R., Ventresca M., Brignardello-Petersen R., Laisaar K.-T., Kowalski S., Baldeh T., Zhang Y., Raid U., Neumann I., Norris S.L., Thornton J., Harbour R., Treweek S., Guyatt G., Alonso-Coello P., Reinap M., Brozek J., Oxman A., Akl E.A., Guidelines 2.0: Systematic development of a comprehensive checklist for a successful guideline enterprise . (2014) *CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE*, 14 (9), 1135-1149.
- ▶ Urrutia G., Systematic reviews in nutrition: A necessary step forward. (2014) *REVISTA ESPANOLA DE NUTRICION HUMANA Y DIETETICA*, 18 (3), 116-117.

Evaluation of Public Health Policies and Programmes

Coordinator

Carles Ariza ASPB
cariza@aspb.cat

Members

Francesc Centrich ASPB
Xavier Contente HSCSP RI
Anna García ASPB
Gabriel Leon ASPB
María José López ASPB
Gloria Muñoz ASPB
Anna Pérez ASPB
Vanessa Puig HSCSP RI
Rosa Puigpinós ASPB
Francesca Sánchez ASPB
Gemma Serral ASPB
Joan Ramon Villalbí ASPB



Main Lines of Research

Evaluation of Public Health Policies and Programmes

- ▶ Monitoring of behaviours and other health risk factors such as environmental exposure.
- ▶ Process and impact evaluation of public health programmes and services (school-based prevention programmes for obe-

sity, smoking, alcohol and cannabis consumption, breast cancer screening programmes and memory training workshops for elderly people).

- ▶ Evaluation of ICT innovation in public health.
- ▶ Evaluation of food contaminants.

Challenges

- ▶ Promote research into the evaluation of policies and programmes.
- ▶ Support the debate on conceptual and methodological aspects of results evaluation in prevention and health promotion.

- ▶ Consolidate the group's research, fostering less developed aspects such as financial assessment and evaluation of health protection interventions.

- ▶ Develop a theoretical corpus of concepts, principles, methods and examples that contribute to filling the gap in under- and postgraduate teaching regarding the design and evaluation of risk prevention and health promotion interventions.

Awards

- ▶ Prevenció de l'obesitat infantil a Barcelona - Creixem sans POIBA. Premi "Diario Médico" categoría "Las mejores ideas del año". 27 October 2014.

- ▶ POIBA, Proyecto de Prevención de la Obesidad en Barcelona. Primer accesit VIII Premios "Estrategia NAOS" 2014, Agencia Española de Consumo, Seguridad Alimentaria y Nutrición (AECOSAN).

Active Grants

- ▶ Anna Pérez Giménez. Ensayo clínico aleatorizado para evaluar la eficacia de los talleres de entrenamiento de la memoria en personas de 65 a 80 años. MINECO-IS-CIII Projecte 2011. PI11/02060. Duration: 01/01/12-31/12/14. €43,750.

Note: Total amount granted to PI. It does not include indirect costs.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Clinical Epidemiology and Healthcare Services (PI: Xavier Bonfill).
- ▶ Transport and Health: Injuries and Mobility (PI: Catherine Pérez).
- ▶ Health Inequalities (PI: Carme Borrell).
- ▶ Epidemiology of Addictions (PI: M. Teresa Brugal).

External Collaborations

- ▶ CIBER-Epidemiology and Public Health (Group 18: Evaluation of public health policies and programmes).
- ▶ AGAUR Consolidated Research Group (Evaluation of public health policies and programmes).
- ▶ Tobacco Working Group of the Spanish Epidemiology Society.
- ▶ Social Determinants Group of the Spanish Epidemiology Society.
- ▶ Foreign universities: Johns Hopkins University, USA.
- ▶ Spanish universities: Universitat Pompeu Fabra, Universitat

Ramon Llull, Universitat de Vic, Universitat Internacional de Catalunya, Universitat Oberta de Catalunya, Universidad de Santiago de Compostela.

- ▶ Primary care centres: Ciutat Meridiana, Roquetes, Sant Rafael i Sardenya (Barcelona).
- ▶ Catalan Institute of Oncology (ICO).
- ▶ Municipal bodies: Barcelona Sports Institute (IBE), Barcelona Municipal Institute of Education (IME).
- ▶ Regional bodies: Public Health Agency of Catalonia (ASPCAT) (Promoting Health through Physical Activity and Healthy Eating Plan) and Catalan Health Information and Quality Agency (AQUAS).
- ▶ Other bodies: Catalan Recreation Foundation (FCE).
- ▶ Companies: Fontvella and Danone (Health Affairs Departments).

*TIF: 48.0640 **MIF: 2.1847

Scientific Production

Alvarez-Simon D., Cruz M.-J., Untoria M.-D., Munoz X., Villalbi J.R., Morell F., Gomez-Olles S., A rapid test for soy aeroallergens exposure assessment. (2014) PLOS ONE, 9 (2).

IF: 3.2340

Ariza C., Garcia-Continente X., Villalbi J.R., Sanchez-Martinez F., Perez A., Nebot M., Tobacco use by adolescents in Barcelona (Spain) and trends in the last 20 years. (2014) GAC SANIT, 28 (1), 25-33.

IF: 1.1860

Aurrekoetxea J.J., Murcia M., Rebagliato M., Fernandez-Somoano A., Castilla A.M., Guxens M., Lopez M.J., Lertxundi A., Espada M., Tardon A., Ballester F., Santa-Marina L., Factors associated with second-hand smoke exposure in non-smoking pregnant women in Spain: Self-reported exposure and urinary cotinine levels. (2014) SCI TOTAL ENVIRON, 470-471, 1189-1196.

IF: 4.0990

Borrell C., Dominguez-Berjon M.F., Alvarez-Dardet C., Bermudez-Tamayo C., Godoy P., Lopez M.J., Negrin M.T., Perez G., Perez-Farinos N., Ruano A., Cases C.V., Garcia A.M., Gaceta Sanitaria in 2013: Changes, challenges and uncertainties. (2014) GAC SANIT, 28 (2), 96-99.

IF: 1.1860

Borrell C., Mari-Dell'Olmo M., Palencia L., Gotsens M., Burstrom B.O., Dominguez-Berjon F., Rodriguez-Sanz M., Dzurova D., Gandarillas A., Hoffmann R., Kovacs K., Marinacci C., Martikainen P., Pikhart H., Corman D., Rosicova K., Saez M., Santana P., Tarkiainen L., Puigipinos R., Morrison J., Pasarin M.I., Diez E., Socioeconomic inequalities in mortality in 16 European cities.

(2014) SCAND J PUBLIC HEALT, 42 (3), 245-254.

IF: 1.8320

Bosque-Prous M., Espelt A., Guitart A.M., Bartoli M., Villalbi J.R., Brugal M.T., Response to Jernigan & Ross (2014): Alcohol advertising and hazardous drinkers. (2014) ADDICTION, 109 (10), 1645-1646.

IF: 4.7380

Casajuana Kogel C., Cofino R., Lopez M.J., Evaluation of the Health Observatory of Asturias (Spain): Web and social network metrics and health professionals' opinions. (2014) GAC SANIT, 28 (3), 183-189.

IF: 1.1860

Diez E., Daban F., Pasarin M., Artazcoz L., Fuertes C., Lopez M.J., Calzada N., Evaluation of a community program to reduce isolation in older people due to architectural barriers. (2014) GAC SANIT, 28 (5), 386-388.

IF: 1.1860

Fu M., Martinez-Sanchez J.M., Cleries R., Villalbi J.R., Daynard R.A., Connolly G.N., Fernandez E., Opposite trends in the consumption of manufactured and roll-your-own cigarettes in Spain (1991-2020). (2014) BMJ OPEN, 4 (12).

IF: 2.2710

Galan I., Mayo E., Lopez M.J., Perez-Rios M., Fu M., Martinez-Sanchez J.M., Schiaffino A., Moncada A., Montes A., Nebot M., Fernandez E., Validity of self-reported exposure to second-hand smoke in hospitality venues. (2014) ENVIRON RES, 133, 1-3.

IF: 4.3730

Garcia-Continente X., Perez-Gimenez A., Lopez M.J., Nebot M., Potential selection bias in telephone surveys: Landline and mobile

phones. (2014) GAC SANIT, 28 (2), 170-172.

IF: 1.1860

Kumar P., Rubies A., Centrich F., Companyo R., A false positive case due to matrix interference in the analysis of ronidazole residues in muscle tissue using LC-MS/MS. (2014) MEAT SCI, 97 (2), 214-219.

IF: 2.6150

Llorente-Mirandes T., Calderon J., Centrich F., Rubio R., Lopez-Sanchez J.F., A need for determination of arsenic species at low levels in cereal-based food and infant cereals. Validation of a method by IC-ICPMS. (2014) FOOD CHEM, 147, 377-385.

IF: 3.3910

Lopez M.J., Continente X., Being young and working as an epidemiologist: Synergy between risk factors?. (2014) GAC SANIT, 28 (1), 1-3.

IF: 1.1860

Martinez-Sanchez J.M., Sureda X., Fu M., Perez-Ortuno R., Ballbe M., Lopez M.J., Salto E., Pascual J.A., Fernandez E., Secondhand smoke exposure at home: Assessment by biomarkers and airborne markers. (2014) ENVIRON RES, 133, 111-116.

IF: 4.3730

Obradors-Rial N., Ariza C., Muntaner C., Risky alcohol consumption and associated factors in adolescents aged 15 to 16 years in Central Catalonia (Spain): Differences between rural and urban areas. (2014) GAC SANIT, 28 (5), 381-385.

IF: 1.1860

Perello G., Llobet J.M., Gomez-Catalan J., Castell V., Centrich F., Nadal M., Domingo J.L., Hu-

Evaluation of Public Health Policies and Programmes

*TIF: 48.0640 **MIF: 2.1847

Scientific Production

man Health Risks Derived from Dietary Exposure to Toxic Metals in Catalonia, Spain: Temporal Trend. (2014) BIOL TRACE ELEM RES, 162 (1-3), 26-37.

IF: 1.7480

Perez G., Rodriguez-Sanz M., Cirera E., Perez K., Puigpinos R., Borrell C., Commentary: Approaches, strengths, and limitations of avoidable mortality. (2014) J PUBLIC HEALTH POL, 35 (2), 171-184.

IF: 1.7750

Suelves J.M., Villalbi J.R., Bosque-Prous M., Espelt A., Brugal M.T., Specialised treatment for

alcohol abuse or dependence. (2014) REV ESP SALUD PUBLIC, 88 (4), 541-549.

IF: 0.6930

Sureda X., Martinez-Sanchez J.M., Fu M., Perez-Ortuno R., Martinez C., Carabasa E., Lopez M.J., Salto E., Pascual J.A., Fernandez E., Impact of the Spanish smoke-free legislation on adult, non-smoker exposure to secondhand smoke: Cross-sectional surveys before (2004) and after (2012) legislation. (2014) PLOS ONE, 9 (2).

IF: 3.2340

Villalbi J.R., Benavides F.G., Contribute to public health from professional and scientific societies: the Working Group on Alcohol of the Spanish Society of Epidemiology. (2014) REV ESP SALUD PUBLIC, 88 (4), 429-432.

IF: 0.6930

Villalbi J.R., Bosque-Prous M., Gili-Miner M., Espelt A., Brugal M.T., Policies to prevent the harm caused by alcohol. (2014) REV ESP SALUD PUBLIC, 88 (4), 515-528.

IF: 0.6930

Other Publications

- ▶ Garcia-Continente X., Perez-Gimenez A., Espelt A., Nebot Adell M., Factors associated with media use among adolescents: a multilevel approach. (2014) EUROPEAN JOURNAL OF PUBLIC HEALTH, 24 (1), 5-10.

Transport and Health: Injuries and Mobility

Coordinator

Catherine Pérez
cperez@aspb.cat

ASPB

Members

Ana Novoa

ASPB

Marta Olabarria

ASPB

Elena Santamariña

ASPB



Main Lines of Research

- ▶ Public health injury surveillance.
- ▶ Evaluation of road safety strategies at the urban level.
- ▶ Evaluation of road safety strategies in Spain.
- ▶ Indicators of mobility exposure and risk of traffic injuries.
- ▶ Determinants of walking as a mode of transport.
- ▶ Health impact assessment of active transport (walking and cycling).

Research Projects in the Planning and Design Phase

- ▶ Record linkage of health and police registers to study road traffic injury determinants.
- ▶ Inter-sector policies in transport: impact on sustainable environment, health and equity

Challenges

- ▶ Study of the nature of injuries and their severity according to the characteristics of the collision and the vehicles involved, particularly in urban settings.
- ▶ Evaluate road safety policies and interventions.
- ▶ Calculation of risk indicators using mobility exposure.
- ▶ Study motorized and non-motorized mobility and its impact on health.

Doctoral Theses

- ▶ Eva Cirera. Evolució de les lesions en la gent gran. Espanya 2000-2010. Universitat Pompeu Fabra. Director: Catherine Pérez. Date of defense: 17 October 2014.

Grants Awarded in 2014

- ▶ Caterine Pérez. Ajuts de suport als Grups de Recerca de Catalunya. Transport i salut: lesions i mobilitat. AGAUR 2014. SGR 1337. €20,000.*

* Grants applied for by other research institutes.

Note: Total amount granted to PI. It does not include indirect costs.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Health Inequalities (PI: Carme Borrell)
- ▶ Safety indicators for cities IRTAD Cities (Joint Transport Research Centre of the OECD and the International Transport Forum (JTRC)).

External Collaborations

- ▶ All members of the group are members of the Working Group for Health Impact Evaluation of Injuries in Spain (Sociedad Española de Epidemiología), which is led by the IP of the group (Catherine Pérez).
- ▶ All members of the group are members of the group of Social Inequalities of CIBERESP (Consortio de Investigación Biomédica de Epidemiología y Salud Pública).

- ▶ The IP of the group is member of the European Committee of The Transport and Health Study Group (THSG) (UK).
- ▶ Catherine Pérez. Semi-separación de calzadas en carretera convencional: análisis de diferentes sistemas y evaluación de intervenciones ya realizadas. Dirección General de Tráfico. 0100DGT22160. Duration: 2013-2014. €38,701.85. (external contract)
- ▶ Catherine Pérez. Promoció i desenvolupament d'estudis específics d'accidentalitat a la ciutat de Barcelona. Servei de Mobilitat. Ajuntament de Barcelona. Duration: 2014. €27,534.99.
- ▶ Joint action on monitoring injuries in Europe (JAMIE) (European Agency for Health and Consumers).

*TIF: 18.0610 **MIF: 1.8061

Scientific Production

Borrell C., Rodriguez-Sanz M., Bartoll X., Malmusi D., Novoa A.M., The suffering of the population in the economic crisis of the Spanish State. (2014) SALUD COLECT, 10 (1), 95-98.

IF: 0.1020

Cirera E., Perez K., Santamarina-Rubio E., Novoa A.M., Olabarria M., Incidence trends of injury among the elderly in Spain, 2000–2010. (2014) INJURY PREV, 20 (6), 401-407.

IF: 1.8910

Cirera E., Perez K., Santamarina-Rubio E., Novoa A.M., Olabarria M., Improvements in hip fracture incidence counterbalanced by the rise of other fracture types: Data from Spain 2000-2010. (2014) INJURY, 45 (12), 2076-2083.

IF: 2.1370

Dupont E., Commandeur J.J.F., Lassarre S., Bijlvelde F., Martensen H., Antoniou C., Papadimitriou E., Yannis G., Hermans E., Perez K., Santamarina-Rubio E., Usami D.S., Giustiniani G., Latent risk and trend models for

the evolution of annual fatality numbers in 30 European countries. (2014) ACCIDENT ANAL PREV, 71, 327-336.

IF: 2.0700

Gutarra-Vilchez R., Santamarina-Rubio E., Salvador J., Borrell A., Birth defects in medically assisted reproduction pregnancies in the city of Barcelona. (2014) PRENATAL DIAG, 34 (4), 327-334.

IF: 3.2680

Lopez-Ruiz M., Martinez J.M., Perez K., Novoa A.M., Tobias A., Benavides F.G., Impact of road safety interventions on traffic-related occupational injuries in Spain, 2004-2010. (2014) ACCIDENT ANAL PREV, 66, 114-119.

IF: 2.0700

Olabarria M., Perez K., Novoa A.M., Perez K., Santamarina-Rubio E., Daily mobility patterns of an urban population and their relationship to overweight and obesity. (2014) TRANSPORT POLICY, 32, 165-171.

IF: 1.4920

Perez G., Rodriguez-Sanz M., Cirera E., Perez K., Puigpinos R., Borrell C., Commentary: Approaches, strengths, and limitations of avoidable mortality. (2014) J PUBLIC HEALTH POL, 35 (2), 171-184.

IF: 1.7750

Perez K., Segui-Gomez M., Arrufat V., Barberia E., Cabeza E., Cirera E., Gil M., Martin C., Novoa A.M., Olabarria M., Lardelli P., Suelves J.M., Santamarina-Rubio E., Definition of hospital discharge, serious injury and death from traffic injuries. (2014) GAC SANIT, 28 (3), 242-245.

IF: 1.1860

Santamarina-Rubio E., Perez K., Olabarria M., Novoa A.M., Gender differences in road traffic injury rate using time travelled as a measure of exposure. (2014) ACCIDENT ANAL PREV, 65, 1-7.

IF: 2.0700

Other Publications

▶ Pérez K, Santamariña-Rubio E. Col·lisions i lesions de trànsit a Barcelona 2002-2013. Barcelona: Agència de Salut Pública de Barcelona, 2014. DL: B. 27318-2014.

▶ Santamariña-Rubio E, Pérez K. Persones lesionades per trànsit ateses a serveis d'urgències a Barcelona 1997-2013. Barcelona: Agència de Salut Pública de Barcelona, 2014. DL: B.18942-2014.

▶ Santamariña-Rubio E, Pérez K, Castellà J. Persones mortes a Barcelona per lesions per col·lisió de trànsit, 1997-2013. Barcelona: Agència de Salut Pública de Barcelona, 2014. DL: B.15532-2014.

Transmissible Diseases

Coordinator

Joan A. Caylà ASPB
jcayla@aspb.cat

Members

Javier de Benito ASPB
Martí Casals ASPB
Patricia García de Olalla ASPB
Olivia Horna ASPB
Vicente Martín ASPB
Joan Pau Millet ASPB
Ignacio Monedero ASPB
Antonio Moreno ASPB
Àngels Orcau ASPB
Helena Pañella ASPB
Cristina Rius ASPB
M. Teresa Rodrigo ASPB



Main Lines of Research

Application of New Technologies to Tuberculosis Control

- ▶ International diffusion of the new technologies. Google Analytics offers a highly effective system for analysing website visits that enables us to profile visitors (2007, 13,429 visitors, 21% from Latin America).
- ▶ Production of scientific knowledge of relevance on the control, diagnosis, treatment and prevention of tuberculosis (key role in Spain and South America).

Clinical Trials for Tuberculosis Prevention and Treatment

- ▶ Our centre, which is the only such centre in Europe, is part of a network of international centres (in Canada, Brazil, South Africa and Uganda) associated with the Tuberculosis Trials Consortium of the CDCs, promoting international involvement in laying the therapeutic and strategic bases for the treatment of tuberculosis and tubercular infection. Preliminary results have recently been presented at the ICAAC and other important international conferences e.g., the American Thoracic Society (the article with definitive study data is pending publication). A major research line aims to fix the bases for shortening treatment times for tubercular infection and, by extension, ensure compliance and control over the disease.

Community Health Worker's and Notifiable Disease Control

- ▶ The experiment regarding the community health worker's role in the control of notifiable diseases has been presented at tuberculosis and primary care conferences and workshops and in journals (Emerging Infectious Diseases; Ethnicity and Health). Results of a comparative study have recently been presented as a thesis in fulfilment of the master in public health of Pompeu Fabra University and the Autonomous University of Barcelona (an article is undergoing final review before publication).
- ▶ The inclusion of community health workers in tuberculosis programme teams has led to the creation of new tuberculosis consensus protocols. Institute of Health studies are under development with sponsorship from the authorities and we are participating as instructors and students in the first intercultural mediation course in the healthcare arena. The concept of the community health worker has been included in the framework Tuberculosis Prevention and Control Plan for Spain. The short- to medium-term objective is for community health workers to continue working with us and for these professionals to be included in other public health areas.

Challenges

- ▶ Prevent sexually transmitted infections and other transmissible diseases.
- ▶ Evaluate HIV screening programmes in gay saunas.
- ▶ Improve detection and research into causes of hepatitis C.
- ▶ Improve detection and control measures of outbreaks.

Collaborations

External Collaborations

- ▶ CDC.
- ▶ CASCADE.
- ▶ GEMES.
- ▶ SANCO.
- ▶ COHERE.

Awards

- ▶ García de Olalla P, Molas E, Barberà MJ, Martín S, Gosh M, Knobel H, Caylà JA. Efectividad de un programa piloto de estudio de contactos de los nuevos diagnósticos de VIH. Premio a la mejor comunicación. Una visión Multidisciplinar en el Tratamiento y la calidad de vida del paciente con VIH. Madrid, 26 June 2014.

Active Grants

- ▶ Joan A. Caylà Buqueras. Cribado de las enfermedades transmisibles en población inmigrante de un barrio con bajo nivel socio-económico: comparación de dos estrategias. Proyectos de Investigación en Salud 2012. PI12/02573. Duration: 01/01/13-31/12/15. €43,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 64.2960 **MIF: 3.5720

Scientific Production

Casals M., Girabent-Farres M., Carrasco J.L., Methodological quality and reporting of generalized linear mixed models in clinical medicine (2000-2012): A systematic review. (2014) PLOS ONE, 9 (11).

IF: 3.2340

Casals M., Rodrigo T., Camprubi E., Orcau A., Cayla J.A., Tuberculosis and immigration in Spain. Scoping review. (2014) REV ESP SALUD PUBLIC, 88 (6), 803-809.

IF: 0.6930

Culqui D.R., Manzanares-Laya S., Sluis S.L.V.D., Fanlo A.A., Comas R.B., Rossi M., Cayla J.A., Group a β -hemolytic streptococcal pharyngotonsillitis outbreak. (2014) REV SAUDE PUBL, 48 (2).

IF: 0.7330

de Vries G., Aldridge R.W., Cayla J.A., Haas W.H., Sandgren A., van Hest N.A., Abubakar I., Antoine D., Antoun F., de Onate A.W., Codecasa L.R., Dedicoat M., van Deutekom H., Gori A., Hauer B., Hayward A., Huitric E., Jonsen J., Orcau A., Quabeck L., Rodes A., Story A., Wanlin M., Williams P., Andersen P.H.S., Bonita B., Cioran N., Cameron J.C., Davidaviciene E., Kalkouni R., Bulletin K., Korzeniewska M., Martini V., Milanov V., Riekstina V., Valin E.R., Ronning K., Schmidgruber B., Vasankari T., Wallenfels J., Epidemiology of tuberculosis in big cities of the European union and European economic area countries. (2014) EUROSURVEILLANCE, 19 (9).

IF: 5.7220

Dominguez A., Godoy P., Castilla J., Mayoral J.M., Soldevila N., Torner N., Toledo D., Astry J., Tamames S., Garcia-Gutierrez S., Gonzalez-Candelas F., Martin V., Diaz J., Alonso J., Baricot M., Cayla J., Lafuente S., Cenoz M.G., Baz I.M., Quintana J.M., Gonzalez A.B., Knowledge of and attitudes to influenza in unvaccinated primary care physicians and nurses: A cross-sectional study.

(2014) HUM VACC IMMUNOTHER, 10 (8), 2378-2386.

IF: 2.3660

Engsig F.N., Zangerle R., Katsarou O., Dabis F., Reiss P., Gill J., Porter K., Sabin C., Riordan A., Fatkenheuer G., Gutierrez F., Raffi F., Kirk O., Mary-Krause M., Stephan C., De Olalla P.G., Guest J., Samji H., Castagna A., D'Arminio Monforte A., Skaletz-Rorowski A., Ramos J., Lapadula G., Mussini C., Force L., Meyer L., Lampe F., Boufassa F., Bucher H.C., De Wit S., Burkholder G.A., Teira R., Justice A.C., Sterling T.R., M. Crane H., Gerstoft J., Grarup J., May M., Chene G., Ingle S.M., Sterne J., Obel N., Long-term mortality in HIV-positive individuals virally suppressed for ≥ 3 years with incomplete CD4 recovery. (2014) CLIN INFECT DIS, 58 (9), 1312-1321.

IF: 8.8860

Garcia de Olalla P., *et al.* Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. (2014) AIDS, 28 (16), 2461-2473.

IF: 5.5540

Gutierrez S.G., *et al.* Predictive factors of severe multilobar pneumonia and shock in patients with influenza. (2014) EMERG MED J, 31 (4), 301-307.

IF: 1.8430

Hoyos Miller J., Fernandez-Balbuena S., Belza Egozcue M.J., Garcia De Olalla P., Pulido Manzanero J., Molist Sene G., De La Fuente De Hoz L., Time devoted to pre- and post-HIV test counselling in different health services according to participants of a rapid testing program in Madrid, Spain. (2014) ENFERM INFECC MICR CL, 32 (2), 82-86.

IF: 2.1720

Jimenez-Fuentes M.A., Milaauge C., Gomez M.N.A., Peiro J.S., De Souza Galvao M.L.,

Maldonado J., Molina-Pinargote I., Orcau A., Cayla J.A., Screening for active tuberculosis in high-risk groups. (2014) INT J TUBERC LUNG D, 18 (12), 1459-1465.

IF: 2.3150

Marco A., Gallego C., Cayla J.A., Incidence of hepatitis c infection among prisoners by routine laboratory values during a 20-year period. (2014) PLOS ONE, 9 (2).

IF: 3.2340

Plans P., Alvarez E., De Ory F., Campins M., Paya T., Balfagon P., Godoy P., Cayla J., Carerras R., Cabero L., Dominguez A., Prevalence of antibody to bordetella pertussis in neonates and prevalence of recent pertussis infection in pregnant women in Catalonia (Spain) in 2003 and 2013. (2014) PEDIATR INFECT DIS J, 33 (11), 1114-1118.

IF: 2.7230

Podlekareva D.N., Pantelev A.M., Grint D., Post F.A., Miro J.M., Bruyand M., Furrer H., Obel N., Girardi E., Vasilenko A., Losso M.H., Arenas-Pinto A., Cayla J., Rakhmanova A., Zeltina I., Werlinrud A.M., Lundgren J.D., Mocroft A., Kirk O., Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. (2014) EUR RESPIR J, 43 (1), 166-177.

IF: 7.6360

Sala M.R., Broner S., Moreno A., Arias C., Godoy P., Minguell S., Martinez A., Torner N., Bartolome R., de Simon M., Guix S., Dominguez A., Alseda M., Alvarez J., Artigues A., Barrabeig I., J Balanya P., Camps N., Company M., Carol M., Ferrus G., Follia N., Parron I., Recasens A., Rovira A., Torra R., Torres J., Ferrer D., Sanz M., Cornejo T., Bosch A., Pinto R.M., Cases of acute gastroenteritis due to calicivirus in outbreaks: Clinical differences by age and aetiological agent. (2014) CLIN MICROBIOL INFECC, 20 (8), 793-798.

IF: 5.7680

Transmissible Diseases

*TIF: 64.2960 **MIF: 3.5720

Scientific Production

Solano R., Alsedá M., Godoy P., Sanz M., Bartolomé R., Manzanares-Laya S., Domínguez A., Cayla J.A., Person-to-person transmission of norovirus resulting in an outbreak of acute gastroenteritis at a summer camp. (2014) EUR J GASTROEN HEPAT, 26 (10), 1160-1166.

IF: 2.2530

Solano R., Gomez-Barroso D., Simon F., Lafuente S., Simon P., Rius C., Gorrindo P., Toledo D., Cayla J.A., Retrospective space-time cluster analysis of whooping cough re-emergence in Barcelona, Spain, 2000-2011. (2014) GEOSPATIAL HEALTH, 8 (2), 455-461.

IF: 1.1940

Solano R., Rius C., Simon P., Manzanares-Laya S., Ros M., Toledo D., Domínguez A., Cayla J.A., Evaluation of reported cases of pertussis: Epidemiological study in a large city in Spain. (2014) J MED MICROBIOL, 63, 1688-1695.

IF: 2.2480

van Hest N.A., Aldridge R.W., de Vries G., Sandgren A., Hauer B., Hayward A., de Onate W.A., Haas W., Codecasa L.R., Cayla J.A., Story A., Antoine D., Gori A., Quabeck L., Jonsson J., Wanlin M., Orcau A., Rodes A., Dedicoat M., Antoun F., van Deutekom H., Keizer S.T., Abubakar I., Tuberculosis control in big cities and urban risk groups in the European Union: A consensus statement. (2014) EUROSURVEILLANCE, 19 (9).

IF: 5.7220

Health Inequalities

Coordinator

Carme Borrell ASPB
cborrell@aspb.cat

Members

Patricia Altimira ASPB
Lucía Artazcoz ASPB
Xavier Bartoll ASPB
Immaculada Cortés ASPB
Elia Díez ASPB
Mercè Gotsens ASPB
Davide Malmusi ASPB
Marc Marí ASPB
Laia Palència ASPB
M. Isabel Pasarín ASPB
Glòria Pérez ASPB
Maica Rodríguez ASPB
Joaquín Salvador ASPB



Main Lines of Research

- ▶ In-depth health inequalities according to social class in Spain and worldwide.
- ▶ Exploitation of information at the census section level as the maximum disaggregation unit and at higher geographic aggregation levels such as the neighbourhood, town and region.

Gender Inequalities in Health

- ▶ Sexual division between productive and reproductive work (gender roles) and differences in male and female identities as the 2 main structural factors that generate gender inequalities in health.

Social and Political Determinants of Health and Their Impact on Policy Building and Interventions

- ▶ Evidence of the macroeconomic determinants of health inequalities between countries.
- ▶ The impact of the political context on the health of the population and the conclusion that countries with better developed welfare states have better levels of health.

Challenges

Health-Inequalities According to Different Inequality Axes

- ▶ Study of social determinants of health in terms of social class and gender, with the purpose of integrating these 2 axes and analysing inequalities among immigrants.
- ▶ Research into the impact of area of residence, especially smaller urbanized areas, on the health of the population.

Gender Inequalities in Health

- ▶ Further explore the theoretical framework and explanatory charts developed to guide comprehension of the gender determinants that affect health.

Social and Political Determinants of Health and Their Impact on Policy Building and Interventions

- ▶ Study the influence of policies on the health of populations and on social inequalities in health.

Sex and Reproductive Inequalities in Health

- ▶ Establish a line of research to investigate different aspects of sexual and reproductive health (sexuality, contraception, pregnancy, birth, miscarriage, abortion, birth rates, etc).

Doctoral Theses

- ▶ Marco Antonio Cornejo. Salud bucal y su atención en las personas mayores institucionalizadas de Barcelona y el impacto en su calidad de vida. Universitat Pompeu Fabra. Directors: Glòria Pérez, Carme Borrell. Date of defense: 24 April 2014.
- ▶ Roshanak Mehdipanah. Urban Renewal and Health: The effects of the Neighbourhoods Law on health and health inequalities in Barcelona. Universitat Pompeu Fabra. Director: Carme Borrell. Date of defense: 23 May 2014.

Awards

- ▶ Gotsens M. Socioeconomic inequalities in injury mortality in small areas of 15 European cities. V premio del grupo EJE a las mejores contribuciones en el campo de la epidemiología y la salud pública en la modalidad B: mejor artículo científico, 2014.

Active Grants

- ▶ Rosa Puigpinós. Influencia de determinantes sociales, estilos de vida, bienestar emocional y uso de terapias no convencionales en la evolución del cáncer de mama en una cohorte de mujeres diagnosticadas. Proyectos de Investigación en Salud 2013. PI13/01977. Duration: 01/01/14-31/12/16. €64,470.
- ▶ Gloria Pérez. El efecto de la crisis económica en la salud sexual y reproductiva y en las desigualdades sociales y económicas en España y sus Comunidades Autónomas. Proyectos de Investigación en Salud 2013. PI13/02292. Duration: 01/01/14-31/12/16. €26,875.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Carme Borrell. Ajuts de suport als Grups de Recerca de Catalunya. Grup de Determinants socials de la salut i les desigualtats en salut. AGAUR 2014. SGR 815. Duration: 2014-2018.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 79.8310 **MIF: 2.4191

Scientific Production

Artazcoz L., Cortes I., Puig-Barrachina V., Benavides F.G., Escriba-Aguir V., Borrell C., Combining employment and family in Europe: The role of family policies in health. (2014) EUR J PUBLIC HEALTH, 24 (4), 649-655.

IF: 2.5910

Bartoll X., Cortes I., Artazcoz L., Full- and part-time work: Gender and welfare-type differences in European working conditions, job satisfaction, health status, and psychosocial issues. (2014) SCAND J WORK ENV HEA, 40 (4), 370-379.

IF: 3.4540

Bartoll X., Palencia L., Malmusi D., Suhrcke M., Borrell C., The evolution of mental health in Spain during the economic crisis. (2014) EUR J PUBLIC HEALTH, 24 (3), 415-418.

IF: 2.5910

Berra S., Rodriguez-Sanz M., Rajmil L., Pasarin M.I., Borrell C., Experiences with primary care associated to health, socio-demographics and use of services in children and adolescents. (2014) CAD SAUDE PUBLICA, 30 (12), 2607-2618.

IF: 0.9760

Borrell C., Dominguez-Berjon M.F., Alvarez-Dardet C., Bermudez-Tamayo C., Godoy P., Lopez M.J., Negrin M.T., Perez G., Perez-Farinos N., Ruano A., Cases C.V., Garcia A.M., Gaceta Sanitaria in 2013: Changes, challenges and uncertainties. (2014) GAC SANIT, 28 (2), 96-99.

IF: 1.1860

Borrell C., Mari-Dell'Olmo M., Palencia L., Gotsens M., Burstrom B.O., Domin-

guez-Berjon F., Rodriguez-Sanz M., Dzurova D., Gandarillas A., Hoffmann R., Kovacs K., Marinacci C., Martikainen P., Pihart H., Corman D., Rosicova K., Saez M., Santana P., Tarkiainen L., Puigpinos R., Morrison J., Pasarin M.I., Diez E., Socioeconomic inequalities in mortality in 16 European cities. (2014) SCAND J PUBLIC HEALTH, 42 (3), 245-254.

IF: 1.8320

Borrell C., Palencia L., Muntaner C., Urquia M., Malmusi D., O'Campo P., Influence of macrosocial policies on women's health and gender inequalities in health. (2014) EPIDEMIOL REV, 36 (1), 31-48.

IF: 6.6670

Borrell C., Rodriguez-Sanz M., Bartoll X., Malmusi D., Novoa A.M., The suffering of the population in the economic crisis of the Spanish State. (2014) SALUD COLECT, 10 (1), 95-98.

IF: 0.1020

Camprubi L., Diez T., Morrison J., Borrell C., The Ineq-Cities research project on urban health inequalities: Knowledge dissemination and transfer in Spain. (2014) GAC SANIT, 28 (2), 166-169.

IF: 1.1860

Diez E., Daban F., Pasarin M., Artazcoz L., Fuertes C., Lopez M.J., Calzada N., Evaluation of a community program to reduce isolation in older people due to architectural barriers. (2014) GAC SANIT, 28 (5), 386-388.

IF: 1.1860

Diez E., Morrison J., Pons-Vigues M., Borrell C., Corman D., Burstrom B., Domin-

guez-Berjon F., Gandarillas A., Hoffmann R., Santana P., Camprubi L., Municipal interventions against inequalities in health: The view of their managers. (2014) SCAND J PUBLIC HEALTH, 42 (6), 476-487.

IF: 1.8320

Garcia-Subirats I., Vargas I., Mogollon-Perez A.S., De Paepe P., Da Silva M.R.F., Unger J.P., Borrell C., Vazquez M.L., Inequities in access to health care in different health systems: A study in municipalities of central Colombia and north-eastern Brazil. (2014) INT J EQUITY HEALTH, 13 (1).

IF: 1.8010

Garcia-Subirats I., Vargas I., Sanz-Barbero B., Malmusi D., Ronda E., Ballesta M., Vazquez M.L., Changes in access to health services of the immigrant and native-born population in Spain in the context of economic crisis. (2014) INT J ENV RES PUB HE, 11 (10), 10182-10201.

IF: 2.0630

Gil-Gonzalez D., Vives-Cases C., Borrell C., Agudelo-Suarez A.A., Davo-Blanes M.C., Miralles J., Alvarez-Dardet C., Racism, other discriminations and effects on health. (2014) J IMMIGR MINOR HEALT, 16 (2), 301-309.

IF: 1.4820

Gonzalez-Rabago Y., La Parra D., Martin U., Malmusi D., Participation and representation of the immigrant population in the Spanish National Health Survey 2011-2012. (2014) GAC SANIT, 28 (4), 281-286.

IF: 1.1860

Gutarra-Vilchez R., Santamarina-Rubio E., Salvador J., Borrell A., Birth defects in med-

Health Inequalities

*TIF: 79.8310 **MIF: 2.4191

Scientific Production

ically assisted reproduction pregnancies in the city of Barcelona. (2014) *PRENATAL DIAG*, 34 (4), 327-334.

IF: 3.2680

Hoffmann R., Borsboom G., Saez M., Mari Dell'Olmo M., Burstrom B., Corman D., Costa C., Deboosere P., Dominguez-Berjon M.F., Dzurova D., Gandarillas A., Gotsens M., Kovacs K., Mackenbach J., Martikainen P., Maynou L., Morrison J., Palencia L., Perez G., Pikhart H., Rodriguez-Sanz M., Santana P., Saurina C., Tarkiainen L., Borrell C., Social differences in avoidable mortality between small areas of 15 European cities: An ecological study. (2014) *INT J HEALTH GEOGR*, 13.

IF: 2.4470

Kulhanova I., Bacigalupe A., Eikemo T.A., Borrell C., Regidor E., Esnaola S., Mackenbach J.P., Why does Spain have smaller inequalities in mortality? An exploration of potential explanations. (2014) *EUR J PUBLIC HEALTH*, 24 (3), 370-377.

IF: 2.5910

Kulhanova I., Menvielle G., Bopp M., Borrell C., Deboosere P., Eikemo T.A., Hoffmann R., Leinsalu M., Martikainen P., Regidor E., Rodriguez-Sanz M., Rychtarikova J., Wojtyniak B., Mackenbach J.P., Socioeconomic differences in the use of ill-defined causes of death in 16 European countries. (2014) *BMC PUBLIC HEALTH*, 14 (1).

IF: 2.2640

Malmusi D., Drbohlav D., Dzurova D., Palencia L., Borrell C., Inequalities in healthcare access by type of visa in a context of restrictive health insurance policy: the case of Ukrainians in Czechia. (2014) *INT J PUBLIC HEALTH*, 59 (5), 715-719.

IF: 2.7010

Malmusi D., Ortiz-Barreda G., Health inequalities in immigrant populations in Spain. A scoping review. (2014) *REV ESP SALUD PUBLIC*, 88 (6), 687-701.

IF: 0.6930

Malmusi D., Vives A., Benach J., Borrell C., Gender inequalities in health: Exploring

the contribution of living conditions in the intersection of social class. (2014) *GLOBAL HEALTH ACTION*, 7 (1).

IF: 1.9300

Mari-Dell'Olmo M., Gotsens M., Borrell C., Martinez-Beneito M.A., Palencia L., Perez G., Cirera L., Daponte A., Dominguez-Berjon F., Esnaola S., Gandarillas A., Lorenzo P., Martos C., Nolasco A., Rodriguez-Sanz M., Trends in socioeconomic inequalities in ischemic heart disease mortality in small areas of nine Spanish cities from 1996 to 2007 using smoothed ANOVA. (2014) *J URBAN HEALTH*, 91 (1), 46-61.

IF: 1.9020

Mari-Dell'Olmo M., Martinez-Beneito M.A., Gotsens M., Palencia L., A smoothed ANOVA model for multivariate ecological regression. (2014) *STOCH ENV RES RISK A*, 28 (3), 695-706.

IF: 2.0860

Mehdipanah R., Rodriguez-Sanz M., Malmusi D., Muntaner C., Diez E., Bartoll X., Borrell C., The effects of an urban renewal project on health and health inequalities: A quasi-experimental study in Barcelona. (2014) *J EPIDEMIOL COMMUN H*, 68 (9), 811-817.

IF: 3.5010

Morrison J., Pons-Vigues M., Becares L., Burstrom B., Gandarillas A., Dominguez-Berjon F., Diez E., Costa G., Ruiz M., Pikhart H., Marinacci C., Hoffmann R., Santana P., Borrell C., Health inequalities in European cities: Perceptions and beliefs among local policymakers. (2014) *BMJ OPEN*, 4 (5).

IF: 2.2710

Palencia L., Espelt A., Cornejo-Ovalle M., Borrell C., Socioeconomic inequalities in the use of dental care services in Europe: What is the role of public coverage?. (2014) *COMMUNITY DENT ORAL*, 42 (2), 97-105.

IF: 2.0250

Palencia L., Malmusi D., De Moortel D., Artazcoz L., Backhans M., Vanroelen C., Bor-

rell C., The influence of gender equality policies on gender inequalities in health in Europe. (2014) *SOC SCI MED*, 117, 25-33.

IF: 2.8900

Perez G., Rodriguez-Sanz M., Cirera E., Perez K., Puigpinos R., Borrell C., Commentary: Approaches, strengths, and limitations of avoidable mortality. (2014) *J PUBLIC HEALTH POL*, 35 (2), 171-184.

IF: 1.7750

Pons-Vigues M., Diez E., Morrison J., Salas-Nicas S., Hoffmann R., Burstrom B., Van Dijk J.P., Borrell C., Social and health policies or interventions to tackle health inequalities in European cities: A scoping review. (2014) *BMC PUBLIC HEALTH*, 14 (1).

IF: 2.2640

Rius A., Artazcoz L., Guisasaola L., Benach J., Visual impairment and blindness in Spanish adults: Geographic inequalities are not explained by age or education. (2014) *OPHTHALMOLOGY*, 121 (1), 408-416.

IF: 6.1350

Rocha K.B., Muntaner C., Solar O., Borrell C., Bernales P., Gonzalez M.J., Ibanez C., Benach J., Vallebuona C., Social class, psychosocial occupational risk factors, and the association with self-rated health and mental health in Chile. (2014) *CAD SAUDE PUBLICA*, 30 (10), 2219-2234.

IF: 0.9760

Schembari A., Nieuwenhuijsen M.J., Salvador J., de Nazelle A., Cirach M., Dadvand P., Beelen R., Hoek G., Basagana X., Vrijheid M., Traffic-related air pollution and congenital anomalies in Barcelona. (2014) *ENVIRON HEALTH PERSP*, 122 (3), 317-323.

IF: 7.9770

Epidemiology of Addictions

Coordinator

M. Teresa Brugal
tbrugal@aspb.cat

ASPB

Members

Marina Bosque
Albert Espelt
Anna Guitart

ASPB

ASPB

ASPB



Main Lines of Research

Epidemiology of Drug Consumption and Patterns of Use

- ▶ Estimating cocaine use incidence and consumption patterns.
- ▶ Estimating heroin incidence and consumption patterns.
- ▶ Estimating the prevalence of problematic cocaine, heroin and alcohol users.

Health Problems Associated with Drug Use

- ▶ Quality of life and psychiatric comorbidity in cocaine users.
- ▶ Service use in cocaine and alcohol users.
- ▶ Factors associated with cocaine addict and alcoholic retention in treatment programmes.
- ▶ Violent behaviour and aggressive attitudes in young cocaine consumers.

- ▶ Mortality and its determinants in cohorts with substance abuse disorders (alcohol, heroin and cocaine).
- ▶ Factors associated with acute health problems developing after cocaine and heroin use.
- ▶ Social and health discrepancies between immigrants and native drug users.

Health Policies

- ▶ Social inequalities in the evaluation of results and adherence to treatment.
- ▶ Infectious diseases related to drug use.
- ▶ Brief motivational intervention programs as a treatment alternative for teenage users of psychoactive substances.
- ▶ Role of the workplace in drug consumption.

Challenges

Epidemiology of Drug Consumption and Patterns of Use

- ▶ Determine incidence and patterns of cocaine use.
- ▶ Determine incidence and patterns of heroin use.
- ▶ Determine prevalence of cocaine, heroin and alcohol use.

Health Problems Associated with Drug Use

- ▶ Analyse aggressive and violent attitudes and behaviour in young cocaine users.
- ▶ Assess quality of life in users with psychiatric comorbidity.
- ▶ Determine use of services among young heroin, cocaine and alcohol users.
- ▶ Analyse factors associated with retention in treatment programmes for cocaine and alcohol addiction.

- ▶ Assess mortality and its determinants in cohorts of alcohol and cocaine-dependent subjects.
- ▶ Analyse factors associated with acute health problems following cocaine use.
- ▶ Analyse differential social and health determinants among immigrant users of illegal drugs.

Health Policies

- ▶ Evaluate supervised drug consumption rooms and other policies to reduce harm.
- ▶ Study social inequalities in evaluating results and adherence to treatment.
- ▶ Evaluate brief motivational intervention programmes as an alternative to disciplinary measures in teenage users of psychoactive substances.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Evaluation of Public Health Policies and Programmes (PI: Carlos Ariza)
- ▶ Health Inequalities (PI: Carme Borrell)

External Collaborations

- ▶ Several CIBERSAM and CIBERESP groups.

*TIF: 22.3890 **MIF: 1.8658

Scientific Production

Bosque-Prous M., Espelt A., Guitart A.M., Bartroli M., Villalbi J.R., Brugal M.T., Response to Jernigan & Ross (2014): Alcohol advertising and hazardous drinkers. (2014) ADDICTION, 109 (10), 1645-1646.
IF: 4.7380

Chahua M., Sordo L., Barrio G., Domingo-Salvany A., Brugal M.T., Molist G., De la Fuente L., Bravo M.J., Non-fatal opioid overdose and major depression among street-recruited young heroin users and ITINERE project group. (2014) EUR ADDICT RES, 20 (1), 1-7.
IF: 2.1010

Chahua M., Sordo L., Molist G., Domingo-Salvany A., Brugal M.T., De la Fuente L., Bravo M.J., Barrio G., Espelt A., Ballesta R., Cas-tellano Y., Fernandez F., Lacasa D., Pulido J., Albert Sanchez-Niubo F.V.Y., Depression in young regular cocaine users recruited in the community. (2014) GAC SANIT, 28 (2), 155-159.
IF: 1.1860

de la Fuente L., Molist G., Espelt A., Barrio G., Guitart A., Bravo M.J., Brugal M.T., Babin F., Bartroli M., Castellano Y., Domingo-Salvany A., Hernandez T., Indave B., Mesias B., Puerta C., Santos S., Sarasa A., Sordo L., Mortality risk factors and excess mortality in a cohort of cocaine users admitted to drug treatment in Spain. (2014) J SUBST

ABUSE TREAT, 46 (2), 219-226.
IF: 1.9960

Espelt A., Viladrich C., Doval E., Aliaga J., Garcia-Rueda R., Tarrega S., Fair use of tests in health sciences. (2014) GAC SANIT, 28 (5), 408-410.
IF: 1.1860

Palencia L., Espelt A., Cornejo-Ovalle M., Borrell C., Socioeconomic inequalities in the use of dental care services in Europe: What is the role of public coverage?. (2014) COMMUNITY DENT ORAL, 42 (2), 97-105.
IF: 2.0250

Pulido J., Molist G., Domingo-Salvany A., Brugal M.T., Sanchez-Niubo A., Barrio G., de la Fuente L., Bravo M.J., Ambros M., Ballesta R., Bartroli M., Bilbao I., Castellano Y., Espelt A., Fermin Fernandez, Santos S., Sordo L., Vallejo F., Predictors of change in cocaine use in a street-recruited cohort of young cocaine users. (2014) ADDICTION, 109 (6), 954-964.
IF: 4.7380

Saigi N., Espelt A., Folch C., Sarasa-Renedo A., Castellano Y., Majo X., Merono M., Brugal M.T., Casabona J., Casabona J., Folch C., Esteve A., Montoliu A., Munoz R., Gonzalez V., Ausina V., Vecino C., Colom J., Altabas A., Differences in illegal drug consumption

between native and immigrants in a large sample of injected drug users in Catalonia (Spain). (2014) ADICCIONES, 26 (1), 69-76.
IF: 1.1540

Sarasa-Renedo A., Espelt A., Folch C., Vecino C., Majo X., Castellano Y., Casabona J., Brugal M.T., Overdose prevention in injecting opioid users: The role of substance abuse treatment and training programs. (2014) GAC SANIT, 28 (2), 146-154.
IF: 1.1860

Sarasa-Renedo A., Sordo L., Molist G., Hoyos J., Guitart A.M., Barrio G., Health and social harm related alcohol. (2014) REV ESP SALUD PUBLIC, 88 (4), 469-491.
IF: 0.6930

Suelves J.M., Villalbi J.R., Bosque-Prous M., Espelt A., Brugal M.T., Specialised treatment for alcohol abuse or dependence. (2014) REV ESP SALUD PUBLIC, 88 (4), 541-549.
IF: 0.6930

Villalbi J.R., Bosque-Prous M., Gili-Miner M., Espelt A., Brugal M.T., Policies to prevent the harm caused by alcohol. (2014) REV ESP SALUD PUBLIC, 88 (4), 515-528.
IF: 0.6930

Other Publications

- ▶ Garcia-Continente X., Perez-Gimenez A., Espelt A., Nebot Adell M., Factors associated with media use among adolescents: a multilevel approach. (2014) EUROPEAN JOURNAL OF PUBLIC HEALTH, 24 (1), 5-10.

Primary Care Research

Coordinator

Carles Brotons EAP Sardenya
cbrotons@eapsardenya.cat

Members

Berta Agustí EAP Sardenya
Enriqueta Balagué EAP Sardenya
Albert Casasa EAP Sardenya
Marta Coderch EAP Sardenya
Beatriz Delgado EAP Sardenya
Mariano de la Figuera EAP Sardenya
Marisa Galán EAP Sardenya
Rut Gallego EAP Sardenya
Begoña Ichazo EAP Sardenya
Mireia Martínez EAP Sardenya
Laia Menero EAP Sardenya
Rosa Monteserin EAP Sardenya
Irene Moral EAP Sardenya
Aser Muñoz EAP Sardenya
Carme Palasí EAP Sardenya
Maria Amor Peix EAP Sardenya
Mireia Puig EAP Sardenya
Elisabet Rayó EAP Sardenya
Carlen Reyes EAP Sardenya
Jaume Sellarès EAP Sardenya
Anna Soteras EAP Sardenya
Judith Vila EAP Sardenya



Main Lines of Research

- ▶ Cardiovascular prevention in primary care settings.
- ▶ Health promotion in primary care settings.
- ▶ Ageing.
- ▶ Hypertension.
- ▶ Diabetes.
- ▶ Paediatric immunization.

Challenges

- ▶ Enlarge the research team by linking up with other primary care centres associated with the ACEBA Family Medicine Teaching Unit.
- ▶ Cooperate with other research teams in IIB Sant Pau.
- ▶ Cooperate with other European institutions in implementing projects on risk prevention and health promotion in primary care settings.
- ▶ Encourage research into medical ethics in family medicine training.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Clinical Epidemiology and Health Care Services
- ▶ Evaluation of Public Health Policies and Programmes
- ▶ Ageing Institute

External Collaborations

- ▶ FATE project (fall detection in the elderly): Universitat Politècnica de Catalunya, Sistema d'Emergències Mèdiques, TicSalut. Project number: 297178, European Commission, ICT-PSP. Duration: 2011-2015.

Grants Awarded in 2014

- ▶ Carles Brotons Cuixart. Desarrollo de una ecuación de riesgo cardiovascular de por vida en población laboral. Proyectos de Investigación en Salud 2014. PI14/01177. €45,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 47.6790 **MIF: 3.6676

Scientific Production

Brotos C., Calvo-Bonacho E., Moral I., Garcia-Margallo M.T., Cortes-Arcas M.V., Puig M., Vazquez-Pirillo G., Ruilope L.M., Impact of the New American and British guidelines on the management and treatment of dyslipidemia in a Spanish working population. (2014) REV ESP CARDIOL, 67 (11), 906-911.

IF: 3.7920

Brotos C., EUROPREV (European Network for Prevention and Health Promotion). (2014) ATEN PRIM, 46 (SUPPL. 4), 2.

IF: 0.9530

Brotos C., Moral I., Soriano N., Cuixart L., Osorio D., Bottaro D., Puig M., Joaniquet X., Marcos A., Casasa A., Impact of using different score tables for estimating cardiovascular risk. (2014) REV ESP CARDIOL, 67 (2), 94-100.

IF: 3.7920

Castellano J.M., Sanz G., Penalvo J.L., Bansilal S., Fernandez-Ortiz A., Alvarez L., Guzman L., Linares J.C., Garcia F., D'Aniello F., Arnaiz J.A., Varea S., Martinez F., Lorenzatti A., Imaz I., Sanchez-Gomez L.M., Roncaglioni M.C., Baviera M., Smith S.C., Taubert K., Pocock S., Brotos C., Farko M.E., Fuster V., A polypill strategy to improve adherence. (2014) J AM COLL CARDIOL, 64 (20), 2071-2082.

IF: 16.5030

Gabriel R., Brotos C., Tormo M.J., Segura A., Rigo, Elosua R. et al. on behalf of the ERICE Study Group. La ecuación ERICE: primera ecuación autóctona de riesgo cardiovascular para una población mediterránea envejecida y de bajo riesgo em España. (2014) REV ESP CARDIOL, 68, 205-215.

IF: 3.7920

Galan A.M., Cuixart C.B., Alvarez F.V., Rioboo E.M., Banegas J.R.B., Perez J.N., Sanchez J.J.A., Lobos-Bejarano J.M., Sanchez-Pinilla R.O., Orozco-Beltran D., Guillen V.G., Recommendations on prevention of cardiovascular disease. (2014) ATEN PRIM, 46 (SUPPL. 4), 3-15.

IF: 0.9530

Lobos Bejarano J.M., Galve E., Royo-Bordonada M.A., Alegria Ezquerra E., Armario P., Brotos Cuixart C., Camafort Babkowski M., Cordero Fort A., Maiques Galan A., Mantilla Morato T., Perez Perez A., Pedro-Botet J., Villar Alvarez F., Gonzalez-Juanatey J.R., Spanish interdisciplinary committee for cardiovascular disease prevention and the Spanish society of cardiology position statement on dyslipidemia management. Differences between the European and American guidelines. (2014) REV ESP CARDIOL, 67 (11), 913-919.

IF: 3.7920

Marquez-Contreras E., Gil-Guillen V.F., De La Figuera-Von Wichmann M., Franch-Nadal J., Llisterri-Caro J.L., Martell-Claros N., Martin-De Pablos J.L., Casado-Martinez J.J., Bertomeu-Gonzalez V., Pertusa Martinez S., Caratala-Munuera C., Orozco-Beltran D., Lopez-Pineda A., Non-compliance and inertia in hypertensive Spaniards at high cardiovascular risk: CUMPLE study. (2014) CURR MED RES OPIN, 30 (1), 11-17.

IF: 2.6530

Monteserin R., Roberts H.C., Sayer A.A., Role of primary care professionals in the management of sarcopenia. (2014) ATEN PRIM, 46 (9), 455-456.

IF: 0.9530

Mortsiefer A., Ludt S., Pentzek M., Wilm S., Brotos C., Patients' needs and expectations concerning prevention and health advice in primary carer results from the EUROPREVIEW survey. (2014) GESUNDHEITSWESEN, 76 (7), 417-422.

IF: 0.7410

Reyes C., Estrada P., Nogues X., Orozco P., Cooper C., Diez-Perez A., Formiga F., Maclas J.G., Prieto-Alhambra D., The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: A population-based cohort study. (2014) OSTEOPOROSIS INT, 25 (6), 1751-1758.

IF: 4.1690

Reyes C., Estrada P., Nogues X., Orozco P., Cooper C., Diez-Perez A., Formiga F., Gonzalez-Macias J., Prieto-Alhambra D., Erratum to: The impact of common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly men: A population-based cohort study (Osteoporosis International DOI: 10.1007/s00198-014-2682-9). (2014) OSTEOPOROSIS INT, 25 (9), 2333.

IF: 4.1690

Royo-Bordonada M.A., Lobos J.M., Brotos C., Villar F., De Pablo C., Armario P., Cortes O., Gil Nunez A., Lizcano A., De Santiago A., Sans S., The condition of the cardiovascular prevention in Spain. (2014) MED CLIN-BARCELONA, 142 (1), 7-14.

IF: 1.4170

Other Publications

▶ Lobos Bejarano J.M., Galve E., Royo-Bordonada M.A., Alegria Ezquerra E., Armario P., Brotos Cuixart C., Camafort Babkowski M., Cordero Fort A., Maiques Galan A., Mantilla Morato T., Perez Perez A., Botet J.P., Villar Alvarez F., Ramon Gonzalez-Juanatey J., Spanish interdisciplinary committee for cardiovascular disease prevention and the Spanish society of cardiology position statement on dyslipidemia management. Differences between the

European and American guidelines. (2014) PEDIATRIA DE ATENCION PRIMARIA, 16 (64), e161-e172.

▶ Vinyoles E., De La Figuera M., Ferre J., Differential characteristics of the approach to hypertension in the elderly. (2014) FMC FORMACION MEDICA CONTINUADA EN ATENCION PRIMARIA, 21 (1), 38-45.

AREA T2

Molecular, Genomic Kinetic-Dynamic Bases and their Treatment

222 Genomics of Complex Diseases

224 Molecular Bases of Disease

226 Pharmacokinetic/Pharmacodynamic Modelling and Simulation

228 Generation of Advanced Therapy Medicines

ic, Cellular and ases for Diseases nt



Genomics of Complex Diseases

Coordinator

José Manuel Soria HSCSP RI
jsoria@santpau.cat

Members

Helena Brunel HSCSP RI
Sonia López HSCSP RI
Laura Martín HSCSP RI
Ángel Martínez HSCSP RI
Andrey Ziyatdinov HSCSP RI



Main Lines of Research

Genetic Epidemiology and Bioinformatics

- ▶ Algorithms to risk assessment.

Genomics of Complex Diseases

- ▶ Genetic analysis of idiopathic thrombophilia (GAIT).
- ▶ Genetic analysis of osteoporosis (GAO).
- ▶ Genetics of chronic venous insufficiency.
- ▶ Genetics of abdominal aortic aneurysms (TAGA).

- ▶ Modelling Individuals Risk of Thrombosis in Oncology (MIRTO, ONCOTHROMB).

Epigenomics

- ▶ miRNAs as a novel biomarkers in Thromboembolic diseases.

Pharmacogenomics

- ▶ Markers of genetic susceptibility and pharmacogenomics of cardiovascular diseases.

Challenges

- ▶ Consolidate the epigenomic, genetic epidemiology and bioinformatics research lines.
- ▶ Increase human and material resources to achieve the goals defined for different
- ▶ Projects in which we are involved.

- ▶ Coordinate an international cardiovascular genomic project.
- ▶ Continue the agreements with biopharmaceutical companies.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Thrombosis and Haemostasis: Projects: GAIT, MIRTO, RETROVE.
- ▶ Multiorgan Damage – Internal Medicine: Project GAO.
- ▶ Angiology, Vascular Biology and Inflammation: Projects TAGA and GAIT.
- ▶ Inflammation an Vascular Remodelling: Project TAGA.
- ▶ Metabolic Bases of Cardiovascular Risk: Project GAIT.
- ▶ Haematological Diagnosis: Project GAIT.

External Collaborations

- ▶ Clinical Oncology Department, Hospital Gregorio Marañón, Madrid. Project Oncothomb.
- ▶ Centre de Recerca en Enginyeria Biomèdica, Universitat Politècnica de Catalunya, Barcelona. Project SUMMIT.
- ▶ Laboratory Haematolgy, Hospital Timone Marseille, France. Project GAIT.
- ▶ Department of Genetic, University of Genève, Switzerland. Project GAIT.
- ▶ Department of Cardiology, Karolinska Institut, Sweden. Project GAIT.
- ▶ INSERN UMRS 937, Université Pierre et Marie Curie, Paris. Project GAIT.
- ▶ Haematology Department, Karolinska Hospital, Sweden. Project VEREMA.

Active Grants

- ▶ José Manuel Soria Fernández. Ajuts de suport als Grups de Recerca de Catalunya. Grup Genòmica i bioinformàtica de malalties de base genètica complexa. AGAUR 2009. SGR 1240. Duration: 17/09/09-30/04/14. €41,600.
 - ▶ José Manuel Soria Fernández. Identificación de los determinantes genéticos de la vía intrínseca de la coagulación y su implicación en enfermedad tromboembólica. MINECO-ISCIII Project 2011. PI11/00184. Duration: 01/01/12-31/12/14. €236,955.
 - ▶ Georgios Athanasiadis. Contratos Juan de la Cierva 2010. MICINN. JCI-2010-07202. Duration: 03/01/11-02/01/14. €100,980.
 - ▶ Laura Martín Fernández. Contrato FIS Pre-Doc Formación. MINECO-ISCIII Contracte Predoc formació 2012. FI12/00322. Duration: 26/09/12-25/09/16. €85,200.
 - ▶ José Manuel Soria. Redes Temáticas de Investigación Cooperativa (RETIC) 2009, Innovación en Tecnologías Médicas y sanitarias. ITEMAS. Instituto de Salud Carlos III – FIS. Duration: 01/01/10-31/12/14.*
- * Grants applied for by other research institutes.
Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ José Manuel Soria Fernández. Identificación de Mecanismos de Regulación de la Expresión Génica (microRNAs) en la Enfermedad Tromboembólica Venosa. Proyectos de Investigación en Salud 2014. PI14/00582. €111,500.
 - ▶ José Manuel Soria Fernández. Global Omics Linked to an Integral Action on Thrombosis. Acciones de Dinamización Europea Investigación 2014. EUI2013-50833. Duration: 18/09/14-31/03/15. €18,000.
- Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 23.0560 **MIF: 3.8427

Scientific Production

- Athanasiadis G., Malouf J., Hernandez-Sosa N., Martin-Fernandez L., Catalan M., Casademont J., Soria J.M., Linkage and association analyses using families identified a locus affecting an osteoporosis-related trait. (2014) BONE, 60, 98-103.
IF: 3.9730
- Hernandez-de Sosa N., Athanasiadis G., Malouf J., Laiz A., Marin A., Herrera S., Farrerons J., Soria J.M., Casademont J. Heritability of bone mineral density in a multivariate family-based study. (2014). CALCIF TISSUE INT, 94(6).
IF: 3.2720
- Lopez S., Buil A., Souto J.C., Casademont J., Martinez-Perez A., Almasy L., Soria J.M., A genome-wide association study in the genetic analysis of idiopathic thrombophilia project suggests sex-specific regulation of mitochondrial DNA levels. (2014) MITOCHONDRION, 18 (1), 34-40.
IF: 3.2490
- Soria J.M., Morange P.E., Vila J., Souto J.C., Moyano M., Trégouët D.A., Mateo J., Saut N., Salas E., Elosua R. Multilocus genetic risk scores for venous thromboembolism risk assessment. (2014). J AM HEART ASSOC, 23;3(5).
IF: 4.3060
- Sosa N.H.-D., Athanasiadis G., Malouf J., Laiz A., Marin A., Herrera S., Farrerons J., Soria J.M., Casademont J., Heritability of bone mineral density in a multivariate family-based study. (2014) CALCIFIED TISSUE INT, 94 (6), 590-596.
IF: 3.2720
- Souto J.C., Pena G., Ziyatdinov A., Buil A., Lopez S., Fontcuberta J., Soria J.M., A genomewide study of body mass index and its genetic correlation with thromboembolic risk. Results from the GAIT project. (2014) THROMB HAEMOSTASIS, 112 (5), 1036-1043.
IF: 4.9840


Molecular Bases of Disease

Coordinator

Pablo Fuentes-Prior HSCSP RI
pfuentes@santpau.cat

Members

Rosa Anton HSCSP RI
Jonatan Dorca HSCSP RI



Main Lines of Research

Thrombosis and Haemostasis

- ▶ Structural and functional investigations of blood coagulation factors, with emphasis on thrombin generation by the prothrombinase complex and on thrombin interactions with both physiological substrates (factor V, factor VIII and protease-activated receptors) and with exogenous inhibitors from haematophagous animals (e.g. anophelin from *Anopheles* mosquitoes).

Lipid Metabolism and Dyslipidemias

- ▶ Structural and functional analysis of mutant apoA-V proteins identified in individuals with hypertriglyceridaemia.

Neurodegenerative Diseases

- ▶ Analysis of mutations that affect the SMN genes, whose deficiency results in spinal muscular atrophy.
- ▶ Structural and functional investigations of proteins associated with inherited forms of Parkinson disease (PINK1, DJ-1 and Parkin).

Cancer and Innate Immune Responses

- ▶ Structural and functional analysis of innate immune responses mediated by toll-like receptors (TLRs) and, in particular, the role of the major adaptor MyD88.
- ▶ Analysis of mutations and SNPs that affect the TET2 gene and implications for acute myeloid leukaemia.
- ▶ Structural and functional analysis of the microsomal prostaglandin E synthase (mPGES-1) as a target for the generation of novel anti-inflammatory drugs with fewer side effects.

Challenges

- ▶ Consolidate and extend research within the HSCSP Research Institute and the rest of the IIB Sant Pau in a context of limited access to financial support. To this end, the group needs to participate in at least one financed structure-and-function project in each of three major research areas (cardiovascular diseases, neurodegenerative diseases and cancer and innate immune responses).

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Metabolic Bases of Cardiovascular Risk
- ▶ Parkinson Disease and Movement Disorders
- ▶ Haematological Diagnosis
- ▶ Genetic Diseases
- ▶ Angiology, Vascular Biology and Inflammation

External Collaborations

- ▶ Dr. Pereira. Institute of Molecular and Cellular Biology, Porto, Portugal.
- ▶ Dr. Paul E. Bock. Vanderbilt University, Nashville, Tennessee, USA.
- ▶ Dr. Ricardo Gutiérrez-Gallego. IMIM-UPF, Barcelona, Spain.

Active Grants

- ▶ SAF2010-15668. Pablo Fuentes Prior. Bases estructurales de la generación, actividad e inhibición de la trombina. Duration: 01/01/11-31/12/14. Ministerio de Economía y Competitividad. SAF2010-15668. €110,000.

Note: Total amount granted to PI. It does not include indirect costs.

Pharmacokinetic/Pharmacodynamic Modelling and Simulation

Coordinator

Marta Valle HSCSP RI
mvallec@santpau.cat

Members

Javier Estévez HSCSP RI



Main Lines of Research

- ▶ Populational pharmacokinetic analysis aimed at establishing the pharmacokinetic characteristics of drugs and at differentiating and quantifying the degree of intra- and inter-variability.
- ▶ Continuous response analysis aimed at the analysis of effects (in the presence or absence of drugs) where the variable being evaluated changes values gradually.
- ▶ Non-continuous response analysis for responses most frequently observed in clinical practice, such as categorical responses, survival, frequency and censored responses.
- ▶ Simulation of clinical trials and therapy applications aimed at assisting with the design of clinical trials to help the development new drugs (for pharmaceutical companies) and at improving the design of clinical trials (basic research and non-profit clinical studies) and to help in applications of therapeutic monitoring.

Challenges

- ▶ Obtain recognition as an emerging group.
- ▶ Maintain existing external cooperation agreements.
- ▶ Establish new cooperation agreements within the HSCSP RI.
- ▶ Generate sufficient financial resources to maintain and expand group staffing.
- ▶ Communicate the group's activities.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Human Neuropsychopharmacology.
- ▶ Pharmacological Research in Humans.
- ▶ Pharmacy.
- ▶ HIV and AIDS.
- ▶ Epidemiology and Traumatology Services.

External Collaborations

- ▶ Lluita Contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain.
- ▶ Pharmacy Service, Hospital Quiron, Mallorca, Spain.
- ▶ Department of Pharmacology, Liverpool University, UK.
- ▶ Anaesthesiology Service, Hospital del Mar, Barcelona, Spain.

Active
Grants

- ▶ Marta Valle Cano. Contracte Programa d'Estabilització i Intensificació. Departament de Salut - Sistema Nacional de Salut. CES10/010. Duration: 01/01/11-31/12/15. €260,740.

Note: Total amount granted to PI. It does not include indirect costs.

Doctoral
Theses

- ▶ Maria Rita Moreira da Silva. Anàlisi farmacocinètic poblacional de vancomicina en neonatos: disseny de una nova estratègia de dosificació. Universitat Autònoma de Barcelona. Directors: Maria Antònia Mangues, Marta Valle. Date of defense: 16 December 2014.

*TIF: 5.3130 **MIF: 5.3130

Scientific
Production

Molto J., Valle M., Ferrer E., Domingo P., Curran A., Santos J.R., Mateo M.G., Di Yacovo M.S., Miranda C., Podzamczar D., Clotet B., Coll J., Gel S., Llibre J.M., Mothe B., Negro E., Perez-Alvarez N., Sirera G., Rozas N., Vila A., Del Mar Gutierrez M., Mateo G., Burgos J., Navarro J., Ribera E., Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: A randomized clinical trial. (2014) J ANTIMICROB CHEMOTH, 70 (4), 1139-1145.
IF: 5.3130

Generation of Advanced Therapy Medicines

Coordinator

Joan Garcia BST
joangarcia@bst.cat

Members

Marta Caminal BST
Margarita Codinach BST
Ruth Coll BST
Irene Oliver BST
Arnau Pla BST
Noèlia Pujals BST
Luciano Rodríguez BST
Joaquim Vives BST



Main Lines of Research

- ▶ Bioprocessing for cell and tissue production.
- ▶ Regeneration of locomotor systems.
- ▶ Stem cell therapy for the lymphohaematopoietic system.
- ▶ Stem cell therapy for multiple sclerosis.

Challenges

- ▶ Create a section within the Blood and Tissue Bank (BST) with the structure of a pharmaceutical enterprise, capable of developing, trialling, registering and commercializing advanced therapeutic drugs.

Collaborations

- ▶ Enric Cáceres Palou, Hospital Vall d'Hebron, Joan Garcia Lopez, BST (PIs), Prospective randomized clinical trial comparing spinal fusion in patients with degenerative pathology of the lumbar spine, using autologous mesenchymal stem cells immobilized in human bone particles versus autologous iliac crest bone graft from the patient, EC10-209, Spanish Ministry of Health, Social Services and Equality, 2012-2014. One of the recruiting sites is HSCSP (Dr. del Arco).
- ▶ Màrius Aguirre Canyadell (PI, Hospital Vall d'Hebron), Joaquim Vives Armengol,

Marta Caminal Bobet (BST). Estudi experimental de teràpia cel·lular amb cèl·lules mare adultes expandides "ex vivo" immobilitzades en matriu òssia en el tractament de defectes ossis segmentaris. Instituto de Salud Carlos III. PI11/02231. Duration: 2012-2014.

- ▶ Màrius Aguirre Canyadell (PI, Hospital Vall d'Hebron), Arnau Pla Calvet (BST). Tractament de l'osteonecrosi del cap femoral amb teràpia cel·lular avançada i biomaterials en un model experimental oví. Fundació la Marató de TV3. 61/C/2012. Duration: 2013-2015.

Doctoral Theses

- ▶ Marta Caminal-Bobet. Tissue engineering for bone regeneration: in vitro development and in vivo testing in sheep. Directors: Joaquim Vives, Francesc Gòdia. Universitat Autònoma de Barcelona. Date of defense: 3 December 2014.

Active Grants

- ▶ Joan Garcia López. REDONTAP-Continuous Proliferation & Simultaneous Maturation of Haematopoietic Stem Cells into Blood Cell Lineages. Entitat finaçadora: European Commission. 229328. Duration: 2010-2014.*
- ▶ Joan Garcia López. Os injectable combinant hidrogels d'última generació i productes al·logènics bioactius per al tractament de fractures. Ministerio de Economía y Competitividad. IPT-2012-0745-300000. Duration: 2013-2015.*
- ▶ Joan Garcia López. Incorporació a la xarxa TERCEL (Teràpia Cel·lular) de la RETICS. Instituto de Salud Carlos III. RD12/0019/0015. Duration: 2013-2016.*

* Grants applied for by other research institutes.

*TIF: 6.2410 **MIF: 2.0803

Scientific Production

Caminal M., Fonseca C., Peris D., Moll X., Rabanal R.M., Barrachina J., Codina D., Garcia F., Cairo J.J., Godia F., Pla A., Vives J., Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in sheep. (2014) NEW BIOTECHNOL, 31 (5), 492-498.

F: 2.8980

Caminal M., Moll X., Codina D., Rabanal R.M., Morist A., Barrachina J., Garcia F., Pla A., Vives

J., Transitory improvement of articular cartilage characteristics after implantation of poly(lactide:Polyglycolic acid (PLGA) scaffolds seeded with autologous mesenchymal stromal cells in a sheep model of critical-sized chondral defect. (2014) BIOTECHNOL LETT, 36 (10), 2143-2153.

IF: 1.5910

Fonseca C., Caminal M., Peris D., Barrachina J., Fabregas P.J., Garcia F., Cairo J.J., Pla A., Vives J., An arthroscopic approach for

the treatment of osteochondral focal defects with cell-free and cell-loaded PLGA scaffolds in sheep. (2014) CYTOTECHNOLOGY, 66 (2), 345-354.

IF: 1.7520

Associated Groups

232 Emerging Processes in Prevalent Diseases

236 Radiophysics and Radioprotection

238 Paediatrics

240 Ophthalmology

242 Nuclear Medicine

244 Intensive Medicine


248 Pharmacy

250 Dermatology

254 Anaesthesiology

258 Plastic Surgery

260 Palliative Care



262 Andrology

264 Urology

268 Radiation Oncology

270 Locomotor System Research

272 Multiple Sclerosis and Epilepsy Research

274 Pain and Neurosciences

276 Nursing Care Research

278 Reproductive Health

280 Translational Molecular Oncology

282 Cardiac Surgery

Emerging Processes in Prevalent Diseases

Coordinator

Salvador Benito HSCSP
sbenito@santpau.cat

Members

Iván Agra HSCSP
Aitor Alquézar HSCSP
Maite Álvarez HSCSP
Miquel Barcons HSCSP
Marta Blázquez HSCSP
Francisco Caballero HSCSP
Noemí Cerdán HSCSP
Andrés Ceresuela HSCSP
Iván Díaz HSCSP
Verónica Díez HSCSP
José M. Guardiola HSCSP
Héctor Hernández HSCSP
Sergio Herrera HSCSP
Leopoldo Higa HSCSP
Laura Lozano HSCSP
Miriám Mateo HSCSP
Albert Mauri HSCSP
Josep A. Montiel HSCSP
Rosa Moreno HSCSP
Mireia Puig HSCSP
Josep Ris HSCSP
Miguel Santaló HSCSP
Sonia Serradell HSCSP
Olga Trejo HSCSP
Miquel Turbau HSCSP
Esther Vendrell HSCSP



Main Lines of Research

Emerging Processes in Prevalent Diseases

- ▶ Study and analysis of processes frequently observed in emergency departments so as to transfer the results to clinical practice and provide better care to patients.

Clinical Organization and Management (Mireia Puig and Josep Ris)

- ▶ Patient safety and emergency service quality. PI: Maite Álvarez.
- ▶ Nosocomial infection. PI: Albert Mauri.
- ▶ Short-stay unit. PI: JM Guargiola.

Organ Donation and Coordination (Francisco Caballero and Jesús Leal)

Respiratory System Disorders (Salvador Benito)

- ▶ Respiratory pattern analysis in the return to spontaneous breathing. PI: Ivan Díaz.
- ▶ Ventilatory pattern analysis in heart failure. PI: Sergio Herrera.
- ▶ Pneumonia in the emergency department. PI: Miriam Mateo.
- ▶ Noninvasive ventilation. PI: Miquel Turbau.
- ▶ Pulmonary embolism. PI: Laura Lozano.

Cardiovascular System (Miquel Santaló)

- ▶ Acute coronary syndrome in elderly patients. PI: Josep Antoni Montiel.
- ▶ Acute coronary syndrome in women. PI: Marta Blázquez.
- ▶ Ultrasensitive markers in acute coronary syndrome. PI: Leopoldo Higa.
- ▶ Complications in patients implanted with an ICD. PI: Olga Trejo.
- ▶ Cardiac failure. PI: Aitor Alquézar, M. Rizzi.
- ▶ Supraventricular arrhythmias. PI: Aitor Alquézar.

Community Disorders

- ▶ Diabetes care in emergency departments. PI: Iván Agra.
- ▶ Infection in emergency departments. PI: José M. Guardiola.
- ▶ Drug abuse and HIV
- ▶ HCV in patients with HIV. PI: José M. Guardiola.
- ▶ Acute intoxication. PI: Héctor Hernández.

Collaborations

- ▶ Programa ACCORD (Achieving Comprehensive Coordination on Organ Donation throughout the European Union). Prácticas clínicas la final de la vida en pacientes fallecidos con daño cerebral catastrófico y donación de órganos – Accord España. Organización Nacional de Trasplantes and Comisión de Trasplantes del Consejo Interterritorial de Salud.

Doctoral Theses

- ▶ Aitor Alquezar Arbé. Troponina T d'elevada sensibilitat per a l'exclusió precoç de l'infart agut de miocardi sense elevació del segment st. Universitat Autònoma de Barcelona. Directors: Salvador Benito, Miquel Santaló. Date of defense: 23 May 2014.

Awards

- ▶ Guardiola Tey J, Vilanova Rotllant S, Gali Juan M, Güell Espigol L, Mauri Plana A, Montiel Dacosta J, Puig Capmany M. Cultivo Positivo (CP) en Urgencias como factor predictivo independiente asociado a un ingreso de mayor duración en la UEC. Premio a las mejores comunicaciones en enfermedades infecciosas. Congreso SEMES 2014. Málaga, June 2014.

*TIF: 66.1990 **MIF: 3.3100

Scientific Production

Alquezar A., Martin-Sanchez F.J., Carbajosa V., Llorens P., Herrero P., Jacob J., Perez-Dura M.J., Alonso H., Torres Murillo J.M., Garrido M., Lopez-Grima M.L., Pinera P., Epelde F., Alquezar A., Fernandez C., Miro O., Prolonged hospitalization in patients admitted for acute heart failure in the short stay unit (EPICA-UCE study): Study of associated factors. (2014) MED CLIN-BARCELONA, 143 (6), 245-251.

IF: 1.4170

Alquezar Arbe, A., Rodriguez, S., Martinez, D., Gonzalez-Martin, J. Space occupying lesions in the liver and spleen in a 41-year-old man. (2014) MED CLIN, 142 (1), 33-39.

IF: 1.4170

Alquezar-Arbe A., Rizzi M., Alvarez-Albaran M., Coloma-Conde A., Usefulness of the measurement of lactic acid in cerebrospinal fluid. (2014) ENFERM INFECC MICR CL, 32 (9), 620.

IF: 2.1720

Berenguer J., Zamora F.X., Carrero A., Von Wichmann M.A., Crespo M., Lopez-Aldeguer J., Aldamiz-Echevarria T., Montes M., Querada C., Tellez M.J., Galindo M.J., Sanz J., Santos I., Guardiola J.M., Esteban H., Bellon J.M., Gonzalez-Garcia J., Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. (2014) JAIDS-J ACQ IMM DEF, 66 (3), 280-287.

IF: 4.5560

Botto F., et al. Myocardial Injury after Non-cardiac Surgery: A Large, International, Prospective Cohort Study Establishing Diagnostic Criteria, Characteristics, Predictors, and 30-day Outcomes. (2014) ANESTHESIOLOGY, 120 (3), 564-578.

IF: 5.8790

Cabre E., Manosa M., Garcia-Sanchez V., Gutierrez A., Ricart E., Esteve M., Guardiola J., Aguas M., Merino O., Ponferrada A., Gisbert J.P., Garcia-Planella E., Cena G., Cabriada J.L., Montoro M., Domenech E., Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nation-

wide IBD Spanish database. (2014) J CROHNS COLITIS, 8 (7), 654-661.

IF: 6.2340

Curran A., Monteiro P., Domingo P., Villar J., Imaz A., Martinez E., Fernandez I., Knobel H., Podzanczer D., Iribarren J.A., Penaranda M., Crespo M., Ribera E., Navarro J., Vall d'Hebron H., Clinic H., Sant Pau H., del Mar H., Bellvitge H., Iburguren M., Donosti H., Penaranda M., Riera M., Son Espases H., Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: Same results as in clinical trials? The PIMOCES study group. (2014) J ANTIMICROB CHEMOTH, 69 (5), 1390-1396.

IF: 5.3130

Esteban A., Benito S., Frutos-Vivar F., Sometimes, 20 years are many.... (2014) INTENS CARE MED, 40 (10), 1607-1608.

IF: 7.2140

Genebat M., Vera F., Hernandez-Quero J., Domingo P., Guardiola J.M., Martinez-Madrid O., Martinez L., De La Llana F.G., Sanchez-Villegas J., Alvarez H., Marino A., Lluch J.F., Martinez-Perez M.A., Marin J., Ruiz-Mateos E., Leal M., Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfecting subjects. (2014) ANTIVIR RES, 104 (1), 59-61.

IF: 3.9380

Llao J., Naves J.E., Ruiz-Cerulla A., Marin L., Manosa M., Rodriguez-Alonso L., Cabre E., Garcia-Planella E., Guardiola J., Domenech E., Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. (2014) J CROHNS COLITIS, 8 (11), 1523-1528.

IF: 6.2340

Llopis Roca F., Gonzalez-Castillo J., Julian-Jimenez A., Ferre C., Gamazo-Rio J.J., Martinez M., Pinera P., Guardiola J.M., Diez V., Chanovas M., Ruiz M., Candel F.J., Garcia-Lamberechts E.J., Martin F.J., Ibero C., Moya M., Diaz E., Gonzalez F., de Castro C.H., Soriano T., Navarro S., Alvarez A., Marchena P., Quintela Z., Urdanoz C., Velilla

N., Sada M., Mozota J., Lecinena M.A., Diaz E., Capdepon C., Perales R., Sanchez J., Suero C., Salmeron O., del Arco C., Valle B., Onate J., Ortega M., Fernandez M., Huarte I., Masie A.J., Andonegui C., Yague R., Carrion D., Sarra S., Flores S., Boque C., Rodriguez D., Saiz C., Lapuerta L., Antequera M.J., Rivas M.C., Garcia J., Arevalo A., Lopez R., Carazo A.I., Martinez S., Avellaneda C., Review of 1.250 episodes of skin and soft tissue infections attended at 49 hospital emergency departments. (2014) REV ESP QUIM, 27 (2), 115-121.

IF: 0.7970

Llopis Roca F., Juan Pastor A., Ferre Losa C., Martin Sanchez F.J., Llorens Soriano P., Sempere Montes G., et al. Proyecto REGICE: Registro de las unidades de corta estancia en España. Localización, aspectos estructurales y dotación de profesionales (REGICE 1). (2014) EMERGENCIAS, 26: 57-60.

IF: 2.8950

Llopis F., Ferre C., Juan A., Martina F., Sempere G., Llorens P., Navarro C., Martínez M. Proyecto REGICE. Gestión clínica de las unidades de corta estancia en España. (REGICE 2). (2014) EMERGENCIAS (26) 5; 359-62.

IF: 2.8950

Martí, V., Seixo, F., Santalo, M., Serra, A. Antiphospholipid syndrome and acute myocardial infarction: Treatment with thrombectomy and abciximab. (2014) REVISTA PORTUGUESA DE CARDIOLOGIA, 33 (7-8), 465.e1-465.e4.

IF: 0.5250

Martin-Sanchez F.J., Carbajosa V., Llorens P., Herrero P., Jacob J., Pérez-Dura M.J., Alonso H., Torres Murillo J.M., Garrido M., Lopez-Grima M.L., Piñera P., Epelde F., Alquezar A., Fernandez C., Miró O.; on behalf of ICA-SEMES group. Estancia prolongada en pacientes ingresados por insuficiencia cardíaca aguda en la Unidad de Corta Estancia (estudio EPICA-UCE): factores asociados. (2014) MED CLIN (BARC). 15;143 (6): 245-51.

IF: 1.4170

Emerging Processes in Prevalent Diseases

*TIF: 66.1990 **MIF: 3.3100

Scientific Production

Naves J.E., Llao J., Ruiz-Cerulla A., Romero C., Manosa M., Lobaton T., Cabre E., Garcia-Planella E., Guardiola J., Domenech E., Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. (2014) *INFLAMM BOWEL DIS*, 20 (8), 1375-1381.

IF: 4.4640

Puig M., Caballero F., Ris J., Leal J., Why should we consider organ donation in emergencies? The patient's right to be a donor. (2014) *EMERGENCIAS*, 26 (6), 493.

IF: 2.8950

Ramos J.M., Rodriguez-Valero N., Tisiano G., Fano H., Yohannes T., Gosa A., Fruttero E., Reyes F., Gorgolas M., Different profile of intestinal protozoa and helminthic infec-

tions among patients with diarrhoea according to age attending a rural hospital in southern Ethiopia. (2014) *TROP BIOMED*, 31 (2), 392-397.

IF: 0.8500

Real L.M., Neukam K., Herrero R., Guardiola J.M., Reiberger T., Rivero-Juarez A., Salazar J., Mandorfer M., Merino D., Soriano V., Rivero A., Macias J., Pineda J.A., Caruz A., IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians. (2014) *PLOS ONE*, 9 (4).

IF: 3.2340

San-Jose A., Agusti A., Vidal X., Barbe J., Torres O.H., Ramirez-Duque N., Garcia J., Fernandez-Moyano A., Lopez-Soto A., For-

miga F., Aguilera C., Ballarin E., Perez E., Bocanegra C.P., Toscano A., Pal C., Teixidor T., Hernandez M.G., De la Rosa Morales R., Martinez M.N.B., Bosch X., Palau M., Rovira J., Navarro M., Chivite D., Roson B., Vallano A., Cabot C., Ballesteros I., Ruiz D., Turbau M., Ponte P., Ortiz G., Cobas P.-C.R., Gil P., An inter-rater reliability study of the prescribing indicated medications quality indicators of the Assessing Care Of Vulnerable Elders (ACOVE) 3 criteria as a potentially inappropriate prescribing tool. (2014) *ARCH GERONTOL GERIAT*, 58 (3), 460-464.

IF: 1.8530

Other Publications

▶ Giraldo B.F., Calvo A., Martinez B., Arcenales A., Jane R., Benito S., Blood pressure variability analysis in supine and sitting position of healthy subjects. (2014) *IF-MBE PROCEEDINGS*, 41, 1021-1024.

▶ Penacoba Toribio P., Corica Albani M.E., Mayos Perez M., Rodriguez de la Serna A., Rituximab in the treatment of shrinking lung syndrome in systemic lupus erythematosus. (2014) *REUMATOLOGIA CLINICA*, 10 (5), 325-327.

▶ Santaló Bel M., Alquézar Arbé A., Sionis A. Marcadores bioquímicos en el Síndrome

Coronario Agudo. In: *El laboratorio en la patología cardiovascular*. Bayés A., Santaló M., Ordoñez J. Barcelona: Roche; 2014. p 47-86.

▶ Téllez J.P., Herrera S., Benito S., Giraldo B.F. Analysis of the breathing pattern in elderly patients using the Hurst exponent applied to the respiratory flow signal. 2014 CONF PROC IEEE ENG MED BIOL SOC, 3422-5.

▶ Vendrell E., Lanau P., Salat D., Perez V., Serra-Prat M., De Gracia J., Almirall J., Influence of environmental conditions and

exercise on serum immunoglobulin levels in a mushing race. (2014) *ARCHIVOS DE MEDICINA DEL DEPORTE*, 31 (160), 80-84.

Radiophysics and Radioprotection

Coordinator

Montserrat Ribas HSCSP
mribas@santpau.cat

Members

Pablo Carrasco HSCSP
Teresa Eudaldo HSCSP
Núria Jornet HSCSP
Agustín Ruiz HSCSP



Main Lines of Research

External beam radiotherapy

- ▶ Characterization of various in vivo dose measurement detectors for radiation therapy treatments with intensity modulation (IMRT).
- ▶ Validation of dose calculation algorithms for external beam radiotherapy planning systems.
- ▶ Optimization of QA procedures for IMRT, stereotactic body radiation therapy (SBRT) and gating respiratory treatments.

Computed tomography dosimetry

- ▶ Index dose assessment for multislice CT.

Biological dosimetry

- ▶ Cytogenetic evaluation of the relative biological efficacy of low-energy X-rays (in cooperation with the Universitat Autònoma de Barcelona team led by Dr. María Rosa Caballín).

Collaborations

External Collaborations

- ▶ Grup d'estudis citogenètics i moleculars dels efectes de les radiacions ionitzants i del càncer. 2014 SGR 534. Montserrat Ribas, Pablo Carrasco, Teresa Eudaldo, Núria Jornet, Artur Latorre, Agustín Ruiz. 2014-2016.

Active Grants

- ▶ Montserrat Ribas Morales. Impacto dosimétrico del movimiento respiratorio durante la administración del tratamiento de IMRT dinámica. FIS Project 2012. PI12/00521. Duration: 01/01/13-31/12/15. €16,500.
- ▶ Pablo Carrasco. Dosimetría "in vivo" en radioterapia de intensidad modulada en

tratamientos de cáncer de mama. Ayudas para la investigación en oncología 2012. AECC 2012. Duration: 07/02/13-07/02/15. €16,200.

Note: Total amount granted to PI. It does not include indirect costs.

***TIF: 8.4150 **MIF: 2.8050**

Scientific Production

Bueno M., Carrasco P., Jornet N., Munoz-Montplet C., Duch M.A., On the suitability of ultrathin detectors for absorbed dose assessment in the presence of high-density heterogeneities. (2014) MED PHYS, 41 (8).

IF: 2.6350

Enriquez G., Piqueras J., Catala A., Oliva G., Ruiz A., Ribas M., Duran C., Rodrigo C., Rodriguez E., Garriga V., Maristany T., Garcia-Fontecha C., Banos J., Muchart J., Alava F.,

Optimization of radiological scoliosis assessment. (2014) MED CLIN-BARCELONA, 143, 62-67.

IF: 1.4170

Jornet N., Carrasco P., Beltran M., Calvo J.F., Escude L., Hernandez V., Quera J., Saez J., Multicentre validation of IMRT pre-treatment verification: Comparison of in-house and external audit. (2014) RADIOTHER ONCOL, 112 (3), 381-388.

IF: 4.3630

Paediatrics

Coordinator

Eduard Carreras HSCSP
ecarrerasg@santpau.cat

Members

Roser Álvarez HSCSP
Isabel Badell HSCSP
Jesús Carnicer HSCSP
Gemma Carreras HSCSP
Jerónimo Ferrés HSCSP
Gloria M. Fraga HSCSP
M. José García HSCSP
Gemma Ginovart HSCSP
Ester López HSCSP
Elisenda Moliner HSCSP
Núria Pardo HSCSP
Luisa Sisinni HSCSP
Montserrat Torrent HSCSP
Sergi Verd HSCSP



Main Lines of Research

- ▶ Erythropoietin as an alternative to transfusion in paediatrics
- ▶ Clinical application of peritoneal drainage in the treatment of enterocolitis in infants
- ▶ Chronic functional constipation: treatment with PEG
- ▶ Creation of a Catalan diagnostic and clinical monitoring network for rare anaemias due to major haemoglobinopathies
- ▶ Minimal residual disease in risk assessment in the treatment of children with acute lymphoblastic leukaemia in the SHOP protocol (in collaboration with the HSCSP Haematology Department).

Challenges

- ▶ Transplant haematopoietic progenitor cells from alternative donors
- ▶ Make pre-implant genetic diagnoses
- ▶ Transplant haematopoietic progenitor cells in congenital immunodeficiencies
- ▶ Transplant haematopoietic progenitor cells in congenital metabolic pathologies
- ▶ Research congenital immunodeficiencies
- ▶ Research Fanconi anaemia (group recognized by the UAB, Barcelona)
- ▶ Apply adaptive cell immunotherapy to tumours
- ▶ Intervention in postasphyxia neuronal damage in infants with asphyxia by applying therapeutic hypothermia (in the context of a Catalan network)
- ▶ Polytraumatized patient care programme. PPT implementation code in HSCSP and in CatSalut central register
- ▶ Implement a multidisciplinary institutional massive transfusion protocol in the HSCSP.

Collaborations

- ▶ Grupo de investigación clínica vinculado al Centro de Investigación Biomédica en la Red de Enfermedades Raras (CIBERER).
- ▶ G. Fraga (collaborator). Estudio multicéntrico europeo (París, Roma, Barcelona): estudio de Asociación de Genoma Completo (GWAS) para la identificación de factores genéticos de riesgo en pacientes con síndrome nefrótico córtico-sensible (SNCS)/ síndrome nefrótico por lesiones mínimas (SNLM).
- ▶ Grupo de trabajo de la Guía de Práctica Clínica sobre Manejo del Paciente con Reflujo Vesicoureteral primario o esencial. Guía de Práctica Clínica. Manejo del Paciente con Reflujo Vesicoureteral primario o esencial. Actualización. Asociación Española de Nefrología Pediátrica. 2014.
- ▶ Project "Compromiso por la Calidad de las Sociedades Médicas" (coordinated by Ministerio de Sanidad, Servicios Sociales e Igualdad, Sociedad Española de Medicina Interna and GuíaSalud).
- ▶ E. Carreras, S. Brió, E. Moliner. Programa VINCat. Resultats de la vigilància estandaritzada de la incidència de bacterièmia relacionada amb catèter venós central (BRCVC) a les Unitats de Cures Intensives Pediàtriques (UCIP) i Neonatals (UCIN) dels Hospitals de Catalunya.

Active Grants

- ▶ Isabel Badell Serra. Creation of a catalan network for the diagnosis and clinical management of haemoglobinopathies. TELEMRATÓ 2010 Malalties minoritàries. 101731. Duration: 27/01/11-31/07/14. €64,445.23.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2014

- ▶ Gemma Ginovart. Ajuts de suport als Grups de Recerca de Catalunya. Grup Pedagogia Hospitalària en Neonatologia i Pediatria. AGAUR 2014 SGR 806. Duration: 2014-2016.*
- ▶ Isabel Badell. Infusió profilàctica de linfocitos del donante en trasplante de sangre de cordón. Fundació La Marató de TV3. Duration: 2014-2016.*

* Grants applied for by other research institutes.

*TIF: 23.6490 **MIF: 1.8192

Scientific Production

Alcantara-Aragon V., Martinez-Couselo S., Tundidor-Rengel D., Webb S.M., Carreras G., Espinos J.J., Chico A., Blanco-Vaca F., Corcoy R., Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis. (2014) HORM-INT J ENDOCRINO, 13 (4), 585-587.

IF: 1.1980

Ars E., Bernis C., Fraga G., Martinez V., Martins J., Ortiz A., Rodriguez-Perez J.C., Sans L., Torra R., on behalf of the Spanish Working Group on Inherited Kidney Disease. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Full Review. (2014) NEPHROL DIAL TRANSPLANT, 29: iv95-iv105.

IF: 3.5770

Barcos-Munoz F., Moliner-Calderon E., Morales-Prieto R., Carrara-Scialpini L. Neonatal sepsis and meningitis due to Streptococcus pneumoniae. (2014) ENFERM INFECC MICR CL, 32 (1), 58-59.

IF: 2.1720

Carreras-Gonzalez E., Brio-Sanagustin S. Prevención de complicaciones en el transporte interhospitalario aéreo del paciente crítico pediátrico. (2014) AN PEDIATR, 2014;81:205-11.

IF: 0.8330

Diaz de Heredia C., Gonzalez M., Verdeguer A., Elorza I., Rodriguez A., Martinez A., Perez J.M., Badell I., Gonzalez M.E., Olive T., Fernandez J.M., Maldonado M.S., Diaz M.A., Sanchez De Toledo J., Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: A retrospective study using the Spanish Working Party for BMT in Children (GETMON) database. (2014) BONE MARROW TRANSPL, 49 (6), 767-772.

IF: 3.5700

Hurtado Suazo J.A., Garcia Reymundo M., Calvo Aguilar M.J., Ginovart Galiana G., Jimenez Moya A., Trincado Aguinagalde M.J., Demestre Guasch X., Recommendations for the perinatal management and follow up of late preterm newborns. (2014) AN PEDIATR, 81 (5), 327.e1-327.e7.

IF: 0.8330

Moliner Calderon E., Scheibl A., Garcia Borrero M.J., Lopez Bernal E., Ginovart Galiana G., Seizures and influenza virus A H1N1 infection in very low birth weight preterm infant. (2014) AN PEDIATR, 80 (1).

IF: 0.8330

Montañes R., Gracia S., Fraga G.M., J. Escribano, MJ Diez, A. Alonso, V. Garcia. Documento de consenso: recomendaciones sobre la utilización de ecuaciones para la

estimación del filtrado glomerular en niños. (2014) AN PEDIATR (BARC); 80(5): 326.

IF: 0.8330

Trilla C.C., Medina M.C., Ginovart G., Betancourt J., Armengol J.A., Calaf J., Maternal risk factors and obstetric complications in late preterm prematurity. (2014) EUR J OBSTET GYN R B, 179, 105-109.

IF: 1.6950

Verd S., Garcia M.-J., Acid-base equilibrium in premature infants: Don't forget feeding type. (2014) EUR J PEDIATR, 174 (1), 55.

IF: 1.8900

Verd S., Garcia M., Gutierrez A., Moliner E., Lopez E., Ginovart G., Blood biochemical profile of very preterm infants before and after trophic feeding with exclusive human milk or with formula milk. (2014) CLIN BIOCHEM, 47 (7-8), 584-587.

IF: 2.2750

Verd S., Ginovart G., Turon L., Breastfeeding and brain development, is breastfeeding a cause or an effect? (2014) REV NEUROLOGIA, 58 (CONGRESO1), C20-C27.

IF: 0.8300

Verd S., Porta R., Ginovart G., Human milk feeding. (2014) ARCH DIS CHILD-FETAL, 99 (2).

IF: 3.1200

Other Publications

- ▶ Fraga Rodríguez G.M., Huertes Díaz B. Evaluación básica de la función renal en Pediatría. (2014) PROTOC DIAGN TER PEDIATR; 1:21-35.
- ▶ Infante Pina D., Segarra Canton O., Vilalta Casas R., Carnicer de la Pardina J., Lopez Linan M.J., Molera Busoms C., Efficacy, tolerance and safety of polyethylene glycol 3350 plus electrolytes for the treatment of functional constipation in children. (2014) ANALES DE PEDIATRÍA, 80 (5), 278-284.
- ▶ Poliquistosis renal autosómica dominante. 2014. Editrain. IPEM (Instituto de Postgrado de Estudios de Medicina y Salud). ISBN: 978-84-15498-94-0.

Ophthalmology

Coordinator

José A. Buil HSCSP
jbuil@santpau.cat

Members

M. Francisca HSCSP RI
Bassaganyas HSCSP
Anna M. Bruix HSCSP
Zoraida del Campo HSCSP
M. Àngels Conte HSCSP
Jaume Crespi HSCSP
Jesús Díaz HSCSP
Eva García HSCSP
Miguel Ángel Gil HSCSP
Sabina Luna HSCSP
Teresa Marieges HSCSP
Fernando Rodríguez HSCSP
Fernando Sánchez HSCSP
Teresa Solans HSCSP
Jesús Téllez HSCSP
José Ignacio Vela HSCSP



Main Lines of Research

- ▶ Optimization of the functional rehabilitation of patients after cataract surgery using multifocal intraocular lens, and evaluation of vision quality in terms of parameters such as visual acuity, sensitivity to contrast and aberrometry.
- ▶ Comparación de la eficacia y seguridad de ranibizumab en inyección intravítrea frente a la fotocoagulación láser en pacientes con alteración visual secundaria a edema macular diabético.
- ▶ Ocular repercussions of allogeneic medullary transplants and evaluation of the different clinical manifestations and response to treatment in graft-versus-host disease.

*TIF: 10.4600 **MIF: 2.6150

Scientific Production

Marchino T., Ibanez N., Prieto S., Novelli S., Szafranska J., Mozos A., Graell X., Buil J.A., An aggressive primary orbital natural killer/T-cell lymphoma case: Poor response to chemotherapy. (2014) OPTHAL PLAST RECONS, 30 (5), e131-e134.

IF: 0.8810

Martinez-Zapata M.J., Marti-Carvajal A.J., Sola I., Pijoan J.I., Buil-Calvo J.A., Cordero J.A., Evans J.R., Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. (2014) COCHRANE DB SYST REV, 11.

IF: 6.0320

Varon C., Gil M.A., Alba-Bueno F., Cardona G., Vega F., Millan M.S., Buil J.A., Stereo-acuity in

patients implanted with multifocal intraocular lenses: Is the choice of stereotest relevant? (2014) CURR EYE RES, 39 (7), 711-719.

IF: 1.6390

Zenteno J.C., Crespi J., Buentello-Volante B., Buil J.A., Bassaganyas F., Vela-Segarra J.I., Diaz-Cascajosa J., Marieges M.T., Next generation sequencing uncovers a missense mutation in COL4A1 as the cause of familial retinal arteriolar tortuosity. (2014) GRAEF ARCH CLIN EXP, 252 (11), 1789-1794.

IF: 1.9080

Other Publications

- ▶ Garcia Vilaro M., Bassaganyas Vilarrassa F., Vela Segarra J.I., Buil Calvo J.A., Early treatment of idiopathic vasculitis, aneurysms and neuroretinitis (IRVAN). A case report. (2014) ARCHIVOS DE LA SOCIEDAD ESPANOLA DE OFTALMOLOGIA, 89 (3), 117-120.

*Total Impact Factor **Mean Impact Factor

Nuclear Medicine

Coordinator

Ignasi Carrió HSCSP
icarrio@santpau.cat

Members

Carlos Achury HSCSP
Anna Domènech HSCSP
Joan Duch HSCSP
Montserrat Estorch HSCSP
Alejandro Fernández HSCSP
Albert Flotats HSCSP
Rafael Enrique Jaller HSCSP



Main Lines of Research

Oncology

- ▶ New diagnostic methods based on the identification and visualization of molecular targets employing metabolic mechanisms, receptor systems, hypoxia, angiogenesis and apoptosis.
- ▶ New applications for sentinel node detection and radioguided surgery models.

Cardiovascular Research

- ▶ New methods for non-invasive assessment of ischaemic heart disease and heart failure.

- ▶ Cardiovascular functional studies.
- ▶ New methods for assessing cardiac innervation.

Functional Neuroimaging

- ▶ Development of new functional imaging methods for evaluating neurodegenerative diseases (Parkinson, Parkinson-Plus, Alzheimer, MCI).
- ▶ Dopaminergic system studies using IBZM and Datscan.

Challenges

- ▶ Introduce new technologies to clinical research (given that imaging techniques are evolving very rapidly towards multimodal systems that integrate biological, molecular, anatomical and functional information in a single examination) and include these technologies, mainly PET/CT and PET/MR, in the group and hospital's research activities.

New Molecular Imaging Techniques

- ▶ Develop new hybrid molecular imaging technologies, mainly PET/CT and PET/MR,

building on pre-clinical and clinical molecular imaging models developed using SPECT and conventional nuclear medicine technologies.

PET Imaging Biomarkers

- ▶ Develop new PET radioactive tracers to be used as biomarkers in new imaging technologies building on our experience with radioactive tracers to view in vivo diagnostic and therapeutic targets.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Neuroradiology: research into neurological and mental disorders and ageing (Dr. Camacho, member).
- ▶ Oncology, Gynaecology, Surgery, Radiology, Radiotherapy, Nuclear Medicine and Pathology: evaluation of the usefulness of PET CT with 18F-FDG in the staging of locally advanced breast carcinoma (Dr. Duch, PI).

- ▶ Cerebrovascular Diseases (Dr. Carrió, member).

External Collaborations

- ▶ Zhejiang University, Hangzhou, China. Molecular imaging (Prof. Hong Zhang, Prof. Mei Tian)

Doctoral Theses

- ▶ Paloma Pifarré Montaner. Técnica de relajación vs fármaco de síntesis en el tratamiento de la ansiedad del paciente oncológico: estudio del metabolismo cerebral mediante PET con FDG. Universitat Autònoma de Barcelona. Director: Alejandro Fernández. Date of defense: June 2014.
- ▶ M. del Valle Camacho Martí. Utilidad de la gammagrafía de intervención miocárdica con 123I-MIBG en el diagnóstico clínico de la demencia de cuerpos de Levy. Universitat Autònoma de Barcelona. Director: Montserrat Estorch Cabrera. Date of defense: September 2014.

*TIF: 38.6720 **MIF: 3.2227

Scientific Production

- Achury C., Domenech A., Estorch M., Jaller R., Montes A., Carrio I., Ectopic supernumerary kidney. A casual finding. (2014) REV ESP MED NUCL IMA, 33 (6), 384-385. **IF: 1.0540**
- Achury C., Estorch M., Domenech A., Camacho V., Flotats A., Jaller R., Geraldo L., Deportos J., Montes A., Carrio I., Interpretation of thyroid incidentalomas in 18F-FDG PET/CT studies. (2014) REV ESP MED NUCL IMA, 33 (4), 205-209. **IF: 1.0540**
- Beyer T., Flux G., Sattler B., Delaloye A.B., Carrio I., EJNMMI physics - Access is open for open access. (2014) EUR J NUCL MED MOL I, 41 (2), 197-198. **IF: 5.3830**
- Knuuti J., Bengel F., Bax J.J., Kaufmann P.A., Le Guludec D., Perrone Filardi P., Marcassa C., Ajmone Marsan N., Achenbach S., Kit-siou A., Flotats A., Eeckhout E., Minn H., Hesse B., Risks and benefits of cardiac imaging: An analysis of risks related to imaging for coronary artery disease. (2014) EUR HEART J, 35 (10), 633-638. **IF: 15.2030**
- Peix A., Mesquita C.T., Paez D., Pereira C.C., Felix R., Gutierrez C., Jaimovich R., Ianni B.M., Soares Jr. J., Olaya P., Rodriguez M.V., Flotats A., Giubbini R., Travin M., Garcia E.V., Nuclear medicine in the management of patients with heart failure: Guidance from an expert panel of the International Atomic Energy Agency (IAEA). (2014) NUCL MED COMMUN, 35 (8), 818-823. **IF: 1.6690**
- Pons G., Masia J., Loschi P., Nardulli M.L., Duch J., A case of donor-site lymphoedema after lymph node-superficial circumflex iliac artery perforator flap transfer. (2014) J PLAST RECONSTR AES, 67 (1), 119-123. **IF: 1.4210**
- Sampedro F., Domenech A., Escalera S., Obtaining quantitative global tumoral state indicators based on whole-body PET/CT scans: A breast cancer case study. (2014) NUCL MED COMMUN, 35 (4), 362-371. **IF: 1.6690**
- Sampedro F., Domenech A., Escalera S., Static and dynamic computational cancer spread quantification in whole body FDG-PET/CT scans. (2014) J MED IMAG HEALTH IN, 4 (6), 825-831. **IF: 0.5030**
- Sampedro F., Escalera S., Domenech A., Carrio I., A computational framework for cancer response assessment based on oncological PET-CT scans. (2014) COMPUT BIOL MED, 55, 92-99. **IF: 1.2400**
- Underwood S.R., De Bondt P., Flotats A., Marcasa C., Pinto F., Schaefer W., Verberne H.J., The current and future status of nuclear cardiology: A consensus report. (2014) EUR HEART J-CARD IMG, 15 (9), 949-955. **IF: 4.1050**
- Vilades D., Leta R., Moustafa A.-H., Alomar X., Carreras F., Pons-Llado G., Correlation between Agatston scores obtained by cardiac computed tomography studies with and without contrast in asymptomatic population. (2014) REV ESP CARDIOL, 67 (8), 678-679. **IF: 3.7920**
- Zhang H., Tian M., Carrio I., Civelek A.C., Fujibayashi Y., Molecular image-guided theranostic and personalized medicine 2013. (2014) BIOMED RES INT, 2014. **IF: 1.5790**

Other Publications

- ▶ Farre Bernado N., Estorch Cabrera M., Radioterapia en el tratamiento de las metástasis óseas. (2014) DOLOR, 29 (2), 53-59.

Intensive Medicine

Coordinator

Jordi Mancebo HSCSP
jmancebo@santpau.cat

Members

Hernan Marcelo Aguirre HSCSP
Antoni Betbesé HSCSP
Lluís Marruecos HSCSP
Indalecio Morán HSCSP
Elisabet Quintana HSCSP
Ferran Roche HSCSP
Antoni Roglán HSCSP
Juan Sánchez HSCSP
José Alberto Santos HSCSP
Paula Vera HSCSP
Lluís Zapata HSCSP



Main Lines of Research

Acute Respiratory Failure and Artificial Ventilation

- ▶ Non-invasive ventilation.
- ▶ New ventilation modes: proportional-assist ventilation and NAVA.
- ▶ Prone decubitus in acute respiratory dysfunction syndrome (ARDS).
- ▶ Artificial ventilation withdrawal.
- ▶ Expert ventilation systems.
- ▶ Sleep and artificial ventilation.
- ▶ Early and active mobilization of the critical patient.
- ▶ Extracorporeal CO₂ removal in ARDS patients.
- ▶ High-flow oxygen administration by nasal cannula in postextubation phase.
- ▶ Prevalence of drug interactions in critical care unit.

Study of the Usefulness of New Biomarkers in Critically Ill Patients

- ▶ BNP in weaning from mechanical ventilation.
- ▶ Use of the NGAL protein in the renal prognosis of critically ill patients.
- ▶ Strict control of blood glucose in critically ill patients.
- ▶ Prophylaxis of acute gastric mucosal injury in critically ill patients.
- ▶ Study of the haemodynamic effects of different antipyretic drugs in critically ill patients.
- ▶ Influence of position change to supine decubitus position in intra-abdominal pressure.

Challenges

- ▶ Consolidate clinical and physiological research into ventilation in critically ill patients through multicentre and multinational networking.
- ▶ Create a stable and well-trained group of researchers in this discipline.

Collaborations

Collaboration with other IIB Sant Pau Groups

- ▶ Pharmacological Research in Humans.

Awards

- ▶ Jordi Mancebo. Bernhard Dräger Award for Advanced Treatment of Acute Respiratory Failure: GUERIN Claude (FR) - Trans-Pulmonary Pressure and Prone position in ards patients. T3P study. ESCM & Industry Research Awards 2014.

*TIF: 59.8730 **MIF: 4.9894

Scientific Production

Aguirre-Bermeo H., Bottiroli M., Italiano S., Roche-Campo F., Santos J.A., Alonso M., Mancebo J., Pressure support ventilation and proportional assist ventilation during weaning from mechanical ventilation. (2014) *MED INTENSIVA*, 38 (6), 363-370.

IF: 1.3360

Akoumianaki E., Maggiore S.M., Valenza F., Bellani G., Jubran A., Loring S.H., Pelosi P., Talmor D., Grasso S., Chiumello D., Gue Rin C., Patroniti N., Ranieri V.M., Gattinoni L., Nava S., Terragni P.-P., Pesenti A., Tobin M., Mancebo J., Brochard L., The application of esophageal pressure measurement in patients with respiratory failure. (2014) *AM J RESP CRIT CARE*, 189 (5), 520-531.

IF: 12.9960

Dessap A.M., Katsahian S., Roche-Campo F., Varet H., Kouatchet A., Tomicic V., Beduneau G., Sonneville R., Jaber S., Darmon M., Castanares-Zapatero D., Brochard L., Brun-Buisson C., Ventilator-associated pneumonia during weaning from mechanical ventilation: Role of fluid management. (2014) *CHEST*, 146 (1), 58-65.

IF: 7.4830

Drouot X., Bridoux A., Thille A.W., Roche-Campo F., Cordoba-Izquierdo A., Katsahian S., Brochard L., d'Ortho M.-P., Sleep continuity: A new metric to quantify disrupted hypnograms in non-sedated intensive care unit patients. (2014) *CRIT CARE*, 18 (6):628.

IF: 4.4760

Ochagavia A., Baigorri F., Mesquida J., Ayuela J.M., Ferrandiz A., Garcia X., Monge M.I., Mateu L., Sabatier C., Clau-Terre F., Vicho R., Zapata L., Maynar J., Gil A., Hemodynamic monitoring in the critically patient. Recommendations of the cardiological intensive care and cpr working group of the spanish society of intensive care and coronary units. (2014) *MED INTENSIVA*, 38 (3), 154-169.

IF: 1.3360

Parrilla F.J., Moran I., Roche-Campo F., Mancebo J., Ventilatory strategies in obstructive lung disease. (2014) *SEMIN RESP CRIT CARE*, 35 (4), 431-440.

IF: 2.7120

Puntillo K.A., Max A., Timsit J.-F., Vignoud L., Chanques G., Robleda G., Roche-Campo F., Mancebo J., Divatia J.V., Soares M., Ionescu D.C., Grintescu I.M., Vasiliu I.L., Maggiore S.M., Rusinova K., Owczuk R., Egerod I., Papathanasoglou E.D.E., Kyranou M., Joynt G.M., Burghi G., Freebairn R.C., Ho K.M., Kaarlola A., Geritsen R.T., Kesecioglu J., Sulaj M.M.S., Norrenberg M., Benoit D.D., Seha M.S.G., Hennein A., Periera F.J., Benbenishty J.S., Abroug F., Aquilina A., Monte J.R.C., An Y., Azoulay E., Determinants of procedural pain intensity in the intensive care unit: The Europain® study. (2014) *AM J RESP CRIT CARE*, 189 (1), 39-47.

IF: 12.9960

Roche-Campo F., Brochard L., The authors reply. (2014) *CRIT CARE MED*, 42 (1).

IF: 6.3120

Sud S., Friedrich J.O., Adhikari N.K.J., Taccone P., Mancebo J., Polli F., Latini R., Pesenti A., Curley M.A.Q., Fernandez R., Chan M.-C., Beuret P., Voggenreiter G., Sud M., Tognoni G., Gattinoni L., Guerin C., Effect of prone positioning during mechanical ventilation on mortality among patients with acute respiratory distress syndrome: A systematic review and meta-analysis. (2014) *CAN MED ASSOC J*, 186 (10).

IF: 5.9590

Vera P., Palomar M., Alvarez-Lerma F., Quality indicators on the use of antimicrobials in critically ill patients. (2014) *MED INTENSIVA*, 38 (9), 567-574.

IF: 1.3360

Zapata L., Betbese A.J., Roglan A., Ordonez-Llanos J., Use of B-type natriuretic peptides to detect the existence and severity of diastolic dysfunction in non-cardiac critically ill patients: A pilot study. (2014) *MINERVA ANESTESIOLOGIA*, 80 (2), 194-203.

IF: 2.1340

Zaragoza R., Ferrer R., Maseda E., Llinares P., Rodríguez A; ÉPICO Project Group (Paula Vera). ÉPICO project 2.0. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations. (2014) *REV ESP QUIMIOTER*; 27(3): 196-212.

IF: 0.7970

Other Publications

▶ Beduneau G, Pham T, Schortgen F, Chretien J.M., Richard J.C.M., Mercat A, Mancebo J., Brochard L. A new classification for patients weaning from mechanical ventilation. (2014) *INTENSIVE CARE MED*; 40 (Suppl. 1): S14.

▶ Italiano S, Sacchi N, Roche-Campo F, Giménez S, Clos S, Aguirre-Bermeo H, Grandjean J, Maraffi T, Parrilla F.J., Mancebo J. Estudio comparativo del sueño mediante dos modos distintos de ventilación mecánica: PSV VS NAVA. XLIX Congreso Nacional de la Semicyc. Madrid, 15-18 June 2014. (2014) *MED. INTENSIVA*; 38: 345-346.

▶ López P.A., Suárez J.C., Mancebo J, Zapata L. Características clínicas y ecocardiográficas de pacientes críticos en función de la categoría de weaning de la ventilación mecánica. Estudio piloto. X Congreso Panamericano e Ibérico de Medicina Crítica y Terapia Intensiva. XLIX Congreso Nacional de la Semicyc. Madrid, 15-18 June 2014. (2014) *MED. INTENSIVA*; 38: 203-204.

▶ Lopez-Garzón P.A., Suarez-Montero J.C., Mancebo J., Zapata L. Clinical and echocardiographic characteristics of critically ill patients according to weaning categories from mechanical ventilation. A new classification for patients weaning from mechanical ventilation. (2014) *INTENSIVE CARE MED*; 40 (Suppl. 1): S220.

▶ Lopez-Garzon P.A., Suarez-Montero J.C., Olmo A, Betbese A., Roglan A. Incidencia y mortalidad asociada a la disfunción renal aguda en un Servicio de Medicina Intensiva. XXXV Reunión de la Societat Catalana de Medicina Intensiva i Crítica. March 2014. Barcelona.

▶ Maraffi R, Parrilla F.J., Aguirre-Bermeo H, Italiano S, Roche-Campo F, Mancebo J. Seguimiento de la actividad eléctrica diafragmática (EADI) en el periodo pre y post-extubación en pacientes con weaning respiratorio difícil: éxito en extubación y fallo en extubación. X Congreso Panamericano e Ibérico de Medicina

Intensive Medicine

Other Publications

- Crítica y Terapia Intensiva. XLIX Congreso Nacional de la Semicycuc. Madrid, 15-18 June 2014. (2014) MED. INTENSIVA; 38: 15.
- ▶ Rundo A, Restuccia F, Aguirre-Bermeo H, Parrilla F, Italiano S, Roche-Campo F, Mancebo J, Maraffi T. Aproximación de la relación entre la presión muscular y la actividad eléctrica del diafragma. XLIX Congreso Nacional de la Semicycuc. Madrid, 15-18 June 2014. (2014) MED. INTENSIVA; 38: 345.
 - ▶ Rundo A., Restuccia F., Aguirre-Bermeo H., Parrilla F., Marafi T., Italiano S., Roche-Campo F., Mancebo J. Relationship between respiratory muscle pressure and the electrical activity of the diaphragm. A new classification for patients weaning from mechanical ventilation. (2014) INTENSIVE CARE MED; 40 (Suppl. 1): S35.
 - ▶ Suarez J.C., Lopez P.A., Mancebo J, Zapata L. Utilidad del índice combinado de rendimiento miocárdico en el diagnóstico ecocardiográfico de la disfunción sistólica y diastólica en pacientes críticos. XLIX Congreso Nacional de la Semicycuc. Madrid, 15-18 June 2014. (2014) MED. INTENSIVA; 38: 304.
 - ▶ Suarez-Montero J.C., Lopez-Garzon P.A., Olmo A., Betbese A., Morán I., Roglan A. Incidencia y mortalidad asociada a la disfunción renal aguda en un Servicio de Medicina Intensiva. X Congreso Panamericano e Ibérico de Medicina Crítica y Terapia Intensiva. Madrid, June 2014.
 - ▶ Zapata L., López-Garzón P.A., Suarez-Montero J.C., Mancebo J. Tissue Doppler imaging myocardial performance index as a method to evaluate left ventricular diastolic and systolic function in icu patients. A new classification for patients weaning from mechanical ventilation. (2014) INTENSIVE CARE MED; 40 (Suppl. 1): S47.
 - ▶ Informe anual del Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina Intensiva. ENVIN-HELICS. 2014. (Paula Vera Artazcoz, M. Isabel Quintana Tort-Martorell, Juan Carlos Suárez Montero, Paula López Garzón). ISBN: 978-84-940824-5-0.

Pharmacy

Coordinator

M. Antònia Mangués HSCSP
mmangués@santpau.cat

Members

Núria Berga HSCSP RI
Daniel Cardona HSCSP
M. Isabel Castro HSCSP
Edurne Fernández de Gamarra HSCSP
Ana Juanes HSCSP
Montserrat Masip HSCSP
M. Estela Moreno HSCSP
Neus Pagès HSCSP RI
Ainhoa Rodríguez-Arias HSCSP RI
Pilar Ruano HSCSP RI
M. Luisa Sala HSCSP
Laura Tuneu HSCSP



Main Lines of Research

- ▶ Pharmaceutical care.
- ▶ Artificial nutrition.
- ▶ Oncohaematology.
- ▶ Independent clinical trials.

Challenges

- ▶ Evaluate the impact on effectiveness and safety of pharmacological treatments in different pharmaceutical care programmes: clinical pharmacokinetics, health education for outpatients, medicine reconciliation and identification and prevention of medication-related problems.
- ▶ Evaluate the impact of artificial nutrition on the clinical evolution of patients.
- ▶ Study the stability of cytostatics in different conditions of use.
- ▶ Predict response to anti-tumour treatment in a number of tumoural processes.
- ▶ Develop focal adhesion inhibitors, e.g., antitumour agents.
- ▶ Actively cooperate in independent clinical trials performed in the HSCSP.

Collaborations

Collaboration with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs.
- ▶ Spanish Hospital Pharmacy Society (SEFH).
- ▶ Intensive Medicine.
- ▶ Clinical Haematology.
- ▶ Dermatology.
- ▶ Orthopaedics and Traumatology.
- ▶ Digestive Diseases.
- ▶ Edurne Fernández de Gamarra (PI), Drug interactions in patients in an intensive medical

service of a university hospital, HSCSP Intensive Care Group, 2013 (non-funded).

External Collaborations

- ▶ Delgado O, Genúa MI, Ibarra O, Morillo R. Madrid (coordinators), Montse Masip (collaborator), SEFH model for the selection and pharmaceutical care of chronic patients, Spanish Hospital Pharmacy Society (SEFH), 2013.
- ▶ M. Antonia Mangués, Oncogenesis and Antitumour Drugs Consolidated Research Group, Generalitat de Catalunya (AGAUR) 2009-SGR-1437, HSCSP RI, 2009-2013.

Awards

- ▶ Pagès N, Gomis M, Masip M, Mediavilla MM, García-Planella E, Lozano P, Ruppmann H, Tuneu L, Mangués MA. Programa de mejora de la adherencia terapéutica en pacientes con enfermedad inflamatoria intestinal mediante el uso de una aplicación móvil. Según premi en la I Convocatoria Proyectos de

Mejora de Adherencia en Pacientes con Enfermedades Inflamatorias Inmunomediadas de la Sociedad Española de Farmacia Hospitalaria. September de 2014.

Active Grants

- ▶ Ana Juanes Borrego. Programa de atención farmacéutica en pacientes con insuficiencia cardiaca y/o enfermedad pulmonar obstructiva crónica usuarios de un servicio de urgencias hospitalario frente al seguimiento convencional. Joaquim Bonal 2011. Duration: 26/04/11-31/12/14. €15,000.
- ▶ Daniel Serrano Barrena. Contracte MIA 2013. Duration: 25/06/13-24/06/14. €45,222.91.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 7.0060 **MIF: 3.5030

Scientific Production

Alamo P., Gallardo A., Pavon M.A., Casanova I., Trias M., Mangués M.A., Vázquez E., Villaverde A., Mangués R., Cespedes M.V., Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. (2014) DIS MODEL MECH, 7 (3), 387-396.

IF: 4.9730

Garin N., De Pourcq J.T., Martin-Venegas R., Cardona D., Gich I., Mangués M.A., Viscosity differences between thickened beverages suitable for elderly patients with dysphagia. (2014) DYSPHAGIA, 29 (4), 483-488.

IF: 2.0330

Other Publications

- ▶ Mullera Marti M., Riba Sole M., Fernandez De Gamarra Martinez E., Mangués Bafalluy Ma.A., Hypersensitivity reaction to etoposide. A case report. (2014) FARMACIA HOSPITALARIA, 38 (3), 255-256.

Dermatology

Coordinator

Lluís Puig HSCSP
lpuig@santpau.cat

Members

Marta Alegre HSCSP
M. Assumpció Barnadas HSCSP
Eulalia Baselga HSCSP
Joan Dalmau HSCSP
Joan Ramon Garcés HSCSP
M. Pilar Garcia HSCSP
Anna López HSCSP
Caridad Morales HSCSP RI
Esther Roe HSCSP
Verónica Ruiz HSCSP
Sandra Ros HSCSP RI
Laura Salvador HSCSP RI
Esther Serra HSCSP
Jorge Luis Spertino HSCSP RI
Eva Vilarrasa HSCSP



Main Lines of Research

- ▶ Biologic therapy in dermatology.
- ▶ Genome-wide association studies in psoriasis
- ▶ Medical and physical treatment options for vascular tumours.
- ▶ Psychopathological studies of patients with chronic dermatological disorders.
- ▶ Estudi de la immunitat innata i adquirida en malalties dermatològiques mitjades immunològicament.

Challenges

- ▶ Ensure a stable clinical research infrastructure and staff.
- ▶ Foster interdepartmental collaborative research.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Parkinson Disease and Movement Disorders.

Awards

- ▶ "Best in Class" award (*Gaceta Médica*) to the Best Psoriasis Unit of Spain.

Active Grants

- ▶ M. Pilar Garcia Muret. Estudio doble ciego de tratamiento preventivo con alopurinol 3% crema frente a placebo de la eritrodisestesia palmoplantar secundaria al tratamiento con capecitabina. Ministerio de Sanidad y Política Social: EC 2010. EC10-074. Duration: 01/01/11-30/06/14. €33,826.19.

Note: Total amount granted to PI. It does not include indirect costs.

121.0030.480 **MIF: 6.3686

Catala A., Garces J.R., Alegre M., Gich I.J., Puig L., Mohs micrographic surgery for basal cell carcinomas: Results of a Spanish retrospective study and Kaplan-Meier survival analysis of tumour recurrence. (2014) *J EUR ACAD DERMATOL*, 28 (10), 1363-1369.

IF: 2.8260

Hernandez-Martin A., Gilliam A.E., Baselga E., Vicente A., Lam J., Gonzalez-Ensenat M.A., Azorin D., Torrelo A., Hyperpigmented macules on the face of young children: A series of 25 cases. (2014) *J AM ACAD DERMATOL*, 70 (2), 288-290.

IF: 4.4490

Kavanaugh A., Ritchlin C., Rahman P., Puig L., Gottlieb A.B., Li S., Wang Y., Noonan L., Brodmerkel C., Song M., Mendelsohn A.M., McInnes I.B., Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. (2014) *ANN RHEUM DIS*, 73 (6), 1000-1006.

IF: 10.3770

Langley R.G., Elewski B.E., Lebwohl M., Reich K., Griffiths C.E.M., Papp K., Puig L., Nakagawa H., Spelman L., Sigurgeirsson B., Rivas E., Tsai T.-F., Wasel N., Tying S., Salko T., Hampele I., Notter M., Karpov A., Helou S., Papavassiliou C., Secukinumab in plaque psoriasis - Results of two phase 3 trials. (2014) *NEW ENGL J MED*, 371 (4), 326-338.

IF: 55.8730

Lebwohl M.G., Bachelez H., Barker J., Girolomoni G., Kavanaugh A., Langley R.G., Paul C.F., Puig L., Reich K., Van De Kerkhof P.C.M., Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. (2014) *J AM ACAD DERMATOL*, 70 (5).

IF: 4.4490

Lopez-Ferrer A., Dalmau J., Fernandez-Figueras M.T., Puig L., Pityriasis rubra pilaris triggered by photodynamic therapy with response to tumor necrosis factor α -Blocking agents and acitretin. (2014) *CUTIS*, 93 (3).

IF: 0.7190

Mrowietz U., De Jong E.M.G.J., Kragballe K., Langley R., Nast A., Puig L., Reich K., Schmitt J., Warren R.B., A consensus report on appropriate treatment optimization and transitioning in the management of moder-

ate-to-severe plaque psoriasis. (2014) *J EUR ACAD DERMATOL*, 28 (4), 438-453.

IF: 2.8260

Novoa A., Baselga E., Sock-line hyperpigmentation. (2014) *AN PEDIATR*, 81 (6), 401-402.

IF: 0.8330

Paul C., Puig L., Kragballe K., Luger T., Lambert J., Chimenti S., Girolomoni G., Nicolas J.-F., Rizova E., Lavie F., Mistry S., Bergmans P., Barker J., Reich K., Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: A randomized clinical trial (TRANSIT). (2014) *BRIT J DERMATOL*, 170 (2), 425-434.

IF: 4.2750

Puig L., Kirby B., Mallbris L., Strohal R., Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis. (2014) *EUR J DERMATOL*, 24 (3), 305-311.

IF: 1.9900

Puig L., Strohal R., Fuiman J., Pedersen R., Szumski A., Koenig A.S., Robertson D., Drexel H., Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. (2014) *J DERMATOL TREAT*, 25 (6), 470-481.

IF: 1.6690

Reich K., Puig L., Paul C., Kragballe K., Luger T., Lambert J., Chimenti S., Girolomoni G., Nicolas J.-F., Rizova E., Brunori M., Mistry S., Bergmans P., Barker J., One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: The TRANSIT randomized trial in moderate-to-severe plaque psoriasis. (2014) *BRIT J DERMATOL*, 170 (2), 435-444.

IF: 4.2750

Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S., Wang Y., Shen Y.-K., Doyle M.K., Mendelsohn A.M., Gottlieb A.B., Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. (2014) *ANN RHEUM DIS*, 73 (6), 990-999.

IF: 10.3770

Rodriguez-Pardo D., Pigrau C., Lora-Tamayo J., Soriano A., del Toro M.D., Cobo J., Palomino J., Euba G., Riera M., Sanchez-Somoli-

nos M., Benito N., Fernandez-Sampedro M., Sorli L., Guio L., Iribarren J.A., Baraia-Etxaburu J.M., Ramos A., Bahamonde A., Flores-Sanchez X., Corona P.S., Ariza J., Amat C., Larrosa M.N., Puig M., Murillo O., Cabo X., Goenaga M.A., Elola M., De la Herran G., Garcia-Arenzana J.M., Garcia-Ramiro S., Martinez-Pastor J.C., Tornero E., Garcia-Lechuz J.M., Marin M., Villanueva M., Lopez I., Cisterna R., Santamaria J.M., Gomez M.-J., Puente A., Cano P., Horcajada J.P., Gonzalez-Minguez P., Portillo E., Puig L., Franco M., Jordan M., Coll P., Amador-Mellado J., Fuster-Foz C., Garcia-Paino L., Nieto I., Muniain M.A., Suarez A.I., Praena J., Gomez M.-J., Puente A., Maseguer M.A., Garagorri E., Pintado V., Marinescu C., Ramirez A., Montaner F., Munez E., Alvarez T., Garcia R., Puente E., Salas C., Fariñas M.C., Perez J.M., Achabal B.V., Montejo Baranda J.M., Gram-negative prosthetic joint infection: Outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. (2014) *CLIN MICROBIOL INFEC*, 20 (11), O911-O919.

IF: 5.7680

Ruiz Salas V., Alegre M., Garces J.R., Puig L., Locally advanced and metastatic basal cell carcinoma: Molecular pathways, treatment options and new targeted therapies. (2014) *EXPERT REV ANTICANC*, 14 (6), 741-749.

IF: 2.2490

Torres-Pradilla M., Baselga E., Failure of intralesional propranolol in infantile hemangiomas. (2014) *PEDIATR DERMATOL*, 31 (2), 156-158.

IF: 1.0150

Weitz N.A., Bayer M.L., Baselga E., Torres M., Siegel D., Drolet B.A., Frieden I.J., Haggstrom A.N., The biker-glove pattern of segmental infantile hemangiomas on the hands and feet. (2014) *J AM ACAD DERMATOL*, 71 (3), 542-547.

IF: 4.4490

Yelamos O., Catala A., Vilarrasa E., Roe E., Puig L., Acute severe methotrexate toxicity in patients with psoriasis: A case series and discussion. (2014) *DERMATOLOGY*, 229 (4), 306-309.

IF: 1.5690

Yelamos O., Roe E., Baselga E., Puig L., Pediatric cutaneous lupus erythematosus treated with pulsed dye laser. (2014) *PEDIATR DERMATOL*, 31 (1), 113-115.

IF: 1.0150

Dermatology

Other Publications

- ▶ Baselga Torres E., Torres-Pradilla M., Cutaneous manifestations in children with diabetes mellitus and obesity. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (6), 546-557.
- ▶ Canete J.D., Dauden E., Queiro R., Aguilar M.D., Sanchez-Carazo J.L., Carrascosa J.M., Carretero G., Garcia-Vivar M.L., Lazaro P., Lopez-Estebarez J.L., Montilla C., Ramirez J., Rodriguez-Moreno J., Puig L., Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: A Delphi study. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (3), 216-232.
- ▶ Canete J.D., Dauden E., Queiro R., Aguilar M.D., Sanchez-Carazo J.L., Carrascosa J.M., Carretero G., Garcia-Vivar M.L., Lazaro P., Lopez-Estebarez J.L., Montilla C., Ramirez J., Rodriguez-Moreno J., Puig L., Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (3), 216-232.
- ▶ Canete J.D., Puig L., Multidisciplinary teams for psoriatic arthritis: On aims and approaches. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (4), 325-327.
- ▶ Carrascosa J.M., Puig L., IL-17 in psoriasis. The final frontier or just another brick in the wall? (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105, 6-8.
- ▶ Catala A., Barnadas M.A., Munoz C., Puig L., Cutaneous leishmaniasis in a patient receiving infliximab for psoriatic arthritis: Treatment with cryotherapy and intralésional meglumine antimonate. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (7), 714-716.
- ▶ Ferriols A.P., Aguilera J., Aguilera P., De Argila D., Barnadas M.A., De Cabo X., Carrascosa J.M., De Galvez Aranda M.V., Gardezabal J., Gimenez-Arnau A., Lecha M., Lorente J., Martinez-Lozano J.A., Rodriguez Granados M.T., Sola Y., Utrillas M.P., Determination of minimal erythema dose and anomalous reactions to UVA radiation by skin phototype. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (8), 780-788.
- ▶ Fuentes-Finkelstein P., Barnadas M., Gelpi C., Puig L., Pemphigus herpetiformis with progression to pemphigus foliaceus: A case report. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (5), 526-528.
- ▶ Lopez-Ferrer A., Laiz-Alonso A., Actualización en artritis psoriásica. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (10), 913-922.
- ▶ Ortiz De Frutos F.J., Torreló A., De Lucas R., Gonzalez M.A., Alomar A., Vera A., Ros S., Mora A.M., Cuervo J., Patient perspectives on triggers, adherence to medical recommendations, and disease control in atopic dermatitis: The DATOP study. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (5), 487-496.
- ▶ Puig L., Biologic therapies for moderate to severe psoriasis are not interchangeable. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (5), 483-486.
- ▶ Puig L., Biosimilars and reference biologics: Decisions on biosimilar interchangeability require the involvement of dermatologists. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (5), 435-437.
- ▶ Puig L., Carrascosa J.M., Therapeutic implications of IL-17A blockade in psoriasis. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105, 1-5.
- ▶ Puig L., Fan T., Ding Q., Smith N.E., Predictors of biologic treatment of psoriasis: A non-interventional study. (2014) CLINICO ECONOMICS AND OUTCOMES RESEARCH, 6 (1), 93-100.
- ▶ Puig L., Julia A., Marsal S., The pathogenesis and genetics of psoriasis. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (6), 535-545.
- ▶ Puig L., Lopez-Ferrer A., Vilarrasa E., Análisis de coste-eficacia incremental de los tratamientos biológicos para la psoriasis en los momentos de valoración significativos para la práctica clínica. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (10), 951-953.
- ▶ Puig L., Methotrexate: New therapeutic approaches. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (6), 583-589.
- ▶ Puig L., Treatment of moderate to severe plaque psoriasis with biologics: Analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapy. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (4), 401-412.
- ▶ Ros S., Puig L., Carrascosa J.M., Cumulative life course impairment: The imprint of psoriasis on the patient's life. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (2), 128-134.
- ▶ Ruiz V., Manubens E., Puig L., Psoriasis in pregnancy: A review (II). (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (9), 813-821.
- ▶ Ruiz V., Manubens E., Puig L., Psoriasis in pregnancy: A review (I). (2014) Actas Dermo-Sifilográficas, 105 (8), 734-743.
- ▶ Ruiz-Salas V., Alegre M., Lopez-Ferrer A., Garces J.R., Vismodegib: A review. (2014) Actas Dermo-Sifilográficas, 105 (8), 744-751.
- ▶ Sanchez-Regana M., Aldunce Soto M.J., Belinchon Romero I., Ribera Pibernat M., Lafuente-Urrez R.F., Carrascosa Carrillo J.M., Ferrandiz Foraster C., Puig Sanz L., Dauden Tello E., Vidal Sarro D., Ruiz-Villaverde R., Fonseca Capdevila E., Rodriguez Cerdeira M.C., Alsina Gibert M.M., Herrera Acosta E., Marron Moya S.E., Directrices del grupo español de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biológicos en pacientes con psoriasis en localizaciones de difícil tratamiento (uñas, cuero cabelludo, palmas y plantas). (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (10), 923-934.
- ▶ Yelamos O., Barnadas M.A., Diaz C., Puig L., Primary anetoderma associated with primary Sjögren syndrome and anticardiolipin antibodies. (2014) ACTAS DERMO-SIFILIOGRÁFICAS, 105 (1), 99-101.

Anaesthesiology

Coordinator

M. Victoria Moral HSCSP
vmoralg@santpau.cat

Members

Marc Bausili HSCSP
M. Alba Bosch HSCSP
Juan M. Campos HSCSP
Bartomeu Cantalops HSCSP
Joan Ignasi Casas HSCSP
Sebastian Castrillón HSCSP
Estela Clotas HSCSP
Nieves Espinosa HSCSP
J. Antonio Fernández HSCSP
Marta Ferrándiz HSCSP
Adrià Font HSCSP
Josefa Galán HSCSP
Mercedes García HSCSP
M. Àngels Gil de Bernabe HSCSP
Francisco J. González HSCSP
Raul González HSCSP
Rolf Hoffmann HSCSP
Inmaculada India HSCSP
Nadia Diana Kinast HSCSP
Tobias Koller HSCSP
Beatriz Martín HSCSP
Alfonso Martínez HSCSP
Alfredo R. Merten HSCSP
Alexia Nebot HSCSP
Pilar Paniagua HSCSP
Xavier Peláez HSCSP
M. Carmen Pérez HSCSP
Santiago Piñol HSCSP
Miren Revuelta HSCSP
M. Rosario Rivero HSCSP
M. Teresa Rivilla HSCSP
Mireia Rodríguez HSCSP
M. Teresa Santaularia HSCSP
M. Carmen Unzueta HSCSP
Jordi Vila HSCSP
J. Maria Villamor HSCSP



Main Lines of Research

Critical analysis of new clinical technologies

- ▶ Anaconda-inhaled sedation in patients undergoing postoperative mechanical ventilation.
- ▶ New monitoring systems for anaesthesia depth and cerebral oxygen status.

Perioperative medicine

- ▶ Epidemiological study of perioperative morbidity and mortality in collaboration with the epidemiology department of the HSCSP (Iberoamerican Cochrane Centre) and the European Society of Anesthesiology.

Rationalization of perioperative fluid therapy and blood products

- ▶ Institutional protocolization of massive transfusions.
- ▶ Monitoring of critical perioperative coagulopathy.

- ▶ Identification and recovery from preoperative anaemia.
- ▶ Study of the Prevalence of perioperative transfusions.
- ▶ Monitoring of perioperative fluid therapy.

New health service delivery systems

- ▶ Professional team preoperative evaluations.
- ▶ Zero preoperative stay.

Physiology, pharmacology and anaesthetic techniques

- ▶ Intraoperative respiratory physiology.
- ▶ Peripheral nerve blocking for postoperative analgesia in CMA
- ▶ Lipid Rescue due systemic complications after ALR

Challenges

- ▶ Critical analysis of new clinical technologies.
- ▶ Patient blood management.
- ▶ Perioperative medicine.
- ▶ Development of new health service systems.
- ▶ Clinical and preclinical research into physiology, pharmacology and anaesthetic/analgesic techniques.

Collaborations with other IIB Sant Pau Groups

- ▶ MANAGE (Management of myocardial injury after non cardiac surgery): Randomized clinical trial. Centro Cochrane. ClinicalTrials.gov: NCT01661101.

External Collaborations

- ▶ POPULAR (Postanesthesia PULmonary complications After use of muscle Relaxants in Europe), multicentre observational study. European Society of Anaesthesiology (ESA).
- ▶ Analysis of the Hemostatic Potential of Coagulation Factor Concentrates in an In Vitro Model of Extreme Hemodilution. Beca Heimburger.

*TIF: 234.1150 **MIF: 18.0009

Botto F, *et al.* Myocardial Injury after Noncardiac Surgery: A Large, International, Prospective Cohort Study Establishing Diagnostic Criteria, Characteristics, Predictors, and 30-day Outcomes. (2014) ANESTHESIOLOGY, 120 (3), 564-578.

IF: 5.8790

Cegarra-Sanmartin V., Gonzalez-Rodriguez R., Paniagua-Iglesias P., Santamaria-Ortiz A., Cueva L.F., Galan-Serrano J., Victoria Moral-Garcia M., Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. (2014) J CARDIOTHOR VASC AN, 28 (4), 1020-1024.

IF: 1.4630

Devereaux P.J., Mrkobrada M., Sessler D.I., Leslie K., Alonso-Coello P., Kurz A., Villar J.C., Sigamani A., Biccard B.M., Meyhoff C.S., Parlow J.L., Guyatt G., Robinson A., Garg A.X., Rodseth R.N., Botto F., Lurati Buse G., Xavier D., Chan M.T.V., Tiboni M., Cook D., Kumar P.A., Forget P., Malaga G., Fleischmann E., Amir M., Eikelboom J., Mizera R., Torres D., Wang C.Y., VanHelder T., Paniagua P., Berwanger O., Srinathan S., Graham M., Pasin L., Le Manach Y., Gao P., Pogue J., Whitlock R., Lamy A., Kearon C., Baigent C., Chow C., Pettit S., Chrolavicius S., Yusuf S., Aspirin in patients undergoing noncardiac surgery. (2014) NEW ENGL J MED, 370 (16), 1494-1503.

IF: 55.8730

Devereaux P.J., Sessler D.I., Leslie K., Kurz A., Mrkobrada M., Alonso-Coello P., Villar J.C., Sigamani A., Biccard B.M., Meyhoff C.S., Parlow J.L., Guyatt G., Robinson A., Garg A.X., Rodseth R.N., Botto F., Lurati Buse G., Xavier D., Chan M.T.V., Tiboni M., Cook D., Kumar P.A., Forget P., Malaga G., Fleischmann E., Amir M., Eikelboom J., Mizera R., Torres D., Wang C.Y., VanHelder T., Paniagua P., Berwanger O., Srinathan S., Graham M., Pasin L., Le Manach Y., Gao P., Pogue J., Whitlock R., Lamy A., Kearon C., Chow C., Pettit S., Chro-

lavicius S., Yusuf S., Clonidine in patients undergoing noncardiac surgery. (2014) NEW ENGL J MED, 370 (16), 1504-1513.

IF: 55.8730

Garcia-Alvarez M., Marik P., Bellomo R., Sepsis-associated hyperlactatemia. (2014) CRIT CARE, 18 (5).

IF: 4.4760

Garcia-Alvarez M., Marik P., Bellomo R., Stress hyperlactataemia: Present understanding and controversy. (2014) LANCET DIABETES ENDO, 2 (4), 339-347.

IF: 9.1850

Garg A.X., Kurz A., Sessler D.I., Cuerden M., Robinson A., Mrkobrada M., Parikh C.R., Mizera R., Jones P.M., Tiboni M., Font A., Cegarra V., Gomez M.F.R., Meyhoff C.S., VanHelder T., Chan M.T.V., Torres D., Parlow J., Clanchet M.D.N., Amir M., Bidgoli S.J., Pasin L., Martinsen K., Malaga G., Myles P., Acedillo R., Roshanov P.S., Walsh M., Dresser G., Kumar P., Fleischmann E., Villar J.C., Painter T., Biccard B., Bergese S., Srinathan S., Cata J.P., Chan V., Mehra B., Wijesundera D.N., Leslie K., Forget P., Whitlock R., Yusuf S., Devereaux P.J., Perioperative aspirin and clonidine and risk of acute kidney injury: A randomized clinical trial. (2014) JAMA-J AM MED ASSOC, 312 (21), 2254-2264.

IF: 35.2890

Garg A.X., Kurz A., Sessler D.I., Cuerden M., Robinson A., Mrkobrada M., Parikh C., Mizera R., Jones P.M., Tiboni M., Rodriguez R.G., Popova E., Gomez M.F.R., Meyhoff C.S., VanHelder T., Chan M.T.V., Torres D., Parlow J., De Nadal Clanchet M., Amir M., Bidgoli S.J., Pasin L., Martinsen K., Malaga G., Myles P., Acedillo R., Roshanov P., Walsh M., Dresser G., Kumar P., Fleischmann E., Villar J.C., Painter T., Biccard B., Bergese S., Srinathan S., Cata J.P., Chan V., Mehra B., Leslie K., Whitlock R., Devereaux P.J., Aspirin and clonidine in noncardiac surgery: Acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised

controlled trial. (2014) BMJ OPEN, 4 (2).

IF: 2.2710

Iglesias P.P., Ruano S.D., Alvarez-Garcia J., Myocardial injury after noncardiac surgery. (2014) REV ESP CARDIOL, 67 (10), 794-796.

IF: 3.7920

Neto A.S., Hemmes S.N.T., Barbas C.S.V., Beiderlinden M., Fernandez-Bustamante A., Futier E., Hollmann M.W., Jaber S., Kozian A., Licker M., Lin W.-Q., Moine P., Scavonetto F., Schilling T., Selmo G., Severgnini P., Sprung J., Treschan T., Unzueta C., Weingarten T.N., Wolthuis E.K., Wrigge H., de Abreu M.G., Pelosi P., Schultz M.J., Incidence of mortality and morbidity related to postoperative lung injury in patients who have undergone abdominal or thoracic surgery: A systematic review and meta-analysis. (2014) LANCET RESP MED, 2 (12), 1007-1015.

IF: 9.6290

Pajares Ruiz V., Torrego Fernandez A., Puzo Ardanuy C., Gil de Bernabe A., Use of an occlusion balloon in transbronchial lung cryobiopsy. (2014) ARCH BRONCONEUMOL, 50 (7), 306-310.

IF: 1.8230

Pajares V., Puzo C., Castillo D., Lerma E., Angeles Montero M., Ramos-Barbon D., Amor-Carro O., De Bernabe A.G., Franquet T., Plaza V., Hetzel J., Sanchis J., Torrego A., Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: A randomized trial. (2014) RESPIROLOGY, 19 (6), 900-906.

IF: 3.3450

Schultz M.J., Victoria Moral M., Cegarra V., Merten A., Unzueta C., High versus low positive end-expiratory pressure during general anaesthesia for open abdominal surgery (PROVHILO trial): A multicentre randomised controlled trial. (2014) LANCET, 384 (9942), 495-503.

IF: 45.2170

Anaesthesiology

Other Publications

- ▶ Arguis M.J., Navarro R., Regueiro A., Arbelo E., Sierra P., Sabate S., Galan J., Ruiz A., Matute P., Roux C., Gomar C., Rovira I., Mont L., Fita G., Perioperative management of atrial fibrillation. (2014) REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 61 (5), 262-271.
- ▶ Cegarra-Sanmartin V., Gonzalez-Rodriguez R., Paniagua-Iglesias P., Santamaria-Ortiz A., Cueva L.F., Galan-Serrano J., Moral-Garcia M.V., Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. (2014) JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 28 (4), 1008-1012.
- ▶ Ferrandiz Mach M., Santeularia Verges M.T., Catala Puicbo E., Tratamiento analgésico de las metástasis óseas. (2014) DOLOR, 29 (2), 67-85.
- ▶ Fita G., Maestre M.L., Role of intraoperative transesophageal echocardiography in the cardiac surgery. (2014) CIRUGIA CARDIOVASCULAR, 21 (1), 6-8.
- ▶ Gonzalez-Rodriguez R., Munoz Martinez A., Galan Serrano J., Moral Garcia M.V., Health worker exposure risk during inhalation sedation with sevoflurane using the (AnaConDa®) anaesthetic conserving device. (2014) REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 61 (3), 133-139.
- ▶ Kinast N.D., Nebot Galindo A., Cantalops Pericas B., Moral Garcia M.V., Patient with human immunodeficiency virus and an unexpected difficult airway. (2014) REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 61 (7), 407-408.
- ▶ Paniagua Iglesias P., Blood transfusion and infection after cardiac surgery. (2014) CIRUGIA CARDIOVASCULAR, 21 (3), 223-224.
- ▶ Sanchez-Calatrava C.A., Asuero M.S., Moral V. Controversy over the use of hydroxyethyl starch solutions. Is the use of low molecular weight hydroxyethyl starch contraindicated? (2014) REV. ESP. ANESTESIOL REANIM, 61(6): 299-303.

Plastic Surgery

Coordinator

Jaume Masia
jmasia@santpau.cat

HSCSP

Members

Manuel Fernández HSCSP
Susana López HSCSP
María Luisa Nardulli HSCSP
Gemma Pons HSCSP
M. Carmen Vega HSCSP



Main Lines of Research

- ▶ Application of imaging techniques to intraoperative studies of perforators with the aim to improve the design of flaps, evaluate the suitability and viability of perfusion avoiding secondary postoperative complications and vascular complications.
- ▶ Anatomical studies of the variability of perforators in the following regions: internal mammary artery, inferior epigastric system and internal superficial circumflex system.
- ▶ Study of the perioperative and postoperative factors that influence on the viability of the microsurgical free flaps.
- ▶ Research by indocyanine green angiography of the concept of post-vascular balance post dissection of perforator flap.
- ▶ Research by indocyanine green angiography of the relationship between the different anatomical patterns of lymphatic vessels in the upper extremity and its readiness to develop lymphedema in the affected breast cancer patients.
- ▶ Feasibility of the research in animal models of major surgical and nonsurgical techniques existing today to treat secondary lymphatic insufficiency: fat transplant autologous stem cells, stem cell transplantation autologous bone marrow, lymphatic-venous anastomosis flap free vascularised autologous lymph node.

Challenges

- ▶ Consolidate and optimize preoperative management techniques for locating perforating vessels suitable for each microsurgical flap.
- ▶ Minimize intra- and postoperative complications in perforator flaps using new imaging techniques to visualize intraoperatively patterns of vascularisation of the flaps and vascular dominance.
- ▶ Lymphedema prevention in those patients with mastectomy in which we perform searching procedures of sentinel node and / or axillary lymph node dissections using new techniques of surgical treatment for this disease (lymphatic venous anastomosis, transfer of vascularised nodes).
- ▶ Identification by indocyanine green angiography for those patients affected with breast cancer with a major risk of developing secondary lymphedema.

Active Grants

- ▶ Jaume Masia Ayala. European School of Lymphatic Diseases. ERASMUS mobility strategies and removal of barriers to mobility in higher education. E-LYMPH - ERASMUS 527658-LLP-1-2012-1. Duration: 01/10/12-30/09/15. €3,590.
- ▶ Jaume Masia. Modelo experimental comparativo entre trasplante de células madre de tejido adiposo/médula ósea, anastomosis linfaticovenosas, trasplante de ganglios

vascularizados en el linfedema. Proyectos de Investigación en Salud 2013. PI13/02793. Duration: 01/01/14-31/12/16. €29,000.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 4.2270 **MIF: 1.4090

Scientific
Production

Masia J., Olivares L., Koshima I., Teo T.C., Suominen S., Van Landuyt K., Demirtas Y., Becker C., Pons G., Garusi C., Mitsunaga N., Barcelona consensus on supermicrosurgery. (2014) J RECONSTR MICROSURG, 30 (1), 53-58.

IF: 1.3120

Pons G., Masia J., Loschi P., Nardulli M.L., Duch J., A case of donor-site lymphoedema after lymph node-superficial circumflex iliac artery perforator flap transfer. (2014) J PLAST RECONSTR AES, 67 (1), 119-123.

IF: 1.4210

Pons G., Masia J., Sanchez-Porro L., Larranaga J., Clavero J.A., Paramuscular perforators in DIEAP flap for breast reconstruction. (2014) ANN PLAS SURG, 73 (6), 659-661.

IF: 1.4940

Other
Publications

- ▶ Tratamiento quirúrgico (chapter 12). In: Libro Blanco sobre Patología Venosa y Linfática. EDMISA, S.A. Editores Médicos. ISBN 978-84-7714-398-7
- ▶ Lymphovenular anastomosis combined with vascularized lymph node transfer for breast cancer-related lymphedema (chapter XIII). In: World Clinics in Plastic Surgery. Elsevier. ISSN 0094-198.
- ▶ Surgical management of post mastectomy lymphedema. In: Neligan P. (ed) Plastic Surgery 4th edition: Breast volume. Elsevier.

Palliative Care

Coordinator

Antonio Pascual HSCSP
apascual@santpau.cat

Members

Nadia Collette HSCSP RI
Ernest Güell HSCSP
Oscar Fariñas HSCSP
Adelaida Ramos HSCSP



Main Lines of Research

- ▶ Symptom evaluation and control: pain, dyspnoea, cognitive failure, complex situations.
- ▶ End-of-life ethical issues: sedation, expression of a desire for death, euthanasia.
- ▶ Psychosocial care for patients and families: adaptation to the terminal situation, grief, spiritual needs.
- ▶ Training in palliative care: training needs, outcomes.
- ▶ Art therapy.

Challenges

- ▶ Psychosocial care for patients and families.
- ▶ Counselling and hospital sensitization.
- ▶ Quality evaluation and control.
- ▶ Symptom evaluation and control.
- ▶ Integrated care: analysis and care of end-of-life emotional, social and spiritual dimensions and adequate ethical reflection in decision making.

Doctoral Theses

- ▶ Nadia Collette. Art therapy for terminal patients. Universidad de Valencia Director: Pilar Barreto Martín.

Active Grants

- ▶ Antoni Pascual López. Tratamiento quimioterápico vs un programa de apoyo integral (PAI) en pacientes con cáncer avanzado tratados previamente con quimioterapia: ensayo clínico aleatorizado multicéntrico.

MINECO-ISCIII Projecte 2011. PI11/01366. Duration: 01/01/12-31/12/14. €125,100.

Note: Total amount granted to PI. It does not include indirect costs.

***TIF: 2.7950 **MIF: 2.7950**

Scientific Production

Benito E., Oliver A., Galiana L., Barreto P., Pascual A., Gomis C., Barbero J., Development and validation of a new tool for the assessment and spiritual care of palliative care patients. (2014) J PAIN SYMPTOM MANAG, 47 (6).
IF: 2.7950

*Total Impact Factor **Mean Impact Factor

Andrology

Coordinator

Eduard Ruiz-Castañé F. Puigvert
 eruiz@fundaciopuigvert.es

Members

Lluís Bassas F. Puigvert
 Olga Martínez F. Puigvert
 Csilla Krausz F. Puigvert
 Deborah Lo Giacco F. Puigvert
 Osvaldo Rajmil F. Puigvert
 Patricia Ruiz F. Puigvert



Main Lines of Research

- ▶ Genetics applied to male infertility.
- ▶ Optimisation of preimplantation genetics diagnosis and in vitro fertilization techniques.
- ▶ Clinical research into new surgical procedures, drugs and medical devices applied

to andrological diseases and conditions (male sexual dysfunction, hypogonadism, Peyronie disease, premature ejaculation, sexually transmitted diseases).

Challenges

- ▶ Our multidisciplinary team of professionals develops translational research in the field of diagnosis and treatment of andrological disorders. To improve our knowledge and thereby improve healthcare for patients, we seek to continue active projects, develop new lines of investigation,

increase the number of international publications, train professionals and enhance collaboration with hospital and university groups inside and outside the IIB Sant Pau.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Nephrology.

External Collaborations

National

- ▶ Medical and Molecular Genetics Centre (RI)-IDIBELL: genetics applied to infertility.
- ▶ Cellular Biology and Medical Genetics Unit-UAB: preimplantation genetic diagnosis techniques.

International

- ▶ Mario Serio Experimental and Clinical Biomedical Sciences Unit, University of Florence: genetics applied to male infertility.
- ▶ Reproductive Genomics Laboratory, Human Genetics Centre (KU Leuven): genetics applied to male infertility.
- ▶ New England Research Institutes: hypogonadism.
- ▶ European Academy of Andrology: radiology examinations of the male genital tract.

Private

- ▶ Participation in clinical studies including clinical trials and postauthorization studies sponsored by national and international pharmaceutical companies.

Grants Awarded
in 2014

- ▶ Csilla Gabriella Krausz. Estudio genético y genómico de subtipos específicos de azoospermia secretora: desarrollo de nuevas herramientas diagnósticas y pronósticas. Proyectos de Investigación en Salud 2014. PI14/01250. €86,500.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 37.1150 **MIF: 3.7115

Scientific Production

Bonache S., Algaba F, Franco E., Bassas L, Larriba S., Altered gene expression signature of early stages of the germ line supports the pre-meiotic origin of human spermatogenic failure. (2014) *ANDROLOGY-US*, 2 (4), 596-606.

IF: 2.2980

Chianese C., Gunning A.C., Giachini C., Daquin F., Balercia G., Ars E., Lo Giacco D., Ruiz-Castane E., Forti G., Krausz C., X chromosome-linked CNVs in male infertility: Discovery of overall duplication load and recurrent, patient-specific gains with potential clinical relevance. (2014) *PLOS ONE*, 9 (6).

IF: 3.2340

Daina G., Ramos L., Rius M., Obradors A., Del Rey J., Giralt M., Campillo M., Velilla E., Pujol A., Martinez-Pasarell O., Benet J., Navarro J., Non-meiotic chromosome instability in human immature oocytes. (2014) *EUR J HUM GENET*, 22 (2), 202-207.

IF: 4.3490

Krausz C., Chianese C., Lo Giacco D., Tuttmann F., Ferlin A., Ntostis P., Vinci S., Balercia G., Ars E., Ruiz-Castane E., Giglio S., Kliesch S., Forti G., Reply: Y-chromosome microdele-

tions are not associated with SHOX haploinsufficiency. (2014) *HUM REPROD*, 29 (5), 1114-1115.

IF: 4.5690

Lo Giacco D., Chianese C., Ars E., Ruiz-Castan E., Forti G., Krausz C., Recurrent X chromosome-linked deletions: Discovery of new genetic factors in male infertility. (2014) *J MED GENET*, 51 (5), 340-344.

IF: 6.3350

Lo Giacco D., Chianese C., Sanchez-Curbelo J., Bassas L., Ruiz P., Rajmil O., Sarquella J., Vives A., Ruiz-Castañ E., Oliva R., Ars E., Krausz C., Clinical relevance of Y-linked CNV screening in male infertility: New insights based on the 8-year experience of a diagnostic genetic laboratory. (2014) *EUR J HUM GENET*, 22 (6), 754-761.

IF: 4.3490

Martorell M.R., Martinez-Pasarell O., Lopez O., Polo A., Sandalinas M., Garcia-Guixe E., Bassas L., Chromosome 16 abnormalities in embryos and in sperm from a male with a fragile site at 16q22.1. (2014) *CYTOGENET GENOME RES*, 142 (2), 134-139.

IF: 1.5610

Munoz X., Navarro M., Mata A., Bassas L, Larriba S., Association of PIWIL4 genetic variants with germ cell maturation arrest in infertile Spanish men. (2014) *ASIAN J ANDROL*, 16 (6), 931-933.

IF: 2.5960

Ramos L., Del Rey J., Daina G., Garcia-Aragones M., Armengol L., Fernandez-Encinas A., Parriego M., Boada M., Martinez-Pasarell O., Martorell M.R., Casagran O., Benet J., Navarro J., Oligonucleotide arrays vs. Meta-phase-comparative genomic hybridisation and bac arrays for single-cell analysis: First applications to preimplantation genetic diagnosis for robertsonian translocation carriers. (2014) *PLOS ONE*, 9 (11).

IF: 3.2340

Ramos L., Del Rey J., Daina G., Martinez-Pasarell O., Rius M., Tunon D., Campillo M., Benet J., Navarro J., Does the S phase have an impact on the accuracy of comparative genomic hybridization profiles in single fibroblasts and human blastomeres? (2014) *FERTIL STERIL*, 101 (2).

IF: 4.5900

Urology

Coordinator

Humberto
Villavicencio F. Puigvert
hvillavicencio@fundaciopuigvert.es

Members

Ferran Algaba F. Puigvert
Yolanda Arce F. Puigvert
Alberto Breda F. Puigvert
Ana Bujons F. Puigvert
Jorge Caffaratti F. Puigvert
Marco Cosentino F. Puigvert
Sheila Fernández F. Puigvert
José María Gaya F. Puigvert
Fèlix Millán F. Puigvert
Joan Palou F. Puigvert
Óscar Rodríguez F. Puigvert
Ferran Rousaud F. Puigvert



Main Lines of Research

- ▶ Tissue engineering applied to urological oncology and congenital urogenital malformations.
- ▶ Genetic and immunohistochemistry analyses applied to urological cancers (diagnostic and prognostic biomarkers in urine, blood and tissues).
- ▶ Clinical research of new surgical procedures, drugs and medical device products applied to urological oncology, kidney transplantation and benign urogenital pathology (e.g. incontinence, benign hyperplasia of the prostate, lithiasis).

Challenges

- ▶ Translational research in the field of diagnosis and treatment of urological disorders. We seek to continue active projects, develop new lines of investigation, increase the number of international publications, train professionals and increase collaboration with hospital and university groups to improve our knowledge about kidney disorders and thereby improve healthcare for patients.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Nephrology: genetic predisposition to prostate cancer.
- ▶ Clinical Epidemiology and Healthcare: epidemiological studies of urological cancers.
- ▶ Clinical Oncology: detection of prognosis biomarkers for drug response in kidney cancer.

External Collaborations

National academic

- ▶ IDIBELL Molecular Genetics Laboratory: cystine lithiasis.
- ▶ CNIO: biomarkers in bladder cancer.
- ▶ National scientific societies (Spanish Urology Association, etc): clinical studies.

International academic

- ▶ Aarhus University Molecular Genetics Department: bladder cancer.
- ▶ International Robotic Cystectomy Consortium: robotic cystectomy.
- ▶ International Renal Cell Carcinoma-Venous Thrombus Consortium: renal-cava thrombus in kidney cancer.

Private national and international collaborations

- ▶ Clinical trials and postauthorization studies promoted by national and international pharmaceutical companies.

Awards

- ▶ Gaya JM, Ahallal Y, Sánchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Benmamoun M, Cathelineau X. Current, new and novel therapy for castration-resistant prostate cancer. *Expert Review of Anticancer Therapy* 2013, 13(7): 819-827. Best Scientific Publication Reported in any Massmedia. II National Congress of Urology Catalan. Castelldefels, 10 May 2014.
- ▶ Rodríguez N, Bujons A, Caffaratti J, Garat JM, Villavicencio H. Quality of life in women with bladder exstrophy. Best Communication. XXV National Meeting of the AEU Pediatrics Urology Group, LXXIX National Congress of Urology. Tenerife, 14 June 2014.
- ▶ Villavicencio H. Professor Doctor Federico Texo Medal. 51st Argentinian Congress of Urology. Buenos Aires, 29 October 2014.
- ▶ Bujons A, Fernández C. Robotic prostatectomy in a 3 years old child. Best Surgical Video. XIX International Medical Cinema, Health and Telemedicine Contest. IX Iberic Forum of Telemedicine. Badajoz, 17-21 November 2014.
- ▶ Breda A (co-author). Promotion of crossed transplants in Spain. 25th Anniversary of the National Organisation of Transplants Award. Madrid, 22 October 2014.
- ▶ H. Villavicencio. SIU Distinguished Career Award 2014. Glasgow, 12 October 2014.
- ▶ Villavicencio H. Best Spanish Urologist. Forbes. December 2014.
- ▶ Secín F, Álvarez M, Martínez-Piñero L, Santaella F, Rozanec J, Featherstone M, García P, Jurado A, Castillo Cádiz O, Mora I, Vil-loldo G, Villarronga A, Schatloff O, Rovegno A, Monzo Gardiner J, Dávila H, Zequi S, Abreu Clavijo D, Nuñez Bragayrac L, Sotelo R, María Autran A, Finkelstein D, Palou J, Rodríguez-Faba O, Favaretto R, Villavicencio H. Professor Doctor Antonio Puigvert Award. Hispanic American experience in minimally invasive partial nephrectomy. American Confederation of Urology. Uruguay, 27 November 2014.

*TIF: 159.6180 **MIF: 3.7120

Scientific Production

- Ahmed K., Khan S.A., Hayn M.H., Agarwal P.K., Badani K.K., Derya Balbay M., Castle E.P., Dasgupta P., Ghavamian R., Guru K.A., Hemal A.K., Hollenbeck B.K., Kibel A.S., Menon M., Mottrie A., Nepple K., Pattaras J.G., Peabody J.O., Poulakis V., Pruthi R.S., Redorta J.P., Rha K.-H., Richstone L., Saar M., Scherr D.S., Siemer S., Stoeckle M., Wallen E.M., Weizer A.Z., Wiklund P., Wilson T., Woods M., Khan M.S., Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: Results from the international robotic cystectomy consortium. (2014) *EUR UROL*, 65 (2), 340-347.
IF: 13.9380
- Al-Daghmin A., Kauffman E.C., Shi Y., Badani K., Balbay M.D., Canda E., Dasgupta P., Ghavamian R., Grubb III R., Hemal A., Kaouk J., Kibel A.S., Maatman T., Menon M., Mottrie A., Nepple K., Pattaras J.G., Peabody J.O., Poulakis V., Pruthi R., Palou Redorta J., Rha K.-H., Richstone L., Schanne F., Scherr D.S., Siemer S., Stockle M., Wallen E.M., Weizer A., Wiklund P., Wilson T., Wilding G., Woods M., Guru K.A., Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: Results from the International Radical Cystectomy Consortium (IRCC). (2014) *BJU INT*, 114 (1), 98-103.
IF: 3.5330
- Algaba F., Pathological consideration of indolent and clinically non-significant prostate cancer definition. (2014) *ARCH ESP UROL*, 67 (5), 393-399.
IF: 0.3090
- Angulo J.C., Palou J., Garcia-Tello A., De Fata F.R., Rodriguez O., Villavicencio H., Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette- Guérin. (2014) *ACTAS UROL ESP*, 38 (3), 164-171.
IF: 1.0220
- Bach T., Muschter R., Herrmann T.R., Knoll T., Scoffone C.M., Laguna M.P., Skolarikos A., Rischmann P., Janetschek G., De la Rosette J.J., Nagele U., Malavaud B., Breda A., Palou J., Bachmann A., Frede T., Geavlete P., Liatsikos E., Jichlinski P., Schwaibold H.E., Chlosta P., Martov A.G., Lapini A., Schmidbauer J., Djavan B., Stenzl A., Brausi M., Rassweiler J.J., Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: Summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. (2014) *BJU INT*, 115 (1), 14-23.
IF: 3.5330
- Berney D.M., Algaba F., Camparo P., Comperat E., Griffiths D., Kristiansen G., Lopez-Beltran A., Montironi R., Varma M., Egevad L., Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. (2014) *VIRCHOWS ARCH*, 464 (5), 583-587.
IF: 2.6510
- Berney D.M., Algaba F., Camparo P., Comperat E., Griffiths D., Kristiansen G., Lopez-Beltran A., Montironi R., Varma M., Egevad L., The reasons behind variation in Gleason grading of prostatic biopsies: Areas of agreement and misconception among 266 European pathologists. (2014) *HISTOPATHOLOGY*, 64 (3), 405-411.
IF: 3.4530
- Bonache S., Algaba F., Franco E., Bassas L., Larriba S., Altered gene expression signature of early stages of the germ line supports the pre-meiotic origin of human spermatogenic failure. (2014) *ANDROLOGY-US*, 2 (4), 596-606.
IF: 2.2980
- Breda A., Angerri O., Retrograde intrarenal surgery for kidney stones larger than 2.5cm. (2014) *CURR OPIN UROL*, 24 (2), 179-183.
IF: 2.3330
- Bujons A., Caffaratti J., Garat J.M., Villavicencio H., Long-term follow-up of transitional cell carcinoma of the bladder in childhood. (2014) *J PEDIATR UROL*, 10 (1), 167-170.
IF: 0.8980
- Cosentino M., Algaba F., Saldana L., Bujons A., Caffaratti J., Garat J.M., Villavicencio H., Juvenile granulosa cell tumor of the testis: A bilateral and synchronous case. Should testis-sparing surgery be mandatory? (2014) *UROLOGY*, 84 (3), 694-696.
IF: 2.1880
- Doizi S., Knoll T., Scoffone C.M., Breda A., Brehmer M., Liatsikos E., Cornu J.-N., Traxer O., First clinical evaluation of a new innovative ureteral access sheath (Re-Trace™): A European study. (2014) *WORLD J UROL*, 32 (1), 143-147.
IF: 2.6660
- Escudier B., Porta C., Schmidinger M., Algaba F., Patard J.J., Khoo V., Eisen T., Horwich A., Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. (2014) *ANN ONCOL*, 25, iii49-iii56.
IF: 7.04001
- Espinosa M., Ortega R., Sanchez M., Segarra A., Salcedo M.T., Gonzalez F., Camacho R.,

Urology

*TIF: 159.6180 **MIF: 3.7120

Valdivia M.A., Cabrera R., Lopez K., Pinedo F., Gutierrez E., Valera A., Leon M., Cobo M.A., Rodriguez R., Ballar In J., Arce Y., Garc la B., Munoz M.i.D., Association of C4d deposition with clinical outcomes in IgA nephropathy. (2014) CLIN J AM SOC NEPHRO, 9 (5), 897-904.

IF: 4.6130

Gaya J.M., Palou J., Laparoscopic distal ureterectomy for urothelial carcinoma is technically feasible... but is it oncologically safe? (2014) ACTAS UROL ESP, 38 (3), 205-206.

IF: 1.0220

Gomez-Veiga F., Portela-Pereira P., Cozar-Olmo J.M., Ahmed H., Moore C., Dickinson L., Algaba F., Izquierdo L., Alcaraz Asensio A., Martinez-Breijo S., Emberton M., Focal therapy for prostate cancer. rationale, indications and selection. (2014) ACTAS UROL ESP, 38 (6), 405-412.

IF: 1.0220

Gutierrez E., Moreno J.A., Praga M., Gutierrez E., Zamora I., Ballarin J.A., Arce Y., Jimenez S., Quereda C., Olea T., Martinez-Ara J., Segarra A., Bernis C., Garcia A., Goicoechea M., de Vinuesa S.G., Rojas-Rivera J., Persistent microhaematuria with negative or low proteinuria. (2014) NEFROLOGIA, 34 (1), 110-114.

IF: 1.2230

Iczkowski K.A., Egevad L., Ma J., Harding-Jackson N., Algaba F., Billis A., Camparo P., Cheng L., Clouston D., Comperat E.M., Datta M.W., Evans A.G., Griffiths D.F., Guo C.C., Hailamariam S., Huang W., Humphrey P.A., Jiang Z., Kahane H., Kristiansen G., La Rosa F.G., Lopez-Beltran A., MacLennan G.T., Magi-Galluzzi C., Merrimen J., Montironi R., Osunkoya A.O., Picken M.M., Rao N., Shah R.B., Shanks J.H., Shen S.S., Tawfik O.W., True L.D., Van Der Kwast T., Varma M., Wheeler T.M., Zynger D.L., Sahr N., Bostwick D.G., Intraductal carcinoma of the prostate: Interobserver reproducibility survey of 39 urologic pathologists. (2014) ANN DIAGN PATHOL, 18 (6), 333-342.

IF: 1.1170

Kamat A.M., Vlahou A., Taylor J.A., Hudson M.A., Pesch B., Ingersoll M.A., Todenhofer T., van Rhijn B., Kassouf W., Barton Grossman H., Behrens T., Chandra A., Goebell P.J., Palou J., Sanchez-Carbayo M., Schmitz-Drager B.J., Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. (2014) UROL ONCOL-SEMIN ORI, 32 (7), 1069-1077.

IF: 2.7680

Kamat A.M., Witjes J.A., Brausi M., Soloway M., Lamm D., Persad R., Buckley R., Bohle A.,

Colombel M., Palou J., Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. (2014) J UROLOGY, 192 (2), 305-315.

IF: 4.4710

Laguna M.P., Algaba F., Cadeddu J., Clayman R., Gill I., Gueglio G., Hohenfellner M., Joyce A., Landman J., Lee B., Van Poppel H., Current patterns of presentation and treatment of renal masses: A clinical research office of the endourological society prospective study. (2014) J ENDOUROL, 28 (7), 861-870.

IF: 1.7080

Lamm D., Persad R., Brausi M., Buckley R., Witjes J.A., Palou J., Bohle A., Kamat A.M., Colombel M., Soloway M., Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition. (2014) J UROLOGY, 191 (1), 20-27.

IF: 4.4710

Lammers R.J.M., Palou J., Witjes W.P.J., Janzing-Pastors M.H.D., Caris C.T.M., Witjes J.A., Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. (2014) BJU INT, 114 (2), 193-201.

IF: 3.5330

Martinez-Salamanca J.I., Linares E., Gonzalez J., Bertini R., Carballido J.A., Chromecki T., Ciancio G., Daneshmand S., Evans C.P., Gontero P., Haferkamp A., Hohenfellner M., Huang W.C., Koppie T.M., Master V.A., Matloob R., McKiernan J.M., Mlynarczyk C.M., Montorsi F., Nguyen H.G., Novara G., Pahrenik S., Palou J., Pruthi R.S., Ramaswamy K., Faba O.R., Russo P., Shariat S.F., Spahn M., Terrone C., Tilki D., Vergho D., Wallen E.M., Xylinas E., Zigeuner R., Libertino J.A., Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). (2014) CURR UROL REP, 15 (5).

IF: 1.5130

Mengual L., Ars E., Lozano J.J., Bursat M., Izquierdo L., Ingelmo-Torres M., Gaya J.M., Algaba F., Villavicencio H., Ribal M.J., Alcaraz A., Gene expression profiles in prostate cancer: Identification of candidate non-invasive diagnostic markers. (2014) ACTAS UROL ESP, 38 (3), 143-149.

IF: 1.0220

Minana B., Cozar J.M., Palou J., Unda Urzaiz M., Medina-Lopez R.A., Subira Rios J., De La Rosa-Kehrmann F., Chantada-Abal V., Lozano F., Ribal M.J., Rodriguez Fernandez E., Castineiras Fernandez J., Concepcion Masip T., Requena-Tapia M.J., Moreno-Sierra J., Hevia M., Gomez Rodriguez A., Martinez-Balleste-

ros C., Ramos M., Amon Sesmero J.H., Piza Reus P., Bohorquez Barrientos A., Rioja Sanz C., Gomez-Pascual J.A., Hidalgo Zabala E., Parra Escobar J.L., Serrano O., Bladder cancer in Spain 2011: Population based study. (2014) J UROLOGY, 191 (2), 323-328.

IF: 4.4710

Palou J., Factors related to side effects of intravesical bacillus calmette-guérin: Dose, maintenance treatment, and physicians? (2014) EUR UROL, 65 (1), 77-78.

IF: 13.9380

Palou-Redorta J., Roupert M., Gallagher J.R., Heap K., Corbell C., Schwartz B., The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries. (2014) WORLD J UROL, 32 (2), 525-530.

IF: 2.6660

Porpiglia F., Autorino R., Cicione A., Pagliarulo V., Falsaperla M., Volpe A., Gozen A.S., Celia A., De Sio M., Saita A., Damiano R., Zacchero M., Fiori C., Terrone C., Bertolo R., Greco F., Breda A., Lima E., Rassweiler J., Contemporary urologic minilaparoscopy: Indications, techniques, and surgical outcomes in a multi-institutional European cohort. (2014) J ENDOUROL, 28 (8), 951-957.

IF: 1.7080

Portillo J.A., Madero R., Solsona E., Fernandez J.M., Martinez-Pineiro L., Palou J., Montesino M., Martinez-Pineiro J.A., Unda M., Influence of the true number of Bacillus Calmette-Guérin instillations on the prognosis of non-muscle invasive bladder tumors. (2014) ACTAS UROL ESP, 38 (5), 280-284.

IF: 1.0220

Rodriguez Faba O., Breda A., Editorial for a special issue on kidney transplant. (2014) WORLD J UROL, 32 (3), 839-840.

IF: 2.6660

Rodriguez Faba O., Breda A., Erratum to: Editorial for a special issue on kidney transplant (World J Urol, 10.1007/s00345-013-1101-8). (2014) WORLD J UROL, 32 (3), 841.

IF: 2.6660

Rodriguez Faba O., Palou J., Breda A., Maroto P., Fernandez Gomez J.M., Wong A., Villavicencio H., Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma. (2014) UROL INT, 92 (2), 169-173.

IF: 1.4260

Rodriguez-Antolin A., Gomez-Veiga F., Alvarez-Osorio J.K., Carballido-Rodriguez J., Palou-Redorta J., Solsona-Narbon E., Sanchez-Sanchez E., Unda M., Factors that predict the development of bone metastases due to prostate cancer: Recommendations for fol-

*TIF: 159.6180 **MIF: 3.7120

low-up and therapeutic options. (2014) *ACTAS UROL ESP*, 38 (4), 263-269.

IF: 1.0220

Rodriguez-Faba O., Breda A., Villavicencio H., Renal transplantation and polycystic: Surgical considerations. (2014) *ACTAS UROL ESP*, 38 (1), 28-33.

IF: 1.0220

Roupret M., Morgan T.M., Bostrom P.J., Cooperberg M.R., Kutikov A., Linton K.D., Palou J., Martinez-Pineiro L., Van Der Poel H., Wijburg C., Winterbottom A., Woo H.H., Wirth M.P., Catto J.W.F., European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. (2014) *EUR UROL*, 66 (4), 628-632.

IF: 13.9380

Sanguedolce F., Millan-Rodriguez F., Santillana-Altimira J.M., Fantova-Alonso A., Sanchez-Martin F.M., Angerri-Feu O., Martinez J.M.L., Keeley F.X., Joshi H.B., Villavicencio-Mavrich H., The spanish linguistic validation of the ureteral stent symptom questionnaire. (2014) *J ENDOUROLOG*, 28 (2), 237-242.

IF: 1.7080

Schmidt S., Riel R., Frances A., Lorente Garin J.A., Bonfill X., Martinez-Zapata M.J., Morales Suarez-Varela M., dela Cruz J., Emparanza J.I., Sanchez M.-J., Zamora J., Goni J.M.R., Alonso J., Ferrer M., Becerra V., Pardo Y., Fores M.F., Garin O., Villagran C.O., Sunol R., Osorio D., Cosp X.B., Canovas E., Pardo G.S., Bolivar I., Bachs J., Maroto J.P., Quintana M.J., Martinez Zapata M.J., Lorente C.M., Algaba F., Redorta P., Esquena S., Puigvert F., Vernooij R., Marti-

nez A., Pijoan Zubizarreta J.I., Martinez L., Castro Diaz D.M., Bastida J.L., Pacheco A.S., Lopez C.G., Cozar Olmo J.M., Martinez C., Chan D.C., Sanchez Perez M.J., Diaz Moratinos A.I., Luis A.M., Hervas A., Ocana C.V., Varrona C., Burgos J., Polo Rubio J.A., Lopez-Fando Lavalle L., Jimenez Cidre M.A., Garcia A.M., Farras N.P., Lopez R.M., Garcia S.S., Abraira V., Dos Santos V.G., De la Camara A.G., De la Cruz J., Martinez J.P., Munoz H.G., Cabeza Rodriguez M.A., Diaz I.R., Sanz Jaka J.P., Velasquez M.J., Gonzalez A.L., Morales M., Camps C., Diaz C.C., Vidal E.M., Ballester F.S., Juan Escudero J.U., Peidro J.P., Torrecilla J.L., Ramos Campos M.M., Cebollada M.M., Bladder cancer index: Cross-cultural adaptation into Spanish and psychometric evaluation. (2014) *HEALTH QUAL LIFE OUT*, 12 (1).

IF: 2.1200

Schmitz-Drager B.J., Todenhofer T., van Rhijn B., Pesch B., Hudson M.A., Chandra A., Ingersoll M.A., Kassouf W., Palou J., Taylor J., Vlahou A., Behrens T., Critelli R., Grossman H.B., Sanchez-Carbayo M., Kamat A., Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. (2014) *UROLOG ONCOL-SEMIN ORI*, 32 (7), 1061-1068.

IF: 2.7680

Tilki D., Nguyen H.G., Dall'Era M.A., Bertini R., Carballido J.A., Chromecki T., Ciancio G., Daneshmand S., Gontero P., Gonzalez J., Haferkamp A., Hohenfellner M., Huang W.C., Koppie T.M., Lorentz C.A., Mandel P., Mar-

tiniz-Salamanca J.I., Master V.A., Matloob R., McKiernan J.M., Mlynarczyk C.M., Montorsi F., Novara G., Pahernik S., Palou J., Pruthi R.S., Ramaswamy K., Rodriguez Faba O., Russo P., Shariat S.F., Spahn M., Terrone C., Verghe D., Wallen E.M., Xylinas E., Zigeuner R., Libertino J.A., Evans C.P., Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. (2014) *EUR UROL*, 66 (3), 577-583.

IF: 13.9380

Vedder M.M., Marquez M., De Bekker-Grob E.W., Calle M.L., Dyrskjot L., Kogevinas M., Segersten U., Malmstrom P.-U., Algaba F., Beukers W., Orntoft T.F., Zwarthoff E., Real F.X., Malats N., Steyerberg E.W., Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: An international validation in primary tumours. (2014) *PLOS ONE*, 9 (6).

IF: 3.2340

Villavicencio H., To our mentor and friend, professor Solé-Balcells. (2014) *ACTAS UROL ESP*, 38 (8), 489-490.

IF: 1.0220

Witjes J.A., Babjuk M., Gontero P., Jacqmin D., Karl A., Kruck S., Mariappan P., Palou Redorta J., Stenzl A., Van Velthoven R., Zaak D., Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: Evidence review and updated expert recommendations. (2014) *EUR UROL*, 66 (5), 863-871.

IF: 13.9380

Radiation Oncology



Coordinator

Jordi Craven-Bartle
jcraven@santpau.cat

HSCSP

Members

Josep Balart

HSCSP



Main Lines of Research

Research is partially conducted on the premises of the Translational Research Laboratory of the Catalan Oncology Institute (ICO)-Bellvitge Biomedical Research Institute (IDIBELL) under a framework agreement between the HSCSP and the ICO.

Modulation of Radiosensitivity

- ▶ Modulation of radiosensitivity by SRC protein inhibitors in combination with anti-EGFR.
- ▶ Modulation of radiosensitivity by HMG-CoA reductase inhibitors in combination with anti-EGFR.

SBRT for Patients with Lung Cancer and with Oligometastases

- ▶ Stereotactic body radiotherapy techniques in

radical treatment of patients with early-stage non-surgical lung cancer and selected patients with non-surgical oligometastases.

Radiation Therapy Based on PET/CT Functional Imaging of Tumours

- ▶ Implementation of planning techniques for radiotherapy treatment with PET/CT for chest locations and head and neck tumours squamous cell tumours.
- ▶ Image-guided radiotherapy and respiratory movement control.
- ▶ Salvage brachytherapy for local recurrence after external beam radiotherapy in prostate cancer.
- ▶ Hypofractionated intensity-modulated GRT in prostate cancer.

Challenges

- ▶ Establish relatively radioresistant cell lines compared with the parental cells from which they derive (by clonal selection).
- ▶ Determine the resistant phenotype in cultures and xenografts.
- ▶ Determine molecular radioresistance.
- ▶ Evaluate the effect on carcinomas of SRC and HMG-CoA reductase inhibitors in combination with anti-EGFR.
- ▶ Explore signal transduction changes in the EGFR-MAPK pathway and SRC-EGFR/SRC-STAT3 cooperation induced by SRC and HMG-CoA reductase inhibitors.

*TIF: 2.0830 **MIF: 2.0830

Scientific
Production

Henriquez-Hernandez L.A., Valenciano A., Foro-Arnalot P, alvarez-Cubero M.J., Cozar J.M., Suarez-Novo J.F., Castells-Esteve M, Fernandez-Gonzalo P, De-Paula-Carranza B., Ferrer M., Guedea F, Sancho-Pardo G., Craven-Bartle J., Ortiz-Gordillo M.J., Cabrera-Roldan P, Herrera-Ramos E., Rodriguez-Gallego C., Rodriguez-Melcon J.I., Lara P.C., Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression. (2014) BMC MED GENET, 15 (1).
IF: 2.0830

Other Publications

- ▶ Baro M., de Llobet L.I., Figueras A., Skvortsova I., Mesia R., Balart J., Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours.. (2014) British journal of cancer, 111 (7), 1310-1318.
- ▶ de Llobet L.I., Baro M., Mesia R., Balart J., Simvastatin enhances the effects of radiotherapy and cetuximab on a cell line (FaDu) derived from a squamous cell carcinoma of head and neck. (2014) TRANSL ONCOL, 7 (4), 513-522.

Locomotor System Research

Coordinator

Xavier Crusi HSCSP

Members

Xavier Aguilera HSCSP

Helena Bascuñana HSCSP

Rafael Calvo HSCSP

Fernando Celaya HSCSP

Pablo E. Gelber HSCSP

José Carlos González HSCSP

Isidre Gracia HSCSP

Joan C. Monllau HSCSP

M. Josefa Nadal HSCSP

Ana Peiro HSCSP

Ignacio Proubasta HSCSP

Laura Soria HSCSP

M. Teresa Torrades HSCSP

Main Lines of Research

Research is partially conducted on the premises of the Translational Research Laboratory of the Catalan Oncology Institute (ICO)-Bellvitge Biomedical Research Institute (IDIBELL) under a framework agreement between the HSCSP and the ICO.

Antiresorptives in Orthopedic and Trauma Surgery

- ▶ Effect of zoledronic acid (Aclasta) on periprosthetic bone mineral density in patients undergoing total knee arthroplasty. Study approved by the HSCSP ethics committee and authorized by the Spanish Medicines and Health Products Agency (AEMPS) for the out-of-context indication of Aclasta.

Knee

Haemostasis

- ▶ Blood loss control using tranexamic acid in primary prosthetic and knee revision surgery.
- ▶ Retrospective study of revision knee arthroplasty to compare the effects of intravenous tranexamic acid and normal haemostasis.
- ▶ Clinical trial comparing outcomes for intravenous tranexamic acid with fibrin glue (Tissucol) and normal haemostasis in primary knee prosthetic surgery.
- ▶ Observational study of blood loss in redon drainage over time in pertrochanteric hip fractures.

Cartilage

- ▶ Regeneration of cartilage defects using tissue engineering and a matrix seeded with characterized allogeneic chondrocytes.

Meniscus

- ▶ Effect of normal and growth-factor-enriched cell cultures on the meniscal collagen network and glycosaminoglycan expression.
- ▶ In vitro experimental study of the feasibility of a polyurethane replacement meniscus pre-seeded with stem cells.
- ▶ Evolution of allogeneic meniscal transplants and relationship with extrusion.

Hip

- ▶ Coxarthrosis in young adults: etiological study of biomechanical factors.
- ▶ Biomechanics of coxarthrosis in young adults: finite element study.
- ▶ Influence of hip anatomy in early development of coxarthrosis: controlled, prospective radiographic study.

Upper Limb

- ▶ Anatomical study of stabilizing ligaments in the trapeziometacarpal joint: the role played by dorsoradial and anterior oblique ligaments in Bennett and Rolando fractures.
- ▶ Surgical treatment of middle-third clavicle fractures in high-energy trauma in young patients.
- ▶ Retrospective study of the use of vascularized bone graft using the 1,2-ICSR artery in the revascularization of proximal pole necrosis in scaphoid pseudarthrosis.

Active Grants

- ▶ Ana Peiró Ibáñez. Prevención del sangrado postoperatorio en cirugía de resección masiva de tumores óseos: Ensayo clínico multicéntrico, aleatorizado, abierto, paralelo de tres brazos de tratamiento, que evalúa la eficacia del ácido tranexámico tópico versus Evidel tópico. Ministerio de Sanidad, Servicios Sociales e Igualdad: EC 2011. EC11-340. Duration: 01/01/12-30/06/15. €76,960.

- ▶ Pablo E. Gelber Ghertner. Contract with Asociación Española Artroscopia 2011. Duration: 20/12/11-31/12/14. €2,777.77.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 21.9660 **MIF: 2.4407

Scientific
Production

Abat F, Gelber P.E., Polidori F, Monllau J.C, Sanchez-Ibañez J.M. Clinical results after ultrasound-guided intratissue percutaneous electrolysis (EPI®) and eccentric exercise in the treatment of patellar tendinopathy. *KNEE SURG SPORTS TRAUMATOL ARTHROSC* 2014; 23(4): 1046-52.

IF: 3.0530

Benito N., Franco M., Coll P., Galvez M.L., Jordan M., Lopez-Contreras J., Pomar V., Monllau J.C., Mirelis B., Gurgui M., Etiology of surgical site infections after primary total joint arthroplasties. (2014) *J ORTHOP RES*, 32 (5), 633-637.

IF: 2.9860

Castellet E., Ares O., Celaya F, Valenti-Azcarate A., Salvador A., Torres A., Sesma P., Macule F., Leon V., Montanez E., Freire A., Hinarejos P., Montserrat F., Amillo J.R., Transcultural adaptation and validation of the "Hip and Knee" questionnaire into Spanish. (2014) *HEALTH QUAL LIFE OUT*, 12 (1).

IF: 2.1200

Gelber P.E., Batista J., Millan-Billi A., Pauthauer L., Vera S., Gomez-Masdeu M., Monllau J.C., Magnetic resonance evaluation of

TruFit® plugs for the treatment of osteochondral lesions of the knee shows the poor characteristics of the repair tissue. (2014) *KNEE*, 21 (4), 827-832.

IF: 1.9360

Ivorra J.L., Rivero O., Costas J., Iñiesta R., Arrojo M., Ramos-Rios R., Carracedo T., Palomo T., Rodriguez-Jimenez R., Cervilla J., Gutierrez B., Lebourg M., Martinez-Diaz S., Garcia-Giralt N., Torres-Claramunt R., Ribelles J.L.G., Vila-Canet G., Monllau J.C., Cell-free cartilage engineering approach using hyaluronic acid-polycaprolactone scaffolds: A study in vivo. (2014) *J BIOMATER APPL*, 28 (9), 1304-1315.

IF: 2.1970

Molina E., Arango C., Alvarez M., Pascual J.C., Perez V., Saiz P.A., Garcia-Portilla M.P., Bobes J., Gonzalez-Pinto A., Zorrilla I., Haro J.M., Bernardo M., Baca-Garcia E., Gonzalez J.C., Hoenicka J., Molto M.D., Sanjuan J., Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain. (2014) *SCHIZOPHR RES*, 159 (1), 107-113.

IF: 3.9230

Proubasta I.R., Lamas C.G., Natera L., Millan A., Silicone proximal interphalangeal joint arthroplasty for primary osteoarthritis using a volar approach. (2014) *J HAND SURG-AM*, 39 (6), 1075-1081.

IF: 1.6670

Renom M., Conrad A., Bascunana H., Cieza A., Galan I., Kesselring J., Coenen M., Content validity of the Comprehensive ICF Core Set for multiple sclerosis from the perspective of speech and language therapists. (2014) *INT J LANG COMM DIS*, 49 (6), 672-686.

IF: 1.4710

Roman E., Torrades Ma.T., Nadal Ma.J., Cardenas G., Nieto J.C., Vidal S., Bascunana H., Juarez C., Guarner C., Cordoba J., Soriano G., Randomized pilot study: Effects of an exercise programme and leucine supplementation in patients with cirrhosis. (2014) *DIGEST DIS SCI*, 59 (8), 1966-1975.

IF: 2.6130

Other Publications

▶ Abat F, Diesel W.-J., Gelber P.-E., Polidori F, Monllau J.-C., Sanchez-Ibanez J.-M., Effectiveness of the Intratissue Percutaneous Electrolysis (EPI®) technique and isoinertial eccentric exercise in the treatment of patellar tendinopathy at two years follow-up. (2014) *MUSCLES, LIGAMENTS AND TENDONS JOURNAL*, 4 (2), 188-193.

▶ Abat F, Valles S.L., Gelber P.E., Polidori F, Stitik T.P., Garcia-Herberos S., Monllau J.C., Sanchez-Ibanez J.M., Molecular repair mechanisms using the intratissue percutaneous electrolysis technique in patellar tendonitis. (2014) *REVISTA ESPANOLA DE CIRUGIA ORTOPEDICA Y TRAUMATOLOGIA*, 58 (4), 201-205.

▶ Aguilera X., Gonzalez J.C., Celaya F, Jordan M., Diaz-Torne C., Monllau J.C., Total knee arthroplasty in a patient with subcutaneous and intra-articular tophaceous gout - A case report. (2014) *BULLETIN OF THE NYU HOSPITAL FOR JOINT DISEASES*, 72 (2), 173-175.

▶ Cisneros L.N., Gomez E.M., Lucena G.G., Trullols L., Soria L., Peiro A., Calcaneal psuedarthrosis in catastrophic foot. (2014) *REVISTA CUBANA DE ORTOPEDIA Y TRAUMATOLOGIA*, 28 (1), 116-121.

▶ García A.J., Proubasta I., Arriaga N., Gracia I.A. Sarcoma fibroblástico mixoinflamatorio acral: caso clínico y revisión bibliográfica. *REV IBERAMER CIR MANO* 2014; 42 : 157-161.

▶ Malagelada F., Tarrago L.T., Tibrewal S., Ibanez A.P., Jeyaseelan L., Alegria I.G., Pathological fracture in osteosarcoma: Is it always an indication for amputation? (2014) *ORTOPEDIA TRAUMATOLOGIA REHABILITACION*, 16 (1), 67-74.

▶ Natera L., Gelber P.E., Erquicia J.I., Monllau J.C. Primary lipoma arborescens of the knee may involve the development of early osteoarthritis if prompt synovectomy is not performed. *J ORTHOP TRAUMATOL*. 2014; 16(1): 47-53.

▶ Natera L., Gómez M., Lamas C., Proubasta I. Luxación palmar de la articulación metacarpofalángica del pulgar. *TRAUMA FUND MAPFRE* 2014; 25: 1-3.

▶ Natera L., Moya-Gómez E., Lamas-Gómez C., Proubasta I. Proximal interphalangeal joint replacement: A comparison between the volar and dorsal approach. *REV ESP CIR ORTOP TRAUMATOL* 2014; 58:303-308.

▶ Natera L., Sarasquete J.R., Abat F. Anatomic Reconstruction of Chronic Coracoclavicular Ligament Tears: Arthroscopic-Assisted Approach With Nonrigid Mechanical Fixation and Graft Augmentation. *ARTHROSCOPY TECHNIQUES* 2014; 3 (5): e583-e588.

▶ Proubasta I., Natera Cisneros L., Gomez M., Lamas C., Proubasta I., Palmar dislocation of the metacarpophalangeal joint of the thumb. (2014) *TRAUMA (SPAIN)*, 25 (2), 74-76.

▶ Proubasta I., Lamas C., Millán A. Calcificación idiopática digital. *REVISTA IBEROAMERICANA DE CIRUGÍA DE LA MANO* 2014; 42 (1): 47-49.

▶ Proubasta I., Pagonabarraga J., Lamas C., Millan A. Distonia focal de mano. *REV IBERAMER CIR MANO* 2014; 42: 172-182.

Multiple Sclerosis and Epilepsy Research

Coordinator

Antonio Escartín HSCSP
aescartin@santpau.cat

Members

Figuerola Sebastian HSCSP RI
Mariana López HSCSP RI
Miquel Navas HSCSP RI
Luis Querol HSCSP
Nuria Vidal HSCSP RI



Main Lines of Research

- ▶ Neuropsychological impairment in patients with multiple sclerosis.
- ▶ Pharmacogenetics in epilepsy.
- ▶ Neuropsychological impairment in juvenile myoclonic epilepsy.
- ▶ Basic research line.

Challenges

- ▶ Study cognitive evoked potentials in early detection of cognitive impairment in patients with radiologically isolated syndrome, clinically isolated syndrome and newly diagnosed multiple sclerosis.
- ▶ Study the effects of immunomodulatory and immunosuppressive treatments on the cognitive functions of patients with multiple sclerosis.
- ▶ Determine pharmacogenetic variations involving different responses to antiepileptic treatment.
- ▶ Study neuropsychological alterations in patients diagnosed with juvenile myoclonic epilepsy.

*TIF: 33.9170 **MIF: 5.6528

Scientific Production

Diaz-Manera J., Querol L., Alejaldre A., Rojas-García R., Ramos-Fransi A., Gallardo E., Illa I., Severe exacerbation of Andersen-Tawil syndrome secondary to thyrotoxicosis. (2014) *J HUM GENET*, 59 (8), 465-466.

IF: 2.4620

Gallardo E., Martínez-Hernández E., Titulaer M.J., Huijbers M.G., Martínez M.A., Ramos A., Querol L., Diaz-Manera J., Rojas-García R., Hayworth C.R., Verschuuren J.J., Balice-Gordon R., Dalmau J., Illa I., Contactin autoantibodies in myasthenia gravis. (2014) *AUTOIMMUN REV*, 13 (10), 1003-1007.

IF: 7.9330

Labasque M., Hivert B., Nogales-Gadea G., Querol L., Illa I., Faivre-Sarrailh C., Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. (2014) *J BIOL CHEM*, 289 (11), 7907-7918.

IF: 4.5730

Nogales-Gadea G., Ramos-Fransi A., Suarez-Calvet X., Navas M., Rojas-García R., Mosquera J.L., Diaz-Manera J., Querol L., Gallardo E., Illa I., Analysis of serum miRNA profiles of myasthenia gravis patients. (2014) *PLOS ONE*, 9 (3).

IF: 3.2340

Querol L., Nogales-Gadea G., Rojas-García R., Diaz-Manera J., Pardo J., Ortega-Moreno A., Sedano M.J., Gallardo E., Berciano J., Blesa R., Dalmau J., Illa I., Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. (2014) *NEUROLOGY*, 82 (10), 879-886.

IF: 8.2860

Suarez-Calvet X., Gallardo E., Nogales-Gadea G., Querol L., Navas M., Diaz-Manera J., Rojas-García R., Illa I., Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. (2014) *J PATHOL*, 233 (3), 258-268.

IF: 7.4290

*Total Impact Factor **Mean Impact Factor

Pain and Neurosciences

Coordinator

Elena Català
ecatala@santpau.cat

HSCSP

Members

Ana Parera

HSCSP



Main Lines of Research

- ▶ Involvement of brain areas and release of substances in acute and chronic neuropathic pain (in conjunction with HSCSP neuroradiology unit and the Autonomous University of Barcelona).
- ▶ Sleep disturbance on initiating systemic opioid treatment in patients with severe chronic pain and altered sleep patterns.
- ▶ Influence of herniated lumbar disc anatomy on the effectiveness of epidural corticosteroids by the interlaminal, paramedial, transforaminal and caudal routes.
- ▶ Profile in terms of demographics, comorbidities, kind of pain, physical and mental status and disability of patients.

Challenges

- ▶ Establish the possible differences in brain area involvement between acute and chronic pain.
- ▶ Establish the different brain substances expressed in patients affected by acute and chronic neuropathic pain.
- ▶ Determine the extent of chronic pain according to the involvement of different brain areas.
- ▶ Determine whether the intensity of chronic neuropathic pain assessed by the patient is correlated with the patient's psychopathology, essentially anxiety, depression and catastrophizing.
- ▶ Determine the profile of patients who would benefit from treatment with major systemic opioids in relation to night rest and establish the recommendable opioid.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Neuroradiology.

Awards

- ▶ Mercè Genové Cortada. Estudi de les alteracions cerebrals en pacients amb dolor neuropàtic secundari a la infecció pel virus de la Varicel·la Zoster: Herpes Zoster i Neuràlgia Postherpètica. Premi Fernando Vidal 2014. Societat Catalana de Dolor. Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i Balears.
- ▶ Martha Melo. Eficacia y seguridad del parche hemático epidural para el tratamiento de la cefalea hipotensiva. Premi a la millor comunicació oral en la III Reunió de l'Abordatge del Dolor per a Residents i Adjunts Joves. Societat Catalana de Dolor. ACMCB.

**Other
Publications**

- ▶ Ferrandiz Mach M., Santeularia Verges M.T., Catala Puicbo E., Tratamiento analgésico de las metástasis óseas. (2014) DOLOR, 29 (2), 67-85.
- ▶ Puigbo E.C., Canudas M.V.R.E., Imagen y dolor. (2014) DOLOR, 29 (3), 134-136.

Nursing Care Research

Coordinator

Laura López HSCSP

Members

Andrés Aristayeta HSCSP

Gemma Berga HSCSP

Catalina Bou HSCSP

Rafael Calvo HSCSP

M. Pilar Català HSCSP

Queralt Cebrià HSCSP

Alexandra Chapado HSCSP RI

Laura de la Cueva HSCSP

Ascensión García HSCSP

Dolores Gil HSCSP

Montserrat Guillaumet HSCSP

Gemma Guiu HSCSP

Carne Jover HSCSP

Clara Juando HSCSP

María Lacueva HSCSP

Laura López HSCSP

Josefa Mitjans HSCSP

M. Carmen Peñalba HSCSP

Josefa Pirla HSCSP

Maite Ricart HSCSP

Gemma Robleda HSCSP

Marta Romero HSCSP

Alicia Sánchez HSCSP

Montserrat Serra HSCSP

Amalia Sillero HSCSP

María Solà HSCSP



Main Lines of Research

- ▶ Fall prevention and analysis of fall-related factors.
- ▶ Translation and validation of care evaluation questionnaires.
- ▶ Constipation and ageing.
- ▶ Quality of life related to nursing care.
- ▶ Development and application of health science methods: qualitative and qualitative methods, text analysis and discourse analysis.
- ▶ Patient satisfaction with nursing care.
- ▶ Attention to the family.
- ▶ Pain.

Challenges

- ▶ Strengthen implemented research lines and disseminate the results of active projects.
- ▶ Explore the impact of nursing care for patients, strategies for care improvement and the application of results in cure models.
- ▶ Improve the development and understanding of qualitative research in the context of the health sciences and disseminate qualitative methods and analyses of text and discourse as tools in health science research.
- ▶ Create the synergies necessary to consolidate the group's activities.

Collaborations

External Collaborations

- ▶ Gemma Robleda. Estudio multicéntrico de validez y fiabilidad de la Escala de Conductas Indicadoras de Dolor (ESCID) para medir el dolor en pacientes críticos, no comunicativos y sometidos a ventilación mecánica. Instituto de Investigación clínica, Hospital Universitario Puerta de Hierro Majadahonda. Madrid. PI11-00766. Duration: 2012-15.

Active Grants

- ▶ Marta Romero García. Calidad percibida de los cuidados enfermeros por los pacientes críticos: un abordaje mixto. MINECO-IS-CIII Project 2011. PI11/00447. Duration: 01/01/12-31/05/15. €15,500.

Note: Total amount granted to PI. It does not include indirect costs.

Awards

- ▶ M. Navarro-Colom, M.A. Sendra-Lluís, A.M. Castillo-Masa, G. Robleda. Fiabilidad interobservador de la Behavioral Pain Scale en pacientes con ventilación mecánica. Primer Premio a Póster Oral. X Congreso Panamericano e Ibérico de Medicina Crítica y Terapia Intensiva. Madrid, 2014.

*TIF: 15.2710 **MIF: 5.0903

Scientific Production

De-La-Cueva-Ariza L., Romero-García M., Delgado-Hito P., Acosta-Mejuto B., Jover-Sancho C., Ricart-Basagana M.-S.-O.-S.-C.T., Juando-Prats C., Sola-Sole N., Sola-Ribo M., Development of an instrument to measure the degree of critical patient's satisfaction with nursing care: Research protocol. (2014) J ADV NURS, 70 (1), 201-210.

IF: 1.7410

Puntillo K.A., Max A., Timsit J.-F., Vignoud L., Chanques G., Robleda G., Roche-Campo F.,

Mancebo J., Divatia J.V., Soares M., Ionescu D.C., Grintescu I.M., Vasiliu I.L., Maggiore S.M., Rusinova K., Owczuk R., Egerod I., Papanathanassoglou E.D.E., Kyranou M., Joynt G.M., Burghi G., Freebairn R.C., Ho K.M., Kaarlola A., Gerritsen R.T., Kesecioglu J., Sulaj M.M.S., Norrenberg M., Benoit D.D., Seha M.S.G., Hennein A., Periera F.J., Benbenishty J.S., Abroug F., Aquilina A., Monte J.R.C., An Y., Azoulay E., Determinants of procedural pain intensity in the intensive care unit: The Eu-

ropain® study. (2014) AM J RESP CRIT CARE, 189 (1), 39-47.

IF: 12.9960

Robleda G., Sillero-Sillero A., Puig T., Gich I., Banos J.-E., Influence of preoperative emotional state on postoperative pain following orthopedic and trauma surgery. (2014) REV LAT-AM ENFERM, 22 (5), 785-791.

IF: 0.5340

Reproductive Health

Coordinator

Joaquim Calaf HSCSP

Members

Juan M. Adelantado HSCSP

Obdulia Alejos HSCSP

Josep Armengol HSCSP

Josep R. Bordas F. Puigvert

Joan Espinós HSCSP

Josep R. Estadella HSCSP

Misericordia Guinot HSCSP

M. del Carmen Medina HSCSP

Pere Pares F. Puigvert

Juan Parra HSCSP

Ana María Polo F. Puigvert

Josep Oriol Porta HSCSP

Noelia Rams HSCSP

Ramon Rovira HSCSP

María Jesús Saiz F. Puigvert

Raquel Senosiain HSCSP

Marta Simó HSCSP

Cristina Trilla HSCSP



Main Lines of Research

- ▶ Qualitative study of foetal motility by means of 2D ultrasound in foetuses with spinal muscular atrophy.
- ▶ Cutoff point for foetal pyelectasis as a nephrourologic pathology discriminator.
- ▶ Value of foetal nuchal translucency as a marker of neuromuscular diseases and other monogenic diseases.
- ▶ Value of ultrasound in the control of foetal anaemia.
- ▶ Usefulness of Doppler ultrasound of the umbilical artery during the second trimester as a discriminator of pregnancies at high risk of poor perinatal outcomes.

Challenges

- ▶ Consolidate a line of work with the HSCSP genetics department concerning possible early clinical manifestations detectable using 2D and 4D ultrasound in foetuses affected by genetic diseases, particularly neuromuscular disorders, given that the HSCSP is a referral centre for a particular group of rare diseases.
- ▶ Investigate the usefulness of new technologies such as 3D power Doppler angiography of the placenta in the diagnosis and control of certain foetal diseases.
- ▶ Screen for chromosomal abnormalities from the ultrasound and biochemistry points of view, investigating the potential usefulness of the markers used either alone or in combination as indicators of populations at risk of placental insufficiency.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Genetic Diseases.

Active Grants

- ▶ Joan Espinós Gómez. Impacto de la dieta hipocalórica y ejercicio en mujeres con obesidad que se sometan a un ciclo de FIV. MINECO-ISCIII Project 2011. P111/02816. Duration: 01/01/12-31/12/15. €42,909.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 10.7560 **MIF: 1.5366

Scientific Production

Alcantara-Aragon V., Martinez-Couselo S., Tundidor-Rengel D., Webb S.M., Carreras G., Espinos J.J., Chico A., Blanco-Vaca F., Corcoy R., Genetic analysis does not confirm non-classical congenital adrenal hyperplasia in more than a third of the women followed with this diagnosis. (2014) HORM-INT J ENDOCRINO, 13 (4), 585-587.

IF: 1.1980

Calaf J., Lete I., Canals I., Crespo C., Espinos B., Cristobal I., Cost-effectiveness analysis in the treatment of heavy menstrual bleeding in Spain. (2014) EUR J OBSTET GYN R B, 184, 24-31.

IF: 1.6950

Lete I., Calaf J., Lopez-Arregui E., Is there a need for a new abortion law in Spain? (2014) EUR J CONTRACEP REPR, 19 (2), 75-77.

IF: 1.3940

Martorell M.R., Martinez-Pasarell O., Lopez O., Polo A., Sandalinas M., Garcia-Guixe E., Bassas L., Chromosome 16 abnormalities in embryos and in sperm from a male with a fragile site at 16q22.1. (2014) CYTOGENET GENOME RES, 142 (2), 134-139.

IF: 1.5610

Remacha A.F., Zapico E., Sarda M.P., Rojas E., Simo M., Remacha J., Homs R., Queralto J.M., Immune complexes and persistent high levels of serum vitamin B12. (2014) INT J LAB HEMATOL, 36 (1), 92-97.

IF: 1.8190

Trilla C., Senosiain R., Calaf J., Espinos J.J., Effect of changes to cost and availability of emergency contraception on users' profiles in an emergency department in Catalunya. (2014) EUR J CONTRACEP REPR, 19 (4), 259-265.

IF: 1.3940

Trilla C.C., Medina M.C., Ginovart G., Betancourt J., Armengol J.A., Calaf J., Maternal risk factors and obstetric complications in late preterm prematurity. (2014) EUR J OBSTET GYN R B, 179, 105-109.

IF: 1.6950

Other Publications

- ▶ Rams N., Munoz R., Soler C., Parra J., Results of the Gynecologic Imaging Reporting and Data System classification in adnexal masses. (2014) PROGRESOS DE OBSTETRICIA Y GINECOLOGIA, 58 (3), 125-129.

Translational Molecular Oncology

Coordinator

Matilde Parreño HSCSP RI
mparreno@santpau.cat

Members

María Laura Blanco HSCSP



Main Lines of Research

- ▶ In vitro and in vivo studies by genetic manipulation of putative biomarkers of prognosis in squamous cell carcinoma (SCC) in tumour progression and as potential therapeutic targets.
- ▶ Preclinical cancer models to study alternative strategy of treatments in leukemia.

Challenges

- ▶ Evaluate survival pathways and epithelial-mesenchymal transition involving the studied genes.
- ▶ Reinforce and encourage translational research in tumour progression through collaboration with internal and external research groups.
- ▶ Improve a mouse model of cancer, based on implantation of human primary tumour.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Haematological Diagnosis (Josep Nomdedéu):
 - Establishment of "in vivo" model of leukomogenesis.
 - Ajuts de suport als Grups de Recerca de Catalunya. Grup de Diagnòstic Hematològic. AGAUR 2014. SGR 383 2014-SGR-383. Duration: 2014- 2016. €30,000.
- ▶ Ear, Nose and Throat Cancers (Xavier Leon): studies of HNSCC.

- ▶ Angiology, Vascular Biology and Inflammation (Luis Vila, Mercedes Camacho): studies of HNSCC.

External Collaborations

- ▶ Translational Research Laboratory, Institut Català d'Oncologia (ICO) - IDIBELL (Alberto Villanueva): studies of orthotopic tumor models.
- ▶ Cell signalling and checkpoints, Faculty of Medicine, IDIBAPS (Neus Agell and Montserrat Jaumot)

Active Grants

- ▶ Matilde Parreño Gómez. Estudio de marcadores de mal pronóstico en carcinoma escamoso de cabeza y cuello (CECC) y búsqueda de alternativas terapéuticas. FIS Projecte 2009. PI09/0334. Duration: 01/01/10-30/06/14. €151,500.

Note: Total amount granted to PI. It does not include indirect costs.

Cardiac Surgery

Coordinator

Josep M. Padró

HSCSP

Members

Pilar Catalá

Antonino Ginel

Ignasi Julia

HSCSP

José Montiel

Christian Muñoz

HSCSP

Elena Roselló

M. Àngels Siesto

Manel Tauron

Main Lines of Research

- ▶ Off-pump coronary artery by-pass grafting surgery
- ▶ Mitral repair surgery
- ▶ Ascending aorta pathology
- ▶ Pathogenesis of atrial fibrillation after cardiac surgery: electrophysiologic and mitochondrial analysis
- ▶ Follow-up of sutureless aortic valve prosthesis: Perceval S
- ▶ Follow-up of surgical check-list implementation
- ▶ Use of erythropoietin before cardiac surgery
- ▶ Participation in VISION study (Vascular events In Surgery patients cOhort evaluatioN)-Cardiac Surgery

Challenges

- ▶ Consolidation as a research group in different cardiac surgery-related fields, specific sutureless valve prosthesis
 - Perioperative myocardial infarction
- ▶ Participation in the assessment and validation of new products employed in cardiac surgery: haemostatics, sutures, systems for sternal closure...
- ▶ Collaboration with different national and international research teams involved in our lines of study

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Leif Hove-Madsen, ICC-CSCIC.
- ▶ M. Luz Maestre Hittinger. Department of Anaesthesiology.

External Collaborations

- ▶ Elena Domínguez Garrido. Unit of Molecular Diagnosis. Fundación Rioja Salud, La Rioja, Spain.
- ▶ Elisabeth Berastegui. Department of Cardiac Surgery. Hospital Germans Trias i Pujol, Badalona, Spain.

- ▶ Mercé Cladellas Capdevila. Department of Cardiology. Hospital del Mar, Barcelona, Spain.
- ▶ Ignasi Julià Amill. Follow-up of sutureless aortic valve prosthesis Perceval S. Palex Medical, June 2013-June 2014.
- ▶ Elena Roselló Díez. Follow-up of sutureless aortic valve prosthesis Perceval S. Palex Medical, June 2014-September 2015.

Other Publications

- ▶ Catalá A., Barnadas M.A., Muñoz C., Puig L., Cutaneous leishmaniasis in a patient receiving infliximab for psoriatic arthritis: Treatment with cryotherapy and intralesional meglumine antimonate. (2014) Actas Dermo-Sifiliográficas, 105 (7), 714-716.



Sant Pau
Biomedical Research Institute

Sant Antoni Maria Claret, 167
08025 Barcelona
iib@santpau.cat



Institut de Recerca



© Sant Pau Biomedical Research Institute (IIB Sant Pau), 2015
Hospital de la Santa Creu i Sant Pau
Sant Antoni Maria Claret, 167
08025 Barcelona
Spain

Design
Santi Porta

Coordination and Edition
Corporate Communications and Public Relations Department
Hospital de la Santa Creu i Sant Pau

Photography
Hospital de la Santa Creu i Sant Pau Image bank
Alfonso García
David Cuní
iStockphoto